TO STUDY THE ROLE OF BIOMARKERS IN THE DIAGNOSIS OF INVASIVE ASPERGILLOSIS

A THESIS SUBMITTED TO

BABA FARID UNIVERSITY OF HEALTH SCIENCES, FARIDKOT (PUNJAB)

IN THE PARTIAL FULFILLMENT

FOR THE AWARD OF DEGREE OF

DOCTOR OF MEDICINE

IN

MICROBIOLOGY

2024

Submitted By

DR SABRI

DEPARTMENT OF MICROBIOLOGY
DAYANAND MEDICAL COLLEGE AND HOSPITAL
LUDHIANA, PUNJAB

DECLARATION BY THE CANDIDATE

I hereby declare that the thesis entitled "**TO STUDY THE ROLE OF BIOMARKERS IN THE DIAGNOSIS OF INVASIVE ASPERGILLOSIS**" submitted towards partial fulfillment of the requirements for the award of **MD in Microbiology** degree to BFUHS is a compilation of original work carried out by me under the supervision of **Dr. Jyoti Chaudhary**, Professor, Department of Microbiology, **Dr. Veenu Gupta,** Professor & Head, Department of Microbiology and **Dr. Akashdeep Singh**, Professor & Head, Department of Pulmonary Medicine. No part of this thesis has formed the basis for the award of any degree previously.

_____

Dr. SABRI
Department of Microbiology,
Dayanand Medical College & Hospital,
Ludhiana, Punjab

Date:

Place:

CERTIFICATE OF SUPERVISORS

This is to certify that the work incorporated in this thesis entitled "**TO STUDY THE ROLE OF BIOMARKERS IN THE DIAGNOSIS OF INVASIVE ASPERGILLOSIS"** has been carried out by **Dr. Sabri** under our direct supervision. The data incorporated in this thesis is original and genuine and has been carried out by the candidate himself.

Signature of Supervisor

Dr. Jyoti Chaudhary
Professor
Department of Microbiology
DMC&H, Ludhiana

Signature of Co-Supervisors

Dr. Veenu Gupta
Professor & Head
Department of Microbiology
DMC&H, Ludhiana

Dr. Akashdeep Singh
Professor & Head
Department of Pulmonary Medicine
DMC&H, Ludhiana

Date:

ENDORSEMENT BY THE HEAD OF THE INSTITUTE

This is to certify that the thesis entitled "**TO STUDY THE ROLE OF BIOMARKERS IN THE DIAGNOSIS OF INVASIVE ASPERGILLOSIS"** is a bonafide research work done by **Dr. Sabri** under the supervision of **Dr. Jyoti Chaudhary**, Professor, Department of Microbiology, **Dr. Veenu Gupta,** Professor & Head, Department of Microbiology and **Dr. Akashdeep Singh**, Professor & Head, Department of Pulmonary Medicine, in this institution.

Principal
Dr. Gurpreet Singh Wander
Principal
DMC&H, Ludhiana

Date:

COPYRIGHT

Declaration by the Candidate

I hereby declare that the Baba Farid University of Health Sciences, Faridkot, shall have the rights to preserve & use this thesis in print or electronic format for academic/study purpose by the research scholar/students.

Signature

Dr Sabri
Department of Microbiology,
Dayanand Medical College & Hospital,
Ludhiana, Punjab - 141001

Date:

© Baba Farid University of Health Sciences, Faridkot

Dedicated

to

My Parents

Mr Hemraj and

Mrs. Kanta Devi

and My beloved

Brother Neeraj

ACKNOWLEDGEMENT

I would like to express my deep gratitude and appreciation to all those have supported and guided me throughout the journey.

First and foremost, I extend my deepest gratitude to ***Dr. Jyoti Chaudhary****, Professor, Department of Microbiology, whose wisdom, expertise and mentorship have been guiding light of my research journey. Her invaluable guidance and insightful feedback have been instrumental in shaping the direction of this dissertation. I am truly thankful for her dedication to the pursuit of knowledge and her commitment to her student's success.*

I express my sincere appreciation to ***Dr. Akashdeep****, Professor, Department of Chest & TB for his invaluable assistance and support throughout the phases of research.*

I am also indebted to ***Dr. Veenu Gupta*** *Professor & Head, Department of Microbiology, for his scholarly advice and encouragement throughout this research endeavour. His expertise in field of Nephrology has been enlightening, and his constructive criticism has immensely contributed to the refinement of this work. I am fortunate to have had the opportunity to learn from his.*

My gracious thanks to ***Dr. Rama Gupta****, Professor, Department of Microbiology,* ***Dr. Eshani Dewan****, Associate Professor, Department of Microbiology,* ***Dr. Menal Gupta****, Assistant Professor, Department of Microbiology,* ***Dr. Manisha Aggarwal****, Assistant Professor, Department of Microbiology. and to my seniors,* ***Dr. Bavleen****,* ***Dr Monica****,* ***Dr. Harmandeep*** *and* ***Dr. Divjot*** *for helping me thoroughly with the analysis and formatting of this dissertation.*

Mom and Dad, thank you for everything. I am blessed to have you as my constant source of motivation and your sacrifices to provide me with the best of everything have been driving force behind my

accomplishments. This journey and work is a reflection of the values you instilled in me and the love you showered on me. I am always indebted to you.

I am profoundly thankful to my Brother ***Neeraj*** *this journey was Ode to you. Thank you for always standing by me and motivating whenever I hit rock bottom. I am proud of you and hope this accomplishment makes you proud of me.*

Thank you so much to my friends ***Kriptesh Singh, Dr Jaskaran and Dr Gunjan*** *for always pushing me to achieve my best and making me realise in bigger picture. You were the reason I could sustain and handle every challenge with grace. I am grateful to have all of you by my side.*

I would like to thank my friends and colleagues, ***Dr. Manav, Dr. Prabhdeep, Dr Sejshi and Dr. Amarpreet Kaur****, for persistent belief in me and your willingness to lend a helping hand. Countless moments of motivation and laughter we shared made this journey not only academically fulfilling but also personally enriching. I am grateful for the memories we created together.*

This dissertation is a result of collective efforts and encouragement of many and I am sincerely grateful to each and every one of you for being part of this academic endeavour.

Dr. Sabri

ABBREVIATIONS

BAL	Bronchoalveolar lavage
BDG	(1-3)-Beta-D-Glucan
BSI	Bloodstream infections
COPD	Chronic obstructive pulmonary disease
CT	Computed tomography
DAMA	Discharge against medical advice
EIA	Enzyme immunoassay
ET	Endotracheal secretions
GM	Galactomannan
HIV	Human immunodeficiency virus
HSCT	Haematopoeitic stem cell transplant
IA	Invasive aspergillosis
IC	Invasive Candidiasis
ICU	Intensive care units
IFI	Invasive fungal infections
IMF	International monetary fund
KOH	Pottasium hydroxide
LCB	Lactophenol cotton blue
NPV	Negative predictive value
PCR	Polymerase chain reaction
PPV	Positive predictive value
PTZ	Piperacillin-tazobactam
ROC	Receiver operating characteristic
SDA	Sabouraud’s dextrose agar
SOT	Solid organ transplant
Spp.	Species
TB	Tuberculosis
(EORTC/MSG)	European Organization for Research and Treatment of Cancer and Mycoses study group case definitions

ABSTRACT

Introduction: Aspergillus species cause a wide range of diseases, especially in high risk immunocompromised patients. Invasive Aspergillosis(IA) is associated with high morbidity and mortality. Early diagnosis by fungal serological markers helps in time treatment further reduces mortality.

Aims and Objectives-

1. To study the clinic-mycological profile of admitted patients suspected for invasive aspergillosis.
2. To study the positivity and the variables affecting the fungal biomarkers (galactomannan assay / 1-3 β- d- glucan assay).

Materials and Methods- This prospective study was conducted over a period of one year in the Department of Microbiology, Dayanand Medical College and Hospital, Ludhiana. All adult patients admitted with suspicion of Invasive asperigillosis whose requisition for GM assay received in the microbiology department were included. Samples were processed as per standard microbiological method and kit literature for galactomannan asaay, (1-3) β-d- glucan assay and fungus culture.

Results- A total of 1941 cases with suspicion of invasive aspergillosis, predominantly males (64.8%) with mean age 55.7±16.42 were included in the study. Most common presentation was fever (51.2%) followed by cough (51.1%) and dyspnea (30.2%). Out of total, 25% samples were detected positive by Galactomannan assay and among the sample received for fungal culture,4.6% samples showed the growth of aspergillus species. Out of 1327 samples received for (1-3) β d glucan assay 34.7% samples showed positive results. The invasive aspergillosis cases were characterized as possible (25.2%) probable (10.2%), and proven (0.1%) as per EORTC criteria. The sensitivity (51.9%, 62.9%) and specificity (77.1%, 87.8%) of galactomannan assay were determined considering culture and EORTC criteria respectively as gold standard,

Conclusion : The study demonstrated that galactomannan assay and (1-3)-β-d glucan assay are useful diagnostic modality. Thus, these tests are early markers for invasive aspergillosis.

Keywords Fungal smear, Fungal culture, , Invasive aspergillosis, Galactomannan, 1-3 β -d glucan assay.

TABLE OF CONTENTS

S. NO.	TOPIC	PAGES
I	INTRODUCTION	1-4
II	AIMS AND OBJECTIVES	5
III	REVIEW OF LITERATURE	6-11
IV	MATERIALS AND METHODS	12-20
V	OBSERVATIONS AND RESULTS	21-57
VI	DISCUSSION	58-63
VII	SUMMARY AND CONCLUSIONS	64-68
VIII	BIBLIOGRAPHY	69-78
	APPENDICES – I - PROFORMA - MASTER CHART	
	APPENDICES – II - APPROVAL LETTER OF THESIS PLAN - THESIS PLAN	

LIST OF TABLES

Table No.	Title	Page No.
1.	Age wise distribution of suspected invasive aspergillosis cases (n=1941)	22
2.	Sex-wise distribution of suspected invasive aspergillosis cases (n=1941)	23
3.	Area wise distribution of suspected patients of invasive aspergillosis (n=1941)	24
4.	Distribution of patients based on admission in various clinical areas (n=1941)	25
5.	Distribution of risk factors in suspected patients of invasive aspergillosis (n=1941)	26
6.	Distribution of comorbidities in suspected patients of invasive aspergillosis (n=1941)	27
7.	Distribution of suspected patients of invasive aspergillosis on the basis of clinical symptoms (n=1941)	28
8.	Radiological findings in suspected patients of invasive aspergillosis (n=1228)	29
9.	Positivity of Galactomannan assay in suspected patients of invasive aspergillosis (n=1941)	30
10.	Age wise distribution of patients with Positive Galactomannan assay (n=485)	31
11.	Sex-wise distribution of Positive Galactomannan patients (n=485)	32
12.	Area wise distribution of Positive Galactomannan patients (n=485)	33
13.	Distribution of samples received for fungal smear/culture from suspected invasive aspergillosis cases. (n=1159)	34
14.	Findings on KOH mount (n=1159)	35
15.	Sample wise distribution of fungal isolates (n=1159)	36
16.	Distribution of *Aspergillus species*. (n=54)	37
17.	Correlation of fungal smear with fungal culture (n=1159)	38
18.	Correlation of Galactomannan assay with fungal smear (n=1159)	39

19.	Correalation of Galactomannan assay with fungal culture (n=1159)	40
20.	Positivity of (1-3)- β-D-glucan in suspected patients of invasive aspergillosis (n=1327)	41
21.	Correlation of Galactomannan assay with (1-3)- β-D-glucan (n=1327)	42
22.	Sensitivity, Specificity Predictive values and Diagnostic accuracy of Galactomannan assay at different cut-off points (n=485)	43
23.	Correlation of 1-3 β-d-glucan Assay with fungal culture for *Aspergillus* species. (n=787)	46
24.	Sensitivity and specificity of 1-3 β-d-glucan assay considering the Aspergillus culture as gold standard	46
25.	Correlation of fungal biomarkers (galactomannan and /or 1-3 β-d glucan) with Aspergillus culture(n=1159)	47
26.	Sensitivity and specificity of fungal biomarkers considering aspergillus culture as gold standard.	47
27.	Variables affecting Galactomannan positivity	48
28.	Variables affecting 1-3 β-d Glucan Assay positivity	49
29.	Correlation of Biomarkers with usage of antifungals	49
30.	Histopathological findings (n=23)	50
31.	Distribution of patients based on classification as per European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) (n=1941)	51
32.	Sensitivity, specificity, predictive values and diagnostic accuracy of Galactomannan assay according to different estimates.	52
33.	Distribution of patients on the basis of various clinical and demographic factors to determine their associated with Galactomannan Assay test results (n=1941)	54
34.	Outcome of the patients. (n=1941)	57

LIST OF FIGURES

Fig. No.	Title	Page No.
1.	Age wise distribution of suspected invasive aspergillosis cases (n=1941)	22
2.	Sex-wise distribution of suspected invasive aspergillosis cases (n=1941)	23
3.	Area wise distribution of suspected patients of invasive aspergillosis (n=1941)	24
4.	Distribution of patients based on admission in various clinical areas (n=1941)	25
5.	Distribution of risk factors in suspected patients of invasive aspergillosis (n=1941)	26
6.	Distribution of comorbidities in suspected patients of invasive aspergillosis (n=1941)	27
7.	Distribution of suspected patients of invasive aspergillosis on the basis of clinical symptoms (n=1941)	28
8.	Radiological findings in suspected patients of invasive aspergillosis (n=1228)	29
9.	Positivity of Galactomannan assay in suspected patients of invasive aspergillosis (n=1941)	30
10.	Age wise distribution of patients with Positive Galactomannan assay (n=485)	31
11.	Sex-wise distribution of Positive Galactomannan patients (n=485)	32
12.	Area wise distribution of Positive Galactomannan patients (n=485)	33
13.	Findings on KOH mount (n=1159)	35
14.	Sample wise distribution of fungal isolates (n=1159)	36
15.	Distribution of *Aspergillus species* (n=54)	37
16.	Correlation of fungal smear and fungal culture (n=1159)	38
17.	Correlation of Galactomannan assay with fungal smear (n=1159)	39

18.	Correalation of Galactomannan assay with fungal culture (n=1159)	40
19.	Positivity of (1-3)- β-D-glucan in suspected patients of invasive aspergillosis (n=1327)	41
20.	Correlation of Galactomannan assay with (1-3)- β-D-glucan (n=1327)	42
21.	Sensitivity, Specificity Predictive values and Diagnostic accuracy of Galactomannan assay at different cut-off points (n=485)	44
22.	ROC CURVE	45
23.	Distribution of patients based on classification as per European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) (n=1941)	51
24.	Sensitivity, specificity, predictive values and diagnostic accuracy of Galactomannan assay according to different estimates.	53
25.	Outcome of the patients. (n=1941)	57

LIST OF PICTURES

Pic No.	Title
1.	Hyaline septate hyphae
2.	*A.flavus*
3.	*A.fumigatus*
4.	Automated machine for fungal biomarkers.

BABA FARID UNIVERSITY OF HEALTH SCIENCES
Sadiq Road, Faridkot-151203 (Pb.) INDIA
Phone No. 91-1639-256253 and Fax No. 91-1639-256234
Website: www.bfuhs.ac.in, Email: bfuhspc@gmail.com
(BFUHS – UNIVERSITY LIBRARY- Coordinator APC)

11-BFUHS (LI-PC-134)24/724 Dated: July 09, 2024

Plagiarism Verification Certificate

Title of the thesis: **To study the role of fungal biomarkers in the diagnosis of Invasive Aspergillosis**

Total Page: **76 (Seventy-Six only) eFSPC (eFile Sent for Plagiarism Check)**

Researcher: **Sabri**

Supervisor: **Dr. Jyoti Chaudhary**

Research Centre: **Dayanand Medical College and Hospital, Ludhiana**

This is to report that the above thesis was scanned for similarity detection. Process and outcome is given below:

DID:	**2093103**	Software used:	**DRILLBIT**
Date:	**July 09, 2024**	Similarity Index:	**7% (Below 10 Percent)**

Total words count: **12989 (eFSPC)**

The complete report is submitted for review by the Supervisor and Co-Supervisor.

University Coordinator/
Name & Signature (Checked by)
(From University library)

The complete report of the above thesis has been reviewed by the undersigned. (Check Box)

- ☐ The similarity index is below accepted norms.
- ☐ The similarity index is above accepted norms, because of the following reasons:

1.....
2.....
3…….....
4…….....
5……

The thesis may be considered for the award of degree. (Relevant documents attached).

Research Scholar **Supervisor**

INTRODUCTION

Invasive aspergillosis (IA) is linked to significant morbidity and mortality, particularly among high-risk individuals such as those with compromised immune systems and hematological cancers. Prior diagnosis is crucial for effective IA management. The annual occurrence of IA among COPD patients in India is estimated to range from 79,100 cases (with an assumed attack rate of 1.3%) to 239,000 cases (with an assumed attack rate of 3.9%).[1]

IA is frequently discussed in the context of severely immunocompromised individuals, particularly those undergoing periods of neutropenia.[2] The impairment of local immune defenses during these neutropenic phases is well-documented. One of the most significant risk factors identified for IA is the extensive administration of corticosteroids.[3]

Various medical conditions have been linked to an increased risk of developing IA. These conditions include HIV, COPD, especially in individuals treated with corticosteroids either orally or through nebulization, solid organ transplant recipients (with a higher prevalence in lung and heart-lung transplants), and individuals suffering from liver failure.[4] IA is caused by *Aspergillus species*. IA is the leading invasive mold infection. [5-7] Aspergillus is a saprophytic and ubiquitous mold. Its spores are present in both indoor and outdoor air. These spores originate from sources like soil, decomposing plant material, plants and flowers, food, household dust, and building materials. [8,9]

The most common pathogens involved in aspergillosis belongs to several species complexes, including *Aspergillus fumigatus, Aspergillus flavus, Aspergillus terreus, and Aspergillus niger.* Among these species *A. fumigatus* is the most frequently identified, responsible for 60 to 90% of all infections [10,11]. *A. fumigatus* is the major cause of pulmonary aspergillosis, *A. flavus* accounts for about 10% of bronchopulmonary infections, with rhino-cerebral aspergillosis being the most common form of the disease.[12]

In suitable humidity and temperature conditions, Aspergillus can develop into an IA in a patient depending on the balance between the level of exposure and the patient's immune defenses. [13] Aspergillus species form hyphae and produce conidia, which are airborne and infectious. Contamination typically occurs through the airways and lungs are the most common site for IA. All individuals are exposed to Aspergillus spores, but IA mainly develops in severely immunocompromised patients. Aspergillus is not a normal part of the lung's mycobiome and is usually eliminated by the body's natural defenses. [14,15]

The primary line of defense in the host body is innate immunity, with neutrophils playing vital role against mold utilizing various processes such as phagocytosis, oxidative burst, and the more recently identified neutrophil extracellular traps. [16] These initial responses activate adaptive immunity, leading to a T helper cell TH1 response characterized by elevated production of interferon, IL-2, and IL-12, as well as the activation of effector cells. The tolerance is mediated through a TH2 response involving IL-4 and IL10. [17]

In a normal host response, conidia are cleared before they can develop further. The extent to which the host response fails accounts for the wide range of clinical forms of Aspergillus colonization or infections. [16] The symptoms of IA are non-specific, so it is recommended that clinicians adjust their vigilance based on the patient's risk level to ensure timely and appropriate investigations. Often, the first and sometimes only symptom of IA is a fever that does not respond to, or recurs despite, antibiotic treatment. However, fever can be missed in some patients, such as those on corticosteroids. Symptoms associated with pulmonary IA often include cough, sputum production, hemoptysis, pleuritic chest pain or rub, dyspnea, and bronchospasm." Other than the underlying disease and immunosuppression, the primary factors influencing survival are early diagnosis and timely antifungal treatment. [13]

"Diagnosis of IA depends on assessing the risk along with diagnostic evidences, such as distinctive signs in computed tomography (CT) scans, growth of Aspergillus species in cultures, or positive Aspergillus biomarkers. [18,19] The use of nucleic acid testing for IA remains a topic of debate. The 2019 update of the EORTC/MSG definitions of IA, which are designed for scientific research rather than patient care, includes PCR positivity as part of the mycological evidence criteria for probable IA. [20] Current clinical guidelines suggest using PCR in combination with other diagnostic methods, especially antigen testing. [21,22]

Currently, only two antigens are regularly used as biomarkers for systemic Aspergillus infections: 1) galactomannan (GM), a cell wall carbohydrate primarily specific to Aspergillus species. GM testing is well-established and widely conducted in many diagnostic laboratories." Current guidelines consider GM an accurate marker for IA and recommend its use for both diagnostic and screening purposes in high-risk populations. [18,19] Additionally, β-D-Glucan (BDG), a major component of most fungal cell walls, can be detected in the blood of patients with invasive fungal infections, including invasive candidiasis, Pneumocystis pneumonia, and IA. [23,24]

This assay detects (1,3)-β-D-glucan (BDG), a polysaccharide found in the fungal cell wall. Other serological test BDG is a pan-fungal antigen present in species such as *Candida spp, Pneumocystis jivoveci*, *Aspergillus* spp., *Acremonium* spp., *Fusarium* spp. except in Mucrorales *Cryptococcus* spp, and the yeast phase of *Blastomyces dematitidis* [25]

These serological tests for invasive fungal infections can yield a positive result even if the culture test is negative, the fungal species is non-culturable, or obtaining a sample from the patient is difficult due to an underlying condition.

Serological testing provides a faster method for identifying the fungi responsible, aiding in diagnostic decisions. These tests are conducted to detect antigens or antibodies in serum or body fluids of a patient

suspected of having a fungal infection. The benefits of serology-based tests include obtaining rapid results compared to culture methods, their non-invasive nature (using samples like blood, urine, or sputum), and their potential as prognostic markers." [26]

The GM assay, which measures components of the *Aspergillus species'* cell walls, serves as an important diagnostic tool.GM,is the primary antigen detected in IA , and can be identified in BAL and cerebrospinal fluid (CSF), among other samples. [27]

The sensitivity and specificity of this assay range from 67% to 100% and 86% to 100%, respectively.[28,29] Unlike the broad-spectrum BDG marker, GM is specific to Aspergillus. Most healthcare facilities utilize GM for regular diagnostics and monitoring of patients at risk for IA.

This thesis aims to discover the role of fungal biomarkers primarily GM assay in the diagnosis and management of IA and to analyze the variables affecting the incidence and severity of this infection. The objective is to investigate both the diagnostic value of biomarkers and the factors influencing IA development.

As the incidence of invasive fungal infections continues to rise, the development and utilization of reliable fungal biomarkers remain important in improving clinical decision-making and patient care.

AIMS AND OBJECTIVES OF THE STUDY

- To study the clinic-mycological profile of admitted patients suspected for invasive aspergillosis.
- To study the positivity and the variables affecting the fungal biomarkers (GM assay /(1-3) b D Glucan assay).

REVIEW OF LITERATURE

Aspergillus was first described by Michelli in 1729, who beautifully illustrated the fungus in his renowned work, *Nova Geneva Plantarum*. Michelli observed that the conidial head of Aspergillus, with its spore heads radiating from a central structure, resembled an aspergillum—a brush or perforated globe used for sprinkling holy water. Consequently, he named the genus Aspergillus [30] In 1926, Thom and Church first classified the genus and recognized 69 Aspergillus species, grouping them into 11 categories.[31] In 1965, the previous classification of Aspergillus was deemed outdated. Raper and Fennell then detailed 151 species, organizing them into 18 different groups.

The taxonomy of this genus is continually being revised with the use of molecular techniques [32] Of the recognized species in this genus, twenty have been verified to cause human infections, with three consistently identified as etiological agents in 95% of diseases caused by Aspergillus: A. fumigatus, *A. flavus, and A. niger*. Other common species of this genus include *A. terreus, A. glaucus, A. nidulans, A. oryzae*, and A. *clavatus. Aspergillus* species are characterized by the production of hyaline, dichotomously branching, septate hyphae with parallel walls. A specialized hyphal segment known as a foot cell serves as the base for the origin of the conidiophores. The conidiophores terminate in a swollen vesicle, from which one (uniseriate) or two (biseriate) rows of phialides arise. [33]

Gugnani et al. stated that the genus Aspergillus has a tremendous impact on public health, both beneficially through its industrial applications and negatively as plant and human pathogens.[34] Several Aspergillus species are utilized for their rich enzymatic profiles in the industrial production of foods and pharmaceuticals. For example, *Aspergillus niger* is used in the industrial production of citric acid, amylases, pectinases, phytases, and proteases. *Aspergillus terreus* is employed in the production of the cholesterol-lowering drug lovastatin, and *Aspergillus oryzae* is used in the fermentation of soybeans and rice [35] *Aspergillus flavus and Aspergillus*

parasiticus can contaminate several common crops with aflatoxin, a highly toxic carcinogen with immunosuppressive properties [36]

In a study conducted by Maschmeyer et al., it was analyzed that morbidity and mortality caused by IA infections are increasing. This rise is attributed to the growing number of patients with malignancies treated with immunosuppressive therapy and the increasing number of patients undergoing transplantation.[37] In another study, they reported that invasive aspergillosis is a devastating infection affecting severely immunocompromised patients, most commonly those with hematologic malignancies. An increase in the incidence of invasive aspergillosis has also been observed in critically ill patients without traditional risk factors.[38]

A study conducted in 2012 aimed to assess the risk stratification for IA in immunocompromised patients. They found that severe and prolonged neutropenia, hematopoietic stem cell or solid-organ transplantation, corticosteroids, or T cell suppressive agents are considered predisposing factors for invasive aspergillosis. Additional risk factors include impaired innate immunity, diabetes, renal impairment, progression of underlying malignancy, prior respiratory disease, and environmental exposure to fungal spores. The multitude of risk factors and their synergistic effects make risk stratification challenging. [11]

Schwartz et al. assessed the clinical presentation of invasive aspergillosis. The earliest indication of an invasive fungal infection is fever that doesn't respond to broad-spectrum antibiotics. Symptoms may include cough, dyspnea, and pleuritic chest pain, which can manifest early in the course, while hemoptysis typically occurs later. Additionally, involvement of the nasal cavity or sinuses may lead to nasal obstruction, epistaxis, facial pain, periorbital swelling, and palate destruction. Primary cutaneous infections present as non-purulent ulcerations. Other sites of infection may include the central nervous system, resulting in focal neurological findings or meningism. Recognizing symptoms associated with invasive

aspergillosis in at-risk patients should prompt immediate initiation of antifungal therapy, potentially improving treatment outcomes.[39]

Early identification of Invasive Aspergillosis is crucial for improving the survival of affected patients. Arvanitis et al. have emphasized recent developments in the diagnosis of IA along with the challenges associated with their implementation. While traditional diagnostic approaches like histopathology and culture remain the gold standard, they often lack sufficient sensitivity. Newer serological methods, such as galactomannan and beta-glucan assays, are included in clinical guidelines, but their performance is limited in certain clinical settings. Molecular methods like PCR have not yet been widely adopted in clinical practice. Emerging techniques like volatile organic compound detection and lateral flow devices show promise, but the standardization of galactomannan and PCR assays may offer more reliable diagnostic tools in the future. [40]

A cell wall component found in many fungi, (1→3)- β-D-glucan (BG), triggers the activation of factor G in the horseshoe crab coagulation cascade, leading to the activation of a chromogenic substrate. When compared to the galactomannan antigenemia test, the BG test exhibited a sensitivity of 55%, while the EIA showed 100% sensitivity.[41] In another study focusing on non-invasive methods for diagnosing invasive aspergillosis (IA), it was demonstrated that both the (1-3)-beta-D-glucan and GM assay exhibit high sensitivity and specificity. However, their utility is maximized when used in conjunction as a diagnostic strategy for patients with invasive aspergillosis. [42]

Munoz et al. outlined that the diagnosis of invasive aspergillosis (IA) relies on a combination of compatible clinical findings, risk factors, microbial isolation, radiological data, serological detection of antibodies or antigens, or histopathological evidence of invasion. Initially, chest radiographic findings may appear normal in up to 10% of cases. Computed tomography scanning is considered the most effective imaging technique, often revealing lung lesions earlier. Non-invasive techniques such as GM and

(1-3 BDG serve as markers for Aspergillus infection. GM exhibits a high specificity of 85%, while its sensitivity ranges from 30% to 100%. BDG demonstrates a sensitivity ranging from 50% to 87.5%. Furthermore, a specific Aspergillus PCR assay, with a sensitivity and specificity of 100% and 89% respectively, has also been utilized in IA diagnosis.[43]

According to T. Franquet et al., in computed tomography (CT), an aspergilloma is characterized by a mass with soft-tissue attenuation within a lung cavity, producing an "air crescent" sign. Bronchiolitis presents with centrilobular nodules and branching linear or nodular areas of increased attenuation, creating a "tree-in-bud" pattern. Angioinvasive aspergillosis typically exhibits nodules surrounded by a halo of ground-glass attenuation, known as the "halo sign," or pleura-based, wedge-shaped areas of consolidation. In the appropriate clinical context, familiarity with these CT findings may suggest or even aid in establishing the diagnosis.[44]

A retrospective, single-centre cohort study was conducted to assess the utility of radiological examinations in diagnosing and predicting the prognosis of invasive bronchopulmonary aspergillosis (IBPA). Among the 61 patients studied, 21 were classified into the IBPA group, while the remaining 40 were categorized into the non-IBPA group. Analysis of chest CT images revealed that the IBPA group exhibited the highest prevalence of patchiness (76.2%), followed by multiple nodules and patterns indicative of angioinvasion, such as the halo sign, wedge consolidation, and air-crescent sign. The combination of deteriorated chest X-rays with specific laboratory examinations could indicate a diagnosis of IBPA [45]

Maertens et al. conducted a study involving 100 consecutive patients to assess the correlation between antigenemia and other diagnostic indicators. They found that galactomannan detection exhibited a sensitivity of 94.4% and specificity of 98.8%, outperforming other indicators such as unexplained fever, isolation of Aspergillus species, and abnormalities observed on radiological examination. Antigenemia preceded the

diagnosis based on radiological examination or Aspergillus isolation by 8 and 9 days in 80% and 88.8% of patients, respectively. Prospective screening for galactomannan assay allows for earlier diagnosis of aspergillosis compared to conventional diagnostic criteria [46]

The management of invasive aspergillosis (IA) has significantly improved with the implementation of the European Organisation for Research and Treatment of Cancer (EORTC) and the US Mycoses Study Group (MSG) criteria for defining invasive fungal infections. The revised definitions maintain the original classifications of “proven,” “probable,” and “possible” invasive fungal disease. However, the definition of “probable” has been broadened, while the scope of the category “possible” has been narrowed[47]

Various factors influence the accuracy of the test. Aubry et al. highlighted that antibiotics can lead to false-positive results. Among them, patients receiving piperacillin-tazobactam, amoxicillin, or amoxicillin-clavulanate face the greatest challenge.[48] Similar observations were noted in another study, indicating that treatment with antifungal drugs targeting Aspergillus reduces the sensitivity of the GM [49] While antifungal therapy did indeed decrease sensitivity, it did not render the assay completely ineffective for diagnosing aspergillosis.

Another study investigated novel antifungal agents and reported an overall response rate of 40% for posaconazole, 8% for Amphotericin B ($P<0.001$), and 11% for combination therapy ($P<0.002$). As for mortality, aspergillosis resulted in the death of 40% of the posaconazole group, 65% of the AmB group, and 68% of the combination group ($P<0.008$). Multivariate analysis indicated that posaconazole salvage therapy demonstrated superior efficacy and safety compared to Amphotericin alone or in combination with caspofungin for salvage therapy in invasive aspergillosis [50]

A recent prospective study evaluated the use of voriconazole for treating invasive mycoses. The study found that 46% of patients showed a lack of response when trough plasma concentrations were less than or equal to 1

microg/mL, compared to only 12% of patients with trough concentrations greater than 1 microg/mL (p = 0.02). The upper limit of the therapeutic range is determined based on the occurrence of adverse events. Visual disturbances (21%) and elevations in liver transaminase levels (12.4%) were the most common adverse effects associated with voriconazole. Current literature suggests that a higher incidence of adverse effects may be linked to trough concentrations greater than 6 microg/Ml.[51]

A study involving 96 patients was conducted to evaluate the diagnostic potential of three non-invasive tests for IA : GM assay, real-time PCR assay, and (1→3)-β-D-glucan (BDG) test. Based on the ROC curve, the cutoff for the ELISA could be reduced to an optical density index (ODI) of 0.6. Using this cutoff, the sensitivity and specificity of the ELISA, PCR, and BDG tests were 1.00/0.93, 0.55/0.93, and 0.55/0.93, respectively. In conclusion, the GM assay was the most sensitive for predicting the diagnosis of IA when using a reduced cutoff of 0.6 ODI [52]

MATERIALS AND METHODS

This was a prospective study conducted for a period of one year in the Department of Microbiology, Dayanand Medical College and Hospital, Ludhiana.

Our study included samples from patients suspected of pulmonary aspergillosis, such as blood for serological analysis, sputum, bronchoalveolar lavage (BAL), endotracheal secretions, bronchial brushings, specimens obtained via needle aspiration or biopsy for fungal smear and culture.

METHOD OF COLLECTION OF DATA

The data collected was recorded using a structured proforma, which included the following patient details: name, age, gender, Lab ID number, admission date, provisional clinical diagnosis, risk factors, treatment history, hemogram, radiological assessment, histopathological evaluation, microbiological analysis (including Galactomannan assay, fungal smear, and culture), and clinical outcome.

Inclusion Criteria:

- All patients above 18 years of age in ICUS and wards

Exclusion Criteria:

- All patients below 18 years of age.

SOURCE OF DATA

Samples received from all the adult patients suspected of having Invasive Aspergillosis, who were admitted to various wards and ICUs at Dayanand Medical College and Hospital in Ludhiana, were included in the study.

Sample Collection

• **Blood**: Five ml blood was collected by venipuncture in sterile plain vials taking all aseptic precautions.

• **Sputum**: Sputum was collected in a wide mouthed, sterile, leak-proof, screw capped container under all aspectic precautions.[53]

• **Bronchoalveolar Lavage (BAL):** Sample was collected using flexible fiberoptic bronchoscope. About 30-50 ml of physiological saline was infused through fiberoptic bronchoscope into peripheral bronchiolar ramification. The saline was then aspirated and collected in a sterile, robust and leak proof container. [54]

• **Endotracheal (ET) secretions** :. ET secretion was collected using a 22-inch Ramson's 12 F suction catheter with a mucus extractor which was gently introduced through the endotracheal tube for a distance of approximately 25–26 cm. Gentle aspiration was then performed without instilling saline and the catheter was withdrawn from the endotracheal tube. About 2 ml of sterile 0.9% normal saline was injected into it with a syringe to flush the exudates into a sterile container for collection. [55]

Sample Processing:

Galactomannan and (1-3)b-d Glucan tests will be performed for serum samples as per kit protocol.

1)Galactomannan Antigen detection test (FungiXpert Aspergillus Galactomannan Detection Kit(CLIA))

Application of HRP-labeled anti-Aspergillus galactomannan antibody, specimen (control) and magnetic bead coated with Aspergillus galactomannan antibody by chemiluminescence technology and immunoassay sandwich principle. Adding to the reaction cup and mixing, and incubating to form an immune complex of HRP-labeled anti-Aspergillus galactomannan antibody-antigenmagnetic bead coating. After the reaction is completed, the precipitation complex is repeatedly washed by the action of a magnetic field. Add the Chromogen solution A and

Chromogen solution B, and read the illuminance intensity value for 300 s. The intensity of the light signal is positively correlated with the content of galactomannan. The concentration of galactomannan in the sample to be tested is calculated according to the standard curve, and the quantitative detection of Aspergillus galactomannan is realized.

Interpretation:

➢ Sera with an index < 0.5µg/L will be considered as negative for galactomannan antigen.

➢ Sera with an index ≥ 0.5 µg/L will be considered as positive for galactomannan antigen.

Variables such as Mold active antifungal drugs (amphotericin B,voriconazole, itraconazole), antibiotics (piperacillin-tazobactam, amoxacillin-clavulanic acid), steroids, neutropenia will be studied.

2) (1-3) b D Glucan assay (FungiXpert® Fungus (1-3-β-D-Glucan Detection Kit (CLIA))

Application of HRP-labeled anti-Fungus (1-3)-β-D-glucan antibody, specimen (quality control) and magnetic bead coated with Fungus (1-3)-β-D-glucan antibody by chemiluminescence technology and immunoassay sandwich principle. Adding to the reaction cup and mixing, and incubating to form an immune complex of HRP-labeled anti-Fungus (1-3)-β-D-glucan antibody-antigen-magnetic bead coating. After the reaction is completed, the precipitation complex is repeatedly washed by the action of a magnetic field. Add the Chromogen solution, and read the illuminance intensity value after chemiluminescence reaction. The intensity of the light signal is positively correlated with the content of (1-3)-β-D-glucan. The concentration of (1-3)-β-D-glucan in the sample to be tested is calculated according to the standard curve, and the quantitative detection of Fungus (1-3)-β-D-glucan is realized

Interpretation:

NEGATIVE RESULT

(1-3)B-D-glucan values <0.06 ng/mLare interpreted as negative results.

POSITIVE RESULT

Values ≥0.1ng/ml are interpreted as positive results.

1. Microscopic examination and culture of fungus

I. Direct microscopic examination [56,57]

Potassium hydroxide mount: -

Composition of KOH:-

Potassium hydroxide 10 gm

Glycerol 10 ml

Distilled water 80 ml

These ingredients were mixed properly and solution was stored at room temperature.

Slide KOH preparation:

A drop of potassium hydroxide solution was placed on a clean microscope slide. The sample was then transferred to the KOH drop and gently mixed using an inoculating loop. A cover slip was placed over it and the preparation was gently heated over a Bunsen burner flame to accelerate clearing, ensuring it did not dry out. It was then examined under a microscope using low (10×) and high (40×) power objectives.

Tube KOH preparation:

The tube KOH method was used for biopsy specimens, which require a longer time for dissolution. The tissue samples were placed in 10-20% KOH and incubated at 37°C until dissolved. Following dissolution, the samples were examined under a microscope using low (10×) and high (40×) power objectives. Preliminary identification was based on the direct microscopic examination of the clinical sample material. The presence of hyaline, septate fungal hyphae with acute angle branching were suggestive of Aspergillus species.

i. Fungal culture:[56]

Culture media used were:

a) Sabouraud dextrose agar (SDA) with antibiotics and without cycloheximide

Composition and preparation:

Peptone 10 gm
Dextrose 40 gm
Agar 20 gm
Distilled water 1000 ml
Chloramphenicol 50 mg
Gentamicin 20 mg

All ingredients were dissolved by boiling, and antibiotics were added into the SDA during the boiling process but prior to autoclaving. Chloramphenicol or gentamicin was dissolved in 10 ml of 95% alcohol and then added to the boiling medium. The medium was distributed into tubes and autoclaved at 121ºC for 15 minutes. The final pH was adjusted to 5.6. The medium was allowed to cool in a slanted position and stored in the refrigerator.

b) Sabouraud dextrose agar (SDA) with antibiotics and cycloheximide

All ingredients of SDA with antibiotics were thoroughly mixed, and the following antibiotic was added while boiling, but before autoclaving:

Cycloheximide at a concentration of 500mg/1000ml.

Cycloheximide was dissolved in 10ml of acetone, added to the boiling medium, and mixed well. The medium was then removed from heat and mixed thoroughly. It was dispensed into tubes and autoclaved at 121ºC

for 15 minutes, with the final pH adjusted to 5.6. The tubes were then allowed to cool in a slanted position and stored in the refrigerator.

Processing of sample for fungal culture:-

The samples were inoculated into two tubes of Sabouraud dextrose agar (SDA) containing antibiotics (chloramphenicol at 50mg/L and gentamicin at 20mg/L) and cycloheximide (500mg/L), as well as into two tubes of SDA with antibiotics but without cycloheximide. One set of tubes was incubated at 25ºC, while the other set was incubated at 37ºC. The inoculated media were kept for a minimum of three weeks. The tubes were examined daily during the first week and every other day during the second and third weeks. The growth observed was identified based on colony morphology, pigment production, and microscopic examination using a lactophenol cotton blue (LCB) preparation.

- **Lactophenol cotton blue mount preparation:** [56]

Composition and preparation

Phenol crystals 20 ml

Lactic acid 20 ml

Glycerol 40 ml

Distilled water 20 ml

Cotton blue 0.05 gm

All reagents were mixed properly and cotton blue stain was dissolved in distilled water before mixing with remaining reagents.

- **Tease mount preparation** [58]

The growth from the culture tubes was carefully teased onto a glass slide in a drop of LCB stain using two teasing needles. A coverslip was then placed over the sample, and it was examined under a microscope to observe the morphological characteristics of the fungal isolates.

- **Transparency Tape method of preparing LCB mount** [58]

A drop of LCB stain was placed on a clean microscope slide. Using forceps, a piece of clear vinyl adhesive tape, approximately 6-7 cm in length, was introduced into the culture tube. The centre of the adhesive side of the tape was allowed to touch the colony lightly under its own weight. The tape was then transferred to the slide, ensuring that the area with the adhered mycelium made contact with the lactophenol cotton blue stain. The growth of Aspergillus species was considered significant and further processed for identification.

Microscopic examination revealed spores and other relevant structures

Fungal growth	Colonies	Reverse	Conidiophores	Phialides
A. flavus	Velvety, yellow to green or brown	Golden to red brown	Rough, pitted and spiny	Uniseriate & double cover entire vesicle
A.fumigatus	Velvety or powdery, turning to smoky green	White to tan	Smooth	Uniseriate/ biseriate, cover upper half vesicle
A.niger	Woolly, white to yellow turning dark brown to black,	White to yellow	Smooth	Biseriate, covering entire vesicle
A.terreus	Velvety, cinnamon brown	White to brown	Short, smooth	In two rows, compactly columnar
A.glaucus	Green with yellow areas	Yellowish to maroon	Smooth	Single, radiate to loosely columnar

The suspected invasive aspergillosis cases patients were categorized into “proven,” “probable,” and “possible, and “No IA cases” based on risk

factors, microbiological and clinical criteria, as per Invasive Fungal Infections Co-operative 20 Group (IFICG) of the European Organization for Research and Treatment of Cancer and Mycoses study group case definitions (EORTC/MSG) [59]

EORTC CRITERIA:-

Host criteria –

Solid organ transplantation

Prolonged corticosteroid use

HIV patients

Malignancy

Neutropenia

Clinical criteria Presence of 1 of the following three signs of radiology – Dense, well-circumscribed lesion with or without a halo sign – Air-crescent sign – Cavity

Mycological criteria

- Positive indirect tests by galactomannan antigen detection
- Positive direct test by smear/culture

Diagnosis	Criteria+
Proven IA	Histopathological evidence of tissue invasion by filamentous fungi, Isolation of Aspergillus species from a normally sterile but clinically infected body site
Probable IA	One microbiological criteria, and One host criteria, and Clinical criteria
Possible IA	Host criteria, and Presence of microbiological criteria, or Clinical criteria

The results were statically analysed The data were summarized using range, mean ± standard deviation (± SD), frequencies (number of cases), and relative frequencies (percentages) where appropriate. For the comparison of categorical data, the Chi-square ($\chi 2$) test was utilized, and the Fisher exact test was applied when the expected frequency was less than 5. A Receiver Operating Characteristic (ROC) curve was constructed, and the criterion value was determined based on specificity and sensitivity. The Area Under the Curve (AUC) was also calculated. Sensitivity, specificity, accuracy, positive predictive value, and negative predictive value were assessed. A p-value of less than 0.05 was deemed statistically significant. All statistical analyses were conducted using the Statistical Package for the Social Sciences (SPSS) version 21.0 (SPSS Inc., Chicago, IL, USA) for Microsoft Windows.

OBSERVATIONS AND RESULTS

This prospective study was conducted in the Department of Microbiology, Dayanand Medical College and Hospital, Ludhiana. Over a period of 1 year, A total of 2020 samples were received from 1941 patients for Galactomannan Assay test. The first positive sample was included in the study. Repeat samples were excluded and were not used for analysis. Total of 1941 cases from which requisition of the Galactomannan assay was received in Microbiology lab were enrolled in our study. Among the 1941, patients, request for 1-3 β-d-Glucan test was received from 1327 patients. Besides that various clinical samples (1159) were received for fungal culture/fungal smear.

Our study included all inpatients aged 18 years and older. Outpatients and inpatients younger than 18 years were excluded from the study. The cases were classified based on EORTC criteria. including clinical, radiological, serological, and mycological. The sensitivity and specificity of the assay were evaluated at different cut-offs, and the Area under the curve (AUC) was determined by comparing Galactomannan and fungus culture. This study's findings and results were presented through various charts and graphs, accompanied by comprehensive statistical analysis

Table 1: Age wise distribution of suspected invasive aspergillosis cases (n=1941)

Age group (years)	No. of cases (%)
18-30	165 (8.5)
31-40	248 (12.8)
41-50	295 (15.2)
51-60	406 (20.9)
61-70	447 (23.0)
> 70	380 (19.6)
Total	1941 (100.0)

Figure 1: Age wise distribution of suspected invasive aspergillosis cases (n=1941)



In the present study, suspected cases of invasive aspergillosis were most commonly seen in the age group of 51 to 70 years with mean age of 55.71 years, with a standard deviation of 16.42 years.

Table 2: Sex-wise distribution of suspected invasive aspergillosis cases (n=1941)

Sex	No. of cases (%)
F	684 (35.2)
M	1257 (64.8)
Total	1941(100)

Figure 2: Sex-wise distribution of suspected invasive aspergillosis cases (n=1941)



Among the suspected invasive aspergillosis cases , males were (64.8%) predominant as compared to females (35.2%).

Table 3: Area wise distribution of suspected patients of invasive aspergillosis (n=1941)

Area	No. of cases (%)
ICU	424 (21.8)
Ward	1517 (78.2)
Total	1941 (100)

Figure 3: Area wise distribution of suspected patients of invasive aspergillosis (n=1941)



Out of 1941 suspected cases of invasive aspergillosis, majority were admitted in wards (78.2%) while (21.8%) patients were admitted in ICUs .

Table 4: Distribution of patients based on admission in various clinical areas (n=1941)

Diagnosis	No. of cases (%)
Medicine/Chest	808(41.6)
Gastroenterology	405 (20.9)
Nephrology	272 (14.0)
Cardiology	230 (11.8)
Neurology	94 (4.8)
General surgery	73 (3.8)
Oncology	36 (1.9)
Endocrinology	23 (1.2)

Figure 4: Distribution of patients based on admission in various clinical areas (n=1941)



The highest number of patients were admitted to Medicine/Chest(41.6%), followed by Gastroenterology(20.9%), and the least to Endocrinology (1.2%).

Table 5: Distribution of risk factors in suspected patients of invasive aspergillosis (n=1941)

Risk factor	No of cases (%)
Chronic steroid use	523 (26.9)
History of alcohol consumption	143 (7.3)
History of tuberculosis	91 (4.6)
Solid organ transplantation	73 (3.8)
Smoking	63 (3.2)
Malignancy	61 (3.1)
Neutropenia	30 (1.5)
HIV	10 (0.5)

Figure 5 : Distribution of risk factors in suspected patients of invasive aspergillosis (n=1941)



Out of 1941 patients, the most common risk factor was chronic steroid use (26.9%), followed by patients with alcohol use (7.3%) , history of tuberculosis (4.6%)solid organ transplantation (3.8%), smokers (3.2%) malignancy (3.10%), neutropenia (1.50%), and HIV (0.5%).

Table 6: Distribution of comorbidities in suspected patients of invasive aspergillosis (n=1941)

Comorbidity	No of cases (%)
Diabetes Mellitus	857 (44.1)
Hypertension	801(41.2)
HCV	34 (1.7)

Figure 6: Distribution of comorbidities in suspected patients of invasive aspergillosis (n=1941)



The most common comorbidity in suspected patients of invasive aspergillosis was Diabetes Mellitus (44.1%), followed by Hypertension (41.2%), and HCV (1.7%).

Table 7) Distribution of suspected patients of invasive aspergillosis on the basis of clinical symptoms (n=1941)

Symptoms	No. of cases (%)
Fever	994 (51.2)
Cough	992 (51.1)
Dyspnea	586 (30.2)
Chest pain	315 (16.2)

Figure 7: Distribution of suspected patients of invasive aspergillosis on the basis of clinical symptoms (n=1941)



Most common presentation was fever (51.2%) followed by cough (51.1%), dyspnea (30.2%) and chest pain (16.2%)

Table 8: Radiological findings in suspected patients of invasive aspergillosis (n=1228)

HRCT chest	No. of cases (%)
Reticulonodular opacifications	434 (22.4)
Consolidation in lung	360 (18.5)
Pleural effusion	340 (17.5)
Cavitation	94 (4.8)
No anomaly detected	234(12.0%)

Figure 8: Radiological findings in suspected patients of invasive aspergillosis (n=1228)



Most common radiological finding was reticulonodular opacification (22.4%) followed by consolidation (18.5%) followed by pleural effusion (17.5%) and cavitary lesions (4.8%).

Table 9: Positivity of Galactomannan assay in suspected patients of invasive aspergillosis (n=1941)

Galactomannan Assay	No. of cases (%)
Positive	485 (25.0)
Negative	1456 (75.0)
Total	1941(100.0)

Figure 9: Positivity of Galactomannan assay in suspected patients of invasive aspergillosis (n=1941)



Overall Galactomannan assay positivity among suspected patients of invasive aspergillosis was 25 %.

Table 10: Age wise distribution of patients with Positive Galactomannan assay (n=485)

Age Group	No. of cases (%)
18-30	35 (7.2)
31-40	62 (12.8)
41-50	80 (16.5)
51-60	113 (23.3)
61-70	109 (22.5)
>70	86 (17.7)

Figure 10: Age wise distribution of patients with Positive Galactomannan assay (n=485)



In the present study, majority of the patients with Positive Galactomannan test were belonged to the age group of 51 to 70 years (45.8%)

Table 11: Sex-wise distribution of Positive Galactomannan patients (n=485)

Sex	No. of cases (%)
Female	177 (36.5)
Male	308 (63.3)

Figure11: Sex-wise distribution of Positive Galactomannan patients (n=485)



Out of a total 485 Positive Galactomannan patients 63.3% patients were males and 36.5% were females indicating a higher percentage of males with positive Galactomannan assay as compared to females.

Table 12: Area wise distribution of Positive Galactomannan patients (n=485)

Area	No of cases (%)
ICU	147 (30.3)
Ward	338 (69.7)

Figure 12: Area wise distribution of Positive Galactomannan patients (n=485)



Out of 485 Positive Galactomannan patients a majority of them were in the wards 69.7% compared to those in the ICU 30.3%.

Table 13: Distribution of samples received for fungal smear/culture from suspected invasive aspergillosis cases. (n=1159)

Sample	Fungal smear/ Fungal culture (1159) (%)
Sputum	579 (50)
Endotracheal secretions	311 (27)
Ascitic fluid	76 (6.8)
Pleural fluid	62 (5.3)
Urine	34 (2.9)
Percutaneous drain	30 (2.5)
Nasal mucosa	14 (1.2)
Tissue	11 (0.9)
Pus	11 (0.9)
CSF	11 (0.9)
Pericardial fluid	9 (0.7)
Bronchioalveolar Lavage	6 (0.5)
Wound swab	4 (0.3)
Peritoneal fluid	1 (0.1)

Out of various samples received for Fungal smears/Fungus cultures (1159) maximum were sputum (50%) followed by endotracheal secretions (27%), fluids and tissues.

Table 14: Findings on KOH mount (n=1159)

Fungal Smear	No of cases (%)
Budding yeastlike cells with /without pseudo hyphae	399 (34.4)
Hyaline septate fungal hyphae	55 (4.7)
No fungal elements seen	705 (60.9)

Figure 13: Findings on KOH mount (n=1159)



On KOH mount examination, hyaline septate fungal hyphae were found in 4.7% and Budding yeast like cells with/without pseudo hyphae in 34.4%. However, 60.9% of the samples tested did not reveal any fungal element.

Table 15: Sample wise distribution of fungal isolates (n=1159)

Sample	*Candida spp.*(219) (%)	*Aspergillus spp.* (54) (%)
Sputum (579)	151(26.0%)	36 (6.2%)
Endotracheal secretions(311)	59(19.0%)	13(4.1%)
Nasal mucosa (14)	1(7.1%)	3(21.4%)
Urine (34)	5(14.7%)	1(3.2%)
Tissue (11)	2(18.1%)	1(9.0%)
Per cutaneous drain(30)	1(3.3%)	-

Figure 14: Sample wise distribution of fungal isolates (n=1159)



Majority of the *Aspergillus species* was obtained from respiratory samples. Aspergillus spp. were isolated in, 6.2% (36) of sputum samples and 4.1% (13) of endotracheal secretion samples. The presence of Candida spp. in sputum and endotracheal secretions were considered as colonizers.

Table 16: Distribution of *Aspergillus species*. (n=54)

Aspergillus species	Total (%)
Aspergillus flavus	42 (77.7)
Aspergillus fumigatus	12 (22.3)

Figure 15: Distribution of *Aspergillus species* (n=54)



A. flavus was isolated from 77.7%.(42). samples. Samples included sputum 53.7% (29), Endotracheal secretions 16.6% (9), nasal mucosa 5.5% (3) and tissue 1.8%. (1) while *A. fumigatus* was isolated only from 22.3% (12) of the samples (sputum 12.9% (7) ,Endotracheal secretions 7.4% (4) ,Urine 1.8%(1).

Table 17: Correlation of fungal smear with fungal culture (n=1159)

	Fungal culture Positive (n=54)	Fungal culture Negative (n=1105)
Fungal smear positive (n=55)	54	1
Fungal smear negative (n=1104)	0	1104

Figure 16: Correlation of fungal smear and fungal culture (n=1159)



Out of 1159 samples received for fungal culture 4.7 % of patients were positive by both fungal smear and culture while 0.1% of patients had only positive fungal smear.

Table 18: Correlation of Galactomannan assay with fungal smear (n=1159)

Galactomannan assay	Fungal Smear Positive (n=55)	Fungal Smear Negative (n=1104)	p-value
GM assay Positive (n=281)	28	253	0.001
GM assay Negative (n=878)	27	851	

Figure 17: Correlation of Galactomannan assay with fungal smear (n=1159)



Out of 1159 patients with suspicion of invasive aspergillosis, 2.4% of patients were positive by both galactomannan assay and fungal smear. While 21.8% had positive galactomannan assay with negative fungal smear and 2.3% of patients had only positive fungal smear.

Table 19: Correalation of Galactomannan assay with fungal culture (n=1159)

Galactomannan assay	Fungal Culture Positive(n=54)	Fungal Culture Negative(n=1105)	p-value
GM assay Positive (n=281)	28	253	0.001
GM assay Negative (n=878)	26	852	

Figure 18: Correalation of Galactomannan assay with fungal culture (n=1159)



Out of 1159 patients with suspicion of invasive aspergillosis, 2.4% of patients were positive by both galactomannan assay and fungal culture. Positive galactomannan assay with negative fungal culture was seen in 21.8% patients and 2.3% of patients had only positive fungal culture.

Table 20: Positivity of (1-3)- β-D-glucan in suspected patients of invasive aspergillosis (n=1327)

(1-3)- β-D-glucan	No. of cases (%)
Positive	460 (34.7)
Negative	867 (65.3)
Total	1327 (100.0)

Figure 19: Positivity of (1-3)- β-D-glucan in suspected patients of invasive aspergillosis (n=1327)



(1-3)- β-D-glucan positivity among suspected patients of invasive aspergillosis was 34.7%.

Table 21: Correlation of Galactomannan assay with (1-3)- β-D-glucan (n=1327)

Galactomannan assay	(1-3)- β-D-glucan Positive (460)	(1-3)- β-D-glucan Negative (867)	p- value
GM assay Positive (313)	154	159	0.001
GM assay Negative (1014)	306	708	

Figure 20 : Correlation of Galactomannan assay with (1-3)- β-D-glucan (n=1327)



Out of 1941 patients suspected of Invasive Aspergillosis, 1327 patients had received requisition for both Galactomannan and, (1-3)- β-D-glucan, out of which 11.6% (154) patients had both Galactomannan and (1-3)- β-D-glucan positive, while 23% (306) patients were positive for (1-3)- β-D-glucan with negative Galactomannan results.

Table 22: Sensitivity, Specificity Predictive values and Diagnostic accuracy of Galactomannan assay at different cut-off points (n=485)

Galactomannan assay cut-offs	Sensitivity	Specificity	Positive likelihood Ratio	Negative likelihood Ratio	Positive Predictive value	Negative Predictive value	Accuracy
>0.5	51.9%	77.1%	2.3%	0.6%	10.0%	97.0%	75.9%
>0.6	50.0%	81.0%	2.6%	0.6%	11.4%	97.1%	79.6%
>1	35.2%	86.3%	2.6%	0.8%	11.2%	96.5%	84.0%
>2	22.2%	91.0%	2.5%	0.9%	10.8%	96.0%	87.8%
>3	18.5%	93.2%	2.7%	0.9%	11.8%	95.9%	89.7%
>4	16.7%	94.2%	2.9%	0.9%	12.3%	95.9%	90.6%

The table shows that at Low Cut-off Levels (≥ 0.5, ≥ 0.6) there was higher sensitivity but lower specificity. And at high Cut-off Levels (≥ 2, ≥ 3, ≥ 4) there was higher specificity but lower sensitivity. The highest sensitivity was at the cut-off level of ≥ 0.5, and the highest positive predictive value was at the cut-off level of ≥ 4.

Figure 21: Sensitivity, Specificity Predictive values and Diagnostic accuracy of Galactomannan assay at different cut-off points (n=485)



The chart shows that at higher cutoff values there was improved specificity and accuracy but reduced sensitivity.

Figure 22: ROC CURVE



Receiver operating characteristics (ROC) curve using SPSS 21.00 software was calculated by plotting true positive results (sensitivity) versus false positive (1- specificity) at various cut off points. The AUC of 0.663 indicated the diagnostic accuracy.

Table 23: Correlation of 1-3 β-d-glucan Assay with fungal culture for *Aspergillus* species. (n=787)

	Fungus culture positive (35)	Fungus culture negative (752)	p-value
1-3 β-d-glucan Assay Positive (282)	21	261	0.02
1-3 β-d-glucan Assay Negative (505)	14	491	

Out of 787 patients with suspicion of invasive aspergillosis whose requisition for both fungal culture and 1-3-β-d-glucan were received , 2.6% of patients were positive by both 1-3 β-d-glucan assay and fungal culture. 33.1% and 1.7% of patients were positive only by 1-3 β-d-glucan and fungal culture respectively.

Table 24: Sensitivity and specificity of 1-3 β-d-glucan assay considering the Aspergillus culture as gold standard

Statistic	Value
Sensitivity	60.00%
Specificity	65.29%
Positive Likelihood Ratio	1.73
Negative Likelihood Ratio	0.61
Positive Predictive Value	7.45%
Negative Predictive Value	97.23%
Accuracy	65.06%

Table 25: Correlation of fungal biomarkers (galactomannan and /or 1-3 β-d glucan) with Aspergillus culture(n=1159)

Fungal biomarkers	Fungal culture positive (54)	Fungal culture negative (1105)	p-value
Positive (472)	36	436	0.001
Negative (685)	18	669	

Out of total 37.6% of the patients of suspected invasive aspergillosis were detected only by biomarkers while 3.1 % patients were detected positive by both fungal culture and biomarkers.

Table 26: Sensitivity and specificity of fungal biomarkers considering aspergillus culture as gold standard.

Statistic	Value
Sensitivity	66.67%
Specificity	60.54%
Positive Likelihood Ratio	1.69
Negative Likelihood Ratio	0.55
Positive Predictive Value	7.63%
Negative Predictive Value	97.38%
Accuracy	60.83%

The cumulative sensitivity and specificity of galactomannan and 1-3 β-d glucan assay was 66.7% and 60.5% respectively.

Table 27: Variables affecting Galactomannan positivity

Galactomannan Assay					
		Negative	Positive	Total	p-value
Patients on Piperacillin-Tazobactam	No	1314(90.3%)	427 (87.9%)	1741	0.124
	Yes	142(9.7%)	58 (12.1%)	200	
Patients on Amoxycillin-clavulanic acid	No	1444(99.2%)	483 (99.6%)	1927	0.351
	Yes	12(0.8%)	2 (0.4%)	14	
Patients on Meropenam	No	522(35.9%)	179 (36.9%)	701	0.641
	Yes	934(64.1%)	306 (63.1%)	1240	

The use of Piperacillin-Tazobactam, Amoxycillin-clavulanic acid, and Meropenem did not show a significant association with the galactomannan positivity test results.

Table 28 : Variables affecting 1-3 β-d Glucan Assay positivity

		1-3-β-d-Glucan Assay		Total	p-value
		Negative	Positive		
Patients on Meropenam	N	294 (33.9%)	151(32.8%)	445	0.537
	Y	573 (66.1%)	309 (67.2%)	882	
Patients on Amoxycillin-clavulanic acid	N	859 (99.1%)	458 (99.6%)	1317	0.508
	Y	8 (0.9%)	2 (0.4%)	10	
Patients on Piperacillin-Tazobactam	N	800 (92.3%)	400 (87.0%)	1200	0.002
	Y	67 (7.7%)	60 (13.0%)	127	

The use of, Amoxycillin-clavulanic acid Meropenem did not show a significant association with the 1-3 β-D-glucan assay test results. Patients using piperacillin-tazobactam had a significant association with the 1-3 β-D-glucan assay test.

Table 29: Correlation of Biomarkers with usage of antifungals

Patients on antifungals	Galactomannan Assay (1941)		1-3 β-d glucan Assay (1327)		p-value
	Negative	Positive	Negative	Positive	
No	1167 (80.2%)	187 (38.6%)	688 (77%)	254 (55.2%)	0.001
Yes	289 (19.8%)	298 (61.4%)	199 (7.6%)	206 (44.8%)	

Antifungal usage have shown a significant association with both fungal biomarkers (galactomannan assay and 1-3 β- d-glucan) positivity.

Table 30 : Histopathological findings (n=23)

Histopathological findings	No of cases (%)
Positive for *Aspergillus species*	2 (8.6%)
Negative for *Aspergillus species*	21(91.4%)

Out of 23 histopathological samples, 2 were found to be positive for Aspergillus species, while the remaining 21 samples were negative.

Table 31: Distribution of patients based on classification as per European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) (n=1941)

Categories of IA	No of cases (%)
Proven IA	2 (0.10)
Probable IA	199 (10.2%)
Possible IA	490 (25.2%)
No IA	1450 (74.7)

Figure 23: Distribution of patients based on classification as per European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) (n=1941)



All 1941 patients with suspicion of Invasive Aspergillosis were categorized as Proven IA (0.1%), Probable IA (10.2%), Possible IA (25.2%) and No IA (74.7%) Out of total , 25%(489) cases were categorized as Possible IA(Host + microbiological/ clinical criteria), 10.2% (199) were identified as Probable IA (fulfilled both microbiological and clinical criteria along with the host factor) and 0.10% (2) cases were proven by histopathology

Table 32) Sensitivity, specificity, predictive values and diagnostic accuracy of Galactomannan assay according to different estimates.

	Sensitivity	Specificity	Positive predictive value	Negative predictive value	Diagnostic accuracy
Method A	62.93%	87.86%	63.71%	87.50%	81.56%
Method B	93.97%	82.99%	38.72%	99.18%	84.12%
Method C	51.85%	77.10%	9.96%	97.04%	78.93%

In method A , assumed that all patients included in EORTC criteria for invasive aspergillosis were true positive and patients in No Invasive Aspergillosis group were true negative. The estimate showed the sensitivity of 62.9%, specificity of 87.8%, positive predictive value of 63.7%, negative predictive value of 87.9% and diagnostic accuracy of 81.5%.

In Method B, assumed that all the patients in proven and probable category were true positive and patients in No invasive aspergillosis were true negative. The estimate showed the sensitivity of 93.9%, specificity of 82.9%, positive predictive value of 38.7%, negative predictive value of 99.18% and diagnostic accuracy of 84.1%.

In Method C, to calculate the sensitivity and specificity fungus culture was considered as gold standard

Figure: 24 : Sensitivity, specificity, predictive values and diagnostic accuracy of Galactomannan assay according to different estimates.



The chart shows that the Sensitivity was highest in Method B (93.9%), while Specificity was highest in Method A (87.8%) and lowest in Method C (77.1%). Diagnostic Accuracy was highest in Method B (84.1%) and lowest in Method C (78.9%).

Overall, Method B exhibited the highest sensitivity and diagnostic accuracy. Method C showed the lowest sensitivity and diagnostic accuracy.

Table 33: Distribution of patients on the basis of various clinical and demographic factors to determine their associated with Galactomannan Assay test results (n=1941)

		Galactomannan Assay		Total	p-value
		Negative	Positive		
Age Group	1	130 (8.9%)	35(7.2%)	165	0.395
	2	186 (12.8%)	62(12.8%)	248	
	3	215 (14.8%)	80(16.5%)	295	
	4	293 (20.1%)	113(23.3%)	406	
	5	338 (23.2%)	109(22.5%)	447	
	6	294 (20.2%)	86 (17.7%)	380	
Sex	Female	507 (34.8%)	177 (36.5%)	684	0.529
	Male	949 (65.2%)	308 (63.5%)	1257	
Patients with Neutropenia	No	1436 (98.6%)	475 (97.9%)	1911	0.292
	Yes	20 (1.4%)	10 (2.1%)	30	
Patients with Chronic steroid use	No	1198 (82.3%)	220 (45.4%)	1418	0.001
	Yes	258 (17.7%)	265 (54.6%)	523	
Patients with Cavitation on radiological findings	No	1398 (96.0%)	450 (92.8%)	1848	0.003
	Yes	58 (4.0%)	35 (7.2%)	93	

		Galactomannan Assay		Total	p-value
		Negative	Positive		
Patients on Hemodialysis	No	1365 (93.8%)	462 (95.3%)	1827	0.265
	Yes	91 (6.3%)	23 (4.7%)	114	
Patients with Fungal smear Positive	No	852 (58.5%)	253 (52.2%)	1105	0.001
	Yes	26 (1.8%)	28 (5.8%)	54	
Patients with Fungal culture Positive	No	852 (58.5%)	253 (52.2%)	1105	0.001
	Yes	26 (1.8%)	28 (5.8%)	54	
Patients on Piperacillin - Tazobactam	No	1314 (90.3%)	427 (87.9%)	1741	0.124
	Yes	142 (9.7%)	58(12.1%)	200	
Patients on Amoxicillin - clavulanic acid	No	1444 (99.2%)	483 (99.6%)	1927	0.351
	Yes	12 (0.8%)	2 (0.4%)	14	
Patients on Meropenem	No	522 (35.9%)	179 (36.9%)	701	0.641
	Yes	934 (64.1%)	306 (63.1%)	1240	
Patients on Antifungals	No	1167 (80.2.%)	187(38.6%)	1354	0.001
	Yes	289(19.8%)	298 (61.4%)	587	

		Galactomannan Assay		Total	p-value
		Negative	Positive		
Patient distribution on the basis of EORTC	No IA	1274 (87.5%)	176 (36.3%)	1450	0.001
	POSSIBLE IA	190 (12.9%)	300 (61.9%)	490	0.0001
	PROBABLE IA	11 (0.8%)	188 (38.8%)	199	0.001
	PROVEN IA	1 (0.1%)	1 (0.2%)	2	0.415
Outcome	DAMA	345 (23.7%)	127 (26.1%)	472	0.001
	DISCHARGED	1043 (71.6%)	335 (69.1%)	1378	0.247
	EXPIRED	68(4.6%)	23(4.7%)	91	0.9
Total		1456 (100.0%)	485 (100.0%)	1941	

The table shows the comparison of positive and negative galactomannan Assay results across different clinical demographic, microbiological factors including fungal smear and culture results. The factors that showed significant association with galactomannan positivity included chronic steroid use, cavitation on radiological findings, fungal smear, fungal culture, usage of antifungals (p-value < 0.5)

Table 34: Outcome of the patients. (n=1941)

Outcome	No of cases	Percentage (%)
Discharged	1378	71.0%
Dama	472	24.3%
Expired	91	4.7%

Figure 25 : Outcome of the patients. (n=1941)



Out of 1941 patients enrolled in our study, 71% patients were discharged satisfactorily whereas 4.7% patients could not survive.

DISCUSSION

This prospective study took place in the Microbiology Department at Dayanand Medical College and Hospital in Ludhiana. It involved 1941 patients who were suspected of having invasive aspergillosis infections. The present study contributes valuable data on the epidemiology, risk factors, clinical presentation, and diagnostic challenges of invasive aspergillosis in a tertiary care setting. The study examined the demographic, clinical, and microbiological characteristics of these patients.

In this study of 1941 consecutive cases of suspected invasive aspergillosis, the average age of the patients was 55.71 years ±16.42 with an age ranging from 18 to 98 years.

A similar observation was made by Khorvash et al. in their study, where the average age of the patients was 54.95 ± 18.82 years, ranging from 20 to 86 years.[60]. On the other hand, S. Khanna reported a lower average age of invasive aspergillosis patients, which was 32.2 years, with a range from 0.6 to 80 years.[61]

In the current study, suspected cases of invasive aspergillosis were significantly more prevalent in males, accounting for 70.3% of the total cases, compared to 29.7% in females. The higher incidence of suspected invasive aspergillosis in male patients may be due to greater occupational exposure to fungal spores. Men are often engaged in agricultural and outdoor activities, such as handling moldy hay and decaying vegetation, which increases their risk of inhaling Aspergillus spores.

These results align with the study conducted by Swu-Jane which reported a significant male predominance in suspected invasive aspergillosis cases.[62] In their findings, 72% of the patients were male, while only 28% were female, reinforcing the observed trend of higher incidence among males. The study conducted by Cordonnier et al also reported a male predominance in cases of suspected invasive aspergillosis. Alternatively,

Khorvash et al noted a higher incidence of invasive aspergillosis among females (56.1%) compared to males (43.9%).

In our study, the predominant risk factor among patients suspected of having invasive aspergillosis was chronic steroid use (26%). This was followed by history of alcohol consumption (7.3%) ,solid organ transplantation (3.8%,) , smoking (3.2%) malignancy [3.10%], neutropenia, 1.50% HIV (0.50%) The common risk factors observed by Vazquez JA etal were the use of immunosuppressants (39%), solid organ transplant (33%), malignancy (22%).[63] A study conducted at the All India Institute of Medical Sciences, Chhattisgarh, identified the prevalent risk factors for invasive aspergillosis in India. The most common risk factor was hematological malignancy, accounting for 29.41% of cases. This was followed by the use of corticosteroids at 25%, neutropenia at 8.82%, and solid organ transplants at 5.88%.[64]

In the current study, fever (51.20%) was the most frequently observed presentation , followed closely by cough (51.10%), dyspnea (3.20%) and chest pain. These findings are in line with those of Meyer et al., who reported fever as the most prevalent symptom in their study [65] In contrast, the study conducted by N.Tutar observed dyspnea ad the most common clinical presentation. [66]

In our study, reticulonodular opacification was the most common chest radiological finding, present in 22.40% of cases which was followed by consolidation at 18.50% and pleural effusion at 17.50%. These results differ from those reported by Linna Huang et al., who identified consolidation as the most common chest radiological finding, occurring in 23.8% of their cases. [67] In a previous study conducted at our institute on suspected cases of invasive aspergillosis, consolidation was identified as the most frequent radiological finding, occurring in 70% of the cases. This was followed by pleural effusion in 33.8% of the cases, reticulonodular opacification in 25.3%, and cavitatory lesions in 16%.[68]

In our study, 25% of suspected patients of invasive aspergillosis tested positive for the GM assay. This is higher compared to findings of a research where 18.8% of patients were GM positive.[69] Similarly, a study by Jeniffer S et al. reported an overall GM positivity rate of 12.2% [70] Conversely, another study reported that 56% of suspected patients of pulmonary aspergillosis tested positive for the GM assay. [71]

A similar study conducted at our institute in 2018 reported a 40.5% positivity rate for the Galactomannan assay among patients suspected of having invasive aspergillosis, which was higher than the findings of our current study [72] The increased positivity rate in the earlier study may be attributed to the manual method used for GM detection.

Hence possibility of less number of false positive results..

In the current study, the positivity for fungal smears in patients suspected of invasive aspergillosis was 4.7%, while the fungal culture positivity for *Aspergillus species* was observed in 4.6% of the patients. These findings are consistent with another study where the positivity rates were 6.5% for fungal smears and 5.8% for fungal cultures in similar patients. [73] Contrarily, a tertiary care hospital in central India reported a higher fungal culture positivity rate of 14.06% [74] Furthermore, studies by Roohani et al. and Khanna et al. demonstrated significantly higher culture positivity rates of 31.11% and 59.25%, respectively [75,[61] Fungal cultures have limitations due to their lower sensitivity and the time required for results, along with the risk of contamination during processing. In this context, the galactomannan assay plays a crucial role, especially when used alongside chest CT scans, in the diagnosis of invasive aspergillosis .

In our study, the most frequently isolated species was A. flavus, followed by A. fumigatus. This aligns with findings from other research where A. flavus was identified as the predominant pathogen.[61, 69]Similarly the study done in our institute for suspected invasive aspergillosis in 2018 , *A.flavus* (77.4%) was found to be most common species isolated followed by *A.fumigatus* (22.6%) [68] Conversely, in a study conducted at a tertiary

care center in central India, A. fumigatus was reported as the most commonly isolated species [74]

In the current study, the (1-3)-β-D-glucan assay showed a positivity rate of 34.7%. However, a study by White et al. reported a higher positivity rate of 45.4% when tested using the D-BDG method. The elevated positivity rate in White et al.'s study can be due to the inclusion of patients from intensive care or those who had undergone major abdominal surgery, hematology patients including stem cell transplant (SCT) recipients on fluconazole prophylaxis (at risk for invasive aspergillosis (IA) and Pneumocystis pneumonia (PCP)), patients with renal impairment (including transplant recipients at risk for invasive candidiasis (IC) and PCP), and individuals with immunosuppressive conditions such as HIV (at risk for PCP) [76] In another study done in our institute on invasive fungal infections in 2022, (1-3)-β-D-glucan assay positivity was observed as 52.8% [77]

In our study, patients with usage of antifungals showed a significant association with positive biomarker test results. Conversely, the use of Piperacillin- tazobactam, amocxycillin - clavulanic acid , and meropenem did not show a significant association with the galactomannan test results. In another study, serum samples from patients who had received β-lactams were analyzed using the Platelia Aspergillus test. A significant association was found between GM positivity and the administration of β-lactams [78] This may be due to the new method used in our study, which appears to reduce the incidence of false positives. In a research study conducted at Dr. B.R. Ambedkar Institute Rotary Cancer Hospital, AIIMS, New Delhi, India, a double sandwich ELISA GM assay (Platelia Aspergillus,® Bio-Rad Laboratories) was used. The false-positivity rate for samples collected during therapy with amoxicillin-clavulanate was 73.9%, with piperacillin-tazobactam it was 35.7%, and for samples where no such antibiotics were used, it was 24.6% [79]

In our study, out of 1941 consecutive cases suspected of Invasive Aspergillosis, the classification based on the EORTC/MSG criteria was as follows: 0.10% were identified as proven IA, 10.20% as probable IA, 15% as possible IA, and 74.70% as no IA. In a separate research study conducted in Brazil, the EORTC/MSG diagnoses were categorized as follows: possible cases constituted 5.1%, probable cases were 6.4%, and proven cases were 7.3%. [73] Also our intstitute reported proven IA (0%), probable IA (41.9%), possible IA (51.5%) and no cases IA (6.6%).[72]

In our study, sensitivity, specificity, positive predicitive value, negative predictive value and diagnostic accuracy of galactomannan assay were 51.9%, 77.1%, 10.0%, 97.0% and 75.9% respectively. In another study conducted in armed force medical college Pune, they showed the sensitivity, specificity, positive and negative predictive value as 78%, 85%, 84% and 79% respectively [80] Our study demonstrated lower sensitivity and higher specificity compared to a previous study conducted at our institute, which exhibited higher sensitivity and lower specificity. This implies that our study had fewer false positive results.[72] Similarly, the sensitivities and specificities for serum GM were reported as 78.9% and 70.6%, respectively, in earlier studies. These studies utilized manual methods, which resulted in higher sensitivity but lower specificity. [81]

The Receiver Operating Characteristic (ROC) curve was evaluated at different cutoff points to assess the test's performance. The Area Under the ROC Curve (AUC), which indicates the diagnostic accuracy, was found to be 0.663 in our study. Similarly the AUC of 0.636 was evaluated in another study [81]

In comparison, a diagnostic study conducted reported Receiver-operating characteristic (ROC) curve analysis revealed area under the curve (AUC) values of 0.742[80]

These differences in AUC values highlight variations in diagnostic performance across different studies and settings.

In our study Sensitivity and specificity of 1-3 β- d-glucan assay considering culture as gold standard in suspected cases of invasive aspergillosis was 60% and 65.2%. respectively. A metanalysis study has reported higher sensitivity of 1-3 β- d-glucan in proven and probable cases of invasive aspergillosis. [82]

In our study, the mortality rate was 4.6%, excluding patients who were discharged against medical advice and those who requested discharge. When including these patients, the mortality rate among suspected cases of invasive aspergillosis in our study was 29.0%. Another study reported a mortality rate of 30.22% [83] Additionally, a study by N. Tutar et al. found that mortality occurred in 54.5% of patients [66]

SUMMARY AND CONCLUSION

- This prospective study took place in the Microbiology Department at Dayanand Medical College and Hospital in Ludhiana. It involved 1941 patients who were suspected of having invasive aspergillosis infections. The present study contributes valuable data on the epidemiology, risk factors, clinical presentation, and diagnostic challenges of invasive aspergillosis in a tertiary care setting. The study examined the demographic, clinical, and microbiological characteristics of these patients.
- In the present study, suspected cases of invasive aspergillosis were most commonly seen in the age group of 51 to 70 years with mean age of 55.71 years, with a standard deviation of 16.42 years.
- Among the suspected invasive aspergillosis cases , males were (64.8%) predominant as compared to females (35.2%).
- Out of 1941 suspected cases of invasive aspergillosis, majority were admitted in wards (78.2%) while (21.8%) patients were admitted in ICUs.
- The highest number of patients were admitted to Medicine/Chest(41.6%), followed by Gastroenterology(20.9%), and the least to Endocrinology (1.2%).
- Out of 1941 patients, the most common risk factor was chronic steroid use (26.9%), followed by patients with alcohol use (7.3%) , history of tuberculosis (4.6%)solid organ transplantation (3.8%), smokers (3.2%) malignancy (3.10%), neutropenia (1.50%), and HIV (0.5%).
- The most common comorbidity in suspected patients of invasive aspergillosis was Diabetes Mellitus (44.1%), followed by Hypertension (41.2%), and HCV (1.7%).
- Most common presentation was fever (51.2%) followed by cough (51.1%), dyspnea (30.2%) and chest pain (16.2%)

- Most common radiological finding was reticulonodular opacification (22.4%) followed by consolidation (18.5%) followed by pleural effusion (17.5%) and cavitary lesions (4.8%).
- Overall Galactomannan assay positivity among suspected patients of invasive aspergillosis was 25 %.
- In the present study, majority of the patients with Positive Galactomannan test were belonged to the age group of 51 to 70 years (45.8%)
- Out of a total 485 Positive Galactomannan patients 63.3% patients were males and 36.5% were females indicating a higher percentage of males with positive Galactomannan assay as compared to females.
- Out of 485 Positive Galactomannan patients a majority of them were in the wards 69.7% compared to those in the ICU 30.3%
- Out of various samples received for Fungal smears/Fungus cultures (1159) maximum were sputum (50%) followed by endotracheal secretions (27%), fluids and tissues.
- On KOH mount examination, hyaline septate fungal hyphae were found in 4.7% and Budding yeast like cells with/without pseudo hyphae in 34.4%. However, 60.9% of the samples tested did not reveal any fungal element.
- Majority of the *Aspergillus species* was obtained from respiratory samples. Aspergillus spp. were isolated in, 6.2% (36) of sputum samples and 4.1% (13) of endotracheal secretion samples. The presence of Candida spp. in sputum and endotracheal secretions were considered as colonizers.
- *A. flavus* was isolated from 77.7%.(42). samples. Samples included sputum 53.7% (29), Endotracheal secretions 16.6% (9), nasal mucosa 5.5% (3) and tissue 1.8%. (1) while *A. fumigatus* was isolated only from 22.2% (12) of the samples (sputum 12.9% (7) ,Endotracheal secretions 7.4% (4) ,Urine 1.8%(1).

- Out of 1159 samples received for fungal culture 4.7 % of patients were positive by both fungal smear and culture while 0.1% of patients had only positive fungal smear.
- Out of 1159 patients with suspicion of invasive aspergillosis, 2.4% of patients were positive by both galactomannan assay and fungal smear. While 21.8% had positive galactomannan assay with negative fungal smear and 2.3% of patients had only positive fungal smear.
- Out of 1159 patients with suspicion of invasive aspergillosis, 2.4% of patients were positive by both galactomannan assay and fungal culture. Positive galactomannan assay with negative fungal culture was seen in 21.8% patients and 2.3% of patients had only positive fungal culture.
- (1-3)- β-D-glucan positivity among suspected patients of invasive aspergillosis was 34.7%.
- Out of 1941 patients suspected of Invasive Aspergillosis, 1327 patients had received requisition for both Galactomannan and, (1-3)- β-D-glucan, out of which 11.6% (154) patients had both Galactomannan and (1-3)- β-D-glucan positive, while 23% (306) patients were positive for (1-3)- β-D-glucan with negative Galactomannan results.
- At Low Cut-off Levels (≥ 0.5, ≥ 0.6) there was higher sensitivity but lower specificity.

  And at high Cut-off Levels (≥ 2, ≥ 3, ≥ 4) there was higher specificity but lower sensitivity
- The highest sensitivity was at the cut-off level of ≥ 0.5, and the highest positive predictive value was at the cut-off level of ≥ 4.
- Out of 787 patients with suspicion of invasive aspergillosis whose requisition for both fungal culture and 1-3-β-d-glucan were received , 2.6% of patients were positive by both 1-3 β-d-glucan assay and fungal culture. 33.1% and 1.7% of patients were positive only by 1-3 β-d-glucan and fungal culture respectively.

- Out of total 37.6% of the patients of suspected invasive aspergillosis were detected only by biomarkers while 3.1 % patients were detected positive by both fungal culture and biomarkers.
- The cumulative sensitivity and specificity of galactomannan and 1-3 β-d glucan assay was 66.7% and 60.5% respectively.
- The use of Piperacillin-Tazobactam , Amoxycillin-clavulanic acid, and Meropenem did not show a significant association with the galactomannan positivity test results.
- The use of, Amoxycillin-clavulanic acid Meropenem did not show a significant association with the 1-3 β-D-glucan assay test results. Patients using piperacillin-tazobactam had a significant association with the 1-3 β-D-glucan assay test.
- Antifungal usage have shown a significant association with both fungal biomarkers (galactomannan assay and 1-3 β- d-glucan positivity.
- All 1941 patients with suspicion of Invasive Aspergillosis were categorized as Proven IA (0.1%), Probable IA (10.2%), Possible IA (25.2%) and No IA (74.7%)
- Out of 1941 patients enrolled in our study, 71% patients were discharged satisfactorily whereas 4.7% patients could not survive.

CONCLUSION

The prospective one year study demonstrated, Invasive aspergillosis is a major cause of morbidity and mortality in high risk patients. The study indicated that fungal biomarkers are effective diagnostic modalities. Combining both tests for the diagnosis of invasive aspergillosis increases the sensitivity. The use of automated devices may reduce the impact of confounding factors. Fungal biomarkers provide rapid diagnosis of IFI and help in timely treatment further reduces morbidity and mortality.

BIBLIOGRAPHY

1. Ray A, Aayilliath K A, Banerjee S, Chakrabarti A, Denning DW. Burden of Serious Fungal Infections in India. Open Forum Infect Dis. 2022;9:ofac603.
2. Sakr Y, Jaschinski U, Wittebole X, Szakmany T, Lipman J, Ñamendys-Silva SA, et al. Sepsis in Intensive Care Unit Patients: Worldwide Data From the Intensive Care over Nations Audit. Open Forum Infect Dis. 2018;5:ofy313.
3. Mokart D, Darmon M, Schellongowski P, Pickkers P, Soares M, Rello J, et al. Acute respiratory failure in immunocompromised patients: outcome and clinical features according to neutropenia status. Ann Intensive Care. 2020;10:146.
4. Verweij PE, Brüggemann RJM, Azoulay E, Bassetti M, Blot S, Buil JB, et al. Taskforce report on the diagnosis and clinical management of COVID-19 associated pulmonary aspergillosis. Intensive Care Med. 2021;47:819-34.
5. Montagna MT, Caggiano G, Lovero G, De Giglio O, Coretti C, Cuna T, et al. Epidemiology of invasive fungal infections in the intensive care unit: results of a multicenter Italian survey (AURORA Project). Infection. 2013;41:645–53.
6. Pappas PG, Alexander BD, Andes DR, Hadley S, Kauffman CA, Freifeld A, et al. Invasive fungal infections among organ transplant recipients: results of the transplant-associated infection surveillance network (TRANSNET). Clin Infect Dis. 2010;50:1101–11.
7. Souza L, Nouér SA, Morales H, Simões B, Solza C, Queiroz-Telles F, et al. Epidemiology of invasive fungal disease in haematologic patients. Mycoses. 2021;64:252-56.
8. Hajjeh RA, Warnock DW. Counterpoint: invasive aspergillosis and the environment--rethinking our approach to prevention. Clin Infect Dis. 2001;33:1549-52.

9. Ledoux MP, Guffroy B, Nivoix Y, Simand C, Herbrecht R. Invasive Pulmonary Aspergillosis. Semin Respir Crit Care Med. 2020;41:80-98.
10. Latgé JP, Chamilos G. Aspergillus fumigatus and Aspergillosis in 2019. Clin Microbiol Rev. 2019;33:e00140-18.
11. Chakrabarti A, Chatterjee SS, Das A, Shivaprakash MR. Invasive Aspergillosis in developing countries. Med Mycol. 2011;49:S35–47.
12. Rudramurthy SM, Paul RA, Chakrabarti A, Mouton JW, Meis JF. Invasive Aspergillosis by Aspergillus flavus: Epidemiology, Diagnosis, Antifungal Resistance, and Management. J Fungi (Basel). 2019;5:55.
13. Kosmidis C, Denning DW. The clinical spectrum of pulmonary aspergillosis. Thorax. 2015;70:270-7.
14. Ledoux MP, Herbrecht R. Invasive Pulmonary Aspergillosis. J Fungi (Basel).2023;9:131.
15. Cui L, Morris A, Huang L, Beck JM, Twigg HL 3rd, von Mutius E, et al. The microbiome and the lung. Ann Am Thorac Soc. 2014;11:S227-32.
16. Lass-Flörl C, Roilides E, Löffler J, Wilflingseder D, Romani L. Minireview: host defence in invasive aspergillosis. Mycoses. 2013;56:403-13.
17. Zhong H, Lu RY, Wang Y. Neutrophil extracellular traps in fungal infections: A seesaw battle in hosts. Front Immunol. 2022;13:977493.
18. Ostrosky-Zeichner L. Invasive mycoses: diagnostic challenges. Am J Med. 2012;125:S14-24.
19. Kanj A, Abdallah N, Soubani AO. The spectrum of pulmonary aspergillosis. Respir Med. 2018;141:121-31.
20. Ullmann AJ, Aguado JM, Arikan-Akdagli S, Denning DW, Groll AH, Lagrou K, et al. Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. Clin Microbiol Infect. 2018;24:e1-e38.
21. Patterson TF, Thompson GR 3rd, Denning DW, Fishman JA, Hadley S, Herbrecht R, et al. Practice Guidelines for the Diagnosis and

Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;63:e1-e60.

22. Donnelly JP, Chen SC, Kauffman CA, Steinbach WJ, Baddley JW, Verweij PE, et al. Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clin Infect Dis. 2020;71:1367-76.
23. Obayashi T, Yoshida M, Mori T, Goto H, Yasuoka A, Iwasaki H, et al. Plasma (1-->3)-beta-D-glucan measurement in diagnosis of invasive deep mycosis and fungal febrile episodes. Lancet. 1995;345:17-20.
24. Gow NAR, Latge JP, Munro CA. The Fungal Cell Wall: Structure, Biosynthesis, and Function. In. The Fungal Kingdom, Heitman J, Howlett BJ Eds. American Society of Microbiology: Washington, DC, USA, 2018.
25. Tissot F, Lamoth F, Hauser PM, Orasch C, Flückiger U, Siegemund M, et al. β-glucan antigenemia anticipates diagnosis of blood culture-negative intraabdominal candidiasis. Am J Respir Crit Care Med. 2013;188:1100-9.
26. Kozel TR, Wickes B. Fungal diagnostics. Cold Spring Harb Perspect Med. 2014;4:a019299.
27. Zhou W, Li H, Zhang Y, Huang M, He Q, Li P, et al. Diagnostic value of galactomannan antigen test in serum and bronchoalveolar lavage fuid samples from patients with nonneutropenic invasive pulmonary aspergillosis. J Clin Microbiol. 2017;55:2153–61.
28. Ulusakarya A, Chachaty E, Vantelon JM, Youssef A, Tancrède C, Pico JL, et al. Surveillance of Aspergillus galactomannan antigenemia for invasive aspergillosis by enzyme-linked immunosorbent assay in neutropenic patients treated for hematological malignancies. Hematol J. 2000;1:111–6.
29. Maertens J, Verhaegen J, Lagrou K, Van Eldere J, Boogaerts M. Screening for circulating galactomannan as a noninvasive diagnostic

tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation. Blood. 2001;97:1604–10.

30. George R, Thompson III, Thomas F. Patterson. Pulmonary Aspergillosis. Semin Respir Crit Care Med. 2008;29:103-10.
31. Chander J. In: Textbook of Medical Mycology, 3rd edition. Mehta; New Delhi: 2009.
32. Dagenais TRT, Keller NP. Pathogenesis of Aspergillus fumigatus in invasive aspergillosis. Clin Microbiol Rev. 2009;22:447-65.
33. Wild CP. Aflatoxin exposure in developing countries: the critical interface of agriculture and health. Food Nutr Bull. 2007;28:S372-80.
34. Maschmeyer G, Haas A, Cornely OA. Invasive aspergillosis: epidemiology, diagnosis and management in immunocompromised patients. Drugs. 2007;67:1567-601.
35. Dimopoulos G, Frantzeskaki F, Poulakou G, Armaganidis A. Invasive aspergillosis in the intensive care unit. Ann N Y Acad Sci. 2012;1272:31-9.
36. Stevens DA, Melikian GL. Aspergillosis in the 'Nonimmunocompromised'. Immunol Invest. 2011;40:751-66.
37. Cordonnier C, Botterel F, Ben Amor R, Pautas C, Maury S, Kuentz M. Correlation between galactomannan antigen levels in serum and neutrophil counts in haematological patients with invasive aspergillosis. Clin Microbiol Infect. 2009;15:81-6.
38. Aliyali M, Hedayati MT, Habibi MR, Khodavaisy S. Clinical risk factors and bronchoscopic features of invasive aspergillosis in Intensive Care Unit patients. J Prev Med Hyg. 2013;54:80-82.
39. Camargo JF, Husain S. Immune correlates of protection in human invasive aspergillosis. Clin Infect Dis. 2014;59:569–77.
40. Munoz P, Guinea J, Bouza E. Update on invasive aspergillosis: clinical and diagnostic aspects. Clin Microbiol Infect. 2006;12:24–39.

41. Schütte M, Thullier P, Pelat T, Wezler X, Rosenstock P, Hinz D, et al. Identification of a putative Crf splice variant and generation of recombinant antibodies for the specific detection of Aspergillus fumigatus. PLoS One. 2009;4:e6625.
42. Huang L, He H, Ding Y, Jin J, Zhan Q. Values of radiological examinations for the diagnosis and prognosis of invasive bronchial-pulmonary aspergillosis in critically ill patients with chronic obstructive pulmonary diseases. Clin Respir J. 2018;12:499-509.
43. Maertens J, Eldere JV, Verhaegen J, Verbeken E, Verschakelen J, Boogaerts M. Use of circulating galactomannan screening for early diagnosis of invasive aspergillosis in allogeneic stem cell transplant recipients. J Infect Dis. 2002;186:1297-306.
44. Zhang S, Wang S, Wan Z, Li R, Yu J. The diagnosis of invasive and noninvasive pulmonary aspergillosis by serum and bronchoalveolar lavage fluid galactomannan assay-galactomannan assay. BioMed Res Int. 2015;2015;1-5.
45. Raad II, Hanna HA, Boktour M, Jiang Y, Torres HA, Afif C, et al. Novel antifungal agents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies: posaconazole compared with high-dose lipid formulations of amphotericin B alone or in combination With caspofungin. Leukemia. 2007;22:496-503.
46. Steinbach WJ, Stevens DA. Review of newer antifungal and immunomodulatory strategies for invasive aspergillosis. Clin Infect Dis. 2003;37:S157-87.
47. Franquet T, Müller NL, Giménez A, Guembe P, de La Torre J, Bagué S. Spectrum of pulmonary aspergillosis: histologic, clinical, and radiologic findings. Radiographics. 2001;21:825-37
48. Stynen D, Sarfari J, Goris A, Prevost MC, Lesourd M, Kamphuis H, et al . Rat monoclonal antibodies against Aspergillus galactomannan. Infect Immun. 1992;60:2237-45.

49. Miyazaki T, Kohno S, Mitsutake K, Maesaki S, Tanaka K, Ishikawa N, et al. Plasma (133)-b-D-Glucan and Fungal Antigenemia in Patients with Candidemia, Aspergillosis, and Cryptococcosis. J Clin Microbiol. 1995;33: 3115-8.
50. Paassen JV, Russcher A, Wingerden AVV, Verweij PE, Kuijper EJ. Emerging aspergillosis by azole-resistant Aspergillus fumigatus at an intensive care unit in the Netherlands-2010 to 2013. Euro Surveill. 2016;21:1-10.
51. Hahn T, Cummings KM, Michalek AM, Lipman BJ, Segal BH, McCarthy PL Jr. Efficacy of high-efficiency particulate air filtration in preventing aspergillosis in immunocompromised patients with hematologic malignancies. Infect Control Hosp Epidemiol. 2002;23:525-31.
52. Loeffler J, Hafner J, Mengoli C, Wirth C, Heussel CP, Löffler C, White PL, Ullmann AJ, Michel D, Wiegering V, Wölfl M, Schlegel PG, Einsele H, Springer J, Eyrich M. Prospective Biomarker Screening for Diagnosis of Invasive Aspergillosis in High-Risk Pediatric Patients. J Clin Microbiol. 2016;55:101-9.
53. Sarrafzadeh SA, Hoseinpoor Rafati A, Ardalan M, Mansouri D, Tabarsi P, Pourpak Z. The accuracy of serum galactomannan assay in diagnosing invasive pulmonary aspergillosis. Iran J Allergy Asthma Immunol. 2010;9:149-55.
54. Wild CP. Aflatoxin exposure in developing countries: the critical interface of agriculture and health. Food Nutr Bull. 2007;28:S372-80.
55. Xess I, Mohanty S, Jain N, Banerjee U. Prevalence of aspergillus species in clinical samples isolated in an Indian tertiary care hospital. Indian J Med Sci. 2004;58:513-9
56. Chander J. In: Textbook of Medical Mycology, 3rd edition. Mehta; New Delhi: 2009.
57. Xess I, Mohanty S, Jain N, Banerjee U. Prevalence of Aspergillus species in clinical samples isolated in an Indian tertiary care hospital. Indian J Med Sci. 2004;58:513-9.

58. Wild CP. Aflatoxin exposure in developing countries: the critical interface of agriculture and health. Food and Nutrition Bulletin. 2007;28:S372-80.
59. De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, et al. Revised definitions of invasive fungal disease from the European organization for research and treatment of cancer/invasive fungal infections cooperative group and the national institute of allergy and infectious diseases mycoses study group (EORTC/MSG) consensus group. Clinical infectious diseases. 2008;46:1813-21.
60. Khorvash F, Meidani M, Babaei L, Abbasi S, Ataei B, Yaran M. Galactomannan antigen assay from bronchoalveolar lavage fluid in diagnosis of invasive pulmonary aspergillosis in intensive care units patients. Adv Biomed Res. 2014;3:68-70.
61. Khanna S, Oberoi JK, Datta S, Aggarwal S, Wattal C. Variables affecting the performance of galactomannan assay in high-risk patients at a Tertiary Care Centre in India. Indian J Med Microbiol. 2013;31:34-9.
62. Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis. 2001;32:358-66.
63. Vazquez JA, Paula Tovar-Torres M, Hingwe A, Cheema F, Welch VL, Ford KD. The changing epidemiology of invasive aspergillosis in the non-traditional host: risk factors and outcomes. Pulm Crit Care Med. 2016;1:67-71.
64. Keche A, Patil G, Ganga RT, Sahu D. Galactomannan Antigen Assay for Diagnosis of Invasive Aspergillosis: A Study from a Tertiary Care Hospital of Central India. J Pure Appl Microbiol. 2024;18:878-85.
65. Mikulska M, Furfaro E, Del Bono V, Raiola AM, Ratto S, Bacigalupo A, et al. Piperacillin/tazobactam (Tazocin™) seems to be no longer responsible for false-positive results of the galactomannan assay. J Antimicrob Chemother. 2012;67:1746-8.

66. Tutar N, Metan G, Koc AN, Yilmaz I, Bozkurt I, Ozer S, et al. Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease. Multidiscip Respir Med. 2013;8:59.
67. Huang L, He H, Ding Y, Jin J, Zhan Q. Values of radiological examinations for the diagnosis and prognosis of invasive bronchial-pulmonary aspergillosis in critically ill patients with chronic obstructive pulmonary diseases. The clinical respiratory journal. 2018;12:499-509.
68. Kaur S, Gupta V, Chhina DK, Singh A, Sharma D. Mycological and serological study of invasive Aspergillosis in a tertiary care hospital. Journal of Microbiology and Infectious Diseases. 2018;8:8-12.
69. de Oliveira Cunha D, Cordeiro JA, de Paula HD, Ataides FS, Vilanova-Costa CS, Saddi VA, et al. Epidemiological evaluation of patients submitted to the galactomannan test with suspected invasive aspergillosis. Revista de Patologia Tropical/Journal of Tropical Pathology. 2021;50:107-19.
70. Jeniffer S. dos Santos a, Djuli M. Hermes a, Alessandro C. Pasqualotto b,c,∗Galactomannan use in clinical practice: providing free testing is not the full answerb raz j inf e c t di s . 2018;22:37–40.
71. Kaur B, Gupta V, Kashyap AK, Chaudhary J. Clinico-mycological profile of suspected pulmonary aspergillosis cases. Journal of Clinical and Scientific Research. 2023;12:S33-7.
72. Kaur S, Gupta V, Chhina DK, Singh A, Sharma D. Mycological and serological study of invasive Aspergillosis in a tertiary care hospital. Journal of Microbiology and Infectious Diseases. 2018;8:8-12.
73. de Oliveira Cunha D, Cordeiro JA, de Paula HD, Ataides FS, Vilanova-Costa CS, Saddi VA, et al. Epidemiological evaluation of patients submitted to the galactomannan test with suspected invasive aspergillosis. Revista de Patologia Tropical/Journal of Tropical Pathology. 2021;50:107-19.

74. Keche A, Patil G, Ganga RT, Sahu D. Galactomannan Antigen Assay for Diagnosis of Invasive Aspergillosis: A Study from a Tertiary Care Hospital of Central India. J Pure Appl Microbiol. 2024;18:878-85.
75. Roohani AH, Fatima N, Shamim M, Khan HM, Akhtar A. Distribution of Galactomannan antigen in BAL and serum samples among Aspergillus isolates and its correlation with culture among Immunocompetent and Immunocompromised patients in Aligarh region, a north India town. Annals Pathol Lab Med. 2019;6:A414-20.
76. White PL, Price JS, Posso RB, Barnes RA. An evaluation of the performance of the Dynamiker® Fungus (1-3)-β-D-Glucan Assay to assist in the diagnosis of invasive aspergillosis, invasive candidiasis and Pneumocystis pneumonia. Medical mycology. 2017;55:843-50.
77. Sandhar TK, Chhina DK, Gupta V, Chaudhary J. Role of (1-3)-B-D-glucan test in the diagnosis of invasive fungal infections among high-risk patients in a tertiary care hospital. Journal of Laboratory Physicians. 2022;14:306-11.
78. Aubry A, Porcher R, Bottero J, Touratier S, Leblanc T, Brethon B, et al. Occurrence and kinetics of false-positive Aspergillus galactomannan test results following treatment with beta-lactam antibiotics in patients with hematological disorders. J Clin Microbiol. 2006;44:389-94.
79. Kumar M, Mugunthan M. β-d-Glucan and Aspergillus Galactomannan assays in the diagnosis of invasive fungal infections. medical journal armed forces india. 2019;75:357-60.
80. Chun JY, Jeong SJ, Kim S, Choi S, Lee JH, Chung HS, et al. Performance of the galactomannan test for the diagnosis of invasive pulmonary aspergillosis using non-invasive proximal airway samples. Journal of Infection. 2024;88:106159.
81. Dabas Y, Mohan A, Xess I. Serum galactomannan antigen as a prognostic and diagnostic marker for invasive aspergillosis in heterogeneous medicine ICU patient population. PLoS One. 2018;13:e0196196.

82. Huang QY, Li PC, Yue JR. Diagnostic performance of serum galactomannan and β-D-glucan for invasive aspergillosis in suspected patients: A meta-analysis. Medicine. 2024 Feb 2;103(5):e37067.
83. Sun KS, Tsai CF, Chen SC, Huang WC. Clinical outcome and prognostic factors associated with invasive pulmonary aspergillosis: an 11-year follow-up report from Taiwan. PLoS One. 2017;12:e0186422.

Picture 1: KOH mount showing Hyaline septate fungal hyphae 40X



Picture 2: Aspergillus flavus in LPCB mount (40X)



Picture 3: *Aspergillus fumigatus* in LPCB mount (40X)

Picture 4: FACIS Automated machine for fungal biomarkers

KEY TO MASTER CHART

GM Assay	Galactomannan Assay
1-3 BDG-	1-3 β-d- glucan
Neg	Negative
P	Positive
Y	Yes
N	No
NG	No Growth
NR	Not received
PTZ	Piperacillin and tazobactam

S. no	MRD No.	Lab No	NAME	DOR Sample	AGE	SEX	GMRepeat	DOA	AREA	SUB AREA WISE	Sample	DOR Sample	FEVER	COUGH	SOB	CHEST PAIN	DM	HTN	Alcoholic	Smoker	Neutropenia	TBHistory	Chronic steroid use	Solid organ transplantation	Malignancy	HIV	HCV	HB	TLC/DLC	NEUTROPHIL COUNT	CT CHEST _PLEURAL EFFUSION	CONSOLIDATION IN LUNG	CAVITATION	RETICULONODULAR OPACITIES	Histopathology for aspergillus species
1	1402065	501	CR	10/25/2022	40	M	N	10/23/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	10/25/2022	Y	N	N	N	N	N	Y	Y	N	N	N	N	N	N	N	6.9	30.3	60	Y	N	N	N	NR
2	1468887	512	GM	3/2/2023	48	M	N	2/23/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	3/2/2023	N	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	12.1	23.1	86	N	N	N	N	NR
3	514994	728	PK	3/28/2023	64	M	N	3/19/2023	WARD	RENAL DISEASE	SERUM	3/28/2023	Y	N	N	N	N	N	N	N	Y	N	Y	N	N	N	N	12	0.2	15	N	N	N	N	NR
4	360835	749	S	3/31/2023	69	F	N	3/31/2023	ICU	RENAL DISEASE	SERUM	3/31/2023	Y	Y	Y	N	N	N	N	N	N	N	Y	N	N	N	N	8.9	7.8	67.5	N	Y	N	Y	Normal
5	986583	750	D	3/31/2023	70	M	N	3/27/2023	ICU	GASTROINTESTINAL TRACT DISEASE	SERUM	3/31/2023	N	N	N	N	N	N	N	N	N	N	y	N	N	N	N	8.2	4	50.5	N	N	N	N	NR
6	1488593	751	DS	3/31/2023	60	M	N	3/27/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	3/31/2023	Y	N	N	N	N	Y	N	N	N	N	N	N	N	N	N	8.3	1	67	Y	N	N	N	NR
7	435035	752	VP	3/31/2023	76	M	N	3/15/2023	ICU	CARDIOVASCULAR DISEASE	SERUM	3/31/2023	N	N	N	Y	N	N	N	N	N	N	Y	N	N	N	Y	8.9	2	68	N	N	N	N	NR
9	1489908	742	DS	3/30/2023	25	M	N	3/29/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	3/30/2023	Y	N	Y	N	N	N	Y	Y	N	N	N	N	N	N	Y	13	27	80.4	N	Y	N	Y	NR
10	1490125	744	VP	3/30/2023	27	F	N	3/30/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	3/30/2023	N	N	N	N	N	N	N	N	N	N	Y	N	N	N	N	13.1	9.5	71.9	N	N	N	N	NR
11	629727	745	SK	3/31/2023	66	F	N	3/21/2023	ICU	GASTROINTESTINAL TRACT DISEASE	SERUM	3/31/2023	N	N	N	N	Y	N	N	N	N	N	Y	N	N	N	N	6	5	69	N	N	N	N	NR
12	1484014	747	BK	3/31/2023	55	M	N	3/20/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	3/31/2023	Y	Y	Y	N	N	N	N	N	N	N	Y	N	N	N	N	9.9	12	87	N	N	N	N	NR
13	1490495	746	HS	3/31/2023	48	M	N	3/30/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	3/31/2023	N	Y	Y	N	N	N	N	N	N	Y	Y	N	N	N	N	10	7	80	N	N	Y	N	NR
14	1490402	748	DK	3/31/2023	51	F	N	3/30/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	3/31/2023	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	N	7.6	20	90	N	N	N	N	NR
15	1242418	741	UK	3/30/2023	56	F	N	3/30/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	3/30/2023	Y	N	N	N	Y	Y	N	N	N	N	Y	N	N	N	Y	7.3	15.4	79.7	Y	N	N	N	NR
16	1485609	740	CK	3/30/2023	65	F	N	3/22/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	3/30/2023	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	6.9	8.2	59	N	N	N	N	Normal
17	1490039	739	SK	3/30/2023	54	F	N	3/30/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	3/30/2023	Y	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	14.4	10	57.4	N	N	N	N	NR
18	1487674	738	BS	3/30/2023	50	M	N	3/25/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	3/30/2023	Y	Y	Y	N	Y	Y	Y	Y	N	N	Y	N	N	N	N	13	15	90	N	N	N	Y	NR
19	1489954	737	PL	3/30/2023	70	F	N	3/29/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	3/30/2023	Y	N	Y	N	Y	N	N	N	N	N	N	N	N	N	N	7.4	19	78.8	N	N	N	N	NR
20	1484097	736	HB	3/29/2023	24	F	N	3/25/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	3/29/2023	N	Y	N	N	N	N	N	N	N	N	Y	N	N	N	N	11	11.9	72	N	N	N	N	NR
21	1489352	735	MA	3/29/2023	43	F	N	3/29/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	3/29/2023	N	Y	Y	Y	N	Y	N	Y	N	N	N	N	N	N	N	11.6	14	76	N	N	N	N	NR
22	1489275	733	IC	3/29/2023	29	F	N	3/28/2023	WARD	DERMATOLOGY	SERUM	3/29/2023	N	N	N	N	N	N	N	N	N	N	Y	N	N	N	N	14	25	60	N	N	N	N	NR
23	1488651	732	R	3/29/2023	37	M	N	3/28/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	3/29/2023	Y	N	N	N	N	N	Y	N	N	N	Y	N	N	N	N	11.6	16	83.6	N	N	N	N	NR
24	1489223	730	DS	3/28/2023	65	M	N	3/28/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	3/28/2023	N	N	Y	N	Y	Y	N	N	N	N	N	Y	N	N	N	15.3	18	83	N	N	N	N	NR
25	1488643	727	RL	3/28/2023	72	M	N	3/28/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	3/28/2023	N	Y	N	N	Y	N	N	N	N	Y	N	N	N	N	N	8.6	7.8	65.3	N	N	N	N	NR
26	1461851	726	TK	3/27/2023	57	F	N	3/26/2023	ICU	RENAL DISEASE	SERUM	3/27/2023	N	N	Y	N	Y	Y	N	N	N	N	Y	N	N	N	N	9.1	7.4	80	N	Y	N	N	NR
27	1487640	725	HS	3/27/2023	42	M	N	3/25/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	3/27/2023	N	N	N	N	N	N	N	N	N	N	Y	N	N	N	N	13	26	86	N	N	N	N	NR
28	43902	724	JS	3/27/2023	62	M	P	3/24/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	3/27/2023	N	N	N	N	Y	N	N	N	N	N	Y	N	N	N	N	9.9	12	85	N	N	Y	N	NR
29	1481626	723	HS	3/27/2023	25	M	N	3/15/2023	ICU	GENERAL SURGERY	SERUM	3/27/2023	N	Y	N	N	N	N	N	N	N	N	Y	N	N	N	N	11.2	15	75	N	Y	N	N	NR
30	1486632	722	SS	3/27/2023	37	M	N	3/23/2023	ICU	GASTROINTESTINAL TRACT DISEASE	SERUM	3/27/2023	N	Y	N	N	N	N	N	N	N	N	Y	N	N	N	N	9.9	18	83.5	N	Y	N	N	NR
31	1480146	720	SS	3/26/2023	37	M	N	3/13/2023	ICU	GASTROINTESTINAL TRACT DISEASE	SERUM	3/26/2023	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	11.6	12	85	N	N	N	Y	NR
32	1483672	719	ZS	3/26/2023	33	M	N	3/19/2023	ICU	GASTROINTESTINAL TRACT DISEASE	SERUM	3/26/2023	N	Y	N	N	N	N	N	N	N	N	N	Y	N	N	N	12.8	24	72.7	Y	N	N	N	NR
33	1486595	718	IS	3/26/2023	34	M	N	3/23/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	3/26/2023	N	N	N	N	N	N	N	N	N	N	Y	Y	N	N	N	12.7	15	84	N	N	N	N	NR
34	1457394	709	NK	3/25/2023	37	M	N	3/21/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	3/25/2023	N	N	N	N	N	N	N	N	N	N	Y	Y	N	N	N	13.6	11	68	N	N	N	Y	NR
35	1481193	707	BK	3/25/2023	60	F	N	3/15/2023	WARD	GENERAL SURGERY	SERUM	3/25/2023	Y	Y	N	N	Y	N	N	N	N	N	N	N	N	N	N	7.4	17	94.6	N	N	N	Y	NR
36	1483712	708	HK	3/24/2023	60	F	N	3/19/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	3/24/2023	N	Y	Y	N	Y	Y	N	N	N	N	N	N	N	N	N	11.3	31	87	N	N	N	N	Normal
37	401473	710	JV	3/25/2023	45	F	N	3/20/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	3/25/2023	Y	Y	N	N	N	N	N	N	N	N	N	Y	N	N	N	9.9	16	74.2	N	N	N	Y	NR
38	1384909	711	CS	3/25/2023	80	M	N	2/21/2023	ICU	CARDIOVASCULAR DISEASE	SERUM	3/25/2023	N	N	N	Y	Y	Y	N	N	N	N	N	N	N	N	N	10	14	90.7	N	N	N	N	NR
39	1460286	713	G	3/25/2023	33	M	N	3/25/2023	ICU	NEUROLOGICAL DISEASE	SERUM	3/25/2023	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	14.5	8.6	59.3	N	Y	N	Y	NR
40	181003	714	JK	3/25/2023	74	F	N	3/16/2023	ICU	RENAL DISEASE	SERUM	3/25/2023	Y	N	N	N	Y	Y	N	N	N	N	N	Y	N	N	N	7.9	12.8	87	N	N	N	N	NR
41	1480815	715	S	3/26/2023	64	M	N	3/14/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	3/26/2023	N	Y	Y	N	N	N	N	N	N	N	Y	N	N	N	N	11.9	9.9	91.8	Y	Y	N	N	NR
42	1477431	631	AS	3/18/2023	30	M	N	3/9/2023	ICU	NEUROLOGICAL DISEASE	SERUM	3/18/2023	N	N	N	N	N	N	N	N	N	N	Y	N	N	N	N	13	27	90.4	N	Y	Y	Y	NR
43	1483109	632	JS	3/18/2023	66	M	N	3/18/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	3/18/2023	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	14.7	14	77.1	N	N	N	Y	NR
44	1271425	700	BC	3/23/2023	68	M	N	3/15/2023	ICU	NEUROLOGICAL DISEASE	SERUM	3/23/2023	N	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	12.6	12	69.9	N	Y	N	Y	NR
45	147654	727	RL	3/23/2023	41	M	N	3/27/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	3/23/2023	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	12	9	69	N	N	N	N	NR
46	1480159	701	D	3/23/2023	64	F	N	3/13/2023	ICU	CARDIOVASCULAR DISEASE	SERUM	3/23/2023	N	N	N	Y	Y	Y	N	N	N	N	N	N	N	N	N	8.1	5.7	74.1	N	N	N	N	NR

S. no	MRD No.	Lab No	Distribution of clinical samples received	Fungal smear Positive for Hyaline Septate Fungal Hyphae	CANDIDA IN (BODY FLUIDS AND BLOOD CULTURE)	CANDIDA IN BODY FUILDS	FUNGAL CULTURE FOR ASPERGILLUS SPECIES	Fungal Cuture	GMSAASSAY	1-3 BDG	PTZ	ANTIFUNGAL	Heamo Dylasis	AUGMENTIN	MEROPENEM	Provisional diagnosis	Outcome	TOTAL EORTC PATIENTS	PROVEN	POSSIBLE	PROBABLE	NO INVASIVE ASPERGILLOSI
1	1402065	501	SPUTUM	Neg	-	-	Neg	NG	0.24	0.01	N	N	N	N	N	DM type2 with Lower respiratory tract infection wioth anemia with AKI with fluid overload	DISCHARGE ON REQUEST	N	N	N	N	Y
2	1468887	512	SPUTUM	Neg	-	-	Neg	NG	0.1	0.03	N	N	N	N	N	PNEUMONIA	DISCHARGE	N	N	N	N	Y
3	514994	728	NR	NR	-	-	NR	NR	8.8	0.54	N	Y	Y	N	N	RA, BYCYPTOPENIA ACUTE ON CKD	DISCHARGE ON REQUEST	Y	N	Y	N	N
4	360835	749	SPUTUM	P	-	-	P	ASPERGILLUS FLAVUS	14.04	0.03	N	Y	Y	N	N	HTN, AKI ON CKD, LRTI, CAD	DISCHARGE	Y	N	Y	Y	N
5	986583	750	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.14	0.02	N	N	N	N	Y	CIRRHOES WITH PORTAL HTN	DISCHARGE	N	N	N	N	Y
6	1488593	751	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.12	3.44	Y	N	N	N	Y	COPD	DISCHARGE	N	N	N	N	Y
7	435035	752	NR	NR	-	-	NR	NR	0.17	0.04	N	Y	N	N	N	PARKINSONISM	DISCHARGE	N	N	N	N	Y
9	1489908	742	PLEURAL FLUID	Neg	-	-	Neg	NG	0.11	0.03	N	N	N	N	N	HCV REACTIVE, DRUG ABSUER, INFECTIVE ENDOCORDITS	DISCHARGE	Y	N	Y	N	N
10	1490125	744	SPUTUM	Neg	-	-	Neg	NG	0.1	0.02	N	N	N	Y	N	ALLERGIC BRONCHOPULMONARY ASPERGILIUS HEMOPTYSIS	DISCHARGE	N	N	N	N	Y
11	629727	745	ASCITIC FLUID	Neg	-	-	Neg	NG	0.11	0.04	N	N	N	N	Y	CLD WITH PORTAL HTN	DISCHARGE	N	N	N	N	Y
12	1484014	747	SPUTUM	Neg	-	-	Neg	CANDIDA	0.15	0.03	N	N	N	N	Y	COPD WITH CHRONIC SMOKER, ACUTE EXACERBATION WITH LRTI PULMONARY KOCHS	DISCHARGE ON REQUEST	N	N	N	N	Y
13	1490495	746	SPUTUM	Neg	-	-	Neg	NG	0.3	9.32	Y	N	N	N	N	OLD TB CASE	DISCHARGE ON REQUEST	Y	N	Y	N	N
14	1490402	748	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.15	0.05	Y	N	N	N	Y	SEPSIS SHOCK	DISCHARGE	N	N	N	N	Y
15	1242418	741	NR	NR	-	-	NR	NR	0.12	0.05	Y	N	N	N	Y	HCV REACTIVE, B/L P/E, DM, HTN	DISCHARGE ON REQUEST	Y	N	Y	N	N
16	1485609	740	NR	NR	-	-	NR	NR	0.11	0.02	N	N	N	N	Y	ON ATT	DISCHARGE	N	N	N	N	Y
17	1490039	739	SPUTUM	Neg	-	-	Neg	CANDIDA	0.1	0.08	Y	N	N	N	N	HIGH FEVER	DISCHARGE	N	N	N	N	Y
18	1487674	738	SPUTUM	P	-	-	Neg	NG	0.13	0.09	Y	Y	N	N	N	HTN, DM-II, HYPERTENSION, LRTI, BRONCHIAL ASTHMA	DISCHARGE	Y	N	Y	Y	N
19	1489954	737	NR	NR	-	-	NR	NR	0.1	0.01	Y	N	N	N	Y	LRTI, SEPSIS, DM, HTN	DISCHARGE	N	N	N	N	Y
20	1484097	736	SPUTUM	Neg	-	-	Neg	NG	0.1	0.04	N	N	N	N	y	ALLERGIC BRONCHOPULMORY ASPERGELIOUS HEMOPTYS	DISCHARGE	N	N	N	N	Y
21	1489352	735	NR	NR	-	-	NR	NR	0.1	0.02	N	N	N	N	Y	B/L PNEUMONITIC VIRAL AKI	DISCHARGE ON REQUEST	N	N	N	N	Y
22	1489275	733	NR	NR	-	-	NR	NR	0.1	0.02	N	N	N	N	Y	PSORIASIS	DISCHARGE	N	N	N	N	Y
23	1488651	732	NR	NR	-	-	NR	NR	0.16	0.02	N	N	N	N	Y	CIRRHOSIS LIVER WITH PORTAL HTN	DISCHARGE	N	N	N	N	Y
24	1489223	730	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.1	0.03	N	Y	N	N	Y	CKD WITH DM, HTN, SEPSIS, LRTI	DISCHARGE ON REQUEST	N	N	N	N	Y
25	1488643	727	PLEURAL FLUID	Neg	-	-	Neg	NG	0.03	0.13	N	Y	N	N	N	TYPE-2 DM, PULMONARY KOCH'S, RIGHT SIDED P/E,OLD PTCA	DISCHARGE ON REQUEST	N	N	N	N	Y
26	1461851	726	NR	NR	-	-	NR	NR	0.12	4.66	Y	Y	Y	N	N	TYPE-2 DM, HTN, CKD, B/L P/E, FUNGAL LRTI	DISCHARGE	Y	N	Y	N	N
27	1487640	725	NR	NR	-	-	NR	NR	0.16	0.12	N	N	N	N	Y	CIRRHOSIS	DISCHARGE	N	N	N	N	Y
28	43902	724	SPUTUM	P	-	-	P	ASPERGILLUS FLAVUS	13.84	0.03	Y	Y	N	N	N	REACTIVATION OF TB	DAMA	Y	N	Y	Y	N
29	1481626	723	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.13	0.03	N	Y	N	N	N	OLD RSA CASE OF HYDROPNEUMNO THORAX	DAMA	Y	N	Y	N	N
30	1486632	722	NR	NR	-	-	NR	NR	0.13	0.03	N	N	N	N	Y	COPD	DISCHARGE ON REQUEST	Y	N	Y	N	N
31	1480146	720	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.1	0.03	N	N	N	N	Y	PANCREATITIS	DISCHARGE	N	N	N	N	Y
32	1483672	719	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.13	0.03	N	N	N	N	N	HEPATITIS A REACTIVE	DISCHARGE	Y	N	Y	N	N
33	1486595	718	NR	NR	-	-	NR	NR	0.1	0.03	N	N	N	N	Y	ACUTE NECTORIZING PANCREATITIS	DISCHARGE	N	N	N	N	Y
34	1457394	709	NR	NR	-	-	NR	NR	0.1	0.02	N	N	N	N	N	PANCREATITIS	DISCHARGE	Y	N	Y	N	N
35	1481193	707	SPUTUM	Neg	-	-	Neg	NG	0.12	0.03	N	N	N	N	Y	COPD	EXPIRED	N	N	N	N	Y
36	1483712	708	NR	NR	-	-	NR	NR	0.1	0.02	N	Y	N	N	N	LRTI	DISCHARGE ON REQUEST	N	N	N	N	Y
37	401473	710	SPUTUM	Neg	-	-	Neg	NG	0.1	0.01	N	N	N	N	N	LRTI (VIRAL PNEUMONOTIS), HYPOTHYROIDISM	DAMA	Y	N	Y	N	N
38	1384909	711	NR	NR	-	-	NR	NR	0.11	0.04	N	N	N	N	N	DM, HTN, CAD, CHOLELITHIASIS	DISCHARGE	N	N	N	N	Y
39	1460286	713	SPUTUM	Neg	-	-	Neg	NG	0.11	0.04	N	N	N	N	Y	SDH WITH SEPSIS	DISCHARGE	N	N	N	N	Y
40	181003	714	ASCITIC FLUID	Neg	-	-	Neg	NG	14.65	0.02	N	Y	Y	N	N	CKD WITH HTN	DAMA	Y	N	Y	N	N
41	1480815	715	SPUTUM	Neg	-	-	Neg	CANDIDA	0.1	0.05	N	N	N	N	N	LRTI, COPD, AKI, BACTERIAL PNEUMONIA	DISCHARGE	Y	N	Y	N	N
42	1477431	631	NR	NR	-	-	NR	NR	0.22	0.02	Y	N	N	N	N	SEIZURE	DISCHARGE ON REQUEST	Y	N	Y	N	N
43	1483109	632	SPUTUM	Neg	-	-	Neg	NG	0.14	0.82	N	Y	N	N	Y	LVF WITH FLUID OVERLOAD	DISCHARGE	N	N	N	N	Y
44	1271425	700	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.13	0.02	N	N	N	N	N	DM, POST CABG, LATERAL MODULARY SYNDROME	DISCHARGE	N	N	N	N	Y
45	147654	727	NR	NR	-	-	NR	NR	0.03	0.02	N	N	N	N	N	DM	DISCHARGE	N	N	N	N	Y
46	1480159	701	WOUND SWAB	Neg	-	-	Neg	NG	0.1	0.04	N	N	N	N	Y	PORTAL CABG, DM, HTN	DAMA	N	N	N	N	Y

S. no	MRD No.	Lab No	NAME	DOR Sample	AGE	SEX	GMRepeat	DOA	AREA	SUB AREA WISE	Sample	DOR Sample	FEVER	COUGH	SOB	CHEST PAIN	DM	HTN	Alcoholic	Smoker	Neutropenia	TBHistory	Chronic steroid use	Solid organ transplantation	Malignancy	HIV	HCV	HB	TLC/DLC	NEUTROPHIL COUNT	CT CHEST _PLEURAL EFFUSION	CONSOLIDATION IN LUNG	CAVITATION	RETICULONODULAR OPACITIES	Histopathology for aspergillus species
47	399657	704	DJ	3/24/2023	82	M	N	3/10/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	3/24/2023	N	Y	Y	N	N	N	N	N	N	N	Y	N	N	N	N	8.2	10.3	93.2	Y	N	N	N	NR
48	1480166	602	VB	3/14/2023	67	M	N	3/14/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	3/14/2023	Y	N	N	N	N	Y	N	N	N	N	Y	N	N	N	N	9.3	6.6	95.7	N	N	N	N	NR
49	1476191	553	SG	3/7/2023	39	M	N	3/5/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	3/7/2023	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	13	11.96	69.3	N	N	N	N	NR
50	1475943	552	RK	3/7/2023	35	F	N	3/6/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	3/7/2023	N	Y	N	Y	N	N	N	N	N	N	Y	N	N	N	N	11	15	69.4	N	Y	N	N	NR
51	157186	589	RC	3/12/2023	67	M	N	2/22/2023	ICU	CARDIOVASCULAR DISEASE	SERUM	3/12/2023	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	12	5.5	48	N	N	N	N	NR
52	863402	539	SD	3/4/2023	74	F	N	2/25/2023	ICU	ONCOLOGICAL	SERUM	3/4/2023	N	N	N	N	N	Y	N	N	N	N	N	N	Y	N	N	9.1	7.4	73.1	N	Y	N	Y	NR
54	168458	537	SJ	3/4/2023	77	M	N	2/23/2023	ICU	CARDIOVASCULAR DISEASE	SERUM	3/4/2023	Y	Y	N	Y	Y	N	N	N	N	N	N	N	N	N	N	12	6.7	69.9	N	N	N	Y	NR
55	1471420	545	BP	3/6/2023	67	M	N	2/27/2023	ICU	ONCOLOGICAL	SERUM	3/6/2023	N	N	N	N	N	N	Y	Y	N	N	N	N	N	N	N	7.8	17	84.4	N	N	N	N	Normal
56	1315378	546	VK	3/6/2023	72	M	N	3/3/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	3/6/2023	N	Y	N	N	Y	N	N	N	N	N	N	N	N	N	N	6.1	11	71	N	N	N	N	NR
57	1468509	514	RK	3/1/2023	68	M	N	3/1/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	3/1/2023	N	N	Y	N	Y	N	N	N	N	N	N	N	N	N	N	11.2	8.4	88	N	N	N	N	NR
58	1471149	502	BS	2/28/2023	67	M	N	2/27/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	2/28/2023	N	Y	N	N	N	N	N	N	N	N	Y	N	N	N	N	9.2	7.5	74	N	N	Y	N	NR
59	32934	503	KK	2/28/2023	73	F	N	2/17/2023	ICU	CARDIOVASCULAR DISEASE	SERUM	2/28/2023	Y	Y	N	Y	N	Y	N	N	N	N	N	N	N	N	N	11.7	9.3	72	N	N	N	N	NR
61	1006380	572	NG	3/10/2023	46	F	N	3/8/2023	WARD	RENAL DISEASE	SERUM	3/10/2023	Y	Y	N	N	N	N	N	N	N	N	Y	Y	N	N	N	9.7	7.4	79.2	N	Y	N	Y	NR
62	1477653	570	JD	3/10/2023	40	F	N	3/9/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	3/10/2023	Y	N	N	N	N	N	N	N	N	N	Y	N	N	Y	N	9.6	8.4	97.2	N	N	N	N	NR
63	1477573	603	M	3/14/2023	19	F	N	3/9/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	3/14/2023	N	Y	Y	N	N	N	N	N	N	N	Y	N	N	N	N	9.9	36.8	45	N	N	N	N	NR
64	1479028	609	BK	3/15/2023	27	M	N	3/11/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	3/15/2023	Y	N	Y	N	N	N	N	N	N	N	N	N	N	N	N	15	15	77	Y	Y	N	N	NR
66	1479203	601	GG	3/14/2023	62	M	N	3/11/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	3/14/2023	N	Y	Y	N	Y	Y	Y	N	N	N	N	N	N	N	N	7.3	1.3	77.2	Y	Y	N	N	NR
67	1201061	594	DK	3/12/2023	66	F	N	3/12/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	3/12/2023	Y	Y	Y	N	N	N	N	N	N	Y	N	N	N	N	N	10.5	10	65.3	N	N	N	Y	NR
68	1496942	592	KD	3/12/2023	55	F	N	3/9/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	3/12/2023	N	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	9.5	7.9	84.7	N	N	N	Y	NR
69	1476678	581	GS	3/11/2023	58	M	N	3/7/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	3/11/2023	N	N	N	N	N	Y	N	N	N	N	Y	N	N	N	N	10.5	8	76.7	N	N	N	N	NR
70	825005	580	AB	3/11/2023	66	F	N	3/9/2023	WARD	RENAL DISEASE	SERUM	3/11/2023	Y	N	Y	N	Y	Y	N	N	N	N	N	Y	N	N	N	9.7	14.2	81.9	Y	N	N	N	NR
71	1477402	574	GS	3/10/2023	37	M	N	3/9/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	3/10/2023	N	Y	N	N	N	N	N	N	N	N	N	Y	N	N	N	15	12	89	N	N	N	N	NR
72	773791	519	KS	3/2/2023	48	M	N	2/25/2023	WARD	RENAL DISEASE	SERUM	3/2/2023	Y	Y	N	N	N	N	N	N	N	N	N	Y	N	N	N	7	14.4	88	N	Y	N	Y	NR
73	202831	531	RD	3/4/2023	41	F	N	3/3/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	3/4/2023	N	Y	Y	N	Y	N	N	N	N	Y	N	N	N	N	N	11.3	5.7	70.4	N	N	Y	N	NR
74	1461701	523	SK	3/2/2023	53	M	N	3/1/2023	WARD	CARDIOVASCULAR DISEASE	SERUM	3/2/2023	N	N	N	Y	Y	Y	N	N	N	N	N	N	N	N	N	13	13	67	N	Y	N	N	NR
75	1473465	527	PS	3/3/2023	60	M	N	3/2/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	3/3/2023	Y	Y	Y	N	Y	Y	N	N	N	N	N	N	N	N	N	12.3	23	92	N	Y	Y	N	NR
76	1472724	832	SK	3/4/2023	44	M	N	2/1/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	3/4/2023	N	Y	N	N	Y	N	N	N	N	N	N	N	N	N	N	13.6	4.19	66.8	N	N	Y	N	NR
77	1481660	622	KK	3/16/2023	89	F	N	3/15/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	3/16/2023	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	9.3	21	94.1	N	N	N	N	NR
78	1077297	625	RK	3/18/2023	60	M	N	3/14/2023	WARD	CARDIOVASCULAR DISEASE	SERUM	3/18/2023	Y	Y	Y	Y	Y	Y	N	N	N	N	N	N	N	N	N	13	6.7	73.9	N	N	Y	Y	NR
79	1474973	615	OP	4/3/2023	58	M	N	3/5/2023	ICU	GASTROINTESTINAL TRACT DISEASE	SERUM	4/3/2023	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	10.9	19.7	83.2	N	N	N	N	NR
80	1477212	619	MM	3/16/2023	39	F	N	3/9/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	3/16/2023	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	10	11	71	N	N	N	N	NR
81	7680	621	SK	3/16/2023	36	F	N	3/16/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	3/16/2023	N	N	N	N	N	N	N	N	N	N	Y	N	N	N	N	10.7	11	46	N	N	N	N	NR
82	1460197	612	SK	3/15/2023	61	F	N	3/14/2023	WARD	RENAL DISEASE	SERUM	3/15/2023	Y	Y	N	N	Y	Y	N	N	N	Y	N	N	N	N	N	9.9	16	63	N	N	N	N	NR
83	420313	557	KB	3/8/2023	61	F	N	3/7/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	3/8/2023	N	N	N	Y	N	N	N	N	N	N	N	N	N	N	N	8.8	13.8	80	N	N	N	N	NR
84	1442325	567	RK	3/9/2023	72	M	N	3/22/2023	ICU	CARDIOVASCULAR DISEASE	SERUM	3/9/2023	Y	N	N	Y	N	Y	N	N	N	N	N	N	N	N	N	9.1	18.6	80.9	Y	N	N	N	NR
85	1360898	561	BR	3/8/2023	63	M	N	2/26/2023	ICU	RENAL DISEASE	SERUM	3/8/2023	N	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	13.9	5.3	77.5	N	N	N	N	NR
87	1479140	588	JN	3/12/2023	48	F	N	3/11/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	3/12/2023	N	Y	Y	N	N	N	N	Y	N	N	N	N	N	N	N	10.8	9.7	86.1	N	Y	N	N	NR
88	1472119	508	C	3/1/2023	23	F	N	2/28/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	3/1/2023	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	8.9	2.8	77	N	N	N	N	NR
89	1471410	507	BS	2/28/2023	70	M	N	2/27/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	2/28/2023	Y	Y	Y	N	N	N	N	N	N	N	Y	N	N	N	N	11.2	11	94.5	N	N	N	N	NR
90	1471532	499	MK	2/28/2023	38	F	N	2/28/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	2/28/2023	Y	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	14.8	25	87	N	N	N	N	NR
91	1471402	501	PK	2/28/2023	59	M	N	2/27/2023	ICU	GENERAL SURGERY	SERUM	2/28/2023	Y	N	N	N	N	N	N	N	N	N	Y	N	N	N	N	12.3	38	82	N	N	N	N	NR
92	1440329	500	RS	2/28/2023	70	M	N	1/1/2023	ICU	GENERAL SURGERY	SERUM	2/28/2023	N	N	N	N	N	N	N	N	N	N	Y	N	N	N	N	10	13.8	82	N	N	N	N	NR
93	1470527	498	AK	2/28/2023	72	F	N	2/26/2023	ICU	CARDIOVASCULAR DISEASE	SERUM	2/28/2023	Y	Y	Y	Y	Y	Y	N	N	N	N	N	Y	N	N	N	13.3	17	91.7	Y	N	N	N	NR
94	1463368	513	SD	3/1/2023	28	F	N	2/27/2023	WARD	GENERAL SURGERY	SERUM	3/1/2023	N	N	N	N	N	N	N	N	N	N	Y	N	N	N	N	10.1	11.7	69	N	Y	N	N	NR
95	1466733	509	BS	3/1/2023	39	M	N	2/20/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	3/1/2023	N	N	N	N	N	N	N	N	N	N	Y	N	N	N	N	8.5	28	89.7	N	N	N	N	NR
96	1452312	511	PS	3/1/2023	78	M	N	2/1/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	3/1/2023	Y	N	N	N	N	N	N	N	N	N	Y	Y	N	N	N	11	19	92	N	N	N	N	NR
97	1308739	506	SK	2/28/2023	28	M	N	2/27/2023	ICU	GASTROINTESTINAL TRACT DISEASE	SERUM	2/28/2023	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	8	2.5	58	Y	N	N	Y	NR

S. no	MRD No.	Lab No	Distribution of clinical samples received	Fungal smear Positive for Hyaline Septate Fungal Hyphae	CANDIDA IN (BODY FLUIDS AND BLOOD CULTURE)	CANDIDA IN BODY FUILDS	FUNGAL CULTURE FOR ASPERGILLUS SPECIES	Fungal Cuture	GMSAASSAY	1-3 BDG	PTZ	ANTIFUNGAL	Heamo Dylasis	AUGMENTIN	MEROPENEM	Provisional diagnosis	Outcome	TOTAL EORTC PATIENTS	PROVEN	POSSIBLE	PROBABLE	NO INVASIVE ASPERGILLOSI
47	399657	704	PUS	Neg	-	-	Neg	NG	0.12	0.32	N	N	N	N	N	COPD	EXPIRED	Y	N	Y	N	N
48	1480166	602	SPUTUM	Neg	-	-	Neg	NG	0.22	0.01	Y	N	N	N	N	ILD WITH RA	DAMA	N	N	N	N	Y
49	1476191	553	SPUTUM	Neg	-	-	Neg	NG	0.76	0.02	N	Y	N	N	N	AFI	DISCHARGE	N	N	N	N	Y
50	1475943	552	SPUTUM	Neg	-	-	Neg	NG	6.86	0.04	N	Y	N	N	Y	HYPOTHYROIDISM, ALLERGIC BRONCHO PULMONARY ASPERGELIOUS, LEFT PLEURAL EFFUSION	DISCHARGE	Y	N	Y	Y	N
51	157186	589	SPUTUM	Neg	-	-	Neg	NG	0.13	0.02	N	N	N	N	N	PTCA, HTN, DM	DISCHARGE	N	N	N	N	Y
52	863402	539	SPUTUM	Neg	-	-	Neg	NG	14.16	0.1	N	Y	N	N	N	SEVERE APLASTIC ANEAMIA POST ATG, GLOMEULO NEPHRITIS	DISCHARGE	Y	N	Y	Y	N
54	168458	537	SPUTUM	Neg	-	-	Neg	NG	0.11	0.05	N	N	N	N	Y	CABG ANGIRA	DISCHARGE	N	N	N	N	Y
55	1471420	545	SPUTUM	Neg	-	-	Neg	NG	0.17	0.03	N	N	N	N	N	CA LUNG	DISCHARGE	N	N	N	N	Y
56	1315378	546	SPUTUM	Neg	-	-	Neg	NG	0.1	0.02	N	N	N	N	Y	DVT RIGHT LOWER LIMB	DISCHARGE	N	N	N	N	Y
57	1468509	514	SPUTUM	Neg	-	-	Neg	NG	0.13	0.04	N	N	N	N	Y	BRONCHIAL ASTHMA, LRTI, OSTEOPEROTIC MULTIPLE FRACTURE, DM	DAMA	N	N	N	N	Y
58	1471149	502	SPUTUM	Neg	-	-	Neg	NG	0.1	0.05	N	N	N	N	N	INFECTION BRONCHIOLITS	DISCHARGE ON REQUEST	Y	N	Y	N	N
59	32934	503	SPUTUM	Neg	-	-	Neg	NG	0.12	0.06	N	Y	N	N	Y	POST CABG, HTN, COPD, CAD	EXPIRED	N	N	N	N	Y
61	1006380	572	SPUTUM	Neg	-	-	Neg	NG	0.11	0.03	N	Y	N	N	Y	POST RENAL TRANSPLANT, CKD	DISCHARGE	Y	N	Y	N	N
62	1477653	570	SPUTUM	Neg	-	-	Neg	NG	2.92	0.06	N	N	N	N	N	HIV	DISCHARGE	Y	N	Y	Y	N
63	1477573	603	SPUTUM	Neg	-	-	Neg	NG	0.12	0.01	N	N	N	N	N	K/C/O- BRONCHIAL ASTHMA, LRTI, INFECTION BRONCHIOLITS	DISCHARGE	N	N	N	N	Y
64	1479028	609	SPUTUM	Neg	-	-	Neg	NG	0.12	1.16	N	N	N	N	Y	INFECTIVE BRONCHICOLITS	DISCHARGE	N	N	N	N	Y
66	1479203	601	SPUTUM	Neg	-	-	Neg	NG	0.11	0.01	Y	Y	N	N	N	DM, HTN WITH CIRROHIS LIVER	DISCHARGE	N	N	N	N	Y
67	1201061	594	SPUTUM	Neg	-	-	Neg	NG	0.1	0.05	Y	N	N	N	N	ILD, OLD PULMONARY KOCHS, LRTI	DISCHARGE ON REQUEST	N	N	N	N	Y
68	1496942	592	SPUTUM	Neg	-	-	Neg	NG	0.11	0.2	N	N	N	N	Y	LRTI, UTI, AKI	DISCHARGE ON REQUEST	N	N	N	N	Y
69	1476678	581	SPUTUM	Neg	-	-	Neg	NG	2.05	0.03	N	N	N	N	Y	LLD WITH PORTAL HTN	DISCHARGE ON REQUEST	Y	N	Y	Y	N
70	825005	580	SPUTUM	Neg	-	-	Neg	NG	0.15	9.35	N	Y	N	N	Y	POST RENAL TRANSPLANT	DISCHARGE	Y	N	Y	N	N
71	1477402	574	SPUTUM	Neg	-	-	Neg	NG	0.14	0.04	N	N	N	N	N	ILD WITH SAROIDERS, NSIP, TRANSPLANT, RESOLY	DISCHARGE	N	N	N	N	Y
72	773791	519	SPUTUM	Neg	-	-	Neg	CANDIDA	0.1	0.03	N	N	Y	N	N	POST LRAR, UTI SEPSIS, ACUTE CKD, DM	DISCHARGE	Y	N	Y	N	N
73	202831	531	SPUTUM	Neg	-	-	Neg	CANDIDA	0.11	0.03	N	N	N	N	Y	FEVER, LRTI, PULMONARY KOCHS	DISCHARGE	N	N	N	N	Y
74	1461701	523	SPUTUM	Neg	-	-	Neg	NG	0.11	0.01	N	N	N	N	Y	CAD, HTN, TVD, PTCA	DISCHARGE	N	N	N	N	Y
75	1473465	527	SPUTUM	Neg	-	-	Neg	NG	1.59	0.01	N	Y	N	N	Y	DM, HTN, CAD, UTI SEPSIS, LRTI	DAMA	N	N	N	N	Y
76	1472724	832	SPUTUM	P	-	-	P	ASPERGILLUS FLAVUS	1.05	9.3	Y	Y	N	N	N	AFI, LDM	DAMA	N	N	N	N	Y
77	1481660	622	SPUTUM	Neg	-	-	Neg	NG	0.12	0.02	N	N	N	N	Y	CAD WITH HTN, COPD	DAMA	N	N	N	N	Y
78	1077297	625	SPUTUM	Neg	-	-	Neg	NG	0.11	0.05	N	N	N	N	N	TUBURCULAR D/E DRUG INDUCED COAGULOPATHY	DISCHARGE ON REQUEST	N	N	N	N	Y
79	1474973	615	SPUTUM	Neg	-	-	Neg	NG	0.92	0.03	Y	N	N	N	Y	DRY COUGH	DISCHARGE	N	N	N	N	Y
80	1477212	619	SPUTUM	Neg	-	-	Neg	NG	12.79	0.6	Y	Y	N	N	Y	COUGH WITH EXPECTORATION	DISCHARGE	N	N	N	N	Y
81	7680	621	SPUTUM	Neg	-	-	Neg	NG	0.1	0.04	N	N	N	Y	N	ABPA	DISCHARGE	N	N	N	N	Y
82	1460197	612	SPUTUM	Neg	-	-	Neg	NG	0.11	0.02	Y	N	Y	N	Y	CKD, HTN, DM	DISCHARGE	N	N	N	N	Y
83	420313	557	NR	NR	-	-	NR	NR	0.13	0.03	N	N	N	N	N	DM	EXPIRED	N	N	N	N	Y
84	1442325	567	SPUTUM	Neg	-	-	Neg	NG	0.17	0.01	N	N	N	N	N	OLD DVT, HTN, COPD, AKI SEPSIS	EXPIRED	N	N	N	N	Y
85	1360898	561	NR	NR	-	-	NR	NR	0.16	0.05	N	N	Y	N	N	PROSTATOMEGALY GRADENI	DISCHARGE	N	N	N	N	Y
87	1479140	588	SPUTUM	Neg	-	-	Neg	NG	0.11	0.01	N	Y	N	N	N	POST DIABETIC, CHRONIC SMOKER, LRTI	DAMA	N	N	N	N	Y
88	1472119	508	SPUTUM	Neg	-	-	Neg	NG	0.11	0.06	N	N	N	N	Y	LRTI	DISCHARGE	N	N	N	N	Y
89	1471410	507	SPUTUM	Neg	-	-	Neg	NG	0.11	0.04	N	N	N	N	N	COPD	DISCHARGE	N	N	N	N	Y
90	1471532	499	SPUTUM	Neg	-	-	Neg	NG	0.12	0.02	N	Y	N	N	Y	BRONCHIAL ASTHMA	DISCHARGE	N	N	N	N	Y
91	1471402	501	NR	NR	-	-	NR	NR	0.11	0.02	N	N	N	N	Y	PYOGENIC MENINGITIS	DISCHARGE	N	N	N	N	Y
92	1440329	500	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.16	0.02	N	N	N	N	N	SAH, SDH	DISCHARGE	N	N	N	N	Y
93	1470527	498	NR	NR	-	-	NR	NR	0.12	0.03	N	N	N	N	Y	CKD, HTN, LRTI	DISCHARGE	Y	N	Y	N	N
94	1463368	513	NR	NR	-	-	NR	NR	13	0.05	N	Y	N	N	N	PANCREATITIS WITH CHOLILITHIASIS	DISCHARGE	Y	N	Y	Y	N
95	1466733	509	NR	NR	-	-	NR	NR	0.55	0.05	N	Y	N	N	Y	CLD	DISCHARGE	Y	N	Y	N	N
96	1452312	511	NR	NR	-	-	NR	NR	0.1	0.04	N	N	N	N	Y	CAD, POST PTCA, HTN, LRTI	DISCHARGE	N	N	N	N	Y
97	1308739	506	NR	NR	-	-	NR	NR	0.1	0.06	N	N	N	N	Y	TUBERCULOSIS, B/L P/E	DISCHARGE	N	N	N	N	Y

S. no	MRD No.	Lab No	NAME	DOR Sample	AGE	SEX	GMRepeat	DOA	AREA	SUB AREA WISE	Sample	DOR Sample	FEVER	COUGH	SOB	CHEST PAIN	DM	HTN	Alcoholic	Smoker	Neutropenia	TBHistory	Chronic steroid use	Solid organ transplantation	Malignancy	HIV	HCV	HB	TLC/DLC	NEUTROPHIL COUNT	CT CHEST _PLEURAL EFFUSION	CONSOLIDATION IN LUNG	CAVITATION	RETICULONODULAR OPACITIES	Histopathology for aspergillus species
98	1476099	560	PV	3/8/2023	36	F	N	3/6/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	3/8/2023	Y	Y	N	N	N	N	N	N	N	N	Y	N	N	N	N	8.5	13.2	76.5	N	N	N	N	NR
99	574523	562	ML	3/8/2023	78	M	N	3/7/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	3/8/2023	Y	N	Y	N	Y	Y	N	N	N	N	Y	N	N	N	N	10	5.1	86	N	N	N	N	NR
100	1476777	563	SD	3/8/2023	28	F	N	3/7/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	3/8/2023	Y	Y	N	N	N	N	N	N	N	Y	N	N	N	N	N	11	7.1	86.5	N	Y	N	N	NR
101	1474284	564	JS	3/8/2023	65	M	N	3/7/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	3/8/2023	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	13	7.8	46	N	N	N	Y	Normal
102	1476848	565	SP	3/8/2023	32	M	N	3/8/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	3/8/2023	N	N	N	N	N	N	N	N	N	N	Y	N	N	N	N	8.1	15	66.5	Y	N	Y	Y	NR
103	1390373	547	NS	3/6/2023	47	M	N	3/6/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	3/6/2023	N	N	N	N	N	N	N	N	N	N	N	N	Y	N	N	9	13.7	90.4	N	Y	N	N	NR
104	693107	548	SL	3/6/2023	26	M	N	3/4/2023	ICU	CARDIOVASCULAR DISEASE	SERUM	3/6/2023	Y	Y	N	Y	N	Y	N	Y	N	Y	Y	N	N	N	N	10.5	13	74.5	N	N	N	N	NR
105	1471395	549	HS	3/6/2023	63	M	N	2/27/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	3/6/2023	Y	N	N	N	Y	Y	N	N	N	N	N	N	N	Y	N	10.5	1.5	86.5	N	Y	N	N	NR
106	1461072	550	JS	3/7/2023	82	M	N	3/1/2023	ICU	GASTROINTESTINAL TRACT DISEASE	SERUM	3/7/2023	N	N	N	N	N	N	N	N	N	N	Y	N	N	N	N	9.4	8.5	70.7	N	N	N	N	NR
107	1474991	551	V	3/7/2023	47	M	N	3/5/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	3/7/2023	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	10	15	72.2	N	N	N	N	NR
108	1476664	555	MK	3/7/2023	30	M	N	3/7/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	3/7/2023	N	N	N	N	N	N	Y	N	N	N	Y	N	N	N	N	11	23	88.3	Y	N	N	N	NR
109	1476037	566	GS	3/9/2023	36	M	N	3/6/2023	ICU	GASTROINTESTINAL TRACT DISEASE	SERUM	3/9/2023	N	N	N	N	N	N	Y	N	N	N	Y	N	N	N	N	7.7	22	80.4	N	N	N	N	NR
111	1441065	613	R	3/14/2023	71	F	N	3/4/2023	ICU	GASTROINTESTINAL TRACT DISEASE	SERUM	3/14/2023	Y	N	N	N	N	N	N	N	N	N	Y	N	N	N	N	7	8.9	76.3	N	N	N	N	NR
112	1469572	614	AN	3/15/2023	68	M	N	3/15/2023	ICU	GASTROINTESTINAL TRACT DISEASE	SERUM	3/15/2023	Y	Y	N	N	N	N	N	N	N	N	Y	N	N	N	N	12.1	4.44	52.1	N	N	N	N	NR
113	1476229	628	KT	3/18/2023	71	F	N	3/7/2023	ICU	GENERAL SURGERY	SERUM	3/18/2023	Y	N	N	N	N	N	N	N	N	N	Y	N	N	N	N	9.7	13	74.6	Y	N	N	N	NR
114	1480802	627	PK	3/18/2023	36	M	N	3/15/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	3/18/2023	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	13	4.18	62	N	N	N	N	NR
115	1480241	624	S	3/17/2023	37	F	N	3/14/2023	WARD	RENAL DISEASE	SERUM	3/17/2023	Y	Y	N	N	N	N	N	N	N	N	Y	N	N	N	N	4.2	24	91.7	Y	N	N	N	NR
116	1480934	623	GS	3/17/2023	23	F	N	3/15/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	3/17/2023	Y	Y	N	N	N	N	N	N	Y	N	N	N	N	N	N	8.9	15	91.8	Y	N	N	N	NR
117	1470457	510	DD	3/1/2023	70	F	N	2/26/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	3/1/2023	Y	Y	N	N	Y	N	N	N	N	N	N	N	N	N	N	9.6	14	92	N	N	N	N	NR
118	1474332	530	CK	3/3/2023	63	F	N	3/3/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	3/3/2023	Y	Y	N	N	Y	N	N	N	N	N	N	N	N	N	N	10.6	18	62.6	Y	Y	N	Y	NR
119	158958	529	M	3/3/2023	47	F	N	2/26/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	3/3/2023	Y	Y	N	N	N	N	N	N	N	N	Y	N	N	N	Y	13	11	77	N	N	N	N	NR
120	1469050	528	SG	3/3/2023	34	M	N	2/23/2023	ICU	GASTROINTESTINAL TRACT DISEASE	SERUM	3/3/2023	Y	N	N	N	N	N	N	N	N	N	Y	N	N	N	N	16.4	9.4	81.4	Y	N	N	N	NR
121	1034290	526	SD	3/3/2023	87	F	N	3/2/2023	WARD	RENAL DISEASE	SERUM	3/3/2023	Y	Y	Y	N	N	N	N	N	N	N	Y	N	N	N	N	6.8	9.3	89	Y	N	N	N	NR
122	709709	522	SS	3/2/2023	59	F	N	2/21/2023	WARD	CARDIOVASCULAR DISEASE	SERUM	3/2/2023	N	N	N	Y	Y	Y	N	N	N	N	N	N	N	N	N	9.8	59.5	81.6	N	N	N	N	NR
123	1387283	521	DS	3/2/2023	77	M	N	2/23/2023	ICU	RENAL DISEASE	SERUM	3/2/2023	N	N	Y	N	Y	Y	N	N	N	N	N	N	N	N	N	11	10	66	Y	N	N	N	NR
124	1466045	525	AS	3/3/2023	43	M	N	2/24/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	3/3/2023	N	Y	Y	N	N	Y	N	N	N	N	N	N	N	N	N	13.1	9.1	94.6	N	N	N	N	NR
125	1461539	524	AK	3/3/2023	35	F	N	2/27/2023	ICU	GASTROINTESTINAL TRACT DISEASE	SERUM	3/3/2023	N	N	N	N	N	Y	N	N	N	N	Y	N	N	N	N	5.8	19	86.5	N	N	N	N	NR
126	1472716	517	VK	3/1/2023	54	M	N	3/1/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	3/1/2023	N	N	N	N	N	N	N	N	N	N	Y	N	N	N	N	6.2	20	92	N	N	N	N	NR
127	1449747	518	ML	3/2/2023	63	M	N	2/15/2023	ICU	GASTROINTESTINAL TRACT DISEASE	SERUM	3/2/2023	N	Y	N	N	N	Y	N	N	N	N	Y	N	N	N	N	11	7	67	Y	N	N	N	NR
128	898436	513	AS	3/10/2023	68	M	N	3/6/2023	WARD	CARDIOVASCULAR DISEASE	SERUM	3/10/2023	Y	N	N	Y	Y	N	N	N	N	N	N	Y	N	N	N	8.9	9.7	73	Y	N	N	N	NR
129	1477136	575	JR	3/10/2023	71	M	N	3/9/2023	WARD	NEUROLOGICAL DISEASE	SERUM	3/10/2023	N	N	N	N	Y	Y	N	N	N	N	N	N	N	N	N	9.5	10	66	N	N	N	N	NR
132	1457105	579	SS	3/11/2023	77	F	N	2/24/2023	WARD	NEUROLOGICAL DISEASE	SERUM	3/11/2023	N	N	N	N	N	Y	N	N	N	N	Y	N	N	N	N	7	5.1	78	N	N	N	N	NR
133	1476798	582	PS	3/11/2023	37	M	N	3/8/2023	ICU	GENERAL SURGERY	SERUM	3/11/2023	Y	N	Y	N	N	N	N	N	N	N	Y	N	N	N	N	13	6.8	88	N	N	N	N	Normal
134	1469802	583	MS	3/11/2023	49	M	N	2/25/2023	ICU	GASTROINTESTINAL TRACT DISEASE	SERUM	3/11/2023	N	N	N	N	N	N	N	N	N	N	Y	N	N	N	N	10.6	24	80	N	N	N	N	NR
135	1478468	584	ML	3/11/2023	50	M	N	3/10/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	3/11/2023	N	N	N	N	N	N	N	N	N	N	Y	N	N	N	N	10.2	10	75.7	N	Y	N	N	NR
136	1478203	585	JS	3/12/2023	33	M	N	3/10/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	3/12/2023	N	N	Y	N	N	N	N	N	N	N	Y	N	N	N	N	12.2	19	79	Y	N	N	N	NR
137	1476163	586	S	3/12/2023	24	M	N	3/11/2023	ICU	RENAL DISEASE	SERUM	3/12/2023	Y	N	Y	N	N	N	N	N	N	N	N	N	N	N	N	9.2	16.5	89	N	Y	N	N	NR
138	1478579	587	MS	3/12/2023	40	F	N	3/11/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	3/12/2023	N	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	12.6	9.8	90.7	N	N	N	Y	NR
139	1479204	595	PK	3/13/2023	40	F	N	3/11/2023	WARD	CARDIOVASCULAR DISEASE	SERUM	3/13/2023	Y	N	Y	Y	Y	Y	N	N	N	N	N	Y	N	N	N	10	16	87	N	N	N	N	NR
140	1479208	590	S	3/12/2023	46	F	N	3/12/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	3/12/2023	Y	N	Y	N	N	N	N	N	N	N	N	N	N	N	N	3.4	10.1	83.21	Y	N	N	N	NR
141	1469392	593	UP	3/12/2023	72	M	N	2/24/2023	ICU	NEUROLOGICAL DISEASE	SERUM	3/12/2023	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	13	24	78.5	N	N	N	N	NR
142	656492	596	SK	3/13/2023	81	M	N	3/6/2023	ICU	GENERAL SURGERY	SERUM	3/13/2023	N	N	N	N	Y	Y	N	N	N	N	N	N	N	N	N	8.7	19	72	N	N	N	N	NR
143	1478495	598	K	3/14/2023	77	F	N	3/10/2023	ICU	GASTROINTESTINAL TRACT DISEASE	SERUM	3/14/2023	N	N	N	N	N	N	N	N	N	N	Y	N	N	N	N	8.2	5.8	70	N	N	N	N	NR
144	1476914	597	AS	3/13/2023	55	M	N	8/3/20223	WARD	RESPIRATORY TRACT DISEASE	SERUM	3/13/2023	N	N	N	N	N	N	N	N	N	N	Y	N	N	N	N	11.5	48	89.6	N	Y	N	Y	NR
146	1480866	606	AS	3/14/2023	39	M	N	3/14/2023	WARD	ACUTE FEBRILE ILLNESS	SERUM	3/14/2023	N	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	10.2	10	96.1	N	N	N	N	NR
147	1480360	600	HR	3/14/2023	76	M	N	3/14/2023	WARD	RENAL DISEASE	SERUM	3/14/2023	Y	Y	N	N	Y	Y	N	N	N	N	Y	N	N	N	N	9.9	9.3	70	N	N	N	N	NR
149	330357	604	NK	3/14/2023	81	F	N	1/7/2023	ICU	CARDIOVASCULAR DISEASE	SERUM	3/14/2023	Y	Y	N	Y	N	Y	N	N	N	N	Y	N	N	N	N	9.9	10	73.2	N	N	N	N	NR

S. no	MRD No.	Lab No	Distribution of clinical samples received	Fungal smear Positive for Hyaline Septate Fungal Hyphae	CANDIDA IN (BODY FLUIDS AND BLOOD CULTURE)	CANDIDA IN BODY FUILDS	FUNGAL CULTURE FOR ASPERGILLUS SPECIES	Fungal Cuture	GMSAASSAY	1-3 BDG	PTZ	ANTIFUNGAL	Heamo Dylasis	AUGMENTIN	MEROPENEM	Provisional diagnosis	Outcome	TOTAL EORTC PATIENTS	PROVEN	POSSIBLE	PROBABLE	NO INVASIVE ASPERGILLOSI
98	1476099	560	NR	NR	-	-	NR	NR	0.12	0.02	N	N	N	N	Y	FLUID OVERLOAD	DISCHARGE	N	N	N	N	Y
99	574523	562	NR	NR	-	-	NR	NR	0.11	0.08	N	N	N	N	N	ET TUBE INCUBATION, AKI, CHRONIC DVT, INFECTIOUS PNEUMONIA	DISCHARGE	N	N	N	N	Y
100	1476777	563	NR	NR	-	-	NR	NR	0.13	0.05	N	N	N	N	N	LRTI	DAMA	N	N	N	N	Y
101	1474284	564	NR	NR	-	-	NR	NR	0.11	-	N	N	N	N	N	OPACIFICATION	DISCHARGE	N	N	N	N	Y
102	1476848	565	PUS	Neg	-	-	Neg	NG	2	0.03	N	N	N	N	N	ACUTE NECROTISING PANCREATITIS	DISCHARGE	Y	N	Y	Y	N
103	1390373	547	BAL	Neg	-	-	Neg	NG	1.12	0.28	N	N	N	N	N	NASOPHRANGAL ANGRIOFIBROMA	DISCHARGE	Y	N	Y	Y	N
104	693107	548	NR	NR	-	-	NR	NR	0.11	0.03	Y	Y	N	N	N	CAD, DM,HTN	DISCHARGE ON REQUEST	N	N	N	N	Y
105	1471395	549	NR	NR	-	-	NR	NR	0.1	-	N	Y	N	N	Y	HIV+VE, HTN, DM	DISCHARGE	Y	N	Y	N	N
106	1461072	550	ASCITIC FLUID	Neg	-	-	Neg	NG	0.11	0.02	N	N	N	N	N	CAD, HTN, CKD	DAMA	N	N	N	N	Y
107	1474991	551	NR	NR	-	-	NR	NR	0.1	-	N	N	N	N	Y	TYPE-II DM, HTN	DAMA	N	N	N	N	Y
108	1476664	555	NR	NR	-	-	NR	NR	0.13	-	N	N	N	N	Y	ACUTE PANCREATITIS	DISCHARGE	Y	N	Y	N	N
109	1476037	566	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	1.27	0.03	N	N	N	N	N	PANCREATITIS	DISCHARGE	Y	N	Y	N	N
111	1441065	613	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.17	9.21	Y	N	N	N	Y	CLD WITH PORTAL HTN	DISCHARGE	N	N	N	N	Y
112	1469572	614	NR	NR	-	-	NR	NR	0.12	0.02	N	N	N	N	Y	CROHIS DISEASE	DISCHARGE	N	N	N	N	Y
113	1476229	628	NR	NR	-	-	NR	NR	9.25	-	N	Y	N	N	Y	LAPROTOMY	DISCHARGE	Y	N	Y	Y	N
114	1480802	627	NR	NR	-	-	NR	NR	0.11	-	Y	N	N	N	N	RIGHT NEPHOLITHIASIS, LRTI, HICCUPS	DISCHARGE	N	N	N	N	Y
115	1480241	624	NR	NR	-	-	NR	NR	0.04	0.1	N	N	Y	N	Y	CKD	DISCHARGE	Y	N	Y	N	N
116	1480934	623	NR	NR	-	-	NR	NR	0.12	-	N	N	N	N	N	PULMONARY TUBERCULOSIS, ON ATT	DISCHARGE	N	N	N	N	Y
117	1470457	510	NR	NR	-	-	NR	NR	0.12	-	N	N	N	N	Y	LRTI	DISCHARGE ON REQUEST	N	N	N	N	Y
118	1474332	530	NR	NR	-	-	NR	NR	0.11	-	N	Y	N	N	Y	LRTI	DISCHARGE ON REQUEST	N	N	N	N	Y
119	158958	529	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.1	0.03	N	N	N	N	Y	LRTI, COPD	EXPIRED	N	N	N	N	Y
120	1469050	528	NR	NR	-	-	NR	NR	0.03	0.04	N	N	N	N	Y	ACUTE PANCREATITIS NECROTOZING	DISCHARGE	Y	N	Y	N	N
121	1034290	526	NR	NR	-	-	NR	NR	0.18	0.04	N	N	N	N	Y	CHRONIC KIDNEY DISEASE	DISCHARGE	N	N	N	N	Y
122	709709	522	NR	NR	-	-	NR	NR	16.27	0.03	N	Y	N	N	N	DM, HTN, LRTI, SHOCK SEPSIS	DISCHARGE	N	N	N	N	Y
123	1387283	521	NR	NR	-	-	NR	NR	0.11	0.11	N	N	Y	N	N	DM, HTN, CAD	DISCHARGE	N	N	N	N	Y
124	1466045	525	NR	NR	-	-	NR	NR	0.12	2.15	N	Y	N	N	N	-	DISCHARGE	N	N	N	N	Y
125	1461539	524	NR	NR	-	-	NR	NR	0.12	0.02	N	N	N	N	Y	CHRONIC LIVER DISEASE, HTN, PORTAL CHOLITHIASIS	DISCHARGE	N	N	N	N	Y
126	1472716	517	NR	NR	-	-	NR	NR	0.1	-	N	N	N	N	Y	EBV INFECTION, MINIMAL ASCITES	DISCHARGE	N	N	N	N	Y
127	1449747	518	ASCITIC FLUID	Neg	-	-	Neg	NG	0.15	-	N	Y	N	N	N	ALD WITH CLD, PORTAL HTN, UTI	DISCHARGE ON REQUEST	Y	N	Y	N	N
128	898436	513	NR	NR	-	-	NR	NR	0.1	0.02	N	N	Y	N	Y	DM, CKD, HTN, AFI, LRTI	DISCHARGE ON REQUEST	Y	N	Y	N	N
129	1477136	575	NR	NR	-	-	NR	NR	0.1	-	Y	N	N	N	N	HTN, DM-II, SKULL BASE OSTEONYCTITS	EXPIRED	N	N	N	N	Y
132	1457105	579	NR	NR	-	-	NR	NR	0.13	0.03	N	N	N	N	N	CVA, HTN, HYPOTHYROIDISM	DISCHARGE	N	N	N	N	Y
133	1476798	582	NR	NR	-	-	NR	NR	0.16	0.03	N	N	N	N	N	SAIO, HAS	DISCHARGE	N	N	N	N	Y
134	1469802	583	NR	NR	-	-	NR	NR	0.17	0.03	N	N	N	N	Y	CLD WITH PORTAL HTN	DISCHARGE	N	N	N	N	Y
135	1478468	584	ASCITIC FLUID	Neg	-	-	Neg	NG	10.87	-	N	Y	N	N	Y	CLD WITH PORTAL HTN	DISCHARGE	Y	N	Y	Y	N
136	1478203	585	ASCITIC FLUID	Neg	-	-	Neg	NG	0.06	0.12	N	Y	N	N	N	ACUTE NECROTISING PANCREATITIS	DISCHARGE	Y	N	Y	N	N
137	1476163	586	NR	NR	-	-	NR	NR	0.1	0.02	N	Y	Y	N	Y	PULMONARY RENAL SYNDROME, LRTI, RENAL FAILURE	DAMA	N	N	N	N	Y
138	1478579	587	NR	NR	-	-	NR	NR	0.1	-	Y	N	N	N	N	LRTI	DAMA	N	N	N	N	Y
139	1479204	595	NR	NR	-	-	NR	NR	0.12	0.23	Y	N	N	N	N	DM, HTN, CKD	DAMA	N	N	N	N	Y
140	1479208	590	NR	NR	-	-	NR	NR	0.14	-	N	N	N	N	N	PANCA B/L LUNG CONSOLIDATION, SEVERE ANEMIA, AKI	DISCHARGE	N	N	N	N	Y
141	1469392	593	NR	NR	-	-	NR	NR	0.11	0.2	N	N	N	N	Y	SAH, SDH	DISCHARGE	N	N	N	N	Y
142	656492	596	NR	NR	-	-	NR	NR	10.78	0.02	Y	N	N	N	N	TYPE-II DM, HTN, OLD CVA, HYPOTHYROIDISM	DISCHARGE	N	N	N	N	Y
143	1478495	598	NR	NR	-	-	NR	NR	1.4	0.02	N	Y	N	N	Y	CIRRHOSIS, PORTAL HTN	DAMA	Y	N	Y	N	N
144	1476914	597	BAL	Neg	-	-	Neg	NG	0.11	-	Y	N	N	N	Y	COPD	EXPIRED	Y	N	Y	N	N
146	1480866	606	NR	NR	-	-	NR	NR	0.12	-	Y	N	N	N	N	ACUTE FABRILE ILLNESS	DISCHARGE	N	N	N	N	Y
147	1480360	600	NR	NR	-	-	NR	NR	0.17	0.02	N	N	Y	N	N	CKD	DISCHARGE	N	N	N	N	Y
149	330357	604	NR	NR	-	-	NR	NR	0.22	0.03	N	N	N	N	Y	POST OPERATIVE CRANIOTOMY	DISCHARGE	N	N	N	N	Y

S. no	MRD No.	Lab No	NAME	DOR Sample	AGE	SEX	GMRepeat	DOA	AREA	SUB AREA WISE	Sample	DOR Sample	FEVER	COUGH	SOB	CHEST PAIN	DM	HTN	Alcoholic	Smoker	Neutropenia	TBHistory	Chronic steroid use	Solid organ transplantation	Malignancy	HIV	HCV	HB	TLC/DLC	NEUTROPHIL COUNT	CT CHEST _PLEURAL EFFUSION	CONSOLIDATION IN LUNG	CAVITATION	RETICULONODULAR OPACITIES	Histopathology for aspergillus species
150	1468394	610	RK	3/15/2023	25	M	N	2/22/2023	ICU	GENERAL SURGERY	SERUM	3/15/2023	N	N	N	N	N	N	N	N	N	N	Y	N	N	N	N	12	8.8	79	N	N	N	N	NR
151	1479411	607	SK	3/15/2023	29	M	N	3/13/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	3/15/2023	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	10.6	22	69.4	N	N	N	N	NR
152	1471386	608	SS	3/15/2023	42	M	N	2/27/2023	ICU	GASTROINTESTINAL TRACT DISEASE	SERUM	3/15/2023	N	N	N	N	N	N	N	N	N	N	Y	N	N	N	N	10.1	23	87	Y	N	N	N	NR
153	1475059	569	SP	3/9/2023	85	M	N	3/5/2023	ICU	RENAL DISEASE	SERUM	3/9/2023	Y	Y	N	N	Y	Y	N	N	N	N	N	Y	N	N	N	9.6	10.7	71.5	N	Y	N	N	NR
154	1474982	571	HS	3/10/2023	33	M	N	3/4/2023	ICU	GASTROINTESTINAL TRACT DISEASE	SERUM	3/10/2023	N	N	N	N	N	N	N	N	N	N	Y	N	N	N	N	9.4	27	92.8	Y	N	N	N	NR
156	239190	556	SJ	3/7/2023	63	F	N	3/6/2023	WARD	CARDIOVASCULAR DISEASE	SERUM	3/7/2023	N	N	Y	Y	Y	Y	N	N	N	N	N	N	N	N	N	7.7	4.3	77.6	N	N	N	N	NR
157	148091	505	SS	3/1/2023	78	M	N	2/23/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	3/1/2023	Y	Y	N	N	N	N	N	N	N	N	Y	N	N	N	N	13	6.4	66.4	N	N	N	N	NR
158	1470544	504	MS	2/28/2023	40	M	N	2/26/2023	WARD	CARDIOVASCULAR DISEASE	SERUM	2/28/2023	Y	Y	N	Y	N	N	N	N	Y	N	N	N	Y	N	N	6.9	0.7	0.2	N	N	N	N	NR
159	1450699	515	RR	3/1/2023	62	F	N	1/24/2023	ICU	NEUROLOGICAL DISEASE	SERUM	3/1/2023	N	N	Y	N	Y	Y	N	N	N	N	Y	N	N	N	N	11.4	28	85.6	N	N	N	N	NR
160	1474997	544	SG	3/5/2023	40	M	N	3/5/2023	ICU	CARDIOVASCULAR DISEASE	SERUM	3/5/2023	N	Y	Y	Y	N	N	N	N	N	N	N	Y	N	N	N	9.7	7.2	86.1	N	N	N	N	NR
161	1287339	542	RP	3/5/2023	63	M	N	3/4/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	3/5/2023	N	N	N	N	Y	Y	N	N	N	N	N	Y	N	N	N	10	6.4	78.2	N	N	N	N	NR
162	1473470	541	SM	3/5/2023	35	M	N	3/2/2023	ICU	GASTROINTESTINAL TRACT DISEASE	SERUM	3/5/2023	Y	N	N	N	Y	N	N	N	N	N	N	N	N	N	N	11	45	77	N	N	N	N	NR
163	1470336	536	PR	3/4/2023	66	F	N	2/25/2023	ICU	CARDIOVASCULAR DISEASE	SERUM	3/4/2023	N	N	Y	Y	Y	Y	N	N	N	N	N	N	N	N	N	6.5	6.9	61.3	Y	N	N	N	NR
164	1153694	543	VK	3/5/2023	66	F	P	3/4/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	3/5/2023	Y	N	Y	N	N	Y	N	N	N	N	Y	N	N	N	N	8.8	14	79.5	N	Y	N	N	NR
165	1469058	534	KK	3/4/2023	55	F	N	2/23/2023	WARD	DERMATOLOGY	SERUM	3/4/2023	N	N	N	N	N	Y	N	N	N	N	N	Y	N	N	N	6.8	11	84	N	N	N	N	NR
166	1474385	533	DR	3/4/2023	82	M	N	3/3/2023	ICU	CARDIOVASCULAR DISEASE	SERUM	3/4/2023	N	N	Y	Y	N	Y	N	N	N	N	N	N	N	N	N	13	15	86.2	N	N	N	N	NR
167	196312	540	SK	3/5/2023	74	M	N	1/23/2023	ICU	CARDIOVASCULAR DISEASE	SERUM	3/5/2023	N	N	N	Y	N	N	N	N	N	N	N	N	N	N	N	8.2	7	89.5	N	N	N	N	NR
168	1475767	559	BN	3/8/2023	66	M	N	3/6/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	3/8/2023	N	Y	Y	N	N	Y	N	N	N	N	Y	N	N	N	N	14	4	78.3	N	N	N	N	NR
170	1471137	520	DL	3/2/2023	80	M	N	2/27/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	3/2/2023	Y	Y	Y	N	Y	N	N	N	N	N	Y	N	N	N	N	9.9	11.8	89	N	N	N	N	NR
171	1463323	647	GS	3/20/2023	30	M	N	3/20/2023	ICU	GENERAL SURGERY	SERUM	3/20/2023	N	N	N	N	N	N	N	N	N	N	Y	N	N	N	N	17	13.2	84.3	Y	N	N	N	NR
172	1479225	649	HK	3/21/2023	60	F	N	3/12/2023	ICU	GASTROINTESTINAL TRACT DISEASE	SERUM	3/21/2023	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	14.5	11	85	N	N	Y	N	NR
173	1476872	650	SK	3/22/2023	63	F	P	3/8/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	3/22/2023	N	N	Y	N	N	N	N	N	N	N	Y	N	N	N	N	17	13	85.5	N	N	N	Y	NR
174	200597	651	KK	3/21/2023	71	F	N	3/20/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	3/21/2023	Y	N	Y	N	Y	Y	N	N	N	N	Y	N	N	N	N	12.7	28	91.9	N	N	N	N	NR
175	1483620	652	NK	3/21/2023	45	F	N	3/18/2023	ICU	GENERAL SURGERY	SERUM	3/21/2023	N	N	N	N	N	N	N	N	N	N	Y	N	N	N	N	12.1	5.4	86.3	N	N	N	Y	NR
176	1484586	655	SS	3/22/2023	60	M	N	3/20/2023	ICU	RENAL DISEASE	SERUM	3/22/2023	Y	N	Y	N	Y	Y	N	N	N	N	N	Y	N	N	N	12.9	18	93.6	N	N	N	N	NR
177	239263	654	AK	3/21/2023	61	M	N	3/24/2023	WARD	RENAL DISEASE	SERUM	3/21/2023	Y	Y	Y	Y	Y	N	N	N	N	N	N	N	N	N	N	14	10	86.4	N	N	N	N	NR
178	1483757	656	GK	3/22/2023	75	F	P	3/19/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	3/22/2023	Y	N	Y	N	Y	N	N	N	N	N	N	N	N	N	N	8.8	8.1	62.1	Y	Y	N	N	NR
180	1484547	658	VS	3/22/2023	20	M	N	3/20/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	3/22/2023	Y	Y	N	N	N	N	N	N	N	N	Y	N	N	Y	Y	11.5	14.2	56.5	N	Y	Y	N	NR
181	1480822	659	SS	3/22/2023	73	M	N	3/14/2023	WARD	GENERAL SURGERY	SERUM	3/22/2023	Y	N	N	N	Y	Y	N	N	N	N	N	N	N	N	N	9.3	16	79.1	N	N	N	N	NR
182	1393618	661	PS	3/22/2023	67	M	N	3/21/2023	WARD	RENAL DISEASE	SERUM	3/22/2023	Y	N	Y	N	Y	Y	N	N	N	N	N	N	N	N	N	6.2	9.4	79.5	N	N	N	N	NR
183	1484591	662	NS	3/22/2023	32	M	N	3/20/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	3/22/2023	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	17	15	67.5	N	N	N	Y	NR
184	1485302	663	HS	3/22/2023	55	F	N	3/22/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	3/22/2023	Y	N	N	N	N	Y	N	N	N	N	Y	N	N	N	N	9.6	32.2	78	N	N	N	N	NR
185	1483648	664	RS	3/22/2023	28	M	N	3/18/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	3/22/2023	N	N	N	N	N	N	N	N	N	N	Y	N	N	N	N	7.7	14	78.9	N	N	N	N	NR
186	1442809	665	SV	3/22/2023	79	F	N	3/20/2023	ICU	CARDIOVASCULAR DISEASE	SERUM	3/22/2023	Y	N	N	Y	N	Y	N	N	N	N	Y	N	N	N	N	12.3	11	86	N	N	N	Y	NR
187	1480062	666	RK	3/22/2023	65	M	N	3/13/2023	WARD	CARDIOVASCULAR DISEASE	SERUM	3/22/2023	Y	N	Y	Y	N	N	N	Y	N	N	Y	N	N	N	N	11	11.5	80	N	N	N	Y	NR
188	1460302	667	SS	3/22/2023	49	M	N	3/22/2023	WARD	GENERAL SURGERY	SERUM	3/22/2023	N	N	N	N	Y	N	N	N	N	N	Y	N	N	N	N	8.6	27	22	N	N	N	N	NR
189	1483660	669	JS	3/23/2023	32	M	N	3/19/2023	ICU	GASTROINTESTINAL TRACT DISEASE	SERUM	3/23/2023	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	6.7	12.89	75.9	N	Y	N	Y	NR
190	1483087	629	MS	3/18/2023	47	M	N	3/17/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	3/18/2023	Y	Y	Y	N	N	Y	N	N	N	N	N	N	N	N	N	12.7	6.4	83.3	N	N	N	N	NR
191	1480064	646	JK	3/20/2023	52	F	N	3/13/2023	ICU	GASTROINTESTINAL TRACT DISEASE	SERUM	3/20/2023	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	9.3	8.8	48.9	N	N	N	N	NR
192	1483559	645	SS	3/20/2023	32	M	N	3/18/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	3/20/2023	Y	Y	Y	N	N	N	N	N	N	N	Y	N	N	N	N	12.9	27	86.6	Y	N	Y	Y	NR
193	1482035	644	BS	3/20/2023	63	M	N	3/16/2023	ICU	GASTROINTESTINAL TRACT DISEASE	SERUM	3/20/2023	N	N	N	N	N	N	N	N	N	N	Y	N	N	N	N	8.7	16	83.4	N	N	N	N	NR
194	1484438	643	HS	3/20/2023	72	M	N	3/20/2023	WARD	RENAL DISEASE	SERUM	3/20/2023	N	N	Y	N	N	Y	N	N	N	N	N	Y	N	N	N	6.1	16	85.1	N	N	N	N	NR
195	919438	642	A	3/19/2023	45	F	N	3/18/2023	WARD	RENAL DISEASE	SERUM	3/19/2023	N	N	N	N	N	Y	N	N	N	Y	N	Y	N	N	N	11	9	80.7	N	N	N	N	NR
196	1472130	640	M	3/19/2023	38	F	N	3/1/2023	WARD	GENERAL SURGERY	SERUM	3/19/2023	Y	Y	N	N	N	N	N	N	N	N	Y	N	N	N	N	9.1	6.7	61.7	N	N	N	N	Y
197	1443238	639	JP	3/19/2023	50	M	N	3/15/2023	ICU	GASTROINTESTINAL TRACT DISEASE	SERUM	3/19/2023	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	N	12.4	13.8	58	N	N	N	N	NR
198	1483149	638	V	3/19/2023	62	F	N	3/18/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	3/19/2023	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	12.16	19.43	80.3	N	Y	N	N	NR
200	1479064	648	KR	3/21/2023	77	F	N	3/11/2023	ICU	GASTROINTESTINAL TRACT DISEASE	SERUM	3/21/2023	N	N	N	N	N	N	N	N	N	N	Y	N	N	N	N	11.3	20	87.3	N	N	N	N	NR
202	1481724	636	LS	3/19/2023	65	M	N	3/16/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	3/19/2023	Y	Y	N	N	Y	Y	N	N	N	N	Y	N	N	N	N	12	15	72.8	N	N	N	Y	NR

S. no	MRD No.	Lab No	Distribution of clinical samples received	Fungal smear Positive for Hyaline Septate Fungal Hyphae	CANDIDA IN (BODY FLUIDS AND BLOOD CULTURE)	CANDIDA IN BODY FUILDS	FUNGAL CULTURE FOR ASPERGILLUS SPECIES	Fungal Cuture	GMSAASSAY	1-3 BDG	PTZ	ANTIFUNGAL	Heamo Dylasis	AUGMENTIN	MEROPENEM	Provisional diagnosis	Outcome	TOTAL EORTC PATIENTS	PROVEN	POSSIBLE	PROBABLE	NO INVASIVE ASPERGILLOSI
150	1468394	610	NR	NR	-	-	NR	NR	0.12	-	N	N	N	N	Y	RSA, EDH, IVH, SAH	DISCHARGE	N	N	N	N	Y
151	1479411	607	NR	NR	-	-	NR	NR	0.11	-	Y	N	N	N	N	ACUTE FABRILE ILLNESS	DISCHARGE	N	N	N	N	Y
152	1471386	608	ASCITIC FLUID	Neg	-	-	Neg	NG	0.13	0.02	N	N	N	N	N	CLD WITH PORTAL HTN	DISCHARGE	Y	N	Y	N	N
153	1475059	569	NR	NR	-	-	NR	NR	13.65	0.05	N	Y	Y	N	Y	CKD, HTN	DISCHARGE	Y	N	Y	Y	N
154	1474982	571	PLEURAL FLUID	Neg	-	-	Neg	NG	0.16	2.61	N	Y	N	N	Y	ACUTE PANCREATITIS	DISCHARGE	Y	N	Y	N	N
156	239190	556	NR	NR	-	-	NR	NR	0.18	0.02	N	N	N	N	N	PARENCHYMAL CHANGES	DISCHARGE	N	N	N	N	Y
157	148091	505	NR	NR	-	-	NR	NR	0.14	-	N	N	N	N	N	POST COVID, VIRAL PNEUMONIA	DISCHARGE	N	N	N	N	Y
158	1470544	504	NR	NR	-	-	NR	NR	0.11	0.03	N	N	N	N	Y	HODGEKIN LYMPHOMA, B/M TRANSPLANT AFI	DISCHARGE	N	N	N	N	Y
159	1450699	515	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.18	0.04	N	N	N	N	Y	LEFT MCA INFORICT	DISCHARGE	N	N	N	N	Y
160	1474997	544	NR	NR	-	-	NR	NR	0.1	0.03	N	N	N	N	Y	DM, CKD, LRTI, AFI	DISCHARGE	N	N	N	N	Y
161	1287339	542	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.12	8.08	N	N	N	N	Y	LRTI, CKD	DISCHARGE	Y	N	Y	N	N
162	1473470	541	NR	NR	-	-	NR	NR	0.12	0.02	N	N	N	N	Y	CHOLILITHIASIS, ASCITES	DISCHARGE	N	N	N	N	Y
163	1470336	536	NR	NR	-	-	NR	NR	0.13	0.04	N	N	N	N	Y	DM, HTN, CAD	DISCHARGE	N	N	N	N	Y
164	1153694	543	NR	NR	-	-	NR	NR	11.82	-	Y	N	N	N	N	AFI, HTN	DAMA	Y	N	Y	Y	N
165	1469058	534	NR	NR	-	-	NR	NR	0.1	2.97	N	N	N	N	N	CKD, DM, HYPERTENSION	DISCHARGE	N	N	N	N	Y
166	1474385	533	NR	NR	-	-	NR	NR	0.11	0.04	Y	N	N	N	N	LRTI	DAMA	N	N	N	N	Y
167	196312	540	NR	NR	-	-	NR	NR	1.67	0.03	N	N	N	N	N	HTN, CABG, ANEMIA, CKD, HTN	EXPIRED	N	N	N	N	Y
168	1475767	559	NR	NR	-	-	NR	NR	0.12	-	N	Y	N	N	Y	DENGUE FEVER, ARDS, PORTAL HTN, AKI SHOCK SEPSIS	DISCHARGE	N	N	N	N	Y
170	1471137	520	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.1	-	N	Y	N	N	N	COPD	EXPIRED	N	N	N	N	Y
171	1463323	647	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.1	0.04	N	N	N	N	N	CLD WITH NECROTISING PANCREATITIS	DISCHARGE	Y	N	Y	N	N
172	1479225	649	SPUTUM	Neg	-	-	Neg	NG	0.12	8.07	N	Y	N	N	N	CLD, MILD ASCITES, CHOLITITHIASIS	DISCHARGE	N	N	N	N	Y
173	1476872	650	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.82	0.23	N	Y	N	N	N	CLD, LRTI, FUNGAL SEPSIS	DISCHARGE	Y	N	Y	Y	N
174	200597	651	SPUTUM	Neg	-	-	Neg	NG	0.14	9.19	N	Y	N	N	Y	BRONCHIAL ASTHMA, DM, HTN	DISCHARGE	N	N	N	N	Y
175	1483620	652	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.1	4.44	N	Y	N	N	Y	OPACIFICATION	DISCHARGE	N	N	N	N	Y
176	1484586	655	NR	NR	-	-	NR	NR	0.1	0.02	N	N	Y	N	Y	CKD, SHOCK	DISCHARGE	N	N	N	N	Y
177	239263	654	SPUTUM	Neg	-	-	Neg	NG	0.1	0.02	N	Y	N	N	Y	CKD, LRTI, DM, FEVER, COPD	DISCHARGE	N	N	N	N	Y
178	1483757	656	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	10.78	-	N	N	N	N	Y	LRTI	DISCHARGE	N	N	N	N	Y
180	1484547	658	NR	NR	-	-	NR	NR	0.11	0.02	N	Y	N	N	Y	HIV+VE, LRTI, HEPATITIS C REACTIVE	DISCHARGE	Y	N	Y	N	N
181	1480822	659	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	CANDIDA	0.12	-	N	N	N	N	N	ABDOMINAL PAIN	DISCHARGE	N	N	N	N	Y
182	1393618	661	NR	NR	-	-	NR	NR	0.11	0.02	Y	N	Y	N	Y	TYPE-2 DM, HTN, LRTI. B/L PLEURAL EFFUSION	DISCHARGE	N	N	N	N	Y
183	1484591	662	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.13	0.02	N	N	N	N	Y	HEPATOMEGALY	DISCHARGE	N	N	N	N	Y
184	1485302	663	NR	NR	-	-	NR	NR	0.11	-	N	Y	N	N	N	HTN, SEIZURE DISORDER, OSA, LRTI, INFLUENZA AKI	DISCHARGE	N	N	N	N	Y
185	1483648	664	NR	NR	-	-	NR	NR	0.11	0.03	Y	N	N	N	N	GB MALL EDEMA	DISCHARGE	N	N	N	N	Y
186	1442809	665	SPUTUM	Neg	-	-	Neg	NG	0.13	0.03	N	N	N	Y	N	HTN, RA	DISCHARGE ON REQUEST	Y	N	Y	N	N
187	1480062	666	SPUTUM	Neg	-	-	Neg	CANDIDA	0.19	0.04	N	N	N	N	Y	K/C/O- CLD	DISCHARGE ON REQUEST	Y	N	Y	N	N
188	1460302	667	SPUTUM	Neg	-	-	Neg	NG	0.1	0.64	N	N	N	N	Y	CHOLRCYSTECTOMY, NEUROSECTOMY, NECROTIZING PANCREATITIS	DISCHARGE ON REQUEST	N	N	N	N	Y
189	1483660	669	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.13	0.03	N	N	N	N	Y	PULMONARY EDEMA	DAMA	N	N	N	N	Y
190	1483087	629	SPUTUM	Neg	-	-	Neg	NG	0.14	0.04	Y	Y	N	N	N	PNEUMONIA, TYPE-2 DM, HTN	DAMA	N	N	N	N	Y
191	1480064	646	NR	NR	-	-	NR	NR	0.1	0.05	N	N	N	N	Y	CHOLILITHIASIS	DISCHARGE	N	N	N	N	Y
192	1483559	645	SPUTUM	Neg	-	-	Neg	NG	0.1	3.05	N	Y	N	N	Y	COMMUNITY ACQUIRED PNEUMONIA	DISCHARGE	Y	N	Y	N	N
193	1482035	644	ASCITIC FLUID	Neg	-	-	Neg	NG	13.64	0.02	N	Y	N	N	Y	CIRRHOSIS, PORTAL HTN	DISCHARGE	Y	N	Y	N	N
194	1484438	643	NR	NR	-	-	NR	NR	0.14	-	Y	N	Y	N	N	CKD, HTN	DISCHARGE	N	N	N	N	Y
195	919438	642	SPUTUM	Neg	-	-	Neg	NG	0.11	-	N	N	Y	N	Y	CKD	DISCHARGE	N	N	N	N	Y
196	1472130	640	SPUTUM	Neg	-	-	Neg	NG	0.18	8	Y	Y	N	N	N	VENTILATED ASSICIATED PNEUMONIA	DISCHARGE	Y	Y	N	N	N
197	1443238	639	SPUTUM	Neg	-	-	Neg	NG	0.17	0.03	Y	N	N	N	Y	CLD WITH PORTAL HTN	DISCHARGE	N	N	N	N	Y
198	1483149	638	SPUTUM	Neg	-	-	Neg	NG	11.98	0.03	N	Y	N	N	N	LRTI	DISCHARGE	N	N	N	N	Y
200	1479064	648	NR	NR	-	-	NR	NR	0.04	2.78	N	N	N	N	N	PERIPANCREATIC NECROTISING PANCUAS	DISCHARGE	N	N	N	N	Y
202	1481724	636	SPUTUM	Neg	-	-	Neg	NG	0.66	-	N	N	N	N	N	AKI, DM, HTN,B/L PNEUMONITS SEPSIS	DISCHARGE	Y	N	Y	Y	N

S. no	MRD No.	Lab No	NAME	DOR Sample	AGE	SEX	GMRepeat	DOA	AREA	SUB AREA WISE	Sample	DOR Sample	FEVER	COUGH	SOB	CHEST PAIN	DM	HTN	Alcoholic	Smoker	Neutropenia	TBHistory	Chronic steroid use	Solid organ transplantation	Malignancy	HIV	HCV	HB	TLC/DLC	NEUTROPHIL COUNT	CT CHEST _PLEURAL EFFUSION	CONSOLIDATION IN LUNG	CAVITATION	RETICULONODULAR OPACITIES	Histopathology for aspergillus species
203	1480928	635	VK	3/19/2023	65	M	N	3/15/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	3/19/2023	N	Y	Y	N	Y	Y	N	N	N	Y	N	N	N	N	N	10.7	8	87.1	Y	Y	N	N	NR
204	772501	634	PS	3/18/2023	67	M	N	3/15/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	3/18/2023	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	8.7	9.4	79	N	N	N	N	NR
205	1476575	633	DS	3/18/2023	80	M	N	3/18/2023	WARD	NEUROLOGICAL DISEASE	SERUM	3/18/2023	N	N	N	N	Y	Y	N	N	N	N	Y	N	N	N	N	14	12.43	81	N	Y	Y	N	NR
206	1353599	441	MP	2/21/2023	81	M	N	2/20/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	2/21/2023	Y	Y	Y	N	N	N	N	Y	N	N	Y	N	N	N	N	9.8	15.4	86.9	N	N	N	Y	NR
207	1397083	440	PG	2/21/2023	60	F	N	2/3/2023	ICU	NEUROLOGICAL DISEASE	SERUM	2/21/2023	N	N	N	N	Y	N	N	N	N	N	Y	N	N	N	N	6.2	4.4	75.8	N	N	N	N	NR
208	1461890	435	SK	2/20/2023	45	F	N	2/12/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	2/20/2023	Y	N	Y	N	Y	N	N	N	N	N	Y	N	N	N	N	5.6	13.2	88.5	N	N	N	N	NR
209	1459626	429	KR	2/19/2023	70	M	N	2/8/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	2/19/2023	N	N	N	N	Y	Y	N	N	N	N	Y	N	N	N	N	11.5	8.4	70	N	N	N	N	NR
210	1465237	428	MK	2/19/2023	60	F	P	2/17/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	2/19/2023	Y	N	Y	N	Y	Y	N	N	N	N	Y	N	N	N	N	9.4	45	95.4	N	Y	N	N	NR
211	422262	469	SK	2/23/2023	65	F	N	2/23/2023	WARD	RENAL DISEASE	SERUM	2/23/2023	Y	N	N	N	N	N	N	N	N	N	N	N	Y	N	N	10.6	21	70	N	N	N	N	NR
212	1469076	470	SA	2/24/2023	30	F	N	2/23/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	2/24/2023	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	11	13	70	N	N	N	N	NR
214	96264	461	SK	2/22/2023	74	M	N	1/25/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	2/22/2023	N	Y	Y	N	Y	Y	N	N	N	N	N	Y	N	N	N	7.2	6.3	73.9	N	N	N	N	NR
215	1468365	460	MK	2/22/2023	57	F	N	2/22/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	2/22/2023	Y	Y	N	N	Y	N	N	N	N	N	N	N	N	N	N	10.1	20	89	N	Y	N	Y	NR
216	1433990	459	BS	2/22/2023	55	M	N	2/21/2023	ICU	GENERAL SURGERY	SERUM	2/22/2023	N	N	N	N	N	Y	N	N	N	N	N	N	N	N	N	11.1	10.1	66.8	N	N	N	N	NR
218	430708	464	JL	2/23/2023	62	M	N	2/21/2023	ICU	GASTROINTESTINAL TRACT DISEASE	SERUM	2/23/2023	N	N	N	N	Y	Y	N	N	N	N	Y	N	N	N	N	9.4	260	67	Y	N	N	N	NR
219	1466920	463	SL	2/23/2023	65	M	N	2/21/2023	ICU	NEUROLOGICAL DISEASE	SERUM	2/23/2023	N	N	N	N	N	N	N	N	N	N	Y	N	N	N	N	13	19	75.3	N	N	Y	N	NR
220	1467606	462	SS	2/23/2023	45	M	N	2/21/2023	ICU	GASTROINTESTINAL TRACT DISEASE	SERUM	2/23/2023	N	N	N	N	N	N	N	N	N	N	Y	N	N	N	N	11	25	88	N	N	N	N	NR
221	1455822	290	SS	2/3/2023	45	M	N	2/21/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	2/3/2023	Y	Y	Y	N	Y	Y	N	N	N	N	N	N	N	N	N	8.8	21	98.1	N	N	N	N	NR
222	1455270	278	SS	2/2/2023	25	M	N	2/1/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	2/2/2023	Y	Y	Y	N	N	N	N	N	N	N	Y	N	N	N	Y	14.2	16.94	91	N	N	N	N	NR
223	1449776	283	KR	2/2/2023	55	F	P	1/25/2023	ICU	CARDIOVASCULAR DISEASE	SERUM	2/2/2023	N	Y	N	Y	Y	Y	N	N	N	N	Y	Y	N	N	N	15	6.8	54.5	Y	Y	N	Y	NR
224	1469107	489	KK	2/27/2023	41	M	N	2/24/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	2/27/2023	N	Y	N	N	Y	N	N	N	N	N	N	N	N	N	N	14.2	5.4	68	N	N	N	N	NR
225	1470586	488	VB	2/27/2023	33	F	N	2/27/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	2/27/2023	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	11.4	7	78.7	N	N	N	N	NR
226	1238116	490	JS	2/19/2023	42	M	N	2/18/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	2/19/2023	Y	Y	Y	N	N	N	N	N	N	N	Y	N	N	N	N	10.4	30	80	Y	N	Y	N	NR
227	1470595	492	AK	2/28/2023	27	M	N	2/27/2023	ICU	GASTROINTESTINAL TRACT DISEASE	SERUM	2/28/2023	N	N	N	N	N	N	N	N	N	N	Y	N	N	N	N	11	9	64.9	Y	N	N	N	NR
228	1460780	493	KS	2/28/2023	48	M	N	2/21/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	2/28/2023	Y	N	N	N	N	N	N	N	N	N	Y	N	N	N	N	8.2	25	82	N	Y	N	N	NR
229	1264042	486	DK	2/27/2023	89	F	N	2/21/2023	ICU	CARDIOVASCULAR DISEASE	SERUM	2/27/2023	Y	Y	N	Y	Y	N	N	N	N	N	N	N	N	N	N	10	4.1	76	N	N	N	N	NR
231	1459618	473	PS	2/24/2023	60	F	N	2/8/2023	WARD	RENAL DISEASE	SERUM	2/24/2023	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	7	11.7	77.8	N	N	N	N	NR
232	1457476	474	RS	2/25/2023	48	M	N	2/6/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	2/25/2023	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	14	13	72.97	N	N	N	N	NR
233	1468971	476	KK	2/25/2023	26	F	N	2/23/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	2/25/2023	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	12	15	65	N	N	N	N	NR
234	1469769	478	JK	2/25/2023	70	F	N	2/24/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	2/25/2023	N	N	N	N	N	N	N	N	Y	N	N	N	N	N	N	7	23	7	N	N	Y	N	Normal
235	1454456	479	BK	2/25/2023	60	F	N	1/31/2023	WARD	ENDOCRINOLOGY	SERUM	2/25/2023	Y	Y	Y	N	Y	N	N	N	N	Y	Y	N	N	N	N	9.8	19	90	N	N	Y	N	Normal
236	1470136	480	UJ	2/25/2023	68	M	N	2/25/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	2/25/2023	Y	Y	Y	N	N	Y	N	N	N	N	N	N	N	N	N	10	11	77	N	N	N	N	NR
237	1468990	482	AR	2/26/2023	67	F	N	2/23/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	2/26/2023	N	Y	N	N	N	N	N	N	N	N	Y	N	N	N	N	8.2	14	73.2	N	N	N	N	NR
238	1470426	487	CK	2/26/2023	49	F	N	2/2/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	2/26/2023	Y	Y	Y	N	Y	N	N	N	N	N	Y	N	N	N	N	9.4	22	91.8	Y	N	N	N	NR
239	171401	483	DK	2/26/2023	68	M	N	2/22/2023	WARD	RENAL DISEASE	SERUM	2/26/2023	N	N	Y	N	N	N	N	N	N	N	N	N	N	N	N	7.1	12.2	74.2	N	N	N	N	NR
241	1307932	485	GK	2/27/2023	46	F	N	2/26/2023	WARD	RENAL DISEASE	SERUM	2/27/2023	N	N	Y	N	Y	Y	N	N	N	N	Y	N	N	N	N	9.2	15	82	Y	N	N	N	NR
242	1468451	466	MK	2/23/2023	65	F	N	2/23/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	2/23/2023	Y	N	Y	N	Y	Y	N	N	N	N	N	N	N	N	N	10.6	23	93	N	N	N	N	NR
245	1465367	447	RK	2/21/2023	85	M	N	2/17/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	2/21/2023	Y	Y	N	N	Y	Y	N	N	N	N	Y	N	N	N	N	10.5	15	73	N	N	N	N	NR
246	1464348	449	D	2/21/2023	47	F	N	2/16/2023	WARD	GENERAL SURGERY	SERUM	2/21/2023	N	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	8.8	6.89	70	N	N	N	N	NR
247	577126	450	PG	2/21/2023	35	F	N	2/19/2023	WARD	CARDIOVASCULAR DISEASE	SERUM	2/21/2023	N	N	N	Y	Y	Y	N	N	N	N	N	N	N	N	N	9	11.5	70	N	N	N	N	NR
248	1467574	451	US	2/21/2023	77	F	N	2/21/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	2/21/2023	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	10.3	19.4	93	N	N	N	N	NR
250	1466897	453	TS	2/22/2023	45	M	N	2/20/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	2/22/2023	Y	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	10.4	11.8	79.4	N	N	N	N	NR
251	1453213	454	MS	2/22/2023	58	M	N	1/28/2023	WARD	CARDIOVASCULAR DISEASE	SERUM	2/22/2023	N	Y	Y	Y	N	N	N	N	N	N	N	N	N	N	N	10.6	11	89.2	Y	N	N	N	NR
252	1461795	455	MM	2/22/2023	62	M	N	2/12/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	2/22/2023	N	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	10	19	93	N	Y	Y	N	NR
254	1312232	430	SK	2/20/2023	52	F	N	2/18/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	2/20/2023	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	11.9	6.5	55	N	N	N	N	NR
255	1464646	432	AS	2/20/2023	52	M	N	2/16/2023	ICU	GASTROINTESTINAL TRACT DISEASE	SERUM	2/20/2023	N	N	N	N	N	Y	N	N	N	N	N	N	N	N	N	11.6	9.6	75.5	N	N	N	N	NR

S. no	MRD No.	Lab No	Distribution of clinical samples received	Fungal smear Positive for Hyaline Septate Fungal Hyphae	CANDIDA IN (BODY FLUIDS AND BLOOD CULTURE)	CANDIDA IN BODY FUILDS	FUNGAL CULTURE FOR ASPERGILLUS SPECIES	Fungal Cuture	GMSAASSAY	1-3 BDG	PTZ	ANTIFUNGAL	Heamo Dylasis	AUGMENTIN	MEROPENEM	Provisional diagnosis	Outcome	TOTAL EORTC PATIENTS	PROVEN	POSSIBLE	PROBABLE	NO INVASIVE ASPERGILLOSI
203	1480928	635	SPUTUM	Neg	-	-	Neg	NG	0.15	0.04	N	N	N	N	Y	CKD, DM, OLD KOCH'S, CAD,CLD	DISCHARGE ON REQUEST	N	N	N	N	Y
204	772501	634	SPUTUM	Neg	-	-	Neg	NG	0.1	0.03	N	N	N	N	N	HTN, LRTI, TYPE-2 DM	DISCHARGE ON REQUEST	N	N	N	N	Y
205	1476575	633	SPUTUM	Neg	-	-	Neg	NG	0.11	2.55	N	N	N	N	N	MASSIVE HEMOPTYSIS IN LEFT UPPER ZONE, THICK CAVITATORY LESION, HTN, TYPE-2 DM	DISCHARGE ON REQUEST	Y	N	Y	N	N
206	1353599	441	SPUTUM	Neg	-	-	Neg	NG	0.18	0.04	Y	Y	N	N	N	COPD, LRTI, TYPE-2 RF	DAMA	Y	N	Y	N	N
207	1397083	440	ASCITIC FLUID	Neg	-	-	Neg	NG	0.12	4	N	N	N	N	Y	SDH, (A/H/O- FALL) SAH	DISCHARGE ON REQUEST	N	N	N	N	Y
208	1461890	435	NR	NR	-	-	NR	NR	0.12	0.02	N	N	N	N	Y	CARDIOMEGALY WITH PERICARDIAL EFFUSION, LRTI, UTI, LV DYSFUNCTION	DISCHARGE ON REQUEST	N	N	N	N	Y
209	1459626	429	NR	NR	-	-	NR	NR	0.13	8.35	N	N	N	N	Y	CIRRHOSIS, PORTAL HTN	DISCHARGE	N	N	N	N	Y
210	1465237	428	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.86	-	N	N	N	N	Y	CIRRHOSIS, PORTAL HTN	EXPIRED	Y	N	Y	Y	N
211	422262	469	URINE	Neg	-	-	Neg	NG	0.16	0.03	N	N	Y	N	N	TYPE-2 DM, HTN, CA BREAST POST LEFT MASTECTOMY	EXPIRED	N	N	N	N	Y
212	1469076	470	SPUTUM	Neg	-	-	Neg	NG	0.1	-	Y	N	N	N	N	ACUTE RESPIRATORY DISTRESS SYNDROME	DISCHARGE	N	N	N	N	Y
214	96264	461	SPUTUM	Neg	-	-	Neg	CANDIDA	2.66	-	N	Y	N	N	Y	TYPE-2 DM, HTN, CAD, CKD, CLD, UTI, LRTI	DISCHARGE ON REQUEST	Y	N	Y	N	N
215	1468365	460	SPUTUM	Neg	-	-	Neg	NG	0.15	0.02	N	N	N	N	Y	INFECTIVE, LRTI	DISCHARGE	N	N	N	N	Y
216	1433990	459	NR	NR	-	-	NR	NR	0.16	0.02	N	N	N	N	Y	IVH	DISCHARGE	N	N	N	N	Y
218	430708	464	PLEURAL FLUID	Neg	-	-	Neg	NG	0.14	0.61	N	N	N	N	Y	CIRRHOSIS, PORTAL HTN	DISCHARGE	Y	N	Y	N	N
219	1466920	463	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.13	0.02	N	N	N	N	Y	IVH, CLD	DISCHARGE	Y	N	Y	N	N
220	1467606	462	NR	NR	-	-	NR	NR	0.1	2.4	N	N	N	N	Y	ACUTE PANCREATITIS	DISCHARGE	N	N	N	N	Y
221	1455822	290	NR	NR	-	-	NR	NR	0.79	-	N	Y	N	N	Y	DKA, LRTI, TYPE-2 RESPIRATORY FAILURE	DISCHARGE	N	N	N	N	Y
222	1455270	278	NR	NR	-	-	NR	NR	11	-	N	Y	N	N	Y	ACUTE PANCREATITIS, HCV REACTIVE	DISCHARGE	N	N	N	N	Y
223	1449776	283	NR	NR	-	-	NR	NR	0.76	0.03	N	Y	N	N	Y	DM, HTN, CKD	DISCHARGE	Y	N	Y	Y	N
224	1469107	489	SPUTUM	Neg	-	-	Neg	NG	0.12	4.78	N	Y	N	N	N	DM-2, COUGH	DAMA	N	N	N	N	Y
225	1470586	488	SPUTUM	Neg	-	-	Neg	CANDIDA	0.12	0.03	Y	N	N	N	N	LRTI WITH 5TH MONTH PREGNANCY	DISCHARGE ON REQUEST	N	N	N	N	Y
226	1238116	490	SPUTUM	Neg	-	-	Neg	NG	13.4	-	N	Y	N	N	N	CLD, JAUNDICE	DAMA	Y	N	Y	Y	N
227	1470595	492	NR	NR	-	-	NR	NR	0.11	0.05	N	N	N	N	Y	ACUTE PANCREATITIS, RIGHT PLEURAL EFFUSION	DISCHARGE	Y	N	Y	N	N
228	1460780	493	NR	NR	-	-	NR	NR	6.13	0.77	N	N	N	N	Y	CLD WITH PORTAL HTN	DISCHARGE	Y	N	Y	Y	N
229	1264042	486	NR	NR	-	-	NR	NR	0.11	0.04	N	N	N	N	Y	BA, NEPHRECTOMY RIGHT SIDE	DISCHARGE	N	N	N	N	Y
231	1459618	473	NR	NR	-	-	NR	NR	0.11	-	N	N	Y	N	Y	HTN WITH LEFT ECTOPIC KIDNEY, SEPSIS, LRTI	DISCHARGE ON REQUEST	N	N	N	N	Y
232	1457476	474	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.13	-	N	N	N	N	N	LRTI	DISCHARGE ON REQUEST	N	N	N	N	Y
233	1468971	476	SPUTUM	Neg	-	-	Neg	NG	0.11	-	N	Y	N	N	N	PNEUMONITIS	DAMA	N	N	N	N	Y
234	1469769	478	NR	NR	-	-	NR	NR	0.14	-	N	N	N	N	Y	PANCYTOPENIA	EXPIRED	Y	N	Y	N	N
235	1454456	479	SPUTUM	Neg	-	-	Neg	NG	0.66	0.02	N	Y	N	N	N	B/L CAVITATORY, OLD PULMONARY KOCH'S, DISCHARGE DATE LESION	DISCHARGE	Y	N	Y	Y	N
236	1470136	480	SPUTUM	Neg	-	-	Neg	NG	0.23	0.02	N	N	N	N	Y	LRTI WITH HTN	DISCHARGE	N	N	N	N	Y
237	1468990	482	NR	NR	-	-	NR	NR	0.15	0.02	N	Y	N	N	N	LRTI	DISCHARGE	N	N	N	N	Y
238	1470426	487	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	1.15	-	N	Y	N	N	N	DM, B/L PNEUMONITIS	DISCHARGE	Y	N	Y	Y	N
239	171401	483	NR	NR	-	-	NR	NR	0.11	0.02	N	N	N	N	N	CKD, CAD, FLUID OVERLOAD, ACUTE CKD	DISCHARGE	N	N	N	N	Y
241	1307932	485	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.16	-	N	N	N	N	Y	CKD	DISCHARGE	Y	N	Y	N	N
242	1468451	466	NR	NR	-	-	NR	NR	0.1	0.02	Y	N	N	N	N	TYPE-2 DM, HTN, RIGHT DIABETIC FOOT, INFECTION BRONCHOLITIS	EXPIRED	N	N	N	N	Y
245	1465367	447	SPUTUM	Neg	-	-	Neg	NG	0.11	-	Y	N	N	N	N	INFECTIOUS BRONCHIOLITS	DISCHARGE	N	N	N	N	Y
246	1464348	449	NR	NR	-	-	NR	NR	0.16	2.02	N	N	N	N	Y	PLEURAL EFFUSION	DISCHARGE	N	N	N	N	Y
247	577126	450	NR	NR	-	-	NR	NR	0.19	0.11	Y	Y	N	N	N	CAD, HTN, DM	DAMA	N	N	N	N	Y
248	1467574	451	NR	NR	-	-	NR	NR	0.12	-	Y	N	N	N	N	LRTI, HTN, DM	DAMA	N	N	N	N	Y
250	1466897	453	ASCITIC FLUID	Neg	-	-	Neg	NG	0.12	-	N	N	N	N	Y	CIRRHOSIS, PORTAL HTN	DISCHARGE	N	N	N	N	Y
251	1453213	454	SPUTUM	Neg	-	-	Neg	CANDIDA	0.12	-	N	N	N	Y	N	OLD TB REINFECTION	DISCHARGE	N	N	N	N	Y
252	1461795	455	SPUTUM	Neg	-	-	Neg	NG	0.12	-	N	N	N	N	Y	LRTI	DISCHARGE	N	N	N	N	Y
254	1312232	430	SPUTUM	Neg	-	-	Neg	NG	0.12	-	Y	N	N	N	N	ACUTE FIBRILE ILLNESS	DISCHARGE	N	N	N	N	Y
255	1464646	432	NR	NR	-	-	NR	NR	0.12	0.02	Y	N	N	N	N	CIRRJOSIS WITH PORTAL HTN, MILD ASCITES	DISCHARGE	N	N	N	N	Y

S. no	MRD No.	Lab No	NAME	DOR Sample	AGE	SEX	GMRepeat	DOA	AREA	SUB AREA WISE	Sample	DOR Sample	FEVER	COUGH	SOB	CHEST PAIN	DM	HTN	Alcoholic	Smoker	Neutropenia	TBHistory	Chronic steroid use	Solid organ transplantation	Malignancy	HIV	HCV	HB	TLC/DLC	NEUTROPHIL COUNT	CT CHEST _PLEURAL EFFUSION	CONSOLIDATION IN LUNG	CAVITATION	RETICULONODULAR OPACITIES	Histopathology for aspergillus species
256	1461058	433	PS	2/20/2023	43	M	N	2/10/2023	WARD	RENAL DISEASE	SERUM	2/20/2023	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	8.9	15.2	90.9	Y	N	N	N	NR
257	1462581	434	DL	2/20/2023	50	M	N	2/13/2023	WARD	CARDIOVASCULAR DISEASE	SERUM	2/20/2023	N	N	N	Y	N	N	N	N	N	N	N	N	N	N	N	13	11	74.4	N	N	N	N	NR
259	1458188	436	KL	2/20/2023	63	M	N	2/6/2023	ICU	RENAL DISEASE	SERUM	2/20/2023	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	8.1	29	80	N	N	N	N	NR
260	1466833	438	AK	2/20/2023	44	F	N	2/20/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	2/20/2023	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	9.7	4.04	75.5	N	N	N	N	NR
261	1464598	439	SK	2/20/2023	56	F	N	2/16/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	2/20/2023	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	9.3	10.6	75.1	Y	N	N	N	NR
262	1467394	491	BS	2/28/2023	75	M	N	2/21/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	2/28/2023	Y	Y	Y	N	N	N	N	N	N	N	Y	N	N	N	N	11.5	18	89.2	N	N	N	N	NR
263	1470554	495	BS	2/28/2023	40	M	N	2/26/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	2/28/2023	N	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	6.8	8.7	59.3	N	N	N	N	NR
264	1454781	497	SD	2/27/2023	45	F	N	2/26/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	2/27/2023	Y	Y	N	N	N	N	N	N	N	Y	Y	N	N	N	N	9.8	9.2	71.4	N	N	N	N	NR
265	1471421	496	SS	2/28/2023	69	M	N	2/28/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	2/28/2023	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	15	18	78.2	N	N	N	N	NR
266	153068	494	RM	2/28/2023	56	M	N	2/24/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	2/28/2023	Y	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	9.8	14	79	N	N	Y	N	NR
267	1457599	328	MP	2/9/2023	73	M	N	2/6/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	2/9/2023	N	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	10	9.6	90	N	N	N	N	NR
268	1463998	398	BS	2/16/2023	63	M	N	2/15/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	2/16/2023	Y	Y	N	N	Y	N	N	N	N	N	N	N	N	N	N	9.4	1.4	87	N	N	N	N	NR
269	1464093	399	NS	2/16/2023	60	M	P	2/16/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	2/16/2023	Y	N	Y	N	N	Y	N	N	N	Y	Y	N	N	N	Y	13	26	92	N	N	N	Y	NR
270	1462704	400	YJ	2/17/2023	66	F	N	2/14/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	2/17/2023	Y	Y	Y	N	Y	Y	N	N	N	N	N	N	N	N	N	13.6	17	84	N	N	N	Y	NR
271	1462348	401	KK	2/17/2023	73	M	N	2/13/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	2/17/2023	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	11	6.1	80.6	N	N	N	N	NR
272	1461882	402	NS	2/17/2023	31	M	N	2/12/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	2/17/2023	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	14	6.9	57.9	Y	N	N	N	NR
273	1464358	403	RS	2/17/2023	38	M	P	2/16/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	2/17/2023	N	N	N	N	N	N	N	N	N	N	Y	N	N	N	N	12	19	74	N	Y	N	N	NR
274	1460358	404	A	2/17/2023	20	M	N	2/10/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	2/17/2023	Y	N	N	N	N	N	N	N	N	N	Y	N	N	N	N	12.6	10.7	83.6	Y	N	N	N	NR
275	1353770	405	MS	2/17/2023	51	M	N	2/3/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	2/17/2023	N	N	N	N	N	Y	N	N	N	N	Y	N	N	N	N	10.3	9.5	71.8	N	Y	N	N	NR
276	1464704	406	RK	2/20/2023	60	F	N	2/17/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	2/20/2023	Y	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	11	19	79.9	N	N	N	N	NR
278	1463892	409	P	2/17/2023	42	M	N	2/15/2023	WARD	NEUROLOGICAL DISEASE	SERUM	2/17/2023	N	N	N	N	Y	N	N	N	N	Y	Y	N	N	N	N	14	9.11	78	N	N	N	N	NR
279	1461740	410	ZB	2/17/2023	47	F	N	2/11/2023	ICU	GENERAL SURGERY	SERUM	2/17/2023	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	8.9	11.6	87.2	Y	N	N	N	Normal
281	689555	412	PS	2/17/2023	44	M	N	2/14/2023	WARD	RENAL DISEASE	SERUM	2/17/2023	N	N	Y	N	Y	Y	N	N	N	N	N	N	N	N	N	9.5	6.6	92.7	N	Y	N	N	NR
282	761093	413	MS	2/17/2023	79	M	N	2/9/2023	ICU	CARDIOVASCULAR DISEASE	SERUM	2/17/2023	Y	N	Y	Y	Y	Y	N	N	N	N	N	N	N	N	N	9.4	33	83	N	N	N	N	NR
283	1455215	415	CK	2/18/2023	45	F	N	2/1/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	2/18/2023	Y	N	N	N	N	N	N	N	N	N	Y	N	N	N	Y	9.6	15	82.6	Y	N	N	N	NR
284	1001938	419	PK	2/18/2023	54	F	N	2/15/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	2/18/2023	N	Y	Y	N	N	Y	N	N	N	N	Y	N	N	N	N	11	13.1	90.5	N	N	N	N	NR
285	770752	446	MC	2/21/2023	81	M	N	2/20/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	2/21/2023	Y	Y	Y	N	Y	Y	N	N	N	N	N	N	N	N	N	11	10.7	86	N	N	N	Y	NR
286	1466703	445	BK	2/21/2023	35	F	N	2/20/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	2/21/2023	N	Y	Y	N	N	N	N	N	N	Y	N	N	N	N	N	13.1	23.9	94.5	N	N	N	N	NR
290	1441053	442	VS	2/11/2023	45	M	N	2/6/2023	WARD	RENAL DISEASE	SERUM	2/11/2023	Y	Y	N	N	N	N	N	N	N	N	N	Y	N	N	N	9	11	71.9	Y	N	N	N	NR
291	1458230	335	RM	2/9/2023	32	M	N	2/6/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	2/9/2023	Y	N	Y	N	N	N	N	N	N	N	Y	N	N	N	N	16.6	6	55	N	N	N	N	NR
293	1451747	321	JS	2/8/2023	46	M	N	2/3/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	2/8/2023	N	N	N	N	N	Y	N	N	N	N	N	N	N	N	N	6.6	10.2	73.5	Y	Y	N	N	NR
294	725714	322	PG	2/8/2023	80	F	N	2/2/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	2/8/2023	Y	N	N	N	Y	Y	N	N	N	N	Y	N	N	N	N	10	16	75	N	N	N	Y	NR
295	1457209	323	RK	2/20/2023	32	F	N	2/4/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	2/20/2023	N	N	N	N	N	N	N	N	N	N	Y	N	N	N	N	7.3	31	78	N	N	N	N	NR
296	1458848	326	KK	2/8/2023	60	F	N	2/7/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	2/8/2023	N	Y	Y	N	Y	Y	N	N	N	N	N	N	N	N	Y	8	15	80	N	N	N	N	NR
297	947738	320	NR	2/7/2023	80	M	N	1/27/2023	ICU	NEUROLOGICAL DISEASE	SERUM	2/7/2023	N	N	N	N	N	N	N	N	N	N	Y	N	N	N	N	7	11.4	89	Y	N	N	N	NR
298	1453318	319	KL	2/7/2023	84	M	N	1/29/2023	ICU	CARDIOVASCULAR DISEASE	SERUM	2/7/2023	N	N	N	Y	Y	Y	N	N	N	N	N	N	N	N	N	8.9	12.7	81.9	N	N	N	N	NR
299	1453251	339	BK	2/10/2023	50	F	P	1/29/2023	ICU	RENAL DISEASE	SERUM	2/10/2023	Y	N	N	N	N	N	N	N	N	N	Y	N	N	N	N	6.9	14	85	Y	N	N	N	NR
300	1452548	348	AS	2/11/2023	85	M	N	2/10/2023	WARD	RENAL DISEASE	SERUM	2/11/2023	Y	Y	N	N	N	N	N	N	N	N	N	Y	N	N	N	7.6	4.7	70.7	Y	N	N	N	NR
301	1458964	347	KS	2/11/2023	50	M	N	2/10/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	2/11/2023	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	N	12	7	66	Y	N	N	N	NR
302	654871	345	SK	2/10/2023	76	F	N	2/3/2023	WARD	RENAL DISEASE	SERUM	2/10/2023	N	Y	Y	N	N	N	N	N	N	N	N	Y	N	N	N	13	24	96.2	Y	N	N	N	NR
303	1450023	344	RR	2/10/2023	84	F	N	2/6/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	2/10/2023	N	Y	Y	N	Y	Y	N	N	N	N	Y	N	N	N	N	9.6	33	92	N	N	N	N	NR
304	1257592	346	PK	2/10/2023	61	M	N	2/9/2023	WARD	CARDIOVASCULAR DISEASE	SERUM	2/10/2023	N	Y	N	Y	Y	Y	N	N	N	N	N	N	N	N	N	11.6	15	68.1	N	N	N	N	NR
305	1457296	343	KK	2/10/2023	67	F	N	2/5/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	2/10/2023	Y	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	12	13	95	Y	N	N	N	NR
306	1460318	341	UK	2/10/2023	27	M	N	2/9/2023	WARD	CARDIOVASCULAR DISEASE	SERUM	2/10/2023	Y	Y	Y	Y	N	N	N	N	N	N	N	N	N	N	Y	5.6	21	53	N	N	N	N	NR

S. no	MRD No.	Lab No	Distribution of clinical samples received	Fungal smear Positive for Hyaline Septate Fungal Hyphae	CANDIDA IN (BODY FLUIDS AND BLOOD CULTURE)	CANDIDA IN BODY FUILDS	FUNGAL CULTURE FOR ASPERGILLUS SPECIES	Fungal Cuture	GMSAASSAY	1-3 BDG	PTZ	ANTIFUNGAL	Heamo Dylasis	AUGMENTIN	MEROPENEM	Provisional diagnosis	Outcome	TOTAL EORTC PATIENTS	PROVEN	POSSIBLE	PROBABLE	NO INVASIVE ASPERGILLOSI
256	1461058	433	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.1	-	Y	N	Y	N	N	PANCREATITIS	DISCHARGE	N	N	N	N	Y
257	1462581	434	NR	NR	-	-	NR	NR	0.12	0.02	N	N	N	N	Y	AFI, AKI	DISCHARGE	N	N	N	N	Y
259	1458188	436	SPUTUM	Neg	-	-	Neg	NG	0.05	0.22	N	N	N	N	N	AKI	DISCHARGE	N	N	N	N	Y
260	1466833	438	NR	NR	-	-	NR	NR	0.13	0.04	N	N	N	N	N	ACUTE FIBRILE ILLNESS	DAMA	N	N	N	N	Y
261	1464598	439	ASCITIC FLUID	Neg	-	-	Neg	NG	0.12	-	N	N	N	N	Y	CIRRHOSIS, PORTAL HTN	DAMA	N	N	N	N	Y
262	1467394	491	SPUTUM	Neg	-	-	Neg	NG	0.11	5	N	Y	N	N	Y	LRTI WITH PORTAL HTN, ARDS	DISCHARGE ON REQUEST	N	N	N	N	Y
263	1470554	495	NR	NR	-	-	NR	NR	0.12	1.7	N	N	N	N	Y	CLD WITH PORTAL HTN	DISCHARGE	N	N	N	N	Y
264	1454781	497	SPUTUM	Neg	-	-	Neg	NG	4.98	-	Y	Y	N	N	N	ABPA	DISCHARGE	Y	N	Y	N	N
265	1471421	496	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.21	-	N	N	N	N	Y	HEPATOMEGALY WITH FATTY LIVER	DISCHARGE	N	N	N	N	Y
266	153068	494	SPUTUM	Neg	-	-	Neg	NG	0.1	0.05	N	N	N	N	N	INFECTIOUS BRONCHIOLITIS	DISCHARGE	N	N	N	N	Y
267	1457599	328	SPUTUM	Neg	-	-	Neg	NG	0.14	-	N	N	N	N	N	COPD WITH NODULES B/L, CLD	DISCHARGE	N	N	N	N	Y
268	1463998	398	NR	NR	-	-	NR	NR	0.1	-	N	N	N	N	N	LRTI	DISCHARGE	N	N	N	N	Y
269	1464093	399	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	9.57	0.55	N	Y	Y	N	Y	OLD PULMONARY TB, HCV REACTIVE, COPD, FUNGAL SEPSIS, AKI	DAMA	Y	N	Y	Y	N
270	1462704	400	SPUTUM	Neg	-	-	Neg	NG	0.11	0.02	N	N	N	N	N	TYPE-2 DM, LRTI, INFECTIVE BRONCHIOLITS	DAMA	N	N	N	N	Y
271	1462348	401	NR	NR	-	-	NR	NR	0.11	0.55	N	N	N	N	Y	CAD WITH HTN, POST PPI	DAMA	N	N	N	N	Y
272	1461882	402	NR	NR	-	-	NR	NR	0.21	0.02	N	N	N	N	Y	ACUTE FIBRILIS ILLNESS WITH B/L PLEURAL EFFUSION	DISCHARGE	N	N	N	N	Y
273	1464358	403	NR	NR	-	-	NR	NR	0.52	0.02	N	Y	N	N	Y	ACUTE NECROTISING PANCREATITIS	DISCHARGE ON REQUEST	Y	N	Y	Y	N
274	1460358	404	NR	NR	-	-	NR	NR	0.11	0.04	N	N	N	N	N	ACUTE PANCREATITIS, MODERATE ASCITES, MODERATE PLEURAL EFFUSION	DAMA	Y	N	Y	N	N
275	1353770	405	NR	NR	-	-	NR	NR	6.23	0.51	N	Y	N	N	Y	CLD WITH PORTAL HTN	DISCHARGE	Y	N	Y	Y	N
276	1464704	406	SPUTUM	Neg	-	-	Neg	NG	0.12	0.04	N	Y	N	N	N	COPD, HYPORHYROIDISM, TYPE-2 RESPIRATORY FAILURE, INFECTIOUS BRONCHIOLITS	DISCHARGE ON REQUEST	N	N	N	N	Y
278	1463892	409	NR	NR	-	-	NR	NR	0.11	0.02	N	N	N	N	N	TYPE-2 DM, CERVICAL COMPRESSION, MYCLOPATHY	DISCHARGE	N	N	N	N	Y
279	1461740	410	NR	NR	-	-	NR	NR	0.11	0.02	N	N	N	N	Y	POST OPERATIVE COLECTOMY	DISCHARGE ON REQUEST	N	N	N	N	Y
281	689555	412	NR	NR	-	-	NR	NR	0.12	0.03	N	N	Y	N	Y	HTN, TYPE-2 DM, ACUTE CKD, FLUID OVERLOAD	DISCHARGE ON REQUEST	N	N	N	N	Y
282	761093	413	NR	NR	-	-	NR	NR	0.11	0.02	N	N	N	N	Y	TYPE-2 DM, UTI, CKD, HTN, RETINOPATHY	DISCHARGE	N	N	N	N	Y
283	1455215	415	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	CANDIDA	0.24	0.04	N	N	N	N	N	CLD WITH PORTAL HTN, HEPA. C REACTIVE, B/L PLEURAL EFFUSION, CMV INFECTION	DAMA	Y	N	Y	N	N
284	1001938	419	SPUTUM	Neg	-	-	Neg	CANDIDA	0.13	0.03	N	N	N	Y	N	HTN, BRONCHIAL ASTHMA, ABPA, LRTI, TYPE-2 RESPIRATORY FAILURE	DISCHARGE ON REQUEST	N	N	N	N	Y
285	770752	446	SPUTUM	Neg	-	-	Neg	NG	0.23	0.02	N	N	N	N	Y	LRTI	EXPIRED	N	N	N	N	Y
286	1466703	445	SPUTUM	P	-	-	P	ASPERGILLUS FLAVUS	0.18	8.14	N	Y	N	N	Y	OLD PULMONARY KOCH'S, ABPA, BRONCHIAL ASTHAMA	DISCHARGE	N	N	N	N	Y
290	1441053	442	NR	NR	-	-	NR	NR	0.02	0.11	N	N	N	N	Y	POS RENAL TRANSPLANT, B/L PLEURAL EFFUSION, PANCREATITIS	DISCHARGE	Y	N	Y	N	N
291	1458230	335	NR	NR	-	-	NR	NR	0.22	-	N	N	N	N	N	LEFT PNEUMONOTHORAX	DISCHARGE	N	N	N	N	Y
293	1451747	321	SPUTUM	Neg	-	-	Neg	NG	0.11	-	N	N	N	N	Y	CLD, SEVERE ANEMIA	DISCHARGE	N	N	N	N	Y
294	725714	322	SPUTUM	Neg	-	-	Neg	CANDIDA	0.12	-	N	Y	N	N	N	DM, RA, HTN, LRTI, CKD, UTI	EXPIRED	Y	N	Y	N	N
295	1457209	323	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.2	0.02	N	N	N	N	N	IVIG	DAMA	N	N	N	N	Y
296	1458848	326	NR	NR	-	-	NR	NR	0.17	-	N	N	N	N	Y	HTN, TYPE-2 DM, COPD, SEPSIS, LRTI, HCV REACTIVE	EXPIRED	N	N	N	N	Y
297	947738	320	NR	NR	-	-	NR	NR	1.11	0.12	N	Y	N	N	N	SDH	EXPIRED	Y	N	Y	Y	N
298	1453318	319	NR	NR	-	-	NR	NR	0.05	0.2	N	Y	N	N	Y	CAD, HTN, DM	DISCHARGE ON REQUEST	N	N	N	N	Y
299	1453251	339	SPUTUM	P	-	-	P	ASPERGILLUS FLAVUS	2.89	0.02	N	N	N	N	Y	FUNGAL SEPSIS, AKI	DISCHARGE ON REQUEST	Y	N	Y	Y	N
300	1452548	348	SPUTUM	Neg	-	-	Neg	CANDIDA	0.23	0.53	Y	N	Y	N	N	CKD	DAMA	Y	N	Y	N	N
301	1458964	347	NR	NR	-	-	NR	NR	0.2	-	N	N	N	N	N	CIRRHOSIS, PORTAL HTN, MODERATE ASCITES	DISCHARGE ON REQUEST	N	N	N	N	Y
302	654871	345	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	CANDIDA	8.05	0.03	N	N	N	N	Y	CKD, LRTI	DAMA	Y	N	Y	Y	N
303	1450023	344	SPUTUM	P	-	-	P	ASPERGILLUS FLAVUS	1.87	8.29	N	Y	N	N	Y	B/L MERAIC PATTERN	DISCHARGE	Y	N	Y	Y	N
304	1257592	346	NR	NR	-	-	NR	NR	0.11	-	N	N	N	N	N	CAD	DISCHARGE ON REQUEST	N	N	N	N	Y
305	1457296	343	SPUTUM	P	-	-	P	ASPERGILLUS FLAVUS	0.06	8.02	N	N	N	N	Y	LRTI, FUNGAL SEPSIS, RESPIRATORY FAILURE	DISCHARGE ON REQUEST	N	N	N	N	Y
306	1460318	341	NR	NR	-	-	NR	NR	0.11	0.02	N	N	N	N	Y	ANEMIA, HCV REACTIVE	DISCHARGE	N	N	N	N	Y

S. no	MRD No.	Lab No	NAME	DOR Sample	AGE	SEX	GMRepeat	DOA	AREA	SUB AREA WISE	Sample	DOR Sample	FEVER	COUGH	SOB	CHEST PAIN	DM	HTN	Alcoholic	Smoker	Neutropenia	TBHistory	Chronic steroid use	Solid organ transplantation	Malignancy	HIV	HCV	HB	TLC/DLC	NEUTROPHIL COUNT	CT CHEST _PLEURAL EFFUSION	CONSOLIDATION IN LUNG	CAVITATION	RETICULONODULAR OPACITIES	Histopathology for aspergillus species
307	1453195	337	AG	2/10/2023	56	M	N	1/28/2023	WARD	RENAL DISEASE	SERUM	2/10/2023	N	N	N	N	Y	N	N	N	N	N	N	N	N	N	N	7.6	14	81	N	N	N	N	NR
308	1458195	342	GK	2/10/2023	24	F	N	2/6/2023	ICU	CARDIOVASCULAR DISEASE	SERUM	2/10/2023	N	Y	N	Y	N	N	N	N	N	N	N	N	N	N	N	8.1	4.6	83	N	N	N	N	NR
309	1454615	338	D	2/10/2023	23	M	N	1/31/2023	WARD	NEUROLOGICAL DISEASE	SERUM	2/10/2023	Y	N	N	Y	N	N	N	N	N	N	N	N	N	N	N	13	11	88	Y	N	N	N	NR
310	219143	352	SS	2/11/2023	70	M	N	2/5/2023	ICU	CARDIOVASCULAR DISEASE	SERUM	2/11/2023	Y	Y	N	Y	Y	Y	N	N	N	N	N	N	N	N	N	8.7	14.2	84.7	Y	N	N	N	NR
311	218040	349	GC	2/11/2023	71	M	N	2/10/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	2/11/2023	Y	Y	N	N	Y	Y	N	N	N	Y	Y	N	N	N	N	9.7	12.2	80	N	Y	N	N	NR
312	1459679	350	HS	2/11/2023	34	M	N	2/9/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	2/11/2023	N	N	Y	N	Y	N	N	N	N	N	N	N	N	N	N	7.4	9.9	76	N	N	N	N	NR
313	1461574	351	BS	2/11/2023	65	M	N	2/11/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	2/11/2023	Y	Y	N	N	Y	N	N	N	N	N	N	N	N	N	N	11	31	96.7	N	N	Y	Y	NR
314	1461205	353	NS	2/11/2023	42	M	N	2/7/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	2/11/2023	N	Y	Y	N	Y	N	N	N	N	N	N	N	N	N	N	5.9	14	77	N	N	N	N	NR
315	440219	354	SP	2/11/2023	79	M	N	2/10/2023	ICU	CARDIOVASCULAR DISEASE	SERUM	2/11/2023	N	N	Y	Y	Y	Y	N	N	N	N	N	N	N	N	N	12	28	90	N	N	N	N	NR
317	1445865	325	KS	2/8/2023	53	M	N	1/28/2023	WARD	CARDIOVASCULAR DISEASE	SERUM	2/8/2023	Y	Y	N	Y	Y	N	N	N	N	N	N	N	N	N	N	12	8.5	61.6	N	N	N	N	Normal
318	923815	327	HS	2/9/2023	77	M	N	2/3/2023	ICU	CARDIOVASCULAR DISEASE	SERUM	2/9/2023	N	Y	Y	Y	N	Y	N	N	N	N	Y	N	N	N	N	14	15	65	N	N	N	N	NR
319	1273102	340	MS	2/10/2023	42	M	N	2/9/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	2/10/2023	Y	Y	N	N	Y	N	N	N	N	N	N	N	N	N	N	12	2.8	86	N	N	N	N	NR
320	60204	324	SK	2/8/2023	70	M	N	1/8/2023	ICU	RENAL DISEASE	SERUM	2/8/2023	N	N	N	N	Y	Y	N	N	N	N	N	N	N	N	N	11	10.3	69	N	N	N	N	NR
321	1457204	356	SK	2/4/2023	57	F	N	2/4/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	2/4/2023	N	N	Y	N	N	N	N	N	Y	N	Y	N	N	N	N	10	0.7	35.5	N	Y	N	N	Normal
322	1461019	357	LR	2/12/2023	65	F	N	2/10/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	2/12/2023	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	12	10	84	N	N	N	N	NR
323	1454063	358	DK	2/12/2023	30	M	N	1/30/2023	WARD	GENERAL SURGERY	SERUM	2/12/2023	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	10	26	84	Y	N	N	Y	NR
324	1456972	317	GK	2/7/2023	64	M	P	2/4/2023	ICU	CARDIOVASCULAR DISEASE	SERUM	2/7/2023	Y	Y	N	Y	N	N	N	N	N	N	Y	N	N	N	N	12	7.7	85.4	Y	Y	N	N	NR
325	1461651	355	MK	2/12/2023	59	M	N	2/11/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	2/12/2023	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	12.8	8.2	80.5	N	N	N	N	Normal
326	170028	385	VS	2/15/2023	59	F	N	2/11/2023	WARD	ONCOLOGICAL	SERUM	2/15/2023	Y	N	N	N	N	Y	N	N	N	N	N	N	N	N	N	6.5	4.9	70.4	N	N	N	N	NR
327	1424547	383	AK	2/15/2023	56	M	N	2/12/2023	WARD	NEUROLOGICAL DISEASE	SERUM	2/15/2023	Y	N	Y	N	N	N	N	N	N	Y	N	N	N	N	N	12	8.1	81	N	Y	N	N	NR
328	1463028	382	PR	2/15/2023	62	F	N	2/14/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	2/15/2023	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	N	5.3	1.3	69.4	N	N	N	N	Normal
329	1461041	381	MR	2/15/2023	31	M	N	2/10/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	2/15/2023	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	14	23	90	N	N	N	N	NR
330	1461815	380	MS	2/15/2023	48	M	N	2/12/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	2/15/2023	N	N	N	N	N	N	Y	N	N	N	N	N	N	N	N	11.8	11	79.2	N	N	N	N	NR
331	1460339	378	V	2/20/2023	60	M	N	2/10/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	2/20/2023	N	N	N	N	Y	N	Y	Y	N	Y	N	N	N	N	N	12.2	6.5	85.2	N	N	N	N	NR
332	298663	377	PK	2/14/2023	84	F	N	2/4/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	2/14/2023	Y	N	N	N	Y	Y	N	N	N	N	Y	N	N	N	N	8.8	12.2	83.9	N	N	N	N	NR
333	1462683	376	MK	2/14/2023	35	M	N	2/13/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	2/14/2023	Y	N	Y	N	N	N	N	N	N	N	N	N	N	N	N	10	11.8	67.2	N	N	N	Y	NR
334	1079693	373	SR	2/13/2023	33	F	N	2/8/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	2/13/2023	Y	N	N	N	N	N	N	N	N	N	Y	N	N	N	N	6.8	6.15	78.3	N	Y	Y	N	NR
335	1462699	386	AS	2/15/2023	43	M	N	2/13/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	2/15/2023	N	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	7.2	8.2	85.1	Y	Y	N	N	NR
336	78571	387	MS	2/15/2023	50	M	N	2/14/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	2/15/2023	Y	Y	N	N	N	Y	N	N	N	N	Y	N	N	N	N	14.2	9.5	75.6	N	N	N	N	NR
337	27034	359	SJ	2/13/2023	73	F	N	2/10/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	2/13/2023	N	Y	N	N	N	Y	N	N	N	N	Y	N	N	N	N	9.4	12.6	86	N	N	N	N	NR
338	1461867	361	VD	2/12/2023	64	F	N	2/12/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	2/12/2023	Y	N	Y	N	Y	N	N	N	N	N	N	N	N	N	N	7.6	8.4	68	N	N	N	N	NR
339	1443284	363	CR	2/13/2023	60	M	N	2/9/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	2/13/2023	Y	N	N	N	N	N	Y	N	N	N	N	N	N	N	N	9.8	7.6	79.5	N	N	N	N	NR
340	1461862	362	RK	2/12/2023	79	M	N	2/12/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	2/12/2023	Y	Y	Y	N	N	N	N	N	N	Y	N	N	N	N	N	9	10	90	N	N	N	N	NR
341	1460265	364	VK	2/13/2023	64	M	N	2/9/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	2/13/2023	Y	Y	Y	N	N	Y	N	N	N	N	N	N	N	N	N	11.5	11	65.5	N	N	N	N	NR
342	1461777	365	AS	2/12/2023	39	M	N	2/11/2023	WARD	RENAL DISEASE	SERUM	2/12/2023	Y	N	Y	N	N	N	N	N	N	N	N	N	N	N	N	8.5	6.5	80	N	N	N	N	NR
344	1458376	367	JS	2/13/2023	70	M	N	2/9/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	2/13/2023	N	Y	Y	N	Y	N	N	N	N	N	Y	N	N	N	N	10	16	87.2	N	Y	Y	N	NR
346	1461704	369	SK	2/13/2023	53	M	N	2/1/2023	WARD	CARDIOVASCULAR DISEASE	SERUM	2/13/2023	Y	Y	N	Y	N	Y	N	N	N	N	N	N	N	N	N	15	8	63	N	Y	N	Y	NR
347	666817	370	SR	2/15/2023	62	F	N	2/10/2023	WARD	RENAL DISEASE	SERUM	2/15/2023	N	N	N	N	Y	Y	N	N	N	N	N	N	N	N	N	11	22.1	92	N	N	N	N	NR
348	795193	332	HL	2/9/2023	70	M	N	2/4/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	2/9/2023	N	N	N	N	Y	Y	Y	N	N	N	N	N	N	N	N	9.6	31	84.2	N	N	N	N	NR
349	1331829	331	M	2/9/2023	56	F	N	2/5/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	2/9/2023	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	10	10	76	N	N	N	N	NR
350	1457293	329	UR	2/9/2023	50	F	N	2/5/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	2/9/2023	Y	Y	Y	N	Y	N	N	N	N	N	N	N	N	N	N	10	9	89	N	N	N	Y	NR
351	1461917	384	SS	2/15/2023	36	M	N	2/13/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	2/15/2023	Y	N	Y	N	N	N	N	N	N	N	N	N	N	N	N	11.6	9.8	88	N	N	N	Y	NR
352	1458882	372	VK	2/13/2023	23	F	N	2/7/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	2/13/2023	N	N	N	N	N	N	N	N	N	Y	N	N	N	N	N	7.5	17	94.2	N	Y	Y	N	NR
353	1460963	371	GS	2/13/2023	36	M	N	2/10/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	2/13/2023	N	N	N	N	N	N	Y	N	N	N	N	N	N	N	N	9.6	13.9	90.2	Y	N	N	N	NR
354	1258903	333	AK	2/2/2023	70	M	P	1/20/2023	ICU	CARDIOVASCULAR DISEASE	SERUM	2/2/2023	N	Y	N	Y	Y	N	N	N	N	N	N	N	N	N	N	12	10.2	73.8	N	N	N	N	NR
356	1458948	330	SJ	2/9/2023	30	M	P	2/7/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	2/9/2023	Y	Y	Y	N	N	Y	N	N	N	N	Y	N	N	N	N	12	14	81	N	N	N	N	NR

S. no	MRD No.	Lab No	Distribution of clinical samples received	Fungal smear Positive for Hyaline Septate Fungal Hyphae	CANDIDA IN (BODY FLUIDS AND BLOOD CULTURE)	CANDIDA IN BODY FUILDS	FUNGAL CULTURE FOR ASPERGILLUS SPECIES	Fungal Cuture	GMSAASSAY	1-3 BDG	PTZ	ANTIFUNGAL	Heamo Dylasis	AUGMENTIN	MEROPENEM	Provisional diagnosis	Outcome	TOTAL EORTC PATIENTS	PROVEN	POSSIBLE	PROBABLE	NO INVASIVE ASPERGILLOSI
307	1453195	337	NR	NR	-	-	NR	NR	0.19	-	N	N	N	N	N	CKD, DM, HTN, ACUTE PANCREATITIS, CHOLITIHISIS	DAMA	N	N	N	N	Y
308	1458195	342	PLEURAL FLUID	Neg	-	-	Neg	NG	4.74	3.94	Y	Y	N	N	N	FATTY LIVER,	DISCHARGE	N	N	N	N	Y
309	1454615	338	NR	NR	-	-	NR	NR	0.25	1.25	Y	N	N	N	N	ISCHAEMIC MYELOPATHY	DISCHARGE	N	N	N	N	Y
310	219143	352	SPUTUM	Neg	-	-	Neg	CANDIDA	0.11	0.03	N	N	N	N	Y	DM, HTN, OLD CVA	DISCHARGE	N	N	N	N	Y
311	218040	349	NR	NR	-	-	NR	NR	9	-	Y	Y	N	N	N	COPD, LARGE CONSOLIDATION, DM, HTN, PULMONARY KOCH'S	DAMA	Y	N	Y	Y	N
312	1459679	350	CSF	Neg	-	-	Neg	NG	0.16	1.64	Y	Y	N	N	N	DM, UTI, LRTI, BED SORES	DISCHARGE	N	N	N	N	Y
313	1461574	351	NR	NR	-	-	NR	NR	0.13	-	N	N	N	N	Y	BRONCHIOLITS	EXPIRED	N	N	N	N	Y
314	1461205	353	NASAL MUCOSA	P	-	-	P	ASPERGILLUS FLAVUS	0.11	9.13	N	Y	N	N	Y	DM-II	DISCHARGE	N	N	N	N	Y
315	440219	354	NR	NR	-	-	NR	NR	0.2	4.3	Y	Y	N	N	N	CAD	DISCHARGE	N	N	N	N	Y
317	1445865	325	TISSUE	Neg	-	-	Neg	NG	0.15	0.03	N	N	N	N	N	DM, CHOLILITHIASIS	DISCHARGE	N	N	N	N	Y
318	923815	327	SPUTUM	Neg	-	-	Neg	CANDIDA	0.18	-	N	N	N	N	N	HTN, COPD, LRTI	DISCHARGE	N	N	N	N	Y
319	1273102	340	NR	NR	-	-	NR	NR	1.36	-	N	Y	N	N	N	INFLUENZA	DISCHARGE	N	N	N	N	Y
320	60204	324	SPUTUM	Neg	-	-	Neg	NG	0.16	0.02	N	N	Y	N	Y	HTN, CKD, DM, OLD CVA, LRTI, UTI	DISCHARGE	N	N	N	N	Y
321	1457204	356	NR	NR	-	-	NR	NR	4.78	0.05	N	N	N	N	N	ARDS, HYPOTHYROIDISM, POST VIRAL PNEUMONIA	DAMA	Y	N	Y	Y	N
322	1461019	357	PLEURAL FLUID	Neg	-	-	Neg	NG	0.2	0.03	N	N	N	N	Y	CLD, PORTAL HTN, CHOLITHIASIS	DAMA	N	N	N	N	Y
323	1454063	358	PUS	Neg	-	-	Neg	NG	0.13	0.04	N	N	N	N	N	ACUTE PANCREATITIS, PLEURAL EFFUSION	DISCHARGE	N	N	N	N	Y
324	1456972	317	NR	NR	-	-	NR	NR	1.04	0.03	N	Y	N	N	N	DM, BRONCHIAL ASTHMA, CAD, AKI, CLD, SEPSIS, LEFT LOWER ZONE PNEUMONIA	DISCHARGE	Y	N	Y	Y	N
325	1461651	355	NR	NR	-	-	NR	NR	0.14	-	N	N	N	N	Y	ACUTE PROCTITIS	DISCHARGE	N	N	N	N	Y
326	170028	385	SPUTUM	Neg	-	-	Neg	NG	8.11	0.15	N	Y	N	N	N	HTN, LRTI, HTN	DISCHARGE	N	N	N	N	Y
327	1424547	383	NR	NR	-	-	NR	NR	0.12	0.02	N	Y	N	N	Y	OLD KOCH'S, RA, CRYPTOCOCAL MENINGITS	DISCHARGE	N	N	N	N	Y
328	1463028	382	NR	NR	-	-	NR	NR	0.11	-	N	Y	N	N	Y	AFI, ANEAMIA	DISCHARGE	N	N	N	N	Y
329	1461041	381	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.23	0.03	N	N	N	N	Y	CO2 INHALATION LUNG INJURY, ARDS	DISCHARGE	N	N	N	N	Y
330	1461815	380	ASCITIC FLUID	Neg	-	-	Neg	NG	0.17	0.03	N	N	N	N	Y	CIRRHOSIS, PORTAL HTN	DISCHARGE	N	N	N	N	Y
331	1460339	378	SPUTUM	Neg	-	-	Neg	NG	0.14	0.04	N	N	N	N	N	OLD KOCH'S, DM, COPD, LRTI, FLUID OVERLOAD	DISCHARGE	N	N	N	N	Y
332	298663	377	SPUTUM	Neg	-	-	Neg	CANDIDA	0.19	0.04	N	N	N	N	Y	CLD, HTN, DM, BRONCHIAL ASTHMA	DISCHARGE	N	N	N	N	Y
333	1462683	376	NR	NR	-	-	NR	NR	0.12	0.03	N	N	N	N	N	LRTI, DM	DISCHARGE	N	N	N	N	Y
334	1079693	373	PUS	Neg	-	-	Neg	NG	0.94	-	Y	N	N	N	N	ANEAMIA PNEUMONIA, CAVITATION	DISCHARGE	Y	N	Y	Y	N
335	1462699	386	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	CANDIDA	0.14	0.93	Y	N	N	N	N	LRTI	DAMA	N	N	N	N	Y
336	78571	387	SPUTUM	Neg	-	-	Neg	NG	0.13	-	Y	N	N	N	N	HTN, COPD, ACUTE EXACRBATION	DISCHARGE ON REQUEST	N	N	N	N	Y
337	27034	359	SPUTUM	Neg	-	-	Neg	NG	0.14	0.02	N	N	N	Y	N	HTN, LRTI, FUNGAL SEPSIS	DAMA	N	N	N	N	Y
338	1461867	361	SPUTUM	Neg	-	-	Neg	NG	0.24	-	N	Y	N	N	N	LRTI FUNGAL, UTI, DM, SMALL RIGHT KIDNEY	DAMA	N	N	N	N	Y
339	1443284	363	NR	NR	-	-	NR	NR	0.11	9.02	N	N	N	N	N	CLD WITH PORTAL HTN	DISCHARGE ON REQUEST	N	N	N	N	Y
340	1461862	362	SPUTUM	Neg	-	-	Neg	NG	0.17	-	N	N	N	N	N	POST COVID, ILD, PULMONARY KOCH'S	DISCHARGE	N	N	N	N	Y
341	1460265	364	ASCITIC FLUID	Neg	-	-	Neg	NG	0.19	1.31	N	N	N	N	Y	CLD WITH PORTAL HTN	EXPIRED	N	N	N	N	Y
342	1461777	365	NR	NR	-	-	NR	NR	0.17	0.02	N	N	Y	N	N	SAH	DAMA	N	N	N	N	Y
344	1458376	367	SPUTUM	Neg	-	-	Neg	CANDIDA	0.13	-	N	N	N	Y	N	DM, OSA, RIGHT CAVITATORY LESION, TB	DISCHARGE	Y	N	Y	N	N
346	1461704	369	SPUTUM	Neg	-	-	Neg	NG	0.15	0.02	N	N	N	N	Y	CAD, HTN, DM, DENGUE, AKI	DISCHARGE	N	N	N	N	Y
347	666817	370	NR	NR	-	-	NR	NR	0.17	0.02	N	N	Y	N	Y	TYPE-2 DM, CAD, SHOCK	DISCHARGE	N	N	N	N	Y
348	795193	332	ASCITIC FLUID	Neg	-	-	Neg	NG	0.12	0.04	N	N	N	N	Y	CLD, PORTAL HTN	DISCHARGE	N	N	N	N	Y
349	1331829	331	NR	NR	-	-	NR	NR	0.11	-	N	N	N	N	Y	EBV	DISCHARGE	N	N	N	N	Y
350	1457293	329	NR	NR	-	-	NR	NR	0.14	-	N	N	N	N	N	TYPE-2 DM, LRTI, HYPOTHYROIDISM	DISCHARGE	N	N	N	N	Y
351	1461917	384	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.13	-	N	N	N	N	Y	SEPSIS SHOCK, AKI, ARDS	DAMA	N	N	N	N	Y
352	1458882	372	NR	NR	-	-	NR	NR	0.13	0.03	N	N	N	N	N	TB, MILD PLEURAL EFFUSION	DISCHARGE ON REQUEST	N	N	N	N	Y
353	1460963	371	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.03	-	N	Y	N	N	N	ACUTE PANCREATITIS, B/L PLEURAL EFFUSION, VAP	DISCHARGE ON REQUEST	N	N	N	N	Y
354	1258903	333	SPUTUM	Neg	-	-	Neg	NG	0.62	0.07	N	N	N	N	N	TYPE-2 DM, CAD, HYPOTHYROIDISM	DISCHARGE	N	N	N	N	Y
356	1458948	330	SPUTUM	Neg	-	-	Neg	NG	1.5	-	N	Y	N	Y	N	ABPA, BRONCHIOLITS	DISCHARGE	Y	N	Y	N	N

S. no	MRD No.	Lab No	NAME	DOR Sample	AGE	SEX	GMRepeat	DOA	AREA	SUB AREA WISE	Sample	DOR Sample	FEVER	COUGH	SOB	CHEST PAIN	DM	HTN	Alcoholic	Smoker	Neutropenia	TBHistory	Chronic steroid use	Solid organ transplantation	Malignancy	HIV	HCV	HB	TLC/DLC	NEUTROPHIL COUNT	CT CHEST _PLEURAL EFFUSION	CONSOLIDATION IN LUNG	CAVITATION	RETICULONODULAR OPACITIES	Histopathology for aspergillus species
357	1304721	318	PA	2/7/2023	71	F	N	2/12/2023	WARD	RENAL DISEASE	SERUM	2/7/2023	N	N	N	N	Y	Y	N	N	N	N	N	N	N	N	N	9.9	14	86	Y	N	N	N	NR
358	930140	426	RR	2/19/2023	57	F	N	2/4/2023	ICU	CARDIOVASCULAR DISEASE	SERUM	2/19/2023	N	Y	Y	Y	Y	Y	N	N	N	N	Y	N	N	N	N	13.9	13	94	N	N	N	N	NR
359	1462660	425	SS	2/19/2023	30	M	N	2/13/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	2/19/2023	Y	Y	Y	N	N	N	N	N	N	N	Y	N	N	N	N	18.2	15.1	95	N	Y	N	N	NR
360	1464082	424	RR	2/18/2023	56	F	P	2/15/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	2/18/2023	N	Y	Y	N	N	Y	N	N	N	N	Y	N	N	N	N	12	14.3	86.9	N	Y	Y	N	NR
361	1465859	423	MR	2/19/2023	71	M	P	2/15/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	2/19/2023	Y	Y	N	N	Y	N	N	N	N	N	Y	N	N	N	N	13.7	7.4	50.6	N	Y	N	N	NR
362	1430451	422	GS	2/18/2023	40	M	N	2/12/2022	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	2/18/2023	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	10.7	37	72.2	Y	Y	N	Y	NR
364	1464628	416	JN	2/18/2023	61	M	N	2/16/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	2/18/2023	Y	Y	Y	N	N	N	N	N	N	N	Y	N	N	N	N	8.3	10.4	78.9	N	Y	Y	N	NR
365	655203	309	ND	2/6/2023	60	F	N	1/25/2023	ICU	GASTROINTESTINAL TRACT DISEASE	SERUM	2/6/2023	N	N	N	N	N	N	N	N	N	N	Y	N	N	N	N	11.9	16.5	94.2	Y	N	N	N	NR
367	1451849	267	D	2/2/2023	61	M	N	1/26/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	2/2/2023	Y	N	N	N	Y	Y	N	N	N	N	N	N	N	N	N	8.2	3.3	86	N	N	N	N	NR
369	1455164	289	GK	2/1/2023	50	F	N	2/1/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	2/1/2023	Y	Y	Y	N	Y	Y	N	N	N	N	N	N	N	N	N	10	10	89	N	Y	N	N	NR
370	1453330	286	AC	2/2/2023	74	M	N	1/29/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	2/2/2023	Y	N	Y	N	Y	Y	N	N	N	N	Y	N	N	N	N	15.1	5.9	68.6	N	Y	N	N	NR
372	1464056	396	MK	2/16/2023	65	F	P	2/15/2023	WARD	CARDIOVASCULAR DISEASE	SERUM	2/16/2023	Y	Y	N	Y	Y	Y	N	N	N	N	N	N	N	N	N	8.3	24	92.2	N	N	Y	N	NR
377	1414496	443	D	2/21/2023	28	F	N	2/20/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	2/21/2023	Y	Y	N	N	Y	N	N	N	N	N	N	N	N	N	N	7.1	15	91	N	N	Y	N	NR
378	1466098	456	PK	2/22/2023	54	M	N	2/20/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	2/22/2023	Y	Y	N	N	N	Y	N	N	N	N	N	N	N	N	N	13	16	84	N	N	N	N	NR
379	224537	457	AS	2/22/2023	58	M	N	2/20/2023	WARD	RENAL DISEASE	SERUM	2/22/2023	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	9.2	9.3	75.2	Y	N	N	N	NR
380	988101	444	YP	2/21/2023	64	M	N	2/14/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	2/21/2023	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	8.4	4.74	78	N	N	N	N	NR
388	1450638	275	VM	2/1/2023	70	M	N	1/24/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	2/1/2023	Y	Y	Y	N	N	Y	N	N	N	N	N	N	N	N	N	10	6.7	81	N	N	N	N	NR
390	1454013	272	GK	2/1/2023	35	F	N	1/30/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	2/1/2023	Y	Y	Y	N	N	N	N	N	N	N	Y	N	N	N	N	10.6	8.4	93	N	N	N	N	NR
391	1240174	269	AR	1/31/2023	55	F	N	1/24/2023	WARD	CARDIOVASCULAR DISEASE	SERUM	1/31/2023	Y	N	Y	Y	N	N	N	N	N	N	N	N	N	N	N	10	17	87	N	N	N	N	NR
392	1452542	271	SG	2/1/2023	65	M	N	1/27/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	2/1/2023	N	N	Y	N	Y	Y	N	N	N	Y	N	N	N	N	N	8	27	87.5	N	Y	N	Y	NR
393	1457350	310	BP	2/6/2023	33	M	N	2/5/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	2/6/2023	N	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	14	19.9	66	N	Y	N	Y	NR
394	1440380	268	V	1/31/2023	30	M	N	1/29/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	1/31/2023	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	10	17	80	N	N	N	N	NR
395	1409536	308	MS	2/6/2023	88	M	N	2/5/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	2/6/2023	N	Y	Y	N	Y	Y	N	N	N	N	N	N	N	N	N	9.6	11	94	N	N	N	N	NR
396	1250705	390	RL	2/16/2023	68	M	N	2/11/2023	WARD	RENAL DISEASE	SERUM	2/16/2023	Y	N	Y	N	Y	N	N	N	N	N	N	N	N	N	N	10	13	87	N	Y	N	N	NR
397	81977	313	RK	2/8/2023	30	F	N	2/5/2023	WARD	ONCOLOGICAL	SERUM	2/8/2023	N	Y	Y	N	N	N	N	N	N	N	N	N	Y	N	N	9.4	12	70	N	N	N	N	NR
398	1461715	417	HS	2/18/2023	65	M	N	2/11/2023	WARD	RENAL DISEASE	SERUM	2/18/2023	N	N	Y	N	Y	N	N	N	N	N	N	N	N	N	N	10	25	85	N	N	N	N	NR
399	1455194	295	SK	2/4/2023	80	F	N	2/1/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	2/4/2023	N	Y	Y	N	N	Y	N	N	N	N	N	N	N	N	N	9.5	17	82	N	N	N	Y	NR
400	1456283	297	JS	2/4/2023	24	M	N	2/3/2023	WARD	RENAL DISEASE	SERUM	2/4/2023	Y	N	Y	N	N	N	N	N	N	N	N	N	N	N	N	11	13	89	N	Y	N	Y	NR
401	1457242	301	J	2/4/2023	71	M	N	2/4/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	2/4/2023	N	N	Y	N	N	N	N	N	N	N	N	N	N	N	N	12	17	84	N	N	N	N	NR
402	1454626	273	JS	2/1/2023	56	M	N	1/31/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	2/1/2023	N	N	N	N	N	N	Y	N	N	N	N	N	N	N	N	10	16	83	N	Y	N	N	NR
404	1464198	397	UR	2/16/2023	71	F	N	2/16/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	2/16/2023	Y	N	Y	N	N	N	N	N	N	N	N	N	N	N	N	12	5.1	83.1	N	N	N	N	NR
406	50716	307	SK	2/5/2023	45	M	N	2/4/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	2/5/2023	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	10	17	89	Y	N	N	N	NR
407	1314462	421	BR	2/18/2023	61	M	N	2/11/2023	ICU	NEUROLOGICAL DISEASE	SERUM	2/18/2023	N	N	Y	N	Y	Y	N	N	N	N	N	N	N	N	N	8.9	7.8	74.9	N	Y	N	N	NR
408	1450577	306	HS	2/5/2023	50	M	N	1/24/2023	ICU	NEUROLOGICAL DISEASE	SERUM	2/5/2023	N	N	N	N	N	N	N	N	N	N	Y	N	N	N	N	10	11	79	N	N	N	N	NR
410	1400823	395	GK	2/15/2023	47	F	N	2/13/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	2/15/2023	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	10.2	14.4	63.3	N	N	N	N	NR
411	1287379	392	HK	2/16/2023	60	F	N	2/12/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	2/16/2023	N	Y	Y	N	Y	Y	N	N	N	N	Y	N	N	N	N	11.6	15	88.3	N	Y	N	N	NR
412	1448485	174	R	1/21/2023	33	M	N	1/19/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	1/21/2023	Y	Y	N	N	N	N	Y	Y	N	N	N	N	N	N	N	17.5	12.9	62	N	N	N	Y	NR
413	1434902	213	OP	1/24/2023	67	M	N	1/24/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	1/24/2023	N	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	15	13	70	N	N	N	N	NR
414	1448493	166	HS	1/24/2023	60	M	N	1/19/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	1/24/2023	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	7	12	94.4	N	N	N	N	NR
415	1450104	214	AM	1/25/2023	60	M	N	1/23/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	1/25/2023	Y	N	Y	N	Y	N	N	N	N	N	N	N	N	N	N	7	3.6	89.8	N	N	N	Y	NR
416	148798	12	NW	1/1/2023	40	M	N	12/29/2022	ICU	CARDIOVASCULAR DISEASE	SERUM	1/1/2023	N	N	Y	Y	N	N	N	N	N	N	N	N	N	N	N	8.6	3.9	78.4	N	N	N	N	NR
417	1440361	26	GK	1/3/2023	50	F	N	1/2/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	1/3/2023	N	N	Y	N	Y	Y	N	N	N	Y	N	N	N	N	N	8.9	18	88	N	Y	Y	N	NR
418	1439262	86	AS	1/10/2023	63	M	N	12/29/2022	WARD	GENERAL SURGERY	SERUM	1/10/2023	N	N	N	N	Y	Y	N	N	N	N	N	N	N	N	N	11.8	35	94.4	Y	N	N	N	NR
420	1443139	89	KK	1/10/2023	57	F	N	1/6/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	1/10/2023	Y	N	Y	N	Y	Y	N	N	N	N	Y	N	N	N	N	6.8	6.4	72	Y	N	N	N	NR
421	1325376	90	SK	1/10/2023	38	F	N	1/10/2023	ICU	CARDIOVASCULAR DISEASE	SERUM	1/10/2023	Y	N	Y	Y	N	N	N	N	N	N	Y	N	N	N	N	7.2	14	80	N	N	N	N	NR
423	1107358	92	SK	1/11/2023	70	F	P	1/4/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	1/11/2023	Y	Y	Y	N	Y	Y	N	N	N	N	Y	N	N	N	N	5.7	3.9	89	Y	N	N	N	NR
424	991672	94	JS	1/11/2023	38	M	N	1/7/2023	WARD	RENAL DISEASE	SERUM	1/11/2023	Y	N	N	N	Y	Y	N	N	N	N	N	N	N	N	Y	8	19	94	N	N	N	Y	NR

S. no	MRD No.	Lab No	Distribution of clinical samples received	Fungal smear Positive for Hyaline Septate Fungal Hyphae	CANDIDA IN (BODY FLUIDS AND BLOOD CULTURE)	CANDIDA IN BODY FUILDS	FUNGAL CULTURE FOR ASPERGILLUS SPECIES	Fungal Cuture	GMSAASSAY	1-3 BDG	PTZ	ANTIFUNGAL	Heamo Dylasis	AUGMENTIN	MEROPENEM	Provisional diagnosis	Outcome	TOTAL EORTC PATIENTS	PROVEN	POSSIBLE	PROBABLE	NO INVASIVE ASPERGILLOSI
357	1304721	318	NR	NR	-	-	NR	NR	0.21	0.04	N	N	Y	N	Y	CKD, DM	DISCHARGE	N	N	N	N	Y
358	930140	426	NR	NR	-	-	NR	NR	0.68	0.02	N	N	N	N	Y	COPD, LRTI, HTN	DISCHARGE	Y	N	Y	N	N
359	1462660	425	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	2.17	0.02	N	N	N	N	N	SDH	DISCHARGE ON REQUEST	Y	N	Y	Y	N
360	1464082	424	SPUTUM	Neg	-	-	Neg	NG	0.94	0.04	N	Y	N	N	N	HTN, ABPA, WOUND SEPSIS, CAVITATORY CONSOLIDATION IN B/L LUNGS	DISCHARGE ON REQUEST	Y	N	Y	Y	N
361	1465859	423	NR	NR	-	-	NR	NR	15.07	-	N	Y	N	N	N	AFI, LRTI	DISCHARGE ON REQUEST	Y	N	Y	Y	N
362	1430451	422	PER CUTANEOUS DRAIN	Neg	-	-	Neg	NG	0.21	0.03	N	N	N	N	N	ACUTE PANCREATITIS, LEFT PLEURAL EFFUSION	DISCHARGE	N	N	N	N	Y
364	1464628	416	SPUTUM	Neg	-	-	Neg	CANDIDA	1.29	0.02	N	Y	N	N	Y	COPD, BRONCHIOLITS	DAMA	Y	N	Y	Y	N
365	655203	309	PLEURAL FLUID	Neg	-	-	Neg	NG	0.5	0.02	N	Y	N	N	N	ACUTE PANCREATITIS, MILD ASCITES	DISCHARGE ON REQUEST	Y	N	Y	Y	N
367	1451849	267	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.23	0.03	N	N	N	N	N	COPD, CKD	DAMA	N	N	N	N	Y
369	1455164	289	NR	NR	-	-	NR	NR	0.76	0.02	N	Y	N	N	N	INFECTIOUS ETIOLOGY	DISCHARGE	N	N	N	N	Y
370	1453330	286	NR	NR	-	-	NR	NR	0.76	-	N	N	N	N	Y	COPD, CKD	DISCHARGE	Y	N	Y	Y	N
372	1464056	396	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	10.42	0.02	N	Y	N	N	Y	LRTI, HTN, DM	DISCHARGE	Y	N	Y	Y	N
377	1414496	443	NR	NR	-	-	NR	NR	0.1	-	N	N	N	N	N	TUBERCULAR PULMONARY	DISCHARGE	N	N	N	N	Y
378	1466098	456	SPUTUM	Neg	-	-	Neg	NG	0.13	0.04	Y	N	N	N	Y	HTN, COPD, LRTI	DISCHARGE	N	N	N	N	Y
379	224537	457	NR	NR	-	-	NR	NR	0.02	0.02	N	N	N	N	Y	DM, HTN, CKD	DISCHARGE	N	N	N	N	Y
380	988101	444	NR	NR	-	-	NR	NR	0.14	0.03	N	N	N	N	Y	CIRRHOSIS, PORTAL HTN	DAMA	N	N	N	N	Y
388	1450638	275	SPUTUM	Neg	-	-	Neg	NG	0.13	0.85	N	Y	N	N	Y	HTN, COPD, LRTI, FUNGAL SEPSIS	DISCHARGE ON REQUEST	N	N	N	N	Y
390	1454013	272	SPUTUM	Neg	-	-	Neg	NG	0.13	-	N	Y	N	N	N	LRTI, FUNGAL SEPSIS	DAMA	N	N	N	N	Y
391	1240174	269	NR	NR	-	-	NR	NR	1.52	1.23	N	Y	N	N	Y	CAG, TVD	DAMA	N	N	N	N	Y
392	1452542	271	SPUTUM	Neg	-	-	Neg	NG	0.23	-	N	N	N	N	Y	TYPE-2 DM, HTN, OLD KOCH'S, CKD	DISCHARGE ON REQUEST	N	N	N	N	Y
393	1457350	310	SPUTUM	Neg	-	-	Neg	NG	0.11	0.03	N	N	N	N	N	B/L PNEUMONITS	DISCHARGE	N	N	N	N	Y
394	1440380	268	ASCITIC FLUID	Neg	-	-	Neg	NG	0.22	-	N	N	N	N	Y	GALL BLADDER SLUDGE, MILD ASCITES	DISCHARGE	N	N	N	N	Y
395	1409536	308	SPUTUM	Neg	-	-	Neg	NG	0.16	-	Y	N	N	N	N	TYPE-2 DM, HTN, OLD CVA, LRTI	DISCHARGE ON REQUEST	N	N	N	N	Y
396	1250705	390	NR	NR	-	-	NR	NR	0.17	1.31	N	Y	Y	N	Y	LRTI	DISCHARGE	N	N	N	N	Y
397	81977	313	SPUTUM	Neg	-	-	Neg	NG	0.14	0.03	N	N	N	N	N	CARCINOMA RIGHT BREAST, LRTI	DISCHARGE	N	N	N	N	Y
398	1461715	417	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.18	0.03	N	N	Y	N	Y	DM, SEPSIS, SHOCK, CKD, UTI	DISCHARGE	N	N	N	N	Y
399	1455194	295	SPUTUM	Neg	-	-	Neg	NG	0.03	-	N	Y	N	N	Y	LRTI, HTN,	DISCHARGE	N	N	N	N	Y
400	1456283	297	NR	NR	-	-	NR	NR	0.1	0.02	N	N	Y	N	Y	CKD, MAXILLARY SINUSITS	DISCHARGE	N	N	N	N	Y
401	1457242	301	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	3.99	-	N	N	N	N	N	RENAL PARINCHYMAL CHANGES	DISCHARGE	N	N	N	N	Y
402	1454626	273	SPUTUM	Neg	-	-	Neg	NG	0.18	0.03	N	N	N	N	Y	DM, LRTI, TB	DISCHARGE ON REQUEST	N	N	N	N	Y
404	1464198	397	NR	NR	-	-	NR	NR	0.1	-	N	N	N	N	N	HTN, COPD, LRTI SEPSIS	DAMA	N	N	N	N	Y
406	50716	307	PLEURAL FLUID	Neg	-	-	Neg	NG	0.11	0.03	N	N	N	N	Y	CIRRHOSIS, PORTAL HTN	DISCHARGE	N	N	N	N	Y
407	1314462	421	SPUTUM	Neg	-	-	Neg	NG	0.14	9.18	N	Y	N	N	Y	TYPE-2 DM, HTN, CAD, CKD, HYPOTHYROIDISM	DISCHARGE	N	N	N	N	Y
408	1450577	306	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.82	0.02	N	Y	N	N	Y	ROAD SIDE ACCIDENT, HEAD INJURY	DISCHARGE	Y	N	Y	N	N
410	1400823	395	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.13	0.02	N	N	N	N	Y	FATTY LIVER,	DAMA	N	N	N	N	Y
411	1287379	392	SPUTUM	Neg	-	-	Neg	NG	0.1	-	N	N	N	N	N	COPD, DM, HTN, LRTI SEPSIS	DISCHARGE	Y	N	Y	N	N
412	1448485	174	NR	NR	-	-	NR	NR	0.15	-	N	Y	N	N	N	SMOKER	DISCHARGE	N	N	N	N	Y
413	1434902	213	SPUTUM	Neg	-	-	Neg	NG	0.12	0.04	Y	N	N	N	N	CAD, POST PTCA	DISCHARGE	N	N	N	N	Y
414	1448493	166	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.1	-	N	N	N	N	N	PNEUMONITIS	DISCHARGE	N	N	N	N	Y
415	1450104	214	SPUTUM	Neg	-	-	Neg	NG	0.23	0.05	Y	N	N	N	Y	CLD	DISCHARGE	N	N	N	N	Y
416	148798	12	PERICARDIAL FLUID	Neg	-	-	Neg	NG	0.5	0.04	N	Y	N	N	N	CAD, LRTI, ASPIRATION PNEUMONIA	DISCHARGE	N	N	N	N	Y
417	1440361	26	NR	NR	-	-	NR	NR	3.64	0.03	N	Y	N	N	Y	LRTI, ON ATT	DISCHARGE	N	N	N	N	Y
418	1439262	86	PERITONEAL FLUID	Neg	-	-	Neg	NG	0.73	0.02	N	Y	N	N	Y	PLEURAL EFFUSION	DISCHARGE	N	N	N	N	Y
420	1443139	89	PLEURAL FLUID	Neg	-	-	Neg	NG	0.13	0.03	N	N	N	N	N	PLEURAL EFFUSION	DISCHARGE	Y	N	Y	N	N
421	1325376	90	NR	NR	-	-	NR	NR	0.56	3.1	N	Y	N	N	Y	ILD, INFECTION	DISCHARGE	N	N	N	N	Y
423	1107358	92	PLEURAL FLUID	Neg	-	-	Neg	NG	3.48	-	N	Y	N	N	Y	LEFT LUNG COLLAPSE	EXPIRED	N	N	N	N	Y
424	991672	94	NR	NR	-	-	NR	NR	0.19	0.02	N	N	Y	N	Y	HCV +VE, CKD	EXPIRED	N	N	N	N	Y

S. no	MRD No.	Lab No	NAME	DOR Sample	AGE	SEX	GMRepeat	DOA	AREA	SUB AREA WISE	Sample	DOR Sample	FEVER	COUGH	SOB	CHEST PAIN	DM	HTN	Alcoholic	Smoker	Neutropenia	TBHistory	Chronic steroid use	Solid organ transplantation	Malignancy	HIV	HCV	HB	TLC/DLC	NEUTROPHIL COUNT	CT CHEST _PLEURAL EFFUSION	CONSOLIDATION IN LUNG	CAVITATION	RETICULONODULAR OPACITIES	Histopathology for aspergillus species
425	333040	95	RK	1/11/2023	66	M	N	1/10/2023	WARD	RENAL DISEASE	SERUM	1/11/2023	Y	Y	N	N	N	N	N	N	N	N	Y	Y	N	N	N	11.4	14	77.4	N	N	N	N	NR
426	441899	96	JK	1/11/2023	52	F	N	1/5/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	1/11/2023	Y	N	N	N	N	N	N	N	N	Y	N	N	N	N	N	6.8	1.3	55	Y	N	N	N	NR
428	1433221	97	SC	1/11/2023	76	M	N	12/16/2022	ICU	CARDIOVASCULAR DISEASE	SERUM	1/11/2023	N	Y	Y	Y	N	Y	N	N	N	N	N	N	N	N	N	12	12	275	N	N	N	N	NR
429	1442294	98	AC	1/11/2023	29	F	N	1/30/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	1/11/2023	N	N	Y	Y	N	N	N	N	N	N	Y	N	N	N	N	11.9	10	74	N	N	N	Y	NR
430	1458965	99	MM	1/11/2023	68	M	N	1/8/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	1/11/2023	Y	N	Y	N	Y	Y	N	N	N	N	Y	N	N	N	N	10.7	16.2	87.4	N	N	N	N	NR
431	1387955	100	RR	1/11/2023	65	F	N	1/11/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	1/11/2023	N	N	Y	N	N	N	N	N	N	N	N	N	N	N	N	10	9.7	79.8	N	N	N	N	NR
432	1434974	101	PD	1/11/2023	74	F	N	1/11/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	1/11/2023	N	Y	Y	N	N	Y	N	N	N	N	N	N	N	N	N	12.7	5.8	62	N	N	N	N	NR
433	1443348	102	GC	1/12/2023	65	M	N	1/9/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	1/12/2023	Y	N	Y	N	N	N	N	N	N	N	N	N	N	N	N	11	4.3	79	N	N	N	N	NR
434	910947	103	RK	1/12/2023	79	M	N	1/2/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	1/12/2023	N	N	N	N	Y	Y	N	N	N	N	Y	N	N	N	N	10	12	74	N	N	N	Y	NR
435	1447989	105	NK	1/12/2023	38	F	N	1/11/2023	WARD	ACUTE FEBRILE ILLNESS	SERUM	1/12/2023	Y	N	Y	N	N	N	N	N	N	N	N	N	N	N	N	10.9	11.8	77.4	N	N	N	N	NR
436	1375334	106	JS	1/12/2023	48	M	N	1/7/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	1/12/2023	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	10	9.4	53	N	N	N	N	NR
437	443654	108	GK	1/12/2023	74	M	N	1/10/2023	WARD	RENAL DISEASE	SERUM	1/12/2023	N	N	N	N	Y	N	N	N	N	N	N	N	N	N	N	9.4	9.6	70	N	N	N	N	NR
439	1443319	107	SS	1/12/2023	53	M	N	1/8/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	1/12/2023	Y	N	Y	N	N	N	N	N	N	N	Y	N	N	N	N	9.8	33	92.7	N	N	N	N	NR
440	919458	108	GS	1/12/2023	40	M	N	1/3/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	1/12/2023	N	N	N	Y	N	N	Y	Y	N	N	N	N	N	N	N	11	83	70	N	N	N	N	NR
442	1202344	112	GK	1/13/2023	55	F	N	1/10/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	1/13/2023	Y	Y	N	N	N	N	N	N	N	N	Y	N	N	N	N	11	20	87	N	N	N	Y	NR
443	1445521	-	HS	1/14/2023	70	M	N	1/13/2023	WARD	ACUTE FEBRILE ILLNESS	SERUM	1/14/2023	Y	N	Y	N	N	N	N	N	N	N	N	N	N	N	N	12	1.55	66	N	N	N	N	NR
444	1445561	120	AR	1/15/2023	66	F	N	1/13/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	1/15/2023	Y	N	Y	N	Y	Y	N	N	N	N	N	N	N	N	N	10	25	96	N	Y	N	N	NR
445	1446755	134	KK	1/17/2023	56	F	N	1/16/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	1/17/2023	Y	Y	N	N	Y	N	N	N	N	N	N	N	N	N	N	10	7.5	77	N	N	N	N	NR
446	1439821	135	ML	1/17/2023	72	M	N	12/30/2022	ICU	CARDIOVASCULAR DISEASE	SERUM	1/17/2023	N	N	Y	Y	Y	Y	N	N	N	N	N	N	N	N	N	9.8	12.2	73	Y	Y	N	N	NR
447	1446719	136	PS	1/17/2023	84	M	N	1/16/2023	ICU	CARDIOVASCULAR DISEASE	SERUM	1/17/2023	Y	Y	Y	Y	Y	Y	N	N	N	N	N	N	N	N	N	9.2	10.8	88	N	N	N	N	NR
448	254495	148	KD	1/18/2023	83	F	N	1/12/2023	ICU	CARDIOVASCULAR DISEASE	SERUM	1/18/2023	N	N	N	Y	Y	Y	N	N	N	N	N	N	N	N	N	8.6	12.2	90	N	N	N	N	NR
449	1444297	151	AS	1/19/2023	27	M	N	1/10/2023	ICU	NEUROLOGICAL DISEASE	SERUM	1/19/2023	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	9.9	19	88	N	N	N	N	NR
450	1447474	152	NS	1/19/2023	70	M	N	1/17/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	1/19/2023	Y	Y	N	N	Y	N	N	N	N	Y	N	N	N	N	N	12	6.91	82.9	N	N	N	N	NR
451	1447879	155	AS	1/19/2023	51	M	P	1/18/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	1/19/2023	Y	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	10.7	17.6	87	N	N	N	N	NR
452	1440471	156	SK	1/19/2023	41	M	N	12/3/2022	ICU	RESPIRATORY TRACT DISEASE	SERUM	1/19/2023	N	Y	Y	N	Y	N	N	N	N	N	N	N	N	N	N	10	5.83	61	N	Y	N	N	NR
453	1447601	157	SS	1/19/2023	50	F	N	1/18/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	1/19/2023	Y	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	10	4.22	75	N	Y	N	Y	NR
454	936409	185	SP	1/22/2023	57	M	N	1/22/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	1/22/2023	N	Y	Y	N	N	N	N	N	N	Y	N	N	N	N	N	10.2	10.6	90	N	N	N	N	NR
455	1447856	159	SK	1/19/2023	36	F	N	1/18/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	1/19/2023	Y	Y	N	N	N	N	N	N	N	Y	Y	N	N	N	N	13	26	95	N	N	N	N	NR
457	1445494	194	MK	1/23/2023	66	F	N	1/13/2023	ICU	CARDIOVASCULAR DISEASE	SERUM	1/23/2023	N	Y	Y	Y	N	Y	N	N	N	N	N	N	N	N	N	9	13	90.1	Y	N	N	N	NR
458	1448727	195	ML	1/23/2023	63	M	N	1/20/2023	WARD	RENAL DISEASE	SERUM	1/23/2023	Y	Y	N	N	Y	N	N	N	N	N	N	N	N	N	N	8.1	5.8	57	N	N	N	N	NR
459	1445979	196	HK	1/23/2023	82	F	N	1/15/2023	WARD	ENDOCRINOLOGY	SERUM	1/23/2023	Y	Y	N	N	Y	Y	N	N	N	N	Y	N	N	N	N	9	27	83	Y	N	Y	Y	NR
460	1447935	197	AK	1/24/2023	73	F	N	1/18/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	1/24/2023	N	N	N	N	Y	Y	N	N	N	N	N	N	N	N	N	5	29	79	N	Y	Y	N	NR
462	1384637	210	SK	1/25/2023	41	M	N	1/25/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	1/25/2023	N	N	N	N	N	N	Y	N	N	N	N	N	N	N	N	8.9	7.6	70.9	Y	N	N	N	NR
463	1194969	230	SK	1/27/2023	63	M	N	1/26/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	1/27/2023	N	Y	Y	N	Y	Y	N	N	N	N	N	N	N	N	N	8	8.6	82	N	N	N	N	NR
464	1451973	231	KK	1/27/2023	30	F	N	1/26/2023	WARD	GENERAL SURGERY	SERUM	1/27/2023	Y	N	Y	N	N	N	N	N	N	N	N	N	N	N	N	13	12.2	81	N	N	N	N	Normal
465	1451711	232	MK	1/27/2023	45	F	N	1/25/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	1/27/2023	Y	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	11.1	7.7	74	N	N	N	N	NR
466	1446747	233	VS	1/27/2023	37	M	N	1/16/2023	ICU	NEUROLOGICAL DISEASE	SERUM	1/27/2023	N	N	N	N	N	N	N	N	N	N	Y	N	N	N	N	9	2.1	91	N	N	N	N	NR
467	1444655	234	SP	1/27/2023	70	M	N	1/20/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	1/27/2023	N	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	12.3	13	84	N	N	N	N	NR
468	1337489	235	AK	1/27/2023	64	M	N	1/25/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	1/27/2023	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	9.7	5.1	47	N	N	N	N	NR
469	1452121	237	RR	1/28/2023	56	M	N	1/27/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	1/28/2023	Y	Y	Y	N	N	Y	N	N	N	N	Y	N	N	N	N	15.6	10	87.1	N	N	N	N	NR
470	1245886	238	PS	1/28/2023	64	M	N	1/23/2023	WARD	ENDOCRINOLOGY	SERUM	1/28/2023	N	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	8.6	26	89.2	Y	N	N	N	NR
471	1350983	227	KD	1/31/2023	56	F	N	1/29/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	1/31/2023	N	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	7.3	2.6	76.7	N	N	N	N	NR
475	1451757	239	MS	1/28/2023	29	F	N	1/26/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	1/28/2023	Y	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	12	13	86.3	N	Y	N	N	NR
476	1453174	253	ML	1/29/2023	75	M	N	1/28/2023	WARD	RENAL DISEASE	SERUM	1/29/2023	N	Y	Y	N	Y	N	N	N	N	N	N	N	N	N	N	9	1.2	81.8	N	N	N	N	NR
477	611496	254	LK	1/29/2023	46	F	N	1/5/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	1/29/2023	N	Y	Y	N	Y	Y	N	N	N	N	Y	N	N	N	N	14.4	13.1	86	N	N	N	N	NR
479	1450977	241	SD	1/28/2023	58	F	N	1/24/2023	WARD	GENERAL SURGERY	SERUM	1/28/2023	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	N	8.1	7.39	79.8	N	N	N	N	NR
480	1446696	242	AS	1/28/2023	85	M	N	1/16/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	1/28/2023	N	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	8.9	9.9	79.2	N	Y	N	N	NR

S. no	MRD No.	Lab No	Distribution of clinical samples received	Fungal smear Positive for Hyaline Septate Fungal Hyphae	CANDIDA IN (BODY FLUIDS AND BLOOD CULTURE)	CANDIDA IN BODY FUILDS	FUNGAL CULTURE FOR ASPERGILLUS SPECIES	Fungal Cuture	GMSAASSAY	1-3 BDG	PTZ	ANTIFUNGAL	Heamo Dylasis	AUGMENTIN	MEROPENEM	Provisional diagnosis	Outcome	TOTAL EORTC PATIENTS	PROVEN	POSSIBLE	PROBABLE	NO INVASIVE ASPERGILLOSI
425	333040	95	NR	NR	-	-	NR	NR	0.7	-	N	Y	Y	N	N	LRTI, CKD, POST COVID	EXPIRED	Y	N	Y	N	N
426	441899	96	SPUTUM	Neg	-	-	Neg	NG	0.2	1.2	N	Y	N	N	N	TB POSITIVE	EXPIRED	N	N	N	N	Y
428	1433221	97	NR	NR	-	-	NR	NR	0.17	0.9	N	Y	N	N	N	STROKE, POST CABG	EXPIRED	N	N	N	N	Y
429	1442294	98	NR	NR	-	-	NR	NR	0.82	0.04	N	Y	N	N	N	ADDISONE DISEASE	DAMA	Y	N	Y	Y	N
430	1458965	99	SPUTUM	Neg	-	-	Neg	NG	0.72	0.03	N	Y	N	N	Y	ASCITES, CIRRHOSIS, HTN	DAMA	Y	N	Y	N	N
431	1387955	100	NR	NR	-	-	NR	NR	0.14	0.03	N	N	N	N	N	LRTI, ILD	EXPIRED	N	N	N	N	Y
432	1434974	101	SPUTUM	Neg	-	-	Neg	NG	0.14	0.12	N	N	N	N	N	ILD, LRTI	EXPIRED	N	N	N	N	Y
433	1443348	102	NR	NR	-	-	NR	NR	0.11	0.04	N	N	N	N	Y	VIRAL PNEUMONIA	EXPIRED	N	N	N	N	Y
434	910947	103	NR	NR	-	-	NR	NR	0.67	-	N	N	N	N	N	CLD	EXPIRED	Y	N	Y	Y	N
435	1447989	105	NR	NR	-	-	NR	NR	0.11	0.02	N	N	N	N	Y	ACUTE FIBRILE ILLNESS	DAMA	N	N	N	N	Y
436	1375334	106	ASCITIC FLUID	Neg	-	-	Neg	NG	10.25	-	N	Y	N	N	Y	FATTY LIVER,	DISCHARGE ON REQUEST	N	N	N	N	Y
437	443654	108	NR	NR	-	-	NR	NR	0.11	-	N	N	Y	N	Y	AKI	DISCHARGE	N	N	N	N	Y
439	1443319	107	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	9.32	-	N	Y	N	N	Y	LRTI, ACUTE FIBRILE ILLNESS	DISCHARGE	Y	N	Y	N	N
440	919458	108	NR	NR	-	-	NR	NR	0.12	-	N	N	N	N	Y	CLD, ASCITES	DISCHARGE	N	N	N	N	Y
442	1202344	112	SPUTUM	Neg	-	-	Neg	CANDIDA	4.24	-	N	Y	N	N	Y	BRONCHIAL ASTHMA, FUNGAL SEPSIS	DISCHARGE	Y	N	Y	N	N
443	1445521	-	NR	NR	-	-	NR	NR	0.5	-	N	N	N	N	N	ACUTE FIBRILE ILLNESS	DISCHARGE	N	N	N	N	Y
444	1445561	120	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.51	-	N	Y	N	N	Y	DM-II	DISCHARGE	N	N	N	N	Y
445	1446755	134	SPUTUM	Neg	-	-	Neg	NG	0.23	-	Y	N	N	N	N	LRTI	DISCHARGE	N	N	N	N	Y
446	1439821	135	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.02	0.05	N	N	N	Y	N	CVA, SEPSIS, PERICARDIAL EFFUSION	DISCHARGE	N	N	N	N	Y
447	1446719	136	NR	NR	-	-	NR	NR	2.12	0.07	N	Y	N	N	N	CABG	DISCHARGE	N	N	N	N	Y
448	254495	148	NR	NR	-	-	NR	NR	0.14	0.04	N	N	N	N	N	ILD, SEPSIS, CKD	DISCHARGE	N	N	N	N	Y
449	1444297	151	NR	NR	-	-	NR	NR	0.16	0.03	N	N	N	N	Y	RSA WITH EDH	DISCHARGE	N	N	N	N	Y
450	1447474	152	NR	NR	-	-	NR	NR	0.13	-	Y	N	N	N	N	INFECTIVE BRONCHIOLITS	DISCHARGE	N	N	N	N	Y
451	1447879	155	SPUTUM	Neg	-	-	Neg	NG	0.83	-	N	Y	N	N	Y	LRTI, SEIZURE	DISCHARGE	N	N	N	N	Y
452	1440471	156	SPUTUM	P	-	-	P	ASPERGILLUS FLAVUS	0.1	-	N	Y	N	N	Y	LRTI	DISCHARGE	N	N	N	N	Y
453	1447601	157	NR	NR	-	-	NR	NR	0.1	-	N	N	N	N	N	H1N1 PNEUMONIA	DISCHARGE	N	N	N	N	Y
454	936409	185	SPUTUM	Neg	-	-	Neg	NG	0.18	-	N	N	N	N	N	COPD, PULM. KOCH'S	DAMA	N	N	N	N	Y
455	1447856	159	SPUTUM	P	-	-	P	ASPERGILLUS FLAVUS	8.65	0.22	N	Y	N	N	Y	ABPA, ASCITES, PLEURAL EFFUSION, PULM. KOCH'S	DISCHARGE ON REQUEST	Y	N	Y	Y	N
457	1445494	194	PLEURAL FLUID	Neg	-	-	Neg	NG	0.15	0.04	N	N	N	N	Y	CAD	EXPIRED	N	N	N	N	Y
458	1448727	195	NR	NR	-	-	NR	NR	0.12	0.02	N	N	N	N	Y	AKI, CLD, LIVER ABCESS	DISCHARGE ON REQUEST	N	N	N	N	Y
459	1445979	196	NR	NR	-	-	NR	NR	0.71	1.91	N	Y	N	N	Y	INFECTIVE BRONCHIOLITS	DISCHARGE	Y	N	Y	Y	N
460	1447935	197	NR	NR	-	-	NR	NR	0.11	-	N	N	N	N	Y	CAD, SEPSIS, HYPOTHYROIDISM, LRTI, CONSOLIDATION	EXPIRED	N	N	N	N	Y
462	1384637	210	NR	NR	-	-	NR	NR	0.1	0.27	N	N	N	N	Y	ASCITES, PLEURAL EFFUSION	DISCHARGE	N	N	N	N	Y
463	1194969	230	NR	NR	-	-	NR	NR	0.14	0.05	N	N	N	N	N	HYPOTHYROIDISM, UTI SEPSIS, LRTI, CKD	DISCHARGE	N	N	N	N	Y
464	1451973	231	NR	NR	-	-	NR	NR	0.21	-	N	N	N	N	Y	LRTI	DISCHARGE	N	N	N	N	Y
465	1451711	232	NR	NR	-	-	NR	NR	0.75	8	N	Y	N	N	Y	LRTI, SEPTIC SHOCK, IMMUNO SUPRESSION	DISCHARGE	N	N	N	N	Y
466	1446747	233	NR	NR	-	-	NR	NR	0.75	8	N	N	N	N	N	SAH, IVH	DISCHARGE	N	N	N	N	Y
467	1444655	234	SPUTUM	Neg	-	-	Neg	NG	0.22	0.25	N	N	N	Y	N	LRTI, INFECTIVE BRONCHIOLITS	DISCHARGE	N	N	N	N	Y
468	1337489	235	ASCITIC FLUID	Neg	-	-	Neg	NG	0.16	1.07	N	N	N	N	Y	CIRRHOSIS, PORTAL HTN	DISCHARGE	N	N	N	N	Y
469	1452121	237	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	1.43	-	N	Y	N	N	N	POST COVID, FUNGAL SEPSIS	DISCHARGE	N	N	N	N	Y
470	1245886	238	PLEURAL FLUID	Neg	-	-	Neg	NG	0.1	0.02	N	N	N	N	Y	HYPOTHYROIDISM, SEPSIS, CYST	DISCHARGE	N	N	N	N	Y
471	1350983	227	NR	NR	-	-	NR	NR	0.2	-	N	N	N	N	Y	ANEMIA, HYPOTHYROIDISM	DISCHARGE	N	N	N	N	Y
475	1451757	239	SPUTUM	Neg	-	-	Neg	CANDIDA	0.05	-	N	Y	N	N	Y	BRONCHIAL ASTHMA, ARDS, SEPSIS, SHOCK	DISCHARGE	N	N	N	N	Y
476	1453174	253	NR	NR	-	-	NR	NR	0.11	0.02	N	N	N	N	Y	AKI	DISCHARGE	N	N	N	N	Y
477	611496	254	SPUTUM	Neg	-	-	Neg	NG	0.12	-	N	N	N	N	N	SLE, ILD, LRTI	DISCHARGE	N	N	N	N	Y
479	1450977	241	NR	NR	-	-	NR	NR	0.15	-	N	N	N	N	Y	CELLULITIS	DISCHARGE	N	N	N	N	Y
480	1446696	242	SPUTUM	Neg	-	-	Neg	NG	0.15	-	N	N	N	N	N	LRTI, OLD CVA	DISCHARGE	N	N	N	N	Y

S. no	MRD No.	Lab No	NAME	DOR Sample	AGE	SEX	GMRepeat	DOA	AREA	SUB AREA WISE	Sample	DOR Sample	FEVER	COUGH	SOB	CHEST PAIN	DM	HTN	Alcoholic	Smoker	Neutropenia	TBHistory	Chronic steroid use	Solid organ transplantation	Malignancy	HIV	HCV	HB	TLC/DLC	NEUTROPHIL COUNT	CT CHEST _PLEURAL EFFUSION	CONSOLIDATION IN LUNG	CAVITATION	RETICULONODULAR OPACITIES	Histopathology for aspergillus species
481	1269677	243	BS	1/28/2023	38	M	N	1/21/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	1/28/2023	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	9.5	6.3	62	N	N	N	N	NR
483	733066	245	MS	1/28/2023	67	M	N	1/24/2023	ICU	CARDIOVASCULAR DISEASE	SERUM	1/28/2023	N	N	Y	Y	Y	Y	N	N	N	Y	N	N	N	N	N	12	11	76	N	N	Y	N	NR
486	813842	257	JK	1/30/2023	62	F	N	1/28/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	1/30/2023	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	7	7.9	91.9	N	N	N	N	NR
487	1445210	248	MS	1/29/2023	23	M	N	1/12/2023	WARD	RENAL DISEASE	SERUM	1/29/2023	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	16.2	15	81.5	N	N	N	N	NR
488	1451825	249	KG	1/29/2023	68	M	N	1/26/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	1/29/2023	Y	N	Y	N	Y	N	N	N	N	N	N	N	N	N	N	12	11	85	Y	N	Y	Y	NR
489	1445305	250	MK	1/29/2023	38	F	N	1/13/2023	WARD	CARDIOVASCULAR DISEASE	SERUM	1/29/2023	Y	Y	N	Y	Y	N	N	N	N	N	N	N	N	N	N	9.4	25	78	Y	Y	N	Y	NR
490	1445884	251	KK	1/29/2023	30	F	N	1/27/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	1/29/2023	Y	N	Y	N	N	N	N	N	N	N	N	N	N	N	N	6.5	2.4	64	Y	N	N	N	NR
491	1181418	3	BS	1/1/2023	35	M	N	12/28/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	1/1/2023	N	N	Y	N	N	N	N	N	N	N	N	N	N	N	N	9.8	11.19	88.4	N	N	N	Y	NR
492	1429822	165	GS	1/12/2023	22	M	P	1/12/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	1/12/2023	N	N	N	N	N	N	Y	N	N	N	Y	N	N	N	N	14.2	21.2	86.1	Y	N	N	N	NR
493	1439361	5	MK	1/1/2023	64	F	N	12/30/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	1/1/2023	N	Y	Y	N	Y	Y	N	N	N	N	N	N	N	N	N	11.6	15.59	90	N	N	N	N	NR
494	1433343	6	JS	1/1/2023	49	M	N	12/17/2022	WARD	CARDIOVASCULAR DISEASE	SERUM	1/1/2023	N	N	Y	Y	Y	Y	N	N	N	N	N	N	N	N	N	12.4	32.5	95.4	Y	N	N	N	NR
495	286023	7	K	1/1/2023	51	F	N	12/26/2022	WARD	RENAL DISEASE	SERUM	1/1/2023	N	Y	Y	N	Y	Y	N	N	N	N	N	Y	N	N	N	10.8	5.3	74.5	Y	N	N	N	NR
496	1438943	9	RS	1/1/2023	67	M	N	12/29/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	1/1/2023	Y	Y	N	N	Y	N	N	N	N	N	Y	N	N	N	N	12.6	15	93.6	N	Y	N	N	NR
497	624213	10	JS	1/1/2023	64	M	N	12/30/2022	WARD	ONCOLOGICAL	SERUM	1/1/2023	N	N	Y	N	N	N	N	N	Y	N	N	N	Y	N	N	12.7	20.6	19	N	N	Y	N	NR
499	1438579	13	SK	1/1/2023	28	F	N	12/28/2022	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	1/1/2023	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	5.5	10.98	65.3	N	N	N	N	NR
500	1420509	14	GS	1/2/2023	41	M	P	12/29/2022	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	1/2/2023	Y	N	Y	N	N	N	N	N	N	N	Y	N	N	N	N	9	33.8	83.8	N	N	N	N	NR
501	85199	15	SL	1/2/2023	72	M	N	12/28/2022	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	1/2/2023	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	N	7.4	4.92	66	N	N	N	N	NR
502	1439970	16	AS	1/2/2023	45	M	N	12/30/2022	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	1/2/2023	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	N	11.6	34.23	92.8	Y	Y	Y	N	NR
504	1432650	8	GS	1/1/2023	25	M	N	12/31/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	1/1/2023	N	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	11	19	98	Y	N	Y	Y	Normal
506	1437109	27	MK	1/3/2023	32	F	N	12/25/2022	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	1/3/2023	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	N	10	10.9	86	Y	N	N	N	NR
507	1356397	28	SB	1/3/2023	71	M	N	1/3/2023	WARD	ACUTE FEBRILE ILLNESS	SERUM	1/3/2023	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	10.7	23	61.4	N	N	N	N	NR
508	1005348	29	GS	1/3/2023	37	M	N	1/3/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	1/3/2023	Y	N	N	N	N	N	N	N	N	N	Y	N	N	N	N	9.2	37	44	Y	N	N	N	NR
509	57301	30	JK	1/3/2023	78	M	N	12/29/2022	ICU	CARDIOVASCULAR DISEASE	SERUM	1/3/2023	N	N	Y	Y	Y	Y	N	N	N	N	N	N	N	N	N	14	9.6	83.4	N	N	N	Y	NR
510	1436022	31	KG	1/4/2023	68	F	N	12/22/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	1/4/2023	Y	Y	Y	N	Y	N	N	N	N	N	N	N	N	N	N	10	17	83	N	N	N	Y	NR
511	1439816	32	BR	1/4/2023	32	F	N	12/30/2022	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	1/4/2023	Y	N	Y	N	N	N	N	N	N	N	N	N	N	N	N	13	15	85	Y	N	N	N	NR
512	1440282	33	AB	1/4/2023	50	F	N	1/30/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	1/4/2023	N	Y	Y	N	Y	N	N	N	N	Y	N	N	N	N	N	10	11.5	72.1	Y	Y	N	N	NR
513	1441314	34	CS	1/4/2023	56	M	N	1/3/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	1/4/2023	Y	Y	N	N	N	N	N	N	N	Y	N	N	N	N	N	10	11.2	65.8	N	Y	N	N	NR
514	476221	35	NU	1/4/2023	74	F	N	1/2/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	1/4/2023	Y	N	Y	N	Y	N	N	N	N	N	N	N	N	N	N	12	20.4	90	Y	Y	N	N	NR
515	853477	52	RK	1/7/2023	50	M	N	1/6/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	1/7/2023	Y	N	Y	N	N	Y	N	N	N	N	N	N	N	N	N	8.2	12.3	81.2	Y	N	N	N	NR
516	1440336	57	HS	1/7/2023	59	M	N	1/1/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	1/7/2023	Y	Y	Y	N	N	N	Y	N	N	Y	Y	N	N	N	N	10	8.5	75	N	N	N	Y	NR
517	681977	58	RK	1/7/2023	77	F	N	1/5/2023	WARD	ONCOLOGICAL	SERUM	1/7/2023	Y	Y	Y	N	N	N	N	N	N	N	N	N	Y	N	N	9.4	14.3	68	N	N	Y	N	NR
518	1443003	59	HS	1/7/2023	40	M	N	1/5/2023	WARD	ACUTE FEBRILE ILLNESS	SERUM	1/7/2023	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	13.8	9.53	65	N	N	N	N	NR
519	1441890	60	RS	1/7/2023	20	M	N	1/5/2023	ICU	NEUROLOGICAL DISEASE	SERUM	1/7/2023	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	N	7.9	15	81.6	N	N	N	Y	NR
521	1442782	62	JS	1/7/2023	21	M	N	1/6/2023	ICU	NEUROLOGICAL DISEASE	SERUM	1/7/2023	Y	N	Y	N	N	N	N	N	N	N	N	N	N	N	N	13.8	15	89	N	N	N	N	NR
522	143978	63	KK	1/8/2023	45	M	N	1/1/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	1/8/2023	N	Y	Y	N	Y	N	N	Y	N	N	N	N	N	N	N	12.6	16	79	N	N	N	N	NR
523	1441235	64	RB	1/8/2023	59	F	N	1/3/2023	WARD	RENAL DISEASE	SERUM	1/8/2023	N	Y	Y	N	Y	Y	N	N	N	N	N	Y	N	N	N	9.8	7.6	54.2	N	N	N	Y	NR
524	1442131	65	AS	1/8/2023	55	M	N	1/5/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	1/8/2023	N	Y	Y	N	N	N	N	N	N	Y	N	N	N	N	N	11	24.6	78	N	N	N	N	NR
525	1092104	66	V	1/8/2023	47	F	P	12/4/2022	ICU	NEUROLOGICAL DISEASE	SERUM	1/8/2023	N	N	N	N	Y	Y	N	N	N	N	Y	N	N	N	N	8.5	1.3	59.9	Y	N	N	N	NR
526	1398766	67	AK	1/8/2023	66	M	N	1/2/2023	WARD	CARDIOVASCULAR DISEASE	SERUM	1/8/2023	Y	N	Y	Y	Y	Y	N	N	N	N	Y	N	N	N	N	11	6.8	70	Y	N	N	N	NR
527	1443174	68	S	1/8/2023	42	M	N	1/7/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	1/8/2023	N	N	N	N	N	N	N	N	N	N	Y	N	Y	N	N	8.9	24	62	N	N	N	Y	NR
528	1443183	69	HS	1/8/2023	50	M	N	1/7/2023	WARD	RENAL DISEASE	SERUM	1/8/2023	N	N	Y	N	Y	Y	N	N	N	N	N	Y	N	N	N	6.9	5.8	75	N	N	N	N	NR
529	325638	70	GS	1/8/2023	52	M	P	1/6/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	1/8/2023	N	N	N	N	Y	Y	N	N	N	N	Y	N	N	N	N	8	7.4	58	Y	N	N	N	NR
530	1442804	71	HK	1/9/2023	46	F	N	1/6/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	1/9/2023	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	9.3	16	79	N	N	N	N	Normal
531	1437779	72	VS	1/9/2023	45	M	N	12/26/2022	ICU	NEUROLOGICAL DISEASE	SERUM	1/9/2023	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	10	25	93	N	N	N	N	NR
532	1438179	73	SK	1/9/2023	28	F	N	12/28/2022	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	1/9/2023	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	5.5	10.98	98	N	N	N	N	NR

S. no	MRD No.	Lab No	Distribution of clinical samples received	Fungal smear Positive for Hyaline Septate Fungal Hyphae	CANDIDA IN (BODY FLUIDS AND BLOOD CULTURE)	CANDIDA IN BODY FUILDS	FUNGAL CULTURE FOR ASPERGILLUS SPECIES	Fungal Cuture	GMSAASSAY	1-3 BDG	PTZ	ANTIFUNGAL	Heamo Dylasis	AUGMENTIN	MEROPENEM	Provisional diagnosis	Outcome	TOTAL EORTC PATIENTS	PROVEN	POSSIBLE	PROBABLE	NO INVASIVE ASPERGILLOSI
481	1269677	243	ASCITIC FLUID	Neg	-	-	Neg	NG	0.19	0.03	N	N	N	N	Y	CLD, PORTAL HTN, ASCITES	DISCHARGE	N	N	N	N	Y
483	733066	245	NR	NR	-	-	NR	NR	0.19	50.15	N	N	N	N	Y	CAD, POST PTCA	DISCHARGE	N	N	N	N	Y
486	813842	257	SPUTUM	Neg	-	-	Neg	NG	0.12	-	Y	N	N	N	Y	HYPERTENSION	DISCHARGE	N	N	N	N	Y
487	1445210	248	PER CUTANEOUS DRAIN	Neg	-	-	Neg	NG	0.19	0.84	N	N	N	N	Y	HERBICIDAL POISONING	DISCHARGE	N	N	N	N	Y
488	1451825	249	NR	NR	-	-	NR	NR	0.16	0.07	N	N	N	N	Y	LRTI	DISCHARGE	N	N	N	N	Y
489	1445305	250	NR	NR	-	-	NR	NR	0.19	0.03	Y	N	N	N	Y	ARDS, ECHO	DISCHARGE	N	N	N	N	Y
490	1445884	251	NR	NR	-	-	NR	NR	0.14	-	N	N	N	N	N	LRTI, ABDOMINAL CYST	DISCHARGE	N	N	N	N	Y
491	1181418	3	NR	NR	-	-	NR	NR	0.13	0.03	N	N	N	N	N	PAH, SHOCK, PULMONARY THROMB EMBOLISM	DISCHARGE	N	N	N	N	Y
492	1429822	165	ASCITIC FLUID	Neg	-	-	Neg	NG	1.22	0.02	N	Y	N	N	Y	NECROTISING	DISCHARGE	Y	N	Y	Y	N
493	1439361	5	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.2	-	N	N	N	N	Y	ASPIRATION PNEUMONIA, RF	DISCHARGE	N	N	N	N	Y
494	1433343	6	NR	NR	-	-	NR	NR	0.14	0.03	N	N	N	N	Y	CAD, POST CABG	DISCHARGE	N	N	N	N	Y
495	286023	7	NR	NR	-	-	NR	NR	3.53	0.03	N	N	ON MAINTENCE HEMODIALYSIS	N	Y	CKD, SEPSIS, KIDNEY FAILURE	DISCHARGE	Y	N	Y	Y	N
496	1438943	9	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	CANDIDA	0.15	0.03	N	N	N	N	Y	LRTI, LOBAR CONSOLIDATION, AKI	EXPIRED	Y	N	Y	N	N
497	624213	10	NR	NR	-	-	NR	NR	13.53	-	N	Y	N	N	Y	POST THYROIDICTOMY	DISCHARGE	Y	N	Y	Y	N
499	1438579	13	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.17	-	N	N	N	N	Y	ABDOMEN PAIN	DISCHARGE	N	N	N	N	Y
500	1420509	14	ASCITIC FLUID	Neg	-	-	Neg	NG	0.85	-	N	Y	N	N	Y	CLD	DISCHARGE	Y	N	Y	N	N
501	85199	15	NR	NR	-	-	NR	NR	0.24	-	N	N	N	N	Y	ACUTE PANCREATITIS	DISCHARGE	N	N	N	N	Y
502	1439970	16	SPUTUM	Neg	-	-	Neg	NG	0.04	-	N	Y	N	N	Y	CLD, RENAL PARENCHYMAL CHANGES, PLEURAL EFFUSION	DISCHARGE	N	N	N	N	Y
504	1432650	8	SPUTUM	Neg	-	-	Neg	CANDIDA	0.22	0.05	N	N	N	N	N	LRTI	DAMA	N	N	N	N	Y
506	1437109	27	NR	NR	-	-	NR	NR	0.58	-	N	Y	N	N	Y	PLEURAL EFFUSION	DISCHARGE	N	N	N	N	Y
507	1356397	28	NR	NR	-	-	NR	NR	0.17	-	N	N	N	N	N	ACUTE FIBRILE CIRRHOSIS	DISCHARGE	N	N	N	N	Y
508	1005348	29	NR	NR	-	-	NR	NR	1.13	-	N	Y	N	N	Y	LIVER DISEASE	DISCHARGE	Y	N	Y	Y	N
509	57301	30	SPUTUM	Neg	-	-	Neg	NG	0.4	-	N	N	N	N	Y	CABG	EXPIRED	N	N	N	N	Y
510	1436022	31	NR	NR	-	-	NR	NR	0.15	0.03	N	N	N	N	N	H1N1 POSITIVE	DISCHARGE	N	N	N	N	Y
511	1439816	32	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.11	-	N	N	N	N	N	PLEURAL EFFUSION	DISCHARGE	N	N	N	N	Y
512	1440282	33	SPUTUM	Neg	-	-	Neg	NG	0.14	-	N	N	N	N	Y	PLEURAL EFFUSION, TB	DISCHARGE	N	N	N	N	Y
513	1441314	34	SPUTUM	Neg	-	-	Neg	NG	0.13	-	N	N	N	N	Y	KOCH'S, LRTI, ILD	DISCHARGE	N	N	N	N	Y
514	476221	35	SPUTUM	Neg	-	-	Neg	NG	0.14	-	N	N	N	N	Y	LRTI, COPD, AKI, CLD	DISCHARGE	N	N	N	N	Y
515	853477	52	SPUTUM	Neg	-	-	Neg	NG	0.1	-	N	N	N	N	N	LRTI, SEPSIS, FLUID OVERLOAD	DISCHARGE	N	N	N	N	Y
516	1440336	57	SPUTUM	Neg	-	-	Neg	NG	1.56	-	N	Y	N	N	Y	AKI, ALCOHOLIC, LRTI	DAMA	Y	N	Y	N	N
517	681977	58	SPUTUM	Neg	-	-	Neg	CANDIDA	0.14	-	N	N	N	N	N	LRTI, CARCENOMA	DISCHARGE	Y	N	Y	N	N
518	1443003	59	SPUTUM	Neg	-	-	Neg	NG	0.18	-	Y	N	N	N	N	ACUTE FIBRILE ILLNESS	DISCHARGE	N	N	N	N	Y
519	1441890	60	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.18	-	N	N	N	N	N	RSA	DISCHARGE	N	N	N	N	Y
521	1442782	62	NASAL MUCOSA	Neg	-	-	Neg	NG	12.03	0.05	Y	Y	N	N	N	LRTI	DISCHARGE	N	N	N	N	Y
522	143978	63	SPUTUM	P	-	-	P	ASPERGILLUS FLAVUS	0.13	-	Y	Y	N	N	N	COPD, LRTI	DISCHARGE	N	N	N	N	Y
523	1441235	64	SPUTUM	Neg	-	-	Neg	NG	1.16	-	N	Y	Y	N	N	CKD	DISCHARGE	Y	N	Y	Y	N
524	1442131	65	SPUTUM	Neg	-	-	Neg	NG	1.84	-	Y	Y	N	N	N	LLD	DISCHARGE	Y	N	Y	N	N
525	1092104	66	NR	NR	-	-	NR	NR	1.23	0.02	N	Y	N	N	N	SEPSIS, SEIZURE DISORDER	DISCHARGE	Y	N	Y	Y	N
526	1398766	67	SPUTUM	Neg	-	-	Neg	CANDIDA	0.22	0.04	N	N	N	N	N	CLD, LRTI, CABG	DISCHARGE	Y	N	Y	N	N
527	1443174	68	NR	NR	-	-	NR	NR	12.4	-	N	Y	N	N	Y	NEPHROLITHIASIS	DISCHARGE	Y	N	Y	Y	N
528	1443183	69	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.71	0.05	N	Y	Y	N	Y	CKD, FLUID OVERLOAD, SEPSIS	DISCHARGE	Y	N	Y	N	N
529	325638	70	PLEURAL FLUID	Neg	-	-	Neg	NG	0.59	-	N	N	N	N	N	CLD, CIRRHOSIS	DISCHARGE	Y	N	Y	Y	N
530	1442804	71	SPUTUM	Neg	-	-	Neg	NG	0.12	-	N	N	N	N	N	RESP. FAILURE	DISCHARGE	N	N	N	N	Y
531	1437779	72	NR	NR	-	-	NR	NR	0.17	-	N	N	N	N	N	EDH, SAH, SDH	DISCHARGE	N	N	N	N	Y
532	1438179	73	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.17	-	N	N	N	N	N	VOMITING	DISCHARGE ON REQUEST	N	N	N	N	Y

S. no	MRD No.	Lab No	NAME	DOR Sample	AGE	SEX	GMRepeat	DOA	AREA	SUB AREA WISE	Sample	DOR Sample	FEVER	COUGH	SOB	CHEST PAIN	DM	HTN	Alcoholic	Smoker	Neutropenia	TBHistory	Chronic steroid use	Solid organ transplantation	Malignancy	HIV	HCV	HB	TLC/DLC	NEUTROPHIL COUNT	CT CHEST _PLEURAL EFFUSION	CONSOLIDATION IN LUNG	CAVITATION	RETICULONODULAR OPACITIES	Histopathology for aspergillus species
533	1443333	74	SS	1/9/2023	43	M	N	1/8/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	1/9/2023	Y	Y	Y	N	Y	N	N	N	N	N	N	N	N	N	N	10.4	11.3	81.6	Y	Y	Y	N	NR
534	248068	75	HS	1/9/2023	61	M	P	1/8/2023	ICU	CARDIOVASCULAR DISEASE	SERUM	1/9/2023	Y	Y	N	Y	Y	Y	N	N	N	N	N	N	N	N	N	10.9	7.7	89	N	N	N	N	NR
535	1442553	76	BK	1/9/2023	73	F	N	1/6/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	1/9/2023	N	Y	Y	N	N	N	N	N	N	N	Y	N	N	N	N	11.1	3.8	70.8	N	N	N	N	NR
536	1443163	77	GS	1/9/2023	52	M	N	1/7/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	1/9/2023	N	N	N	N	Y	Y	N	N	N	N	N	N	N	N	N	6.2	45	91	N	N	N	N	NR
537	1448452	265	SS	1/31/2023	57	M	N	1/19/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	1/31/2023	Y	Y	N	N	N	N	N	N	N	N	Y	N	N	N	N	13	5.37	88	Y	N	N	N	NR
538	1442532	78	NJ	1/9/2023	75	M	N	1/6/2023	WARD	RENAL DISEASE	SERUM	1/9/2023	N	N	Y	N	Y	Y	N	N	N	N	N	Y	N	N	N	5.3	11	97.7	N	Y	N	N	NR
539	1443295	80	RK	1/9/2023	40	M	N	1/8/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	1/9/2023	Y	Y	N	N	N	N	N	N	N	N	Y	N	N	N	N	10	7.8	88	N	Y	N	N	NR
540	957093	81	MC	1/9/2023	41	M	P	1/9/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	1/9/2023	Y	Y	Y	N	N	N	N	N	N	N	Y	N	N	N	N	13	2.92	82.8	N	Y	N	N	NR
541	1443175	82	JK	1/10/2023	46	M	N	1/6/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	1/10/2023	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	11.1	4.4	78.8	N	N	N	N	NR
542	1440285	83	YJ	1/10/2023	59	M	N	1/9/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	1/10/2023	N	N	N	N	Y	Y	N	N	N	N	N	N	N	N	N	11	21	87.9	N	N	N	N	NR
543	868538	84	CS	1/10/2023	65	M	N	12/27/2022	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	1/10/2023	N	N	N	N	Y	Y	N	N	N	N	Y	N	N	N	N	11.8	13	78	Y	N	N	N	NR
544	1443170	85	YS	1/10/2023	68	M	N	1/7/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	1/10/2023	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	15	7.8	71.4	Y	N	N	N	NR
545	1440218	87	KB	1/10/2023	72	F	N	12/31/2022	ICU	CARDIOVASCULAR DISEASE	SERUM	1/10/2023	N	N	Y	Y	N	N	N	N	N	N	N	N	N	N	N	9.2	9	74	N	N	N	N	NR
546	1448508	192	TD	1/23/2023	25	M	N	1/20/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	1/23/2023	N	Y	N	N	N	N	N	N	N	N	Y	N	N	N	N	13.8	17	89.9	N	N	N	N	NR
547	431794	227	K	1/27/2023	67	F	N	1/25/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	1/27/2023	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	9.4	42.8	93	N	N	N	N	NR
548	1451789	225	RS	1/26/2023	53	M	N	1/26/2023	WARD	ACUTE FEBRILE ILLNESS	SERUM	1/26/2023	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	12	14	72.1	N	N	N	N	NR
549	1419128	224	BK	1/26/2023	57	M	N	1/18/2023	WARD	RENAL DISEASE	SERUM	1/26/2023	N	N	N	N	Y	Y	N	N	N	Y	N	N	N	N	N	10	20	80	N	N	N	N	NR
550	1411926	222	VK	1/26/2023	63	M	N	1/17/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	1/26/2023	Y	N	N	N	Y	N	N	N	N	N	N	N	N	N	N	11.9	6.4	74	N	N	N	N	NR
551	1007802	221	KK	1/26/2023	70	F	N	1/20/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	1/26/2023	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	12.2	36.3	75.9	N	N	N	N	NR
553	370240	219	RK	1/26/2023	36	F	N	1/24/2023	WARD	RENAL DISEASE	SERUM	1/26/2023	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	13.5	7.5	82	N	N	N	N	Normal
554	361342	217	M	1/26/2023	74	F	N	1/23/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	1/26/2023	N	N	N	N	Y	Y	N	N	N	N	Y	N	N	N	N	9.8	7.1	63.6	Y	Y	N	N	NR
555	1451744	216	SK	1/26/2023	44	F	N	1/25/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	1/26/2023	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	7.2	11	86.4	N	N	N	N	NR
556	1287294	212	BS	1/25/2023	55	M	N	1/23/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	1/25/2023	Y	N	N	N	Y	N	N	N	N	N	N	N	N	N	N	12.8	20	92.2	N	N	N	N	NR
558	1450471	209	SD	1/25/2023	75	F	N	1/23/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	1/25/2023	Y	N	Y	N	Y	N	N	N	N	N	N	N	N	N	N	11.7	8.6	88	N	N	N	N	NR
559	1439791	22	VS	1/2/2023	39	M	N	12/30/2022	WARD	RENAL DISEASE	SERUM	1/2/2023	N	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	13.3	7.2	83	N	N	N	N	NR
560	1438849	24	S	1/3/2023	36	M	N	12/28/2022	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	1/3/2023	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	11.5	14	84	N	N	N	N	NR
561	1424498	23	KS	1/29/2023	45	M	N	12/27/2022	ICU	GENERAL SURGERY	SERUM	1/29/2023	Y	N	N	N	Y	Y	N	N	N	Y	Y	N	N	N	Y	13	15	59	N	N	N	N	NR
562	108273	41	RK	1/5/2023	60	M	N	1/2/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	1/5/2023	N	Y	Y	N	Y	Y	N	N	N	N	Y	N	N	N	N	11	9.82	91.5	N	N	Y	N	NR
563	1439270	40	BS	1/5/2023	45	M	N	12/29/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	1/5/2023	Y	Y	Y	N	N	N	N	Y	N	N	Y	N	N	N	N	14.5	21	94	N	N	N	N	NR
564	762672	36	MK	1/4/2023	45	F	N	1/2/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	1/4/2023	N	N	Y	N	N	Y	N	N	N	N	Y	N	N	N	N	12.8	18	70	N	N	N	Y	NR
565	1438284	20	NT	1/2/2023	77	M	N	12/27/2022	ICU	RENAL DISEASE	SERUM	1/2/2023	N	N	Y	N	N	Y	N	N	N	N	N	N	N	N	N	14.6	19.2	89	N	N	N	N	NR
566	1434583	55	TR	1/7/2023	65	M	N	1/7/2023	ICU	NEUROLOGICAL DISEASE	SERUM	1/7/2023	N	N	N	N	N	N	N	N	Y	N	Y	N	N	N	N	8.7	22.7	12.7	N	N	N	N	NR
567	308946	42	SK	1/5/2023	83	M	N	1/2/2023	ICU	CARDIOVASCULAR DISEASE	SERUM	1/5/2023	N	N	Y	Y	N	N	N	N	N	N	N	N	N	N	N	9.9	14.6	90.9	Y	N	N	N	NR
569	1445568	204	SS	1/14/2023	60	M	N	1/14/2023	WARD	CARDIOVASCULAR DISEASE	SERUM	1/14/2023	N	N	N	Y	N	N	N	N	Y	N	N	N	N	N	N	8.8	9	37	N	N	N	N	NR
570	1445850	127	MK	1/16/2023	72	F	N	1/14/2023	WARD	CARDIOVASCULAR DISEASE	SERUM	1/16/2023	Y	Y	N	Y	Y	Y	N	N	N	N	Y	N	N	N	N	9.8	9.5	98.5	N	N	N	Y	NR
573	1449739	190	SB	1/23/2023	50	F	N	1/22/2023	WARD	RENAL DISEASE	SERUM	1/23/2023	Y	N	N	N	Y	N	N	N	N	N	N	N	N	N	8.9	19	70.1	Y	N	N	N	NR
574	1444815	100	RR	1/15/2023	85	F	N	1/11/2023	ICU	GASTROINTESTINAL TRACT DISEASE	SERUM	1/15/2023	N	N	N	N	N	Y	N	N	N	N	Y	N	N	N	N	7.5	20	92	N	N	N	Y	NR
575	1444306	125	RK	1/16/2023	35	F	N	1/10/2023	ICU	GASTROINTESTINAL TRACT DISEASE	SERUM	1/16/2023	Y	N	N	N	N	N	N	N	N	N	Y	N	N	N	N	12.7	9.6	79.4	N	N	N	Y	NR
576	1443937	124	KR	1/16/2023	39	M	N	1/10/2023	ICU	GASTROINTESTINAL TRACT DISEASE	SERUM	1/16/2023	N	N	N	N	Y	N	N	N	N	N	Y	N	N	N	N	9.2	16	98	N	N	N	N	NR
577	1447179	184	S	1/23/2023	40	F	N	1/17/2023	ICU	RENAL DISEASE	SERUM	1/23/2023	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	6.3	22	89	N	N	N	N	NR
578	1446371	183	BS	1/23/2023	35	M	N	1/16/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	1/23/2023	N	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	12.9	29.1	95	N	N	N	N	NR
579	1445845	182	GK	1/23/2023	29	F	N	1/14/2023	ICU	GASTROINTESTINAL TRACT DISEASE	SERUM	1/23/2023	N	N	N	N	N	N	N	N	N	N	Y	N	N	N	N	9.3	10.1	49.4	Y	N	N	N	NR
580	1445078	178	ML	1/23/2023	82	M	N	1/12/2023	ICU	CARDIOVASCULAR DISEASE	SERUM	1/23/2023	N	Y	Y	Y	Y	N	N	N	N	N	N	N	N	N	N	12.7	13.8	81.3	N	N	N	N	NR
581	1449130	177	UR	1/23/2023	68	F	N	1/20/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	1/23/2023	N	Y	Y	N	Y	N	N	N	N	N	N	N	N	N	N	10.8	14	90.8	N	N	N	N	NR
582	1346968	179	SR	1/23/2023	60	F	P	1/17/2023	ICU	GASTROINTESTINAL TRACT DISEASE	SERUM	1/23/2023	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	12	7.4	72.3	N	N	N	N	NR
583	1448527	181	SS	1/23/2023	66	F	N	1/20/2023	ICU	GASTROINTESTINAL TRACT DISEASE	SERUM	1/23/2023	N	N	N	N	Y	Y	N	N	N	N	Y	N	N	N	N	9	10.7	73.9	N	N	N	N	NR

S. no	MRD No.	Lab No	Distribution of clinical samples received	Fungal smear Positive for Hyaline Septate Fungal Hyphae	CANDIDA IN (BODY FLUIDS AND BLOOD CULTURE)	CANDIDA IN BODY FUILDS	FUNGAL CULTURE FOR ASPERGILLUS SPECIES	Fungal Cuture	GMSAASSAY	1-3 BDG	PTZ	ANTIFUNGAL	Heamo Dylasis	AUGMENTIN	MEROPENEM	Provisional diagnosis	Outcome	TOTAL EORTC PATIENTS	PROVEN	POSSIBLE	PROBABLE	NO INVASIVE ASPERGILLOSI
533	1443333	74	SPUTUM	Neg	-	-	Neg	NG	0.16	8.32	N	Y	N	Y	N	FUNGAL SEPSIS, PLEURAL EFFUSION	DISCHARGE ON REQUEST	N	N	N	N	Y
534	248068	75	SPUTUM	Neg	-	-	Neg	NG	1.89	-	N	Y	N	N	N	INFECTIVE ENDOCRATITIS	EXPIRED	N	N	N	N	Y
535	1442553	76	SPUTUM	Neg	-	-	Neg	NG	0.16	0.03	N	N	N	Y	N	ASTHMA, ACUTE EXECUBATION	DAMA	N	N	N	N	Y
536	1443163	77	ASCITIC FLUID	Neg	-	-	Neg	NG	0.17	-	N	N	N	N	Y	LLD	DISCHARGE	N	N	N	N	Y
537	1448452	265	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.54	0.02	N	Y	N	N	Y	AKI, SEPSIS, FUNGAL SEPSIS	DISCHARGE	Y	N	Y	Y	N
538	1442532	78	NR	NR	-	-	NR	NR	0.69	0.05	N	Y	Y	N	Y	CKD, LRTI, SEPSIS	DISCHARGE	Y	N	Y	Y	N
539	1443295	80	NASAL MUCOSA	Neg	-	-	Neg	NG	16.15	1.15	N	Y	N	N	Y	LRTI	DISCHARGE	Y	N	Y	Y	N
540	957093	81	SPUTUM	Neg	-	-	Neg	CANDIDA	8.95	0.02	N	Y	N	N	N	LRTI, VIRAL PNEUMONIA	DISCHARGE	Y	N	Y	Y	N
541	1443175	82	NR	NR	-	-	NR	NR	0.11	-	N	N	N	N	N	ACUTE PANCREATITIS	DISCHARGE	N	N	N	N	Y
542	1440285	83	SPUTUM	Neg	-	-	Neg	NG	0.21	-	N	N	N	N	N	CLD	DISCHARGE	N	N	N	N	Y
543	868538	84	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	9.23	0.03	N	Y	N	N	Y	LIVER DISEASE	DISCHARGE	Y	N	Y	Y	N
544	1443170	85	SPUTUM	Neg	-	-	Neg	NG	0.1	-	Y	N	N	N	Y	COPD, PLEURAL EFFUSION	DISCHARGE	N	N	N	N	Y
545	1440218	87	NR	NR	-	-	NR	NR	0.14	8.21	N	Y	N	N	N	CAD, HYPOTHYROIDISM	DISCHARGE	N	N	N	N	Y
546	1448508	192	SPUTUM	Neg	-	-	Neg	NG	0.11	-	N	N	N	N	Y	PLEURAL EFFUSION, PNEUMONOTHORAX	DISCHARGE	N	N	N	N	Y
547	431794	227	NR	NR	-	-	NR	NR	0.11	-	N	Y	N	N	N	INFECTIOUS BRONCHIOLITS	DISCHARGE	N	N	N	N	Y
548	1451789	225	NR	NR	-	-	NR	NR	0.12	-	Y	N	N	N	N	ACUTE FIBRILE ILLNESS	DISCHARGE	N	N	N	N	Y
549	1419128	224	NR	NR	-	-	NR	NR	0.14	-	N	Y	N	N	Y	CKD, SEPSIS	DISCHARGE	N	N	N	N	Y
550	1411926	222	NR	NR	-	-	NR	NR	0.04	0.14	N	N	N	N	Y	DM-II	DISCHARGE	N	N	N	N	Y
551	1007802	221	NR	NR	-	-	NR	NR	0.12	-	N	N	N	N	N	CKD, LRTI, COAGULOPATHY	DISCHARGE	N	N	N	N	Y
553	370240	219	SPUTUM	Neg	-	-	Neg	NG	0.13	8.06	N	Y	Y	N	N	LRTI	DAMA	N	N	N	N	Y
554	361342	217	NR	NR	-	-	NR	NR	0.74	0.04	N	N	N	N	N	CLD	DISCHARGE	Y	N	Y	Y	N
555	1451744	216	SPUTUM	Neg	-	-	Neg	NG	0.11	-	N	N	N	N	N	ACUTE FIBRILE ILLNESS	DISCHARGE	N	N	N	N	Y
556	1287294	212	NR	NR	-	-	NR	NR	0.14	-	Y	N	N	N	Y	ILD	DISCHARGE	N	N	N	N	Y
558	1450471	209	SPUTUM	Neg	-	-	Neg	NG	0.13	0.05	N	N	N	N	Y	COPD	DISCHARGE	N	N	N	N	Y
559	1439791	22	SPUTUM	Neg	-	-	Neg	NG	0.1	0.03	N	N	Y	N	Y	SEPSIS, LRTI	DISCHARGE	N	N	N	N	Y
560	1438849	24	NR	NR	-	-	NR	NR	0.15	-	N	N	N	N	N	PAIN ABDOMEN	DISCHARGE	N	N	N	N	Y
561	1424498	23	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.61	-	N	Y	N	N	Y	HCV+VE, IV DRUG ABUSE	DISCHARGE	Y	N	Y	N	N
562	108273	41	SPUTUM	P	-	-	P	ASPERGILLUS FLAVUS	1	9.42	N	Y	N	N	Y	HYPERTENSION	DISCHARGE	Y	N	Y	Y	N
563	1439270	40	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	2.12	0.02	N	Y	N	N	N	DRUG ABUSER, LRTI, SEPSIS	DISCHARGE	Y	N	Y	N	N
564	762672	36	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.56	-	N	N	N	N	Y	INFECTIVE ETIOLOGY	DISCHARGE	Y	N	Y	Y	N
565	1438284	20	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	8.4	0.03	Y	Y	N	N	N	HYPERTENSION	DISCHARGE	N	N	N	N	Y
566	1434583	55	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	2.38	0.02	N	N	N	N	Y	SDH, SAH	EXPIRED	Y	N	Y	N	N
567	308946	42	SPUTUM	Neg	-	-	Neg	NG	0.18	0.05	Y	Y	N	N	N	LVD,CAD, HYPOTHYROIDISM	DAMA	N	N	N	N	Y
569	1445568	204	NR	NR	-	-	NR	NR	0.15	1.52	N	Y	N	N	Y	MULTIPLE MYCLOMA	DISCHARGE ON REQUEST	N	N	N	N	Y
570	1445850	127	NR	NR	-	-	NR	NR	11.77	-	N	Y	N	N	Y	COPD, LRTI, POST TB	DAMA	Y	N	Y	Y	N
573	1449739	190	NR	NR	-	-	NR	NR	0.15	0.04	Y	N	Y	N	N	PLEURAL EFFUSION	DISCHARGE	N	N	N	N	Y
574	1444815	100	NR	NR	-	-	NR	NR	11.56	-	N	N	N	N	Y	ACUTE PANCREATITIS, CHOLIDOCOLITHIASIS	DISCHARGE	Y	N	Y	Y	N
575	1444306	125	NR	NR	-	-	NR	NR	1.86	1.08	N	Y	N	N	Y	LIVER CIRRHOSIS	DISCHARGE	Y	N	Y	Y	N
576	1443937	124	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	CANDIDA	3.54	0.04	N	Y	N	N	N	CHOLITHIASIS	DISCHARGE	Y	N	Y	N	N
577	1447179	184	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.13	-	N	N	Y	N	N	CKD	DISCHARGE	N	N	N	N	Y
578	1446371	183	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.17	-	N	N	N	N	Y	INTESTINAL EMPHYSEMA	DISCHARGE	N	N	N	N	Y
579	1445845	182	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.18	0.02	N	N	N	N	Y	ASCITES	DISCHARGE	Y	N	Y	N	N
580	1445078	178	NR	NR	-	-	NR	NR	0.11	-	N	N	N	N	Y	CKD, POST PTCA	DISCHARGE	N	N	N	N	Y
581	1449130	177	NR	NR	-	-	NR	NR	0.12	-	N	N	N	N	Y	LRTI	DISCHARGE	N	N	N	N	Y
582	1346968	179	ASCITIC FLUID	Neg	-	-	Neg	NG	0.05	-	Y	N	N	N	N	CIRRHOSIS, SDH	DISCHARGE	N	N	N	N	Y
583	1448527	181	NR	NR	-	-	NR	NR	0.55	0.04	N	Y	N	N	Y	HYPERTENSION	DISCHARGE	Y	N	Y	N	N

S. no	MRD No.	Lab No	NAME	DOR Sample	AGE	SEX	GMRepeat	DOA	AREA	SUB AREA WISE	Sample	DOR Sample	FEVER	COUGH	SOB	CHEST PAIN	DM	HTN	Alcoholic	Smoker	Neutropenia	TBHistory	Chronic steroid use	Solid organ transplantation	Malignancy	HIV	HCV	HB	TLC/DLC	NEUTROPHIL COUNT	CT CHEST _PLEURAL EFFUSION	CONSOLIDATION IN LUNG	CAVITATION	RETICULONODULAR OPACITIES	Histopathology for aspergillus species
584	1138879	189	NS	1/23/2023	68	M	N	1/12/2023	WARD	RENAL DISEASE	SERUM	1/23/2023	N	N	N	N	Y	Y	N	N	N	N	Y	N	N	N	N	10.1	7.8	61.3	N	N	Y	N	NR
585	1449679	186	SK	1/23/2023	55	M	N	1/20/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	1/23/2023	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	13.2	18.6	92.3	N	N	N	N	NR
586	1445830	187	KK	1/23/2023	42	F	N	1/14/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	1/23/2023	N	N	N	N	N	N	N	N	N	N	Y	N	N	N	N	8.4	2	91.3	N	N	N	Y	NR
587	1447933	188	AS	1/23/2023	66	M	N	1/18/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	1/23/2023	N	N	N	N	Y	Y	N	N	N	N	N	N	N	N	N	6.3	9.8	81.5	N	N	N	N	NR
588	386346	191	KK	1/23/2023	32	F	N	1/22/2023	WARD	RENAL DISEASE	SERUM	1/23/2023	N	N	N	N	Y	N	N	N	N	N	N	Y	N	N	N	8.1	8.33	84.3	N	N	N	N	NR
589	1447917	180	HK	1/21/2023	70	F	N	1/21/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	1/21/2023	Y	N	Y	N	Y	Y	N	N	N	N	Y	N	N	N	N	10	17	93.5	N	N	N	Y	NR
591	1412140	199	RK	1/24/2023	50	M	N	1/22/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	1/24/2023	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	11.7	9.1	73.4	Y	N	N	N	NR
592	1441828	193	RS	1/23/2023	53	M	N	1/9/2023	ICU	GASTROINTESTINAL TRACT DISEASE	SERUM	1/23/2023	N	N	N	N	N	N	N	N	N	N	Y	N	N	N	N	8.9	8.9	63.5	N	N	N	N	NR
593	6485	203	SK	1/25/2023	42	M	P	1/25/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	1/25/2023	N	Y	Y	Y	Y	N	N	N	N	N	N	N	Y	N	N	14.7	4.7	53.2	N	Y	N	N	NR
594	1449831	205	B	1/25/2023	65	M	N	1/22/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	1/25/2023	N	N	N	N	Y	Y	N	N	Y	N	N	N	Y	N	N	8.1	11.8	25.6	N	N	N	Y	NR
595	1326826	204	SS	1/25/2023	50	M	N	1/8/2023	ICU	GASTROINTESTINAL TRACT DISEASE	SERUM	1/25/2023	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	10.3	7.9	65	N	N	N	N	NR
596	375054	208	HS	1/25/2023	67	M	N	1/23/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	1/25/2023	N	N	Y	N	Y	Y	N	N	N	N	N	N	N	N	N	11.4	9.3	94.6	N	N	N	N	NR
597	1439254	207	HR	1/25/2023	59	M	N	1/17/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	1/25/2023	N	N	N	N	Y	N	N	N	N	N	N	N	N	N	N	10.1	16.8	79.9	Y	N	N	N	NR
598	528376	206	LC	1/24/2023	59	M	N	1/18/2023	WARD	RENAL DISEASE	SERUM	1/24/2023	Y	N	N	N	Y	N	N	N	N	N	N	N	N	N	N	9.1	7.1	61	N	N	N	N	NR
599	547042	202	HS	1/24/2023	72	M	N	1/12/2023	WARD	CARDIOVASCULAR DISEASE	SERUM	1/24/2023	N	N	N	Y	Y	Y	N	N	N	N	N	N	N	N	N	10.2	9.1	65.5	N	N	N	N	NR
600	1397410	201	JN	1/24/2023	67	M	N	1/23/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	1/24/2023	N	Y	N	N	Y	N	N	N	N	Y	N	N	N	N	N	11.5	5.5	72.9	N	N	N	N	Normal
601	1450933	223	SK	1/26/2023	60	F	N	1/24/2023	WARD	CARDIOVASCULAR DISEASE	SERUM	1/26/2023	N	N	Y	Y	Y	N	N	N	N	N	N	N	N	N	N	9.6	8	82	N	N	N	N	NR
602	1451792	226	NK	1/27/2023	57	F	N	1/26/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	1/27/2023	Y	N	Y	N	N	N	N	N	N	N	Y	N	N	N	N	12.3	17.1	83.6	N	N	N	N	NR
603	1432532	215	GS	1/25/2023	58	M	N	1/24/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	1/25/2023	N	Y	Y	Y	N	N	N	N	N	N	N	N	N	N	N	15.3	79	80.7	N	N	N	N	NR
604	831558	228	PK	1/25/2023	54	M	N	1/23/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	1/25/2023	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	9.1	15.02	92.2	N	N	N	N	NR
605	1450522	200	BS	1/24/2023	62	M	N	1/23/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	1/24/2023	Y	Y	Y	N	Y	Y	N	Y	N	N	N	N	N	N	N	10.2	7.9	68.9	Y	Y	N	N	NR
606	1451672	218	GS	1/25/2023	49	M	N	1/25/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	1/25/2023	Y	N	Y	Y	N	N	N	N	N	Y	N	N	N	N	N	10.7	25.4	78.4	N	N	N	N	NR
607	1441816	38	DD	1/4/2023	38	M	N	1/4/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	1/4/2023	Y	N	Y	N	N	N	N	N	N	N	N	N	N	N	Y	5.5	6.7	94.1	N	Y	N	N	NR
608	1441318	56	J	1/7/2023	40	F	N	1/3/2023	WARD	RENAL DISEASE	SERUM	1/7/2023	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	8.9	14	86	N	N	N	N	NR
609	1440255	19	PK	1/2/2023	60	F	N	1/1/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	1/2/2023	Y	Y	Y	N	Y	Y	N	N	N	N	N	N	N	N	N	11	5	50.3	N	N	N	N	NR
610	1440365	47	RK	1/5/2023	36	F	N	1/2/2023	ICU	NEUROLOGICAL DISEASE	SERUM	1/5/2023	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	N	8.3	9.8	91.3	N	N	N	N	NR
611	1431161	18	DK	1/2/2023	42	M	N	12/13/2022	ICU	NEUROLOGICAL DISEASE	SERUM	1/2/2023	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	9.6	6.6	62.4	Y	N	N	N	NR
612	1436358	39	BS	1/5/2023	60	M	N	12/23/2022	WARD	RENAL DISEASE	SERUM	1/5/2023	N	N	Y	N	Y	Y	N	N	N	N	N	N	N	N	N	8.9	17.8	88	N	N	N	N	NR
614	1139825	50	MR	1/6/2023	59	F	N	1/6/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	1/6/2023	Y	N	Y	N	N	Y	N	N	N	N	N	N	N	N	N	13.9	12	93	N	N	N	N	NR
615	1422611	35	NS	1/6/2023	36	M	N	12/19/2022	ICU	GASTROINTESTINAL TRACT DISEASE	SERUM	1/6/2023	N	N	N	N	N	N	N	N	N	N	N	N	N	N	Y	13.3	21.9	73.9	Y	N	N	N	NR
616	1442811	53	JK	1/7/2023	62	F	N	1/6/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	1/7/2023	Y	N	Y	N	N	N	N	N	N	N	N	N	N	N	N	8.8	4.9	74.3	N	N	N	N	NR
617	7343	48	BK	1/7/2023	43	F	N	1/6/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	1/7/2023	N	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	12.8	9.3	76.5	N	N	N	N	NR
618	1447934	164	VL	1/20/2023	70	M	N	1/18/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	1/20/2023	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	11.5	6.4	90.7	N	N	N	N	NR
619	1433914	161	GS	1/20/2023	63	M	P	12/19/2022	ICU	GENERAL SURGERY	SERUM	1/20/2023	N	N	N	N	Y	N	N	N	N	N	Y	N	N	N	N	14	22	80	N	N	N	N	Normal
620	534371	153	DS	1/19/2023	55	M	P	1/16/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	1/19/2023	N	N	Y	Y	Y	N	N	N	N	N	Y	N	N	N	N	11.4	6.8	50	Y	N	N	N	NR
621	1448427	142	GS	1/20/2023	57	M	N	1/19/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	1/20/2023	Y	N	N	N	Y	N	N	N	N	N	N	N	N	N	N	13	20.8	88	N	N	N	N	Normal
622	1446742	145	RA	1/18/2023	75	M	N	1/16/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	1/18/2023	Y	N	N	Y	Y	N	N	N	N	N	N	Y	N	N	N	9	11.6	86.3	N	N	N	N	NR
623	1446927	144	KS	1/17/2023	53	M	N	1/17/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	1/17/2023	N	N	N	Y	Y	Y	N	N	N	N	N	N	N	N	N	11.27	6.7	86.4	Y	N	N	N	NR
624	1446006	123	PC	1/15/2023	75	M	N	1/15/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	1/15/2023	Y	N	Y	N	Y	Y	N	N	N	Y	Y	N	N	N	N	9	18	96.3	Y	N	N	N	NR
625	1447196	142	GK	1/17/2023	55	F	N	1/17/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	1/17/2023	Y	N	Y	N	Y	Y	N	N	N	N	N	N	N	N	N	8.5	11.1	86.2	N	Y	Y	N	NR
626	1445923	117	BR	1/15/2023	59	M	N	1/15/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	1/15/2023	Y	Y	N	N	Y	N	N	Y	N	N	Y	N	N	N	N	10	7.9	72	N	N	N	Y	NR
627	1446000	113	S	1/17/2023	76	M	N	1/15/2023	WARD	CARDIOVASCULAR DISEASE	SERUM	1/17/2023	Y	N	Y	Y	N	Y	N	N	N	N	N	N	N	N	N	10	24.4	80	N	N	N	N	NR
628	1441796	130	GK	1/17/2023	71	F	N	1/4/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	1/17/2023	N	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	7.9	20.2	88	N	N	N	N	NR
629	1447247	143	SK	1/17/2023	93	F	N	1/16/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	1/17/2023	Y	N	Y	N	Y	Y	N	N	N	N	N	N	N	N	N	9	15	70	N	N	N	N	NR
630	1446751	145	RK	1/17/2023	58	M	N	1/16/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	1/17/2023	N	Y	Y	N	N	N	N	N	N	Y	N	N	N	N	N	13.7	13	83.3	N	N	N	N	NR
631	935373	-	DK	1/15/2023	45	M	N	1/13/2023	WARD	RENAL DISEASE	SERUM	1/15/2023	N	N	Y	N	N	Y	N	N	N	N	N	N	N	N	N	15.4	7.5	83.1	N	Y	N	N	NR

S. no	MRD No.	Lab No	Distribution of clinical samples received	Fungal smear Positive for Hyaline Septate Fungal Hyphae	CANDIDA IN (BODY FLUIDS AND BLOOD CULTURE)	CANDIDA IN BODY FUILDS	FUNGAL CULTURE FOR ASPERGILLUS SPECIES	Fungal Cuture	GMSAASSAY	1-3 BDG	PTZ	ANTIFUNGAL	Heamo Dylasis	AUGMENTIN	MEROPENEM	Provisional diagnosis	Outcome	TOTAL EORTC PATIENTS	PROVEN	POSSIBLE	PROBABLE	NO INVASIVE ASPERGILLOSI
584	1138879	189	NR	NR	-	-	NR	NR	0.55	0.04	Y	N	Y	N	Y	LIVER DISEASE, CHOLILITHAISIS	DISCHARGE	Y	N	Y	Y	N
585	1449679	186	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.15	-	N	N	N	N	N	COPD	DISCHARGE	N	N	N	N	Y
586	1445830	187	NR	NR	-	-	NR	NR	1.9	-	N	N	N	N	Y	AKI	DISCHARGE	Y	N	Y	Y	N
587	1447933	188	NR	NR	-	-	NR	NR	0.19	0.05	Y	N	N	N	Y	CIRRHOSIS, PORTAL HTN	DISCHARGE	N	N	N	N	Y
588	386346	191	NR	NR	-	-	NR	NR	0.16	1.2	N	N	N	N	N	CKD	DISCHARGE	N	N	N	N	Y
589	1447917	180	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	8.69	0.02	N	N	N	N	Y	CHRONIC OBSTRICTIVE PULMONARY DISEASE	DISCHARGE	Y	N	Y	Y	N
591	1412140	199	NR	NR	-	-	NR	NR	0.1	-	N	N	N	N	N	CKD	DISCHARGE ON REQUEST	N	N	N	N	Y
592	1441828	193	NR	NR	-	-	NR	NR	0.65	8.02	N	N	N	N	N	CHOLITHIASIS	DISCHARGE	Y	N	Y	N	N
593	6485	203	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	2.84	0.05	N	N	N	N	N	ENLARGED MEDIASTIC NODULES	DISCHARGE ON REQUEST	Y	N	Y	Y	N
594	1449831	205	NR	NR	-	-	NR	NR	2.91	0.51	N	Y	N	N	Y	AKI	DISCHARGE	Y	N	Y	Y	N
595	1326826	204	NR	NR	-	-	NR	NR	0.3	-	Y	N	N	N	N	CIRRHOSIS, ASCITES, PORTAL HTN	DISCHARGE	N	N	N	N	Y
596	375054	208	SPUTUM	Neg	-	-	Neg	NG	0.25	-	N	N	N	N	Y	POST CABG	DISCHARGE	N	N	N	N	Y
597	1439254	207	NR	NR	-	-	NR	NR	0.14	-	N	N	N	N	Y	CLD	DISCHARGE	N	N	N	N	Y
598	528376	206	PLEURAL FLUID	Neg	-	-	Neg	NG	0.13	0.03	N	N	Y	N	N	CKD	DISCHARGE	N	N	N	N	Y
599	547042	202	NR	NR	-	-	NR	NR	0.2	-	N	N	Y	N	N	OSA, CKD	DISCHARGE	N	N	N	N	Y
600	1397410	201	SPUTUM	Neg	-	-	Neg	NG	0.12	-	N	N	N	N	N	PULMONARY TUBERCULOSIS	DISCHARGE	N	N	N	N	Y
601	1450933	223	NR	NR	-	-	NR	NR	0.85	0.04	N	N	N	N	N	LRTI	DISCHARGE	N	N	N	N	Y
602	1451792	226	SPUTUM	Neg	-	-	Neg	NG	8.59	-	N	Y	N	N	Y	COPD	DISCHARGE	Y	N	Y	N	N
603	1432532	215	NR	NR	-	-	NR	NR	0.15	-	N	N	N	N	N	DYSPNEA	DISCHARGE	N	N	N	N	Y
604	831558	228	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.55	1.02	Y	Y	N	N	N	LRTI	DISCHARGE	N	N	N	N	Y
605	1450522	200	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.1	-	N	Y	N	N	Y	SMOKER, COPD, LRTI, SEPSIS	DISCHARGE	N	N	N	N	Y
606	1451672	218	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.1	-	N	Y	N	N	Y	TB, RESPIRATORY FAILURE	DISCHARGE	N	N	N	N	Y
607	1441816	38	NR	NR	-	-	NR	NR	0.14	-	N	N	N	N	N	SOB	DISCHARGE	N	N	N	N	Y
608	1441318	56	NR	NR	-	-	NR	NR	0.11	0.02	N	N	Y	N	N	CKD	DISCHARGE	N	N	N	N	Y
609	1440255	19	NR	NR	-	-	NR	NR	0.16	-	Y	Y	N	N	N	LRTI, H1N1	DISCHARGE	N	N	N	N	Y
610	1440365	47	NR	NR	-	-	NR	NR	0.17	0.02	Y	N	N	N	N	OSMOTIC DENYCLINATION SYNDROME	DISCHARGE	N	N	N	N	Y
611	1431161	18	NR	NR	-	-	NR	NR	0.15	0.03	N	N	N	N	N	PLEURAL EFFUSION	DISCHARGE	N	N	N	N	Y
612	1436358	39	URINE	Neg	-	-	Neg	NG	0.1	0.04	N	N	N	N	Y	CKD	DISCHARGE	N	N	N	N	Y
614	1139825	50	NR	NR	-	-	NR	NR	0.12	0.03	Y	N	N	N	N	LUNG DISEASE	DISCHARGE	N	N	N	N	Y
615	1422611	35	NR	NR	-	-	NR	NR	0.1	29.72	N	N	N	N	Y	INTESTINAL PERFORATION	DISCHARGE	N	N	N	N	Y
616	1442811	53	NR	NR	-	-	NR	NR	0.1	-	Y	Y	N	N	N	COPD	DISCHARGE	N	N	N	N	Y
617	7343	48	NR	NR	-	-	NR	NR	0.24	-	N	N	N	N	Y	FIBROITIC CHANGES IN UPPER LOBE	DISCHARGE	N	N	N	N	Y
618	1447934	164	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	1.2	-	N	N	N	N	N	DM-II	DISCHARGE	N	N	N	N	Y
619	1433914	161	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	1.1	-	N	N	N	N	N	ACUTE PANCREATITIS	DISCHARGE	Y	N	Y	N	N
620	534371	153	NR	NR	-	-	NR	NR	0.53	0.06	N	N	N	N	N	CLD, ASCITES	DISCHARGE	Y	N	Y	Y	N
621	1448427	142	NR	NR	-	-	NR	NR	1.5	-	N	N	N	N	N	HYPERTENSION	DISCHARGE	N	N	N	N	Y
622	1446742	145	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	10.71	0.02	N	N	N	N	Y	LRTI, CKD, FUNGAL INFECTION	DISCHARGE	Y	N	Y	N	N
623	1446927	144	SPUTUM	Neg	-	-	Neg	NG	9.37	8.25	N	N	N	N	N	PLEURAL EFFUSION	DISCHARGE	N	N	N	N	Y
624	1446006	123	NR	NR	-	-	NR	NR	2.01	8.63	N	Y	N	N	N	LRTI, ILD, FUNGAL SEPSIS	DISCHARGE	Y	N	Y	Y	N
625	1447196	142	NR	NR	-	-	NR	NR	2.25	-	N	N	N	N	Y	LRTI	DISCHARGE	N	N	N	N	Y
626	1445923	117	SPUTUM	Neg	-	-	Neg	NG	2.53	1.68	N	Y	N	N	Y	SEPSIS	DISCHARGE	Y	N	Y	Y	N
627	1446000	113	NR	NR	-	-	NR	NR	0.13	0.04	N	N	N	N	Y	INFECTIVE ETIOLOGY	DISCHARGE	N	N	N	N	Y
628	1441796	130	SPUTUM	Neg	-	-	Neg	NG	0.14	-	N	N	N	N	Y	PULMONARY EDEMA	DISCHARGE	N	N	N	N	Y
629	1447247	143	SPUTUM	Neg	-	-	Neg	NG	0.5	-	N	N	N	N	N	HIGH FEVER	DISCHARGE	N	N	N	N	Y
630	1446751	145	SPUTUM	Neg	-	-	Neg	NG	0.17	0.03	Y	N	N	N	N	TB POSITIVE	DISCHARGE	N	N	N	N	Y
631	935373	-	SPUTUM	Neg	-	-	Neg	NG	0.14	0.02	N	N	Y	N	Y	CKD	DISCHARGE	N	N	N	N	Y

S. no	MRD No.	Lab No	NAME	DOR Sample	AGE	SEX	GMRepeat	DOA	AREA	SUB AREA WISE	Sample	DOR Sample	FEVER	COUGH	SOB	CHEST PAIN	DM	HTN	Alcoholic	Smoker	Neutropenia	TBHistory	Chronic steroid use	Solid organ transplantation	Malignancy	HIV	HCV	HB	TLC/DLC	NEUTROPHIL COUNT	CT CHEST _PLEURAL EFFUSION	CONSOLIDATION IN LUNG	CAVITATION	RETICULONODULAR OPACITIES	Histopathology for aspergillus species
633	1444958	129	GS	1/17/2023	73	M	N	1/12/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	1/17/2023	N	N	Y	N	N	N	N	N	N	N	N	N	N	N	N	11.2	24	97	N	N	N	N	NR
634	1444336	132	TK	1/17/2023	82	M	N	1/10/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	1/17/2023	N	Y	Y	N	N	Y	N	N	N	N	N	N	N	N	N	7.5	13	89.6	Y	N	N	N	NR
635	1443906	115	NK	1/15/2023	40	M	N	1/9/2023	ICU	GASTROINTESTINAL TRACT DISEASE	SERUM	1/15/2023	N	N	N	N	Y	N	N	N	N	N	N	N	N	N	N	13	10.6	86.3	Y	N	N	N	NR
636	1445572	119	MD	1/15/2023	80	F	N	1/14/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	1/15/2023	Y	N	Y	N	Y	Y	N	N	N	N	N	N	N	N	N	9.6	13.97	91.6	N	N	N	N	NR
637	1445227	122	S	1/15/2023	72	M	N	1/12/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	1/15/2023	Y	N	Y	Y	Y	Y	N	N	N	N	Y	N	N	N	N	13.5	13	83	N	N	N	N	NR
638	1441361	168	KL	1/21/2023	75	M	N	1/3/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	1/21/2023	N	N	N	N	Y	Y	N	N	N	N	N	N	N	N	N	14	8.7	67	N	N	N	N	NR
639	1449148	176	SM	1/21/2023	57	M	N	1/20/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	1/21/2023	N	N	Y	N	Y	Y	N	N	N	N	N	N	N	N	N	8	6.6	77	N	N	N	N	NR
640	140809	173	AK	1/21/2023	72	M	N	1/17/2023	WARD	RENAL DISEASE	SERUM	1/21/2023	Y	N	Y	N	Y	Y	N	N	N	N	N	N	N	N	N	11.6	17	81.6	Y	N	N	Y	NR
641	1446787	172	GS	1/21/2023	73	M	N	1/17/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	1/21/2023	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	8.6	4.5	71.4	N	N	N	N	NR
642	1442837	170	JK	1/21/2023	37	F	N	1/6/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	1/21/2023	Y	N	Y	N	N	N	N	N	N	N	Y	N	N	N	N	11.5	14.3	86.7	N	N	N	N	NR
644	224609	37	JK	1/4/2023	75	F	N	1/1/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	1/4/2023	N	N	N	N	N	N	N	N	N	N	Y	N	N	N	N	5.6	5.8	46.1	N	N	N	Y	NR
645	586316	46	HK	1/5/2023	65	F	N	1/5/2023	WARD	RENAL DISEASE	SERUM	1/5/2023	N	N	N	N	Y	N	N	N	N	N	N	Y	N	N	N	9.1	9.9	60	N	N	N	N	NR
646	1434712	44	AR	1/5/2023	61	F	N	1/3/2023	ICU	RENAL DISEASE	SERUM	1/5/2023	N	N	N	N	Y	Y	N	N	N	N	N	Y	N	N	N	7.6	6.6	85	N	N	N	N	NR
647	1442858	54	SR	1/7/2023	65	M	N	1/7/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	1/7/2023	Y	N	Y	N	N	N	N	N	N	N	Y	N	N	N	N	13.9	5	90.6	Y	N	N	N	NR
648	1441800	43	IC	1/5/2023	75	F	N	1/4/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	1/5/2023	N	N	N	N	Y	Y	N	N	N	N	Y	N	N	N	N	14	16	92	N	N	N	N	NR
649	1445243	139	SA	1/17/2023	50	M	N	1/13/2023	ICU	GASTROINTESTINAL TRACT DISEASE	SERUM	1/17/2023	Y	N	Y	N	Y	N	N	N	N	N	N	N	N	N	N	10.2	30.2	96.5	N	N	N	N	NR
650	1445879	116	GS	1/15/2023	45	M	N	1/14/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	1/15/2023	Y	N	N	N	Y	N	N	N	N	Y	N	N	N	N	N	11	9.4	68.9	N	N	N	N	NR
651	1447920	167	BS	1/21/2023	40	M	N	1/18/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	1/21/2023	Y	N	Y	N	Y	N	N	N	N	N	N	N	N	N	N	13.9	19	95.9	N	Y	Y	Y	NR
652	1399065	171	PS	1/21/2023	61	M	N	1/15/2023	ICU	GASTROINTESTINAL TRACT DISEASE	SERUM	1/21/2023	N	N	N	N	N	N	N	N	N	N	Y	N	N	N	N	11.8	25	92.9	N	Y	N	N	NR
654	365902	160	DS	1/19/2023	48	M	N	1/17/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	1/19/2023	Y	N	Y	N	N	N	N	N	N	N	N	N	N	N	N	14.8	40	92	Y	Y	N	N	NR
656	1445178	149	KJ	1/19/2023	47	F	N	1/12/2023	ICU	GASTROINTESTINAL TRACT DISEASE	SERUM	1/19/2023	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	13.4	15.15	83.5	N	N	N	N	NR
657	1445427	150	G	1/19/2023	43	M	N	1/13/2023	ICU	GASTROINTESTINAL TRACT DISEASE	SERUM	1/19/2023	Y	N	N	N	Y	N	N	N	N	N	N	N	N	N	Y	8.4	9.61	75.3	N	N	N	N	NR
658	67045	252	KK	1/29/2023	75	M	N	1/28/2023	ICU	GASTROINTESTINAL TRACT DISEASE	SERUM	1/29/2023	N	N	N	N	Y	N	N	N	N	N	N	N	N	N	N	10.3	11.6	68.9	N	N	N	N	NR
659	1375789	240	GN	1/29/2023	68	M	N	1/27/2023	ICU	GASTROINTESTINAL TRACT DISEASE	SERUM	1/29/2023	Y	N	Y	N	N	Y	N	N	N	N	Y	N	N	N	N	11.5	13	85	N	N	N	N	NR
661	1453122	247	VK	1/29/2023	63	M	N	1/28/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	1/29/2023	Y	N	Y	N	N	N	Y	N	N	Y	N	N	N	N	N	14.4	23.5	89	N	Y	N	N	NR
662	974264	266	P	1/30/2023	71	F	P	1/24/2023	WARD	CARDIOVASCULAR DISEASE	SERUM	1/30/2023	N	N	Y	Y	Y	Y	N	N	N	N	Y	N	N	N	N	10.4	7.9	78.7	N	N	N	N	NR
663	894183	258	RK	1/30/2023	53	F	N	1/29/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	1/30/2023	Y	N	Y	N	N	N	N	N	N	N	N	N	N	N	N	13.5	14.9	91.7	N	N	N	N	NR
664	1445855	264	BS	1/30/2023	33	M	N	1/14/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	1/30/2023	Y	N	Y	N	N	N	N	N	N	N	N	N	N	N	N	9.5	7.27	61.8	Y	N	N	N	NR
665	1451233	263	CP	1/30/2023	37	M	N	1/25/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	1/30/2023	N	N	Y	N	N	N	N	N	N	N	Y	N	N	N	N	13.5	28.2	68	N	N	N	N	NR
666	163853	262	J	1/30/2023	54	M	P	1/26/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	1/30/2023	Y	N	Y	N	N	N	N	N	N	N	Y	N	N	N	N	13	11.72	75.5	N	N	N	Y	NR
667	1453333	259	RR	1/30/2023	35	F	N	1/29/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	1/30/2023	Y	N	Y	N	N	N	N	N	N	N	N	N	N	N	N	10.9	8.1	79.4	N	N	N	N	NR
668	1451831	261	JK	1/30/2023	30	F	N	1/26/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	1/30/2023	Y	N	Y	N	N	N	N	N	N	N	N	N	N	N	N	6.5	7.7	78.8	N	Y	N	Y	NR
669	1453549	260	KS	1/30/2023	47	M	N	1/30/2023	ICU	GASTROINTESTINAL TRACT DISEASE	SERUM	1/30/2023	Y	N	Y	N	Y	N	N	N	N	N	N	N	N	N	N	12.5	8.9	71.3	N	N	N	N	NR
673	1483629	832	JS	4/14/2023	35	M	P	4/13/2023	ICU	GASTROINTESTINAL TRACT DISEASE	SERUM	4/14/2023	N	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	8	11	82	Y	N	N	N	NR
675	1493118	830	GS	4/14/2023	69	M	N	4/4/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	4/14/2023	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	12.3	9.3	77	N	N	N	N	NR
676	1496236	829	PL	4/14/2023	42	M	N	4/10/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	4/14/2023	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	9.9	14	73.2	N	N	N	N	NR
677	1497457	828	PR	4/14/2023	30	F	N	4/11/2023	WARD	DERMATOLOGY	SERUM	4/14/2023	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	10.4	5	76.4	N	N	N	N	NR
678	1498019	827	BS	4/13/2023	45	M	N	4/12/2023	WARD	RENAL DISEASE	SERUM	4/13/2023	N	N	N	N	Y	N	N	N	N	N	N	Y	N	N	N	7.8	7	86.9	Y	N	N	N	NR
679	1465282	826	SK	4/13/2023	40	F	N	4/11/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	4/13/2023	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	13.9	6.4	81.6	N	N	N	N	NR
680	1498340	825	SR	4/13/2023	42	F	N	4/12/2023	WARD	CARDIOVASCULAR DISEASE	SERUM	4/13/2023	N	N	N	Y	Y	Y	N	N	N	N	N	N	N	N	N	10.9	20	76.2	N	N	N	N	NR
681	1498321	824	DS	4/12/2023	74	M	N	4/12/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	4/12/2023	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	14.2	10	91	N	N	N	N	NR
683	1492588	821	R	4/12/2023	40	M	N	4/4/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	4/12/2023	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	13	11	83	Y	N	N	N	NR
684	1496909	820	KB	4/12/2023	80	F	N	4/10/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	4/12/2023	N	N	Y	N	N	Y	N	N	N	N	N	N	N	N	N	8.7	26	88	Y	N	N	N	NR
685	1494864	819	KL	4/12/2023	55	M	N	4/18/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	4/12/2023	N	N	Y	N	Y	Y	N	N	N	N	Y	N	N	N	N	12.5	10.3	68	N	Y	N	Y	NR
686	1497618	818	HS	4/12/2023	21	M	N	4/11/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	4/12/2023	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	12	12	51.5	N	N	N	N	NR

S. no	MRD No.	Lab No	Distribution of clinical samples received	Fungal smear Positive for Hyaline Septate Fungal Hyphae	CANDIDA IN (BODY FLUIDS AND BLOOD CULTURE)	CANDIDA IN BODY FUILDS	FUNGAL CULTURE FOR ASPERGILLUS SPECIES	Fungal Cuture	GMSAASSAY	1-3 BDG	PTZ	ANTIFUNGAL	Heamo Dylasis	AUGMENTIN	MEROPENEM	Provisional diagnosis	Outcome	TOTAL EORTC PATIENTS	PROVEN	POSSIBLE	PROBABLE	NO INVASIVE ASPERGILLOSI
633	1444958	129	SPUTUM	Neg	-	-	Neg	NG	0.12	-	N	N	N	N	Y	PULMONARY INFECTION	DISCHARGE	N	N	N	N	Y
634	1444336	132	SPUTUM	Neg	-	-	Neg	NG	0.18	-	N	N	N	N	Y	PLEURAL EFFUSION	DISCHARGE	N	N	N	N	Y
635	1443906	115	ASCITIC FLUID	Neg	Y	-	Neg	NG	0.11	0.08	N	Y	N	N	Y	PLEURAL EFFUSION	DISCHARGE	N	N	N	N	Y
636	1445572	119	NR	NR	-	-	NR	NR	0.16	-	N	N	N	N	Y	HYPERTENSION	DISCHARGE	N	N	N	N	Y
637	1445227	122	SPUTUM	Neg	-	-	Neg	CANDIDA	0.14	0.03	N	N	N	N	Y	SOB	EXPIRED	N	N	N	N	Y
638	1441361	168	SPUTUM	Neg	-	-	Neg	CANDIDA	0.5	-	N	Y	N	N	N	LEFT SIDE WEAKNESS	DAMA	N	N	N	N	Y
639	1449148	176	SPUTUM	Neg	-	-	Neg	NG	0.4	-	N	N	N	N	N	SOB	DISCHARGE ON REQUEST	N	N	N	N	Y
640	140809	173	NR	NR	-	-	NR	NR	0.3	-	N	N	N	N	Y	HIGH FEVER	EXPIRED	N	N	N	N	Y
641	1446787	172	SPUTUM	Neg	-	-	Neg	NG	0.1	-	N	N	N	N	Y	CHOLITHIASIS	EXPIRED	N	N	N	N	Y
642	1442837	170	SPUTUM	Neg	-	-	Neg	NG	0.5	-	N	N	N	N	Y	LRTI	DISCHARGE	Y	N	Y	N	N
644	224609	37	NR	NR	-	-	NR	NR	1.56	-	N	Y	N	N	N	CLD	EXPIRED	Y	N	Y	Y	N
645	586316	46	NR	NR	-	-	NR	NR	0.53	0.02	Y	N	N	N	Y	CKD	DISCHARGE ON REQUEST	Y	N	Y	N	N
646	1434712	44	NR	NR	-	-	NR	NR	1.28	0.04	N	Y	N	N	N	CKD, LRTI, SEPSIS	DISCHARGE	Y	N	Y	N	N
647	1442858	54	NR	NR	-	-	NR	NR	0.53	-	Y	Y	N	N	N	ASCITES	DISCHARGE	Y	N	Y	Y	N
648	1441800	43	NR	NR	-	-	NR	NR	8.58	-	N	Y	N	N	N	UTI, ARTHRITIS, SEPSIS	DISCHARGE	Y	N	Y	N	N
649	1445243	139	NR	NR	-	-	NR	NR	0.12	0.05	N	N	N	N	Y	PANCREATITIS, RENAL FAILURE	DISCHARGE	N	N	N	N	Y
650	1445879	116	SPUTUM	Neg	-	-	Neg	NG	0.25	-	Y	N	N	N	N	FUNGAL SEPSIS	DISCHARGE	N	N	N	N	Y
651	1447920	167	SPUTUM	Neg	-	-	Neg	NG	11.25	-	N	N	N	N	Y	CONSOLIDATION IN LUNG	DISCHARGE	N	N	N	N	Y
652	1399065	171	NR	NR	-	-	NR	NR	14.76	6.24	N	N	N	N	Y	INFECTIVE BRONCHOPNEUMONIA	DISCHARGE	Y	N	Y	Y	N
654	365902	160	NR	NR	-	-	NR	NR	0.12	-	N	Y	N	N	Y	PLEURAL EFFUSION	DISCHARGE	N	N	N	N	Y
656	1445178	149	NR	NR	-	-	NR	NR	0.18	-	N	Y	N	N	Y	SEPSIS SHOCK	DISCHARGE	N	N	N	N	Y
657	1445427	150	NR	NR	-	-	NR	NR	0.2	0.05	N	N	N	N	Y	AKI, SHOCK	DISCHARGE	N	N	N	N	Y
658	67045	252	SPUTUM	Neg	-	-	Neg	NG	0.55	0.05	N	N	N	N	Y	ALTERED SENSORIUM	DISCHARGE	N	N	N	N	Y
659	1375789	240	PLEURAL FLUID	Neg	-	-	Neg	NG	11.92	0.85	N	N	N	N	Y	CLD, HERNIA REPAIR	DISCHARGE	Y	N	Y	N	N
661	1453122	247	SPUTUM	Neg	-	-	Neg	NG	0.1	-	N	N	N	N	N	LRTI, KOCH'S	DISCHARGE	N	N	N	N	Y
662	974264	266	SPUTUM	Neg	-	-	Neg	NG	0.76	0.04	N	N	N	N	Y	ASTHMA	DISCHARGE ON REQUEST	Y	N	Y	N	N
663	894183	258	NR	NR	-	-	NR	NR	0.16	-	N	N	N	N	Y	FIBRILE ILLNESS	DAMA	N	N	N	N	Y
664	1445855	264	NR	NR	-	-	NR	NR	0.17	-	Y	N	N	N	Y	ASCITES	DISCHARGE ON REQUEST	N	N	N	N	Y
665	1451233	263	NR	NR	-	-	NR	NR	1.14	2.95	N	N	N	N	Y	PANCREATITIS, RENAL DISEASE	DISCHARGE	Y	N	Y	N	N
666	163853	262	NR	NR	-	-	NR	NR	1.67	-	N	Y	N	N	N	-	DISCHARGE	Y	N	Y	Y	N
667	1453333	259	NR	NR	-	-	NR	NR	5.6	0.03	Y	N	N	N	N	INFECTIVE ETIOLOGY	DISCHARGE	N	N	N	N	Y
668	1451831	261	NR	NR	-	-	NR	NR	0.65	0.69	N	Y	N	N	N	INFECTIVE ETIOLOGY	DISCHARGE	N	N	N	N	Y
669	1453549	260	SPUTUM	Neg	-	-	Neg	NG	0.53	-	N	Y	N	N	N	DM	DISCHARGE	N	N	N	N	Y
673	1483629	832	NR	NR	-	-	NR	NR	14.2	0.17	N	N	N	N	Y	LRTI	EXPIRED	N	N	N	N	Y
675	1493118	830	ASCITIC FLUID	Neg	-	-	Neg	NG	0.13	0.03	N	N	N	N	Y	MULTIPLE PANCREATIC CYST	DISCHARGE	N	N	N	N	Y
676	1496236	829	NR	NR	-	-	NR	NR	0.2	0.02	N	N	N	N	Y	PANCREATITIS	DISCHARGE	N	N	N	N	Y
677	1497457	828	NR	NR	-	-	NR	NR	0.12	-	N	N	N	N	Y	DRUG REACTION	DISCHARGE	N	N	N	N	Y
678	1498019	827	ASCITIC FLUID	Neg	-	-	Neg	NG	0.1	0.02	N	N	N	N	Y	POST RENAL TRANSPLANT	DISCHARGE	Y	N	Y	N	N
679	1465282	826	NR	NR	-	-	NR	NR	0.15	0.02	N	N	N	N	Y	ASCITES, CIRRHOSIS	DISCHARGE	N	N	N	N	Y
680	1498340	825	NR	NR	-	-	NR	NR	0.16	0.02	Y	N	N	N	N	UTI	DISCHARGE	N	N	N	N	Y
681	1498321	824	NR	NR	-	-	NR	NR	0.11	0.02	N	N	N	N	Y	PNEUMONIA, AKI	DISCHARGE	N	N	N	N	Y
683	1492588	821	NR	NR	-	-	NR	NR	0.15	0.02	N	N	N	N	Y	CARCINOMA STOMACH	DISCHARGE	N	N	N	N	Y
684	1496909	820	NR	NR	-	-	NR	NR	0.1	-	N	N	N	N	Y	PLEURAL EFFUSION	DISCHARGE	N	N	N	N	Y
685	1494864	819	SPUTUM	Neg	-	-	Neg	CANDIDA	0.13	-	N	N	N	N	Y	COPD, LRTI	DISCHARGE	Y	N	Y	N	N
686	1497618	818	NR	NR	-	-	NR	NR	0.14	0.03	N	N	N	N	Y	PANCREATITIS	DISCHARGE	N	N	N	N	Y

S. no	MRD No.	Lab No	NAME	DOR Sample	AGE	SEX	GMRepeat	DOA	AREA	SUB AREA WISE	Sample	DOR Sample	FEVER	COUGH	SOB	CHEST PAIN	DM	HTN	Alcoholic	Smoker	Neutropenia	TBHistory	Chronic steroid use	Solid organ transplantation	Malignancy	HIV	HCV	HB	TLC/DLC	NEUTROPHIL COUNT	CT CHEST _PLEURAL EFFUSION	CONSOLIDATION IN LUNG	CAVITATION	RETICULONODULAR OPACITIES	Histopathology for aspergillus species
687	1494513	817	SS	4/11/2023	37	M	N	4/6/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	4/11/2023	N	N	N	N	N	Y	N	N	N	N	Y	N	N	N	Y	9.7	5.7	67.4	N	N	N	N	NR
689	1469029	773	PK	4/11/2023	48	F	P	2/23/2023	ICU	GASTROINTESTINAL TRACT DISEASE	SERUM	4/11/2023	N	N	N	N	Y	N	N	N	N	N	N	N	N	N	N	9.9	15	57.2	Y	Y	N	N	NR
690	1410957	772	SL	4/3/2023	72	F	N	3/22/2023	WARD	RENAL DISEASE	SERUM	4/3/2023	Y	Y	N	N	Y	N	N	N	N	N	N	N	N	N	N	7.6	8.3	61.1	Y	Y	N	N	Normal
692	492753	771	AK	4/3/2023	57	F	N	3/29/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	4/3/2023	Y	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	10.7	20	69	N	N	N	N	NR
693	197988	769	GS	4/3/2023	75	M	N	3/31/2023	WARD	ENDOCRINOLOGY	SERUM	4/3/2023	N	N	N	N	Y	N	N	N	N	N	N	N	N	N	N	10	12	78	Y	N	N	N	NR
694	1489250	768	JK	4/2/2023	41	M	N	3/28/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	4/2/2023	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	10	12	70	N	N	N	N	NR
695	1450733	766	AS	4/2/2023	35	M	N	4/2/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	4/2/2023	Y	N	Y	N	N	N	N	N	N	N	Y	N	N	N	N	10.5	25	86.6	N	N	N	N	NR
696	778714	885	PK	4/25/2023	52	M	N	4/2/2023	WARD	GENERAL SURGERY	SERUM	4/25/2023	N	N	N	N	Y	Y	N	N	N	N	N	N	N	N	N	7.1	21	77	N	N	N	N	NR
697	1208514	886	RK	4/25/2023	59	M	N	4/12/2023	WARD	CARDIOVASCULAR DISEASE	SERUM	4/25/2023	N	N	Y	Y	Y	N	N	N	N	N	N	N	N	N	N	8.8	17	88	Y	Y	N	N	NR
698	1281714	887	SM	4/25/2023	73	F	N	4/25/2023	WARD	ONCOLOGICAL	SERUM	4/25/2023	Y	N	N	N	N	N	N	N	N	N	N	N	Y	N	N	9	14	65	N	N	N	N	NR
699	1502634	888	MS	4/26/2023	55	M	N	4/20/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	4/26/2023	N	N	N	N	Y	N	N	N	N	N	Y	N	N	N	N	8.6	8.5	42	N	N	N	N	NR
700	895211	890	BS	4/26/2023	76	M	N	4/24/2023	WARD	RENAL DISEASE	SERUM	4/26/2023	N	Y	N	N	Y	N	N	N	N	N	N	N	N	N	N	11.4	15	93.2	N	N	Y	N	NR
701	1504936	893	BK	4/25/2023	67	F	N	4/24/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	4/25/2023	N	Y	N	N	N	Y	N	N	N	N	Y	N	N	N	N	10.2	8.5	80	Y	Y	N	Y	NR
703	1487252	895	S	4/27/2023	69	F	P	4/25/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	4/27/2023	N	N	Y	N	N	Y	N	N	N	N	Y	N	N	N	N	7.4	6.7	66	N	N	N	Y	NR
704	1495694	896	NS	4/27/2023	62	M	N	4/19/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	4/27/2023	N	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	10	7	67	N	N	N	N	NR
705	1506247	897	SS	4/27/2023	42	M	N	4/26/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	4/27/2023	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	6.5	22	67	N	N	N	N	NR
706	199960	900	SA	4/28/2023	87	M	N	4/26/2023	ICU	CARDIOVASCULAR DISEASE	SERUM	4/28/2023	N	N	N	Y	Y	N	N	N	N	N	N	N	N	N	N	16	14	90	N	Y	N	Y	NR
707	1505595	901	JS	4/28/2023	60	M	N	4/25/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	4/28/2023	Y	Y	Y	N	N	Y	N	N	N	N	N	N	N	N	N	9.9	20	93	Y	N	N	N	NR
708	1504924	902	N	4/28/2023	24	F	N	4/24/2023	WARD	GENERAL SURGERY	SERUM	4/28/2023	N	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	10	7	72	Y	Y	N	N	NR
709	1505567	903	TR	4/28/2023	83	M	N	4/25/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	4/28/2023	Y	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	8.8	11	83	N	N	N	N	NR
710	1506366	904	M	4/28/2023	26	M	N	4/27/2023	WARD	GENERAL SURGERY	SERUM	4/28/2023	N	N	N	N	N	N	N	N	N	N	N	N	Y	N	Y	7.2	2	56	N	N	N	Y	NR
711	1504868	905	BS	4/28/2023	90	M	N	4/24/2023	ICU	CARDIOVASCULAR DISEASE	SERUM	4/28/2023	N	N	N	Y	N	N	N	N	N	N	N	N	N	N	N	9.5	20	56	Y	N	N	N	NR
712	1502694	906	A	4/28/2023	48	F	N	4/21/2023	ICU	CARDIOVASCULAR DISEASE	SERUM	4/28/2023	N	N	N	Y	Y	N	N	N	N	N	N	N	N	N	N	11	18	89	N	N	N	N	NR
714	1429446	908	AS	4/28/2023	63	M	N	4/28/2023	WARD	CARDIOVASCULAR DISEASE	SERUM	4/28/2023	N	N	N	Y	Y	Y	N	N	N	N	N	N	N	N	N	7	10	72	Y	N	N	N	NR
715	1386425	909	JK	4/29/2023	50	F	P	4/29/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	4/29/2023	Y	Y	Y	N	N	N	N	N	N	N	Y	N	N	N	N	10.9	15.8	83.9	N	N	N	Y	NR
716	153775	910	AA	4/29/2023	80	F	N	4/19/2023	WARD	CARDIOVASCULAR DISEASE	SERUM	4/29/2023	N	N	N	Y	Y	Y	N	N	N	N	N	Y	N	N	N	9.4	11.1	72	N	N	N	N	NR
717	996037	911	AK	4/29/2023	64	M	N	4/27/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	4/29/2023	N	Y	Y	N	Y	N	N	N	N	Y	N	N	N	N	N	8	20	85	N	N	Y	N	NR
718	1505645	912	KS	4/30/2023	82	M	N	4/26/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	4/30/2023	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	11	2.6	90.1	N	Y	N	Y	NR
720	1485926	755	NG	4/1/2023	62	M	N	3/22/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	4/1/2023	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	13	14	59	N	N	N	N	NR
721	1482946	756	GS	4/1/2023	59	M	N	4/16/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	4/1/2023	Y	N	Y	N	N	N	N	N	N	N	Y	N	N	N	N	9.3	15	58	N	N	Y	N	NR
722	711671	757	SA	4/1/2023	82	M	N	3/16/2023	WARD	CARDIOVASCULAR DISEASE	SERUM	4/1/2023	N	N	N	Y	Y	Y	N	N	N	N	N	N	N	N	N	10	10	72	Y	Y	N	N	NR
723	1491041	758	P	4/1/2023	47	F	N	3/31/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	4/1/2023	N	N	Y	N	N	N	N	N	N	N	Y	N	N	N	N	8.8	10.2	83	N	N	N	Y	NR
724	1488591	759	RK	4/1/2023	40	M	N	3/27/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	4/1/2023	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	9	10	88	N	Y	N	N	NR
725	67505	760	GS	4/1/2023	37	M	N	4/14/2023	WARD	CARDIOVASCULAR DISEASE	SERUM	4/1/2023	N	N	N	Y	N	N	N	N	N	N	N	N	N	N	N	12	10	82	N	N	N	N	NR
726	581769	761	SK	4/2/2023	41	F	N	3/30/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	4/2/2023	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	11	5	44	N	N	N	N	NR
727	1489348	762	JS	4/2/2023	58	M	N	3/29/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	4/2/2023	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	13	5.9	72.2	Y	N	N	N	NR
728	63635	763	SS	4/2/2023	40	M	N	3/30/2023	WARD	RENAL DISEASE	SERUM	4/2/2023	Y	Y	N	N	N	Y	N	N	N	N	Y	Y	N	N	N	10.5	7.2	62	N	N	N	N	NR
729	1489957	764	SK	4/2/2023	35	M	N	4/26/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	4/2/2023	N	N	N	N	N	N	N	N	N	N	N	N	N	N	Y	13	10	72	N	N	N	N	NR
730	1484553	765	RS	4/2/2023	35	M	N	3/20/2023	WARD	CARDIOVASCULAR DISEASE	SERUM	4/2/2023	N	N	Y	Y	N	Y	N	N	N	N	N	N	N	N	N	12	7	60.2	Y	N	N	N	NR
731	1494508	812	KK	4/11/2023	53	F	N	4/6/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	4/11/2023	N	Y	Y	N	Y	N	N	N	N	Y	N	N	N	N	N	8	10	82	N	N	N	N	NR
734	1495918	814	DS	4/11/2023	45	M	N	4/8/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	4/11/2023	Y	N	N	N	N	Y	N	N	N	N	N	N	N	N	N	10	10	82	N	N	N	N	NR
736	767943	810	P	4/10/2023	57	M	N	4/8/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	4/10/2023	Y	N	Y	N	N	N	N	Y	N	N	Y	N	N	Y	N	11	9.7	92.9	Y	N	N	N	NR
737	442606	774	P	4/3/2023	25	F	N	4/3/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	4/3/2023	Y	N	Y	N	N	N	N	N	N	N	N	N	N	N	N	14	19	93	N	N	N	N	NR
738	1441809	775	MS	2/4/2023	37	M	N	2/4/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	2/4/2023	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	9.1	9.2	68.9	N	Y	N	N	NR
739	719432	776	S	4/3/2023	37	M	N	3/28/2023	WARD	RENAL DISEASE	SERUM	4/3/2023	N	Y	Y	N	N	N	N	N	N	N	Y	N	N	N	N	9.1	10.49	71.2	Y	N	N	N	NR
740	1490366	777	GK	4/3/2023	80	F	N	3/30/2023	ICU	CARDIOVASCULAR DISEASE	SERUM	4/3/2023	N	N	N	Y	Y	Y	N	N	N	N	N	N	N	N	N	10	24	89	N	N	N	Y	NR
741	1489285	778	T	4/4/2023	63	M	N	3/28/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	4/4/2023	N	N	N	N	Y	N	N	N	N	N	N	N	N	N	N	12	33.5	93.3	Y	N	N	N	NR

S. no	MRD No.	Lab No	Distribution of clinical samples received	Fungal smear Positive for Hyaline Septate Fungal Hyphae	CANDIDA IN (BODY FLUIDS AND BLOOD CULTURE)	CANDIDA IN BODY FUILDS	FUNGAL CULTURE FOR ASPERGILLUS SPECIES	Fungal Cuture	GMSAASSAY	1-3 BDG	PTZ	ANTIFUNGAL	Heamo Dylasis	AUGMENTIN	MEROPENEM	Provisional diagnosis	Outcome	TOTAL EORTC PATIENTS	PROVEN	POSSIBLE	PROBABLE	NO INVASIVE ASPERGILLOSI
687	1494513	817	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	4	-	N	N	N	N	Y	CLD, CELLULITIS, LRTI	DISCHARGE	Y	N	Y	N	N
689	1469029	773	SPUTUM	Neg	-	-	Neg	NG	0.54	0.02	N	Y	N	N	Y	PLEURAL EFFUSION	DISCHARGE	N	N	N	N	Y
690	1410957	772	PLEURAL FLUID	Neg	-	-	Neg	NG	0.11	0.03	N	N	N	N	Y	FLUID OVERLOAD, HTN	DISCHARGE	N	N	N	N	Y
692	492753	771	SPUTUM	Neg	-	-	Neg	NG	0.12	-	N	N	N	N	Y	LRTI	DISCHARGE	N	N	N	N	Y
693	197988	769	NR	NR	-	-	NR	NR	0.11	0.02	N	N	N	N	Y	PLEURAL EFFUSION	DISCHARGE	N	N	N	N	Y
694	1489250	768	ASCITIC FLUID	Neg	-	-	Neg	NG	0.1	0.03	N	N	N	N	Y	CIRRHOSIS	DISCHARGE	N	N	N	N	Y
695	1450733	766	SPUTUM	Neg	-	-	Neg	NG	1.67	0.03	N	N	N	N	Y	ABPA, LRTI	DISCHARGE	Y	N	Y	N	N
696	778714	885	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.18	0.75	N	N	N	N	Y	OLD CVA	DISCHARGE	N	N	N	N	Y
697	1208514	886	PLEURAL FLUID	Neg	-	-	Neg	NG	0.13	0.02	N	N	N	N	Y	NODULAR CONSOLIDATION	DISCHARGE	N	N	N	N	Y
698	1281714	887	NR	NR	-	-	NR	NR	0.15	-	N	N	N	N	Y	CA BREAST	DISCHARGE	Y	N	Y	N	N
699	1502634	888	NR	NR	-	-	NR	NR	1.63	-	N	N	N	N	Y	NECROTISING, PANCREATITIS	DISCHARGE	Y	N	Y	N	N
700	895211	890	NR	NR	-	-	NR	NR	0.19	0.03	N	N	N	N	N	COPD	DISCHARGE	N	N	N	N	Y
701	1504936	893	SPUTUM	Neg	-	-	Neg	NG	0.16	-	N	N	N	N	Y	PNEUMONIA, POST COVID	DISCHARGE	Y	N	Y	N	N
703	1487252	895	NR	NR	-	-	NR	NR	0.73	0.05	N	Y	N	N	Y	CLD, ASTHMA, LRTI	DISCHARGE	Y	N	Y	Y	N
704	1495694	896	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	CANDIDA	0.12	0.02	N	N	N	N	Y	NECROTISING	DISCHARGE	N	N	N	N	Y
705	1506247	897	ASCITIC FLUID	Neg	-	-	Neg	NG	0.13	0.02	N	N	N	N	Y	PANCREATITIS	DISCHARGE	N	N	N	N	Y
706	199960	900	NR	NR	-	-	NR	NR	0.1	0.02	N	N	N	N	N	CABG	DISCHARGE	N	N	N	N	Y
707	1505595	901	SPUTUM	Neg	-	-	Neg	NG	0.17	0.17	N	Y	N	N	Y	CKD, LRTI	DISCHARGE	N	N	N	N	Y
708	1504924	902	PLEURAL FLUID	Neg	-	-	Neg	NG	0.36	0.03	N	N	N	N	N	LSCS	DISCHARGE	N	N	N	N	Y
709	1505567	903	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	CANDIDA	0.23	0.05	N	N	N	N	Y	LRTI, AKI, SHOCK	DISCHARGE	N	N	N	N	Y
710	1506366	904	NR	NR	-	-	NR	NR	8.24	8.13	N	Y	N	N	N	ADENOCORICNOMA COLON	DISCHARGE	Y	N	Y	Y	N
711	1504868	905	SPUTUM	Neg	-	-	Neg	NG	0.13	0.09	N	Y	N	N	Y	SEPSIS, LRTI, AKI	DISCHARGE	N	N	N	N	Y
712	1502694	906	PERICARDIAL FLUID	Neg	-	-	Neg	NG	0.1	0.03	N	N	N	N	N	COPD	DISCHARGE	N	N	N	N	Y
714	1429446	908	PERICARDIAL FLUID	Neg	Y	-	Neg	NG	0.11	0.05	N	N	N	N	N	CKD, POST CAD	DISCHARGE	N	N	N	N	Y
715	1386425	909	SPUTUM	Neg	-	-	Neg	NG	0.9	0.04	N	Y	N	N	Y	LRTI, LUNG DISEASE	DISCHARGE	Y	N	Y	Y	N
716	153775	910	SPUTUM	Neg	-	-	Neg	NG	0.21	0.02	N	N	N	N	N	POST RENAL TRANSPLANT	DISCHARGE	Y	N	Y	N	N
717	996037	911	SPUTUM	Neg	-	-	Neg	CANDIDA	0.1	-	N	Y	N	N	N	SEPSIS, KOCH'S	DISCHARGE	N	N	N	N	Y
718	1505645	912	NR	NR	-	-	NR	NR	0.23	0.96	N	Y	N	N	Y	LRTI, SEPSIS	DAMA	N	N	N	N	Y
720	1485926	755	NR	NR	-	-	NR	NR	0.13	-	N	N	N	N	Y	PANCREATITIS	DISCHARGE	N	N	N	N	Y
721	1482946	756	SPUTUM	P	-	-	P	ASPERGILLUS FUMIGATUS	0.22	-	N	Y	N	N	N	LRTI	DISCHARGE	Y	N	Y	Y	N
722	711671	757	NR	NR	-	-	NR	NR	0.95	0.02	N	Y	N	N	Y	CAD, HYPOTHYROIDISM	DISCHARGE	N	N	N	N	Y
723	1491041	758	SPUTUM	Neg	-	-	Neg	CANDIDA	0.19	0.03	N	Y	N	N	N	ASTHMA	DISCHARGE	Y	N	Y	N	N
724	1488591	759	SPUTUM	Neg	-	-	Neg	CANDIDA	0.15	0.02	N	N	N	N	Y	PNEUMONIA	DISCHARGE	N	N	N	N	Y
725	67505	760	NR	NR	-	-	NR	NR	0.13	0.04	N	N	N	N	Y	CAD	DISCHARGE	N	N	N	N	Y
726	581769	761	SPUTUM	Neg	-	-	Neg	NG	0.15	-	N	N	N	N	N	LRTI	DISCHARGE	N	N	N	N	Y
727	1489348	762	SPUTUM	Neg	-	-	Neg	NG	0.12	0.02	N	Y	N	N	N	PANCREATITIS	DISCHARGE	N	N	N	N	Y
728	63635	763	SPUTUM	Neg	-	-	Neg	NG	0.9	0.04	N	Y	N	N	N	LRTI, ASTHMA	DAMA	Y	N	Y	N	N
729	1489957	764	NR	NR	-	-	NR	NR	0.16	-	N	N	N	N	N	HCV +VE, OPIOID TOXICITY	DAMA	N	N	N	N	Y
730	1484553	765	SPUTUM	Neg	-	-	Neg	CANDIDA	0.15	0.02	N	N	N	N	Y	SEPSIS, AKI, ANEMIA	DISCHARGE	N	N	N	N	Y
731	1494508	812	NR	NR	-	-	NR	NR	8.02	0.5	N	Y	N	N	Y	LRTI	DISCHARGE	N	N	N	N	Y
734	1495918	814	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	9.28	8.31	N	Y	N	N	Y	LRTI	DISCHARGE	N	N	N	N	Y
736	767943	810	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	CANDIDA	0.21	-	N	N	N	N	Y	COPD, KOCH'S	DAMA	Y	N	Y	N	N
737	442606	774	SPUTUM	Neg	-	-	Neg	NG	0.11	-	N	N	N	N	N	SOB	DISCHARGE ON REQUEST	N	N	N	N	Y
738	1441809	775	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	CANDIDA	0.13	-	N	Y	N	N	Y	CIRROHIS, HTN	DISCHARGE	N	N	N	N	Y
739	719432	776	PER CUTANEOUS DRAIN	Neg	-	-	Neg	NG	0.13	0.04	N	N	N	N	Y	CKD	DAMA	Y	N	Y	N	N
740	1490366	777	URINE	Neg	-	-	Neg	NG	0.15	3.88	N	Y	N	N	Y	SEPSIS	DISCHARGE	N	N	N	N	Y
741	1489285	778	NR	NR	-	-	NR	NR	0.18	0.04	N	N	N	N	Y	NECROTISING	DISCHARGE	N	N	N	N	Y

S. no	MRD No.	Lab No	NAME	DOR Sample	AGE	SEX	GMRepeat	DOA	AREA	SUB AREA WISE	Sample	DOR Sample	FEVER	COUGH	SOB	CHEST PAIN	DM	HTN	Alcoholic	Smoker	Neutropenia	TBHistory	Chronic steroid use	Solid organ transplantation	Malignancy	HIV	HCV	HB	TLC/DLC	NEUTROPHIL COUNT	CT CHEST _PLEURAL EFFUSION	CONSOLIDATION IN LUNG	CAVITATION	RETICULONODULAR OPACITIES	Histopathology for aspergillus species
742	1491087	779	DR	4/4/2023	61	M	N	4/4/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	4/4/2023	N	Y	Y	N	Y	N	N	N	N	N	N	N	N	N	N	9.2	39	66	N	N	N	Y	NR
744	139925	781	SD	4/4/2023	31	F	P	4/4/2023	ICU	GASTROINTESTINAL TRACT DISEASE	SERUM	4/4/2023	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	14	18	81	N	N	N	N	NR
746	1183723	783	JS	4/4/2023	73	M	N	4/1/2023	WARD	RENAL DISEASE	SERUM	4/4/2023	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	9.2	14.6	87.4	N	N	Y	Y	NR
747	34583	784	GS	4/4/2023	57	M	N	4/3/2023	ICU	NEUROLOGICAL DISEASE	SERUM	4/4/2023	N	N	N	N	N	Y	N	N	N	N	N	N	N	N	N	8.2	14.6	82.1	N	Y	N	Y	NR
749	1487864	786	TS	4/5/2023	50	M	-	4/2/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	4/5/2023	N	N	N	N	Y	Y	N	N	N	N	Y	N	N	N	N	8.3	9.8	88.4	Y	N	N	N	NR
750	1414074	787	HS	4/5/2023	53	M	N	3/29/2023	WARD	RENAL DISEASE	SERUM	4/5/2023	Y	Y	N	N	Y	Y	N	N	N	N	Y	N	N	N	Y	9.1	20.9	58.1	Y	N	N	N	NR
751	1486213	788	AS	4/5/2023	60	M	N	4/3/2023	WARD	RENAL DISEASE	SERUM	4/5/2023	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	7.1	2.1	54	Y	N	N	N	NR
752	1479161	789	DR	4/5/2023	66	M	N	4/3/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	4/5/2023	Y	Y	N	N	N	N	N	Y	N	Y	Y	N	N	N	N	7.7	25.6	90.9	N	N	N	N	NR
754	1034137	791	MS	4/5/2023	63	M	P	4/4/2023	ICU	GASTROINTESTINAL TRACT DISEASE	SERUM	4/5/2023	N	N	N	N	N	N	N	N	N	N	Y	N	N	N	N	10	22	89	N	N	N	N	NR
759	1494567	796	NL	4/8/2023	62	M	P	4/7/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	4/8/2023	Y	N	N	N	Y	N	N	N	N	N	Y	N	N	N	N	8.2	31.7	94.4	N	N	N	N	NR
760	1480623	797	PK	4/8/2023	65	M	N	4/1/2023	WARD	NEUROLOGICAL DISEASE	SERUM	4/8/2023	Y	Y	N	N	N	N	N	N	N	N	Y	N	N	N	N	8.6	26.4	88.4	N	N	N	N	NR
761	136789	798	VP	4/8/2023	84	M	N	4/7/2023	WARD	NEUROLOGICAL DISEASE	SERUM	4/8/2023	N	Y	N	N	Y	Y	N	N	N	Y	N	N	N	N	N	12	5.7	70	N	N	N	N	NR
763	1490426	800	GS	4/9/2023	80	M	N	3/30/2023	WARD	GENERAL SURGERY	SERUM	4/9/2023	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	10.8	20.3	67	N	N	N	N	NR
764	1495948	801	FC	4/8/2023	70	M	N	4/8/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	4/8/2023	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	7.9	10.91	92.5	Y	N	N	N	NR
765	1486562	802	SS	4/9/2023	49	M	N	3/23/2023	WARD	RENAL DISEASE	SERUM	4/9/2023	Y	N	N	N	N	Y	N	N	N	N	N	N	N	N	N	8.5	6.23	91.3	N	Y	N	N	NR
768	1495206	805	HK	4/10/2023	68	M	N	4/7/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	4/10/2023	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	10.8	14.5	83.3	N	Y	Y	N	NR
769	1398440	806	GS	4/10/2023	30	M	N	4/10/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	4/10/2023	N	N	N	N	N	N	Y	N	N	N	N	N	N	N	N	8.9	6	81.7	N	N	N	N	NR
770	1496035	807	SK	4/10/2023	55	M	P	4/10/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	4/10/2023	Y	Y	N	N	N	N	N	Y	N	N	Y	N	N	N	N	11.7	19.2	90.4	N	N	N	Y	NR
771	1469979	808	SK	4/10/2023	76	M	N	4/7/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	4/10/2023	N	N	N	N	Y	N	N	N	N	N	Y	N	N	N	N	8	6.3	75.5	Y	N	N	N	NR
773	1495897	835	JK	4/14/2023	74	F	N	4/8/2023	WARD	CARDIOVASCULAR DISEASE	SERUM	4/14/2023	N	Y	N	Y	N	Y	N	N	N	N	N	N	N	N	N	10	15	74	Y	N	N	N	NR
775	1330089	837	JS	4/15/2023	43	M	P	4/12/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	4/15/2023	N	N	N	N	Y	N	N	N	N	N	N	N	N	N	N	11.7	10.3	52.8	N	N	N	N	NR
776	1499071	838	GK	4/15/2023	67	F	P	4/14/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	4/15/2023	N	Y	Y	N	N	Y	N	N	N	N	Y	N	N	N	N	10.4	10.1	55.3	N	Y	N	N	NR
777	1496077	840	KL	4/15/2023	45	M	N	4/10/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	4/15/2023	N	N	N	N	Y	Y	N	N	N	N	N	N	N	N	N	12.3	7.37	51	Y	N	N	N	NR
778	1471380	842	KK	4/15/2023	65	F	N	4/7/2023	WARD	ONCOLOGICAL	SERUM	4/15/2023	N	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	8.5	16	22.4	N	N	N	Y	NR
779	1376073	843	SL	4/15/2023	64	M	N	4/13/2023	WARD	RENAL DISEASE	SERUM	4/15/2023	N	Y	Y	N	Y	Y	N	N	N	N	N	Y	N	N	N	6.8	10.4	80.2	N	Y	N	N	NR
780	1499845	844	SK	4/15/2023	68	M	N	4/15/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	4/15/2023	N	Y	Y	Y	N	N	N	N	N	N	Y	N	N	N	N	11.8	13.3	93.5	N	N	N	N	NR
781	1495344	845	RS	4/16/2023	41	M	N	4/8/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	4/16/2023	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	8.4	2.2	68.9	N	N	N	N	NR
782	1499874	846	SB	4/16/2023	66	F	N	4/15/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	4/16/2023	Y	Y	N	Y	N	Y	N	N	N	N	Y	N	N	N	N	12.2	8.8	96.6	N	N	N	Y	NR
783	1499345	848	SS	4/16/2023	63	M	P	4/15/2023	WARD	RENAL DISEASE	SERUM	4/16/2023	Y	Y	N	Y	Y	Y	N	N	N	N	N	Y	N	N	N	11.5	12.1	51.5	N	Y	N	N	NR
784	193439	849	AS	4/17/2023	33	M	N	3/29/2023	WARD	ENDOCRINOLOGY	SERUM	4/17/2023	Y	N	Y	N	N	N	N	N	N	N	Y	N	N	N	N	9.8	5.1	77.1	N	Y	N	Y	NR
785	1497630	850	HS	4/17/2023	25	M	N	4/11/2023	WARD	RENAL DISEASE	SERUM	4/17/2023	Y	N	Y	N	N	N	N	N	N	N	Y	N	N	Y	N	10	11.27	60.5	N	N	N	N	NR
786	822404	851	PL	4/17/2023	66	M	N	4/19/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	4/17/2023	Y	Y	N	N	Y	N	N	N	N	N	Y	N	Y	N	N	9.4	9.5	77.9	N	N	N	Y	NR
787	1500723	852	K	4/17/2023	38	M	N	4/17/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	4/17/2023	N	N	N	N	N	N	Y	Y	N	N	N	N	N	N	N	8	14.2	88.3	Y	Y	N	N	NR
788	1500686	853	PS	4/18/2023	56	M	N	4/17/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	4/18/2023	N	N	N	N	Y	N	N	N	N	N	N	N	N	N	N	6.9	18.5	92.9	Y	N	N	N	NR
789	1499520	855	RS	4/18/2023	78	M	N	4/15/2023	WARD	NEUROLOGICAL DISEASE	SERUM	4/18/2023	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	11.8	6.48	78.1	N	N	N	Y	NR
790	1284193	856	RC	4/18/2023	61	M	N	4/13/2023	WARD	NEUROLOGICAL DISEASE	SERUM	4/18/2023	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	10.2	21	97.7	N	Y	N	Y	NR
792	1499806	858	RK	4/19/2023	50	M	N	4/15/2023	WARD	RENAL DISEASE	SERUM	4/19/2023	N	Y	Y	N	Y	Y	N	N	N	N	Y	N	N	N	N	7.9	10.5	62	N	Y	N	N	NR
793	1497654	860	GS	4/19/2023	47	M	N	4/11/2023	WARD	NEUROLOGICAL DISEASE	SERUM	4/19/2023	N	N	N	N	Y	Y	N	N	N	N	Y	N	N	N	N	14	9.8	94	N	N	N	N	NR
794	126199	861	JS	4/19/2023	51	M	N	4/18/2023	WARD	RENAL DISEASE	SERUM	4/19/2023	Y	Y	N	N	N	Y	N	N	N	N	N	Y	N	N	N	13.3	4.7	71.4	N	N	N	Y	NR
795	1499848	862	AK	4/19/2023	55	M	N	4/15/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	4/19/2023	Y	Y	N	Y	N	Y	N	N	N	N	N	N	N	N	N	12.7	11.3	87.6	N	N	N	N	NR
796	1500407	863	PK	4/20/2023	50	F	P	4/17/2023	ICU	GASTROINTESTINAL TRACT DISEASE	SERUM	4/20/2023	N	N	N	N	Y	N	N	N	N	N	Y	N	N	N	N	8	13	58.7	N	N	N	N	NR
797	677104	864	KK	4/20/2023	80	F	N	4/18/2023	WARD	GENERAL SURGERY	SERUM	4/20/2023	N	N	Y	N	Y	N	N	N	N	N	N	N	N	N	N	10.3	7.1	64.5	Y	N	N	N	NR
798	993180	865	AR	4/20/2023	55	F	N	4/13/2023	WARD	RENAL DISEASE	SERUM	4/20/2023	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	9.8	8.4	85.5	Y	N	N	N	NR
799	1435765	866	TL	4/21/2023	78	M	N	4/18/2023	WARD	RENAL DISEASE	SERUM	4/21/2023	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	7.5	8.4	86.9	Y	N	N	N	NR
800	1502640	867	SS	4/21/2023	32	M	N	4/20/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	4/21/2023	N	N	Y	N	N	N	N	N	Y	N	N	N	N	N	N	11.1	19.25	9.6	N	N	N	N	NR
801	1498900	868	MK	4/21/2023	54	F	N	4/21/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	4/21/2023	N	N	N	N	Y	Y	N	N	Y	N	N	N	N	N	N	10.2	10	16	N	Y	N	Y	NR
803	955381	871	HS	4/21/2023	56	M	N	4/18/2023	WARD	RENAL DISEASE	SERUM	4/21/2023	Y	N	N	N	Y	N	N	N	N	N	N	N	N	N	N	8	47.3	91.5	Y	N	N	N	NR

S. no	MRD No.	Lab No	Distribution of clinical samples received	Fungal smear Positive for Hyaline Septate Fungal Hyphae	CANDIDA IN (BODY FLUIDS AND BLOOD CULTURE)	CANDIDA IN BODY FUILDS	FUNGAL CULTURE FOR ASPERGILLUS SPECIES	Fungal Cuture	GMSAASSAY	1-3 BDG	PTZ	ANTIFUNGAL	Heamo Dylasis	AUGMENTIN	MEROPENEM	Provisional diagnosis	Outcome	TOTAL EORTC PATIENTS	PROVEN	POSSIBLE	PROBABLE	NO INVASIVE ASPERGILLOSI
742	1491087	779	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	CANDIDA	0.3	-	N	Y	N	N	N	AKI	DISCHARGE	N	N	N	N	Y
744	139925	781	NR	NR	-	-	NR	NR	1.5	-	N	N	N	N	N	VOMITING	DISCHARGE	N	N	N	N	Y
746	1183723	783	SPUTUM	P	-	-	P	ASPERGILLUS FLAVUS	0.11	0.04	N	Y	N	N	Y	CKD, LRTI	DISCHARGE	N	N	N	N	Y
747	34583	784	NASAL MUCOSA	P	-	-	P	ASPERGILLUS FLAVUS	0.11	-	N	N	N	N	Y	CONSOLIDATION IN LUNG	DISCHARGE	N	N	N	N	Y
749	1487864	786	ASCITIC FLUID	Neg	-	-	Neg	NG	9.7	0.03	N	Y	N	N	Y	CIRRHOSIS, HTN	DISCHARGE	Y	N	Y	Y	N
750	1414074	787	PER CUTANEOUS DRAIN	Neg	-	-	Neg	NG	0.16	0.17	N	N	N	N	Y	UTI, CKD	DAMA	Y	N	Y	N	N
751	1486213	788	URINE	Neg	Y	Y	Neg	CANDIDA	0.1	0.02	N	Y	N	N	Y	POST STENTING	DISCHARGE	N	N	N	N	Y
752	1479161	789	SPUTUM	Neg	-	-	Neg	CANDIDA	0.2	-	N	Y	N	N	Y	KOCH'S, UTI, SEPSIS	DISCHARGE	N	N	N	N	Y
754	1034137	791	ASCITIC FLUID	Neg	-	-	Neg	NG	0.77	0.03	N	Y	N	N	Y	CIRRHOSIS, HTN	DISCHARGE	Y	N	Y	N	N
759	1494567	796	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	4.02	-	N	Y	N	N	Y	SEPSIS, LRTI	DISCHARGE ON REQUEST	Y	N	Y	N	N
760	1480623	797	NR	NR	-	-	NR	NR	0.11	-	N	Y	N	N	Y	ILD, SEPSIS	DISCHARGE ON REQUEST	N	N	N	N	Y
761	136789	798	SPUTUM	Neg	-	-	Neg	NG	0.11	-	N	N	N	N	N	ON ATT	DISCHARGE ON REQUEST	N	N	N	N	Y
763	1490426	800	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.18	0.04	N	N	N	N	Y	NON HYDEGKIN LYMPHOMA	EXPIRED	N	N	N	N	Y
764	1495948	801	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	CANDIDA	0.16	-	N	N	N	N	N	CIRRHOSIS	DISCHARGE	N	N	N	N	Y
765	1486562	802	ASCITIC FLUID	Neg	-	-	Neg	NG	0.19	-	N	N	N	N	N	ILD, LIVER DISEASE	DAMA	N	N	N	N	Y
768	1495206	805	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	CANDIDA	0.9	-	N	Y	N	N	Y	LRTI	DISCHARGE	N	N	N	N	Y
769	1398440	806	ASCITIC FLUID	Neg	-	-	Neg	NG	0.23	0.02	N	N	N	N	Y	CIRRHOSIS, HTN	DISCHARGE	N	N	N	N	Y
770	1496035	807	SPUTUM	Neg	-	-	Neg	CANDIDA	1.7	-	N	Y	N	N	N	COPD, LRTI	DISCHARGE	Y	N	Y	Y	N
771	1469979	808	SPUTUM	Neg	-	-	Neg	CANDIDA	0.11	0.03	N	N	N	N	Y	CLD	DISCHARGE	N	N	N	N	Y
773	1495897	835	NR	NR	-	-	NR	NR	0.18	0.02	N	N	N	N	Y	LRTI	DISCHARGE	N	N	N	N	Y
775	1330089	837	NR	NR	-	-	NR	NR	0.15	0.02	N	N	N	N	Y	CIRRHOSIS	DISCHARGE	N	N	N	N	Y
776	1499071	838	SPUTUM	Neg	-	-	Neg	CANDIDA	0.55	-	N	Y	N	N	Y	ASTHMA	DISCHARGE	Y	N	Y	Y	N
777	1496077	840	NR	NR	-	-	NR	NR	0.18	0.02	N	N	N	N	Y	LRTI	DISCHARGE	N	N	N	N	Y
778	1471380	842	NR	NR	-	-	NR	NR	0.15	-	N	N	N	N	Y	AML, CLL	DISCHARGE	N	N	N	N	Y
779	1376073	843	SPUTUM	Neg	-	-	Neg	CANDIDA	0.13	0.02	N	Y	Y	N	Y	CKD, LRTI	DISCHARGE	Y	N	Y	N	N
780	1499845	844	SPUTUM	Neg	-	-	Neg	CANDIDA	0.14	-	N	Y	N	N	Y	ILD	DISCHARGE	N	N	N	N	Y
781	1495344	845	ASCITIC FLUID	Neg	-	-	Neg	NG	0.12	0.02	N	N	N	N	Y	CLD, PORTAL HTN	DISCHARGE	N	N	N	N	Y
782	1499874	846	SPUTUM	Neg	-	-	Neg	CANDIDA	0.1	-	N	Y	N	N	Y	ILD, LRTI	DISCHARGE	Y	N	Y	N	N
783	1499345	848	CSF	Neg	-	-	Neg	NG	1.4	0.02	N	Y	Y	N	Y	CKD, LRTI	DAMA	Y	N	Y	Y	N
784	193439	849	BAL	Neg	-	-	Neg	NG	0.11	0.02	N	Y	N	N	Y	CKD, AKI, SEPSIS	DISCHARGE ON REQUEST	Y	N	Y	N	N
785	1497630	850	SPUTUM	Neg	-	-	Neg	NG	0.17	1.75	N	N	Y	N	Y	FUNGALSEPSIS, PNEUMONIA	DAMA	N	N	N	N	Y
786	822404	851	SPUTUM	Neg	-	-	Neg	CANDIDA	0.12	0.04	N	Y	N	N	Y	CELL LYMPHOMA	DISCHARGE	Y	N	Y	N	N
787	1500723	852	ASCITIC FLUID	Neg	-	-	Neg	NG	0.31	2.54	N	Y	N	N	Y	PANCREATITIS	DISCHARGE	N	N	N	N	Y
788	1500686	853	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.14	0.02	N	N	N	N	Y	AKI	DISCHARGE	N	N	N	N	Y
789	1499520	855	URINE	Neg	-	-	Neg	NG	0.14	8.03	N	Y	N	N	Y	OPACIFICATION	DISCHARGE	N	N	N	N	Y
790	1284193	856	SPUTUM	Neg	-	-	Neg	CANDIDA	0.17	0.92	N	Y	N	N	Y	LRTI, KOCH'S	DAMA	N	N	N	N	Y
792	1499806	858	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.11	0.02	N	N	N	N	Y	CKD, LRTI	DISCHARGE	Y	N	Y	N	N
793	1497654	860	CSF	Neg	-	-	Neg	NG	0.17	-	Y	N	N	N	N	MENINGITIS	DISCHARGE ON REQUEST	N	N	N	N	Y
794	126199	861	SPUTUM	Neg	-	-	Neg	NG	0.12	0.04	N	N	Y	N	Y	CKD	DISCHARGE ON REQUEST	Y	N	Y	N	N
795	1499848	862	SPUTUM	Neg	-	-	Neg	CANDIDA	0.14	-	N	Y	N	N	Y	LRTI	DAMA	N	N	N	N	Y
796	1500407	863	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	1.72	1.48	N	N	N	N	Y	CKD	DAMA	Y	N	Y	N	N
797	677104	864	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.12	0.04	N	N	N	N	N	ACTIVE TB INFECTION	DAMA	N	N	N	N	Y
798	993180	865	NR	NR	-	-	NR	NR	0.17	-	N	N	N	N	Y	AKI	DISCHARGE ON REQUEST	N	N	N	N	Y
799	1435765	866	ASCITIC FLUID	Neg	-	-	Neg	NG	0.1	0.21	N	N	N	N	Y	CAD, AKI	DISCHARGE ON REQUEST	N	N	N	N	Y
800	1502640	867	NR	NR	-	-	NR	NR	0.14	-	N	N	N	N	Y	SOB	DISCHARGE	N	N	N	N	Y
801	1498900	868	SPUTUM	Neg	-	-	Neg	NG	0.16	0.02	N	N	N	N	Y	ARTHRITIS	DISCHARGE	Y	N	Y	N	N
803	955381	871	PLEURAL FLUID	Neg	Y	-	Neg	NG	0.12	3	N	Y	N	N	Y	CKD, SEPSIS	DISCHARGE	N	N	N	N	Y

S. no	MRD No.	Lab No	NAME	DOR Sample	AGE	SEX	GMRepeat	DOA	AREA	SUB AREA WISE	Sample	DOR Sample	FEVER	COUGH	SOB	CHEST PAIN	DM	HTN	Alcoholic	Smoker	Neutropenia	TBHistory	Chronic steroid use	Solid organ transplantation	Malignancy	HIV	HCV	HB	TLC/DLC	NEUTROPHIL COUNT	CT CHEST _PLEURAL EFFUSION	CONSOLIDATION IN LUNG	CAVITATION	RETICULONODULAR OPACITIES	Histopathology for aspergillus species
804	1501405	872	BS	4/22/2023	54	M	N	4/21/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	4/22/2023	N	N	N	N	Y	N	N	N	N	N	N	N	N	N	N	11.3	9.5	76.9	N	N	N	N	NR
806	1502044	874	SG	4/22/2023	56	M	N	4/19/2023	WARD	RENAL DISEASE	SERUM	4/22/2023	N	Y	Y	N	N	Y	N	N	N	N	N	N	N	N	N	7	12	52	N	N	N	Y	NR
807	1490874	875	SR	4/23/2023	72	F	N	4/21/2023	WARD	NEUROLOGICAL DISEASE	SERUM	4/23/2023	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	9.1	12.8	76.5	Y	N	N	N	NR
808	1480946	877	VK	4/23/2023	41	M	P	3/15/2023	ICU	GASTROINTESTINAL TRACT DISEASE	SERUM	4/23/2023	N	N	N	N	N	N	N	N	N	N	Y	N	N	N	N	7.8	15.7	79.4	N	N	N	N	NR
809	1499894	878	MS	4/24/2023	45	M	P	4/16/2023	ICU	GASTROINTESTINAL TRACT DISEASE	SERUM	4/24/2023	N	N	N	Y	N	N	N	N	N	N	Y	N	N	N	N	12.2	7.2	70.3	N	N	N	N	NR
810	1503456	879	KK	4/24/2023	34	F	N	4/21/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	4/24/2023	N	N	N	N	N	N	N	N	N	N	Y	N	N	N	N	10.6	8.5	54.4	N	N	N	N	NR
811	1497121	880	SD	4/24/2023	71	F	P	4/11/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	4/24/2023	N	Y	Y	N	Y	Y	N	N	N	N	N	N	N	N	N	7.8	20.1	87.8	N	Y	N	N	NR
812	1504942	882	UA	4/24/2023	36	F	N	4/24/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	4/24/2023	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	N	11.9	9.8	60.5	N	N	N	Y	NR
813	1061610	883	V	4/25/2023	71	M	N	4/3/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	4/25/2023	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	11.6	5.8	63.9	N	N	N	Y	NR
814	1504585	884	SS	4/25/2023	59	M	N	4/24/2023	WARD	RENAL DISEASE	SERUM	4/25/2023	Y	N	N	N	Y	Y	N	N	N	N	N	N	N	N	Y	8	8.2	86.5	N	N	N	Y	NR
815	1143903	899	OP	4/28/2023	73	M	N	4/21/2023	WARD	RENAL DISEASE	SERUM	4/28/2023	Y	N	Y	N	Y	Y	N	N	N	N	Y	N	N	N	N	9.5	10.4	73	Y	N	N	N	NR
816	1603846	2433	SS	12/1/2023	29	M	P	10/7/2023	ICU	GASTROINTESTINAL TRACT DISEASE	SERUM	12/1/2023	N	N	N	N	N	N	N	N	N	N	Y	N	N	N	N	7.4	7	79	Y	N	N	N	NR
817	1625564	2434	KR	2/27/2023	72	M	N	11/18/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	-	Y	Y	N	N	Y	N	N	N	N	N	N	N	N	N	N	8.3	18	89	N	N	N	Y	NR
818	1608370	2435	A	12/1/2023	46	M	N	12/1/2023	WARD	NEUROLOGICAL DISEASE	SERUM	12/1/2023	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	9.8	5.1	44	N	N	N	N	NR
819	1631030	2436	RS	12/1/2023	48	M	N	11/30/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	12/1/2023	N	N	N	N	N	N	Y	Y	N	N	N	N	N	N	N	7.2	18	92	N	N	N	N	NR
820	1623837	2437	RS	12/1/2023	62	M	N	11/15/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	12/1/2023	Y	Y	N	N	Y	N	Y	Y	N	N	N	N	N	N	N	11.8	37	79	N	Y	N	Y	NR
822	1353075	2439	J	11/28/2023	67	M	N	11/28/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	11/28/2023	Y	N	Y	N	Y	Y	N	N	N	N	Y	N	N	N	N	14	11	82	N	N	N	N	NR
823	1631292	2440	NS	12/2/2023	50	M	N	11/30/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	12/2/2023	N	N	N	N	N	Y	N	N	N	N	N	N	N	N	N	7.1	24	82	N	N	N	N	NR
824	213960	2441	RP	12/2/2023	71	F	N	11/21/2023	WARD	RENAL DISEASE	SERUM	12/2/2023	Y	Y	Y	N	Y	N	N	N	N	N	N	Y	N	N	N	6.8	15	72	N	N	N	N	NR
825	1632574	2442	U	12/2/2023	59	M	N	12/2/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	12/2/2023	Y	N	Y	N	Y	Y	N	N	N	N	Y	N	Y	N	N	12	14	78	N	N	N	N	NR
826	1625522	2443	S	12/3/2023	38	M	N	11/18/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	12/3/2023	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	15	16	95	N	N	N	N	NR
828	1632060	2445	H	12/3/2023	60	M	N	12/1/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	12/3/2023	N	N	Y	Y	Y	Y	N	N	N	N	N	N	N	N	N	11	8.3	84	N	N	N	N	NR
829	1628152	2446	AS	12/4/2023	30	M	N	11/23/2023	ICU	GASTROINTESTINAL TRACT DISEASE	SERUM	12/4/2023	N	Y	Y	N	N	N	N	N	N	N	Y	N	N	N	N	14	12	85	N	N	N	N	NR
830	1629438	2447	J	12/4/2023	36	F	N	11/26/2023	WARD	RENAL DISEASE	SERUM	12/4/2023	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	9.3	37	94	N	N	N	N	NR
831	1632737	2448	HS	12/4/2023	42	M	N	12/3/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	12/4/2023	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	11	15	81	N	N	N	N	NR
833	1607789	2450	G	12/4/2023	27	M	N	10/21/2023	WARD	ONCOLOGICAL	SERUM	12/4/2023	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	11	6	56	N	Y	N	Y	NR
835	1628817	2452	MS	12/4/2023	59	M	N	11/24/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	12/4/2023	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	8.9	11	89	Y	N	N	N	NR
836	1631459	2453	S	12/4/2023	34	M	N	11/30/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	12/4/2023	Y	N	Y	N	N	N	N	N	N	N	N	N	N	N	N	9.8	22	93	N	N	N	N	NR
837	1632755	2454	G	12/5/2023	52	M	N	12/3/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	12/5/2023	N	Y	Y	N	Y	Y	N	N	N	N	N	N	N	N	N	13	15	80	N	N	N	Y	NR
838	1633445	2455	PL	12/5/2023	65	M	N	12/4/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	12/5/2023	Y	N	N	N	Y	N	N	N	N	N	Y	N	N	N	N	8.5	9.6	66	N	N	Y	N	NR
839	1632677	2456	JS	12/5/2023	73	M	N	12/3/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	12/5/2023	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	11	92	88	Y	N	N	N	NR
840	1632744	2457	TS	12/3/2023	81	M	N	12/3/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	12/3/2023	N	N	N	N	Y	N	N	N	N	N	N	N	N	N	N	12	25	84	N	Y	Y	N	NR
841	542524	2458	V	12/6/2023	69	F	N	11/30/2023	WARD	CARDIOVASCULAR DISEASE	SERUM	12/6/2023	N	N	N	Y	Y	Y	N	N	N	N	N	N	N	N	N	10	29	94	Y	N	N	N	NR
842	1627020	2459	KS	12/6/2023	72	M	N	11/22/2023	WARD	RENAL DISEASE	SERUM	12/6/2023	N	N	Y	N	Y	Y	Y	Y	N	N	N	N	N	N	N	8.4	14	77	Y	N	N	N	NR
843	1550088	2460	BS	12/7/2023	70	M	N	11/20/2023	WARD	RENAL DISEASE	SERUM	12/7/2023	Y	N	Y	N	N	N	N	N	N	N	Y	N	N	N	N	8.5	24	85	Y	N	N	N	NR
844	1633457	2461	GD	12/7/2023	67	F	N	12/4/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	12/7/2023	N	Y	Y	N	Y	Y	N	N	N	N	N	N	N	N	N	8.9	14	89	N	Y	N	Y	NR
845	306118	2462	RK	12/7/2023	53	M	N	11/30/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	12/7/2023	Y	Y	N	N	Y	N	N	N	N	N	N	N	N	N	N	8.6	33	89	N	N	N	Y	NR
846	647990	2463	RP	12/7/2023	75	M	N	12/5/2023	ICU	CARDIOVASCULAR DISEASE	SERUM	12/7/2023	N	N	N	Y	Y	Y	N	N	N	N	N	N	N	N	N	12	11	79	N	Y	N	N	NR
847	1629363	2464	GM	12/8/2023	69	M	N	11/26/2023	ICU	NEUROLOGICAL DISEASE	SERUM	12/8/2023	N	N	N	N	Y	Y	N	N	N	N	N	N	N	N	N	9.9	12	82	N	N	N	N	NR
848	1620866	2465	AR	12/8/2023	55	F	N	11/8/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	12/8/2023	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	N	13	13	75	N	N	N	N	NR
849	1632785	2466	SK	12/8/2023	65	F	N	12/4/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	12/8/2023	N	Y	N	N	Y	N	N	N	Y	N	Y	N	N	N	N	6.6	0.7	33	N	Y	N	Y	NR
850	1562508	2467	MK	12/8/2023	67	F	N	12/7/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	12/8/2023	Y	Y	N	N	N	Y	N	N	N	N	N	N	N	N	N	9.1	9.7	91	N	N	N	N	NR
851	1521720	2468	BS	12/9/2023	55	M	N	11/28/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	12/9/2023	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	14	16	85	N	N	N	N	NR
853	1626050	2471	NS	12/9/2023	58	M	N	12/8/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	12/9/2023	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	10	24	76	N	Y	N	Y	NR
855	1621772	2474	RJ	12/9/2023	24	M	N	11/10/2023	ICU	NEUROLOGICAL DISEASE	SERUM	12/9/2023	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	7.7	15	90	Y	N	N	N	NR
856	1635136	2475	PS	12/10/2023	60	M	N	12/7/2023	WARD	RENAL DISEASE	SERUM	12/10/2023	Y	N	N	N	Y	N	N	N	N	N	N	N	N	N	N	13	9.9	66	N	Y	N	Y	NR

S. no	MRD No.	Lab No	Distribution of clinical samples received	Fungal smear Positive for Hyaline Septate Fungal Hyphae	CANDIDA IN (BODY FLUIDS AND BLOOD CULTURE)	CANDIDA IN BODY FUILDS	FUNGAL CULTURE FOR ASPERGILLUS SPECIES	Fungal Cuture	GMSAASSAY	1-3 BDG	PTZ	ANTIFUNGAL	Heamo Dylasis	AUGMENTIN	MEROPENEM	Provisional diagnosis	Outcome	TOTAL EORTC PATIENTS	PROVEN	POSSIBLE	PROBABLE	NO INVASIVE ASPERGILLOSI
804	1501405	872	NR	NR	-	-	NR	NR	0.12	-	N	N	N	N	Y	LIVER ABSCESS	DISCHARGE	N	N	N	N	Y
806	1502044	874	NR	NR	-	-	NR	NR	0.28	0.02	N	N	N	N	Y	AKI	DISCHARGE	N	N	N	N	Y
807	1490874	875	NR	NR	-	-	NR	NR	0.17	0.04	N	N	N	N	Y	CVA	DISCHARGE	N	N	N	N	Y
808	1480946	877	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.52	0.03	N	N	N	N	Y	PANCREATITIS	DISCHARGE	Y	N	Y	N	N
809	1499894	878	NR	NR	-	-	NR	NR	2.22	0.03	N	N	N	N	N	PANCREATITIS	DISCHARGE	Y	N	Y	N	N
810	1503456	879	SPUTUM	Neg	-	-	Neg	CANDIDA	0.15	-	N	N	N	N	Y	ALLERGIC BRONCH. PULMONARY ASPERGILIOUS	DISCHARGE	N	N	N	N	Y
811	1497121	880	SPUTUM	Neg	-	-	Neg	CANDIDA	1.06	2.45	N	N	N	N	Y	PULMONARY EMPHYSEMA	DISCHARGE	N	N	N	N	Y
812	1504942	882	SPUTUM	Neg	-	-	Neg	NG	0.5	-	Y	N	N	N	N	LRTI	DISCHARGE	N	N	N	N	Y
813	1061610	883	ASCITIC FLUID	Neg	-	-	Neg	NG	0.11	0.05	N	N	N	N	Y	CKD	DISCHARGE	N	N	N	N	Y
814	1504585	884	NR	NR	-	-	NR	NR	0.13	0.09	Y	N	N	N	N	CKD	DISCHARGE	N	N	N	N	Y
815	1143903	899	PLEURAL FLUID	Neg	-	-	Neg	NG	0.14	0.03	N	N	N	N	Y	CKD	DISCHARGE	Y	N	Y	N	N
816	1603846	2433	PER CUTANEOUS DRAIN	Neg	-	-	Neg	NG	0.56	-	N	Y	N	N	Y	PANCREATITIS	DISCHARGE	Y	N	Y	Y	N
817	1625564	2434	SPUTUM	Neg	-	-	Neg	CANDIDA	0.1	0.47	N	N	N	N	Y	LRTI	DISCHARGE	N	N	N	N	Y
818	1608370	2435	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.1	0.02	N	N	N	N	Y	DIFFUSED CEREBRAL STROPLY	DISCHARGE	N	N	N	N	Y
819	1631030	2436	NR	NR	-	-	NR	NR	0.1	0.02	N	N	N	N	Y	CIRRHOSIS WITH PORTAL HTN	DAMA	N	N	N	N	Y
820	1623837	2437	NR	NR	-	-	NR	NR	0.1	0.02	N	N	N	N	Y	CLD, SEPSIS, AKI	DISCHARGE ON REQUEST	N	N	N	N	Y
822	1353075	2439	SPUTUM	Neg	-	-	Neg	CANDIDA	0.08	82.16	N	Y	N	N	N	COPD, AKI	DISCHARGE	N	N	N	N	Y
823	1631292	2440	NR	NR	-	-	NR	NR	0.1	-	N	N	N	N	Y	HEPATOSPLEMOMEGALY	DISCHARGE	N	N	N	N	Y
824	213960	2441	SPUTUM	Neg	-	-	Neg	NG	1.25	0.02	Y	N	N	N	Y	COPD, CKD	DISCHARGE	Y	N	Y	N	N
825	1632574	2442	NR	NR	-	-	NR	NR	0.6	0.02	N	N	N	N	N	ILD, MALIGNANT CA PANCREAS	DAMA	Y	N	Y	N	N
826	1625522	2443	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.1	0.02	N	N	N	N	Y	NECROTISING, PANCREATITIS	DISCHARGE ON REQUEST	N	N	N	N	Y
828	1632060	2445	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.16	-	N	N	N	N	Y	CLD	DAMA	N	N	N	N	Y
829	1628152	2446	SPUTUM	Neg	-	-	Neg	NG	0.59	0.02	N	N	N	N	Y	PANCREATITIS	DISCHARGE ON REQUEST	Y	N	Y	N	N
830	1629438	2447	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	CANDIDA	0.21	0.02	N	N	N	N	Y	UTI	DAMA	N	N	N	N	Y
831	1632737	2448	NR	NR	-	-	NR	NR	0.1	0.02	N	N	N	N	Y	PANCREATITIS	DISCHARGE	N	N	N	N	Y
833	1607789	2450	NR	NR	-	-	NR	NR	0.1	0.02	N	Y	N	N	N	CA COLONE	DISCHARGE	N	N	N	N	Y
835	1628817	2452	PLEURAL FLUID	Neg	-	-	Neg	NG	0.1	-	N	N	N	N	N	HYPOTHYROIDISM	DAMA	N	N	N	N	Y
836	1631459	2453	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.1	0.02	N	N	N	N	Y	LRTI, SEPSIS	DAMA	N	N	N	N	Y
837	1632755	2454	SPUTUM	Neg	-	-	Neg	NG	0.1	-	N	N	N	N	N	ASTHMA, ABPA	DISCHARGE	N	N	N	N	Y
838	1633445	2455	NASAL MUCOSA	P	-	-	P	ASPERGILLUS FLAVUS	0.61	0.02	N	N	N	N	Y	FUNGAL SEPSIS	DAMA	Y	N	Y	Y	N
839	1632677	2456	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.54	0.02	N	Y	N	N	Y	CAD, LRTI	DAMA	N	N	N	N	Y
840	1632744	2457	SPUTUM	Neg	-	-	Neg	NG	0.11	0.02	N	N	N	N	Y	CHOLETHIASIS	DISCHARGE	N	N	N	N	Y
841	542524	2458	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.1	0.02	Y	N	N	N	Y	CAD PNEUMONIA	DISCHARGE	N	N	N	N	Y
842	1627020	2459	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.1	0.02	N	N	Y	N	N	AKI	DISCHARGE	N	N	N	N	Y
843	1550088	2460	URINE	Neg	-	-	Neg	NG	0.1	0.02	N	Y	N	N	Y	UTI, CKD	DISCHARGE	Y	N	Y	N	N
844	1633457	2461	NR	NR	-	-	NR	NR	0.1	-	N	Y	N	N	N	SEPSIS, LRTI	DISCHARGE ON REQUEST	N	N	N	N	Y
845	306118	2462	NR	NR	-	-	NR	NR	0.1	0.02	N	N	N	N	Y	DIABETIC FOOT, POST PTCA	DISCHARGE	N	N	N	N	Y
846	647990	2463	NR	NR	-	-	NR	NR	0.1	-	N	N	N	N	Y	UTI,CABG	DISCHARGE	N	N	N	N	Y
847	1629363	2464	SPUTUM	Neg	-	-	Neg	NG	0.1	0.02	N	N	N	N	Y	SAH	DISCHARGE	N	N	N	N	Y
848	1620866	2465	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.18	0.02	N	N	N	N	N	NECRITISING, PANCREATITIS	DISCHARGE	N	N	N	N	Y
849	1632785	2466	SPUTUM	Neg	Y	-	Neg	NG	0.1	0.02	N	Y	N	N	N	HYPOTHYROIDISM	DAMA	Y	N	Y	N	N
850	1562508	2467	SPUTUM	Neg	-	-	Neg	NG	0.1	0.41	Y	N	N	N	N	ILD	DAMA	N	N	N	N	Y
851	1521720	2468	NR	NR	-	-	NR	NR	0.16	0.02	N	N	N	N	Y	PANCREATITIS	DISCHARGE	N	N	N	N	Y
853	1626050	2471	SPUTUM	Neg	-	-	Neg	NG	0.12	-	N	N	N	N	N	LRTI, ABPA	DAMA	N	N	N	N	Y
855	1621772	2474	ENDOTRACHEAL SECRETIONS	Neg	Y	-	Neg	NG	0.1	8.07	N	N	N	N	N	L3L4 BULGING	DISCHARGE	N	N	N	N	Y
856	1635136	2475	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	CANDIDA	8.63	-	N	N	N	N	N	AKI, LRTI	DISCHARGE ON REQUEST	N	N	N	N	Y

S. no	MRD No.	Lab No	NAME	DOR Sample	AGE	SEX	GMRepeat	DOA	AREA	SUB AREA WISE	Sample	DOR Sample	FEVER	COUGH	SOB	CHEST PAIN	DM	HTN	Alcoholic	Smoker	Neutropenia	TBHistory	Chronic steroid use	Solid organ transplantation	Malignancy	HIV	HCV	HB	TLC/DLC	NEUTROPHIL COUNT	CT CHEST _PLEURAL EFFUSION	CONSOLIDATION IN LUNG	CAVITATION	RETICULONODULAR OPACITIES	Histopathology for aspergillus species
857	1636337	2476	BK	12/10/2023	75	F	N	12/9/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	12/10/2023	Y	Y	N	N	Y	N	N	N	N	N	N	N	N	N	N	10	12	86	N	N	N	N	NR
858	1347242	2477	AR	12/10/2023	73	F	N	12/10/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	12/10/2023	N	Y	Y	N	Y	Y	N	N	Y	N	N	N	N	N	N	9.6	26	20	N	Y	N	Y	NR
859	1631814	2478	T	12/11/2023	46	M	N	12/1/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	12/11/2023	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	10.7	14	66	N	N	N	N	NR
860	1634020	2479	JS	12/11/2023	62	M	N	12/5/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	12/11/2023	Y	N	Y	N	N	Y	N	N	N	N	Y	N	N	N	N	10.3	4.9	69	Y	Y	N	N	NR
861	1627669	2480	KK	12/11/2023	54	M	N	12/5/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	12/11/2023	Y	Y	N	N	N	N	N	N	N	N	Y	N	N	N	N	16.4	19.4	86	Y	N	N	Y	NR
862	1635790	2481	JS	12/12/2023	22	M	N	12/10/2023	WARD	GENERAL SURGERY	SERUM	12/12/2023	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	10	8.6	91	Y	N	N	N	NR
863	1219412	2482	VK	12/12/2023	64	M	N	12/9/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	12/12/2023	N	Y	Y	N	Y	Y	N	N	N	N	N	N	N	N	N	9.9	16	90	N	Y	N	Y	NR
864	1340106	2483	AS	12/12/2023	69	M	N	12/5/2023	WARD	RENAL DISEASE	SERUM	12/12/2023	Y	N	N	N	Y	N	N	N	N	N	N	N	N	N	N	7.9	11	88	N	Y	N	Y	NR
865	1504952	2484	RS	12/12/2023	73	M	N	11/23/2023	ICU	CARDIOVASCULAR DISEASE	SERUM	12/12/2023	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	N	12	27	79	N	N	N	N	NR
866	1632477	2485	MD	12/12/2023	83	F	N	12/4/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	12/12/2023	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	10	17	90.5	N	Y	N	Y	NR
867	1414374	2486	SK	12/12/2023	45	M	N	12/11/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	12/12/2023	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	10	10	72	N	N	N	N	NR
868	1166470	2487	SS	12/16/2023	85	F	N	12/20/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	12/16/2023	Y	N	Y	N	Y	N	N	N	N	N	N	N	N	N	N	9.5	8.8	91	N	Y	N	Y	NR
869	563465	2488	KD	12/12/2023	87	F	N	12/11/2023	ICU	CARDIOVASCULAR DISEASE	SERUM	12/12/2023	Y	N	Y	Y	N	Y	N	N	N	N	N	N	N	N	N	6.2	8.4	68	N	Y	N	Y	NR
870	1633467	2489	RS	12/12/2023	32	M	N	12/4/2023	WARD	RENAL DISEASE	SERUM	12/12/2023	N	N	N	N	N	N	Y	Y	N	N	N	N	N	N	N	11.3	10	74	N	N	N	N	NR
871	1637669	2490	JS	12/12/2023	40	M	N	12/12/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	12/12/2023	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	13	26	85	Y	N	N	N	NR
872	1632033	2491	SK	12/13/2023	63	F	N	12/7/2023	WARD	CARDIOVASCULAR DISEASE	SERUM	12/13/2023	Y	Y	N	Y	N	Y	N	N	N	N	Y	N	N	N	N	7.8	1.7	65	N	N	N	Y	NR
873	1277798	2492	PS	12/13/2023	71	M	N	12/9/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	12/13/2023	N	N	N	N	Y	N	N	N	N	N	Y	N	N	N	N	12	8	76	Y	N	N	N	NR
874	1634135	2493	GS	12/13/2023	44	M	N	12/5/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	12/13/2023	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	10	16	79	N	N	N	N	NR
875	1636498	2495	KS	12/13/2023	39	M	N	12/10/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	12/13/2023	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	8.9	17	88	N	Y	N	Y	NR
876	1636440	2496	AS	12/13/2023	64	M	N	12/10/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	12/13/2023	Y	N	Y	N	Y	Y	N	N	N	N	N	N	N	N	N	17	13	81	N	N	N	Y	NR
877	1632562	2497	HS	12/13/2023	82	M	N	12/6/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	12/13/2023	Y	Y	N	N	Y	Y	N	N	N	N	Y	N	N	N	N	11	14	85	N	Y	N	Y	NR
878	1637763	2498	SK	12/13/2023	58	M	N	12/12/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	12/13/2023	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	13	6	93	N	Y	N	Y	NR
879	1637721	2499	RK	12/13/2023	62	M	N	12/12/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	12/13/2023	Y	N	Y	N	N	N	N	N	Y	N	N	N	N	N	N	7.8	12.3	10	Y	Y	N	N	NR
880	1637911	2500	R	12/13/2023	34	F	P	12/13/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	12/13/2023	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	9.5	19.25	79	N	Y	Y	Y	NR
881	1632142	2502	MK	12/14/2023	63	F	N	12/2/2023	WARD	CARDIOVASCULAR DISEASE	SERUM	12/14/2023	N	Y	Y	Y	Y	Y	N	N	N	N	Y	N	N	N	N	10	10	79	N	Y	N	Y	NR
882	620378	2504	BK	12/15/2023	67	F	N	12/8/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	12/15/2023	Y	Y	N	N	N	Y	N	N	N	N	N	N	N	N	N	11	12	96	N	Y	N	Y	NR
883	1638234	2505	DS	12/16/2023	47	M	N	12/13/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	12/16/2023	Y	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	11	13	89	N	N	N	N	NR
884	1638354	2506	MK	12/15/2023	30	M	N	12/14/2023	WARD	NEUROLOGICAL DISEASE	SERUM	12/15/2023	N	N	N	N	N	Y	N	N	N	N	N	N	N	N	N	15	12	49	N	N	N	Y	NR
885	1638758	2507	BS	12/15/2023	22	M	N	12/14/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	12/15/2023	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	11	21	83	Y	N	N	N	NR
886	1439754	2508	KS	12/16/2023	68	M	N	12/13/2023	WARD	NEUROLOGICAL DISEASE	SERUM	12/16/2023	N	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	8.1	9.9	79	N	N	N	N	NR
887	1294637	2509	MS	12/16/2023	23	M	N	12/16/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	12/16/2023	Y	Y	N	N	N	Y	N	N	N	N	Y	N	N	N	N	17	17	75	N	N	N	Y	NR
888	1222815	2510	PK	12/16/2023	66	M	N	12/12/2023	ICU	RENAL DISEASE	SERUM	12/16/2023	N	N	N	N	Y	N	N	N	N	N	N	Y	N	N	N	9	9	85	Y	N	N	N	NR
889	1637201	2511	MS	12/17/2023	20	M	N	12/11/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	12/17/2023	N	N	N	N	N	N	N	N	N	N	Y	N	N	N	N	7.5	9.6	54	N	N	N	Y	NR
890	1639819	2512	SK	12/18/2023	60	M	N	12/16/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	12/18/2023	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	8.9	8	69	N	N	N	N	NR
891	1639365	2513	K	12/18/2023	34	M	N	12/15/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	12/18/2023	N	Y	N	Y	N	N	N	N	N	N	N	N	N	N	N	10	18	77	N	N	Y	Y	NR
892	1609251	2514	BS	12/18/2023	43	M	N	12/14/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	12/18/2023	N	Y	N	N	Y	N	N	N	N	N	Y	N	N	N	N	12	11	91	N	N	N	N	NR
893	1637163	2515	RK	12/18/2023	45	M	N	12/11/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	12/18/2023	N	N	N	N	N	N	Y	N	N	N	N	N	N	N	N	10	12	74	N	N	N	N	NR
894	1639996	2516	JK	12/18/2023	45	F	N	12/17/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	12/18/2023	N	N	Y	N	N	Y	N	N	N	N	Y	N	N	N	N	9.6	20	92	N	Y	N	N	NR
895	1639909	2517	S	12/18/2023	58	F	N	12/16/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	12/18/2023	Y	Y	N	Y	Y	N	N	N	N	N	N	N	N	N	N	13	11	89	N	N	N	Y	NR
896	1639456	2518	MS	12/18/2023	75	M	N	12/15/2023	WARD	RENAL DISEASE	SERUM	12/18/2023	N	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	9.4	9	70	N	N	N	Y	NR
897	1637672	2520	BM	12/19/2023	80	M	N	12/12/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	12/19/2023	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	12	10	75	Y	N	N	N	NR
898	1638573	2521	JS	12/19/2023	73	M	N	12/15/2023	WARD	RENAL DISEASE	SERUM	12/19/2023	N	Y	Y	N	N	N	N	N	N	N	N	N	Y	N	N	10	18	79	N	N	N	N	NR
899	1638775	2522	RK	12/19/2023	50	F	N	12/14/2023	WARD	ONCOLOGICAL	SERUM	12/19/2023	Y	Y	N	N	N	N	N	N	Y	N	N	N	Y	N	N	9.1	1.4	19	Y	N	N	N	NR
900	1638260	2523	AK	12/19/2023	62	F	N	12/13/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	12/19/2023	N	Y	Y	N	Y	Y	N	N	N	N	Y	N	N	N	N	11	15	92	N	N	N	Y	NR
901	1640145	2524	GK	12/19/2023	51	F	N	12/18/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	12/19/2023	N	Y	Y	N	N	N	N	N	N	N	N	N	Y	N	N	11	11	87	N	Y	N	Y	NR
902	1637222	2525	RP	12/20/2023	62	M	N	12/12/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	12/20/2023	N	N	N	N	N	N	Y	N	N	N	N	N	N	N	N	8.2	6	82	N	N	N	N	NR
903	1639414	2526	PS	12/20/2023	43	M	N	12/15/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	12/20/2023	N	Y	Y	N	N	Y	N	Y	N	N	N	N	N	N	N	10	22	79	N	Y	N	Y	NR

S. no	MRD No.	Lab No	Distribution of clinical samples received	Fungal smear Positive for Hyaline Septate Fungal Hyphae	CANDIDA IN (BODY FLUIDS AND BLOOD CULTURE)	CANDIDA IN BODY FUILDS	FUNGAL CULTURE FOR ASPERGILLUS SPECIES	Fungal Cuture	GMSAASSAY	1-3 BDG	PTZ	ANTIFUNGAL	Heamo Dylasis	AUGMENTIN	MEROPENEM	Provisional diagnosis	Outcome	TOTAL EORTC PATIENTS	PROVEN	POSSIBLE	PROBABLE	NO INVASIVE ASPERGILLOSI
857	1636337	2476	PLEURAL FLUID	Neg	-	-	Neg	NG	0.24	-	N	N	N	N	N	SEIZURES	DAMA	N	N	N	N	Y
858	1347242	2477	NR	NR	-	-	NR	NR	0.1	0.02	N	N	N	N	Y	LRTI	DAMA	Y	N	Y	N	N
859	1631814	2478	NR	NR	-	-	NR	NR	0.1	0.02	N	N	N	N	Y	CLD WITH PORTAL HTN	DISCHARGE	N	N	N	N	Y
860	1634020	2479	ENDOTRACHEAL SECRETIONS	P	-	-	P	ASPERGILLUS FLAVUS	8.35	0.12	N	Y	N	N	Y	SEPSIS, LRTI	DAMA	Y	N	Y	Y	N
861	1627669	2480	SPUTUM	Neg	-	-	Neg	NG	2	-	N	N	N	N	Y	PANCREATITIS	DISCHARGE	Y	N	Y	Y	N
862	1635790	2481	NR	NR	-	-	NR	NR	0.13	0.04	N	N	N	N	N	ACCIDENTAL BURNS	DISCHARGE	N	N	N	N	Y
863	1219412	2482	PLEURAL FLUID	Neg	-	-	Neg	NG	0.1	0.03	N	N	N	N	Y	LRTI	DISCHARGE	N	N	N	N	Y
864	1340106	2483	NR	NR	-	-	NR	NR	0.1	-	N	N	Y	N	Y	CKD, SEPSIS	DAMA	N	N	N	N	Y
865	1504952	2484	NR	NR	-	-	NR	NR	0.1	0.05	N	N	N	N	N	CAD, SEPSIS	DISCHARGE	N	N	N	N	Y
866	1632477	2485	SPUTUM	Neg	-	-	Neg	CANDIDA	0.1	0.02	N	N	N	N	N	LRTI	DISCHARGE	N	N	N	N	Y
867	1414374	2486	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.1	0.02	N	N	N	N	Y	CLD	DISCHARGE	N	N	N	N	Y
868	1166470	2487	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.1	0.04	N	Y	N	N	N	CVA, ASTHMA, AKI	DISCHARGE	N	N	N	N	Y
869	563465	2488	NR	NR	-	-	NR	NR	0.1	0.02	N	N	N	N	Y	COPD	DAMA	N	N	N	N	Y
870	1633467	2489	NR	NR	-	-	NR	NR	0.1	0.02	N	N	N	N	N	AKI, SEPSIS	DAMA	N	N	N	N	Y
871	1637669	2490	NR	NR	-	-	NR	NR	0.1	0.02	N	N	N	N	Y	LRTI	DISCHARGE ON REQUEST	N	N	N	N	Y
872	1632033	2491	NR	NR	-	-	NR	NR	0.1	0.02	N	Y	N	N	Y	LRTI	DISCHARGE	Y	N	Y	N	N
873	1277798	2492	NR	NR	-	-	NR	NR	0.58	0.02	N	Y	N	N	Y	CIRRHOSIS WITH PORTAL HTN	DAMA	Y	N	Y	Y	N
874	1634135	2493	NR	NR	-	-	NR	NR	0.1	0.02	N	N	N	N	Y	NECROTISING, PANCREATITIS	DISCHARGE	N	N	N	N	Y
875	1636498	2495	SPUTUM	Neg	-	-	Neg	NG	0.21	0.02	N	N	N	N	Y	AKI, LRTI	DAMA	N	N	N	N	Y
876	1636440	2496	SPUTUM	Neg	-	-	Neg	CANDIDA	12.59	8.33	N	Y	N	N	N	FUNGAL SEPSIS	DISCHARGE	N	N	N	N	Y
877	1632562	2497	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.75	-	N	Y	N	N	N	AKI, LRTI	DAMA	Y	N	Y	Y	N
878	1637763	2498	SPUTUM	Neg	-	-	Neg	NG	0.11	0.2	N	N	N	N	N	LRTI, SEPSIS	DISCHARGE	N	N	N	N	Y
879	1637721	2499	NR	NR	-	-	NR	NR	0.1	0.02	N	N	N	N	Y	MYCLOID LEUKEMIA	DISCHARGE	Y	N	Y	N	N
880	1637911	2500	SPUTUM	Neg	-	-	Neg	NG	0.77	-	N	Y	N	Y	N	SEPSIS	DISCHARGE	N	N	N	N	Y
881	1632142	2502	SPUTUM	Neg	-	-	Neg	NG	0.1	-	N	N	N	N	N	LRTI, SEPSIS, UTI	DISCHARGE	Y	N	Y	N	N
882	620378	2504	SPUTUM	Neg	-	-	Neg	CANDIDA	0.1	0.2	Y	N	N	N	N	ILD, KOCHS	DAMA	N	N	N	N	Y
883	1638234	2505	NR	NR	-	-	NR	NR	0.1	0.2	N	N	N	N	N	SEPSIS	DISCHARGE	N	N	N	N	Y
884	1638354	2506	NR	NR	-	-	NR	NR	0.1	0.03	N	Y	N	Y	N	FUNGAL SINUSITIS	DISCHARGE	N	N	N	N	Y
885	1638758	2507	NR	NR	-	-	NR	NR	0.1	0.03	N	N	N	N	Y	PANCREATITIS	DISCHARGE	N	N	N	N	Y
886	1439754	2508	NR	NR	-	-	NR	NR	0.1	-	N	N	N	N	N	OLD CVA	DISCHARGE	N	N	N	N	Y
887	1294637	2509	NR	NR	-	-	NR	NR	0.62	0.02	N	N	N	N	N	SLE, LRTI	DISCHARGE ON REQUEST	Y	N	Y	Y	N
888	1222815	2510	PLEURAL FLUID	Neg	-	-	Neg	NG	0.57	0.19	N	N	Y	N	Y	CKD, LRTI, CAD	DISCHARGE	Y	N	Y	Y	N
889	1637201	2511	NR	NR	-	-	NR	NR	10.69	0.03	N	Y	N	N	Y	PANCREATITIS	DISCHARGE	Y	N	Y	Y	N
890	1639819	2512	NR	NR	-	-	NR	NR	0.1	0.02	N	N	N	N	Y	NECROTISING, PANCREATITIS	DISCHARGE	N	N	N	N	Y
891	1639365	2513	SPUTUM	Neg	-	-	Neg	NG	0.1	-	N	N	N	N	N	ABPA	DISCHARGE	N	N	N	N	Y
892	1609251	2514	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.92	0.14	N	N	N	N	N	PYODERMA GANGRENOSUM, NASAL AND CUTANEOUS VASCULITIS	DISCHARGE	Y	N	Y	N	N
893	1637163	2515	NR	NR	-	-	NR	NR	0.1	0.02	N	N	N	N	Y	CLD	DISCHARGE	N	N	N	N	Y
894	1639996	2516	SPUTUM	Neg	-	-	Neg	CANDIDA	0.55	-	N	Y	N	N	Y	COPD, LRTI	DISCHARGE ON REQUEST	Y	N	Y	Y	N
895	1639909	2517	NR	NR	-	-	NR	NR	1.7	0.02	N	Y	N	N	N	LRTI	DAMA	N	N	N	N	Y
896	1639456	2518	SPUTUM	Neg	-	-	Neg	NG	0.1	8.01	N	Y	Y	N	Y	CKD	DISCHARGE	N	N	N	N	Y
897	1637672	2520	SPUTUM	Neg	-	-	Neg	CANDIDA	0.11	0.03	N	Y	N	N	Y	CIRRHOSIS WITH PORTAL HTN	DISCHARGE	N	N	N	N	Y
898	1638573	2521	SPUTUM	Neg	-	-	Neg	NG	0.1	-	N	Y	N	N	N	AKI, CARCINOMA	DISCHARGE	N	N	N	N	Y
899	1638775	2522	SPUTUM	Neg	-	-	Neg	NG	0.13	-	N	Y	N	N	Y	LRTI, CLL	DISCHARGE	Y	N	Y	N	N
900	1638260	2523	SPUTUM	Neg	-	-	Neg	NG	0.1	0.02	N	N	N	N	Y	LRTI, OSA	DISCHARGE ON REQUEST	Y	N	Y	N	N
901	1640145	2524	ENDOTRACHEAL SECRETIONS	P	-	-	P	ASPERGILLUS FUMIGATUS	10.39	0.89	N	Y	N	N	Y	RECTAL CARCINOMA	DAMA	Y	N	Y	Y	N
902	1637222	2525	SPUTUM	Neg	-	-	Neg	NG	0.1	0.03	N	N	N	N	Y	CLD WITH PORTAL HTN	DISCHARGE	N	N	N	N	Y
903	1639414	2526	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.1	-	N	Y	N	N	N	COPD, LRTI, AKI	DAMA	N	N	N	N	Y

S. no	MRD No.	Lab No	NAME	DOR Sample	AGE	SEX	GMRepeat	DOA	AREA	SUB AREA WISE	Sample	DOR Sample	FEVER	COUGH	SOB	CHEST PAIN	DM	HTN	Alcoholic	Smoker	Neutropenia	TBHistory	Chronic steroid use	Solid organ transplantation	Malignancy	HIV	HCV	HB	TLC/DLC	NEUTROPHIL COUNT	CT CHEST _PLEURAL EFFUSION	CONSOLIDATION IN LUNG	CAVITATION	RETICULONODULAR OPACITIES	Histopathology for aspergillus species
905	1479102	2528	BS	12/20/2023	60	M	N	12/17/2023	WARD	RENAL DISEASE	SERUM	12/20/2023	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	7.4	14	91	N	Y	N	Y	NR
906	1640035	2529	SS	12/20/2023	44	M	N	12/18/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	12/20/2023	N	N	Y	N	Y	Y	Y	Y	N	N	N	N	N	N	N	15	12	88	N	Y	N	Y	NR
907	1639948	2530	V	12/20/2023	48	M	N	12/17/2023	WARD	RENAL DISEASE	SERUM	12/20/2023	Y	N	Y	N	N	N	N	N	N	N	Y	N	N	Y	N	11	8.9	87.2	N	Y	N	Y	NR
908	833683	2531	DN	12/20/2023	56	M	N	12/15/2023	ICU	RENAL DISEASE	SERUM	12/20/2023	Y	N	Y	N	N	Y	N	N	N	N	N	Y	N	N	N	6.7	10	94	N	Y	N	N	NR
909	1471675	2532	GS	12/20/2023	46	M	N	12/15/2023	WARD	RENAL DISEASE	SERUM	12/20/2023	N	Y	Y	N	Y	Y	N	N	N	N	N	N	N	N	N	7.6	5.5	69	Y	Y	N	N	NR
910	1638313	2533	KK	12/20/2023	27	M	N	12/14/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	12/20/2023	N	Y	Y	N	N	Y	N	N	N	N	N	N	N	N	N	11	23	86	N	Y	N	Y	NR
911	1635042	2534	PS	12/20/2023	63	M	N	12/7/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	12/20/2023	Y	N	N	Y	N	Y	Y	Y	N	N	N	N	N	N	N	9.3	36	85	N	Y	N	Y	NR
912	1593838	2535	PR	12/20/2023	60	F	N	12/18/2023	WARD	RENAL DISEASE	SERUM	12/20/2023	N	Y	Y	N	N	N	N	N	N	N	N	Y	N	N	N	11	8	94.7	N	Y	N	N	NR
913	1639918	2536	S	12/20/2023	27	M	N	12/17/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	12/20/2023	N	Y	Y	N	N	N	N	N	N	N	Y	N	N	N	N	10.7	11	79	N	N	N	Y	NR
914	30839	2537	HS	12/20/2023	56	M	N	12/15/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	12/20/2023	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	Y	13	10	79	N	N	Y	N	NR
915	1635840	2538	KS	12/20/2023	26	M	N	12/8/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	12/20/2023	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	9.1	22	85	N	N	N	N	NR
916	1638248	2539	KD	12/20/2023	52	F	N	12/13/2023	ICU	GENERAL SURGERY	SERUM	12/20/2023	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	7.9	20	87	N	N	N	N	NR
917	1632726	2540	TS	12/20/2023	71	M	N	12/3/2023	WARD	CARDIOVASCULAR DISEASE	SERUM	12/20/2023	Y	N	N	Y	Y	Y	N	N	N	N	N	N	N	N	N	10	23	86	N	N	N	N	NR
918	1640727	2541	BS	12/21/2023	71	M	N	12/18/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	12/21/2023	Y	N	Y	N	N	Y	N	Y	N	N	Y	N	N	N	N	14	20	93	Y	N	N	N	NR
920	1640699	2543	GS	12/21/2023	60	M	N	12/18/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	12/21/2023	Y	Y	N	N	Y	Y	N	N	N	N	Y	N	N	N	N	13	6	75	N	Y	N	Y	NR
921	1557021	2544	SK	12/21/2023	60	F	N	12/21/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	12/21/2023	Y	N	N	N	N	N	N	N	N	N	N	N	Y	N	N	16	11	78	N	N	Y	N	NR
923	1640010	2546	HS	12/22/2023	38	M	N	12/17/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	12/22/2023	Y	N	N	N	N	N	N	N	N	N	Y	N	N	N	N	6.6	16	85	N	N	N	N	NR
924	1617779	2547	RK	12/22/2023	32	M	N	11/3/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	12/22/2023	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	8.4	28	90	N	N	N	N	NR
925	1632615	2548	DK	12/22/2023	70	F	N	12/20/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	12/22/2023	N	N	N	N	N	Y	N	N	N	N	Y	N	N	N	N	12	21	79	N	N	N	N	NR
926	1468972	2549	HK	12/23/2023	68	F	N	12/18/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	12/23/2023	Y	N	Y	N	Y	N	N	N	N	N	N	N	N	N	N	10	5.4	52	Y	N	N	N	NR
927	1643234	2550	K	12/26/2023	78	F	N	12/23/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	12/26/2023	Y	Y	N	N	N	Y	N	N	N	N	N	N	N	N	N	8.1	8	91	Y	N	N	N	NR
928	1641303	2551	S	12/23/2023	54	F	N	12/19/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	12/23/2023	N	Y	Y	N	Y	Y	N	N	N	N	N	N	N	N	N	8.9	16	87	N	N	N	Y	NR
929	1587207	2552	GJ	12/23/2023	62	M	N	12/12/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	12/23/2023	N	N	Y	N	N	Y	N	N	N	N	Y	N	N	N	N	9.6	11	81	Y	N	N	N	NR
930	1642698	2553	KD	12/23/2023	62	F	N	12/22/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	12/23/2023	N	Y	Y	N	Y	Y	N	N	N	N	Y	N	N	N	N	10	17	83	N	N	N	Y	NR
931	1641850	2554	KS	12/23/2023	38	M	N	12/20/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	12/23/2023	N	N	N	N	N	N	N	N	N	N	Y	N	N	N	N	9.3	19	49	N	N	Y	N	NR
932	1642844	2555	SK	12/23/2023	50	F	N	12/25/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	12/23/2023	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	13	8	96	N	Y	N	Y	NR
933	1642845	2556	PK	12/23/2023	75	F	N	12/22/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	12/23/2023	Y	Y	Y	N	N	Y	N	N	N	N	N	N	N	N	N	12	7.2	90	Y	N	N	N	NR
934	1635807	2557	HS	12/23/2023	66	M	N	12/8/2023	WARD	RENAL DISEASE	SERUM	12/23/2023	Y	Y	N	N	Y	Y	N	N	N	N	N	Y	N	N	N	9.3	10	87	N	Y	N	N	NR
935	126145	2558	K	12/24/2023	61	M	N	12/20/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	12/24/2023	Y	N	N	N	Y	Y	N	N	N	N	N	N	N	N	N	8.3	1	57	N	Y	N	Y	NR
936	1640639	2559	RG	12/24/2023	34	M	N	12/18/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	12/24/2023	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	13.3	11	81	N	N	Y	N	NR
937	1642389	2560	KD	12/24/2023	65	F	N	12/22/2023	WARD	RENAL DISEASE	SERUM	12/24/2023	N	N	Y	N	Y	Y	N	N	N	N	N	Y	N	N	N	9.2	7.2	93	N	N	N	Y	NR
938	1640717	2561	PS	12/24/2023	65	M	N	12/18/2023	WARD	RENAL DISEASE	SERUM	12/24/2023	Y	Y	N	N	Y	N	N	N	N	N	N	N	N	N	N	9.9	7	97	N	Y	N	N	NR
939	1378089	2562	VD	12/25/2023	58	F	N	12/23/2023	WARD	RENAL DISEASE	SERUM	12/25/2023	Y	Y	N	N	N	N	N	N	N	N	Y	N	N	N	N	9.6	10	88	N	Y	N	Y	NR
940	1642293	2563	AK	12/25/2023	64	F	N	12/21/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	12/25/2023	Y	N	Y	N	Y	N	N	N	N	N	N	N	N	N	N	11	28	85	N	N	N	N	NR
941	1570719	2564	DG	12/25/2023	55	M	N	12/20/2023	ICU	GASTROINTESTINAL TRACT DISEASE	SERUM	12/25/2023	N	N	N	N	N	N	N	N	N	N	Y	N	N	N	N	8.3	30	83	N	N	N	N	NR
942	31974	2565	AS	12/25/2023	76	M	N	12/26/2023	ICU	CARDIOVASCULAR DISEASE	SERUM	12/25/2023	Y	N	N	Y	N	Y	N	N	N	N	N	N	N	N	N	10	10	72	N	N	N	N	NR
943	1643373	2566	PK	12/25/2023	51	F	N	12/24/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	12/25/2023	N	N	N	N	Y	N	N	N	Y	N	N	N	N	N	N	10.3	1.2	28	Y	N	N	N	NR
945	1641911	2568	S	12/25/2023	74	M	N	12/21/2023	ICU	GASTROINTESTINAL TRACT DISEASE	SERUM	12/25/2023	Y	Y	N	Y	Y	Y	N	N	N	N	Y	N	N	N	N	7.4	19	96	N	N	N	N	NR
946	1629853	2569	VP	12/25/2023	69	M	N	11/27/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	12/25/2023	N	N	Y	N	N	N	N	N	N	N	N	N	N	N	N	10	7.5	94	N	Y	N	N	NR
947	1643217	2570	HK	12/26/2023	75	F	N	12/23/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	12/26/2023	Y	Y	N	N	N	N	N	N	N	N	Y	N	N	N	N	10	22	73	N	Y	N	N	NR
948	1640645	2571	AK	12/23/2023	67	M	N	12/18/2023	WARD	RENAL DISEASE	SERUM	12/23/2023	N	Y	N	Y	Y	N	N	N	N	N	N	N	N	N	N	7.3	12	95	N	Y	N	Y	NR
949	1636368	2574	LS	12/26/2023	54	M	N	12/23/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	12/26/2023	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	14.1	16	85.3	N	N	N	N	NR
951	32381	2576	K	12/27/2023	63	F	N	12/26/2023	WARD	ACUTE FEBRILE ILLNESS	SERUM	12/27/2023	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	9.3	10	95	N	N	N	N	NR
952	1642264	2577	KK	12/27/2023	57	F	N	12/21/2023	WARD	RENAL DISEASE	SERUM	12/27/2023	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	9.5	12	65	N	N	N	Y	NR
954	1639412	2579	S	12/27/2023	46	M	N	12/15/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	12/27/2023	N	N	N	N	N	N	Y	N	N	N	N	N	N	N	N	11	10	56	N	N	N	N	NR
956	1642371	2581	SS	12/28/2023	45	M	N	12/21/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	12/28/2023	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	16	19	90	N	N	N	N	NR
957	1643281	2582	SK	12/28/2023	23	M	N	12/23/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	12/28/2023	Y	Y	N	N	N	N	N	N	N	N	N	N	Y	N	N	12	11	84	N	Y	N	N	NR
958	1643341	2583	MK	12/28/2023	74	F	N	12/24/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	12/28/2023	N	Y	Y	N	N	Y	N	N	N	N	N	N	N	N	N	9.2	24	81	N	Y	N	N	NR

S. no	MRD No.	Lab No	Distribution of clinical samples received	Fungal smear Positive for Hyaline Septate Fungal Hyphae	CANDIDA IN (BODY FLUIDS AND BLOOD CULTURE)	CANDIDA IN BODY FUILDS	FUNGAL CULTURE FOR ASPERGILLUS SPECIES	Fungal Cuture	GMSAASSAY	1-3 BDG	PTZ	ANTIFUNGAL	Heamo Dylasis	AUGMENTIN	MEROPENEM	Provisional diagnosis	Outcome	TOTAL EORTC PATIENTS	PROVEN	POSSIBLE	PROBABLE	NO INVASIVE ASPERGILLOSI
905	1479102	2528	SPUTUM	Neg	-	-	Neg	CANDIDA	0.1	0.02	N	Y	Y	N	Y	AKI, LRTI	DISCHARGE	N	N	N	N	Y
906	1640035	2529	NR	NR	-	-	NR	NR	0.11	0.02	N	N	N	N	N	LRTI, DVT	DISCHARGE ON REQUEST	N	N	N	N	Y
907	1639948	2530	NR	NR	-	-	NR	NR	0.1	-	N	Y	N	N	Y	AKI	DAMA	Y	N	Y	N	N
908	833683	2531	NR	NR	-	-	NR	NR	0.98	-	N	Y	Y	N	Y	CKD, LRTI, SEPSIS	DAMA	Y	N	Y	Y	N
909	1471675	2532	NR	NR	-	-	NR	NR	0.4	0.02	N	N	Y	N	Y	CKD, LRTI	DISCHARGE ON REQUEST	N	N	N	N	Y
910	1638313	2533	SPUTUM	Neg	-	-	Neg	CANDIDA	0.1	-	N	N	N	N	Y	LRTI, TB CASE	DISCHARGE	N	N	N	N	Y
911	1635042	2534	PLEURAL FLUID	Neg	-	-	Neg	NG	0.69	0.02	N	Y	N	N	Y	LRTI, SEPSIS	DAMA	N	N	N	N	Y
912	1593838	2535	NR	NR	-	-	NR	NR	0.69	0.51	N	Y	N	N	Y	CKD, LRTI	DAMA	Y	N	Y	Y	N
913	1639918	2536	SPUTUM	Neg	-	-	Neg	NG	0.21	0.02	N	N	N	N	N	AKI, ILD	DISCHARGE	Y	N	Y	N	N
914	30839	2537	SPUTUM	Neg	-	-	Neg	NG	0.1	-	N	N	N	N	N	ABPA, HYPOTHYROIDISM	DISCHARGE	N	N	N	N	Y
915	1635840	2538	PUS	Neg	-	-	Neg	NG	0.1	0.02	N	N	N	N	Y	PANCREATITIS	DISCHARGE	N	N	N	N	Y
916	1638248	2539	NR	NR	-	-	NR	NR	0.14	0.19	N	N	N	N	Y	LAPROTOMY	DISCHARGE	N	N	N	N	Y
917	1632726	2540	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.1	0.02	N	N	N	N	Y	CAD	DISCHARGE	N	N	N	N	Y
918	1640727	2541	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	CANDIDA	1.29	8.45	N	Y	N	N	Y	LRTI, SEPSIS	DAMA	Y	N	Y	Y	N
920	1640699	2543	NR	NR	-	-	NR	NR	0.84	-	N	Y	N	N	Y	COPD	DISCHARGE	Y	N	Y	Y	N
921	1557021	2544	NR	NR	-	-	NR	NR	8.44	0.48	N	Y	N	N	Y	MYELODYSPLASTIC SYNDROME	DAMA	Y	N	Y	Y	N
923	1640010	2546	NR	NR	-	-	NR	NR	3.86	0.03	N	Y	N	N	Y	CLD WITH PORTAL HTN	DISCHARGE	Y	N	Y	N	N
924	1617779	2547	TISSUE	Neg	-	-	Neg	NG	0.24	0.02	N	N	N	N	Y	PANCREATITIS	DISCHARGE	N	N	N	N	Y
925	1632615	2548	NR	NR	-	-	NR	NR	0.8	0.02	N	N	N	N	Y	CIRRHOSIS	DISCHARGE	Y	N	Y	N	N
926	1468972	2549	BAL	Neg	-	-	Neg	NG	0.11	-	N	N	N	N	N	LRTI, HYPOTHYROIDISM	DISCHARGE	N	N	N	N	Y
927	1643234	2550	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.1	0.02	N	N	N	N	Y	LRTI, SEPSIS	DAMA	N	N	N	N	Y
928	1641303	2551	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.2	0.03	N	N	N	N	Y	AKI, SEPSIS	DAMA	N	N	N	N	Y
929	1587207	2552	NR	NR	-	-	NR	NR	8.23	0.025	N	Y	N	N	N	ASTHMA	DISCHARGE ON REQUEST	Y	N	Y	Y	N
930	1642698	2553	NR	NR	-	-	NR	NR	0.1	0.03	N	N	N	N	N	COPD	DISCHARGE	N	N	N	N	Y
931	1641850	2554	NR	NR	-	-	NR	NR	8.41	0.03	N	Y	N	N	Y	PANCREATITIS	DISCHARGE ON REQUEST	Y	N	Y	Y	N
932	1642844	2555	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.55	0.02	N	N	N	N	Y	PNEUMONIA, ARDS	DAMA	N	N	N	N	Y
933	1642845	2556	NR	NR	-	-	NR	NR	0.1	0.02	N	N	N	N	N	H1N1 I INFLUENZA	DISCHARGE ON REQUEST	N	N	N	N	Y
934	1635807	2557	NR	NR	-	-	NR	NR	0.98	0.05	N	Y	Y	N	Y	CKD	DAMA	Y	N	Y	Y	N
935	126145	2558	NR	NR	-	-	NR	NR	0.1	5.58	N	Y	N	N	N	CNS VASCULITS	DAMA	N	N	N	N	Y
936	1640639	2559	SPUTUM	P	-	-	P	ASPERGILLUS FUMIGATUS	0.2	-	N	Y	N	N	Y	LRTI	DISCHARGE	N	N	N	N	Y
937	1642389	2560	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.61	0.02	N	N	Y	N	N	CKD	DAMA	Y	N	Y	Y	N
938	1640717	2561	NR	NR	-	-	NR	NR	0.1	0.02	N	N	Y	N	Y	CKD, LRTI	DISCHARGE	N	N	N	N	Y
939	1378089	2562	NR	NR	-	-	NR	NR	9.5	0.56	Y	N	Y	N	N	CKD, LRTI, SEPSIS	DAMA	Y	N	Y	Y	N
940	1642293	2563	NR	NR	-	-	NR	NR	0.1	0.02	N	N	N	N	N	ASTHMA, HYPOTHYROIDISM	DAMA	N	N	N	N	Y
941	1570719	2564	NR	NR	-	-	NR	NR	0.96	0.03	N	Y	N	N	Y	CIRRHOSIS WITH PORTAL HTN	DISCHARGE ON REQUEST	Y	N	Y	N	N
942	31974	2565	SPUTUM	Neg	-	-	Neg	CANDIDA	0.67	-	N	N	N	N	Y	CAD	DISCHARGE	N	N	N	N	Y
943	1643373	2566	NR	NR	-	-	NR	NR	0.1	0.05	N	N	N	N	Y	PANIC ATTACKS	DAMA	Y	N	Y	N	N
945	1641911	2568	NR	NR	-	-	NR	NR	0.57	0.5	N	N	N	N	Y	OLD CVA	DISCHARGE	Y	N	Y	N	N
946	1629853	2569	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.12	-	N	N	N	N	N	SEPSIS, ON ATT	DAMA	N	N	N	N	Y
947	1643217	2570	NR	NR	-	-	NR	NR	7.5	0.23	N	Y	N	N	N	LRTI, SEPSIS, ASTHMA	DISCHARGE ON REQUEST	Y	N	Y	Y	N
948	1640645	2571	SPUTUM	Neg	-	-	Neg	CANDIDA	0.24	0.02	Y	N	N	N	N	FLUID OVERLOAD	DISCHARGE	N	N	N	N	Y
949	1636368	2574	NR	NR	-	-	NR	NR	0.1	0.04	N	N	N	N	Y	PANCREATITIS	DISCHARGE	N	N	N	N	Y
951	32381	2576	NR	NR	-	-	NR	NR	0.89	-	N	N	N	N	Y	AFI	DISCHARGE	N	N	N	N	Y
952	1642264	2577	SPUTUM	Neg	-	-	Neg	NG	0.1	0.02	N	N	Y	N	Y	CKD	DAMA	N	N	N	N	Y
954	1639412	2579	NR	NR	-	-	NR	NR	0.1	0.04	N	N	N	N	Y	PANCREATITIS	DISCHARGE ON REQUEST	N	N	N	N	Y
956	1642371	2581	PER CUTANEOUS DRAIN	Neg	-	-	Neg	NG	0.1	0.1	N	N	N	N	Y	PANCREATITIS	DISCHARGE	N	N	N	N	Y
957	1643281	2582	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.87	0.03	N	N	N	N	N	LRTI, HODGIKEN LYMPHOMA	DAMA	Y	N	Y	Y	N
958	1643341	2583	SPUTUM	Neg	-	-	Neg	CANDIDA	0.85	-	N	Y	N	N	N	LRTI	DISCHARGE	N	N	N	N	Y

S. no	MRD No.	Lab No	NAME	DOR Sample	AGE	SEX	GMRepeat	DOA	AREA	SUB AREA WISE	Sample	DOR Sample	FEVER	COUGH	SOB	CHEST PAIN	DM	HTN	Alcoholic	Smoker	Neutropenia	TBHistory	Chronic steroid use	Solid organ transplantation	Malignancy	HIV	HCV	HB	TLC/DLC	NEUTROPHIL COUNT	CT CHEST _PLEURAL EFFUSION	CONSOLIDATION IN LUNG	CAVITATION	RETICULONODULAR OPACITIES	Histopathology for aspergillus species
959	1643785	2584	MV	12/28/2023	44	F	N	12/26/2023	WARD	CARDIOVASCULAR DISEASE	SERUM	12/28/2023	N	N	Y	Y	Y	N	N	N	N	N	N	N	N	N	10	9.7	64	Y	N	N	N	NR
960	1644854	2585	RB	12/28/2023	66	F	N	12/27/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	12/28/2023	Y	Y	N	N	Y	N	N	N	N	N	N	N	N	N	11.9	17	91	N	Y	N	Y	NR
961	1644867	2586	M	12/28/2023	56	F	N	12/28/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	12/28/2023	Y	Y	N	N	Y	N	N	N	N	N	N	N	N	N	12	3.2	70	N	N	N	N	NR
962	1644649	2587	RS	12/28/2023	74	M	N	12/27/2023	WARD	RENAL DISEASE	SERUM	12/28/2023	Y	Y	N	N	N	Y	N	N	N	N	N	N	N	N	13	13	91	N	Y	N	N	NR
963	1353800	2588	DK	12/28/2023	62	M	N	12/24/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	12/28/2023	N	Y	Y	N	N	N	N	N	N	N	N	N	N	N	11	81	98	N	Y	N	N	NR
964	1643412	2589	NK	12/29/2023	39	F	N	12/24/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	12/29/2023	N	Y	N	N	N	Y	N	N	N	N	N	N	N	N	6.3	16	79	N	Y	N	N	NR
965	1634636	2590	A	12/29/2023	39	M	N	12/27/2023	WARD	ONCOLOGICAL	SERUM	12/29/2023	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	8.3	8.7	79	N	Y	N	N	NR
966	485302	2591	RK	12/29/2023	63	M	N	12/21/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	12/29/2023	N	N	N	N	N	N	Y	Y	N	N	N	N	N	N	N	12	5.9	66	N	N	N	N	NR
967	1644847	2592	N	12/29/2023	50	F	N	12/27/2023	WARD	RENAL DISEASE	SERUM	12/29/2023	N	Y	Y	N	Y	Y	N	N	N	N	N	Y	N	N	N	8.1	18	93	N	N	Y	N	NR
968	1645181	2593	SL	12/29/2023	76	F	N	12/28/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	12/29/2023	Y	N	Y	N	N	Y	N	N	N	N	Y	N	N	N	N	7.9	9.7	80.6	Y	N	N	Y	NR
970	1645291	2595	PJ	12/29/2023	52	F	N	12/28/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	12/29/2023	Y	Y	N	N	N	Y	N	N	N	N	Y	N	N	N	N	11	55	68	N	Y	N	Y	NR
971	1645733	2596	RS	12/29/2023	53	M	P	12/29/2023	WARD	RENAL DISEASE	SERUM	12/29/2023	Y	Y	N	N	Y	Y	N	N	N	N	N	Y	N	N	N	8.3	12	90	Y	N	N	Y	NR
972	1645280	2597	VR	12/29/2023	44	F	N	12/28/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	12/29/2023	N	Y	Y	N	Y	Y	N	N	N	N	N	N	N	N	N	11	55	80	N	N	N	Y	NR
973	1580428	2598	KR	12/30/2023	68	F	N	12/23/2023	WARD	RENAL DISEASE	SERUM	12/30/2023	N	Y	Y	N	Y	Y	N	N	N	N	N	N	N	N	N	8.2	7.9	71	N	N	N	N	NR
974	1638290	1	SS	12/30/2023	73	M	N	12/13/2023	WARD	RENAL DISEASE	SERUM	12/30/2023	Y	Y	N	N	N	N	N	N	N	N	Y	N	N	N	12	15	91	N	N	N	N	NR
975	1644988	2	JK	12/30/2023	42	F	N	12/28/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	12/30/2023	Y	Y	N	Y	Y	N	N	N	N	N	N	N	N	N	N	12	6	79	N	Y	N	Y	NR
976	1637782	3	BK	12/31/2023	64	F	N	12/29/2023	WARD	RENAL DISEASE	SERUM	12/31/2023	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	11	6.4	57	N	N	N	N	NR
977	1643403	4	SP	12/30/2023	40	M	N	12/24/2023	WARD	CARDIOVASCULAR DISEASE	SERUM	12/30/2023	N	N	N	Y	N	N	N	N	N	N	N	N	N	N	N	13	13	78	N	Y	N	Y	NR
978	1644337	5	DS	12/31/2023	34	M	N	12/26/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	12/31/2023	N	Y	Y	N	N	N	N	N	N	N	Y	N	N	N	N	10	6	75	N	N	N	N	NR
979	1645907	6	SB	12/31/2023	57	F	N	12/30/2023	ICU	NEUROLOGICAL DISEASE	SERUM	12/31/2023	N	N	Y	N	Y	N	N	N	N	N	N	N	N	N	N	14	16	83	N	N	N	N	NR
980	172085	7	NB	12/31/2023	71	F	N	12/29/2023	WARD	CARDIOVASCULAR DISEASE	SERUM	12/31/2023	N	N	N	Y	N	Y	N	N	N	N	N	N	N	N	N	9.3	11	82	Y	N	N	Y	NR
981	310576	8	OP	12/31/2023	76	M	N	12/28/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	12/31/2023	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	10	17	71.8	N	N	N	Y	NR
982	1054609	9	RK	12/31/2023	60	M	N	12/23/2023	WARD	RENAL DISEASE	SERUM	12/31/2023	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	9.3	12	83	N	Y	N	Y	NR
983	532209	10	AK	12/31/2023	51	M	N	12/25/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	12/31/2023	Y	Y	N	N	Y	N	N	N	N	N	N	N	N	N	N	9.2	4.3	70.6	N	N	N	N	NR
984	453625	11	MS	1/1/2024	85	M	N	12/26/2023	ICU	CARDIOVASCULAR DISEASE	SERUM	1/1/2024	Y	Y	N	Y	Y	Y	N	N	N	N	N	N	N	N	N	12	14	94	N	N	N	N	NR
985	1638253	12	SK	12/31/2024	36	M	N	12/13/2023	ICU	NEUROLOGICAL DISEASE	SERUM	12/31/2024	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	10	12	74	N	N	N	N	NR
986	1635178	13	ML	1/1/2024	85	M	N	12/7/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	1/1/2024	Y	Y	N	N	N	Y	N	N	N	N	N	N	N	N	N	12	5.6	53	N	N	N	N	NR
987	918473	14	GR	1/1/2024	70	M	N	12/23/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	1/1/2024	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	12	21	90	N	N	N	Y	NR
988	1644181	15	RK	1/1/2024	25	F	N	12/26/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	1/1/2024	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	N	6.9	23	73.8	N	N	N	N	NR
989	1521223	16	RG	1/1/2024	56	M	N	11/21/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	1/1/2024	Y	N	N	N	Y	Y	N	N	N	N	N	N	N	N	N	11	11	92	Y	N	N	N	NR
990	1620517	17	NG	1/1/2024	68	F	N	12/28/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	1/1/2024	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	11.8	19	89	N	N	N	N	NR
991	1640729	18	KD	1/1/2024	61	M	N	12/18/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	1/1/2024	Y	N	Y	N	Y	Y	N	N	N	N	N	N	N	N	N	10	14	91	N	Y	N	Y	NR
992	1643674	20	SA	1/2/2024	75	M	N	12/25/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	1/2/2024	N	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	13	15	82	N	Y	N	Y	NR
993	1639440	21	KP	1/2/2024	79	M	N	12/30/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	1/2/2024	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	10	8	79	N	N	N	N	NR
994	1173818	22	BS	1/2/2024	62	M	N	12/21/2023	WARD	RENAL DISEASE	SERUM	1/2/2024	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	9	19	81	N	N	N	N	NR
995	1646275	23	MK	1/2/2024	45	M	N	12/30/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	1/2/2024	Y	N	Y	N	N	N	N	N	N	N	N	N	N	N	N	10	2	79	N	Y	N	Y	NR
996	1646258	24	V	1/2/2024	72	M	N	1/1/2024	WARD	RESPIRATORY TRACT DISEASE	SERUM	1/2/2024	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	10	17	79	N	N	N	Y	NR
997	1644006	25	RS	1/2/2024	46	M	N	12/16/2023	WARD	RENAL DISEASE	SERUM	1/2/2024	N	N	N	N	Y	Y	N	N	N	N	N	N	N	N	N	6.1	8.6	73	N	N	N	N	NR
998	1646299	26	CS	1/2/2024	73	M	N	12/31/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	1/2/2024	N	N	Y	N	N	Y	N	N	N	N	Y	N	N	N	N	17	19	89	Y	N	N	Y	NR
999	878118	27	RG	1/2/2024	56	M	N	12/30/2023	WARD	CARDIOVASCULAR DISEASE	SERUM	1/2/2024	N	N	Y	Y	N	Y	N	N	N	N	N	N	N	N	N	12	5	90	N	N	N	N	NR
1000	1646703	28	BS	1/3/2024	68	M	N	1/1/2024	WARD	RESPIRATORY TRACT DISEASE	SERUM	1/3/2024	N	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	13.1	17	85	N	N	N	N	NR
1001	1642684	29	PK	1/3/2024	62	F	N	12/22/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	1/3/2024	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	10	7.2	72	Y	N	N	N	NR
1002	90142	30	KK	1/3/2024	75	F	N	12/29/2023	ICU	GASTROINTESTINAL TRACT DISEASE	SERUM	1/3/2024	N	N	N	N	N	N	Y	Y	N	N	Y	N	N	N	N	9.1	3.5	83	N	N	N	N	NR
1004	1626973	32	RS	1/2/2024	49	F	N	12/22/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	1/2/2024	Y	N	Y	N	N	N	N	N	N	N	N	N	N	N	N	10	10	79	N	N	N	N	NR
1005	1645324	33	SS	1/2/2024	82	M	N	12/29/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	1/2/2024	N	N	Y	N	Y	Y	N	N	N	N	N	N	N	N	N	10.2	16	75	Y	N	N	N	NR
1006	1634145	34	RK	1/2/2024	50	M	N	12/6/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	1/2/2024	N	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	8.9	11	83	N	Y	N	Y	NR

S. no	MRD No.	Lab No	Distribution of clinical samples received	Fungal smear Positive for Hyaline Septate Fungal Hyphae	CANDIDA IN (BODY FLUIDS AND BLOOD CULTURE)	CANDIDA IN BODY FUILDS	FUNGAL CULTURE FOR ASPERGILLUS SPECIES	Fungal Cuture	GMSAASSAY	1-3 BDG	PTZ	ANTIFUNGAL	Heamo Dylasis	AUGMENTIN	MEROPENEM	Provisional diagnosis	Outcome	TOTAL EORTC PATIENTS	PROVEN	POSSIBLE	PROBABLE	NO INVASIVE ASPERGILLOSI
959	1643785	2584	SPUTUM	Neg	-	-	Neg	CANDIDA	0.1	0.02	N	N	N	N	N	LRTI	DAMA	N	N	N	N	Y
960	1644854	2585	NR	NR	-	-	NR	NR	0.1	0.04	N	N	N	N	Y	LRTI	DISCHARGE ON REQUEST	N	N	N	N	Y
961	1644867	2586	NR	NR	-	-	NR	NR	0.21	0.02	N	N	N	N	N	LRTI, H1N1 +VE	DISCHARGE	N	N	N	N	Y
962	1644649	2587	NR	NR	-	-	NR	NR	0.1	0.05	N	Y	Y	N	Y	KOCHS, H1N1 +VE	DISCHARGE	N	N	N	N	Y
963	1353800	2588	SPUTUM	Neg	-	-	Neg	NG	0.1	-	N	N	N	N	Y	TB +VE	DISCHARGE	N	N	N	N	Y
964	1643412	2589	SPUTUM	Neg	-	-	Neg	NG	0.16	-	N	N	N	N	Y	LRTI, COPD	DISCHARGE	N	N	N	N	Y
965	1634636	2590	SPUTUM	Neg	-	-	Neg	CANDIDA	0.19	0.62	N	Y	N	N	N	H1N1 +VE	DISCHARGE	N	N	N	N	Y
966	485302	2591	NR	NR	-	-	NR	NR	0.1	0.03	N	N	N	N	Y	CIRRHOSIS WITH PORTAL HTN	DISCHARGE	N	N	N	N	Y
967	1644847	2592	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	12.57	0.73	N	Y	Y	N	Y	CKD	DISCHARGE ON REQUEST	Y	N	Y	Y	N
968	1645181	2593	NR	NR	-	-	NR	NR	0.51	-	N	Y	N	N	N	ASTHMA	DISCHARGE	Y	N	Y	Y	N
970	1645291	2595	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.19	0.11	N	N	N	N	Y	LRTI	DISCHARGE	Y	N	Y	N	N
971	1645733	2596	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	CANDIDA	1.07	-	N	Y	N	N	Y	CKD	DAMA	Y	N	Y	Y	N
972	1645280	2597	NR	NR	-	-	NR	NR	0.1	0.02	N	Y	N	N	N	SEPSIS	DISCHARGE	N	N	N	N	Y
973	1580428	2598	NR	NR	-	-	NR	NR	0.1	0.02	N	N	N	N	Y	UTI, SEPSIS, AKI	DISCHARGE	N	N	N	N	Y
974	1638290	1	SPUTUM	Neg	-	-	Neg	CANDIDA	0.1	0.18	N	N	N	N	Y	AKI, SEPSIS	DISCHARGE	N	N	N	N	Y
975	1644988	2	SPUTUM	Neg	-	-	Neg	NG	0.14	-	N	N	N	N	Y	LRTI	DISCHARGE	N	N	N	N	Y
976	1637782	3	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.1	0.04	Y	N	N	N	N	LRTI, AKI	DAMA	N	N	N	N	Y
977	1643403	4	NR	NR	-	-	NR	NR	0.1	-	N	N	N	N	Y	H1N1 +VE	DISCHARGE	N	N	N	N	Y
978	1644337	5	CSF	Neg	-	-	Neg	NG	4.43	8.12	N	Y	N	N	Y	FUNGAL SEPSIS	DISCHARGE	Y	N	Y	N	N
979	1645907	6	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	CANDIDA	0.1	0.02	N	N	N	N	N	SOL	DISCHARGE	N	N	N	N	Y
980	172085	7	PLEURAL FLUID	Neg	-	-	Neg	NG	0.1	-	N	N	N	N	Y	LRTI, HYPOTHYROIDISM, AKI	DISCHARGE ON REQUEST	N	N	N	N	Y
981	310576	8	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	CANDIDA	0.66	0.3	N	N	N	N	N	LRTI	DISCHARGE ON REQUEST	N	N	N	N	Y
982	1054609	9	NR	NR	-	-	NR	NR	0.1	-	Y	N	N	N	N	CKD, LRTI, SEPSIS	DAMA	N	N	N	N	Y
983	532209	10	PLEURAL FLUID	Neg	-	-	Neg	NG	0.23	-	N	N	Y	N	Y	CIRRHOSIS WITH PORTAL HTN	DISCHARGE ON REQUEST	N	N	N	N	Y
984	453625	11	SPUTUM	Neg	-	-	Neg	CANDIDA	0.12	0.02	N	N	N	N	Y	LRTI	DISCHARGE	N	N	N	N	Y
985	1638253	12	NR	NR	-	-	NR	NR	0.12	0.11	N	N	N	N	Y	SDH, SAH	EXPIRED	N	N	N	N	Y
986	1635178	13	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.12	0.04	N	N	N	N	Y	LRTI, CIRRHOSIS, SEPSIS	DISCHARGE ON REQUEST	N	N	N	N	Y
987	918473	14	NR	NR	-	-	NR	NR	0.19	-	N	Y	N	N	N	ILD, CAD	DAMA	N	N	N	N	Y
988	1644181	15	NR	NR	-	-	NR	NR	0.13	0.02	N	N	N	N	Y	SEPSIS	DISCHARGE	N	N	N	N	Y
989	1521223	16	NR	NR	-	-	NR	NR	0.1	0.02	N	N	N	N	Y	SEPSIS	DISCHARGE	N	N	N	N	Y
990	1620517	17	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	CANDIDA	0.18	8.02	N	Y	N	N	Y	PARKISONISM	DISCHARGE	N	N	N	N	Y
991	1640729	18	SPUTUM	Neg	-	-	Neg	NG	0.1	0.03	N	N	N	N	Y	NECROTISING	DISCHARGE ON REQUEST	N	N	N	N	Y
992	1643674	20	SPUTUM	Neg	-	-	Neg	CANDIDA	0.1	-	Y	N	N	N	N	COPD, KOCH'S	DISCHARGE	N	N	N	N	Y
993	1639440	21	NR	NR	-	-	NR	NR	0.2	8.05	N	Y	N	N	Y	PANCREATITIS	DISCHARGE	N	N	N	N	Y
994	1173818	22	NR	NR	-	-	NR	NR	0.23	0.02	N	N	N	N	Y	CKD	DISCHARGE	N	N	N	N	Y
995	1646275	23	NR	NR	-	-	NR	NR	0.1	0.23	N	Y	N	N	N	LRTI, SEPSIS	DISCHARGE ON REQUEST	N	N	N	N	Y
996	1646258	24	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.1	0.02	N	N	N	N	Y	CAD	DISCHARGE	N	N	N	N	Y
997	1644006	25	NR	NR	-	-	NR	NR	0.1	0.6	N	N	N	N	Y	SEPSIS, CKD	DISCHARGE ON REQUEST	N	N	N	N	Y
998	1646299	26	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.18	0.07	N	N	N	N	N	LRTI, AKI	DISCHARGE ON REQUEST	Y	N	Y	N	N
999	878118	27	SPUTUM	Neg	-	-	Neg	CANDIDA	0.13	0.09	N	Y	N	N	N	COPD	DISCHARGE	N	N	N	N	Y
1000	1646703	28	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	CANDIDA	0.2	8	N	N	N	N	N	H1N1 +VE	DAMA	N	N	N	N	Y
1001	1642684	29	NR	NR	-	-	NR	NR	0.1	0.04	N	N	N	N	N	LRTI	DISCHARGE	N	N	N	N	Y
1002	90142	30	NR	NR	-	-	NR	NR	0.55	0.05	N	Y	N	N	Y	CIRRHOSIS WITH PORTAL HTN	DISCHARGE	Y	N	Y	N	N
1004	1626973	32	PER CUTANEOUS DRAIN	Neg	-	-	Neg	NG	0.1	-	N	N	N	N	Y	PANCREATITIS	DISCHARGE ON REQUEST	N	N	N	N	Y
1005	1645324	33	NR	NR	-	-	NR	NR	0.1	0.02	N	N	N	N	N	LRTI, AKI	DISCHARGE ON REQUEST	N	N	N	N	Y
1006	1634145	34	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	1.92	-	N	Y	N	N	Y	OPACIFICATION	DAMA	N	N	N	N	Y

S. no	MRD No.	Lab No	NAME	DOR Sample	AGE	SEX	GMRepeat	DOA	AREA	SUB AREA WISE	Sample	DOR Sample	FEVER	COUGH	SOB	CHEST PAIN	DM	HTN	Alcoholic	Smoker	Neutropenia	TBHistory	Chronic steroid use	Solid organ transplantation	Malignancy	HIV	HCV	HB	TLC/DLC	NEUTROPHIL COUNT	CT CHEST _PLEURAL EFFUSION	CONSOLIDATION IN LUNG	CAVITATION	RETICULONODULAR OPACITIES	Histopathology for aspergillus species
1007	1566104	36	MS	1/3/2024	37	M	N	1/2/2024	ICU	RESPIRATORY TRACT DISEASE	SERUM	1/3/2024	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	14	26	59	N	Y	N	N	NR
1008	1642833	37	JS	1/3/2024	37	M	N	12/22/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	1/3/2024	Y	Y	Y	N	N	N	N	N	N	N	N	N	N	N	11	20	61	N	Y	Y	N	NR
1009	1643405	38	KG	1/3/2024	70	M	P	12/24/2023	WARD	CARDIOVASCULAR DISEASE	SERUM	1/3/2024	Y	Y	N	Y	N	Y	N	N	N	N	Y	N	N	N	N	11	26.7	97	N	N	N	N	NR
1010	1646337	39	SK	1/4/2024	64	F	N	12/31/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	1/4/2024	N	Y	Y	Y	N	Y	N	N	N	N	N	N	N	N	N	12	21	85	N	N	N	N	NR
1011	827273	40	AK	1/4/2024	65	F	N	12/18/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	1/4/2024	Y	Y	Y	N	N	N	N	N	N	N	N	N	N	N	8.6	24	95	N	N	N	N	NR
1012	1521863	41	SA	1/4/2024	65	M	P	12/26/2023	WARD	CARDIOVASCULAR DISEASE	SERUM	1/4/2024	Y	Y	N	Y	Y	Y	N	N	N	N	N	N	N	N	12	17	94	N	N	N	N	NR
1013	1647164	42	MK	1/4/2024	36	M	N	1/2/2024	WARD	RESPIRATORY TRACT DISEASE	SERUM	1/4/2024	Y	Y	N	N	N	Y	N	N	N	N	N	N	N	N	11	22	74	N	N	N	Y	NR
1014	1646396	43	AS	1/4/2024	36	F	N	12/31/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	1/4/2024	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	7.2	6	96	N	N	N	N	NR
1015	1645290	44	P	1/4/2024	32	M	N	12/28/2023	WARD	RENAL DISEASE	SERUM	1/4/2024	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	7.2	7	90	Y	N	N	N	NR
1016	1647777	45	RS	1/4/2024	61	M	N	1/3/2024	WARD	CARDIOVASCULAR DISEASE	SERUM	1/4/2024	N	Y	Y	Y	Y	N	N	N	N	N	N	N	N	N	11	19	92	Y	N	N	N	NR
1017	1647843	46	JS	1/4/2024	48	M	N	1/3/2024	WARD	RESPIRATORY TRACT DISEASE	SERUM	1/4/2024	Y	Y	N	N	N	N	Y	N	N	N	N	N	N	N	11.5	15	83	N	N	N	N	NR
1018	1386594	47	S	1/5/2024	83	F	N	1/3/2024	WARD	RESPIRATORY TRACT DISEASE	SERUM	1/5/2024	Y	Y	N	N	Y	Y	N	N	N	N	Y	N	N	N	N	11	16	83	Y	N	N	Y	NR
1019	1644334	48	BS	1/5/2024	44	M	N	12/26/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	1/5/2024	N	N	N	N	N	N	Y	Y	N	N	N	N	N	N	16	11	89	N	N	N	N	NR
1021	1645892	51	BK	1/6/2024	58	M	N	12/29/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	1/6/2024	Y	N	Y	N	Y	Y	N	N	N	N	N	N	N	N	15	18	82	N	N	N	Y	NR
1023	1645859	53	RK	1/6/2024	55	M	N	12/30/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	1/6/2024	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	8.6	15	84.8	Y	N	N	N	NR
1024	840284	54	SG	1/6/2024	67	F	N	12/22/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	1/6/2024	Y	N	Y	Y	Y	Y	N	N	N	N	N	N	N	N	11	15	80	Y	N	N	N	NR
1025	1644304	55	HK	1/6/2024	65	F	N	12/26/2023	WARD	CARDIOVASCULAR DISEASE	SERUM	1/6/2024	N	N	Y	Y	N	Y	N	N	N	N	N	N	N	N	8	19	87	N	N	N	N	NR
1026	154911	56	CK	1/6/2024	72	F	N	1/4/2024	WARD	RESPIRATORY TRACT DISEASE	SERUM	1/6/2024	Y	Y	N	N	N	N	N	N	N	N	Y	N	N	N	12	14	76	N	N	N	Y	NR
1027	1644529	57	HS	1/7/2024	55	M	N	12/27/2023	ICU	CARDIOVASCULAR DISEASE	SERUM	1/7/2024	N	N	Y	Y	N	Y	N	N	N	N	N	N	N	N	13	15	86	N	N	N	N	NR
1028	1628197	58	HK	1/7/2024	30	M	N	1/6/2024	WARD	NEUROLOGICAL DISEASE	SERUM	1/7/2024	N	N	N	N	N	N	N	N	N	N	N	N	N	N	15	21	79	N	N	N	N	NR
1029	295602	59	GS	1/7/2024	90	M	N	1/6/2024	ICU	RESPIRATORY TRACT DISEASE	SERUM	1/7/2024	Y	Y	N	N	N	Y	N	N	N	N	N	N	N	N	10.4	9.8	96	Y	N	N	N	NR
1030	1648964	60	SD	1/7/2024	62	F	N	1/5/2024	WARD	RENAL DISEASE	SERUM	1/7/2024	N	Y	Y	N	Y	Y	N	N	N	N	N	N	N	N	9.6	8.1	76	N	N	N	N	NR
1031	36120	61	SK	1/7/2024	83	M	N	12/25/2023	ICU	CARDIOVASCULAR DISEASE	SERUM	1/7/2024	N	N	N	Y	Y	Y	N	N	N	N	N	N	N	N	11	18	83	Y	N	N	N	NR
1032	1533943	62	JS	1/7/2024	72	M	N	1/2/2024	WARD	RESPIRATORY TRACT DISEASE	SERUM	1/7/2024	Y	N	Y	N	N	Y	N	N	N	N	N	N	N	N	9.1	30	91	N	Y	N	Y	NR
1033	854514	63	SR	1/7/2024	79	F	N	1/5/2024	ICU	RESPIRATORY TRACT DISEASE	SERUM	1/7/2024	Y	N	Y	Y	N	Y	N	N	N	N	N	N	N	N	12	35	87	N	N	N	N	NR
1034	1608401	64	BS	1/7/2024	65	M	N	1/7/2024	WARD	RESPIRATORY TRACT DISEASE	SERUM	1/7/2024	Y	Y	N	N	N	N	N	N	N	N	Y	N	N	N	8.5	24	93	N	N	N	Y	NR
1035	894464	65	SL	1/7/2024	65	M	N	1/7/2024	WARD	RESPIRATORY TRACT DISEASE	SERUM	1/7/2024	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	6.9	15	88	N	N	N	N	NR
1036	1646662	66	PP	1/8/2024	21	M	N	1/1/2024	WARD	GENERAL SURGERY	SERUM	1/8/2024	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	10	17	82	N	N	N	N	NR
1037	1647135	67	SK	1/8/2024	66	F	N	1/2/2024	WARD	RESPIRATORY TRACT DISEASE	SERUM	1/8/2024	Y	N	Y	N	Y	Y	N	N	N	N	N	N	N	N	11	19	88	N	Y	N	N	NR
1038	1645458	68	MR	1/8/2024	48	F	N	12/29/2023	WARD	CARDIOVASCULAR DISEASE	SERUM	1/8/2024	Y	Y	N	Y	N	N	N	N	N	N	N	N	N	N	8.1	10	83	N	N	N	N	NR
1039	1542097	69	KK	1/8/2024	52	F	N	1/2/2024	WARD	ONCOLOGICAL	SERUM	1/8/2024	Y	Y	N	N	N	N	N	N	N	N	N	N	Y	N	N	9.1	7.2	84	Y	N	N	N	NR
1040	471001	71	R	1/8/2024	57	F	N	1/8/2024	WARD	RESPIRATORY TRACT DISEASE	SERUM	1/8/2024	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	13	15	56	N	N	N	Y	NR
1041	1650520	72	BK	1/9/2024	48	F	N	1/8/2024	WARD	RENAL DISEASE	SERUM	1/9/2024	Y	Y	N	N	Y	N	N	N	N	N	Y	N	N	N	9.5	18	90	N	N	N	N	NR
1042	1649009	74	RP	1/9/2024	54	M	N	1/5/2024	WARD	RESPIRATORY TRACT DISEASE	SERUM	1/9/2024	N	Y	Y	N	N	N	N	N	N	N	N	N	N	N	8.9	55	96	N	Y	N	Y	NR
1043	1650529	75	KK	1/9/2024	45	F	N	1/8/2024	ICU	RESPIRATORY TRACT DISEASE	SERUM	1/9/2024	Y	Y	N	Y	N	Y	N	N	N	N	Y	N	N	N	N	12	35	97	N	N	Y	N	NR
1045	1628702	77	AS	1/9/2024	72	M	N	1/3/2024	ICU	CARDIOVASCULAR DISEASE	SERUM	1/9/2024	Y	Y	N	Y	Y	Y	N	N	N	N	N	N	N	N	11	9.7	78	Y	N	N	Y	NR
1047	1645298	79	GS	1/10/2024	46	M	N	12/28/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	1/10/2024	N	N	N	N	N	N	N	N	N	N	Y	N	N	N	N	10	7	74	N	N	N	N	NR
1048	1649744	80	AS	1/10/2024	40	M	N	1/7/2024	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	1/10/2024	N	N	N	N	N	N	N	N	N	N	N	N	N	N	14	10	63	Y	N	N	N	NR
1049	1643752	81	GJ	1/10/2024	62	F	N	12/25/2023	WARD	CARDIOVASCULAR DISEASE	SERUM	1/10/2024	N	Y	Y	Y	N	Y	N	N	N	N	N	N	N	N	10	11	89	Y	N	N	N	NR
1051	1651099	83	SK	1/11/2024	71	M	N	1/10/2024	WARD	RESPIRATORY TRACT DISEASE	SERUM	1/11/2024	N	Y	Y	N	Y	Y	N	N	N	N	N	N	N	N	8.5	12	83	N	Y	N	N	NR
1052	1651135	84	NK	1/10/2024	77	F	N	1/10/2024	ICU	GASTROINTESTINAL TRACT DISEASE	SERUM	1/10/2024	Y	Y	N	N	N	N	N	N	N	N	Y	N	N	N	N	9.1	14	84	N	N	N	N	NR
1053	1649748	85	AK	1/10/2024	78	F	N	1/7/2024	ICU	RESPIRATORY TRACT DISEASE	SERUM	1/10/2024	Y	Y	N	N	N	N	N	N	N	N	Y	N	N	N	N	9.3	22	93.5	N	N	Y	N	NR
1054	1651403	86	PN	1/10/2024	57	F	N	1/10/2024	WARD	NEUROLOGICAL DISEASE	SERUM	1/10/2024	N	N	N	N	N	Y	N	N	N	N	N	N	N	N	N	3.6	8.7	93	N	N	N	N	NR
1055	1646154	87	VK	1/11/2024	42	F	N	1/8/2024	WARD	RESPIRATORY TRACT DISEASE	SERUM	1/11/2024	N	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	10	12	89	N	Y	N	Y	NR

S. no	MRD No.	Lab No	Distribution of clinical samples received	Fungal smear Positive for Hyaline Septate Fungal Hyphae	CANDIDA IN (BODY FLUIDS AND BLOOD CULTURE)	CANDIDA IN BODY FUILDS	FUNGAL CULTURE FOR ASPERGILLUS SPECIES	Fungal Cuture	GMSAASSAY	1-3 BDG	PTZ	ANTIFUNGAL	Heamo Dylasis	AUGMENTIN	MEROPENEM	Provisional diagnosis	Outcome	TOTAL EORTC PATIENTS	PROVEN	POSSIBLE	PROBABLE	NO INVASIVE ASPERGILLOSI
1007	1566104	36	SPUTUM	P	-	-	P	ASPERGILLUS FLAVUS	0.12	0.02	N	N	N	N	N	SEPSIS	DISCHARGE	N	N	N	N	Y
1008	1642833	37	CSF	Neg	-	-	Neg	NG	0.14	0.02	N	N	N	N	N	AKI, SEPSIS	DAMA	N	N	N	N	Y
1009	1643405	38	PER CUTANEOUS DRAIN	Neg	-	-	Neg	NG	6.11	0.02	N	N	N	N	N	ARDS	DISCHARGE	Y	N	Y	N	N
1010	1646337	39	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.22	0.02	N	N	N	N	Y	LRTI, CAD	DAMA	N	N	N	N	Y
1011	827273	40	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	CANDIDA	1.82	0.72	N	N	N	N	N	LRTI, SEPSIS	DAMA	N	N	N	N	Y
1012	1521863	41	NR	NR	-	-	NR	NR	2.67	0.88	Y	Y	N	N	Y	PNEUMONIA	DAMA	N	N	N	N	Y
1013	1647164	42	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	1.04	0.02	N	N	N	N	N	LRTI, PNEUMONIA	DISCHARGE	N	N	N	N	Y
1014	1646396	43	NR	NR	-	-	NR	NR	0.1	-	N	N	N	N	Y	AKI, SEIZURES	EXPIRED	N	N	N	N	Y
1015	1645290	44	NR	NR	-	-	NR	NR	0.17	0.04	N	N	Y	N	Y	CKD, SEPSIS	DISCHARGE	N	N	N	N	Y
1016	1647777	45	NR	NR	-	-	NR	NR	0.1	0.02	N	N	N	N	N	LRTI, CAD	EXPIRED	N	N	N	N	Y
1017	1647843	46	ASCITIC FLUID	Neg	-	-	Neg	NG	0.1	-	N	N	N	N	Y	ALCOHOLIC	DAMA	N	N	N	N	Y
1018	1386594	47	NR	NR	-	-	NR	NR	0.1	0.02	N	N	N	N	N	LRTI, HYPOTHYROIDISM	DISCHARGE	Y	N	Y	N	N
1019	1644334	48	NR	NR	-	-	NR	NR	0.1	0.02	N	N	N	N	Y	PANCREATITIS, ASCITES	DAMA	N	N	N	N	Y
1021	1645892	51	SPUTUM	P	-	-	P	ASPERGILLUS FLAVUS	0.1	-	N	N	N	N	Y	H1N1 +VE, SEPSIS	DISCHARGE ON REQUEST	N	N	N	N	Y
1023	1645859	53	PUS	Neg	-	-	Neg	NG	0.1	8.02	N	Y	N	N	N	CAD, UTI	DAMA	N	N	N	N	Y
1024	840284	54	SPUTUM	Neg	-	-	Neg	NG	0.1	0.06	N	N	N	N	N	ACUTE CVA	DISCHARGE	N	N	N	N	Y
1025	1644304	55	PER CUTANEOUS DRAIN	Neg	-	-	Neg	NG	0.3	-	N	N	N	N	N	CAD, CKD	EXPIRED	N	N	N	N	Y
1026	154911	56	SPUTUM	Neg	-	-	Neg	NG	0.1	0.02	N	N	N	N	Y	OPACIFICATION	DISCHARGE	Y	N	Y	N	N
1027	1644529	57	NR	NR	-	-	NR	NR	0.78	0.02	N	N	N	N	N	ACS	DISCHARGE	N	N	N	N	Y
1028	1628197	58	NR	NR	-	-	NR	NR	0.12	0.02	N	N	N	N	N	LRTI, SEPSIS	DISCHARGE	N	N	N	N	Y
1029	295602	59	NR	NR	-	-	NR	NR	0.1	-	N	N	N	N	N	BA, LRTR	DISCHARGE	N	N	N	N	Y
1030	1648964	60	NR	NR	-	-	NR	NR	6.95	-	N	Y	Y	N	N	AKI	DISCHARGE ON REQUEST	N	N	N	N	Y
1031	36120	61	NR	NR	-	-	NR	NR	0.19	0.03	N	N	N	N	Y	LRTI, CABG	EXPIRED	N	N	N	N	Y
1032	1533943	62	SPUTUM	Neg	-	-	Neg	NG	0.1	0.02	N	N	N	N	Y	LRTI, CLD	DAMA	N	N	N	N	Y
1033	854514	63	NR	NR	-	-	NR	NR	3.9	-	N	Y	N	N	N	LRTI, HYPOTHYROIDISM	DISCHARGE ON REQUEST	N	N	N	N	Y
1034	1608401	64	ASCITIC FLUID	Neg	-	-	Neg	NG	0.1	0.02	N	N	N	N	N	SEPSIS, CAD	DAMA	Y	N	Y	N	N
1035	894464	65	SPUTUM	Neg	-	-	Neg	CANDIDA	0.47	0.02	N	N	N	N	Y	LRTI, AKI	DISCHARGE	N	N	N	N	Y
1036	1646662	66	ENDOTRACHEAL SECRETIONS	Neg	Y	-	Neg	NG	0.1	0.04	N	N	N	N	Y	LAPROTOMY	DISCHARGE	N	N	N	N	Y
1037	1647135	67	SPUTUM	Neg	-	-	Neg	NG	0.1	-	N	N	N	N	N	LRTI, CKD	DISCHARGE	N	N	N	N	Y
1038	1645458	68	NR	NR	-	-	NR	NR	0.1	0.02	N	N	N	N	N	AFI	EXPIRED	N	N	N	N	Y
1039	1542097	69	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.1	0.02	N	N	N	N	N	CA BREAST	DISCHARGE	Y	N	Y	N	N
1040	471001	71	NR	NR	-	-	NR	NR	0.1	-	N	N	N	N	N	LRTI, KOCH'S	DISCHARGE ON REQUEST	N	N	N	N	Y
1041	1650520	72	NR	NR	Y	-	NR	NR	2.15	8.15	N	Y	Y	N	Y	CKD	DISCHARGE	Y	N	Y	N	N
1042	1649009	74	PLEURAL FLUID	Neg	-	-	Neg	NG	0.14	0.03	N	N	N	N	Y	CA ALVEOUS	DISCHARGE	N	N	N	N	Y
1043	1650529	75	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	CANDIDA	8.61	8.24	N	N	N	N	Y	LRTI	DISCHARGE	Y	N	Y	Y	N
1045	1628702	77	SPUTUM	Neg	-	-	Neg	NG	0.1	-	N	N	N	N	N	HYPOTHYROIDISM, CAD	DISCHARGE ON REQUEST	N	N	N	N	Y
1047	1645298	79	ASCITIC FLUID	Neg	-	-	Neg	NG	1.65	0.03	N	Y	N	N	Y	PANCRETITIS	DISCHARGE	Y	N	Y	N	N
1048	1649744	80	NR	NR	-	-	NR	NR	0.1	0.02	N	N	N	N	Y	PANCRETITIS	DISCHARGE	N	N	N	N	Y
1049	1643752	81	NR	NR	-	-	NR	NR	0.1	-	N	Y	N	N	N	LRTI, ASTHMA	DISCHARGE	N	N	N	N	Y
1051	1651099	83	SPUTUM	Neg	-	-	Neg	NG	0.26	0.02	N	N	N	N	N	LRTI, SEPSIS	DISCHARGE ON REQUEST	N	N	N	N	Y
1052	1651135	84	ASCITIC FLUID	Neg	-	-	Neg	NG	0.51	-	N	N	N	N	Y	ASCITES	DISCHARGE	Y	N	Y	N	N
1053	1649748	85	ENDOTRACHEAL SECRETIONS	P	-	-	P	ASPERGILLUS FLAVUS	0.91	-	N	Y	N	N	Y	ASCITES	DISCHARGE	Y	N	Y	Y	N
1054	1651403	86	NASAL MUCOSA	Neg	-	-	Neg	NG	0.1	0.03	N	Y	N	N	Y	SEPSIS	DAMA	N	N	N	N	Y
1055	1646154	87	NR	NR	-	-	NR	NR	0.1	-	N	N	N	N	Y	LRTI	DISCHARGE	N	N	N	N	Y

S. no	MRD No.	Lab No	NAME	DOR Sample	AGE	SEX	GMRepeat	DOA	AREA	SUB AREA WISE	Sample	DOR Sample	FEVER	COUGH	SOB	CHEST PAIN	DM	HTN	Alcoholic	Smoker	Neutropenia	TBHistory	Chronic steroid use	Solid organ transplantation	Malignancy	HIV	HCV	HB	TLC/DLC	NEUTROPHIL COUNT	CT CHEST _PLEURAL EFFUSION	CONSOLIDATION IN LUNG	CAVITATION	RETICULONODULAR OPACITIES	Histopathology for aspergillus species
1056	1649478	88	SS	1/11/2024	36	M	N	1/6/2024	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	1/11/2024	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	9	24	80	N	N	N	N	NR
1057	1646391	89	PV	1/11/2024	65	M	N	12/31/2023	WARD	CARDIOVASCULAR DISEASE	SERUM	1/11/2024	Y	N	Y	Y	N	Y	N	N	N	N	Y	N	N	N	N	9.5	6	79	N	N	N	N	NR
1059	1650313	92	J	1/11/2024	55	F	N	1/8/2024	WARD	ENDOCRINOLOGY	SERUM	1/11/2024	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	8.2	10	64	N	Y	N	N	NR
1060	1518385	93	MD	1/11/2024	46	F	N	1/10/2024	WARD	RENAL DISEASE	SERUM	1/11/2024	Y	Y	N	N	Y	Y	N	N	N	N	Y	N	N	Y	N	5.5	8	92	N	Y	N	Y	NR
1061	1648949	94	SD	1/11/2024	74	F	N	1/5/2024	WARD	RENAL DISEASE	SERUM	1/11/2024	Y	Y	N	N	N	Y	N	N	N	N	N	N	N	N	N	7.1	9.8	79	N	Y	N	N	NR
1062	26650	95	DK	1/12/2024	80	F	N	1/8/2024	ICU	CARDIOVASCULAR DISEASE	SERUM	1/12/2024	Y	N	Y	Y	N	Y	N	N	N	N	N	N	N	N	N	12	15	87	N	N	N	N	NR
1064	1424528	97	SK	1/12/2024	87	F	N	1/6/2024	WARD	RENAL DISEASE	SERUM	1/12/2024	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	9.1	9.2	92	N	Y	N	Y	NR
1065	1651085	98	RM	1/12/2024	78	M	N	1/7/2024	ICU	CARDIOVASCULAR DISEASE	SERUM	1/12/2024	N	Y	Y	Y	Y	Y	N	N	N	N	N	N	N	N	N	9.2	12	72	Y	N	N	N	NR
1067	1651081	100	JS	1/12/2024	28	M	N	1/9/2024	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	1/12/2024	Y	Y	N	N	N	Y	N	N	N	N	N	N	N	N	Y	10	15	90	N	N	N	N	NR
1068	1277346	101	SK	1/12/2024	81	F	N	1/4/2024	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	1/12/2024	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	14	12	58	N	N	N	N	NR
1069	1433939	102	HK	1/12/2024	52	F	N	1/11/2024	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	1/12/2024	N	N	N	N	N	N	N	N	N	N	Y	N	N	N	N	14	12	60	N	Y	N	N	NR
1070	1649733	105	GS	1/12/2024	73	M	N	1/7/2024	WARD	CARDIOVASCULAR DISEASE	SERUM	1/12/2024	Y	Y	N	Y	Y	Y	N	N	N	N	N	N	N	N	N	10	22	79	Y	N	N	N	NR
1071	1643734	106	DR	1/12/2024	60	M	N	1/1/2024	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	1/12/2024	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	11	10.9	84	N	N	N	N	NR
1072	1651395	107	KG	1/13/2024	64	F	N	1/10/2024	ICU	RESPIRATORY TRACT DISEASE	SERUM	1/13/2024	Y	Y	N	N	N	Y	N	N	N	N	Y	N	N	N	N	11.5	15	73.3	N	N	N	Y	NR
1073	1648425	109	HS	1/13/2024	66	M	N	1/5/2024	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	1/13/2024	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	9.7	9.7	69	N	N	N	N	NR
1074	1498402	110	SS	1/13/2024	25	M	N	1/10/2024	WARD	RENAL DISEASE	SERUM	1/13/2024	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	9.6	3	73	N	N	N	Y	NR
1075	1652086	111	BS	1/13/2024	49	M	N	1/11/2024	WARD	GENERAL SURGERY	SERUM	1/13/2024	N	N	N	N	Y	N	N	N	N	N	Y	N	N	N	N	15.4	5.4	82.9	N	N	N	N	NR
1076	1517801	112	V	1/14/2024	73	F	N	1/11/2024	ICU	RESPIRATORY TRACT DISEASE	SERUM	1/14/2024	N	Y	Y	N	Y	Y	N	N	N	N	Y	N	N	N	N	12	14	90	N	N	N	Y	NR
1077	5239	113	PR	1/14/2024	80	M	N	1/11/2024	WARD	RESPIRATORY TRACT DISEASE	SERUM	1/14/2024	N	Y	Y	N	N	N	Y	Y	N	N	N	N	N	N	N	12.5	13	87	N	N	N	N	NR
1079	1652912	115	PK	1/14/2024	56	M	N	1/13/2024	ICU	RESPIRATORY TRACT DISEASE	SERUM	1/14/2024	Y	Y	N	N	Y	N	N	N	N	N	N	N	N	N	N	10	13	79	N	N	N	Y	NR
1080	584239	117	NG	1/15/2024	48	F	N	1/9/2024	ICU	RESPIRATORY TRACT DISEASE	SERUM	1/15/2024	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	8.6	20	96.7	N	N	N	N	NR
1081	1652773	118	LR	1/15/2024	55	M	N	1/13/2024	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	1/15/2024	N	N	N	N	N	N	N	N	N	N	Y	N	N	N	N	11.7	9.7	70.6	N	N	N	Y	NR
1082	1365372	119	KS	1/15/2024	66	M	N	1/13/2024	WARD	RENAL DISEASE	SERUM	1/15/2024	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	7.8	5.5	87	N	Y	N	N	NR
1083	1653112	122	SK	1/16/2024	62	F	N	1/15/2024	WARD	RESPIRATORY TRACT DISEASE	SERUM	1/16/2024	Y	Y	Y	N	Y	Y	N	N	N	N	Y	N	N	N	N	10.7	21	63	N	N	N	Y	NR
1084	1647116	123	HK	1/16/2024	63	F	N	1/2/2024	WARD	RENAL DISEASE	SERUM	1/16/2024	N	Y	Y	N	Y	Y	N	N	N	N	Y	N	N	N	N	8.4	10	92	N	N	N	N	NR
1085	1653642	125	BR	1/16/2024	85	M	N	1/15/2024	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	1/16/2024	N	N	N	N	Y	Y	N	N	N	N	Y	N	N	N	N	13	7.5	88	N	N	N	N	NR
1086	1653701	126	AS	1/16/2024	32	M	N	1/24/2024	WARD	RENAL DISEASE	SERUM	1/16/2024	Y	Y	N	N	Y	Y	N	N	N	N	Y	N	N	N	N	11	33	76	N	N	N	N	NR
1089	1651565	129	HS	1/17/2024	41	M	N	1/10/2024	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	1/17/2024	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	7.3	16	62	N	N	N	Y	NR
1090	1652439	130	NG	1/17/2024	62	M	N	1/12/2024	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	1/17/2024	Y	N	N	N	Y	N	N	N	N	N	N	N	Y	N	N	7.2	2.2	73	N	N	N	Y	NR
1091	280641	132	T	1/17/2024	47	F	N	1/15/2024	WARD	RESPIRATORY TRACT DISEASE	SERUM	1/17/2024	Y	N	N	N	Y	Y	N	N	N	N	N	N	N	N	N	10.7	8.7	55	N	N	Y	N	NR
1092	1652952	133	PD	1/17/2024	58	F	N	1/11/2024	WARD	GENERAL SURGERY	SERUM	1/17/2024	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	14	23	82	N	N	N	N	NR
1093	1654715	134	S	1/17/2024	66	M	N	1/17/2024	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	1/17/2024	Y	Y	N	N	N	Y	N	N	N	N	N	N	N	N	N	11	10	78.9	N	Y	Y	N	NR
1094	1647303	135	AS	1/17/2024	33	M	N	1/3/2024	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	1/17/2024	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	9.2	16	84.8	N	N	N	Y	NR
1095	1563395	136	HS	1/18/2024	34	M	N	1/17/2024	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	1/18/2024	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	12	3.8	44	N	N	N	Y	NR
1096	1107022	137	SG	1/18/2024	67	F	N	1/18/2024	WARD	CARDIOVASCULAR DISEASE	SERUM	1/18/2024	N	Y	N	Y	Y	Y	N	N	N	N	N	N	N	N	N	12	8.7	87	N	Y	N	N	NR
1097	1653986	139	BS	1/18/2024	54	M	N	1/16/2024	WARD	RESPIRATORY TRACT DISEASE	SERUM	1/18/2024	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	14	23	78	N	N	N	N	NR
1098	1647904	140	SK	1/18/2024	31	M	N	1/14/2024	WARD	NEUROLOGICAL DISEASE	SERUM	1/18/2024	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	12	22	92	N	N	N	N	NR
1099	550803	141	GS	1/19/2024	54	M	N	1/13/2024	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	1/19/2024	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	10	10	82	N	Y	N	Y	NR
1100	1643362	142	PS	1/19/2024	58	M	N	1/16/2024	WARD	ONCOLOGICAL	SERUM	1/19/2024	Y	Y	N	N	N	N	N	N	N	N	Y	N	Y	N	N	8	9	85	N	N	N	Y	NR
1101	1633453	143	SK	1/19/2024	49	F	P	1/8/2024	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	1/19/2024	N	N	N	N	N	N	N	N	N	N	Y	N	N	N	N	9.5	20	92	N	N	Y	N	NR
1102	1652424	144	MS	1/19/2024	50	M	N	1/12/2024	WARD	CARDIOVASCULAR DISEASE	SERUM	1/19/2024	Y	Y	N	Y	N	Y	N	N	N	N	N	N	N	N	N	18	16	85	N	N	N	N	NR
1104	1654636	146	SK	1/19/2024	55	F	N	1/17/2024	WARD	RESPIRATORY TRACT DISEASE	SERUM	1/19/2024	Y	Y	N	Y	N	N	N	N	N	N	N	N	N	N	N	9.7	3.1	83	Y	N	N	N	NR
1105	1654299	147	DJ	1/19/2024	86	F	N	1/16/2024	ICU	CARDIOVASCULAR DISEASE	SERUM	1/19/2024	Y	Y	N	Y	Y	Y	N	N	N	N	N	N	N	N	N	10	18	73	N	N	N	N	NR
1106	1654909	148	NM	1/20/2024	61	F	N	1/17/2024	WARD	CARDIOVASCULAR DISEASE	SERUM	1/20/2024	Y	Y	N	Y	N	N	N	N	N	N	N	N	N	N	N	8.1	5	66	N	N	N	N	NR
1107	1651065	149	M	1/20/2024	37	M	N	1/9/2024	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	1/20/2024	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	7.7	16	80	N	N	N	N	NR
1108	1653722	150	HK	1/20/2024	55	F	P	1/15/2024	WARD	RESPIRATORY TRACT DISEASE	SERUM	1/20/2024	Y	Y	N	N	Y	N	N	N	N	N	N	N	N	N	N	6.2	11	90	N	Y	N	Y	NR

S. no	MRD No.	Lab No	Distribution of clinical samples received	Fungal smear Positive for Hyaline Septate Fungal Hyphae	CANDIDA IN (BODY FLUIDS AND BLOOD CULTURE)	CANDIDA IN BODY FUILDS	FUNGAL CULTURE FOR ASPERGILLUS SPECIES	Fungal Cuture	GMSAASSAY	1-3 BDG	PTZ	ANTIFUNGAL	Heamo Dylasis	AUGMENTIN	MEROPENEM	Provisional diagnosis	Outcome	TOTAL EORTC PATIENTS	PROVEN	POSSIBLE	PROBABLE	NO INVASIVE ASPERGILLOSI
1056	1649478	88	NR	NR	-	-	NR	NR	0.12	0.02	N	N	N	N	Y	ASCITES	DISCHARGE	N	N	N	N	Y
1057	1646391	89	NR	NR	-	-	NR	NR	0.1	0.02	N	N	N	N	N	LRTI	EXPIRED	N	N	N	N	Y
1059	1650313	92	SPUTUM	Neg	-	-	Neg	NG	0.1	-	N	N	N	N	N	TB +VE	DISCHARGE ON REQUEST	N	N	N	N	Y
1060	1518385	93	SPUTUM	Neg	-	-	Neg	CANDIDA	0.1	-	N	Y	Y	N	Y	CKD	DISCHARGE	Y	N	Y	N	N
1061	1648949	94	NR	NR	-	-	NR	NR	0.1	-	N	N	N	N	Y	CKD	DISCHARGE	N	N	N	N	Y
1062	26650	95	NR	NR	-	-	NR	NR	0.1	0.02	N	N	N	N	Y	SEPSIS, CKD	DISCHARGE	N	N	N	N	Y
1064	1424528	97	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.1	-	N	N	N	N	Y	LRTI, CKD	DISCHARGE	N	N	N	N	Y
1065	1651085	98	NR	NR	-	-	NR	NR	0.1	-	Y	N	N	N	N	CAD	DISCHARGE	N	N	N	N	Y
1067	1651081	100	NR	NR	-	-	NR	NR	0.1	-	N	N	N	N	Y	HCV +VE	DISCHARGE	N	N	N	N	Y
1068	1277346	101	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.1	-	N	N	N	N	Y	CIRRHOSIS	DISCHARGE	N	N	N	N	Y
1069	1433939	102	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	3.62	-	N	Y	N	N	Y	CONSOLIDATION IN LUNG	DISCHARGE	Y	N	Y	Y	N
1070	1649733	105	SPUTUM	Neg	-	-	Neg	NG	0.13	0.02	Y	N	N	N	Y	CAD	EXPIRED	N	N	N	N	Y
1071	1643734	106	SPUTUM	Neg	-	-	Neg	CANDIDA	0.1	0.02	N	N	N	N	Y	PANCREATITIS	DISCHARGE	N	N	N	N	Y
1072	1651395	107	NR	NR	-	-	NR	NR	0.1	-	N	N	N	N	Y	LRTI, HYPOTHYROIDISM	DISCHARGE ON REQUEST	Y	N	Y	N	N
1073	1648425	109	NR	NR	-	-	NR	NR	0.1	0.02	N	N	N	N	Y	PANCREATITIS	DISCHARGE	N	N	N	N	Y
1074	1498402	110	NR	NR	-	-	NR	NR	0.1	0.02	Y	N	N	N	N	LRTI, CKD	DISCHARGE ON REQUEST	N	N	N	N	Y
1075	1652086	111	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	CANDIDA	1.76	0.46	N	Y	N	N	Y	DIAPHIAGNETIC HERNIA	DISCHARGE	Y	N	Y	N	N
1076	1517801	112	NR	NR	-	-	NR	NR	0.1	-	Y	N	N	N	N	ILD	EXPIRED	Y	N	Y	N	N
1077	5239	113	SPUTUM	Neg	-	-	Neg	NG	0.1	-	N	N	N	N	Y	LRTI	EXPIRED	N	N	N	N	Y
1079	1652912	115	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.13	0.82	N	N	N	N	N	LRTI	DISCHARGE	N	N	N	N	Y
1080	584239	117	SPUTUM	Neg	-	-	Neg	NG	0.1	-	N	N	N	N	Y	SHOGUN SYNDROME	DISCHARGE ON REQUEST	N	N	N	N	Y
1081	1652773	118	NR	NR	-	-	NR	NR	0.74	0.02	N	Y	N	N	Y	CIRRHOSIS	DISCHARGE	Y	N	Y	Y	N
1082	1365372	119	SPUTUM	Neg	-	-	Neg	CANDIDA	0.1	0.02	N	N	N	N	Y	DM	DISCHARGE	N	N	N	N	Y
1083	1653112	122	SPUTUM	Neg	-	-	Neg	NG	0.1	-	N	N	N	N	N	LRTI, ANEMIA	DISCHARGE	Y	N	Y	N	N
1084	1647116	123	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.1	0.03	N	N	Y	N	Y	CKD, LRTI, HYPOTHYROIDISM	DISCHARGE ON REQUEST	N	N	N	N	Y
1085	1653642	125	ASCITIC FLUID	Neg	-	-	Neg	NG	0.81	0.02	N	Y	N	N	Y	CIRRHOSIS	DISCHARGE	Y	N	Y	N	N
1086	1653701	126	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	2.96	0.02	N	N	N	N	Y	LRTI, SEIZURE	EXPIRED	Y	N	Y	N	N
1089	1651565	129	SPUTUM	Neg	-	-	Neg	NG	0.1	0.02	N	N	N	N	Y	CIRRHOSIS WITH PORTAL HTN	DISCHARGE	N	N	N	N	Y
1090	1652439	130	NR	NR	-	-	NR	NR	7	0.02	N	Y	N	N	N	MULTIPLE MYCLOMA	EXPIRED	Y	N	Y	Y	N
1091	280641	132	SPUTUM	Neg	-	-	Neg	CANDIDA	0.02	-	N	N	N	N	Y	LRTI	DISCHARGE	N	N	N	N	Y
1092	1652952	133	NR	NR	-	-	NR	NR	0.1	0.05	Y	N	N	N	Y	40% BURN	EXPIRED	N	N	N	N	Y
1093	1654715	134	SPUTUM	Neg	-	-	Neg	CANDIDA	0.1	-	N	Y	N	N	Y	CIRRHOSIS WITH PORTAL HTN	DISCHARGE	N	N	N	N	Y
1094	1647303	135	SPUTUM	Neg	-	-	Neg	NG	0.1	0.03	N	N	N	N	Y	CIRRHOSIS	DISCHARGE	N	N	N	N	Y
1095	1563395	136	SPUTUM	Neg	-	-	Neg	NG	0.1	0.27	N	N	N	N	Y	CIRRHOSIS	DISCHARGE ON REQUEST	N	N	N	N	Y
1096	1107022	137	SPUTUM	Neg	-	-	Neg	CANDIDA	0.1	0.22	N	N	N	N	N	H1N1 +VE	DAMA	N	N	N	N	Y
1097	1653986	139	NR	NR	-	-	NR	NR	0.1	-	N	N	N	N	N	LRTI	DISCHARGE	N	N	N	N	Y
1098	1647904	140	NR	NR	-	-	NR	NR	0.1	0.03	N	N	N	N	Y	SUBARACHNOID HEMAIRAGE	EXPIRED	N	N	N	N	Y
1099	550803	141	ASCITIC FLUID	Neg	-	-	Neg	NG	0.1	0.02	N	N	N	N	Y	CIRRHOSIS WITH PORTAL HTN	DISCHARGE ON REQUEST	N	N	N	N	Y
1100	1643362	142	NR	NR	-	-	NR	NR	0.1	0.15	N	Y	N	N	N	LRTI, SEPSIS	EXPIRED	Y	N	Y	N	N
1101	1633453	143	NR	NR	-	-	NR	NR	2.71	-	N	Y	N	N	Y	PANCREATITIS	DISCHARGE	Y	N	Y	Y	N
1102	1652424	144	NR	NR	-	-	NR	NR	0.36	0.02	N	N	N	N	Y	CAD	DISCHARGE	N	N	N	N	Y
1104	1654636	146	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.1	0.02	N	N	N	N	N	LRTI, CKD	DISCHARGE ON REQUEST	N	N	N	N	Y
1105	1654299	147	SPUTUM	Neg	-	-	Neg	NG	0.1	0.02	N	N	N	N	N	CAD, SEPSIS	DISCHARGE	N	N	N	N	Y
1106	1654909	148	NR	NR	-	-	NR	NR	0.1	-	N	N	N	N	N	COPD, LRTI	DISCHARGE	N	N	N	N	Y
1107	1651065	149	PER CUTANEOUS DRAIN	Neg	-	-	Neg	NG	0.12	0.02	N	N	N	N	Y	PANCREATITIS	DAMA	N	N	N	N	Y
1108	1653722	150	SPUTUM	Neg	-	-	Neg	CANDIDA	0.58	0.58	N	Y	N	N	Y	PNEUMONITS	DISCHARGE	N	N	N	N	Y

S. no	MRD No.	Lab No	NAME	DOR Sample	AGE	SEX	GMRepeat	DOA	AREA	SUB AREA WISE	Sample	DOR Sample	FEVER	COUGH	SOB	CHEST PAIN	DM	HTN	Alcoholic	Smoker	Neutropenia	TBHistory	Chronic steroid use	Solid organ transplantation	Malignancy	HIV	HCV	HB	TLC/DLC	NEUTROPHIL COUNT	CT CHEST _PLEURAL EFFUSION	CONSOLIDATION IN LUNG	CAVITATION	RETICULONODULAR OPACITIES	Histopathology for aspergillus species
1111	1628132	153	VK	1/21/2024	56	M	N	1/17/2024	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	1/21/2024	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	12	13	72	N	N	N	N	NR
1112	1644311	155	NS	1/21/2024	74	M	N	1/26/2024	WARD	NEUROLOGICAL DISEASE	SERUM	1/21/2024	N	Y	N	N	N	Y	N	N	N	N	N	N	N	N	N	10	22	93	N	N	N	N	NR
1113	1652633	156	JS	1/21/2024	47	M	N	1/13/2024	WARD	RESPIRATORY TRACT DISEASE	SERUM	1/21/2024	N	Y	N	N	N	N	N	N	N	N	Y	N	N	N	N	10	8.85	76	N	N	N	N	NR
1114	1655533	157	MC	1/22/2024	56	M	N	1/19/2024	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	1/22/2024	N	N	N	N	N	N	N	N	N	N	Y	N	N	N	N	7.1	18	72	N	Y	N	Y	NR
1115	1654673	158	RK	1/22/2024	45	F	N	1/17/2024	WARD	CARDIOVASCULAR DISEASE	SERUM	1/22/2024	N	N	N	Y	Y	N	N	N	N	N	N	N	N	N	N	11	12	88	N	Y	N	Y	NR
1116	1653035	159	DS	1/22/2024	68	M	N	1/14/2024	ICU	RESPIRATORY TRACT DISEASE	SERUM	1/22/2024	Y	N	N	N	N	Y	N	N	N	N	Y	N	N	N	N	9.8	11	93	N	N	N	N	NR
1117	1655477	160	PK	1/22/2024	60	F	N	1/19/2024	ICU	RESPIRATORY TRACT DISEASE	SERUM	1/22/2024	Y	Y	N	Y	N	N	N	N	N	N	N	N	N	N	N	14	23	91	Y	N	Y	N	NR
1118	1652824	161	HS	1/23/2024	51	M	N	1/13/2024	WARD	CARDIOVASCULAR DISEASE	SERUM	1/23/2024	N	N	N	Y	Y	Y	N	N	N	N	N	N	N	N	N	9.6	28	93	N	N	N	N	NR
1120	1655532	164	AK	1/23/2024	73	M	N	1/19/2024	WARD	RENAL DISEASE	SERUM	1/23/2024	N	N	Y	N	Y	Y	N	N	N	N	N	N	N	N	N	9	25	76	N	N	N	N	NR
1121	977822	165	MN	1/23/2024	74	M	N	1/19/2024	WARD	RENAL DISEASE	SERUM	1/23/2024	Y	Y	N	N	N	N	N	N	N	N	Y	N	N	N	9.7	18	88	N	N	N	Y	NR
1122	1652908	166	VK	1/24/2024	39	M	N	1/13/2024	WARD	CARDIOVASCULAR DISEASE	SERUM	1/24/2024	Y	Y	N	Y	N	N	N	Y	N	N	N	N	N	N	N	10	10	92	N	N	N	N	NR
1123	1656620	167	DR	1/24/2024	62	M	N	1/20/2024	WARD	RESPIRATORY TRACT DISEASE	SERUM	1/24/2024	Y	Y	N	N	N	N	Y	N	N	N	N	N	N	N	N	17	16	72	N	Y	N	N	NR
1124	1616774	168	VB	1/24/2024	36	M	N	1/1/2024	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	1/24/2024	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	9.3	16	72	N	N	N	N	NR
1125	1239269	170	AK	1/23/2024	52	M	N	1/7/2024	WARD	RENAL DISEASE	SERUM	1/23/2024	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	6.1	24	88	Y	N	N	N	NR
1126	1652101	172	MM	1/23/2024	84	M	N	1/12/2024	WARD	CARDIOVASCULAR DISEASE	SERUM	1/23/2024	Y	Y	N	Y	N	Y	N	N	N	N	N	N	N	N	N	8.9	10.4	89	N	N	N	N	NR
1127	1656640	173	BD	1/24/2024	54	M	N	1/20/2024	WARD	RESPIRATORY TRACT DISEASE	SERUM	1/24/2024	Y	Y	N	N	Y	N	N	N	N	N	N	N	N	N	N	10	12	93	N	N	N	N	NR
1128	1654953	174	BK	1/24/2024	60	F	N	1/18/2024	WARD	RESPIRATORY TRACT DISEASE	SERUM	1/24/2024	Y	Y	N	N	N	Y	N	N	N	N	Y	N	N	N	N	9.7	10	93	N	Y	N	N	NR
1129	1649234	175	SJ	1/24/2024	68	F	N	1/6/2024	WARD	CARDIOVASCULAR DISEASE	SERUM	1/24/2024	N	N	N	Y	Y	Y	N	N	N	N	N	N	N	N	N	10	32	89	N	N	N	N	NR
1130	1647311	176	AC	1/24/2024	43	M	N	1/22/2024	WARD	RENAL DISEASE	SERUM	1/24/2024	N	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	9.3	7	42	Y	N	N	N	NR
1131	1656646	177	JK	1/24/2024	57	M	N	1/21/2024	WARD	RESPIRATORY TRACT DISEASE	SERUM	1/24/2024	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	10	4.9	90	N	N	N	N	NR
1132	1651070	178	GS	1/24/2024	72	M	N	1/9/2024	WARD	GENERAL SURGERY	SERUM	1/24/2024	N	Y	Y	N	N	N	N	N	N	N	Y	N	N	N	N	12	26	96	N	Y	N	N	NR
1134	1646967	180	GS	1/24/2024	30	M	N	1/23/2024	WARD	NEUROLOGICAL DISEASE	SERUM	1/24/2024	N	Y	N	N	N	N	N	N	N	N	Y	N	N	N	N	10	24	79	N	Y	N	Y	NR
1135	1248176	181	RJ	1/25/2024	64	M	N	1/24/2024	WARD	RENAL DISEASE	SERUM	1/25/2024	Y	Y	N	N	N	N	N	N	N	N	Y	N	N	N	N	11	10	66	N	N	Y	N	NR
1136	1655529	182	VK	1/25/2024	43	F	N	1/19/2024	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	1/25/2024	N	Y	N	N	N	N	N	N	N	N	Y	N	N	N	N	10	0.81	76	N	N	N	N	NR
1137	1231420	183	BK	1/25/2024	67	F	N	1/24/2024	WARD	RESPIRATORY TRACT DISEASE	SERUM	1/25/2024	Y	Y	N	N	N	N	N	N	N	N	Y	N	N	N	N	11	7.5	95	N	Y	N	Y	NR
1138	1658011	184	JK	1/25/2024	42	F	N	1/23/2024	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	1/25/2024	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	10	10	72	Y	N	N	N	NR
1139	981293	185	PS	1/25/2024	58	M	N	1/15/2024	WARD	RENAL DISEASE	SERUM	1/25/2024	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	11	7.8	85	N	Y	N	Y	NR
1140	1658807	186	VS	1/25/2024	37	M	N	1/25/2024	WARD	CARDIOVASCULAR DISEASE	SERUM	1/25/2024	N	N	N	Y	N	N	N	N	N	N	N	N	N	N	N	16	21	80	Y	N	N	N	NR
1141	1656517	187	KS	1/25/2024	60	M	N	1/20/2024	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	1/25/2024	Y	N	Y	N	Y	Y	N	N	N	N	N	N	N	N	N	9.6	7.9	79	N	N	N	N	NR
1142	1643360	189	SC	1/25/2024	77	M	N	12/24/2023	WARD	CARDIOVASCULAR DISEASE	SERUM	1/25/2024	N	N	N	Y	Y	Y	N	N	N	N	N	N	N	N	N	10	9.7	67	N	Y	N	N	NR
1143	878085	190	SK	1/26/2024	81	M	N	1/24/2024	WARD	RESPIRATORY TRACT DISEASE	SERUM	1/26/2024	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	10	20	96	N	N	N	Y	NR
1144	1658771	191	HS	1/27/2024	66	M	N	1/24/2024	WARD	NEUROLOGICAL DISEASE	SERUM	1/27/2024	N	N	N	Y	N	N	N	N	N	N	Y	N	N	N	N	10	10	72	N	N	N	Y	NR
1145	1657566	193	AK	1/26/2024	38	F	N	1/22/2024	WARD	RESPIRATORY TRACT DISEASE	SERUM	1/26/2024	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	7.2	18	87	N	N	N	N	NR
1146	1659622	196	RK	1/27/2024	55	F	N	1/26/2024	WARD	RESPIRATORY TRACT DISEASE	SERUM	1/27/2024	Y	Y	N	N	N	N	N	N	N	N	Y	N	N	N	N	10	24	83	Y	N	N	Y	NR
1147	433899	197	R	1/27/2024	50	F	N	1/26/2024	WARD	RESPIRATORY TRACT DISEASE	SERUM	1/27/2024	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	10	8.1	80	N	N	N	Y	NR
1148	1545529	198	SK	1/27/2024	24	M	N	1/22/2024	WARD	RENAL DISEASE	SERUM	1/27/2024	N	Y	N	N	N	N	N	N	N	N	N	Y	N	N	N	8.4	6.5	92	N	N	N	N	NR
1149	1656890	199	HS	1/27/2024	63	M	N	1/21/2024	WARD	CARDIOVASCULAR DISEASE	SERUM	1/27/2024	N	N	N	Y	Y	Y	N	N	N	N	Y	N	N	N	N	10	10	92	Y	N	N	N	NR
1150	168809	200	BS	1/27/2024	60	M	N	1/23/2024	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	1/27/2024	N	N	N	N	Y	N	N	N	N	N	Y	N	N	N	N	10	20	92	N	N	N	N	NR
1151	1659069	201	KS	1/27/2024	60	M	N	1/25/2024	WARD	RESPIRATORY TRACT DISEASE	SERUM	1/27/2024	Y	Y	N	N	Y	Y	N	N	N	N	Y	N	N	N	N	10	10	83	N	N	N	N	NR
1153	211236	203	SS	1/28/2024	82	F	N	1/16/2024	WARD	RENAL DISEASE	SERUM	1/28/2024	Y	Y	N	N	N	N	N	N	N	N	Y	N	N	N	9.8	19	93	N	N	N	N	NR
1154	1655517	204	JS	1/28/2024	54	M	P	1/18/2024	WARD	RESPIRATORY TRACT DISEASE	SERUM	1/28/2024	Y	Y	N	N	N	N	Y	Y	N	N	N	N	N	N	N	10	11	92	N	N	N	Y	NR
1155	1679651	205	GL	1/28/2024	58	M	N	1/28/2024	WARD	RESPIRATORY TRACT DISEASE	SERUM	1/28/2024	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	10	13	89	N	Y	N	N	NR
1156	1644640	206	RS	1/28/2024	61	M	N	1/22/2024	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	1/28/2024	N	N	N	N	Y	N	N	N	N	N	N	N	N	N	N	10	11	77	N	N	N	Y	NR
1157	1656104	207	NS	1/28/2024	58	M	N	1/20/2024	WARD	CARDIOVASCULAR DISEASE	SERUM	1/28/2024	N	N	N	Y	Y	N	N	N	N	N	N	N	N	N	N	13	26	90	N	N	N	N	NR
1158	1660207	208	BB	1/29/2024	76	M	N	1/21/2024	WARD	RESPIRATORY TRACT DISEASE	SERUM	1/29/2024	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	10	4.6	83	N	Y	N	Y	NR
1159	1455812	209	JS	1/29/2024	54	M	N	1/21/2024	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	1/29/2024	N	N	N	N	N	N	Y	N	N	N	Y	N	N	N	N	10	28	83	N	N	Y	N	NR
1160	1648902	210	SP	1/29/2024	75	M	N	1/5/2024	WARD	RENAL DISEASE	SERUM	1/29/2024	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	10	12	92	N	N	Y	N	NR

S. no	MRD No.	Lab No	Distribution of clinical samples received	Fungal smear Positive for Hyaline Septate Fungal Hyphae	CANDIDA IN (BODY FLUIDS AND BLOOD CULTURE)	CANDIDA IN BODY FUILDS	FUNGAL CULTURE FOR ASPERGILLUS SPECIES	Fungal Cuture	GMSAASSAY	1-3 BDG	PTZ	ANTIFUNGAL	Heamo Dylasis	AUGMENTIN	MEROPENEM	Provisional diagnosis	Outcome	TOTAL EORTC PATIENTS	PROVEN	POSSIBLE	PROBABLE	NO INVASIVE ASPERGILLOSI
1111	1628132	153	NR	NR	-	-	NR	NR	0.12	0.02	N	N	N	N	Y	PANCREATITIS	DISCHARGE	N	N	N	N	Y
1112	1644311	155	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	CANDIDA	0.1	0.02	N	N	N	N	N	LRTI, SEPSIS	DISCHARGE	N	N	N	N	Y
1113	1652633	156	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.1	0.02	N	Y	N	N	Y	SEPSIS	DAMA	N	N	N	N	Y
1114	1655533	157	NR	NR	-	-	NR	NR	3.16	0.02	N	Y	N	N	Y	CLD WITH PORTAL HTN	DISCHARGE ON REQUEST	Y	N	Y	Y	N
1115	1654673	158	NR	NR	-	-	NR	NR	0.12	0.02	N	Y	N	N	N	ARDS, LRTI	DISCHARGE	N	N	N	N	Y
1116	1653035	159	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	CANDIDA	0.53	8.83	N	Y	N	N	Y	ARDS	DISCHARGE	Y	N	Y	N	N
1117	1655477	160	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.1	8.01	N	N	N	N	N	ARDS	DISCHARGE ON REQUEST	N	N	N	N	Y
1118	1652824	161	SPUTUM	Neg	-	-	Neg	NG	0.1	0.02	Y	N	N	N	N	CAD	EXPIRED	N	N	N	N	Y
1120	1655532	164	PER CUTANEOUS DRAIN	Neg	-	-	Neg	NG	0.1	-	N	N	Y	N	Y	CKD, CYSTITS	EXPIRED	N	N	N	N	Y
1121	977822	165	SPUTUM	Neg	-	-	Neg	CANDIDA	8.32	8.42	N	Y	Y	N	Y	CKD	EXPIRED	Y	N	Y	Y	N
1122	1652908	166	NR	NR	-	-	NR	NR	0.1	0.02	Y	N	N	N	Y	CAD	DISCHARGE	N	N	N	N	Y
1123	1656620	167	NR	NR	-	-	NR	NR	0.16	0.9	N	Y	N	N	N	COPD, KOCH'S	DISCHARGE ON REQUEST	N	N	N	N	Y
1124	1616774	168	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.1	-	N	N	N	N	Y	NECROTISING	DISCHARGE ON REQUEST	N	N	N	N	Y
1125	1239269	170	ASCITIC FLUID	Neg	-	-	Neg	NG	0.1	0.19	N	N	N	N	N	LRTI, CKD, SEPSIS	EXPIRED	N	N	N	N	Y
1126	1652101	172	SPUTUM	Neg	-	-	Neg	CANDIDA	0.1	0.04	N	N	N	N	N	COPD, UTI	DAMA	N	N	N	N	Y
1127	1656640	173	SPUTUM	Neg	-	-	Neg	NG	8.39	9.67	N	Y	N	N	N	H1N1 +VE	DAMA	N	N	N	N	Y
1128	1654953	174	NR	NR	-	-	NR	NR	0.51	-	N	N	N	N	N	SEPSIS, LRTI	DISCHARGE	Y	N	Y	Y	N
1129	1649234	175	NR	NR	-	-	NR	NR	0.1	0.02	N	N	N	N	N	CAD, UTI, SEPSIS	EXPIRED	N	N	N	N	Y
1130	1647311	176	URINE	Neg	Y	Y	Neg	CANDIDA	0.1	0.02	N	Y	N	N	N	CLD	DAMA	N	N	N	N	Y
1131	1656646	177	SPUTUM	Neg	-	-	Neg	NG	0.1	-	N	N	N	N	N	CAD, BPH	DAMA	N	N	N	N	Y
1132	1651070	178	SPUTUM	Neg	-	-	Neg	NG	0.55	6.94	N	N	N	N	N	CKD, ILD	DAMA	Y	N	Y	Y	N
1134	1646967	180	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	13.77	9.07	N	Y	N	N	Y	LRTI	DISCHARGE	Y	N	Y	Y	N
1135	1248176	181	SPUTUM	P	-	-	P	ASPERGILLUS FLAVUS	0.1	0.02	N	Y	Y	N	N	ABPA	DISCHARGE	Y	N	Y	Y	N
1136	1655529	182	PER CUTANEOUS DRAIN	Neg	Y	Y	Neg	CANDIDA	1.02	0.02	N	Y	N	N	Y	NECROTISING	DISCHARGE	Y	N	Y	N	N
1137	1231420	183	NR	NR	-	-	NR	NR	1.32	-	N	Y	N	N	Y	ILD, FUNGAL SEPSIS	DISCHARGE	Y	N	Y	Y	N
1138	1658011	184	NR	NR	-	-	NR	NR	0.17	0.04	N	N	N	N	Y	GASTRITIS	DISCHARGE	N	N	N	N	Y
1139	981293	185	SPUTUM	Neg	-	-	Neg	CANDIDA	0.1	0.02	N	N	Y	N	Y	CKD	DISCHARGE	N	N	N	N	Y
1140	1658807	186	NR	NR	-	-	NR	NR	10.26	-	N	Y	N	N	N	LRTI	EXPIRED	N	N	N	N	Y
1141	1656517	187	ENDOTRACHEAL SECRETIONS	Neg	Y	-	Neg	CANDIDA	0.1	0.02	N	Y	N	N	Y	CLD, CKD	DAMA	N	N	N	N	Y
1142	1643360	189	SPUTUM	Neg	-	-	Neg	CANDIDA	0.04	1.2	N	Y	N	N	N	AKI, ILD	EXPIRED	N	N	N	N	Y
1143	878085	190	SPUTUM	Neg	-	-	Neg	NG	0.1	0.38	N	Y	N	N	N	COPD, LRTI	DISCHARGE	N	N	N	N	Y
1144	1658771	191	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	1.54	-	N	Y	N	N	Y	KOCHS, RSA	DISCHARGE	Y	N	Y	Y	N
1145	1657566	193	SPUTUM	Neg	-	-	Neg	NG	0.4	0.2	N	Y	N	N	N	UTI, SEPSIS, LRTI	DAMA	N	N	N	N	Y
1146	1659622	196	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	1.18	0.02	N	N	N	N	N	LRTI	DISCHARGE ON REQUEST	Y	N	Y	Y	N
1147	433899	197	NR	NR	-	-	NR	NR	0.1	-	N	N	N	N	N	LRTI	DAMA	N	N	N	N	Y
1148	1545529	198	NR	NR	-	-	NR	NR	0.1	0.14	N	Y	Y	N	Y	SEPSIS, KOCHS	DISCHARGE	N	N	N	N	Y
1149	1656890	199	NR	NR	-	-	NR	NR	0.76	0.02	N	Y	N	N	Y	LRTI	EXPIRED	Y	N	Y	Y	N
1150	168809	200	NR	NR	-	-	NR	NR	1.81	0.02	N	N	N	N	N	PANCREATITIS	DISCHARGE	Y	N	Y	N	N
1151	1659069	201	NR	NR	-	-	NR	NR	9.25	0.33	N	Y	N	N	N	LRTI	DISCHARGE	Y	N	Y	N	N
1153	211236	203	PUS	Neg	-	-	Neg	NG	0.18	0.37	N	N	Y	N	N	CKD	DAMA	N	N	N	N	Y
1154	1655517	204	SPUTUM	Neg	-	-	Neg	NG	10.14	0.02	N	Y	N	N	Y	LRTI, VIRAL PNEUMONITS	DISCHARGE	N	N	N	N	Y
1155	1679651	205	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.18	-	N	N	N	N	Y	LRTI, SEPSIS	DAMA	N	N	N	N	Y
1156	1644640	206	NR	NR	-	-	NR	NR	0.1	0.18	N	N	N	N	Y	LIVER DISEASE	DISCHARGE	N	N	N	N	Y
1157	1656104	207	PER CUTANEOUS DRAIN	Neg	-	-	Neg	NG	0.05	0.1	Y	N	N	N	N	CAD	EXPIRED	N	N	N	N	Y
1158	1660207	208	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.25	-	N	N	N	N	Y	LRTI, SEPSIS	DISCHARGE	N	N	N	N	Y
1159	1455812	209	NR	NR	-	-	NR	NR	8.24	-	N	Y	N	N	Y	CLD WITH PORTAL HTN	DISCHARGE	Y	N	Y	Y	N
1160	1648902	210	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.16	0.04	N	N	Y	N	Y	CKD	DISCHARGE	N	N	N	N	Y

S. no	MRD No.	Lab No	NAME	DOR Sample	AGE	SEX	GMRepeat	DOA	AREA	SUB AREA WISE	Sample	DOR Sample	FEVER	COUGH	SOB	CHEST PAIN	DM	HTN	Alcoholic	Smoker	Neutropenia	TBHistory	Chronic steroid use	Solid organ transplantation	Malignancy	HIV	HCV	HB	TLC/DLC	NEUTROPHIL COUNT	CT CHEST _PLEURAL EFFUSION	CONSOLIDATION IN LUNG	CAVITATION	RETICULONODULAR OPACITIES	Histopathology for aspergillus species
1161	1657324	211	JK	1/29/2024	50	M	N	1/22/2024	WARD	RESPIRATORY TRACT DISEASE	SERUM	1/29/2024	Y	Y	N	N	N	N	N	N	N	N	Y	N	N	N	N	13	7.2	98	Y	N	N	N	NR
1162	1659129	213	PK	1/29/2024	57	M	N	1/28/2024	WARD	RESPIRATORY TRACT DISEASE	SERUM	1/29/2024	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	10	16	77	N	N	Y	N	NR
1163	1660701	214	GS	1/29/2024	60	M	N	1/28/2024	WARD	RESPIRATORY TRACT DISEASE	SERUM	1/29/2024	N	Y	N	N	Y	N	Y	Y	N	N	N	N	N	N	N	10.2	7.1	74	N	N	N	N	NR
1164	1660371	216	SC	1/30/2024	68	M	N	2/3/2024	WARD	RESPIRATORY TRACT DISEASE	SERUM	1/30/2024	N	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	10	8	78	N	N	N	N	NR
1165	1565288	217	GK	1/30/2024	73	F	N	1/24/2024	WARD	RESPIRATORY TRACT DISEASE	SERUM	1/30/2024	Y	Y	Y	N	Y	N	N	N	N	N	Y	N	N	N	N	10.3	7.1	63	N	N	N	N	NR
1166	1658222	219	AK	1/30/2024	60	M	N	1/24/2024	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	1/30/2024	N	N	N	N	Y	N	N	N	N	N	N	N	N	N	N	10	9	94	Y	N	N	N	NR
1167	1654583	220	MS	1/30/2024	75	M	N	1/17/2024	WARD	RESPIRATORY TRACT DISEASE	SERUM	1/30/2024	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	8.3	15	97	Y	N	N	N	NR
1168	1602064	221	JS	1/30/2024	60	M	N	1/22/2024	WARD	RESPIRATORY TRACT DISEASE	SERUM	1/30/2024	Y	N	Y	N	N	N	N	N	N	N	N	N	N	N	N	10	8.6	88	N	N	N	N	NR
1169	1660327	222	KG	1/29/2024	48	M	N	1/27/2024	WARD	RESPIRATORY TRACT DISEASE	SERUM	1/29/2024	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	10	10	92	N	N	N	N	NR
1170	1647707	226	SK	1/30/2024	76	F	N	1/3/2024	WARD	RENAL DISEASE	SERUM	1/30/2024	Y	Y	N	N	Y	N	N	N	N	N	N	Y	N	N	N	8.3	10	60	N	N	N	N	NR
1171	110778	227	SM	1/30/2024	57	M	N	1/29/2024	WARD	RENAL DISEASE	SERUM	1/30/2024	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	10	17	96	N	N	N	N	NR
1172	1659381	228	AR	1/30/2024	40	F	N	1/26/2024	WARD	RESPIRATORY TRACT DISEASE	SERUM	1/30/2024	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	8.5	12	64	N	Y	N	Y	NR
1173	1340927	229	CK	1/31/2024	66	F	N	1/26/2024	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	1/31/2024	Y	Y	N	N	N	Y	N	N	N	N	N	N	N	N	Y	9.4	6.7	94	N	N	Y	N	NR
1174	1646236	230	SK	1/31/2024	33	F	N	12/30/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	1/31/2024	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	10	17	86	N	N	N	N	NR
1175	1661906	231	NG	1/31/2024	45	F	N	1/30/2024	WARD	RESPIRATORY TRACT DISEASE	SERUM	1/31/2024	Y	Y	N	N	N	N	N	N	N	Y	N	N	N	N	N	10	18	90	N	Y	Y	N	NR
1177	1401507	2217	SK	11/1/2022	66	F	N	10/22/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/1/2022	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	9.6	36	84.1	Y	N	N	N	NR
1178	869459	2218	MS	11/1/2022	67	M	N	10/22/2022	WARD	RENAL DISEASE	SERUM	11/1/2022	Y	Y	N	N	N	N	N	N	N	N	Y	N	N	N	N	9	14.5	97.5	N	N	N	N	NR
1179	1403866	2219	AK	11/1/2022	64	M	N	10/27/2022	WARD	GENERAL SURGERY	SERUM	11/1/2022	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	N	9.6	10	73	N	N	N	N	NR
1180	1405222	2220	DD	11/1/2022	60	F	N	10/29/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/1/2022	Y	N	Y	N	N	N	N	N	N	N	Y	N	N	N	N	11.3	13.1	73.5	Y	N	N	N	NR
1181	1406595	2221	IB	11/1/2022	69	F	N	11/1/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/1/2022	Y	Y	N	N	N	Y	N	N	N	N	N	N	N	N	N	7.9	15.7	92.7	N	N	N	N	NR
1182	1406280	2222	HS	11/1/2022	59	M	N	11/1/2022	WARD	CARDIOVASCULAR DISEASE	SERUM	11/1/2022	N	N	Y	Y	Y	Y	N	N	N	N	N	N	N	N	N	12	9.5	75	Y	N	N	N	NR
1183	1403894	2223	DS	11/1/2022	79	M	N	10/27/2022	ICU	CARDIOVASCULAR DISEASE	SERUM	11/1/2022	N	N	Y	Y	Y	Y	N	N	N	N	N	N	N	N	N	8	9	80	Y	N	N	N	NR
1184	1405239	2224	GK	11/1/2022	48	F	N	10/29/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/1/2022	N	Y	N	Y	N	N	N	N	N	N	N	N	N	N	N	8.4	25.5	79.9	N	N	N	N	NR
1185	1406221	2225	VK	11/2/2022	57	M	N	10/31/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/2/2022	Y	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	8.7	28	94.9	N	N	Y	N	NR
1186	520087	2226	MR	11/2/2022	54	M	N	10/30/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/2/2022	N	Y	Y	Y	N	N	N	N	N	N	Y	N	N	N	N	10.8	23.8	87.8	N	N	N	Y	NR
1187	1376660	2227	R	11/2/2022	41	M	N	10/31/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/2/2022	Y	Y	N	Y	N	N	N	N	N	N	N	N	N	N	N	9.4	21.3	90	N	N	N	N	NR
1188	1396395	2228	S	11/2/2022	73	M	N	2/11/2022	WARD	RENAL DISEASE	SERUM	11/2/2022	Y	N	Y	N	Y	Y	N	N	N	N	N	N	N	N	N	9.3	14	80	N	N	Y	N	NR
1189	347599	2229	KS	11/2/2022	36	M	N	10/27/2022	WARD	CARDIOVASCULAR DISEASE	SERUM	11/2/2022	N	N	N	Y	Y	Y	Y	Y	N	N	N	N	Y	N	N	10	13	70	N	N	Y	N	NR
1190	1406971	2230	JS	11/2/2022	54	M	P	11/1/2022	WARD	RENAL DISEASE	SERUM	11/2/2022	Y	Y	Y	N	Y	Y	N	N	N	N	N	N	N	N	N	7.7	6.5	92.4	N	N	N	N	NR
1191	1403813	2231	P	11/2/2022	42	F	N	10/27/2022	WARD	CARDIOVASCULAR DISEASE	SERUM	11/2/2022	N	N	Y	Y	Y	Y	N	N	N	N	N	N	N	N	N	9.4	9.5	77.9	Y	N	N	N	NR
1192	5099	2232	J	11/3/2022	57	F	N	11/1/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/3/2022	N	Y	Y	Y	Y	N	N	N	N	Y	N	N	N	N	N	9.6	11.3	66.1	N	Y	Y	N	NR
1193	1393771	2233	AK	11/15/2022	83	F	N	10/27/2022	WARD	GENERAL SURGERY	SERUM	11/15/2022	Y	N	N	N	Y	Y	N	N	N	N	N	N	N	N	N	7	10.2	82.8	N	N	Y	N	NR
1194	953437	2234	DS	11/5/2022	68	M	P	11/2/2022	WARD	GENERAL SURGERY	SERUM	11/5/2022	Y	Y	Y	N	N	N	N	N	N	Y	N	Y	N	N	12.4	16.7	83.3	N	N	N	Y	NR
1195	1407588	2235	LS	11/3/2022	55	M	N	11/2/2022	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	11/3/2022	N	N	N	N	N	Y	Y	N	N	N	N	N	N	N	N	7.8	8.6	66.9	N	N	N	N	NR
1196	1227550	2236	SS	11/3/2022	64	M	N	10/30/2022	WARD	RENAL DISEASE	SERUM	11/3/2022	N	Y	Y	N	Y	Y	N	N	N	N	N	N	N	N	N	7.4	2.4	52.8	Y	N	N	N	NR
1197	1406989	2237	AS	11/3/2022	35	M	N	11/1/2022	WARD	CARDIOVASCULAR DISEASE	SERUM	11/3/2022	Y	Y	Y	Y	Y	Y	N	N	N	N	N	N	N	N	N	15	10	74	Y	N	N	N	NR
1198	1405229	2238	HS	11/3/2022	50	M	N	10/29/2022	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	11/3/2022	Y	N	N	N	N	N	Y	N	N	N	Y	N	N	N	N	10.2	17.9	83.7	N	N	N	N	NR
1199	1401451	2239	TD	11/3/2022	78	F	N	10/21/2022	ICU	CARDIOVASCULAR DISEASE	SERUM	11/3/2022	N	Y	N	Y	N	Y	N	N	N	N	N	N	N	N	N	7	11	80	N	N	N	N	NR
1200	385756	2240	GS	11/3/2022	70	M	N	10/16/2022	WARD	GENERAL SURGERY	SERUM	11/3/2022	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	7.8	10.4	79	N	N	N	Y	NR
1201	1402161	2241	DS	11/4/2022	70	M	N	10/24/2022	WARD	NEUROLOGICAL DISEASE	SERUM	11/4/2022	N	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	11.2	20.6	80	Y	N	N	N	NR
1202	184258	2242	BS	11/4/2022	69	M	N	21-10-2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/4/2022	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	10	9	92.5	N	N	N	N	NR
1203	1397990	2243	RS	11/4/2022	55	M	N	10/15/2022	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	11/4/2022	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	12.5	8.4	72.6	Y	N	N	N	NR
1204	1402056	2244	SL	11/4/2022	61	M	N	10/23/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/4/2022	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	9.5	6.21	63.6	N	Y	N	Y	NR
1205	1331822	2245	K	11/4/2022	37	F	N	11/3/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/4/2022	Y	N	N	N	N	N	N	N	N	N	Y	N	N	N	N	10	12	84	N	N	N	N	NR
1206	1401457	2246	RS	11/4/2022	28	F	N	10/21/2022	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	11/4/2022	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	11	4.3	75.5	Y	N	N	N	NR
1207	1293439	2247	AS	11/4/2022	33	M	N	10/31/2022	WARD	RENAL DISEASE	SERUM	11/4/2022	Y	Y	N	N	N	Y	N	N	N	N	N	N	N	N	N	6.6	5.76	78	N	Y	N	Y	NR
1208	1011308	2248	SB	11/4/2022	60	F	N	11/4/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/4/2022	N	Y	N	N	N	N	N	N	N	N	Y	N	N	N	N	10.7	4	63.2	N	N	N	Y	NR
1210	1405424	2250	SS	11/5/2022	67	M	N	10/30/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/5/2022	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	10.7	37.8	85.1	N	Y	N	N	NR

S. no	MRD No.	Lab No	Distribution of clinical samples received	Fungal smear Positive for Hyaline Septate Fungal Hyphae	CANDIDA IN (BODY FLUIDS AND BLOOD CULTURE)	CANDIDA IN BODY FUILDS	FUNGAL CULTURE FOR ASPERGILLUS SPECIES	Fungal Cuture	GMSAASSAY	1-3 BDG	PTZ	ANTIFUNGAL	Heamo Dylasis	AUGMENTIN	MEROPENEM	Provisional diagnosis	Outcome	TOTAL EORTC PATIENTS	PROVEN	POSSIBLE	PROBABLE	NO INVASIVE ASPERGILLOSI
1161	1657324	211	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	1.18	-	Y	N	N	N	N	ARDS, PNEUMONITIS	DISCHARGE	Y	N	Y	Y	N
1162	1659129	213	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	1.57	0.02	N	N	N	N	Y	H1N1 +VE	DISCHARGE	N	N	N	N	Y
1163	1660701	214	SPUTUM	Neg	-	-	Neg	CANDIDA	0.47	0.02	N	N	N	N	N	HYPOTHYROIDISM, PANCREATITS	DAMA	N	N	N	N	Y
1164	1660371	216	SPUTUM	Neg	-	-	Neg	CANDIDA	4.66	-	N	Y	N	N	N	CAD, LRTI	DISCHARGE	N	N	N	N	Y
1165	1565288	217	SPUTUM	Neg	-	-	Neg	CANDIDA	0.1	-	N	N	N	N	Y	ILD	DISCHARGE	N	N	N	N	Y
1166	1658222	219	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.17	0.02	N	N	N	N	Y	CLD WITH PORTAL HTN	DISCHARGE ON REQUEST	N	N	N	N	Y
1167	1654583	220	NR	NR	-	-	NR	NR	0.67	-	N	N	N	N	Y	LRTI	DAMA	N	N	N	N	Y
1168	1602064	221	NR	NR	-	-	NR	NR	0.1	-	N	N	N	N	Y	ILD, PAH	DISCHARGE	N	N	N	N	Y
1169	1660327	222	SPUTUM	Neg	-	-	Neg	NG	0.16	-	N	N	N	N	Y	UTI	DISCHARGE	N	N	N	N	Y
1170	1647707	226	NR	NR	Y	-	NR	NR	4.7	6.94	N	N	N	N	Y	CKD, UTI, ASTHMA	DAMA	Y	N	Y	N	N
1171	110778	227	SPUTUM	Neg	-	-	Neg	NG	0.15	0.05	N	N	N	N	Y	LRTI, CKD	DISCHARGE	N	N	N	N	Y
1172	1659381	228	SPUTUM	Neg	-	-	Neg	NG	0.14	-	N	N	N	N	N	VIRAL PNEUMONIA	DISCHARGE	N	N	N	N	Y
1173	1340927	229	NR	NR	-	-	NR	NR	0.1	-	N	N	N	N	Y	HCV +VE	DISCHARGE ON REQUEST	N	N	N	N	Y
1174	1646236	230	NR	NR	-	-	NR	NR	0.19	0.02	N	N	N	N	Y	PANCREATITIS	DISCHARGE	N	N	N	N	Y
1175	1661906	231	NR	NR	-	-	NR	NR	0.17	0.04	N	N	N	N	Y	LRTI	DAMA	N	N	N	N	Y
1177	1401507	2217	NR	NR	-	-	NR	NR	0.2	-	N	N	N	N	Y	LRTI, ACUTE NECROTISING, PANCREATITIS	DISCHARGE ON REQUEST	N	N	N	N	Y
1178	869459	2218	NR	NR	-	-	NR	NR	0.14	330.53	Y	N	Y	N	Y	CLD, CKD, CIRRHOSIS	DISCHARGE ON REQUEST	N	N	N	N	Y
1179	1403866	2219	NR	NR	-	-	NR	NR	0.15	213.04	N	N	N	N	Y	CHOLICYTITS	EXPIRED	N	N	N	N	Y
1180	1405222	2220	SPUTUM	Neg	-	-	Neg	CANDIDA	0.47	112.42	N	Y	N	N	Y	LRTI, FUNGAL SEPSIS, AKI	DISCHARGE ON REQUEST	Y	N	Y	Y	N
1181	1406595	2221	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	CANDIDA	0.23	-	N	N	N	N	Y	LRTI, HTN	EXPIRED	N	N	N	N	Y
1182	1406280	2222	NR	NR	-	-	NR	NR	0.22	88.72	Y	N	N	N	Y	CAD, DM, HTN	DISCHARGE ON REQUEST	N	N	N	N	Y
1183	1403894	2223	NR	NR	-	-	NR	NR	0.24	257.94	N	N	N	N	Y	CAD, HTN	DAMA	N	N	N	N	Y
1184	1405239	2224	TISSUE	P	-	-	P	ASPERGILLUS FLAVUS	0.15	57.91	N	N	N	N	Y	BREAST DISEASE	DISCHARGE ON REQUEST	N	N	N	N	Y
1185	1406221	2225	ENDOTRACHEAL SECRETIONS	P	-	-	P	ASPERGILLUS FLAVUS	0.39	183.75	N	Y	N	N	N	H1N1, ARDS, SEPSIS	DAMA	N	N	N	N	Y
1186	520087	2226	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.43	-	Y	N	N	N	N	LRTI	DISCHARGE	Y	N	Y	N	N
1187	1376660	2227	NR	NR	-	-	NR	NR	2.37	-	Y	N	N	N	N	ACUTE FILBILE ILLNESS	DISCHARGE	N	N	N	N	Y
1188	1396395	2228	NR	NR	-	-	NR	NR	0.27	56.2	N	Y	N	N	N	PARKISONS, CKD	DAMA	N	N	N	N	Y
1189	347599	2229	SPUTUM	Neg	-	-	Neg	NG	0.57	37.49	Y	N	N	N	Y	LUNG BIOPSY	DISCHARGE	Y	N	Y	Y	N
1190	1406971	2230	NR	NR	-	-	NR	NR	0.96	427.8	N	Y	Y	N	Y	H1N1, FUNGAL SEPSIS, CKD	DISCHARGE	N	N	N	N	Y
1191	1403813	2231	PLEURAL FLUID	Neg	-	-	Neg	NG	0.96	52.88	Y	N	N	N	Y	CAD	DISCHARGE	N	N	N	N	Y
1192	5099	2232	SPUTUM	Neg	-	-	Neg	CANDIDA	0.12	37.94	N	N	N	N	N	PULM.KOCH'S	DISCHARGE	N	N	N	N	Y
1193	1393771	2233	PER CUTANEOUS DRAIN	Neg	-	-	Neg	NG	0.021	-	N	N	N	N	N	LRTI, SEPSIS, ASTHMA	DAMA	N	N	N	N	Y
1194	953437	2234	SPUTUM	Neg	-	-	Neg	CANDIDA	1.5	523	N	Y	N	N	Y	FUNGAL SEPSIS	DISCHARGE	Y	N	Y	Y	N
1195	1407588	2235	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.29	-	N	N	N	N	Y	CLD	DISCHARGE	N	N	N	N	Y
1196	1227550	2236	SPUTUM	Neg	-	-	Neg	NG	0.19	-	N	Y	N	N	Y	CAD, FLUID OVERLOAD, CKD	DISCHARGE	N	N	N	N	Y
1197	1406989	2237	PER CUTANEOUS DRAIN	Neg	-	-	Neg	NG	0.11	47.6	N	N	N	N	N	LRTI	DISCHARGE	N	N	N	N	Y
1198	1405229	2238	NR	NR	-	-	NR	NR	0.82	88.03	N	Y	N	N	Y	PANCREATITIS	DISCHARGE	Y	N	Y	N	N
1199	1401451	2239	PLEURAL FLUID	Neg	-	-	Neg	NG	0.28	55.01	N	N	N	N	N	LRTI	DISCHARGE	N	N	N	N	Y
1200	385756	2240	NR	NR	-	-	NR	NR	0.48	89.69	N	N	N	N	N	AKI	DISCHARGE	N	N	N	N	Y
1201	1402161	2241	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	2.52	50.15	N	N	N	N	N	LRTI, CAD	DAMA	N	N	N	N	Y
1202	184258	2242	NR	NR	-	-	NR	NR	0.44	-	N	N	N	N	N	ALLERGIC PRONCHITS	DISCHARGE ON REQUEST	N	N	N	N	Y
1203	1397990	2243	NR	NR	-	-	NR	NR	0.26	-	N	N	N	N	Y	PANCREATITIS	DISCHARGE ON REQUEST	N	N	N	N	Y
1204	1402056	2244	SPUTUM	Neg	-	-	Neg	CANDIDA	0.09	-	N	Y	N	N	Y	LRTI	DISCHARGE	N	N	N	N	Y
1205	1331822	2245	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.21	-	N	N	N	N	N	KOCH'S, TUBERCULAR MENINGITIS	DISCHARGE	N	N	N	N	Y
1206	1401457	2246	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.08	73.33	N	N	N	N	Y	SMALL BOWEL OBSTRUCTION	DISCHARGE	N	N	N	N	Y
1207	1293439	2247	BAL	Neg	-	-	Neg	NG	0.27	383.62	Y	Y	N	N	N	CKD	DISCHARGE	N	N	N	N	Y
1208	1011308	2248	SPUTUM	Neg	-	-	Neg	NG	0.26	133.53	N	Y	N	N	N	OPACIFICATION	DISCHARGE	Y	N	Y	N	N
1210	1405424	2250	TISSUE	Neg	-	-	Neg	NG	3.54	523	N	Y	N	N	Y	LRTI	DISCHARGE	N	N	N	N	Y

S. no	MRD No.	Lab No	NAME	DOR Sample	AGE	SEX	GMRepeat	DOA	AREA	SUB AREA WISE	Sample	DOR Sample	FEVER	COUGH	SOB	CHEST PAIN	DM	HTN	Alcoholic	Smoker	Neutropenia	TBHistory	Chronic steroid use	Solid organ transplantation	Malignancy	HIV	HCV	HB	TLC/DLC	NEUTROPHIL COUNT	CT CHEST _PLEURAL EFFUSION	CONSOLIDATION IN LUNG	CAVITATION	RETICULONODULAR OPACITIES	Histopathology for aspergillus species
1211	1251325	2251	VR	11/5/2022	67	F	N	11/2/2022	WARD	RENAL DISEASE	SERUM	11/5/2022	Y	N	N	N	Y	Y	N	N	N	N	N	N	N	N	N	10	14.6	74.5	N	N	N	Y	NR
1212	1397513	2252	KK	11/5/2022	48	F	N	10/14/2022	WARD	GENERAL SURGERY	SERUM	11/5/2022	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	5.6	19.6	85	N	N	N	N	NR
1213	1408393	2253	PK	11/6/2022	60	F	N	11/4/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/6/2022	Y	Y	N	N	Y	N	N	N	N	N	N	N	N	N	N	10.9	8.8	53.9	Y	N	N	N	NR
1214	1287899	2254	SD	11/6/2022	51	F	N	11/1/2022	WARD	RENAL DISEASE	SERUM	11/6/2022	N	Y	Y	N	N	Y	N	N	N	N	N	N	N	N	Y	8.6	6.5	78.9	N	Y	N	Y	NR
1215	1408536	2255	PK	11/6/2022	56	F	N	11/4/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/6/2022	Y	N	Y	N	Y	N	N	N	N	N	Y	N	N	N	N	9.9	9.4	87.9	N	Y	N	Y	NR
1216	1409732	2256	US	11/7/2022	51	F	N	11/6/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/7/2022	N	Y	Y	N	Y	N	N	N	N	N	N	N	N	N	N	5.7	17.6	88.4	N	Y	N	N	NR
1217	1404677	2257	AK	11/7/2022	24	M	N	10/28/2022	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	11/7/2022	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	7.4	13.1	73	N	N	N	N	NR
1218	1409660	2258	PL	11/7/2022	69	M	N	11/6/2022	ICU	CARDIOVASCULAR DISEASE	SERUM	11/7/2022	N	N	Y	Y	N	Y	N	N	N	N	Y	N	N	N	N	11	13.3	77	Y	N	N	N	NR
1219	1410633	2259	RP	11/7/2022	51	M	N	11/7/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/7/2022	N	Y	Y	N	Y	Y	N	N	N	N	N	N	N	N	N	10	8.37	94.2	N	N	Y	N	NR
1220	1393777	2260	BK	11/8/2022	61	M	N	10/8/2022	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	11/8/2022	N	N	N	N	N	N	Y	N	N	N	N	N	N	N	N	7.2	4.6	68.2	Y	N	N	N	NR
1221	1404646	2261	SK	11/8/2022	34	M	N	10/28/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/8/2022	Y	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	10.4	13.1	80.1	N	N	N	Y	NR
1222	1409802	2262	RJ	11/8/2022	73	M	N	11/7/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/8/2022	N	N	Y	N	Y	Y	N	N	N	N	N	N	N	N	N	8.8	9.4	64.1	N	N	N	Y	NR
1223	1406231	2263	GK	11/9/2022	50	F	N	10/31/2022	WARD	ENDOCRINOLOGY	SERUM	11/9/2022	N	N	N	N	N	N	Y	N	N	N	Y	N	N	N	N	10	24	90.3	N	N	N	Y	NR
1224	49334	2264	IS	11/9/2022	58	M	N	11/8/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/9/2022	N	N	N	N	N	N	Y	N	N	N	N	N	N	N	N	7.4	18.3	88.3	N	N	N	N	NR
1225	1407799	2265	J	11/9/2022	49	M	N	7/11/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/9/2022	N	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	10	12	99	Y	N	N	N	NR
1226	1010768	2266	J	11/9/2022	48	F	N	11/5/2022	WARD	RENAL DISEASE	SERUM	11/9/2022	N	N	Y	N	N	N	N	N	N	N	Y	Y	N	N	N	16	6.8	76	Y	N	N	N	NR
1227	1408330	2267	SP	11/9/2022	40	M	N	11/3/2022	WARD	RENAL DISEASE	SERUM	11/9/2022	N	Y	Y	N	Y	Y	N	N	N	N	Y	N	N	N	N	6.6	16	85.8	N	N	N	Y	NR
1228	141060	2268	KS	11/9/2022	74	M	N	11/7/2022	WARD	ENDOCRINOLOGY	SERUM	11/9/2022	N	N	N	N	N	N	Y	N	N	N	N	N	N	N	N	10.4	17.4	82.5	N	N	N	N	NR
1229	1407296	2269	SA	11/9/2022	60	M	N	11/8/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/9/2022	Y	Y	N	N	Y	N	N	N	N	Y	N	N	N	N	N	11.8	5.88	67.6	N	N	N	Y	NR
1230	1410992	2270	JS	11/9/2022	53	M	N	11/8/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/9/2022	Y	Y	N	N	N	N	N	N	N	N	Y	N	N	N	N	10	12	97	N	N	N	Y	NR
1231	1403112	2271	SD	11/9/2022	74	F	N	10/26/2022	WARD	CARDIOVASCULAR DISEASE	SERUM	11/9/2022	N	Y	Y	Y	Y	Y	N	N	N	N	N	N	N	N	N	12	22	92	N	N	N	N	NR
1232	1410606	2272	KS	11/9/2022	74	M	N	11/7/2022	WARD	ENDOCRINOLOGY	SERUM	11/9/2022	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	10.4	17.4	82.5	N	N	N	N	NR
1233	1411705	2273	D	11/9/2022	68	M	N	11/9/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/9/2022	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	10.4	11.8	89.8	N	N	N	Y	NR
1234	657559	2274	RP	11/10/2022	63	M	N	11/2/2022	WARD	ENDOCRINOLOGY	SERUM	11/10/2022	N	N	N	N	N	N	Y	N	N	N	Y	N	N	N	N	7.7	18.37	75	N	N	N	N	NR
1235	1409744	2275	IS	11/10/2022	32	M	N	11/6/2022	WARD	RENAL DISEASE	SERUM	11/10/2022	Y	Y	N	N	N	N	N	N	N	N	N	N	Y	N	N	11.5	9.6	75.5	N	N	N	N	NR
1236	1406263	2276	BD	11/10/2022	74	F	N	11/1/2022	WARD	NEUROLOGICAL DISEASE	SERUM	11/10/2022	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	10.8	20.1	85.2	N	N	N	N	NR
1237	1408514	2277	P	11/10/2022	35	M	N	11/4/2022	WARD	CARDIOVASCULAR DISEASE	SERUM	11/10/2022	Y	Y	N	Y	N	Y	Y	Y	N	N	N	N	N	N	Y	7.8	22	85	N	N	Y	N	NR
1238	1312589	2278	RK	11/10/2022	65	F	N	11/8/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/10/2022	N	Y	Y	N	Y	N	N	N	N	N	N	N	N	N	N	9.4	6.6	67.1	N	N	Y	N	NR
1239	1408296	2279	BK	11/11/2022	64	F	N	11/3/2022	WARD	RENAL DISEASE	SERUM	11/11/2022	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	12.9	8.4	51.2	N	N	N	N	NR
1240	1398335	2280	G	11/11/2022	25	M	N	11/5/2022	WARD	ENDOCRINOLOGY	SERUM	11/11/2022	N	N	N	N	N	N	Y	N	N	N	N	N	N	N	N	5.8	25.2	70	N	N	Y	Y	NR
1241	805285	2281	K	11/11/2022	65	M	N	11/10/2022	WARD	ENDOCRINOLOGY	SERUM	11/11/2022	N	Y	Y	N	Y	Y	N	N	N	N	N	N	N	N	N	7.1	10.4	62.3	N	Y	N	Y	NR
1242	149483	2282	RK	11/11/2022	75	M	N	11/9/2022	ICU	CARDIOVASCULAR DISEASE	SERUM	11/11/2022	N	Y	Y	Y	Y	Y	N	N	N	N	N	Y	N	N	N	10	9.8	81	N	Y	N	Y	NR
1243	1411065	2283	GK	11/11/2022	67	F	N	11/9/2022	WARD	CARDIOVASCULAR DISEASE	SERUM	11/11/2022	N	Y	N	Y	Y	Y	N	N	N	N	N	N	N	N	N	10	10	89	N	N	N	N	NR
1244	1412545	2284	KM	11/11/2022	31	M	P	11/11/2022	WARD	NEUROLOGICAL DISEASE	SERUM	11/11/2022	Y	N	N	N	N	N	N	N	N	N	Y	N	N	N	N	11.3	12.3	94.7	N	Y	N	Y	NR
1245	1412522	2285	UR	11/11/2022	56	F	N	11/17/2022	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	11/11/2022	N	Y	Y	N	Y	Y	N	N	N	N	Y	N	N	N	N	8.8	5.35	67.8	N	Y	N	N	NR
1246	1405268	2286	HK	11/11/2022	54	F	N	10/29/2022	WARD	NEUROLOGICAL DISEASE	SERUM	11/11/2022	N	N	N	N	N	N	N	N	N	N	Y	N	N	N	N	11.8	7.4	77	N	N	N	N	NR
1247	1401163	2287	R	11/12/2022	54	M	N	10/28/2022	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	11/12/2022	N	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	7.7	11.1	77.6	N	Y	N	Y	NR
1248	1408033	2288	BS	11/12/2022	40	M	N	11/3/2022	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	11/12/2022	Y	Y	N	N	N	N	Y	N	N	N	Y	N	N	N	N	10.4	11	78.2	N	N	N	N	NR
1249	1413008	2289	GK	11/12/2022	58	F	N	11/11/2022	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	11/12/2022	N	N	N	N	N	N	N	N	N	N	Y	N	N	N	N	10	10.8	59.1	Y	N	N	N	NR
1250	1412029	2290	P	11/12/2022	19	M	N	11/10/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/12/2022	Y	Y	N	Y	N	N	N	N	N	N	N	N	N	N	N	11.6	10.9	69.3	N	Y	N	Y	NR
1251	1413032	2291	K	11/12/2022	53	F	N	11/11/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/12/2022	N	Y	Y	N	Y	N	N	N	N	N	N	N	N	N	N	7.3	12	73.2	Y	N	N	N	NR
1252	1411770	2292	GK	11/12/2022	50	F	N	11/10/2022	WARD	RHEUMATOLOGY	SERUM	11/12/2022	N	N	N	N	N	N	N	N	Y	N	Y	N	N	N	N	6.5	0.5	13.4	N	N	N	N	NR
1253	1406921	2293	H	11/12/2022	55	M	N	11/1/2022	WARD	RENAL DISEASE	SERUM	11/12/2022	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	9.1	6.7	83	Y	N	N	N	NR
1255	1409719	2295	P	11/13/2022	56	M	P	11/6/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/13/2022	Y	Y	N	N	Y	N	N	N	N	N	Y	N	N	N	Y	11.8	10.8	82.8	N	Y	N	Y	NR
1256	1410372	2296	S	11/13/2022	60	F	N	11/7/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/13/2022	Y	Y	N	N	N	N	N	N	Y	N	N	N	N	N	N	12.5	0.5	1	N	Y	N	N	NR
1257	1409589	2297	R	11/13/2022	45	M	N	11/5/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/13/2022	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	14	11.9	62.8	N	N	N	Y	NR
1259	1408310	2299	SB	11/13/2022	78	F	N	11/3/2022	ICU	CARDIOVASCULAR DISEASE	SERUM	11/13/2022	N	Y	Y	Y	Y	Y	N	N	N	N	N	N	N	N	N	9.7	17	80	Y	N	N	N	NR
1260	1413605	2300	PP	11/13/2022	60	M	N	11/12/2022	WARD	RENAL DISEASE	SERUM	11/13/2022	N	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	9	31.27	91.3	N	Y	N	N	NR
1261	1413732	2301	JG	11/13/2022	35	M	P	11/13/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/13/2022	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	11	10.8	78.3	N	N	Y	N	NR

S. no	MRD No.	Lab No	Distribution of clinical samples received	Fungal smear Positive for Hyaline Septate Fungal Hyphae	CANDIDA IN (BODY FLUIDS AND BLOOD CULTURE)	CANDIDA IN BODY FUILDS	FUNGAL CULTURE FOR ASPERGILLUS SPECIES	Fungal Cuture	GMSAASSAY	1-3 BDG	PTZ	ANTIFUNGAL	Heamo Dylasis	AUGMENTIN	MEROPENEM	Provisional diagnosis	Outcome	TOTAL EORTC PATIENTS	PROVEN	POSSIBLE	PROBABLE	NO INVASIVE ASPERGILLOSI
1211	1251325	2251	NR	NR	-	-	NR	NR	0.31	21.93	N	N	N	N	Y	AKI, SEPSIS	DISCHARGE	N	N	N	N	Y
1212	1397513	2252	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.16	105.6	N	Y	N	N	Y	PANCREATITIS	DISCHARGE	N	N	N	N	Y
1213	1408393	2253	NR	NR	-	-	NR	NR	0.42	-	Y	N	N	N	Y	UTI SEPSIS	DISCHARGE ON REQUEST	N	N	N	N	Y
1214	1287899	2254	NR	NR	-	-	NR	NR	0.15	-	N	N	N	N	Y	LRTI, CKD	DAMA	N	N	N	N	Y
1215	1408536	2255	NR	NR	-	-	NR	NR	1.16	-	N	Y	N	N	N	ABPA	DAMA	Y	N	Y	Y	N
1216	1409732	2256	NASAL MUCOSA	Neg	-	-	Neg	NG	0.11	44.96	N	N	N	N	N	ALLERGIC BRONCHITIS	DAMA	N	N	N	N	Y
1217	1404677	2257	NR	NR	-	-	NR	NR	0.34	-	N	N	N	N	Y	GASTRITIS	DISCHARGE ON REQUEST	N	N	N	N	Y
1218	1409660	2258	SPUTUM	Neg	-	-	Neg	NG	1.73	-	N	Y	N	N	N	FUNGAL SEPSIS, LRTI	DISCHARGE	Y	N	Y	Y	N
1219	1410633	2259	SPUTUM	Neg	-	-	Neg	NG	0.42	-	N	N	N	N	N	LRTI	DISCHARGE ON REQUEST	N	N	N	N	Y
1220	1393777	2260	NR	NR	-	-	NR	NR	0.16	-	N	N	N	N	Y	CLD	EXPIRED	N	N	N	N	Y
1221	1404646	2261	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.28	196.5	N	N	N	N	N	FUNGAL SEPSIS	DISCHARGE	N	N	N	N	Y
1222	1409802	2262	NR	NR	-	-	NR	NR	0.89	180.4	N	Y	N	N	N	CAD, PNEUMONIA	DISCHARGE ON REQUEST	N	N	N	N	Y
1223	1406231	2263	PLEURAL FLUID	Neg	-	-	Neg	NG	0.76	-	Y	Y	N	N	Y	PANCREATITIS	DISCHARGE	Y	N	Y	Y	N
1224	49334	2264	NR	NR	-	-	NR	NR	0.24	-	N	N	N	N	Y	PANCREATITIS	DISCHARGE	N	N	N	N	Y
1225	1407799	2265	NR	NR	-	-	NR	NR	4.76	-	N	Y	N	N	Y	LRTI	DISCHARGE	N	N	N	N	Y
1226	1010768	2266	NR	NR	-	-	NR	NR	0.18	93.46	N	Y	N	N	N	POST LRAR, CKD	DAMA	Y	N	Y	N	N
1227	1408330	2267	NR	NR	-	-	NR	NR	0.52	217.22	N	Y	N	N	Y	CKD	DISCHARGE ON REQUEST	Y	N	Y	Y	N
1228	141060	2268	NR	NR	-	-	NR	NR	0.38	-	N	N	N	N	Y	GASTRITIS	EXPIRED	N	N	N	N	Y
1229	1407296	2269	SPUTUM	Neg	-	-	Neg	NG	0.34	-	N	N	N	N	N	KOCH'S	DISCHARGE ON REQUEST	N	N	N	N	Y
1230	1410992	2270	SPUTUM	Neg	-	-	Neg	NG	0.55	40.3	Y	Y	N	N	N	LRTI	DAMA	Y	N	Y	Y	N
1231	1403112	2271	NR	NR	-	-	NR	NR	0.36	19.24	N	N	N	N	Y	COPD	DISCHARGE ON REQUEST	N	N	N	N	Y
1232	1410606	2272	NR	NR	-	-	NR	NR	0.38	-	N	N	N	N	N	VOMITING	DAMA	N	N	N	N	Y
1233	1411705	2273	SPUTUM	Neg	-	-	Neg	NG	0.23	63.1	N	N	N	N	Y	DM	DAMA	N	N	N	N	Y
1234	657559	2274	NR	NR	-	-	NR	NR	2.56	-	N	Y	N	N	Y	CLD	DISCHARGE	Y	N	Y	N	N
1235	1409744	2275	SPUTUM	Neg	-	-	Neg	NG	0.09	34.12	N	N	N	N	N	RENAL CARCINOMA	DISCHARGE	N	N	N	N	Y
1236	1406263	2276	NR	NR	-	-	NR	NR	0.21	-	Y	N	N	N	Y	SUB ACUTE INJURY	DISCHARGE	N	N	N	N	Y
1237	1408514	2277	PLEURAL FLUID	Neg	-	-	Neg	NG	0.24	114.63	N	Y	N	N	Y	INFECTIVE ENDOCARDITS	DISCHARGE	N	N	N	N	Y
1238	1312589	2278	NR	NR	-	-	NR	NR	0.29	42.04	N	N	N	N	Y	KOCH'S	DISCHARGE	N	N	N	N	Y
1239	1408296	2279	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	1.65	43.93	N	N	N	N	Y	AKI	DISCHARGE	N	N	N	N	Y
1240	1398335	2280	SPUTUM	Neg	-	-	Neg	CANDIDA	0.06	54.38	Y	N	N	N	Y	PANCREATITIS	DISCHARGE	N	N	N	N	Y
1241	805285	2281	NR	NR	-	-	NR	NR	0.32	-	N	N	N	N	N	AKI	DISCHARGE	N	N	N	N	Y
1242	149483	2282	SPUTUM	Neg	-	-	Neg	NG	0.6	97.86	N	N	N	N	Y	CKD	DISCHARGE	Y	N	Y	Y	N
1243	1411065	2283	SPUTUM	Neg	-	-	Neg	NG	0.19	48.13	Y	N	N	N	Y	CAD	DAMA	N	N	N	N	Y
1244	1412545	2284	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.65	287.55	Y	N	N	N	Y	ON TRACHEOSTOMY	DISCHARGE ON REQUEST	Y	N	Y	Y	N
1245	1412522	2285	SPUTUM	Neg	-	-	Neg	NG	0.83	-	N	Y	N	N	N	CIRRHOSIS	EXPIRED	Y	N	Y	Y	N
1246	1405268	2286	NR	NR	-	-	NR	NR	0.5	13.6	Y	N	N	N	Y	INTRAPARENCHYNAL BLEED	DISCHARGE	Y	N	Y	N	N
1247	1401163	2287	ASCITIC FLUID	Neg	-	-	Neg	NG	0.47	-	Y	N	N	N	Y	CLD WITH PORTAL HTN	DISCHARGE ON REQUEST	N	N	N	N	Y
1248	1408033	2288	ASCITIC FLUID	Neg	-	-	Neg	NG	1.94	62.17	N	N	N	N	Y	CLD WITH PORTAL HTN	DISCHARGE	Y	N	Y	N	N
1249	1413008	2289	SPUTUM	Neg	-	-	Neg	NG	0.91	-	N	Y	N	N	Y	PANCREATITIS	DISCHARGE ON REQUEST	Y	N	Y	Y	N
1250	1412029	2290	SPUTUM	Neg	-	-	Neg	NG	0.13	46.08	N	N	N	N	N	PULM. THROMBOEMBOLISM	DISCHARGE	N	N	N	N	Y
1251	1413032	2291	NR	NR	-	-	NR	NR	0.25	-	N	N	N	N	Y	LRTI	DISCHARGE	N	N	N	N	Y
1252	1411770	2292	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	CANDIDA	2.5	503.56	Y	Y	N	N	Y	RA SEROPOSITIVE	DISCHARGE	Y	N	Y	N	N
1253	1406921	2293	SPUTUM	Neg	-	-	Neg	CANDIDA	0.09	83.78	N	Y	N	N	Y	CKD	DISCHARGE	N	N	N	N	Y
1255	1409719	2295	SPUTUM	Neg	-	-	Neg	CANDIDA	3.18	-	N	Y	N	N	Y	LRTI, FUGAL SEPSIS	DISCHARGE	Y	N	Y	Y	N
1256	1410372	2296	SPUTUM	P	-	-	P	ASPERGILLUS FLAVUS	3.32	523	N	Y	N	N	N	LRTI	DAMA	Y	N	Y	Y	N
1257	1409589	2297	SPUTUM	Neg	-	-	Neg	NG	0.17	-	Y	N	N	N	Y	SCLEROSIS	DISCHARGE ON REQUEST	N	N	N	N	Y
1259	1408310	2299	SPUTUM	Neg	-	-	Neg	NG	0.37	161.73	N	N	N	N	N	LRTI	EXPIRED	N	N	N	N	Y
1260	1413605	2300	SPUTUM	Neg	-	-	Neg	NG	0.39	101.69	Y	N	N	N	Y	CLD, LRTI, AKI	DISCHARGE ON REQUEST	N	N	N	N	Y
1261	1413732	2301	SPUTUM	Neg	-	-	Neg	NG	2.53	49.41	N	N	N	N	Y	INFLUENZA	DISCHARGE	N	N	N	N	Y

S. no	MRD No.	Lab No	NAME	DOR Sample	AGE	SEX	GMRepeat	DOA	AREA	SUB AREA WISE	Sample	DOR Sample	FEVER	COUGH	SOB	CHEST PAIN	DM	HTN	Alcoholic	Smoker	Neutropenia	TBHistory	Chronic steroid use	Solid organ transplantation	Malignancy	HIV	HCV	HB	TLC/DLC	NEUTROPHIL COUNT	CT CHEST _PLEURAL EFFUSION	CONSOLIDATION IN LUNG	CAVITATION	RETICULONODULAR OPACITIES	Histopathology for aspergillus species
1262	1411618	2302	HS	11/13/2022	21	M	N	11/9/2022	WARD	CARDIOVASCULAR DISEASE	SERUM	11/13/2022	N	N	Y	Y	N	N	N	N	N	N	N	N	N	N	N	10	12	82	Y	N	N	N	NR
1263	1413500	2303	BK	11/13/2022	67	M	N	11/12/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/13/2022	Y	Y	N	N	N	N	N	N	N	N	Y	N	N	N	N	13	14.5	89.2	N	N	N	N	NR
1264	1413734	2304	VS	11/13/2022	24	M	N	11/13/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/13/2022	Y	Y	N	N	N	N	N	N	N	N	Y	N	N	N	N	10	10	92	N	N	N	N	NR
1266	1372290	2306	DK	11/14/2022	56	F	N	11/11/2022	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	11/14/2022	N	N	N	N	Y	N	N	N	N	N	N	N	N	N	N	11.7	9	85.6	N	N	N	N	NR
1267	1413765	2307	RR	11/14/2022	56	F	N	11/13/2022	WARD	RENAL DISEASE	SERUM	11/14/2022	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	8.9	13.18	69.1	Y	N	N	N	NR
1269	1413661	2309	BS	11/14/2022	57	M	P	11/13/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/14/2022	Y	Y	N	N	N	N	N	N	N	N	Y	N	N	N	N	11	10.4	91.7	N	N	N	N	NR
1270	1335946	2310	R	11/14/2022	57	M	N	11/10/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/14/2022	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	10	10	79	Y	N	N	N	NR
1271	1412355	2311	JC	11/14/2022	78	M	N	11/11/2022	WARD	ACUTE FEBRILE ILLNESS	SERUM	11/14/2022	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	12.1	26.1	94.2	N	N	N	N	NR
1272	1414514	2312	SK	11/14/2022	29	M	N	11/14/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/14/2022	Y	N	N	N	N	N	Y	N	N	N	N	N	N	N	N	7	1.9	75.4	N	N	N	N	NR
1273	1406351	2313	SL	11/14/2022	87	M	N	11/1/2022	WARD	RENAL DISEASE	SERUM	11/14/2022	Y	Y	N	N	Y	Y	N	N	N	N	Y	N	N	N	N	7.5	6.2	93.2	N	N	N	Y	NR
1274	1399433	2314	SS	11/15/2022	44	M	N	11/9/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/15/2022	Y	Y	N	N	Y	N	N	N	N	N	Y	N	N	N	N	10.3	11.7	82.3	N	Y	N	N	NR
1275	1412365	2315	PS	11/15/2022	18	M	N	11/11/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/15/2022	Y	Y	N	N	Y	N	N	N	N	N	N	N	N	N	N	10.4	7.1	59.2	N	N	N	N	NR
1276	1309828	2316	RK	11/15/2022	59	M	N	11/14/2022	WARD	ONCOLOGICAL	SERUM	11/15/2022	Y	Y	N	N	N	N	N	N	N	N	N	N	Y	N	N	7.5	2.1	69.8	Y	N	N	N	NR
1277	1412305	2317	DS	11/15/2022	72	M	N	11/10/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/15/2022	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	N	9.2	5.5	71.1	N	Y	N	N	NR
1279	1408284	2319	CS	11/15/2022	74	M	N	11/3/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/15/2022	N	Y	Y	N	N	N	N	N	N	N	Y	N	N	N	N	11.1	9	94	N	N	N	Y	NR
1280	1413594	2320	PL	11/15/2022	50	M	N	11/12/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/15/2022	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	9.9	13.95	94.4	N	N	N	Y	NR
1281	1371383	2321	AS	11/16/2022	55	M	N	10/31/2022	WARD	ONCOLOGICAL	SERUM	11/16/2022	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	N	9.9	5.65	91.7	N	N	N	N	NR
1282	1410663	2322	V	11/16/2022	42	M	N	11/8/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/16/2022	Y	Y	N	N	N	N	N	N	N	N	Y	N	N	N	N	8.9	8.69	71.2	N	Y	N	Y	NR
1283	1399037	2323	I	11/16/2022	75	F	N	11/15/2022	WARD	RENAL DISEASE	SERUM	11/16/2022	N	Y	Y	N	Y	Y	N	N	N	N	Y	N	N	N	N	9.7	5	90.8	N	N	N	N	NR
1284	1243717	2324	G	11/17/2022	35	M	N	11/13/2022	WARD	RENAL DISEASE	SERUM	11/17/2022	N	Y	N	N	N	Y	N	N	N	Y	N	N	N	N	N	9.7	9.4	87.4	N	Y	Y	N	NR
1286	1373232	2326	RG	11/17/2022	48	M	N	11/5/2022	ICU	NEUROLOGICAL DISEASE	SERUM	11/17/2022	N	N	N	N	N	N	N	N	N	N	Y	N	N	N	N	9	10.1	66	N	N	Y	N	NR
1287	1413764	2327	B	11/17/2022	63	M	N	11/13/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/17/2022	Y	Y	N	N	Y	N	Y	Y	N	N	N	N	N	N	N	11.9	6.08	65.7	N	Y	N	Y	NR
1288	1415181	2328	BK	11/17/2022	50	F	N	11/15/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/17/2022	Y	Y	N	N	N	Y	N	N	N	N	Y	N	N	N	N	11.9	11.3	91.7	N	Y	N	Y	NR
1289	1415757	2329	KK	11/17/2022	55	F	N	11/16/2022	WARD	RENAL DISEASE	SERUM	11/17/2022	Y	Y	N	N	Y	Y	N	N	N	N	Y	N	N	N	N	7.7	14.27	76.6	N	N	N	N	NR
1290	1371433	2330	LS	11/17/2022	31	M	N	10/2/2022	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	11/17/2022	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	7.3	26.3	83.3	Y	N	N	N	NR
1291	1396476	2331	S	11/17/2022	72	M	N	11/4/2022	WARD	RENAL DISEASE	SERUM	11/17/2022	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	7.7	17	89.6	N	Y	N	Y	NR
1292	1404655	2332	N	11/17/2022	57	F	N	10/28/2022	WARD	CARDIOVASCULAR DISEASE	SERUM	11/17/2022	Y	Y	N	Y	Y	Y	N	N	N	N	N	N	N	N	N	10	10	98	Y	N	N	N	NR
1293	1313028	2333	SS	11/18/2022	50	M	N	10/29/2022	WARD	ENDOCRINOLOGY	SERUM	11/18/2022	N	N	N	N	Y	N	N	N	N	N	Y	N	N	N	N	6.3	6.4	76.2	N	N	N	N	NR
1294	1410518	2334	SK	11/18/2022	60	F	N	11/15/2022	WARD	RENAL DISEASE	SERUM	11/18/2022	Y	Y	N	N	N	N	N	N	N	N	Y	N	N	N	N	8.8	7.5	74.8	N	N	Y	N	NR
1295	1414359	2335	CG	11/18/2022	55	M	N	11/14/2022	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	11/18/2022	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	10.7	20.7	89.9	N	N	N	N	NR
1297	1414539	2337	JK	11/19/2022	48	F	N	11/14/2022	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	11/19/2022	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	9.9	9.5	94.1	N	N	N	Y	NR
1298	1414543	2338	BK	11/19/2022	84	F	N	11/14/2022	ICU	CARDIOVASCULAR DISEASE	SERUM	11/19/2022	N	N	N	Y	N	N	N	N	N	N	N	N	N	N	N	12	12	89	N	N	N	N	NR
1299	1412856	2339	GK	11/19/2022	48	F	N	11/11/2022	WARD	RENAL DISEASE	SERUM	11/19/2022	Y	Y	N	N	N	Y	N	N	N	N	Y	N	N	N	N	6	18.5	84.8	Y	Y	N	N	NR
1300	483518	2340	PK	11/19/2022	73	F	N	11/17/2022	WARD	RENAL DISEASE	SERUM	11/19/2022	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	10.7	19.8	91.2	N	N	N	N	NR
1301	1417108	2341	V	11/19/2022	21	M	P	11/19/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/19/2022	N	Y	N	N	N	N	N	N	N	N	Y	N	N	N	N	12	7.5	57.2	N	N	N	Y	NR
1302	1413793	2342	G	11/19/2022	31	M	N	11/14/2022	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	11/19/2022	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	8.7	29	87.5	N	N	N	N	NR
1303	1335953	2343	SK	11/19/2022	59	F	P	11/18/2022	WARD	CARDIOVASCULAR DISEASE	SERUM	11/19/2022	N	Y	N	Y	Y	N	N	N	N	N	Y	N	N	N	N	16	24	79	N	N	N	N	NR
1304	1416370	2344	NJ	11/19/2022	34	F	N	11/17/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/19/2022	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	7.8	0.8	70.9	N	Y	N	N	NR
1305	1414402	2345	A	11/19/2022	56	M	N	11/14/2022	WARD	ENDOCRINOLOGY	SERUM	11/19/2022	N	N	N	N	N	N	Y	Y	N	N	N	N	N	N	N	11.4	24.6	76	N	N	N	N	NR
1306	1408998	2346	HS	11/20/2022	70	M	N	11/4/2022	WARD	NEUROLOGICAL DISEASE	SERUM	11/20/2022	N	N	N	N	Y	Y	N	N	N	N	N	N	N	N	N	10.5	12.7	65	N	N	N	N	NR
1307	80204	2347	S	11/20/2022	71	M	N	11/15/2022	WARD	RENAL DISEASE	SERUM	11/20/2022	N	N	Y	N	Y	Y	N	N	N	N	N	N	N	N	N	9.5	6.6	69.5	Y	N	N	N	NR
1308	1413713	2348	SG	11/20/2022	52	F	N	11/13/2022	WARD	NEUROLOGICAL DISEASE	SERUM	11/20/2022	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	8.5	21.2	73.4	N	Y	N	N	NR
1309	1417738	2349	SK	11/21/2022	62	F	N	11/20/2022	WARD	NEUROLOGICAL DISEASE	SERUM	11/21/2022	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	10	22	89	N	N	N	N	NR
1310	1413574	2350	JS	11/21/2022	40	M	N	11/12/2022	WARD	RENAL DISEASE	SERUM	11/21/2022	Y	Y	N	N	Y	N	Y	N	N	N	N	N	N	N	N	14.3	11.3	58.3	N	N	N	Y	NR
1311	1391001	2351	MS	11/21/2022	55	M	N	10/31/2022	WARD	CARDIOVASCULAR DISEASE	SERUM	11/21/2022	Y	N	N	Y	Y	Y	N	N	N	N	N	N	N	N	N	10	12	99	Y	N	N	N	NR
1313	1417727	2353	D	11/21/2022	46	M	N	11/20/2022	WARD	RENAL DISEASE	SERUM	11/21/2022	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	8.8	48.34	95.4	N	N	N	N	NR
1315	1413706	2355	RC	11/21/2022	76	M	N	11/13/2022	WARD	CARDIOVASCULAR DISEASE	SERUM	11/21/2022	N	N	Y	Y	Y	Y	N	N	N	N	N	N	N	N	N	10	22	98	Y	N	N	N	NR
1316	1400370	2356	P	11/21/2022	50	M	N	11/19/2022	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	11/21/2022	N	Y	N	N	Y	N	N	N	N	N	N	N	N	N	N	7	7.3	76.5	N	N	N	N	NR

S. no	MRD No.	Lab No	Distribution of clinical samples received	Fungal smear Positive for Hyaline Septate Fungal Hyphae	CANDIDA IN (BODY FLUIDS AND BLOOD CULTURE)	CANDIDA IN BODY FUILDS	FUNGAL CULTURE FOR ASPERGILLUS SPECIES	Fungal Cuture	GMSAASSAY	1-3 BDG	PTZ	ANTIFUNGAL	Heamo Dylasis	AUGMENTIN	MEROPENEM	Provisional diagnosis	Outcome	TOTAL EORTC PATIENTS	PROVEN	POSSIBLE	PROBABLE	NO INVASIVE ASPERGILLOSI
1262	1411618	2302	PLEURAL FLUID	Neg	-	-	Neg	NG	0.18	27.85	N	N	N	N	Y	BRUCELLOSIS	DISCHARGE	N	N	N	N	Y
1263	1413500	2303	NR	NR	-	-	NR	NR	0.36	-	N	N	N	N	Y	ILD, LRTI	DISCHARGE	N	N	N	N	Y
1264	1413734	2304	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.1	-	N	N	N	N	N	ABPA	DISCHARGE	N	N	N	N	Y
1266	1372290	2306	NR	NR	-	-	NR	NR	3.47	-	N	N	N	N	Y	GASTRITIS	DAMA	N	N	N	N	Y
1267	1413765	2307	NR	NR	-	-	NR	NR	0.23	181.7	N	N	Y	N	Y	HYPOTHYROIDISM, LRTI, CKD	DAMA	N	N	N	N	Y
1269	1413661	2309	ENDOTRACHEAL SECRETIONS	P	-	-	P	ASPERGILLUS FLAVUS	0.74	-	N	Y	N	N	Y	LRTI	DISCHARGE	Y	N	Y	Y	N
1270	1335946	2310	CSF	Neg	-	-	Neg	NG	0.29	-	N	N	N	N	Y	MCA ANEURYSM CLIPPING	DISCHARGE	N	N	N	N	Y
1271	1412355	2311	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.24	79.16	Y	Y	N	N	Y	AFI	DISCHARGE	N	N	N	N	Y
1272	1414514	2312	NR	NR	-	-	NR	NR	0.2	64.14	N	N	N	N	Y	TB, GRANU MATOUS	DISCHARGE	N	N	N	N	Y
1273	1406351	2313	SPUTUM	P	-	-	P	ASPERGILLUS FLAVUS	0.35	186.97	N	N	Y	N	Y	CKD	DISCHARGE	Y	N	Y	Y	N
1274	1399433	2314	SPUTUM	Neg	-	-	Neg	NG	0.56	-	N	N	N	N	N	LRTI	DISCHARGE	Y	N	Y	Y	N
1275	1412365	2315	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.22	69.34	N	N	N	N	Y	LRTI	DISCHARGE	N	N	N	N	Y
1276	1309828	2316	NR	NR	-	-	NR	NR	1.01	-	Y	N	N	N	Y	CA COLON	DISCHARGE	Y	N	Y	Y	N
1277	1412305	2317	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	2.35	186.97	N	Y	N	N	N	DENGUE FEVER, GI BLEED	DISCHARGE	N	N	N	N	Y
1279	1408284	2319	SPUTUM	Neg	-	-	Neg	NG	0.38	-	N	N	N	N	N	COPD, BRONCHO PNEUMONIA	DISCHARGE	Y	N	Y	N	N
1280	1413594	2320	SPUTUM	Neg	-	-	Neg	NG	0.32	191.29	N	N	N	N	Y	LRTI	DISCHARGE ON REQUEST	N	N	N	N	Y
1281	1371383	2321	SPUTUM	Neg	-	-	Neg	NG	0.75	-	N	N	N	N	N	BODY ACHE	DAMA	N	N	N	N	Y
1282	1410663	2322	SPUTUM	Neg	-	-	Neg	NG	0.4	-	N	Y	N	N	N	DENGUE FEVER	DAMA	Y	N	Y	N	N
1283	1399037	2323	SPUTUM	Neg	-	-	Neg	NG	2.63	523	N	N	N	N	Y	CKD	DISCHARGE ON REQUEST	Y	N	Y	N	N
1284	1243717	2324	PLEURAL FLUID	Neg	-	-	Neg	NG	0.24	219.74	N	N	N	N	Y	CKD, KOCH'S	DISCHARGE ON REQUEST	N	N	N	N	Y
1286	1373232	2326	ENDOTRACHEAL SECRETIONS	P	-	-	P	ASPERGILLUS FLAVUS	1.54	57.01	N	Y	N	N	Y	Heamorhagic cavities	DISCHARGE	Y	N	Y	Y	N
1287	1413764	2327	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.22	-	N	N	N	N	Y	SEPSIS, SMOKER	DISCHARGE	N	N	N	N	Y
1288	1415181	2328	SPUTUM	Neg	-	-	Neg	NG	0.12	32.03	N	N	N	N	Y	VIRAL PNEUMONIA	DAMA	Y	N	Y	N	N
1289	1415757	2329	NR	NR	-	-	NR	NR	0.15	36.56	N	N	N	N	Y	FIBRILE ILLNESS	DISCHARGE	N	N	N	N	Y
1290	1371433	2330	NR	NR	-	-	NR	NR	0.23	523	N	Y	N	N	Y	PANCREATITIS	DISCHARGE	N	N	N	N	Y
1291	1396476	2331	NR	NR	-	-	NR	NR	0.12	77.04	N	N	N	N	Y	UTI, CKD	DISCHARGE	N	N	N	N	Y
1292	1404655	2332	NR	NR	-	-	NR	NR	0.1	198.61	Y	N	N	N	Y	CAD	DISCHARGE	N	N	N	N	Y
1293	1313028	2333	NR	NR	-	-	NR	NR	0.99	-	N	N	N	N	Y	PANCREATITIS	DISCHARGE	Y	N	Y	N	N
1294	1410518	2334	SPUTUM	Neg	-	-	Neg	NG	0.16	-	Y	N	N	N	N	RA, AKI, SEPSIS	DISCHARGE	Y	N	Y	N	N
1295	1414359	2335	ASCITIC FLUID	Neg	-	-	Neg	NG	0.09	-	N	N	N	N	Y	CLD WITH PORTAL HTN	DISCHARGE ON REQUEST	N	N	N	N	Y
1297	1414539	2337	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.2	98.52	N	N	N	N	Y	Carcinoma ceacum	EXPIRED	N	N	N	N	Y
1298	1414543	2338	NR	NR	-	-	NR	NR	0.11	122.09	Y	N	N	N	Y	HYPOTHYROIDISM,SHOCK	DISCHARGE	N	N	N	N	Y
1299	1412856	2339	NR	NR	-	-	NR	NR	0.12	99.38	N	N	N	N	N	SEPSIS	DISCHARGE	Y	N	Y	N	N
1300	483518	2340	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.12	102.78	N	N	N	N	Y	CKD	DISCHARGE	N	N	N	N	Y
1301	1417108	2341	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.61	81.6	N	Y	N	N	N	FUNGAL SEPSIS	DISCHARGE	Y	N	Y	Y	N
1302	1413793	2342	NR	NR	-	-	NR	NR	0.48	81.19	N	N	N	N	Y	CLD WITH PORTAL HTN	DISCHARGE	N	N	N	N	Y
1303	1335953	2343	NR	NR	-	-	NR	NR	0.36	184.37	N	N	N	N	N	CAD, TVD	DISCHARGE	N	N	N	N	Y
1304	1416370	2344	NR	NR	-	-	NR	NR	0.36	35.57	N	N	N	N	Y	LRTI	DISCHARGE	N	N	N	N	Y
1305	1414402	2345	NR	NR	-	-	NR	NR	0.77	158.38	N	N	N	N	Y	VEIN THROMBOSIS	DISCHARGE	N	N	N	N	Y
1306	1408998	2346	URINE	Neg	-	-	Neg	NG	0.34	100.22	N	N	N	N	Y	MCA TERITORY INFACT	DISCHARGE	N	N	N	N	Y
1307	80204	2347	NR	NR	-	-	NR	NR	0.24	165.75	N	Y	N	N	N	PARKINSONIUM, CKD	DISCHARGE	N	N	N	N	Y
1308	1413713	2348	NR	NR	-	-	NR	NR	0.23	87.16	N	N	N	N	Y	CVA, SEPSIS	DISCHARGE	N	N	N	N	Y
1309	1417738	2349	NASAL MUCOSA	Neg	-	-	Neg	NG	0.22	101.47	Y	N	N	N	Y	IVH	DISCHARGE	N	N	N	N	Y
1310	1413574	2350	SPUTUM	P	-	-	P	ASPERGILLUS FLAVUS	2.89	-	N	Y	N	N	N	AKI, TB	DAMA	N	N	N	N	Y
1311	1391001	2351	NR	NR	-	-	NR	NR	0.55	297.31	N	N	N	N	N	LRTI	DISCHARGE	N	N	N	N	Y
1313	1417727	2353	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.16	72.23	N	N	N	N	Y	PNEUMONOTHORAX	DISCHARGE	N	N	N	N	Y
1315	1413706	2355	NR	NR	-	-	NR	NR	0.12	42.34	Y	N	N	N	Y	CAD	DISCHARGE	N	N	N	N	Y
1316	1400370	2356	PUS	Neg	-	-	Neg	NG	0.28	-	N	N	N	N	Y	PANCREATITIS	DISCHARGE	N	N	N	N	Y

S. no	MRD No.	Lab No	NAME	DOR Sample	AGE	SEX	GMRepeat	DOA	AREA	SUB AREA WISE	Sample	DOR Sample	FEVER	COUGH	SOB	CHEST PAIN	DM	HTN	Alcoholic	Smoker	Neutropenia	TBHistory	Chronic steroid use	Solid organ transplantation	Malignancy	HIV	HCV	HB	TLC/DLC	NEUTROPHIL COUNT	CT CHEST _PLEURAL EFFUSION	CONSOLIDATION IN LUNG	CAVITATION	RETICULONODULAR OPACITIES	Histopathology for aspergillus species
1317	1417634	2357	MS	11/21/2022	46	F	N	11/20/2022	WARD	CARDIOVASCULAR DISEASE	SERUM	11/21/2022	Y	Y	N	Y	N	N	N	N	N	N	N	N	N	N	N	6.7	8.3	84	N	N	N	N	NR
1318	465392	2358	M	11/22/2022	71	F	N	11/8/2022	WARD	CARDIOVASCULAR DISEASE	SERUM	11/22/2022	N	Y	Y	Y	N	Y	N	N	N	N	N	N	N	N	N	8.3	15	89	Y	N	N	N	NR
1319	1418575	2359	SS	11/22/2022	67	M	N	11/22/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/22/2022	Y	Y	N	N	Y	N	N	N	N	N	Y	N	N	N	N	12.7	7.34	87.5	N	Y	N	Y	NR
1320	1417725	2360	S	11/22/2022	52	F	N	11/20/2022	WARD	RENAL DISEASE	SERUM	11/22/2022	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	6.1	11.54	77.9	Y	N	N	N	NR
1321	1418340	2361	M	11/22/2022	24	M	N	11/21/2022	WARD	ENDOCRINOLOGY	SERUM	11/22/2022	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	11.8	12.6	92	N	N	N	N	NR
1326	1283354	2366	RK	11/22/2022	51	M	N	11/14/2022	WARD	RENAL DISEASE	SERUM	11/22/2022	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	8.4	7.54	67.5	N	N	N	Y	NR
1327	1363383	2367	AC	11/22/2022	76	M	N	11/21/2022	WARD	CARDIOVASCULAR DISEASE	SERUM	11/22/2022	N	Y	Y	Y	Y	Y	N	N	N	N	N	N	N	N	N	10	10	89	N	N	N	N	NR
1328	1416415	2368	GP	11/22/2022	28	M	N	11/18/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/22/2022	Y	N	Y	N	N	N	N	N	N	Y	Y	N	N	N	N	9.8	13.77	89.2	N	Y	N	N	NR
1329	1414442	2369	SK	11/23/2022	68	M	N	11/14/2022	WARD	GENERAL SURGERY	SERUM	11/23/2022	N	N	N	N	Y	Y	N	N	N	N	N	N	N	N	N	11.7	13.9	92.2	N	N	N	N	NR
1330	1417673	2370	R	11/23/2022	32	M	N	11/20/2022	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	11/23/2022	N	N	N	N	N	N	N	N	N	N	Y	N	N	N	N	8.7	8.8	72.6	N	N	N	N	NR
1331	1417037	2371	UK	11/23/2022	32	F	N	11/19/2022	WARD	ACUTE FEBRILE ILLNESS	SERUM	11/23/2022	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	10.8	26.5	72.4	N	N	N	N	NR
1332	1336490	2372	SS	11/23/2022	65	M	N	11/17/2022	WARD	NEUROLOGICAL DISEASE	SERUM	11/23/2022	N	N	Y	Y	Y	Y	N	N	N	N	N	N	N	N	N	10	10.5	97.2	N	Y	N	Y	NR
1333	1416294	2373	V	11/23/2022	35	M	N	11/17/2022	WARD	GENERAL SURGERY	SERUM	11/23/2022	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	9	17.1	82.9	N	Y	N	Y	NR
1334	1417593	2374	PT	11/24/2022	53	M	N	11/19/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/24/2022	Y	Y	N	N	Y	Y	N	N	N	N	Y	N	N	N	N	8.7	4.4	43.1	N	N	N	Y	NR
1335	1419883	2375	AG	11/24/2022	26	M	N	11/24/2022	WARD	CARDIOVASCULAR DISEASE	SERUM	11/24/2022	N	N	Y	Y	N	N	Y	N	N	N	N	N	N	N	N	7.8	11	72	N	N	N	N	NR
1337	1419792	2377	JS	11/24/2022	58	M	N	11/23/2022	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	11/24/2022	Y	N	N	N	N	N	Y	Y	N	N	N	N	N	N	N	9.2	17.9	86.1	Y	N	N	N	NR
1338	1415100	2378	NS	11/24/2022	71	M	P	11/15/2022	ICU	CARDIOVASCULAR DISEASE	SERUM	11/24/2022	Y	N	Y	Y	Y	Y	N	N	N	N	Y	N	N	N	N	10	15	85	Y	N	N	Y	NR
1339	1418879	2379	RD	11/24/2022	75	F	N	11/22/2022	WARD	ACUTE FEBRILE ILLNESS	SERUM	11/24/2022	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	7	17.02	86.8	N	N	N	N	NR
1340	173145	2380	NS	11/24/2022	71	M	N	11/19/2022	ICU	CARDIOVASCULAR DISEASE	SERUM	11/24/2022	Y	N	N	Y	Y	Y	N	N	N	N	Y	N	N	N	N	13	16	92	N	N	N	N	NR
1341	1418083	2381	JK	11/24/2022	19	F	N	11/22/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/24/2022	Y	Y	N	Y	N	N	N	N	N	Y	Y	N	N	N	N	11.7	5.3	41.5	N	N	N	N	NR
1342	1262282	2382	PK	11/24/2022	65	M	N	11/20/2022	WARD	CARDIOVASCULAR DISEASE	SERUM	11/24/2022	N	Y	Y	Y	Y	Y	N	N	N	N	N	N	N	N	N	6	10.9	65	N	N	N	N	NR
1343	416444	2383	AN	11/25/2022	84	M	N	11/16/2022	ICU	NEUROLOGICAL DISEASE	SERUM	11/25/2022	N	N	N	N	Y	Y	N	N	N	N	N	N	N	N	N	11	13.4	82.1	N	N	N	N	NR
1344	1419838	2384	TL	11/25/2022	58	M	N	11/23/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/25/2022	Y	Y	Y	N	Y	Y	N	N	N	N	N	N	N	N	N	7	16.2	78.7	Y	N	N	N	NR
1345	414397	2385	VK	11/25/2022	70	M	N	11/24/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/25/2022	Y	Y	Y	N	Y	Y	N	N	N	N	N	N	N	N	N	9.3	10.3	89.8	N	N	N	N	NR
1346	1420466	2386	KK	11/25/2022	64	F	N	11/25/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/25/2022	Y	Y	Y	N	Y	Y	N	N	N	N	N	N	N	N	N	10	18	99	N	Y	N	N	NR
1347	1405431	2387	S	11/25/2022	28	M	N	10/31/2022	WARD	GENERAL SURGERY	SERUM	11/25/2022	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	11.8	8.6	72.1	N	N	N	N	NR
1348	1418303	2388	JG	11/25/2022	35	M	N	11/21/2022	WARD	CARDIOVASCULAR DISEASE	SERUM	11/25/2022	N	Y	N	Y	N	N	N	N	N	N	N	N	N	N	N	14	13	80	Y	N	N	N	NR
1349	1417694	2389	KK	11/26/2022	33	M	N	11/20/2022	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	11/26/2022	N	Y	N	N	N	N	Y	N	N	N	N	N	N	N	N	9.7	16.6	91.9	N	Y	N	N	NR
1350	1396842	2390	RS	11/26/2022	59	M	N	11/24/2022	WARD	RENAL DISEASE	SERUM	11/26/2022	N	Y	N	N	Y	Y	N	N	N	N	Y	N	N	N	N	9.7	8.9	93.5	N	N	N	Y	NR
1351	1420821	2391	G	11/26/2022	64	M	N	11/25/2022	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	11/26/2022	N	Y	N	N	Y	Y	N	N	N	N	Y	N	N	N	N	8.2	2.3	72	N	N	N	N	NR
1352	1417757	2392	IS	11/26/2022	34	M	N	11/21/2022	ICU	GASTROINTESTINAL TRACT DISEASE	SERUM	11/26/2022	N	N	N	N	N	N	N	N	N	N	Y	N	N	N	N	12.9	2.2	49	N	N	N	N	NR
1353	1420393	2393	AG	11/26/2022	19	M	N	11/24/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/26/2022	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	12.7	13.6	68.6	N	N	N	N	NR
1355	1150294	2395	SS	11/26/2022	92	M	N	11/26/2022	WARD	NEUROLOGICAL DISEASE	SERUM	11/26/2022	N	Y	N	Y	N	N	N	N	N	N	N	N	N	N	N	10	22	90	N	N	N	N	NR
1356	1418522	2396	SK	11/26/2022	65	F	P	11/21/2022	WARD	CARDIOVASCULAR DISEASE	SERUM	11/26/2022	Y	Y	N	Y	Y	Y	N	N	N	N	Y	N	N	N	N	10	13	87	Y	N	N	N	NR
1357	1419237	2397	BB	11/27/2022	70	M	N	11/23/2022	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	11/27/2022	N	N	N	N	Y	Y	N	N	N	N	N	N	N	N	N	10.2	10	79	Y	N	N	N	NR
1358	1421117	2398	SS	11/27/2022	44	M	N	11/26/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/27/2022	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	5.9	19.4	86	Y	N	N	N	NR
1359	1403030	2399	AS	11/27/2022	60	M	N	10/26/2022	ICU	NEUROLOGICAL DISEASE	SERUM	11/27/2022	N	N	N	N	Y	Y	N	N	N	N	Y	N	N	N	N	11	16.7	85.5	N	N	N	N	NR
1360	1421715	2400	SS	11/27/2022	60	M	N	11/26/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/27/2022	Y	Y	N	Y	N	N	N	N	N	N	Y	N	Y	N	N	9.8	37.3	95.4	Y	N	N	N	NR
1361	1413361	2401	SD	11/27/2022	68	F	N	11/12/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/27/2022	Y	N	Y	N	Y	Y	N	N	N	N	N	N	N	N	N	12	8.2	68.1	N	N	N	N	NR
1363	1421831	2403	SR	11/27/2022	45	F	N	11/27/2022	WARD	CARDIOVASCULAR DISEASE	SERUM	11/27/2022	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	N	10	20	79	N	N	N	N	NR
1365	1393645	2405	SK	11/28/2022	69	F	N	11/27/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/28/2022	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	9.3	22.1	73.1	N	N	N	N	NR
1366	1193910	2406	TL	11/28/2022	64	M	N	9/23/2022	ICU	CARDIOVASCULAR DISEASE	SERUM	11/28/2022	Y	Y	N	Y	Y	Y	N	N	N	N	N	N	N	N	N	10	10	89	Y	N	N	N	NR
1367	1139083	2407	TK	11/28/2022	41	F	N	11/23/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/28/2022	N	Y	N	N	Y	Y	N	N	N	N	Y	N	N	N	N	9.7	5.7	63.1	Y	N	N	N	NR
1368	1418445	2408	SS	11/28/2022	55	M	N	11/21/2022	ICU	NEUROLOGICAL DISEASE	SERUM	11/28/2022	N	N	N	N	N	N	N	N	N	N	Y	N	N	N	N	11	16.2	83.7	N	N	N	N	NR
1369	623853	2409	KS	11/28/2022	52	F	N	11/26/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/28/2022	N	Y	Y	N	Y	Y	N	N	N	N	Y	N	N	N	N	10.2	11.9	79.1	N	N	Y	N	NR

S. no	MRD No.	Lab No	Distribution of clinical samples received	Fungal smear Positive for Hyaline Septate Fungal Hyphae	CANDIDA IN (BODY FLUIDS AND BLOOD CULTURE)	CANDIDA IN BODY FUILDS	FUNGAL CULTURE FOR ASPERGILLUS SPECIES	Fungal Cuture	GMSAASSAY	1-3 BDG	PTZ	ANTIFUNGAL	Heamo Dylasis	AUGMENTIN	MEROPENEM	Provisional diagnosis	Outcome	TOTAL EORTC PATIENTS	PROVEN	POSSIBLE	PROBABLE	NO INVASIVE ASPERGILLOSI
1317	1417634	2357	SPUTUM	Neg	-	-	Neg	NG	0.42	50.53	N	N	N	N	N	AFI, LRTI, ARDS	DISCHARGE	N	N	N	N	Y
1318	465392	2358	NR	NR	-	-	NR	NR	0.28	131.06	N	Y	N	N	N	CAD, HYPORHYROIDISM	DISCHARGE	N	N	N	N	Y
1319	1418575	2359	SPUTUM	P	-	-	P	ASPERGILLUS FLAVUS	0.17	-	N	Y	N	N	N	ASTHMA	DISCHARGE	Y	N	Y	Y	N
1320	1417725	2360	NR	NR	-	-	NR	NR	0.19	30.41	N	N	N	N	Y	UTI, SEPSIS, AKI	DAMA	N	N	N	N	Y
1321	1418340	2361	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.34	-	N	N	N	N	Y	PANCREATITIS	DAMA	N	N	N	N	Y
1326	1283354	2366	NR	NR	-	-	NR	NR	0.23	157.81	N	Y	Y	N	N	LRTI, AKI, FUNGAL SEPSIS	DISCHARGE	N	N	N	N	Y
1327	1363383	2367	NR	NR	-	-	NR	NR	0.07	40.97	Y	N	N	N	Y	CAD	EXPIRED	N	N	N	N	Y
1328	1416415	2368	SPUTUM	P	-	-	P	ASPERGILLUS FLAVUS	0.26	523	N	N	N	N	Y	ABPA, KOCH'S, LRTI, SEPSIS	DISCHARGE	Y	N	Y	Y	N
1329	1414442	2369	NR	NR	-	-	NR	NR	0.75	396.62	N	Y	N	N	Y	CHOLICYTITS	DISCHARGE ON REQUEST	N	N	N	N	Y
1330	1417673	2370	NR	NR	-	-	NR	NR	2.37	300.9	N	N	N	N	Y	GASTRITIS	DAMA	Y	N	Y	N	N
1331	1417037	2371	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	3	523	Y	N	N	N	Y	FIBRILE ILLNESS	DISCHARGE	N	N	N	N	Y
1332	1336490	2372	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.15	523	Y	N	N	N	Y	VIRAL PNEUMONIA	DISCHARGE	N	N	N	N	Y
1333	1416294	2373	PER CUTANEOUS DRAIN	Neg	-	-	Neg	NG	0.27	68.34	N	N	N	N	Y	LRTI	DISCHARGE	N	N	N	N	Y
1334	1417593	2374	SPUTUM	Neg	-	-	Neg	NG	0.12	14.99	N	Y	N	N	N	PNEUMONIA	DISCHARGE	Y	N	Y	N	N
1335	1419883	2375	NR	NR	-	-	NR	NR	0.21	73.76	N	N	N	N	Y	SEPSIS, UTI, HCV +VE, DRUG ABUSER	DISCHARGE	N	N	N	N	Y
1337	1419792	2377	TISSUE	Neg	-	-	Neg	NG	0.17	-	N	N	N	N	Y	CLD WITH PORTAL HTN	DISCHARGE	N	N	N	N	Y
1338	1415100	2378	NR	NR	-	-	NR	NR	0.99	97.47	Y	Y	N	N	N	LRTI, FUNGAL SEPSIS	DISCHARGE	Y	N	Y	Y	N
1339	1418879	2379	NR	NR	-	-	NR	NR	0.3	212.11	Y	N	N	N	Y	FIBRILE ILLNESS	DISCHARGE	N	N	N	N	Y
1340	173145	2380	NR	NR	-	-	NR	NR	0.94	154.36	N	N	N	N	Y	COPD	DISCHARGE	Y	N	Y	N	N
1341	1418083	2381	SPUTUM	Neg	-	-	Neg	NG	0.22	-	N	N	N	N	N	ABPA	DISCHARGE	N	N	N	N	Y
1342	1262282	2382	NR	NR	-	-	NR	NR	0.3	382.68	N	N	N	N	N	CAD	DISCHARGE	N	N	N	N	Y
1343	416444	2383	SPUTUM	Neg	-	-	Neg	NG	0.27	45.17	Y	N	N	N	Y	ACUTE ON CHRONIC SDH	DISCHARGE	N	N	N	N	Y
1344	1419838	2384	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.15	183.12	Y	N	N	N	Y	ACUTE FILBILE ILLNESS	DISCHARGE	N	N	N	N	Y
1345	414397	2385	SPUTUM	Neg	-	-	Neg	NG	0.25	131.68	N	N	N	N	Y	ILD, FIBRILE ILLNESS	DISCHARGE	N	N	N	N	Y
1346	1420466	2386	PER CUTANEOUS DRAIN	Neg	-	-	Neg	NG	0.52	-	Y	N	N	N	Y	LRTI	DISCHARGE	N	N	N	N	Y
1347	1405431	2387	NR	NR	-	-	NR	NR	0.24	39.48	N	N	N	N	Y	SDH, SAH	DISCHARGE	N	N	N	N	Y
1348	1418303	2388	PLEURAL FLUID	Neg	-	-	Neg	NG	0.18	39.71	N	N	N	N	Y	PNEUMONIA, INFLUENZA	DISCHARGE	N	N	N	N	Y
1349	1417694	2389	SPUTUM	Neg	-	-	Neg	NG	0.15	-	N	N	N	N	Y	PANCREATITIS	DISCHARGE	N	N	N	N	Y
1350	1396842	2390	PLEURAL FLUID	Neg	-	-	Neg	NG	0.12	130.34	N	Y	N	N	N	CKD, LRTI, FUNGAL SEPSIS	DAMA	Y	N	Y	N	N
1351	1420821	2391	NR	NR	-	-	NR	NR	1.13	-	Y	N	N	N	Y	RHD, LIVER DISEASE	DAMA	Y	N	Y	N	N
1352	1417757	2392	NR	NR	-	-	NR	NR	0.63	-	N	N	N	N	Y	PANCREATITIS	DAMA	Y	N	Y	N	N
1353	1420393	2393	NR	NR	-	-	NR	NR	1.69	525	N	Y	N	N	Y	UTI	DISCHARGE	N	N	N	N	Y
1355	1150294	2395	NR	NR	-	-	NR	NR	0.92	-	Y	N	N	N	Y	CHEST PAIN	DAMA	N	N	N	N	Y
1356	1418522	2396	NR	NR	-	-	NR	NR	0.5	113.59	N	N	N	N	Y	CAD, CKD, PANCREATITIS	DISCHARGE	Y	N	Y	Y	N
1357	1419237	2397	NR	NR	-	-	NR	NR	0.13	-	Y	N	N	N	Y	PANCREATITIS, PLEURAL EFFUSION	DISCHARGE	N	N	N	N	Y
1358	1421117	2398	NR	NR	-	-	NR	NR	0.2	523	Y	N	N	N	Y	LRTI	DISCHARGE	N	N	N	N	Y
1359	1403030	2399	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.5	-	Y	N	N	N	Y	IVH	DISCHARGE	Y	N	Y	N	N
1360	1421715	2400	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.12	43.14	N	Y	N	N	Y	LRTI, ASTHMA	DISCHARGE	Y	N	Y	N	N
1361	1413361	2401	NR	NR	-	-	NR	NR	0.61	231.01	N	Y	N	N	Y	SEPSIS	DAMA	N	N	N	N	Y
1363	1421831	2403	NR	NR	-	-	NR	NR	1.08	445.32	Y	Y	N	N	Y	LRTI, CAD	DISCHARGE	N	N	N	N	Y
1365	1393645	2405	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.21	151.5	N	N	N	N	N	LRTI, UTI	DISCHARGE	N	N	N	N	Y
1366	1193910	2406	SPUTUM	P	-	-	P	ASPERGILLUS FLAVUS	0.59	-	Y	N	N	N	N	HYPERTENSION	DISCHARGE	N	N	N	N	Y
1367	1139083	2407	NR	NR	-	-	NR	NR	0.21	50.85	N	N	N	N	Y	SHOCK	DAMA	Y	N	Y	N	N
1368	1418445	2408	NR	NR	-	-	NR	NR	0.77	77.71	Y	N	N	N	Y	EDH, SAH	DISCHARGE	Y	N	Y	N	N
1369	623853	2409	SPUTUM	Neg	-	-	Neg	NG	1.16	-	N	Y	N	N	N	LRTI, ABPA	DAMA	Y	N	Y	Y	N

S. no	MRD No.	Lab No	NAME	DOR Sample	AGE	SEX	GMRepeat	DOA	AREA	SUB AREA WISE	Sample	DOR Sample	FEVER	COUGH	SOB	CHEST PAIN	DM	HTN	Alcoholic	Smoker	Neutropenia	TBHistory	Chronic steroid use	Solid organ transplantation	Malignancy	HIV	HCV	HB	TLC/DLC	NEUTROPHIL COUNT	CT CHEST _PLEURAL EFFUSION	CONSOLIDATION IN LUNG	CAVITATION	RETICULONODULAR OPACITIES	Histopathology for aspergillus species
1371	1414649	2411	BS	11/28/2022	61	M	N	11/27/2022	WARD	RENAL DISEASE	SERUM	11/28/2022	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	9.1	8.7	62.7	N	N	N	N	NR
1373	1401449	2413	BK	11/28/2022	32	F	N	11/28/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/28/2022	Y	N	Y	Y	N	N	N	N	N	N	N	N	N	N	N	7.8	31.06	87.8	N	Y	Y	N	NR
1374	280331	2414	NY	11/28/2022	60	M	N	11/23/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/28/2022	Y	N	Y	N	N	N	N	N	N	N	Y	N	N	N	N	14.2	10.3	92.8	N	N	N	Y	NR
1375	1420244	2415	HK	11/28/2022	21	F	N	11/24/2022	ICU	GASTROINTESTINAL TRACT DISEASE	SERUM	11/28/2022	Y	N	N	N	N	N	N	N	N	N	Y	N	N	N	N	9.5	8.2	68.8	N	N	N	N	NR
1376	1302283	2416	SK	11/29/2022	74	M	N	11/25/2022	WARD	ENDOCRINOLOGY	SERUM	11/29/2022	Y	N	N	N	Y	N	Y	N	N	N	Y	N	N	N	N	10	7	88.3	N	N	N	N	NR
1377	1413468	2417	SS	11/29/2022	22	M	N	11/12/2022	ICU	NEUROLOGICAL DISEASE	SERUM	11/29/2022	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	11.6	19.2	79.3	N	N	N	N	NR
1378	1421821	2418	R	11/29/2022	60	F	N	11/27/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/29/2022	N	Y	N	N	Y	Y	N	N	N	N	Y	N	N	N	N	11.2	13.4	84.7	N	Y	N	Y	NR
1379	1305003	2419	MK	11/29/2022	77	F	N	11/29/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/29/2022	Y	Y	N	Y	N	N	N	N	N	N	Y	N	N	N	N	11	8.28	66.8	N	N	Y	N	NR
1380	1410541	2420	KK	11/29/2022	40	F	N	11/26/2022	WARD	NEUROLOGICAL DISEASE	SERUM	11/29/2022	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	11.3	21.26	84.4	N	N	N	Y	NR
1381	1402479	2421	SK	11/29/2022	49	M	N	11/29/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/29/2022	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	11.2	7.5	80.4	N	N	N	Y	NR
1382	1302769	2422	GS	11/30/2022	71	M	N	11/26/2022	WARD	RENAL DISEASE	SERUM	11/30/2022	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	11.6	14.61	84.4	N	Y	N	N	NR
1383	1410416	2423	SK	11/30/2022	40	F	N	11/18/2022	ICU	NEUROLOGICAL DISEASE	SERUM	11/30/2022	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	10	22	89	N	N	N	N	NR
1384	1419035	2424	KK	11/30/2022	38	F	N	11/29/2022	WARD	RHEUMATOLOGY	SERUM	11/30/2022	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	5.3	21.93	92.3	N	Y	N	Y	NR
1386	1414522	2426	DB	11/30/2022	24	M	N	11/14/2022	WARD	GENERAL SURGERY	SERUM	11/30/2022	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	8.7	9.5	68.3	Y	N	N	N	NR
1387	562304	2427	BS	11/30/2022	55	M	N	11/29/2022	WARD	RENAL DISEASE	SERUM	11/30/2022	Y	Y	N	N	Y	N	N	N	N	N	N	N	N	N	N	6.1	11.2	77.3	N	N	N	Y	NR
1388	398787	2428	KL	11/30/2022	66	M	N	11/23/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/30/2022	N	Y	N	Y	Y	Y	N	N	N	N	N	N	N	N	N	8.4	13.14	90.9	Y	N	N	N	NR
1389	183558	2429	AK	11/30/2022	61	M	N	11/29/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/30/2022	Y	Y	N	Y	Y	N	N	N	N	N	N	N	N	N	N	12.3	9.1	91.7	N	N	N	N	NR
1390	1423738	2430	JS	11/30/2022	32	M	N	11/30/2022	WARD	NEUROLOGICAL DISEASE	SERUM	11/30/2022	N	N	N	N	N	N	N	N	N	N	N	N	N	Y	N	9.1	13	79	N	N	N	N	NR
1391	1423688	2431	GS	11/30/2022	80	M	N	11/30/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/30/2022	N	Y	Y	Y	N	Y	Y	N	N	N	Y	N	N	N	N	10	10	81	N	Y	N	Y	NR
1392	1313270	2432	RS	12/1/2022	78	M	N	12/1/2022	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	12/1/2022	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	10	12	89	Y	N	N	N	NR
1393	1421893	2433	P	12/1/2022	45	M	N	11/28/2022	WARD	RENAL DISEASE	SERUM	12/1/2022	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	8.2	43.3	88.5	N	N	Y	N	NR
1394	1418559	2434	GS	12/1/2022	34	M	N	11/22/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	12/1/2022	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	8.1	20.4	96	N	Y	N	N	NR
1395	1393692	2435	TR	12/1/2022	85	M	N	10/7/2022	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	12/1/2022	N	N	N	N	Y	Y	N	N	N	N	Y	N	Y	N	N	9.2	15.4	82.3	N	N	N	N	NR
1396	1423244	2436	MS	12/1/2022	60	M	N	11/29/2022	WARD	RENAL DISEASE	SERUM	12/1/2022	Y	Y	N	N	Y	Y	N	N	N	N	Y	Y	N	N	N	9	19.2	90.1	N	N	N	N	NR
1398	1419882	2438	SG	12/1/2022	74	F	P	11/24/2022	ICU	GASTROINTESTINAL TRACT DISEASE	SERUM	12/1/2022	N	N	N	N	Y	Y	N	N	N	N	Y	N	N	N	N	9.6	14.9	84.4	N	N	N	Y	NR
1399	239145	2439	JK	12/1/2022	77	F	N	11/24/2022	WARD	CARDIOVASCULAR DISEASE	SERUM	12/1/2022	N	N	Y	Y	Y	Y	N	N	N	N	N	N	N	N	N	11.3	15.6	93.2	N	N	N	Y	NR
1400	1423248	2440	BK	12/1/2022	77	F	N	11/29/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	12/1/2022	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	8.9	31.7	85.9	Y	N	N	N	NR
1401	1198903	2443	CL	12/2/2022	76	M	N	12/1/2022	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	12/2/2022	N	Y	Y	N	Y	Y	N	N	N	N	N	N	N	N	N	8.2	13.5	93.6	Y	N	N	N	NR
1402	1423885	2444	DS	12/2/2022	73	M	N	11/30/2022	WARD	CARDIOVASCULAR DISEASE	SERUM	12/2/2022	Y	Y	Y	Y	Y	Y	N	N	N	N	N	N	N	N	N	13	12	79	N	N	N	N	NR
1403	1420225	2445	ND	12/2/2022	42	F	N	11/24/2022	WARD	RENAL DISEASE	SERUM	12/2/2022	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	8	6.5	74.8	N	N	N	N	NR
1404	1414971	2446	RK	12/2/2022	27	M	N	11/15/2022	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	12/2/2022	Y	N	N	N	N	N	Y	N	N	N	N	N	N	N	N	10.6	21.6	85.3	Y	N	N	N	NR
1405	1423766	2447	HS	12/3/2022	79	M	N	11/30/2022	WARD	NEUROLOGICAL DISEASE	SERUM	12/3/2022	N	N	N	N	Y	Y	N	N	N	N	N	N	N	N	N	12.3	10.93	63.1	N	N	N	N	NR
1406	1472673	2448	MS	12/3/2022	62	M	N	11/29/2022	WARD	RENAL DISEASE	SERUM	12/3/2022	Y	Y	N	N	N	N	N	N	N	Y	N	N	N	N	N	8	16	92	N	Y	N	N	NR
1407	1425666	2449	RS	12/3/2022	66	M	N	12/3/2022	WARD	RENAL DISEASE	SERUM	12/3/2022	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	8.1	6.7	85.2	N	N	N	Y	NR
1408	876509	2450	BK	12/3/2022	73	F	N	11/14/2022	WARD	CARDIOVASCULAR DISEASE	SERUM	12/3/2022	N	Y	Y	Y	Y	Y	N	N	N	N	N	N	N	N	N	10	15	74	N	Y	N	N	NR
1409	1424029	2451	PD	12/4/2022	56	F	N	12/1/2022	WARD	RENAL DISEASE	SERUM	12/4/2022	Y	Y	N	N	Y	Y	N	N	N	N	Y	N	N	N	N	11	12	90	N	Y	N	Y	NR
1412	273016	2454	S	12/4/2022	79	F	N	12/4/2022	ICU	CARDIOVASCULAR DISEASE	SERUM	12/4/2022	Y	Y	N	Y	N	Y	N	N	N	N	Y	N	N	N	N	13	7	78	N	Y	N	N	NR
1413	38322	2455	TL	12/4/2022	72	M	N	12/3/2022	ICU	RESPIRATORY TRACT DISEASE	SERUM	12/4/2022	N	Y	Y	N	N	N	N	N	N	Y	Y	N	N	N	N	10.7	6.7	75.8	N	Y	Y	N	NR
1414	1406013	2456	AP	12/5/2022	41	F	N	11/30/2022	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	12/5/2022	N	Y	Y	N	N	N	N	N	N	N	Y	N	N	N	N	12	12	99	N	N	N	N	NR
1415	1421738	2458	SS	12/5/2022	31	F	N	12/4/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	12/5/2022	Y	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	9.9	13.6	60.6	N	Y	N	N	NR
1416	48098	2459	GK	12/5/2022	67	F	N	12/2/2022	WARD	RENAL DISEASE	SERUM	12/5/2022	Y	N	N	N	N	Y	N	N	N	N	N	N	N	N	N	9.7	14	91	N	N	N	N	NR
1418	1425290	2461	JS	12/6/2022	30	M	N	12/2/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	12/6/2022	Y	Y	N	N	N	N	N	N	N	N	Y	N	N	N	N	13.5	6.7	56	N	N	N	Y	NR
1419	1421121	2462	PS	12/6/2022	51	M	N	11/26/2022	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	12/6/2022	N	N	N	N	N	N	N	N	N	N	Y	N	N	N	N	7.3	16.2	82.2	N	Y	N	Y	NR
1420	1425888	2463	NB	12/6/2022	85	F	N	12/3/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	12/6/2022	Y	Y	N	N	Y	Y	N	N	N	Y	Y	N	N	N	N	12	10	80	N	Y	N	N	NR
1421	1425846	2464	P	12/6/2022	53	F	N	12/3/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	12/6/2022	Y	Y	Y	N	Y	Y	N	N	N	N	N	N	Y	N	N	10	17	92	N	Y	Y	N	NR
1422	1404088	2465	RS	12/6/2022	23	M	N	12/5/2022	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	12/6/2022	N	N	N	N	N	N	N	N	N	N	N	N	N	Y	N	10	12	79	N	N	N	N	NR
1423	1425042	2466	HK	12/6/2022	66	F	N	12/2/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	12/6/2022	Y	N	N	N	N	N	N	N	N	N	Y	N	N	N	N	11	13.1	73.1	N	N	N	N	NR

S. no	MRD No.	Lab No	Distribution of clinical samples received	Fungal smear Positive for Hyaline Septate Fungal Hyphae	CANDIDA IN (BODY FLUIDS AND BLOOD CULTURE)	CANDIDA IN BODY FUILDS	FUNGAL CULTURE FOR ASPERGILLUS SPECIES	Fungal Cuture	GMSAASSAY	1-3 BDG	PTZ	ANTIFUNGAL	Heamo Dylasis	AUGMENTIN	MEROPENEM	Provisional diagnosis	Outcome	TOTAL EORTC PATIENTS	PROVEN	POSSIBLE	PROBABLE	NO INVASIVE ASPERGILLOSI
1371	1414649	2411	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.18	121.31	N	N	N	N	Y	CKD	DISCHARGE	N	N	N	N	Y
1373	1401449	2413	PLEURAL FLUID	Neg	-	-	Neg	NG	0.19	47.3	N	N	N	N	Y	WEGNERS GRANULOMATOUS	DISCHARGE	N	N	N	N	Y
1374	280331	2414	NR	NR	-	-	NR	NR	0.5	-	N	N	N	N	N	COPD, KOCH'S	DISCHARGE ON REQUEST	Y	N	Y	Y	N
1375	1420244	2415	NR	NR	-	-	NR	NR	3.1	-	N	Y	N	N	Y	PANCREATITIS	DISCHARGE	Y	N	Y	N	N
1376	1302283	2416	NR	NR	-	-	NR	NR	0.53	523	N	N	N	N	N	CLD, PORTAL HTN	DISCHARGE	Y	N	Y	N	N
1377	1413468	2417	NR	NR	-	-	NR	NR	0.22	67.55	Y	N	N	N	Y	SDH	DISCHARGE	N	N	N	N	Y
1378	1421821	2418	SPUTUM	Neg	-	-	Neg	NG	0.21	105.48	N	N	N	N	Y	LRTI, SEPSIS, AKI	DISCHARGE	Y	N	Y	N	N
1379	1305003	2419	SPUTUM	Neg	-	-	Neg	NG	0.24	-	N	N	N	N	N	ABPA	DISCHARGE	Y	N	Y	N	N
1380	1410541	2420	SPUTUM	Neg	-	-	Neg	NG	0.12	74.85	N	Y	N	N	N	LRTI, SEPSIS	DISCHARGE	N	N	N	N	Y
1381	1402479	2421	SPUTUM	Neg	-	-	Neg	NG	0.15	-	N	Y	N	N	Y	PNEUMONIA	DISCHARGE	N	N	N	N	Y
1382	1302769	2422	NR	NR	-	-	NR	NR	0.11	158.04	Y	N	N	N	Y	LRTI, VIRAL PNEUMONIA	DISCHARGE	N	N	N	N	Y
1383	1410416	2423	NR	NR	-	-	NR	NR	0.11	-	N	N	N	N	Y	SDH	DISCHARGE	N	N	N	N	Y
1384	1419035	2424	SPUTUM	Neg	-	-	Neg	NG	0.11	183.88	N	Y	N	N	N	LRTI	DISCHARGE	N	N	N	N	Y
1386	1414522	2426	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.06	77.46	N	N	N	N	Y	NECROTISING, PANCREATITIS	DISCHARGE	N	N	N	N	Y
1387	562304	2427	NR	NR	-	-	NR	NR	0.07	110.2	N	N	N	N	Y	LRTI	DISCHARGE	N	N	N	N	Y
1388	398787	2428	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	CANDIDA	0.11	93.49	N	N	N	N	Y	ASTHMA, KOCH'S, CKD	DISCHARGE	N	N	N	N	Y
1389	183558	2429	SPUTUM	Neg	-	-	Neg	NG	0.23	36.6	N	N	N	N	N	COPD, LRTI	DISCHARGE	N	N	N	N	Y
1390	1423738	2430	NR	NR	-	-	NR	NR	0.29	523	N	N	N	N	N	HIV+VE, CRYPTOCOCAL MENINGITIS	DISCHARGE	N	N	N	N	Y
1391	1423688	2431	NR	NR	-	-	NR	NR	0.53	289.15	N	N	N	N	Y	CLD, ILD, UTI, FUNGAL SEPSIS	EXPIRED	Y	N	Y	Y	N
1392	1313270	2432	ASCITIC FLUID	Neg	-	-	Neg	NG	0.1	-	N	N	N	N	Y	CLD, PORTAL HTN	DISCHARGE	N	N	N	N	Y
1393	1421893	2433	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.26	103.17	N	Y	N	N	Y	CKD	DISCHARGE	N	N	N	N	Y
1394	1418559	2434	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	CANDIDA	1.47	523	Y	Y	N	N	N	LRTI	DISCHARGE	N	N	N	N	Y
1395	1393692	2435	NR	NR	-	-	NR	NR	0.16	523	N	N	N	N	Y	CLD WITH PORTAL HTN	EXPIRED	N	N	N	N	Y
1396	1423244	2436	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	3.41	523	N	Y	N	N	Y	KIDNEY INJURY	DISCHARGE	Y	N	Y	N	N
1398	1419882	2438	NR	NR	-	-	NR	NR	0.5	-	N	Y	N	N	Y	CROHS	DISCHARGE	Y	N	Y	Y	N
1399	239145	2439	NR	NR	-	-	NR	NR	0.29	310.12	N	Y	N	N	Y	ILD	EXPIRED	N	N	N	N	Y
1400	1423248	2440	NR	NR	-	-	NR	NR	1.04	43.12	Y	Y	N	N	N	LRTI	EXPIRED	N	N	N	N	Y
1401	1198903	2443	SPUTUM	Neg	-	-	Neg	NG	0.14	-	Y	N	N	N	Y	COPD	DAMA	N	N	N	N	Y
1402	1423885	2444	NR	NR	-	-	NR	NR	0.52	-	N	N	N	N	N	FIBRILE ILLNESS	DISCHARGE ON REQUEST	N	N	N	N	Y
1403	1420225	2445	SPUTUM	Neg	-	-	Neg	NG	0.5	22.33	N	N	N	N	Y	CHIKANGUNIYA	DISCHARGE	N	N	N	N	Y
1404	1414971	2446	PER CUTANEOUS DRAIN	Neg	-	-	Neg	NG	0.36	89.33	N	Y	N	N	Y	NECROTISING, PANCREATITIS	DISCHARGE	N	N	N	N	Y
1405	1423766	2447	SPUTUM	Neg	-	-	Neg	NG	0.22	523	N	Y	N	N	N	HYDROCIPHALOIS	DISCHARGE	N	N	N	N	Y
1406	1472673	2448	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.25	-	N	N	N	N	Y	CKD	DISCHARGE	N	N	N	N	Y
1407	1425666	2449	SPUTUM	Neg	-	-	Neg	NG	0.24	-	N	N	N	N	N	CKD, LRTI	DISCHARGE	N	N	N	N	Y
1408	876509	2450	SPUTUM	Neg	-	-	Neg	NG	0.35	523	N	Y	N	N	Y	POST COVID	DISCHARGE	N	N	N	N	Y
1409	1424029	2451	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	CANDIDA	0.49	58.81	N	Y	N	N	N	COPD	DAMA	Y	N	Y	N	N
1412	273016	2454	NR	NR	-	-	NR	NR	0.23	36.01	N	N	N	N	N	LRTI, CVA	DISCHARGE	N	N	N	N	Y
1413	38322	2455	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.65	46.66	N	N	N	N	Y	COPD, LRTI	DISCHARGE	Y	N	Y	Y	N
1414	1406013	2456	NR	NR	-	-	NR	NR	0.59	-	N	N	N	N	Y	CIRRHOSIS	DISCHARGE	Y	N	Y	N	N
1415	1421738	2458	SPUTUM	Neg	-	-	Neg	NG	0.23	-	N	N	N	N	N	HYPOTHYROIDISM	DAMA	N	N	N	N	Y
1416	48098	2459	SPUTUM	Neg	-	-	Neg	NG	0.32	109.94	N	N	Y	N	N	AKI, CLD	DAMA	N	N	N	N	Y
1418	1425290	2461	SPUTUM	Neg	-	-	Neg	NG	0.38	43.04	N	N	N	N	N	LRTI	DISCHARGE	Y	N	Y	N	N
1419	1421121	2462	ASCITIC FLUID	Neg	-	-	Neg	NG	1.05	-	N	Y	N	N	Y	PANCREATITIS	DISCHARGE	Y	N	Y	Y	N
1420	1425888	2463	SPUTUM	Neg	-	-	Neg	CANDIDA	0.16	-	Y	N	N	N	N	KOCHS	DAMA	Y	N	Y	N	N
1421	1425846	2464	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.4	38.57	N	N	N	N	Y	CARCINOMA	DISCHARGE	Y	N	Y	N	N
1422	1404088	2465	ASCITIC FLUID	Neg	-	-	Neg	NG	0.31	-	N	N	N	N	Y	LIVER DISEASE	DISCHARGE ON REQUEST	N	N	N	N	Y
1423	1425042	2466	NR	NR	-	-	NR	NR	0.26	-	N	N	N	N	N	HYDROCIPHALOIS	DISCHARGE ON REQUEST	N	N	N	N	Y

S. no	MRD No.	Lab No	NAME	DOR Sample	AGE	SEX	GMRepeat	DOA	AREA	SUB AREA WISE	Sample	DOR Sample	FEVER	COUGH	SOB	CHEST PAIN	DM	HTN	Alcoholic	Smoker	Neutropenia	TBHistory	Chronic steroid use	Solid organ transplantation	Malignancy	HIV	HCV	HB	TLC/DLC	NEUTROPHIL COUNT	CT CHEST _PLEURAL EFFUSION	CONSOLIDATION IN LUNG	CAVITATION	RETICULONODULAR OPACITIES	Histopathology for aspergillus species
1424	1335874	2467	MC	12/6/2022	81	M	N	12/4/2022	WARD	CARDIOVASCULAR DISEASE	SERUM	12/6/2022	N	Y	N	Y	N	Y	N	N	N	N	N	N	N	N	N	12	12	56	N	N	N	Y	NR
1425	1267418	2468	RK	12/6/2022	56	M	N	12/3/2022	WARD	RENAL DISEASE	SERUM	12/6/2022	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	8.4	1.2	88.7	N	N	N	N	NR
1426	1336719	2469	MD	12/9/2022	61	F	N	12/8/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	12/9/2022	Y	Y	N	Y	Y	Y	N	N	N	N	Y	N	N	N	N	7.3	10.58	75.4	N	N	N	N	NR
1427	1427281	2470	KS	12/7/2022	82	M	N	12/6/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	12/7/2022	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	13.1	13.5	87	N	Y	N	Y	NR
1428	1350965	2471	S	12/7/2022	50	M	N	12/5/2022	WARD	RENAL DISEASE	SERUM	12/7/2022	Y	N	Y	N	N	Y	N	N	N	N	N	N	N	N	N	4	11	86	N	Y	N	Y	NR
1429	1427414	2472	GG	12/7/2022	32	M	N	12/6/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	12/7/2022	Y	N	N	N	Y	Y	N	N	N	N	Y	N	N	N	N	13	15.9	75.3	Y	N	N	N	NR
1430	1471715	2473	SS	12/27/2022	40	M	N	11/26/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	12/27/2022	Y	Y	Y	N	N	N	N	N	N	N	Y	N	Y	N	N	8.9	19	83	N	N	Y	Y	NR
1432	1426846	2476	B	12/8/2022	58	F	N	12/5/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	12/8/2022	N	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	10.9	16.8	93	N	N	N	N	NR
1433	1303560	2477	MS	12/8/2022	41	M	P	11/25/2022	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	12/8/2022	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	9.6	9.24	70.2	Y	N	N	Y	NR
1435	1426927	2479	MS	12/8/2022	58	M	N	12/6/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	12/8/2022	Y	N	N	N	Y	N	Y	N	N	N	N	N	N	N	N	7.5	4.7	60.9	N	N	N	N	NR
1437	1427449	2481	KS	12/8/2022	53	M	N	12/6/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	12/8/2022	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	9.5	41.7	96.2	N	N	N	N	NR
1438	1428430	2482	JK	12/8/2022	74	F	N	12/8/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	12/8/2022	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	9.7	17.7	91	Y	N	N	N	NR
1439	1362790	2483	VK	12/8/2022	30	M	N	12/8/2022	WARD	ONCOLOGICAL	SERUM	12/8/2022	N	Y	N	N	N	N	N	N	N	N	N	N	Y	N	N	13.8	10.5	89.3	N	N	N	N	NR
1440	1395865	2484	R	12/9/2022	28	F	N	10/11/2022	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	12/9/2022	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	10.9	19.3	78.1	N	N	N	N	NR
1441	1427309	2485	MS	12/9/2022	33	M	N	12/6/2022	WARD	ONCOLOGICAL	SERUM	12/9/2022	N	N	N	N	N	N	N	N	Y	N	N	N	Y	N	N	7.4	0.54	3.7	N	N	N	Y	NR
1443	808778	2487	SP	12/9/2022	50	M	N	12/1/2022	WARD	RENAL DISEASE	SERUM	12/9/2022	N	N	N	N	Y	Y	N	N	N	N	N	N	N	N	N	10.7	38.5	94.4	N	N	N	Y	NR
1444	1425797	2488	P	12/9/2022	57	F	N	12/3/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	12/9/2022	N	Y	Y	N	Y	Y	N	N	N	N	N	N	N	N	N	9	7.8	94.4	Y	N	N	N	NR
1445	1424792	2489	ND	12/10/2022	54	F	N	12/4/2022	WARD	CARDIOVASCULAR DISEASE	SERUM	12/10/2022	N	N	Y	Y	Y	Y	N	N	N	N	N	N	N	N	N	9	7.8	74.2	N	N	N	N	NR
1446	346930	2490	KS	12/10/2022	29	M	N	12/9/2022	ICU	GASTROINTESTINAL TRACT DISEASE	SERUM	12/10/2022	N	Y	N	N	N	N	N	N	N	N	N	N	Y	N	N	10	9	54	N	N	N	N	NR
1447	1321739	2491	PK	12/10/2022	64	F	N	11/29/2022	WARD	RENAL DISEASE	SERUM	12/10/2022	N	Y	Y	N	Y	Y	N	N	N	N	N	N	N	N	N	9.9	8.1	62.2	N	N	N	Y	NR
1448	1429164	2492	BR	12/10/2022	76	M	N	12/2/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	12/10/2022	Y	Y	N	N	Y	N	N	N	N	N	Y	N	N	N	N	7	9.6	89.6	Y	N	N	N	NR
1449	1428483	2493	N	12/10/2022	66	M	N	12/8/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	12/10/2022	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	7.3	19.5	89.6	Y	N	N	N	NR
1450	1422471	2494	I	12/10/2022	22	M	N	11/28/2022	WARD	RENAL DISEASE	SERUM	12/10/2022	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	7.3	19.5	82.9	N	N	N	N	NR
1451	1177909	2495	AP	12/10/2022	61	F	N	12/8/2022	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	12/10/2022	N	N	N	N	Y	N	N	N	N	N	N	N	N	N	N	7.2	9.7	70.4	N	N	N	N	NR
1453	1429734	2497	MK	12/11/2022	44	M	N	12/10/2022	WARD	ACUTE FEBRILE ILLNESS	SERUM	12/11/2022	Y	N	Y	N	N	N	N	N	N	N	N	N	N	N	N	10	13.8	76.8	N	N	N	N	NR
1454	1429137	2498	DK	12/11/2022	45	M	N	12/9/2022	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	12/11/2022	N	N	N	N	Y	Y	N	N	N	N	Y	N	N	N	N	8.7	24.2	89.5	N	N	N	N	NR
1455	723926	2499	PK	12/11/2022	57	M	N	12/10/2022	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	12/11/2022	N	N	N	N	N	Y	N	N	N	N	Y	N	N	N	N	11	4.2	72.7	N	N	N	N	NR
1456	1429769	2500	RB	12/11/2022	58	F	N	12/11/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	12/11/2022	N	N	Y	N	Y	Y	N	N	N	N	N	N	N	N	N	9	57.1	94.3	Y	N	N	N	NR
1457	168349	2501	HS	12/11/2022	85	M	N	12/11/2022	WARD	CARDIOVASCULAR DISEASE	SERUM	12/11/2022	N	Y	Y	Y	Y	Y	N	N	N	N	N	N	N	N	N	10	12	90	Y	N	N	N	NR
1458	1424505	2502	IS	12/11/2022	19	M	P	12/1/2022	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	12/11/2022	N	N	N	N	N	N	N	N	N	N	Y	N	N	N	N	10.9	21.3	87.9	N	N	N	N	NR
1459	1337519	2503	KC	12/11/2022	73	M	N	12/9/2022	ICU	NEUROLOGICAL DISEASE	SERUM	12/11/2022	N	N	N	N	Y	Y	N	N	N	N	N	N	N	N	N	10.8	25.8	94	N	N	N	N	NR
1460	986755	2504	MS	12/11/2022	62	M	N	12/4/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	12/11/2022	N	N	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	13.2	9	83.9	N	N	N	N	NR
1461	1429069	2505	NK	12/12/2022	26	F	N	12/9/2022	ICU	GASTROINTESTINAL TRACT DISEASE	SERUM	12/12/2022	N	N	N	N	N	N	N	N	N	N	Y	N	N	N	N	7.4	4.1	80.9	N	N	N	N	NR
1462	1423295	2506	BL	12/12/2022	63	M	N	11/29/2022	ICU	NEUROLOGICAL DISEASE	SERUM	12/12/2022	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	11	8.5	83.6	N	N	N	N	NR
1463	1427468	2507	VK	12/12/2022	67	F	N	12/7/2022	ICU	GENERAL SURGERY	SERUM	12/12/2022	N	N	N	N	N	N	N	N	N	N	Y	N	N	N	N	7.7	7.48	72.5	N	N	N	N	NR
1465	1430520	2509	KK	12/12/2022	57	F	N	12/12/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	12/12/2022	Y	N	N	Y	N	N	N	N	N	N	N	N	N	N	N	9	6.6	86.6	Y	N	N	N	NR
1466	1429441	2510	MK	12/12/2022	24	F	N	12/10/2022	WARD	ACUTE FEBRILE ILLNESS	SERUM	12/12/2022	Y	N	Y	N	N	N	N	N	N	N	N	N	N	N	N	7.1	4.6	86.3	N	N	N	N	NR
1467	1428438	2512	GS	12/13/2022	37	M	N	12/8/2022	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	12/13/2022	Y	N	N	N	N	N	N	N	N	N	Y	N	N	N	N	8.1	18.8	85.5	N	N	N	N	NR
1468	1430293	2513	R	12/13/2022	60	F	N	12/12/2022	WARD	ACUTE FEBRILE ILLNESS	SERUM	12/13/2022	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	N	8.3	18	92.9	N	N	N	N	NR
1469	1428423	2514	SL	12/13/2022	75	F	N	12/8/2022	WARD	CARDIOVASCULAR DISEASE	SERUM	12/13/2022	N	N	Y	Y	Y	Y	N	N	N	N	N	N	N	N	N	10	10	92	Y	N	N	N	NR
1470	1249341	2515	RR	12/13/2022	69	F	N	12/6/2022	WARD	RENAL DISEASE	SERUM	12/13/2022	Y	N	Y	N	Y	Y	N	N	N	N	N	N	N	N	N	9.5	23.8	85.1	Y	N	N	N	NR
1471	1430590	2516	RD	12/13/2022	73	F	N	12/13/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	12/13/2022	Y	N	Y	N	Y	Y	N	N	N	N	N	N	N	N	N	8.3	17.3	79.9	Y	N	N	N	NR
1472	1426101	2517	ML	12/13/2022	58	M	N	12/4/2022	ICU	NEUROLOGICAL DISEASE	SERUM	12/13/2022	N	N	N	N	Y	Y	N	N	N	N	N	N	N	N	N	10.1	6.4	61.5	N	N	N	N	NR
1473	1415157	2518	MS	12/13/2022	30	M	N	11/30/2022	WARD	GENERAL SURGERY	SERUM	12/13/2022	Y	N	Y	N	N	N	N	N	N	N	N	N	N	N	N	8.9	20.9	79.8	N	N	N	N	NR
1474	1428190	2519	BD	12/13/2022	75	F	N	12/12/2022	WARD	CARDIOVASCULAR DISEASE	SERUM	12/13/2022	Y	N	Y	Y	N	Y	N	N	N	N	N	N	N	N	N	10	12	92	Y	N	N	N	NR
1476	1415713	2521	KS	12/14/2022	38	M	N	11/16/2022	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	12/14/2022	N	N	N	N	N	N	Y	N	N	N	N	N	N	N	N	9.9	17.8	86.7	N	N	N	N	NR
1477	1426089	2522	TS	12/14/2022	37	M	N	12/4/2022	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	12/14/2022	N	N	N	N	N	N	Y	N	N	N	N	N	N	N	N	6.2	13.53	67.1	N	N	N	N	NR
1478	1430517	2523	GK	12/14/2022	55	F	N	12/12/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	12/14/2022	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	12.7	10.3	75.5	N	N	N	Y	NR

S. no	MRD No.	Lab No	Distribution of clinical samples received	Fungal smear Positive for Hyaline Septate Fungal Hyphae	CANDIDA IN (BODY FLUIDS AND BLOOD CULTURE)	CANDIDA IN BODY FUILDS	FUNGAL CULTURE FOR ASPERGILLUS SPECIES	Fungal Cuture	GMSAASSAY	1-3 BDG	PTZ	ANTIFUNGAL	Heamo Dylasis	AUGMENTIN	MEROPENEM	Provisional diagnosis	Outcome	TOTAL EORTC PATIENTS	PROVEN	POSSIBLE	PROBABLE	NO INVASIVE ASPERGILLOSI
1424	1335874	2467	SPUTUM	Neg	-	-	Neg	NG	0.12	57.34	N	Y	N	N	Y	CAD, LRTI	DISCHARGE	N	N	N	N	Y
1425	1267418	2468	NR	NR	-	-	NR	NR	1.12	212.44	Y	Y	N	N	Y	GASTRITIS	DISCHARGE	N	N	N	N	Y
1426	1336719	2469	SPUTUM	Neg	-	-	Neg	CANDIDA	0.11	-	N	N	N	N	Y	LRTI	DAMA	N	N	N	N	Y
1427	1427281	2470	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.1	112.06	N	N	N	N	Y	LRTI	DISCHARGE	N	N	N	N	Y
1428	1350965	2471	NR	NR	-	-	NR	NR	0.1	83.89	Y	N	N	N	N	CKD, LRTI	DISCHARGE	N	N	N	N	Y
1429	1427414	2472	PLEURAL FLUID	Neg	-	-	Neg	NG	0.13	0.02	N	Y	N	N	Y	PLEURAL EFFUSION	DISCHARGE	Y	N	Y	N	N
1430	1471715	2473	SPUTUM	Neg	-	-	Neg	NG	0.11	170.46	N	Y	N	N	Y	LRTI, ASCITES	DISCHARGE	Y	N	Y	N	N
1432	1426846	2476	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.54	44.91	N	Y	N	N	Y	FUNGAL SEPSIS	DISCHARGE	N	N	N	N	Y
1433	1303560	2477	NR	NR	-	-	NR	NR	1.04	-	Y	N	N	N	Y	LIVER DISEASE	DISCHARGE	N	N	N	N	Y
1435	1426927	2479	NR	NR	-	-	NR	NR	0.1	101.97	N	N	N	N	Y	UTI	DISCHARGE	N	N	N	N	Y
1437	1427449	2481	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	CANDIDA	0.14	-	Y	N	N	N	Y	LRTI	DISCHARGE	N	N	N	N	Y
1438	1428430	2482	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.13	-	N	N	N	N	Y	LRTI	DISCHARGE	N	N	N	N	Y
1439	1362790	2483	SPUTUM	Neg	-	-	Neg	NG	0.18	101.56	N	Y	N	N	Y	B CELL LYMPHOMA	DISCHARGE	N	N	N	N	Y
1440	1395865	2484	NR	NR	-	-	NR	NR	0.18	523	N	N	N	N	Y	CHOLITHIASIS	DISCHARGE	N	N	N	N	Y
1441	1427309	2485	NR	NR	-	-	NR	NR	0.53	22	N	Y	N	N	N	AML	DISCHARGE	Y	N	Y	Y	N
1443	808778	2487	NR	NR	-	-	NR	NR	0.22	58.93	N	Y	Y	N	Y	CKD	DISCHARGE	N	N	N	N	Y
1444	1425797	2488	SPUTUM	Neg	-	-	Neg	NG	0.63	-	N	Y	N	N	Y	LRTI	DISCHARGE	N	N	N	N	Y
1445	1424792	2489	NR	NR	-	-	NR	NR	0.13	-	Y	N	N	N	Y	CAD	DISCHARGE	N	N	N	N	Y
1446	346930	2490	NR	NR	-	-	NR	NR	0.53	-	N	N	N	N	Y	HODGEKIN LYMPHOMA	DISCHARGE	Y	N	Y	N	N
1447	1321739	2491	SPUTUM	Neg	-	-	Neg	NG	0.14	270.64	N	N	Y	N	Y	CKD	EXPIRED	N	N	N	N	Y
1448	1429164	2492	SPUTUM	Neg	-	-	Neg	CANDIDA	1.19	-	Y	Y	N	N	Y	LRTI	DISCHARGE	Y	N	Y	Y	N
1449	1428483	2493	PLEURAL FLUID	Neg	-	-	Neg	NG	0.11	-	Y	N	N	N	Y	LRTI	DISCHARGE ON REQUEST	N	N	N	N	Y
1450	1422471	2494	NR	NR	-	-	NR	NR	0.12	1.1	N	N	N	N	Y	FIBRILE ILLNESS	DAMA	N	N	N	N	Y
1451	1177909	2495	SPUTUM	Neg	-	-	Neg	CANDIDA	0.15	-	N	Y	N	N	Y	PANCREATITIS	DISCHARGE ON REQUEST	N	N	N	N	Y
1453	1429734	2497	NR	NR	-	-	NR	NR	0.11	0.03	N	N	N	N	N	FIBRILE ILLNESS	DISCHARGE	N	N	N	N	Y
1454	1429137	2498	ASCITIC FLUID	Neg	-	-	Neg	NG	5.24	1.26	N	Y	N	N	Y	CLD	DISCHARGE	Y	N	Y	N	N
1455	723926	2499	NR	NR	-	-	NR	NR	4.15	-	N	Y	N	N	Y	PANCREATITIS	DISCHARGE	Y	N	Y	N	N
1456	1429769	2500	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.12	0.04	N	N	N	N	Y	LRTI	DISCHARGE	N	N	N	N	Y
1457	168349	2501	NR	NR	-	-	NR	NR	6	-	N	Y	N	N	Y	CAD	EXPIRED	N	N	N	N	Y
1458	1424505	2502	PER CUTANEOUS DRAIN	Neg	-	-	Neg	NG	1.14	-	N	N	N	N	Y	NECROTISING, PANCREATITIS	DISCHARGE	Y	N	Y	N	N
1459	1337519	2503	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.51	1.07	N	Y	N	N	Y	DM-II	DISCHARGE	N	N	N	N	Y
1460	986755	2504	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.54	-	N	N	N	N	Y	COPD, LRTI	DISCHARGE	N	N	N	N	Y
1461	1429069	2505	NR	NR	-	-	NR	NR	2.2	0.04	N	Y	N	N	Y	PANCREATITIS	DISCHARGE	Y	N	Y	N	N
1462	1423295	2506	NR	NR	-	-	NR	NR	0.18	1.18	N	N	N	N	Y	INTRA CRANIAL HEMIRAGE	DISCHARGE	N	N	N	N	Y
1463	1427468	2507	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.59	8.08	N	Y	N	N	Y	PANCREATITIS	DISCHARGE	Y	N	Y	N	N
1465	1430520	2509	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.21	9.67	N	Y	N	N	Y	LRTI	DISCHARGE	N	N	N	N	Y
1466	1429441	2510	NR	NR	-	-	NR	NR	0.12	0.02	N	N	N	N	Y	FIBRILE ILLNESS	DISCHARGE	N	N	N	N	Y
1467	1428438	2512	NR	NR	-	-	NR	NR	0.55	-	N	Y	N	N	Y	PANCREATITIS	DISCHARGE	Y	N	Y	N	N
1468	1430293	2513	NR	NR	-	-	NR	NR	0.15	-	N	N	N	N	Y	FIBRILE ILLNESS	DISCHARGE ON REQUEST	N	N	N	N	Y
1469	1428423	2514	NR	NR	-	-	NR	NR	0.14	0.02	Y	N	N	N	Y	CAD	DISCHARGE	N	N	N	N	Y
1470	1249341	2515	SPUTUM	Neg	-	-	Neg	CANDIDA	0.15	0.03	N	N	Y	N	Y	CKD	DISCHARGE	N	N	N	N	Y
1471	1430590	2516	NR	NR	-	-	NR	NR	0.68	-	N	N	N	N	Y	LRTI	DISCHARGE	N	N	N	N	Y
1472	1426101	2517	NR	NR	-	-	NR	NR	0.12	-	N	N	N	N	Y	INTRA CRANIAL HEMIRAGE	DISCHARGE	N	N	N	N	Y
1473	1415157	2518	NR	NR	-	-	NR	NR	0.23	-	N	N	N	N	Y	LRTI	DISCHARGE	N	N	N	N	Y
1474	1428190	2519	NR	NR	-	-	NR	NR	0.22	5.76	N	Y	N	N	Y	CAD, LRTI	DISCHARGE	N	N	N	N	Y
1476	1415713	2521	NR	NR	-	-	NR	NR	0.1	2.15	N	Y	N	N	Y	NECROTISING, PANCREATITIS	DISCHARGE	N	N	N	N	Y
1477	1426089	2522	NR	NR	-	-	NR	NR	0.21	-	N	N	N	N	Y	PANCREATITIS	DISCHARGE	N	N	N	N	Y
1478	1430517	2523	NR	NR	-	-	NR	NR	2.02	-	N	N	N	N	Y	LRTI	DISCHARGE	N	N	N	N	Y

S. no	MRD No.	Lab No	NAME	DOR Sample	AGE	SEX	GMRepeat	DOA	AREA	SUB AREA WISE	Sample	DOR Sample	FEVER	COUGH	SOB	CHEST PAIN	DM	HTN	Alcoholic	Smoker	Neutropenia	TBHistory	Chronic steroid use	Solid organ transplantation	Malignancy	HIV	HCV	HB	TLC/DLC	NEUTROPHIL COUNT	CT CHEST _PLEURAL EFFUSION	CONSOLIDATION IN LUNG	CAVITATION	RETICULONODULAR OPACITIES	Histopathology for aspergillus species
1479	1429857	2524	PK	12/14/2022	36	M	N	12/11/2022	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	12/14/2022	N	N	N	N	N	N	Y	N	N	N	N	N	N	N	N	10.8	10.4	77.4	N	N	N	N	NR
1481	1343864	2526	GS	12/14/2022	60	M	N	12/14/2022	WARD	CARDIOVASCULAR DISEASE	SERUM	12/14/2022	N	N	Y	Y	Y	Y	N	N	N	N	N	N	N	N	N	10	12	92	Y	N	N	N	NR
1482	1429685	2527	KK	12/14/2022	44	F	N	12/14/2022	WARD	ACUTE FEBRILE ILLNESS	SERUM	12/14/2022	N	N	Y	Y	Y	N	N	N	N	N	N	N	N	N	N	12	10	92	Y	N	N	N	NR
1483	1428350	2528	SK	12/14/2022	65	F	N	12/14/2022	WARD	RENAL DISEASE	SERUM	12/14/2022	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	7.2	9.7	93.2	N	N	N	Y	NR
1484	1431858	2529	PK	12/14/2022	37	M	N	12/14/2022	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	12/14/2022	N	N	N	N	N	N	Y	Y	N	N	N	N	N	N	N	9.6	23.68	76.9	N	N	N	N	NR
1485	354747	2530	JK	12/14/2022	59	F	N	12/14/2022	WARD	ONCOLOGICAL	SERUM	12/14/2022	Y	N	Y	N	N	N	N	N	N	N	N	N	Y	N	N	7.1	15.5	82	Y	N	N	N	NR
1486	1416940	2531	JR	12/15/2022	55	M	N	12/11/2022	WARD	ACUTE FEBRILE ILLNESS	SERUM	12/15/2022	N	N	Y	Y	Y	Y	N	N	Y	N	N	N	N	N	N	10	12	23	Y	N	N	N	NR
1487	1427736	2532	PK	12/15/2022	61	F	N	12/7/2022	WARD	CARDIOVASCULAR DISEASE	SERUM	12/15/2022	N	N	Y	Y	Y	Y	N	N	N	N	N	N	N	N	N	12	12	92	Y	N	N	N	NR
1488	1431248	2533	BK	12/15/2022	69	F	N	12/13/2022	WARD	CARDIOVASCULAR DISEASE	SERUM	12/15/2022	N	N	Y	Y	Y	Y	N	N	N	N	N	N	N	N	N	10	10	92	Y	N	N	N	NR
1489	1429835	2534	BS	12/16/2022	46	M	N	12/11/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	12/16/2022	Y	N	Y	N	Y	N	N	N	N	N	N	N	N	N	N	10.8	9.71	56.7	N	N	N	Y	NR
1491	1429986	2536	SS	12/16/2022	59	M	N	12/12/2022	WARD	ACUTE FEBRILE ILLNESS	SERUM	12/16/2022	Y	N	Y	N	Y	Y	N	N	N	N	N	N	N	N	N	8.9	6.46	89.5	N	N	N	N	NR
1492	1359270	2537	A	12/16/2022	28	M	N	12/15/2022	WARD	NEUROLOGICAL DISEASE	SERUM	12/16/2022	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	13.4	6.3	48.9	N	N	N	N	NR
1493	734681	2538	RK	12/16/2022	55	M	N	12/16/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	12/16/2022	Y	N	Y	N	Y	Y	N	N	N	N	Y	N	N	N	N	10.5	9.4	61.3	N	N	N	N	NR
1494	971095	2539	DD	12/16/2022	67	F	N	12/16/2022	ICU	RESPIRATORY TRACT DISEASE	SERUM	12/16/2022	N	N	N	N	N	N	Y	N	N	N	N	N	N	N	N	10.3	12.7	86.5	N	N	N	N	NR
1495	1430523	2540	PK	12/16/2022	31	M	N	12/12/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	12/16/2022	Y	N	Y	N	N	N	N	N	N	N	N	N	N	N	N	9.5	20	85.8	Y	N	N	N	NR
1496	1429558	2541	SS	12/17/2022	59	M	N	12/10/2022	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	12/17/2022	N	N	N	N	N	N	Y	N	N	N	N	N	N	N	N	6.9	11.2	69.9	N	N	N	N	NR
1497	1304061	2542	HS	12/17/2022	71	M	N	12/12/2022	ICU	GASTROINTESTINAL TRACT DISEASE	SERUM	12/17/2022	N	N	N	N	N	N	N	N	N	N	Y	N	N	N	N	7.3	15.1	89.2	N	N	N	N	NR
1498	1429748	2543	M	12/17/2022	90	M	N	12/10/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	12/17/2022	Y	N	Y	N	Y	Y	N	N	N	N	N	N	N	N	N	8.5	11.6	86.1	N	N	N	N	NR
1501	1433676	2546	DS	12/17/2022	38	M	N	12/17/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	12/17/2022	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	10	9.5	87.2	Y	N	N	N	NR
1502	1272946	2547	KK	12/18/2022	29	F	N	12/15/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	12/18/2022	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	9.2	8.2	84.3	N	N	N	N	NR
1503	1056475	2548	JS	12/18/2022	53	M	N	12/14/2022	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	12/18/2022	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	9	8.3	61	N	N	N	N	NR
1504	1406185	2549	HS	12/18/2022	45	M	N	12/9/2022	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	12/18/2022	N	N	N	N	N	N	Y	N	N	N	Y	N	N	N	N	6.4	4.5	70.8	N	N	N	N	NR
1505	1425236	2551	LS	12/18/2022	48	M	N	12/2/2022	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	12/18/2022	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	N	9.5	8.9	84.3	Y	N	N	N	NR
1506	1417632	2552	AD	12/18/2022	60	F	N	12/16/2022	ICU	GASTROINTESTINAL TRACT DISEASE	SERUM	12/18/2022	N	N	N	N	Y	Y	N	N	N	N	N	N	N	N	N	12.1	5.75	90.1	N	N	N	N	NR
1507	1433629	2553	DK	12/18/2022	61	F	N	12/17/2022	WARD	CARDIOVASCULAR DISEASE	SERUM	12/18/2022	N	N	Y	Y	Y	Y	N	N	N	N	N	N	N	N	N	10	10	72	Y	N	N	N	NR
1508	859279	2554	JS	12/18/2022	57	M	N	12/14/2022	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	12/18/2022	N	N	N	N	N	N	Y	Y	N	N	N	N	N	N	N	10.5	14.2	85.3	N	N	N	N	NR
1509	1433781	2555	SS	12/18/2022	52	M	N	12/17/2022	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	12/18/2022	N	N	N	N	Y	N	Y	Y	N	N	N	N	N	N	N	7.3	8.5	70.9	N	N	N	N	NR
1510	1431909	2556	KS	12/18/2022	50	M	N	12/15/2022	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	12/18/2022	Y	N	Y	N	Y	Y	N	N	N	N	Y	N	N	N	N	8.2	5.85	87.5	N	N	N	N	NR
1511	1433838	2557	PK	12/19/2022	41	M	N	12/18/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	12/19/2022	Y	Y	N	N	N	N	N	N	N	N	Y	N	N	N	N	12.6	4.11	60.3	Y	N	N	N	NR
1512	1433776	2558	MB	12/19/2022	85	F	N	12/17/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	12/19/2022	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	9.6	11.2	71.1	Y	N	N	N	NR
1513	1059438	2559	KK	12/19/2022	60	F	P	12/12/2022	WARD	CARDIOVASCULAR DISEASE	SERUM	12/19/2022	N	N	Y	Y	Y	Y	N	N	N	N	N	N	N	N	N	8.6	12.8	71.1	Y	N	N	N	NR
1514	1432577	2560	MB	12/19/2022	60	F	N	12/15/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	12/19/2022	Y	Y	N	N	Y	Y	N	N	N	N	Y	N	N	N	N	8.5	7.7	86.4	N	Y	N	Y	NR
1515	1385214	2561	M	12/19/2022	55	M	N	12/12/2022	WARD	RENAL DISEASE	SERUM	12/19/2022	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	8.6	9.5	69.2	Y	N	N	N	NR
1516	179964	2562	CL	12/19/2022	82	M	N	12/18/2022	ICU	CARDIOVASCULAR DISEASE	SERUM	12/19/2022	Y	N	N	Y	Y	Y	N	N	N	N	N	N	N	N	N	12	10	92	Y	N	N	N	NR
1517	685847	2563	S	12/20/2022	59	F	N	12/20/2022	WARD	CARDIOVASCULAR DISEASE	SERUM	12/20/2022	Y	N	N	Y	Y	Y	N	N	N	N	N	N	N	N	N	12	10	82	Y	N	N	N	NR
1518	638789	2564	SD	12/20/2022	56	F	N	12/19/2022	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	12/20/2022	N	N	N	N	Y	Y	N	N	N	N	Y	N	N	N	N	9.9	10.9	74.4	N	N	N	N	NR
1519	1434554	2565	HR	12/20/2022	47	M	N	12/19/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	12/20/2022	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	12.3	4.3	54.4	Y	N	N	Y	NR
1520	1305618	2566	BK	12/21/2022	79	F	N	12/20/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	12/21/2022	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	9	17.4	86.1	N	N	N	Y	NR
1521	1434499	2567	TS	12/21/2022	28	M	N	12/19/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	12/21/2022	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	12.3	14.3	76.3	N	N	N	N	NR
1522	1433690	2568	PK	12/21/2022	60	F	N	12/17/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	12/21/2022	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	11.8	5.27	62.8	Y	N	N	N	NR
1523	1433877	2569	BK	12/21/2022	59	F	N	12/18/2022	WARD	RENAL DISEASE	SERUM	12/21/2022	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	10.1	7.6	79.6	Y	N	N	N	NR
1525	1426138	2571	MS	12/21/2022	18	F	N	12/19/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	12/21/2022	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	9.2	5.52	60.8	N	N	N	N	NR
1526	1430906	2572	MS	12/21/2022	71	M	N	12/13/2022	WARD	RENAL DISEASE	SERUM	12/21/2022	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	9.8	10.38	91.8	Y	N	N	N	NR
1527	1347	2574	ML	12/21/2022	88	M	P	12/21/2022	ICU	CARDIOVASCULAR DISEASE	SERUM	12/21/2022	N	N	Y	Y	Y	Y	N	N	N	N	N	N	N	N	N	10	10	97	Y	N	N	N	NR
1528	1435635	2575	SS	12/22/2022	57	M	N	12/21/2022	WARD	NEUROLOGICAL DISEASE	SERUM	12/22/2022	N	N	N	N	Y	Y	N	N	N	N	N	N	N	N	N	11.3	9	68.3	N	N	N	N	NR

S. no	MRD No.	Lab No	Distribution of clinical samples received	Fungal smear Positive for Hyaline Septate Fungal Hyphae	CANDIDA IN (BODY FLUIDS AND BLOOD CULTURE)	CANDIDA IN BODY FUILDS	FUNGAL CULTURE FOR ASPERGILLUS SPECIES	Fungal Cuture	GMSAASSAY	1-3 BDG	PTZ	ANTIFUNGAL	Heamo Dylasis	AUGMENTIN	MEROPENEM	Provisional diagnosis	Outcome	TOTAL EORTC PATIENTS	PROVEN	POSSIBLE	PROBABLE	NO INVASIVE ASPERGILLOSI
1479	1429857	2524	NR	NR	-	-	NR	NR	0.11	0.02	N	N	N	N	Y	PANCREATITIS	DISCHARGE ON REQUEST	N	N	N	N	Y
1481	1343864	2526	NR	NR	-	-	NR	NR	0.11	-	Y	N	N	N	Y	CAD	EXPIRED	N	N	N	N	Y
1482	1429685	2527	NR	NR	-	-	NR	NR	0.12	0.2	N	N	N	N	Y	FIBRILE ILLNESS	DISCHARGE	N	N	N	N	Y
1483	1428350	2528	NR	NR	-	-	NR	NR	0.02	12.76	N	N	Y	N	Y	LRTI	DISCHARGE	N	N	N	N	Y
1484	1431858	2529	NR	NR	-	-	NR	NR	0.21	-	N	N	N	N	Y	NECROTISING, PANCREATITIS	DISCHARGE	N	N	N	N	Y
1485	354747	2530	NR	NR	-	-	NR	NR	0.15	0.02	N	N	N	N	Y	BREAST CANCER	DISCHARGE	Y	N	Y	N	N
1486	1416940	2531	NR	NR	-	-	NR	NR	0.2	0.2	N	N	N	N	Y	FIBRILE ILLNESS	DISCHARGE	Y	N	Y	N	N
1487	1427736	2532	SPUTUM	Neg	-	-	Neg	CANDIDA	0.85	0.02	N	Y	N	N	Y	CAD	DISCHARGE	N	N	N	N	Y
1488	1431248	2533	NR	NR	-	-	NR	NR	0.11	2.09	N	Y	N	N	Y	CAD	DISCHARGE ON REQUEST	N	N	N	N	Y
1489	1429835	2534	NR	NR	-	-	NR	NR	0.16	0.05	N	N	N	N	Y	LRTI	DISCHARGE	N	N	N	N	Y
1491	1429986	2536	SPUTUM	Neg	-	-	Neg	NG	0.15	-	N	N	N	N	Y	FIBRILE ILLNESS	DISCHARGE	N	N	N	N	Y
1492	1359270	2537	PER CUTANEOUS DRAIN	Neg	-	-	Neg	NG	0.96	8.06	N	Y	N	N	N	ILH	DISCHARGE	N	N	N	N	Y
1493	734681	2538	NR	NR	-	-	NR	NR	0.5	0.04	N	N	N	N	Y	ALLERGIC BRONCHITIS	DISCHARGE	Y	N	Y	N	N
1494	971095	2539	SPUTUM	Neg	-	-	Neg	NG	0.11	8.06	N	N	N	N	Y	PANCREATITIS	DISCHARGE	N	N	N	N	Y
1495	1430523	2540	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.11	-	N	N	N	N	Y	LRTI	DISCHARGE	N	N	N	N	Y
1496	1429558	2541	NR	NR	-	-	NR	NR	0.14	0.03	N	N	N	N	Y	CLD WITH PORTAL HTN	DISCHARGE	N	N	N	N	Y
1497	1304061	2542	NR	NR	-	-	NR	NR	0.72	0.03	N	N	N	N	Y	CLD WITH PORTAL HTN	DISCHARGE	Y	N	Y	N	N
1498	1429748	2543	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	CANDIDA	0.22	0.04	N	N	N	N	Y	COPD	EXPIRED	N	N	N	N	Y
1501	1433676	2546	NR	NR	-	-	NR	NR	1.85	0.12	N	Y	N	N	Y	LRTI	DISCHARGE ON REQUEST	N	N	N	N	Y
1502	1272946	2547	SPUTUM	Neg	-	-	Neg	CANDIDA	0.16	0.03	N	N	N	N	Y	LRTI	DISCHARGE	N	N	N	N	Y
1503	1056475	2548	NR	NR	-	-	NR	NR	1	-	Y	N	N	N	N	MICROWAVE ABLATION	DISCHARGE	N	N	N	N	Y
1504	1406185	2549	NR	NR	-	-	NR	NR	0.8	-	N	Y	N	N	Y	CLD WITH PORTAL HTN	DISCHARGE	Y	N	Y	N	N
1505	1425236	2551	NR	NR	-	-	NR	NR	0.14	-	N	Y	N	N	N	PANCREATITIS, ASCITES	DISCHARGE	N	N	N	N	Y
1506	1417632	2552	NR	NR	-	-	NR	NR	0.23	-	N	N	N	N	Y	CLD WITH PORTAL HTN	DISCHARGE	N	N	N	N	Y
1507	1433629	2553	SPUTUM	Neg	-	-	Neg	CANDIDA	0.16	0.05	N	N	N	N	Y	CAD	DISCHARGE	N	N	N	N	Y
1508	859279	2554	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.22	0.02	N	N	N	N	Y	CLD WITH PORTAL HTN	DISCHARGE	N	N	N	N	Y
1509	1433781	2555	NR	NR	-	-	NR	NR	0.18	-	N	N	N	N	Y	CLD WITH PORTAL HTN	DISCHARGE	N	N	N	N	Y
1510	1431909	2556	SPUTUM	Neg	-	-	Neg	CANDIDA	0.14	-	Y	N	N	N	N	PANCREATITIS	DISCHARGE	N	N	N	N	Y
1511	1433838	2557	NR	NR	-	-	NR	NR	3.82	0.04	N	Y	N	N	Y	COPD	DISCHARGE	Y	N	Y	Y	N
1512	1433776	2558	NR	NR	-	-	NR	NR	0.11	1.34	N	Y	N	N	Y	COPD, CAD	DISCHARGE	N	N	N	N	Y
1513	1059438	2559	NR	NR	-	-	NR	NR	1.18	0.02	Y	Y	N	N	Y	CAD	DISCHARGE ON REQUEST	N	N	N	N	Y
1514	1432577	2560	SPUTUM	P	-	-	P	ASPERGILLUS FLAVUS	0.69	0.03	N	N	N	N	Y	BRONCHITIS	EXPIRED	Y	N	Y	Y	N
1515	1385214	2561	URINE	Neg	-	-	Neg	NG	0.13	0.02	N	N	Y	N	Y	CKD	DISCHARGE	N	N	N	N	Y
1516	179964	2562	SPUTUM	Neg	-	-	Neg	CANDIDA	0.11	0.02	N	N	N	N	Y	CAD	DISCHARGE	N	N	N	N	Y
1517	685847	2563	NR	NR	Y	-	NR	NR	0.13	0.03	Y	N	N	N	Y	CAD	DISCHARGE	N	N	N	N	Y
1518	638789	2564	SPUTUM	Neg	-	-	Neg	NG	8.68	-	N	Y	N	N	Y	CLD WITH PORTAL HTN	DISCHARGE	Y	N	Y	N	N
1519	1434554	2565	SPUTUM	Neg	-	-	Neg	NG	0.22	2.72	N	Y	N	N	Y	COPD	DISCHARGE	N	N	N	N	Y
1520	1305618	2566	SPUTUM	P	-	-	P	ASPERGILLUS FUMIGATUS	0.19	-	N	Y	N	N	Y	LRTI	DISCHARGE	N	N	N	N	Y
1521	1434499	2567	SPUTUM	Neg	-	-	Neg	NG	0.2	0.04	N	N	N	N	Y	COPD	DISCHARGE	N	N	N	N	Y
1522	1433690	2568	SPUTUM	Neg	-	-	Neg	CANDIDA	0.14	-	N	N	N	N	Y	COPD	DISCHARGE	N	N	N	N	Y
1523	1433877	2569	SPUTUM	Neg	-	-	Neg	NG	0.13	0.04	N	N	N	N	Y	CKD	DISCHARGE	N	N	N	N	Y
1525	1426138	2571	NR	NR	-	-	NR	NR	0.23	0.02	N	N	N	N	Y	COPD	DISCHARGE	N	N	N	N	Y
1526	1430906	2572	NR	NR	-	-	NR	NR	0.17	2.16	N	Y	N	N	Y	COPD	DISCHARGE ON REQUEST	N	N	N	N	Y
1527	1347	2574	NR	NR	-	-	NR	NR	1.08	8.1	N	Y	N	N	Y	CAD	EXPIRED	N	N	N	N	Y
1528	1435635	2575	NASAL MUCOSA	Neg	-	-	Neg	NG	0.67	-	N	N	N	N	Y	CVA	DISCHARGE	N	N	N	N	Y

S. no	MRD No.	Lab No	NAME	DOR Sample	AGE	SEX	GMRepeat	DOA	AREA	SUB AREA WISE	Sample	DOR Sample	FEVER	COUGH	SOB	CHEST PAIN	DM	HTN	Alcoholic	Smoker	Neutropenia	TBHistory	Chronic steroid use	Solid organ transplantation	Malignancy	HIV	HCV	HB	TLC/DLC	NEUTROPHIL COUNT	CT CHEST _PLEURAL EFFUSION	CONSOLIDATION IN LUNG	CAVITATION	RETICULONODULAR OPACITIES	Histopathology for aspergillus species
1529	755015	2576	RK	12/22/2022	71	M	N	12/19/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	12/22/2022	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	7.6	11.8	87	Y	N	N	N	NR
1530	1141156	2577	BS	12/22/2022	72	M	N	12/15/2022	WARD	RENAL DISEASE	SERUM	12/22/2022	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	7.4	22.6	80.6	Y	N	N	N	NR
1531	1435039	2578	RK	12/22/2022	65	M	N	12/20/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	12/22/2022	Y	Y	N	N	Y	Y	N	N	N	N	Y	N	N	N	N	10	9.6	60.5	Y	N	N	N	NR
1532	1435693	2579	J	12/22/2022	70	M	N	12/22/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	12/22/2022	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	9.8	10.1	60.6	N	N	N	N	NR
1533	1432585	2580	N	12/22/2022	21	F	N	12/15/2022	WARD	CARDIOVASCULAR DISEASE	SERUM	12/22/2022	N	Y	N	Y	Y	Y	N	N	N	N	N	N	N	N	N	12	12	89	Y	N	N	N	NR
1534	1433913	2581	S	12/22/2022	40	F	N	12/19/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	12/22/2022	N	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	10.8	12.2	94.4	N	N	N	N	NR
1536	1089770	2583	C	12/23/2022	62	M	N	12/19/2022	ICU	RENAL DISEASE	SERUM	12/23/2022	Y	Y	N	N	Y	Y	N	N	N	N	N	Y	N	N	N	7.4	8.12	90.9	N	N	N	Y	NR
1537	1435832	2584	SS	12/23/2022	88	M	N	12/22/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	12/23/2022	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	10.6	19.3	97.6	Y	N	N	N	NR
1538	1433230	2585	S	12/23/2022	82	F	N	12/16/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	12/23/2022	Y	Y	N	N	Y	N	N	N	N	N	N	N	N	N	N	10.8	10.4	73.6	N	N	N	Y	NR
1541	1435103	2588	RA	12/24/2022	64	F	N	12/21/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	12/24/2022	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	8.4	17.1	81.4	N	N	N	Y	NR
1542	1436645	2589	JS	12/24/2022	39	M	N	12/23/2022	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	12/24/2022	N	N	N	N	Y	Y	Y	Y	N	N	N	N	N	N	N	8.3	33.6	88	N	N	N	N	NR
1543	1436656	2590	RK	12/24/2022	73	F	N	12/24/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	12/24/2022	Y	Y	N	N	Y	Y	N	N	N	Y	N	N	N	N	N	9.3	15.7	84.3	N	Y	N	Y	NR
1544	1246665	2591	ML	12/24/2022	71	M	N	12/16/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	12/24/2022	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	8.8	12.4	83.3	N	N	N	Y	NR
1545	261979	2592	S	12/24/2022	61	M	N	12/23/2022	WARD	ACUTE FEBRILE ILLNESS	SERUM	12/24/2022	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	11.7	8	86.8	N	N	N	N	NR
1546	918259	2593	SS	12/24/2022	78	M	N	12/11/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	12/24/2022	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	12	10	72	Y	N	N	N	NR
1547	997964	2594	DP	12/24/2022	68	M	N	12/12/2022	ICU	GASTROINTESTINAL TRACT DISEASE	SERUM	12/24/2022	N	N	N	N	Y	Y	N	N	N	N	N	N	N	N	N	7.7	11.5	82.2	N	N	N	N	NR
1548	1436611	2595	VK	12/24/2022	67	F	N	12/23/2022	ICU	CARDIOVASCULAR DISEASE	SERUM	12/24/2022	Y	Y	N	Y	Y	Y	N	N	N	N	N	N	N	N	N	12	12	82	Y	N	N	N	NR
1549	1433201	2596	RR	12/24/2022	63	M	N	12/16/2022	ICU	RESPIRATORY TRACT DISEASE	SERUM	12/24/2022	Y	N	Y	N	Y	Y	N	N	N	N	N	N	N	N	N	10.8	21.7	85.9	N	Y	N	Y	NR
1552	1436061	2599	KT	12/24/2022	73	F	N	12/22/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	12/24/2022	N	Y	Y	N	Y	Y	N	N	N	N	N	N	N	N	N	10.2	11.1	87.4	Y	N	N	N	NR
1553	1436980	2600	LD	12/24/2022	68	F	N	12/24/2022	ICU	RESPIRATORY TRACT DISEASE	SERUM	12/24/2022	Y	Y	N	Y	N	N	N	N	N	N	Y	N	N	N	N	9.5	10.9	79.8	N	N	N	N	NR
1555	1436057	2602	SA	12/25/2022	84	M	N	12/22/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	12/25/2022	N	N	Y	N	Y	Y	N	N	N	N	N	N	N	N	N	7.5	7.7	92.1	Y	N	N	N	NR
1556	1437071	2603	AK	12/25/2022	70	M	P	12/25/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	12/25/2022	Y	N	Y	Y	Y	Y	N	N	N	N	Y	N	N	N	N	9.9	15.9	82.5	N	Y	N	Y	NR
1557	1430504	2604	P	12/25/2022	52	F	N	12/12/2022	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	12/25/2022	N	N	N	N	N	N	N	N	N	N	Y	N	N	N	N	9.5	9.1	85.3	N	N	N	N	NR
1558	1436016	2605	RP	12/26/2022	58	M	N	12/22/2022	ICU	NEUROLOGICAL DISEASE	SERUM	12/26/2022	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	14.1	19.1	80.8	N	N	N	N	NR
1559	623619	2606	K	12/26/2022	67	F	N	12/25/2022	WARD	RENAL DISEASE	SERUM	12/26/2022	N	N	Y	N	Y	Y	N	N	N	N	N	Y	N	N	N	7.4	12.82	96.8	Y	N	N	N	NR
1560	1435101	2607	RP	12/26/2022	29	M	N	12/21/2022	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	12/26/2022	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	N	10.2	29.7	89.3	N	N	N	N	NR
1561	1436079	2608	AS	12/26/2022	75	M	N	12/22/2022	WARD	CARDIOVASCULAR DISEASE	SERUM	12/26/2022	N	N	Y	Y	Y	Y	N	N	N	N	N	N	N	N	N	10	12	72	Y	N	N	N	NR
1562	1437127	2609	SD	12/26/2022	45	M	N	12/25/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	12/26/2022	Y	N	Y	N	Y	Y	N	N	N	N	Y	N	N	N	N	10.4	24.8	91.1	N	N	N	Y	NR
1563	1396835	2610	PR	12/26/2022	65	F	N	12/24/2022	WARD	NEUROLOGICAL DISEASE	SERUM	12/26/2022	Y	Y	N	N	Y	N	N	N	N	N	N	N	N	N	N	10.6	10.2	77.7	N	N	N	Y	NR
1564	1432635	2611	SD	12/26/2022	79	F	N	12/16/2022	ICU	GASTROINTESTINAL TRACT DISEASE	SERUM	12/26/2022	N	N	N	N	Y	N	N	N	N	N	Y	N	N	N	N	8.2	16.7	90.6	N	N	N	N	NR
1565	772875	2612	PS	12/26/2022	50	M	N	12/25/2022	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	12/26/2022	N	N	N	N	Y	Y	N	N	N	N	Y	N	N	N	N	8.9	6.1	75.5	N	N	N	N	NR
1566	1437032	2613	JS	12/26/2022	60	M	N	12/24/2022	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	12/26/2022	N	N	N	N	Y	N	N	N	N	N	N	N	N	N	N	8.4	6.5	69.3	N	N	N	N	NR
1567	936869	2614	JJ	12/26/2022	84	F	N	12/20/2022	WARD	ONCOLOGICAL	SERUM	12/26/2022	Y	N	N	N	Y	N	N	N	Y	N	N	N	Y	N	N	9.1	2.7	36.6	N	N	N	N	NR
1568	1437135	2615	RW	12/27/2022	42	F	N	12/25/2022	WARD	GENERAL SURGERY	SERUM	12/27/2022	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	11.7	10.3	82.3	N	N	N	N	NR
1571	1432186	2618	AC	12/27/2022	34	F	P	12/25/2022	ICU	RESPIRATORY TRACT DISEASE	SERUM	12/27/2022	Y	N	Y	N	N	N	N	N	N	N	Y	N	N	N	N	12.9	24.5	88.1	N	N	N	N	NR
1572	1433397	2619	RS	12/27/2022	42	M	N	12/20/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	12/27/2022	N	Y	Y	Y	Y	N	N	N	N	N	Y	N	N	N	N	12.8	3.5	75.7	N	N	N	Y	NR
1576	824515	2623	MK	12/27/2022	34	M	N	12/27/2022	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	12/27/2022	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	9.1	9.7	73.2	N	N	N	N	NR
1577	1438278	2624	TS	12/27/2022	46	M	N	12/27/2022	WARD	RENAL DISEASE	SERUM	12/27/2022	Y	Y	N	N	Y	N	N	N	N	N	N	N	N	N	N	9.8	7.7	75.4	Y	N	N	N	NR
1578	639816	2625	KN	12/28/2022	67	M	N	12/26/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	12/28/2022	Y	Y	N	N	Y	N	N	N	N	N	Y	N	N	N	N	10.5	10.4	83.8	N	Y	N	N	NR
1579	761920	2626	HK	12/28/2022	70	F	N	12/22/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	12/28/2022	Y	Y	N	N	N	Y	N	N	N	N	N	N	N	N	N	11.4	7.3	72.4	N	N	N	N	NR
1580	1437819	2627	RS	12/28/2022	66	M	N	12/27/2022	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	12/28/2022	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	7.5	7.4	80.4	N	N	N	N	NR
1581	1381743	2628	RS	12/28/2022	66	M	N	12/27/2022	ICU	GASTROINTESTINAL TRACT DISEASE	SERUM	12/28/2022	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	9.8	11.6	70.4	N	N	N	N	NR
1582	596244	2629	RS	12/28/2022	65	M	N	12/27/2022	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	12/28/2022	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	8.1	10.8	86.8	N	N	N	N	NR
1583	610858	2630	NK	12/28/2022	56	M	N	12/27/2022	WARD	RENAL DISEASE	SERUM	12/28/2022	Y	Y	N	N	Y	Y	N	N	N	N	N	Y	N	N	N	12.6	9.09	68.9	N	N	N	N	NR
1584	1435816	2631	RS	12/28/2022	87	F	N	12/22/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	12/28/2022	N	N	N	N	Y	N	N	N	N	N	N	N	N	N	N	10.7	8.8	71.4	N	N	N	N	NR

S. no	MRD No.	Lab No	Distribution of clinical samples received	Fungal smear Positive for Hyaline Septate Fungal Hyphae	CANDIDA IN (BODY FLUIDS AND BLOOD CULTURE)	CANDIDA IN BODY FUILDS	FUNGAL CULTURE FOR ASPERGILLUS SPECIES	Fungal Cuture	GMSAASSAY	1-3 BDG	PTZ	ANTIFUNGAL	Heamo Dylasis	AUGMENTIN	MEROPENEM	Provisional diagnosis	Outcome	TOTAL EORTC PATIENTS	PROVEN	POSSIBLE	PROBABLE	NO INVASIVE ASPERGILLOSI
1529	755015	2576	NR	NR	-	-	NR	NR	0.2	0.03	N	N	N	N	Y	COPD	DISCHARGE ON REQUEST	N	N	N	N	Y
1530	1141156	2577	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	CANDIDA	0.15	0.03	Y	N	Y	N	Y	CKD	DISCHARGE	N	N	N	N	Y
1531	1435039	2578	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	CANDIDA	1.14	-	N	Y	N	N	Y	COPD	DISCHARGE	Y	N	Y	Y	N
1532	1435693	2579	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.12	-	N	N	N	N	Y	COPD	DISCHARGE	N	N	N	N	Y
1533	1432585	2580	NR	NR	-	-	NR	NR	0.2	-	Y	N	N	N	Y	CAD	DISCHARGE	N	N	N	N	Y
1534	1433913	2581	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.2	-	N	N	N	N	Y	COPD	DISCHARGE	N	N	N	N	Y
1536	1089770	2583	NR	NR	-	-	NR	NR	1.48	-	N	Y	Y	N	Y	CKD	DISCHARGE	Y	N	Y	Y	N
1537	1435832	2584	NR	NR	-	-	NR	NR	0.18	0.95	N	N	N	N	Y	BRONCHITIS	DISCHARGE	N	N	N	N	Y
1538	1433230	2585	NR	NR	-	-	NR	NR	1.29	1.38	N	Y	N	N	Y	LRTI	DISCHARGE	N	N	N	N	Y
1541	1435103	2588	NR	NR	-	-	NR	NR	0.59	0.02	N	Y	N	N	Y	LRTI	DISCHARGE	N	N	N	N	Y
1542	1436645	2589	NR	NR	-	-	NR	NR	0.12	0.02	N	N	N	N	Y	CLD WITH ASCITES	DISCHARGE	N	N	N	N	Y
1543	1436656	2590	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	CANDIDA	5.91	-	N	Y	N	N	N	KOCHS	DISCHARGE ON REQUEST	N	N	N	N	Y
1544	1246665	2591	NR	NR	-	-	NR	NR	0.23	1.32	N	Y	N	N	Y	COPD	DISCHARGE ON REQUEST	N	N	N	N	Y
1545	261979	2592	SPUTUM	Neg	-	-	Neg	NG	0.11	-	N	N	N	N	Y	FIBRILE ILLNESS	DISCHARGE ON REQUEST	N	N	N	N	Y
1546	918259	2593	NR	NR	-	-	NR	NR	0.2	0.2	N	N	N	N	Y	COPD	DISCHARGE ON REQUEST	N	N	N	N	Y
1547	997964	2594	NR	NR	-	-	NR	NR	0.12	-	N	N	N	N	Y	CLD WITH PORTAL HTN	EXPIRED	N	N	N	N	Y
1548	1436611	2595	NR	NR	-	-	NR	NR	13.33	0.04	Y	Y	N	N	Y	CAD	DISCHARGE	N	N	N	N	Y
1549	1433201	2596	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	18.54	0.9	N	Y	N	N	Y	COPD	DISCHARGE ON REQUEST	N	N	N	N	Y
1552	1436061	2599	SPUTUM	Neg	-	-	Neg	NG	0.14	-	Y	N	N	N	Y	COPD	DISCHARGE	N	N	N	N	Y
1553	1436980	2600	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.12	0.19	N	N	N	N	Y	COPD	DISCHARGE	N	N	N	N	Y
1555	1436057	2602	NR	NR	-	-	NR	NR	0.11	0.03	N	N	N	N	Y	COPD	DISCHARGE	N	N	N	N	Y
1556	1437071	2603	SPUTUM	P	-	-	P	ASPERGILLUS FLAVUS	8.5	0.02	N	Y	N	N	Y	COPD	DISCHARGE	Y	N	Y	Y	N
1557	1430504	2604	ASCITIC FLUID	Neg	-	-	Neg	NG	3.23	-	N	Y	N	N	Y	CLD WITH PORTAL HTN	DISCHARGE ON REQUEST	Y	N	Y	N	N
1558	1436016	2605	NR	NR	-	-	NR	NR	0.16	0.02	N	N	N	N	Y	IVH	DAMA	N	N	N	N	Y
1559	623619	2606	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	7.07	3.94	N	N	N	N	Y	CKD, LRTI	DISCHARGE	Y	N	Y	Y	N
1560	1435101	2607	NR	NR	-	-	NR	NR	0.12	0.05	N	Y	N	N	N	NECROTISING, PANCREATITIS	DISCHARGE	N	N	N	N	Y
1561	1436079	2608	NR	NR	-	-	NR	NR	1.06	0.34	N	Y	N	N	Y	CAD	DISCHARGE	N	N	N	N	Y
1562	1437127	2609	NR	NR	-	-	NR	NR	0.89	0.95	N	Y	N	N	Y	COPD	DISCHARGE	Y	N	Y	Y	N
1563	1396835	2610	SPUTUM	Neg	-	-	Neg	NG	0.83	0.04	Y	Y	N	N	N	CAD	DISCHARGE	N	N	N	N	Y
1564	1432635	2611	SPUTUM	Neg	-	-	Neg	CANDIDA	1.01	0.04	N	Y	N	N	Y	GI BLEED	DISCHARGE	Y	N	Y	N	N
1565	772875	2612	URINE	Neg	-	-	Neg	NG	0.55	-	N	N	N	N	Y	CLD WITH PORTAL HTN	DISCHARGE	Y	N	Y	N	N
1566	1437032	2613	NR	NR	-	-	NR	NR	0.1	-	N	N	N	N	Y	CLD WITH PORTAL HTN	DISCHARGE	N	N	N	N	Y
1567	936869	2614	SPUTUM	Neg	-	-	Neg	CANDIDA	0.13	0.3	N	N	N	N	Y	METASTIC BREAST CA INTESTINAL FIBROSIS	DISCHARGE	Y	N	Y	N	N
1568	1437135	2615	SPUTUM	P	-	-	P	ASPERGILLUS FUMIGATUS	0.82	-	N	N	N	N	N	PAIN ABDOMEN	DISCHARGE	N	N	N	N	Y
1571	1432186	2618	SPUTUM	Neg	-	-	Neg	CANDIDA	0.78	-	Y	N	N	N	N	ASTHMA, ABPA	DISCHARGE	Y	N	Y	Y	N
1572	1433397	2619	NR	NR	-	-	NR	NR	0.62	0.04	N	N	N	N	N	ILD	DISCHARGE	Y	N	Y	Y	N
1576	824515	2623	NR	NR	-	-	NR	NR	4.49	1.4	N	N	N	N	N	PAIN ABDOMEN	DISCHARGE	N	N	N	N	Y
1577	1438278	2624	SPUTUM	Neg	-	-	Neg	NG	0.13	0.03	N	N	N	N	Y	ARF	DISCHARGE	N	N	N	N	Y
1578	639816	2625	SPUTUM	Neg	-	-	Neg	NG	1.01	-	N	Y	N	N	Y	COPD	DISCHARGE	Y	N	Y	Y	N
1579	761920	2626	NR	NR	-	-	NR	NR	0.12	-	N	N	N	N	N	LRTI	DISCHARGE	N	N	N	N	Y
1580	1437819	2627	NR	NR	-	-	NR	NR	3.07	-	N	N	N	N	N	PAIN ABDOMEN	DISCHARGE	N	N	N	N	Y
1581	1381743	2628	URINE	Neg	Y	Y	Neg	CANDIDA	0.11	0.02	N	N	N	N	N	VOMITING	DISCHARGE	N	N	N	N	Y
1582	596244	2629	NR	NR	-	-	NR	NR	0.13	-	N	N	N	N	N	PAIN ABDOMEN	DISCHARGE	N	N	N	N	Y
1583	610858	2630	PER CUTANEOUS DRAIN	Neg	-	-	Neg	NG	2.96	8	N	N	N	N	Y	CKD	DISCHARGE	Y	N	Y	N	N
1584	1435816	2631	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.57	0.04	N	N	N	N	N	DM-II	EXPIRED	N	N	N	N	Y

S. no	MRD No.	Lab No	NAME	DOR Sample	AGE	SEX	GMRepeat	DOA	AREA	SUB AREA WISE	Sample	DOR Sample	FEVER	COUGH	SOB	CHEST PAIN	DM	HTN	Alcoholic	Smoker	Neutropenia	TBHistory	Chronic steroid use	Solid organ transplantation	Malignancy	HIV	HCV	HB	TLC/DLC	NEUTROPHIL COUNT	CT CHEST _PLEURAL EFFUSION	CONSOLIDATION IN LUNG	CAVITATION	RETICULONODULAR OPACITIES	Histopathology for aspergillus species
1585	1437102	2632	MS	12/28/2022	53	M	N	12/25/2022	WARD	NEUROLOGICAL DISEASE	SERUM	12/28/2022	N	N	N	N	N	Y	N	N	N	N	N	N	N	N	N	10	9	60.5	N	N	N	N	NR
1586	1437030	2633	MD	12/28/2022	62	F	N	12/24/2022	WARD	RENAL DISEASE	SERUM	12/28/2022	Y	N	N	N	Y	N	N	N	N	N	N	Y	N	N	N	7.8	31.7	83.1	N	N	N	N	NR
1588	1435009	2635	PS	12/29/2022	48	M	N	12/20/2022	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	12/29/2022	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	7.8	13.4	80.7	N	N	N	N	NR
1590	1436051	2637	K	12/29/2022	21	M	P	12/22/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	12/29/2022	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	12.3	5.7	57.2	N	N	N	N	NR
1591	1394501	2638	A	12/29/2022	63	M	N	12/26/2022	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	12/29/2022	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	7.1	27	88.4	N	N	N	N	NR
1592	453719	2639	BR	12/30/2022	77	M	N	12/22/2022	WARD	CARDIOVASCULAR DISEASE	SERUM	12/30/2022	Y	N	Y	Y	Y	Y	N	N	N	N	N	N	N	N	N	10.1	12.8	86	Y	N	N	N	NR
1593	560253	2640	RK	12/30/2022	67	F	N	12/27/2022	WARD	CARDIOVASCULAR DISEASE	SERUM	12/30/2022	N	N	Y	Y	Y	Y	N	N	N	N	N	N	Y	N	N	8.8	5.9	68	Y	N	N	N	NR
1594	1438725	2641	NB	12/30/2022	53	F	N	12/28/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	12/30/2022	Y	Y	N	N	Y	N	N	N	N	N	N	N	N	N	N	6.3	7.9	94.3	N	Y	N	Y	NR
1595	1277250	2642	KR	12/30/2022	70	F	N	12/23/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	12/30/2022	Y	Y	N	N	N	Y	N	N	N	N	N	N	N	N	N	8.9	10.9	84.8	N	N	N	N	NR
1596	254912	2643	N	12/30/2022	67	M	N	12/29/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	12/30/2022	Y	Y	N	N	Y	Y	N	N	N	N	Y	N	N	N	N	12.5	7.88	91.7	N	N	N	N	NR
1597	1438825	2644	SK	12/30/2022	45	M	N	12/28/2022	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	12/30/2022	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	8.6	10.74	82.3	Y	Y	N	N	NR
1598	1391558	2645	SP	12/30/2022	71	M	N	12/26/2022	WARD	RENAL DISEASE	SERUM	12/30/2022	Y	Y	N	N	N	N	N	N	N	N	Y	N	N	N	N	6.2	20.8	87.6	Y	N	N	N	NR
1600	1438857	2647	JS	12/30/2022	74	M	N	12/29/2022	WARD	CARDIOVASCULAR DISEASE	SERUM	12/30/2022	N	Y	Y	Y	N	N	N	N	N	N	Y	N	N	N	N	8	10	88	Y	N	N	N	NR
1602	1439320	2649	SL	12/30/2022	75	M	N	12/29/2022	WARD	RENAL DISEASE	SERUM	12/30/2022	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	10	17	89	N	N	N	N	NR
1603	1438791	2650	JK	12/30/2022	38	F	N	12/28/2022	WARD	RESPIRATORY TRACT DISEASE	SERUM	12/30/2022	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	11.9	5.1	81.5	N	N	N	N	NR
1604	329639	2651	AN	12/31/2022	68	F	N	12/4/2022	WARD	CARDIOVASCULAR DISEASE	SERUM	12/31/2022	N	N	Y	Y	Y	Y	N	N	N	N	N	N	N	N	N	9.5	15	82	Y	N	N	N	NR
1607	1491649	767	SJ	4/3/2023	47	F	N	3/30/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	4/3/2023	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	9	16	83	N	N	N	N	NR
1614	1492572	170	JS	4/4/2023	73	M	N	4/3/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	4/4/2023	Y	Y	N	Y	N	N	N	N	N	N	N	N	N	N	N	11.9	14.9	80.1	N	N	N	N	NR
1627	1493167	793	S	4/5/2023	19	F	N	4/4/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	4/5/2023	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	8.5	5.3	60	N	N	N	N	NR
1628	1424759	794	GK	4/6/2023	73	F	N	4/3/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	4/6/2023	Y	Y	Y	N	Y	Y	N	N	N	N	N	N	N	N	N	5.6	22.2	87.4	Y	N	N	N	NR
1629	1425871	795	AK	4/7/2023	55	M	N	4/3/2023	WARD	GENERAL SURGERY	SERUM	4/7/2023	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	8.4	4	61.8	Y	N	N	N	NR
1633	1494469	799	GS	4/8/2023	24	M	N	4/6/2023	ICU	NEUROLOGICAL DISEASE	SERUM	4/8/2023	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	12.4	2.16	86.1	Y	N	N	N	NR
1645	1491756	836	GS	4/14/2023	32	M	N	4/2/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	4/14/2023	N	N	N	N	Y	N	N	N	N	N	N	N	N	N	N	11.5	7.47	56.2	Y	N	N	N	NR
1656	997646	848	KS	4/16/2023	92	M	N	4/16/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	4/16/2023	N	Y	N	Y	N	N	N	N	N	N	N	N	N	N	N	12	8	85	N	N	N	N	NR
1697	996057	911	AK	4/30/2023	64	M	N	4/27/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	4/30/2023	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	12.6	14.1	81.1	N	N	N	N	NR
1700	1501944	914	DK	5/1/2023	63	F	N	4/19/2023	WARD	CARDIOVASCULAR DISEASE	SERUM	5/1/2023	N	N	N	Y	Y	Y	N	N	N	N	N	N	Y	N	N	10	17	83	N	Y	N	N	NR
1701	1508249	915	VS	5/1/2023	19	M	P	4/29/2023	WARD	NEUROLOGICAL DISEASE	SERUM	5/1/2023	N	N	Y	N	N	N	N	N	N	N	Y	N	N	N	N	9.3	25.33	86.8	N	Y	N	Y	NR
1702	1469454	916	BH	5/2/2023	57	F	N	4/4/2023	WARD	RENAL DISEASE	SERUM	5/2/2023	N	Y	Y	N	N	N	N	N	N	N	N	N	Y	N	N	9.4	19.5	92.5	N	N	N	N	NR
1703	1350528	917	AS	5/2/2023	64	M	N	4/26/2023	WARD	RENAL DISEASE	SERUM	5/2/2023	Y	Y	N	N	Y	N	N	N	N	N	N	N	N	N	N	10.4	31.7	89.3	N	N	N	N	NR
1704	1358036	918	M	5/3/2023	66	M	N	4/29/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	5/3/2023	N	Y	Y	N	Y	Y	N	N	N	Y	Y	N	N	N	N	11	12.1	77	N	N	N	N	NR
1705	1494542	919	SS	5/3/2023	48	M	N	4/6/2023	ICU	NEUROLOGICAL DISEASE	SERUM	5/3/2023	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	8.4	7.3	70.3	N	N	N	N	NR
1706	1509214	920	PD	5/3/2023	67	M	N	5/1/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	5/3/2023	N	N	N	N	Y	N	N	N	N	N	N	N	N	N	N	10	22	79	Y	N	N	N	NR
1707	1509760	921	JS	5/3/2023	50	M	N	5/2/2023	ICU	RENAL DISEASE	SERUM	5/3/2023	N	Y	Y	N	Y	Y	N	N	N	N	N	Y	N	N	N	7	1.7	95.3	N	N	N	Y	NR
1708	1084136	922	GS	5/3/2023	67	M	P	4/29/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	5/3/2023	N	Y	Y	N	Y	Y	N	N	N	N	N	N	N	N	N	10.7	10.7	90.9	N	N	N	Y	NR
1709	1502687	923	MS	5/3/2023	43	M	N	4/21/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	5/3/2023	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	N	8.3	12.8	79.7	Y	N	N	N	NR
1710	1507949	924	MR	5/3/2023	68	M	N	5/2/2023	WARD	NEUROLOGICAL DISEASE	SERUM	5/3/2023	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	12.8	8.7	69.6	N	N	N	N	NR
1711	1510035	925	GS	5/3/2023	93	M	N	5/3/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	5/3/2023	N	Y	Y	N	Y	Y	N	N	N	N	Y	N	N	N	N	11.7	12.8	63.8	N	Y	N	Y	NR
1712	1335584	926	S	5/4/2023	47	F	N	5/5/2023	WARD	RENAL DISEASE	SERUM	5/4/2023	Y	Y	N	N	N	N	N	N	N	Y	N	N	N	N	N	8.5	10.69	85.3	N	N	N	Y	NR
1713	1510553	927	JS	5/4/2023	73	M	N	5/4/2023	WARD	CARDIOVASCULAR DISEASE	SERUM	5/4/2023	N	N	N	Y	N	N	N	N	N	N	N	N	N	N	N	10	12	79	N	N	N	N	NR
1714	69178	928	RC	5/4/2023	68	M	N	5/3/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	5/4/2023	N	N	N	N	N	N	N	N	Y	N	Y	N	N	N	N	8.3	4.7	30.6	Y	N	N	N	NR
1715	248968	929	IS	5/4/2023	96	M	N	4/25/2023	WARD	CARDIOVASCULAR DISEASE	SERUM	5/4/2023	N	Y	N	Y	Y	Y	N	N	N	N	N	N	N	N	N	12	10	65	N	Y	N	N	NR
1716	1448350	930	KK	5/4/2023	58	F	N	5/2/2023	WARD	RENAL DISEASE	SERUM	5/4/2023	Y	Y	Y	N	Y	Y	N	N	N	N	N	N	N	N	N	9.4	7.9	72.6	N	N	N	N	NR
1717	1508351	931	LS	5/4/2023	18	M	N	4/29/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	5/4/2023	N	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	7.4	13	61.3	N	N	N	N	NR
1718	1144867	932	MK	5/4/2023	73	M	N	5/4/2023	WARD	CARDIOVASCULAR DISEASE	SERUM	5/4/2023	N	Y	N	Y	Y	Y	N	N	N	N	N	N	N	N	N	10	12	69	N	N	N	N	NR
1719	1508442	933	JS	5/4/2023	50	M	N	4/30/2023	WARD	RENAL DISEASE	SERUM	5/4/2023	Y	Y	N	N	N	Y	N	N	N	N	N	Y	N	N	N	8.1	12	79	N	N	N	Y	NR
1720	1509868	934	MS	5/4/2023	70	M	N	5/2/2023	WARD	CARDIOVASCULAR DISEASE	SERUM	5/4/2023	N	Y	N	Y	Y	N	N	N	N	Y	N	N	N	N	N	13	32	90	N	Y	N	N	NR
1721	1504951	935	SK	5/4/2023	55	M	N	4/24/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	5/4/2023	Y	N	N	N	Y	Y	N	N	N	N	N	N	N	N	N	9.7	12.7	83.7	N	N	N	Y	NR

S. no	MRD No.	Lab No	Distribution of clinical samples received	Fungal smear Positive for Hyaline Septate Fungal Hyphae	CANDIDA IN (BODY FLUIDS AND BLOOD CULTURE)	CANDIDA IN BODY FUILDS	FUNGAL CULTURE FOR ASPERGILLUS SPECIES	Fungal Cuture	GMSAASSAY	1-3 BDG	PTZ	ANTIFUNGAL	Heamo Dylasis	AUGMENTIN	MEROPENEM	Provisional diagnosis	Outcome	TOTAL EORTC PATIENTS	PROVEN	POSSIBLE	PROBABLE	NO INVASIVE ASPERGILLOSI
1585	1437102	2632	NR	NR	-	-	NR	NR	0.16	9.34	N	N	N	N	N	HYPERTENSION	DISCHARGE	N	N	N	N	Y
1586	1437030	2633	NR	NR	-	-	NR	NR	11.9	0.02	N	Y	N	N	Y	CKD	DISCHARGE ON REQUEST	Y	N	Y	N	N
1588	1435009	2635	NR	NR	-	-	NR	NR	0.11	0.03	N	N	N	N	N	PAIN ABDOMEN	DISCHARGE	N	N	N	N	Y
1590	1436051	2637	SPUTUM	Neg	-	-	Neg	NG	9.89	0.04	N	Y	N	N	N	AFI	DISCHARGE	N	N	N	N	Y
1591	1394501	2638	NR	NR	-	-	NR	NR	0.17	0.03	N	N	N	N	Y	CLD WITH PORTAL HTN	DISCHARGE	N	N	N	N	Y
1592	453719	2639	PERICARDIAL FLUID	Neg	-	-	Neg	NG	0.11	0.05	N	N	N	N	N	CAD	DISCHARGE	N	N	N	N	Y
1593	560253	2640	NR	NR	-	-	NR	NR	0.55	0.02	N	N	N	N	Y	HYPOTHYROIDISM, CA BREAST	DISCHARGE	Y	N	Y	Y	N
1594	1438725	2641	NR	NR	-	-	NR	NR	0.9	0.02	N	Y	N	N	N	LRTI	DAMA	N	N	N	N	Y
1595	1277250	2642	SPUTUM	Neg	-	-	Neg	NG	0.12	-	N	N	N	N	N	LRTI	DISCHARGE ON REQUEST	N	N	N	N	Y
1596	254912	2643	SPUTUM	Neg	-	-	Neg	NG	1.04	0.19	N	Y	N	N	N	LRTI, COPD	DISCHARGE	Y	N	Y	N	N
1597	1438825	2644	NR	NR	-	-	NR	NR	12.5	-	N	Y	N	N	Y	PLEURAL EFFUSION	DISCHARGE	N	N	N	N	Y
1598	1391558	2645	NR	NR	-	-	NR	NR	0.24	0.03	N	N	N	N	Y	AKI, UTI, LYMPHOMA	DISCHARGE	Y	N	Y	N	N
1600	1438857	2647	NR	NR	-	-	NR	NR	0.94	-	N	Y	N	N	Y	FUNGAL SEPSIS	DISCHARGE	Y	N	Y	Y	N
1602	1439320	2649	NR	NR	-	-	NR	NR	15.12	0.03	N	N	N	N	Y	DRY COUGH	DISCHARGE	N	N	N	N	Y
1603	1438791	2650	NR	NR	-	-	NR	NR	0.18	-	N	N	N	N	Y	LRTI	DISCHARGE	N	N	N	N	Y
1604	329639	2651	NR	NR	-	-	NR	NR	9.87	4.16	Y	Y	N	N	N	CAD, AKI	DISCHARGE	N	N	N	N	Y
1607	1491649	767	NR	NR	-	-	NR	NR	0.6	-	N	N	N	N	N	PAIN ABDOMEN	DISCHARGE	N	N	N	N	Y
1614	1492572	170	SPUTUM	Neg	-	-	Neg	NG	0.11	0.03	N	N	N	N	N	DRY COUGH	DISCHARGE ON REQUEST	N	N	N	N	Y
1627	1493167	793	ASCITIC FLUID	Neg	-	-	Neg	NG	0.11	0.03	N	N	N	N	Y	PERIPORTAL ECHOGATY	DISCHARGE	N	N	N	N	Y
1628	1424759	794	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	CANDIDA	0.13	-	N	Y	N	N	Y	LRTI, SEPSIS	DAMA	N	N	N	N	Y
1629	1425871	795	NR	NR	-	-	NR	NR	0.15	0.07	N	N	N	N	Y	PANCREATITIS	DISCHARGE	N	N	N	N	Y
1633	1494469	799	SPUTUM	Neg	-	-	Neg	NG	0.24	1.82	N	N	N	N	Y	SDH, FRACTURE	DISCHARGE	N	N	N	N	Y
1645	1491756	836	NR	NR	-	-	NR	NR	0.19	0.03	N	N	N	N	Y	PANCREATITIS	DISCHARGE	N	N	N	N	Y
1656	997646	848	NR	NR	-	-	NR	NR	0.3	-	N	N	N	N	N	DRY COUGH	DISCHARGE	N	N	N	N	Y
1697	996057	911	SPUTUM	Neg	-	-	Neg	NG	0.1	-	N	N	N	N	N	PAIN ABDOMEN	DISCHARGE	N	N	N	N	Y
1700	1501944	914	PLEURAL FLUID	Neg	-	-	Neg	NG	0.13	0.03	N	N	N	N	Y	CNS METASTATS	DISCHARGE	Y	N	Y	N	N
1701	1508249	915	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	12.54	8.01	N	N	N	N	Y	LRTI, FUNGAL SEPSIS	DAMA	Y	N	Y	Y	N
1702	1469454	916	SPUTUM	Neg	-	-	Neg	NG	0.11	0.03	N	N	N	N	Y	CARCINOMA	DISCHARGE	N	N	N	N	Y
1703	1350528	917	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	CANDIDA	0.11	1.38	N	Y	N	N	Y	CKD, FLUID OVERLOAD	DISCHARGE ON REQUEST	N	N	N	N	Y
1704	1358036	918	SPUTUM	P	-	-	P	ASPERGILLUS FUMIGATUS	0.67	-	N	Y	N	N	Y	LRTI, FUNGAL SEPSIS	DISCHARGE ON REQUEST	Y	N	Y	N	N
1705	1494542	919	CSF	Neg	-	-	Neg	NG	0.15	-	N	N	N	N	Y	HYDROCEPHALIS	DISCHARGE	N	N	N	N	Y
1706	1509214	920	ASCITIC FLUID	Neg	-	-	Neg	NG	0.11	0.02	N	N	N	N	Y	CIRRHOSIS, PORTAL HTN	DISCHARGE	N	N	N	N	Y
1707	1509760	921	SPUTUM	Neg	-	-	Neg	CANDIDA	12.15	8.01	N	Y	N	N	Y	CKD	DAMA	Y	N	Y	Y	N
1708	1084136	922	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.99	0.13	N	Y	N	N	Y	LRTI	DISCHARGE	N	N	N	N	Y
1709	1502687	923	NR	NR	-	-	NR	NR	0.13	0.02	N	N	N	N	Y	CLD, PORTAL HTN	DISCHARGE	N	N	N	N	Y
1710	1507949	924	NR	NR	-	-	NR	NR	0.14	0.04	N	Y	N	N	N	FOCAL SENSORY SEIZURE NOEPLASTIC	DISCHARGE	N	N	N	N	Y
1711	1510035	925	SPUTUM	Neg	-	-	Neg	NG	0.17	0.02	N	N	N	N	N	VIRAL PNEUMONIA	DISCHARGE	Y	N	Y	N	N
1712	1335584	926	SPUTUM	Neg	-	-	Neg	CANDIDA	0.12	0.03	N	N	N	N	N	CKD, SEPSIS, LRTI, KOCH'S	DISCHARGE	N	N	N	N	Y
1713	1510553	927	NR	NR	-	-	NR	NR	0.11	0.02	N	N	N	N	Y	CAD	DISCHARGE	N	N	N	N	Y
1714	69178	928	NR	NR	-	-	NR	NR	0.61	0.05	N	Y	N	N	Y	CIRRHOSIS, PORTAL HTN	DISCHARGE	Y	N	Y	Y	N
1715	248968	929	SPUTUM	Neg	-	-	Neg	NG	0.14	0.05	N	Y	N	N	N	LRTI	DISCHARGE	N	N	N	N	Y
1716	1448350	930	SPUTUM	Neg	-	-	Neg	NG	0.17	0.03	N	N	N	N	Y	CKD, LRTI	DISCHARGE	N	N	N	N	Y
1717	1508351	931	SPUTUM	Neg	-	-	Neg	NG	0.14	0.07	N	N	N	N	N	MALARIA	DISCHARGE	N	N	N	N	Y
1718	1144867	932	NR	NR	-	-	NR	NR	0.13	-	N	N	N	N	Y	CAD	DISCHARGE	N	N	N	N	Y
1719	1508442	933	NR	NR	-	-	NR	NR	17.16	6.63	N	N	N	N	Y	CKD	DAMA	Y	N	Y	Y	N
1720	1509868	934	SPUTUM	Neg	-	-	Neg	NG	0.24	-	N	N	N	N	Y	CAD, LRTI	DISCHARGE	N	N	N	N	Y
1721	1504951	935	PLEURAL FLUID	Neg	-	-	Neg	NG	0.2	0.03	N	N	N	N	Y	CIRRHOSIS, PORTAL HTN	DISCHARGE	N	N	N	N	Y

S. no	MRD No.	Lab No	NAME	DOR Sample	AGE	SEX	GMRepeat	DOA	AREA	SUB AREA WISE	Sample	DOR Sample	FEVER	COUGH	SOB	CHEST PAIN	DM	HTN	Alcoholic	Smoker	Neutropenia	TBHistory	Chronic steroid use	Solid organ transplantation	Malignancy	HIV	HCV	HB	TLC/DLC	NEUTROPHIL COUNT	CT CHEST _PLEURAL EFFUSION	CONSOLIDATION IN LUNG	CAVITATION	RETICULONODULAR OPACITIES	Histopathology for aspergillus species
1722	1510547	936	RR	5/4/2023	49	M	N	5/4/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	5/4/2023	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	N	8.1	27	86.7	N	N	N	N	NR
1723	1509185	937	KK	5/4/2023	31	M	N	5/1/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	5/4/2023	Y	N	N	N	N	N	Y	N	N	N	N	N	N	N	N	8.5	12.5	71.9	N	N	N	N	NR
1724	1505615	938	VK	5/5/2023	71	M	N	4/25/2023	WARD	ENDOCRINOLOGY	SERUM	5/5/2023	N	Y	N	Y	N	N	N	N	N	N	N	N	N	N	N	8.5	12.5	71.9	Y	N	N	N	NR
1725	1206889	939	MS	5/5/2023	58	F	N	5/1/2023	WARD	RENAL DISEASE	SERUM	5/5/2023	Y	N	Y	N	N	Y	N	N	N	Y	N	N	N	N	N	7.8	4.2	65.8	N	Y	N	N	NR
1726	1511892	940	SK	5/5/2023	49	F	N	5/5/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	5/5/2023	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	8.8	15.1	85.8	N	N	N	N	NR
1727	1511168	941	BS	5/6/2023	45	M	N	5/4/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	5/6/2023	Y	Y	N	N	N	N	N	N	N	N	Y	N	N	N	N	9.2	8.7	62.2	N	Y	N	N	NR
1728	1147859	942	CL	5/6/2023	69	M	N	5/3/2023	WARD	RENAL DISEASE	SERUM	5/6/2023	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	12	12	79	N	N	N	N	NR
1729	1510857	943	SL	5/6/2023	56	M	N	5/4/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	5/6/2023	N	N	N	N	Y	Y	N	N	N	N	N	N	N	N	N	6.7	6.8	49.3	Y	N	N	N	NR
1730	1370773	944	TR	5/6/2023	75	M	N	5/5/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	5/6/2023	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	9.2	8.5	61.2	N	N	N	Y	NR
1733	1509223	947	RK	5/6/2023	57	F	N	5/1/2023	WARD	ONCOLOGICAL	SERUM	5/6/2023	N	Y	Y	N	Y	N	N	N	N	N	Y	N	Y	N	N	6.9	5.6	81.1	N	Y	N	N	NR
1734	1511067	948	RK	5/7/2023	67	F	N	5/4/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	5/7/2023	Y	N	N	N	Y	Y	N	N	N	N	N	N	N	N	N	7.9	13.7	85.8	N	N	N	Y	NR
1735	1512496	949	HS	5/7/2023	54	M	N	5/6/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	5/7/2023	N	N	N	N	N	Y	Y	N	N	N	N	N	N	N	N	9.3	13.6	73.4	N	N	N	N	NR
1736	1512067	950	NS	5/7/2023	78	M	N	5/6/2023	WARD	RENAL DISEASE	SERUM	5/7/2023	Y	Y	N	N	N	Y	N	N	N	N	N	N	N	N	N	7.5	18	65.6	N	Y	N	N	NR
1737	880225	951	HK	5/7/2023	63	F	N	5/4/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	5/7/2023	Y	Y	N	N	N	Y	N	N	N	N	Y	N	N	N	N	11.6	10.3	66.8	N	N	N	Y	NR
1738	1511891	952	RR	5/7/2023	65	F	N	5/5/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	5/7/2023	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	4.63	6.1	77.8	N	N	N	Y	NR
1739	1485147	953	RG	5/7/2023	75	F	N	5/6/2023	WARD	ONCOLOGICAL	SERUM	5/7/2023	Y	Y	N	N	Y	Y	N	N	N	N	N	N	Y	N	N	2.6	12.1	91.9	N	N	N	N	NR
1740	1509267	954	GD	5/8/2023	41	F	N	5/2/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	5/8/2023	Y	Y	N	N	N	N	Y	N	N	N	N	N	N	N	N	10.1	28.3	88.7	N	N	N	N	NR
1741	1511952	955	AC	5/8/2023	36	F	N	5/5/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	5/8/2023	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	10.8	13.7	86.3	N	Y	N	N	NR
1742	1509207	956	JK	5/8/2023	75	F	N	5/1/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	5/8/2023	N	N	N	N	Y	Y	N	N	N	N	N	N	N	N	N	7.8	13.2	62.9	N	N	N	Y	NR
1743	1512564	957	AS	5/8/2023	31	M	N	5/7/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	5/8/2023	Y	N	N	N	N	N	Y	Y	N	N	N	N	N	N	N	7.1	42.2	71.8	Y	N	N	N	NR
1744	1017655	958	KK	5/8/2023	37	M	N	5/8/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	5/8/2023	N	N	N	N	N	N	Y	Y	N	N	N	N	N	N	N	10.4	10.4	74.1	N	N	N	N	NR
1745	1019597	959	UR	5/9/2023	60	F	N	5/6/2023	WARD	RENAL DISEASE	SERUM	5/9/2023	N	Y	Y	N	Y	Y	N	N	N	N	Y	Y	N	N	N	8.1	5	47.6	N	Y	N	N	NR
1746	1282371	960	BK	5/9/2023	71	F	N	5/8/2023	WARD	RENAL DISEASE	SERUM	5/9/2023	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	6.1	25.3	90.4	N	N	N	N	NR
1747	1459566	961	RS	5/9/2023	62	M	N	5/5/2023	WARD	CARDIOVASCULAR DISEASE	SERUM	5/9/2023	N	N	Y	Y	Y	Y	N	N	N	N	Y	N	N	N	N	11	11	69	N	Y	N	N	NR
1748	1510762	962	BS	5/9/2023	60	M	N	5/4/2023	WARD	NEUROLOGICAL DISEASE	SERUM	5/9/2023	Y	Y	N	N	Y	N	N	N	N	N	N	N	N	N	N	13.5	18.6	92.3	N	N	N	N	NR
1749	1345555	963	PK	5/9/2023	57	M	N	4/12/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	5/9/2023	Y	Y	N	N	N	N	N	N	Y	Y	N	N	N	N	N	6.1	5.9	16.1	N	N	N	Y	NR
1750	1437931	964	JS	5/10/2023	47	M	N	5/8/2023	WARD	ONCOLOGICAL	SERUM	5/10/2023	N	Y	Y	N	N	N	Y	Y	N	N	N	N	Y	N	N	8.3	2.88	93.4	N	N	N	Y	NR
1751	1511135	965	RR	5/10/2023	70	F	N	5/4/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	5/10/2023	N	N	N	N	Y	N	N	N	N	N	N	N	N	N	N	11.4	4	75.6	Y	N	N	N	NR
1752	1513599	966	BK	5/10/2023	32	F	N	5/9/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	5/10/2023	N	Y	Y	N	N	N	N	N	N	Y	N	N	N	N	N	12.3	5.1	79.6	N	N	N	N	NR
1753	1478273	967	MK	5/10/2023	53	M	N	5/6/2023	WARD	RENAL DISEASE	SERUM	5/10/2023	N	N	Y	Y	Y	Y	N	N	N	N	N	N	N	N	N	7.3	10	93	N	N	N	N	NR
1754	1337949	968	BS	5/10/2023	66	M	N	5/3/2023	WARD	CARDIOVASCULAR DISEASE	SERUM	5/10/2023	N	N	N	Y	Y	Y	N	N	N	N	N	N	N	N	N	10	10	69	N	N	N	N	NR
1755	1467630	969	UR	5/10/2023	56	F	N	5/8/2023	WARD	CARDIOVASCULAR DISEASE	SERUM	5/10/2023	N	N	N	Y	N	N	N	N	N	N	N	N	N	N	N	10	17	69	N	N	N	N	NR
1756	1506998	970	VK	5/10/2023	52	M	N	4/27/2023	WARD	GENERAL SURGERY	SERUM	5/10/2023	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	8.5	14.7	88.8	N	N	N	Y	NR
1758	1511922	972	SR	5/11/2023	63	M	N	5/5/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	5/11/2023	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	13.6	13.2	71.4	N	N	N	Y	NR
1759	1473494	973	TD	5/11/2023	58	F	N	5/10/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	5/11/2023	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	10	14.7	82.4	N	N	N	Y	NR
1760	1513563	974	NK	5/11/2023	41	F	N	5/9/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	5/11/2023	N	Y	Y	N	Y	Y	N	N	N	N	N	N	N	N	N	6.8	11.8	93.6	N	N	N	N	NR
1761	1396877	975	BS	5/11/2023	42	M	N	5/8/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	5/11/2023	N	N	N	N	Y	N	N	N	N	N	N	N	N	N	N	8.9	10.7	54.8	Y	Y	N	N	NR
1762	1504961	976	HS	5/11/2023	66	M	N	5/11/2023	WARD	RENAL DISEASE	SERUM	5/11/2023	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	7.1	7.54	81.7	N	Y	N	N	NR
1763	1515043	977	BK	5/11/2023	72	F	N	5/11/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	5/11/2023	Y	Y	Y	N	Y	Y	N	N	N	Y	N	N	N	N	N	10.2	28.2	91.5	N	N	N	Y	NR
1764	1493133	978	PK	5/11/2023	39	F	N	5/4/2023	WARD	ONCOLOGICAL	SERUM	5/11/2023	Y	Y	N	N	N	N	N	N	N	N	N	N	Y	N	N	7.9	0.7	21.9	N	Y	N	N	NR
1765	1510248	979	KK	5/12/2023	21	F	N	5/3/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	5/12/2023	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	N	9.9	7.6	45	N	N	N	N	NR
1766	572690	980	HR	5/12/2023	67	M	N	5/8/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	5/12/2023	N	Y	Y	N	Y	Y	N	N	N	Y	N	N	N	N	N	12.5	8.3	92.4	N	N	N	Y	NR
1768	1449691	982	PS	5/13/2023	29	M	N	5/4/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	5/13/2023	N	Y	N	N	N	N	Y	N	N	N	N	N	N	N	N	7	7.5	86	Y	N	N	N	NR
1769	1514234	983	B	5/13/2023	57	F	N	5/10/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	5/13/2023	Y	N	N	N	Y	Y	N	N	N	N	N	N	N	N	N	12.4	10.5	62.4	N	N	N	Y	NR
1770	1502052	984	MK	5/13/2023	57	M	N	4/19/2023	WARD	NEUROLOGICAL DISEASE	SERUM	5/13/2023	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	11.5	15.2	75.5	N	N	N	N	NR
1771	622618	985	GK	5/13/2023	68	F	N	5/11/2023	WARD	CARDIOVASCULAR DISEASE	SERUM	5/13/2023	N	N	Y	Y	Y	Y	N	N	N	N	N	N	N	N	N	12	17	79	N	N	N	N	NR
1772	264953	986	SS	5/13/2023	22	M	N	5/5/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	5/13/2023	Y	Y	Y	N	N	N	N	N	N	N	Y	N	N	N	N	14.1	21.6	89.2	N	N	N	N	NR
1773	1515136	987	HS	5/14/2023	41	M	N	5/11/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	5/14/2023	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	10.2	9.3	63.2	N	N	N	N	NR

S. no	MRD No.	Lab No	Distribution of clinical samples received	Fungal smear Positive for Hyaline Septate Fungal Hyphae	CANDIDA IN (BODY FLUIDS AND BLOOD CULTURE)	CANDIDA IN BODY FUILDS	FUNGAL CULTURE FOR ASPERGILLUS SPECIES	Fungal Cuture	GMSAASSAY	1-3 BDG	PTZ	ANTIFUNGAL	Heamo Dylasis	AUGMENTIN	MEROPENEM	Provisional diagnosis	Outcome	TOTAL EORTC PATIENTS	PROVEN	POSSIBLE	PROBABLE	NO INVASIVE ASPERGILLOSI
1722	1510547	936	NR	NR	-	-	NR	NR	0.1	0.03	N	N	N	N	Y	LIVER DISEASE	DISCHARGE	N	N	N	N	Y
1723	1509185	937	NR	NR	-	-	NR	NR	0.02	-	N	N	N	N	Y	PANCREATITIS	DISCHARGE	N	N	N	N	Y
1724	1505615	938	ASCITIC FLUID	Neg	-	-	Neg	NG	0.16	0.02	N	N	N	N	Y	CLD, PORTAL HTN	DISCHARGE	N	N	N	N	Y
1725	1206889	939	SPUTUM	Neg	-	-	Neg	NG	0.13	0.04	Y	N	N	N	N	CKD, KOCHS	DISCHARGE	N	N	N	N	Y
1726	1511892	940	NASAL MUCOSA	Neg	Y	Y	Neg	CANDIDA	0.11	0.11	N	N	N	N	Y	DM-II	DISCHARGE	N	N	N	N	Y
1727	1511168	941	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.15	0.11	N	N	N	N	Y	LRTI, AKI, PANCREATITIS	DISCHARGE	Y	N	Y	N	N
1728	1147859	942	NR	NR	-	-	NR	NR	0.12	0.04	N	N	N	N	Y	CLD, PORTAL HTN	DISCHARGE	N	N	N	N	Y
1729	1510857	943	NR	NR	-	-	NR	NR	0.13	0.03	N	N	N	N	Y	CLD, PORTAL HTN	DISCHARGE	N	N	N	N	Y
1730	1370773	944	SPUTUM	Neg	-	-	Neg	CANDIDA	0.11	-	N	Y	N	N	Y	LRTI	DISCHARGE	N	N	N	N	Y
1733	1509223	947	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.11	0.02	N	Y	N	N	Y	LRTI, AKI	DISCHARGE	Y	N	Y	N	N
1734	1511067	948	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.17	0.03	N	N	N	N	Y	CLD	DISCHARGE	N	N	N	N	Y
1735	1512496	949	SPUTUM	Neg	-	-	Neg	NG	0.11	0.05	N	N	N	N	Y	PANCREATITIS	DISCHARGE	N	N	N	N	Y
1736	1512067	950	TISSUE	Neg	Y	Y	Neg	CANDIDA	0.12	0.03	N	Y	N	N	N	LRTI, CAD, AKI, SEPSIS	DISCHARGE	N	N	N	N	Y
1737	880225	951	SPUTUM	Neg	-	-	Neg	CANDIDA	0.11	-	N	Y	N	N	Y	ABPA, LRTI	DISCHARGE	Y	N	Y	N	N
1738	1511891	952	SPUTUM	Neg	-	-	Neg	NG	0.15	-	N	N	N	N	N	OLD TB, COPD	DISCHARGE	N	N	N	N	Y
1739	1485147	953	URINE	Neg	-	-	Neg	NG	0.13	0.22	N	N	N	N	N	LRTI	DISCHARGE	N	N	N	N	Y
1740	1509267	954	NR	NR	-	-	NR	NR	0.15	0.02	N	N	N	N	Y	NECROTISING, PANCREATITIS	DISCHARGE	N	N	N	N	Y
1741	1511952	955	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	CANDIDA	0.12	0.03	N	Y	N	N	Y	LRTI	DISCHARGE ON REQUEST	N	N	N	N	Y
1742	1509207	956	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	CANDIDA	0.14	0.04	N	Y	N	N	Y	LRTI	EXPIRED	N	N	N	N	Y
1743	1512564	957	ASCITIC FLUID	Neg	-	-	Neg	NG	0.11	-	N	N	N	N	Y	CLD, PORTAL HTN	DAMA	N	N	N	N	Y
1744	1017655	958	NR	NR	-	-	NR	NR	0.1	0.02	N	N	N	N	Y	PANCREATITIS	DAMA	N	N	N	N	Y
1745	1019597	959	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	CANDIDA	0.14	0.19	N	N	N	N	Y	LRTI, CKD	DISCHARGE	Y	N	Y	N	N
1746	1282371	960	NR	NR	-	-	NR	NR	0.13	0.05	N	N	N	N	N	CKD	DISCHARGE	N	N	N	N	Y
1747	1459566	961	SPUTUM	Neg	-	-	Neg	NG	0.11	0.02	N	N	N	N	N	CKD	DISCHARGE	Y	N	Y	N	N
1748	1510762	962	CSF	Neg	-	-	Neg	NG	0.11	0.05	N	N	N	N	N	MENINGITIS	DISCHARGE	N	N	N	N	Y
1749	1345555	963	NASAL MUCOSA	Neg	-	-	Neg	NG	0.17	0.02	N	Y	N	N	N	MYOLODYSPLASTIC SYNDROME	DISCHARGE	Y	N	Y	N	N
1750	1437931	964	SPUTUM	Neg	-	-	Neg	NG	0.11	-	N	N	N	N	N	CA TONGUE	DISCHARGE	Y	N	Y	N	N
1751	1511135	965	ASCITIC FLUID	Neg	-	-	Neg	NG	0.13	0.04	N	N	N	N	Y	CLD, PORTAL HTN	DISCHARGE	N	N	N	N	Y
1752	1513599	966	SPUTUM	Neg	-	-	Neg	NG	0.1	-	N	N	N	N	Y	LRTI, KOCHS	DISCHARGE	N	N	N	N	Y
1753	1478273	967	SPUTUM	Neg	-	-	Neg	CANDIDA	0.11	0.04	N	N	N	N	Y	CLD, SEPSIS	DISCHARGE	N	N	N	N	Y
1754	1337949	968	PERICARDIAL FLUID	Neg	-	-	Neg	NG	0.14	0.13	N	N	N	N	N	POST CABG	DISCHARGE	N	N	N	N	Y
1755	1467630	969	NR	NR	-	-	NR	NR	0.12	-	N	N	N	N	N	MULTIPLE MYCLOMA	DISCHARGE	N	N	N	N	Y
1756	1506998	970	TISSUE	Neg	Y	Y	Neg	CANDIDA	0.12	0.03	N	Y	N	N	N	PLEURAL EFFUSION	DISCHARGE	N	N	N	N	Y
1758	1511922	972	SPUTUM	Neg	-	-	Neg	CANDIDA	0.17	-	N	N	N	N	N	CVA, LRTI	DISCHARGE	N	N	N	N	Y
1759	1473494	973	ASCITIC FLUID	Neg	-	-	Neg	NG	0.13	0.1	N	N	N	N	Y	CIRRHOSIS	DISCHARGE	N	N	N	N	Y
1760	1513563	974	SPUTUM	Neg	-	-	Neg	NG	0.15	-	N	N	N	N	Y	LRTI	DISCHARGE	N	N	N	N	Y
1761	1396877	975	ASCITIC FLUID	Neg	-	-	Neg	NG	0.15	0.12	N	N	N	N	Y	CIRRHOSIS, PORTAL HTN	DISCHARGE	N	N	N	N	Y
1762	1504961	976	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.14	11.27	N	Y	N	N	Y	CAD, CKD, LRTI	DISCHARGE	N	N	N	N	Y
1763	1515043	977	SPUTUM	Neg	-	-	Neg	CANDIDA	1.71	0.02	N	Y	N	N	Y	KOCHS	DISCHARGE	N	N	N	N	Y
1764	1493133	978	NR	NR	-	-	NR	NR	0.11	-	N	N	N	N	Y	CYCLOPLASTIC LEUKEMIA	DISCHARGE ON REQUEST	Y	N	Y	N	N
1765	1510248	979	NR	NR	-	-	NR	NR	0.14	0.03	N	N	N	N	Y	ILLCERATINE COLITS	DISCHARGE	N	N	N	N	Y
1766	572690	980	SPUTUM	Neg	-	-	Neg	NG	0.16	-	N	N	N	N	Y	LRTI	DAMA	N	N	N	N	Y
1768	1449691	982	NR	NR	-	-	NR	NR	0.11	0.13	N	N	N	N	Y	CLD, PORTAL HTN	DISCHARGE	N	N	N	N	Y
1769	1514234	983	SPUTUM	Neg	-	-	Neg	CANDIDA	0.14	-	N	Y	N	N	Y	CLD, PORTAL HTN	DISCHARGE	N	N	N	N	Y
1770	1502052	984	NR	NR	-	-	NR	NR	0.11	0.04	N	N	N	N	N	HIGH FEVER	DISCHARGE	N	N	N	N	Y
1771	622618	985	NR	NR	-	-	NR	NR	0.13	0.04	N	N	N	N	N	CHEST PAIN	DISCHARGE	N	N	N	N	Y
1772	264953	986	SPUTUM	Neg	-	-	Neg	NG	0.18	0.09	N	N	N	N	N	LRTI	DAMA	N	N	N	N	Y
1773	1515136	987	ENDOTRACHEAL SECRETIONS	P	-	-	P	ASPERGILLUS FUMIGATUS	0.12	0.02	N	N	N	N	N	LRTI, UTI	DISCHARGE	N	N	N	N	Y

S. no	MRD No.	Lab No	NAME	DOR Sample	AGE	SEX	GMRepeat	DOA	AREA	SUB AREA WISE	Sample	DOR Sample	FEVER	COUGH	SOB	CHEST PAIN	DM	HTN	Alcoholic	Smoker	Neutropenia	TBHistory	Chronic steroid use	Solid organ transplantation	Malignancy	HIV	HCV	HB	TLC/DLC	NEUTROPHIL COUNT	CT CHEST _PLEURAL EFFUSION	CONSOLIDATION IN LUNG	CAVITATION	RETICULONODULAR OPACITIES	Histopathology for aspergillus species
1774	1516336	988	AK	5/14/2023	72	M	N	5/12/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	5/14/2023	N	N	N	N	N	N	Y	N	N	N	N	N	N	N	N	8.8	9	77.1	N	Y	N	N	NR
1775	1502444	989	SS	5/14/2023	75	M	N	4/20/2023	WARD	GENERAL SURGERY	SERUM	5/14/2023	Y	Y	N	N	N	N	N	N	N	N	N	N	Y	N	N	7.2	32.18	76	N	N	N	N	NR
1776	1515324	990	SK	5/14/2023	53	F	N	5/11/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	5/14/2023	Y	Y	Y	N	N	N	N	N	Y	N	N	N	N	N	N	14.3	8.3	7.2	N	N	N	N	NR
1777	1515469	991	SS	5/14/2023	73	M	N	5/11/2023	WARD	CARDIOVASCULAR DISEASE	SERUM	5/14/2023	N	Y	N	Y	Y	Y	Y	N	N	N	N	N	N	N	N	14.3	14	70	N	N	N	N	NR
1778	1516153	992	DB	5/14/2023	33	M	N	5/12/2023	WARD	RENAL DISEASE	SERUM	5/14/2023	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	7.3	10.5	82.7	N	Y	N	N	NR
1779	1517105	993	BS	5/14/2023	65	M	N	5/14/2023	WARD	CARDIOVASCULAR DISEASE	SERUM	5/14/2023	N	Y	N	Y	Y	N	N	N	N	N	N	N	N	N	N	12	12	89	N	Y	N	N	NR
1780	883889	994	RM	5/15/2023	60	F	N	5/13/2023	WARD	RENAL DISEASE	SERUM	5/15/2023	Y	Y	N	N	Y	Y	N	N	N	N	Y	N	N	N	N	7.5	12.9	85.4	N	N	N	Y	NR
1781	1215404	995	VK	5/15/2023	70	M	N	5/9/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	5/15/2023	N	N	N	N	Y	N	Y	N	N	N	N	N	N	N	N	7.6	7.5	75.9	Y	N	N	N	NR
1783	1486603	997	UA	5/15/2023	80	F	N	5/4/2023	ICU	CARDIOVASCULAR DISEASE	SERUM	5/15/2023	N	N	Y	Y	Y	Y	N	N	N	N	N	N	N	N	N	7	10	47	N	N	N	N	NR
1784	1292498	998	JS	5/15/2023	56	M	N	5/15/2023	WARD	RENAL DISEASE	SERUM	5/15/2023	Y	Y	N	N	N	Y	N	N	N	N	Y	N	N	N	N	10.7	10.2	85	N	N	N	Y	NR
1785	1488302	999	RK	5/15/2023	21	F	N	5/15/2023	WARD	CARDIOVASCULAR DISEASE	SERUM	5/15/2023	N	N	Y	Y	N	N	N	N	N	N	Y	N	N	N	N	11	17	79	N	N	N	N	NR
1786	1517150	1000	BJ	5/16/2023	45	F	N	5/15/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	5/16/2023	N	N	N	N	Y	Y	Y	N	N	N	N	N	N	N	N	3.17	11.9	74.3	Y	N	N	N	NR
1787	1512634	1001	DR	5/16/2023	58	M	N	5/7/2023	WARD	GENERAL SURGERY	SERUM	5/16/2023	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	8.7	14.6	84.9	N	Y	N	N	NR
1788	1512975	1002	SP	5/16/2023	70	M	N	5/8/2023	WARD	RENAL DISEASE	SERUM	5/16/2023	Y	Y	N	N	N	Y	N	N	N	N	N	N	N	N	N	8.1	5.8	63.2	N	N	N	N	NR
1789	1517881	1004	HS	5/16/2023	43	M	N	5/15/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	5/16/2023	Y	Y	N	N	N	N	N	N	N	N	Y	N	Y	N	N	8.7	26	70.5	N	N	N	N	NR
1790	1517120	1005	SS	5/16/2023	72	M	N	5/14/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	5/16/2023	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	9.7	27.5	85.8	N	N	N	Y	NR
1791	1507781	1006	JS	5/16/2023	41	M	N	4/28/2023	WARD	NEUROLOGICAL DISEASE	SERUM	5/16/2023	Y	Y	N	N	N	N	N	N	N	N	Y	N	N	N	N	11.3	18.3	84.4	N	N	N	N	NR
1792	1518110	1007	PK	5/16/2023	70	M	N	5/16/2023	WARD	RENAL DISEASE	SERUM	5/16/2023	Y	N	N	Y	Y	Y	N	N	N	N	N	Y	N	N	N	8.2	19.8	94	N	Y	N	N	NR
1793	208490	1008	HK	5/16/2023	54	F	N	4/28/2023	WARD	NEUROLOGICAL DISEASE	SERUM	5/16/2023	Y	Y	N	N	Y	Y	N	N	N	N	N	Y	N	N	N	9.2	5.1	72	N	N	N	N	NR
1794	1518242	1009	GS	5/17/2023	40	M	N	5/16/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	5/17/2023	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	N	10.1	18.9	79.5	N	Y	N	N	NR
1795	1518010	1010	SK	5/17/2023	69	F	N	5/16/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	5/17/2023	Y	Y	N	N	N	Y	N	N	N	N	Y	N	N	N	N	8.6	10.4	87.8	N	N	N	N	NR
1797	1518608	1012	SB	5/17/2023	65	F	N	5/17/2023	WARD	RENAL DISEASE	SERUM	5/17/2023	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	10.4	6.9	77.2	N	N	N	Y	NR
1798	1350118	1013	MS	5/18/2023	64	M	N	5/13/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	5/18/2023	Y	Y	N	N	Y	Y	N	N	N	N	Y	Y	N	N	N	7.6	2.5	69.4	N	N	N	Y	NR
1799	1513517	1014	RS	5/18/2023	32	M	N	5/8/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	5/18/2023	Y	N	N	N	N	N	Y	N	N	N	N	N	N	N	N	9.5	15.5	81.8	N	Y	N	N	NR
1800	1519164	1015	IK	5/18/2023	91	M	N	5/17/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	5/18/2023	N	Y	Y	N	Y	Y	N	N	Y	N	Y	N	N	N	N	7.7	6.6	16.9	N	N	N	N	NR
1803	1516319	1018	NP	5/18/2023	76	M	N	5/12/2023	WARD	RENAL DISEASE	SERUM	5/18/2023	Y	Y	N	N	Y	Y	Y	N	N	N	N	N	N	N	N	12.1	14.9	85.9	N	N	N	N	NR
1804	1519231	1019	VK	5/18/2023	47	M	N	5/17/2023	WARD	RENAL DISEASE	SERUM	5/18/2023	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	10.5	14.7	85.5	N	Y	N	N	NR
1806	1519210	1021	SS	5/19/2023	75	M	P	5/17/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	5/19/2023	Y	Y	N	N	Y	Y	N	N	N	Y	N	N	N	N	N	11.5	6.7	91.6	N	N	N	Y	NR
1807	1135109	1022	JS	5/19/2023	72	M	N	5/18/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	5/19/2023	N	Y	Y	N	Y	N	N	N	N	N	N	N	N	N	N	5.8	3.8	60.5	N	Y	N	N	NR
1808	1514131	1023	JK	5/19/2023	20	M	N	5/18/2023	WARD	GENERAL SURGERY	SERUM	5/19/2023	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	N	8.7	11.7	85.3	N	N	N	N	NR
1809	1514722	1024	JS	5/19/2023	22	M	N	5/10/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	5/19/2023	N	N	N	N	N	N	Y	N	N	N	N	N	N	N	N	11.6	10.7	54	N	N	N	N	NR
1810	1519832	1025	AS	5/19/2023	70	M	N	5/18/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	5/19/2023	Y	Y	N	N	N	Y	N	N	N	N	Y	N	N	N	N	8.1	14.5	71.2	N	Y	N	N	NR
1811	1511102	1026	GK	5/19/2023	84	F	N	5/4/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	5/19/2023	N	Y	Y	N	Y	Y	N	N	N	N	Y	N	N	N	N	8.3	11.6	87.9	N	N	N	N	NR
1812	1517003	1027	AT	5/19/2023	63	F	N	5/13/2023	WARD	CARDIOVASCULAR DISEASE	SERUM	5/19/2023	N	N	Y	Y	Y	Y	N	N	N	N	N	N	N	N	N	9	12	93	N	N	N	N	NR
1813	1520513	1028	NS	5/19/2023	66	M	N	5/19/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	5/19/2023	Y	N	Y	N	N	Y	N	N	N	N	N	N	N	N	N	9.5	6.38	75.9	N	N	N	Y	NR
1814	1519744	1029	JS	5/19/2023	57	M	N	5/18/2023	WARD	CARDIOVASCULAR DISEASE	SERUM	5/19/2023	N	N	Y	Y	Y	Y	N	N	N	N	N	N	N	N	N	9.2	20	92	Y	N	N	N	NR
1815	1520539	1030	JS	5/19/2023	42	M	N	5/19/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	5/19/2023	N	N	N	N	N	N	Y	N	N	N	N	N	N	N	N	9	29.8	80.8	N	N	N	N	NR
1816	1518564	1031	AS	5/19/2023	21	M	N	5/19/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	5/19/2023	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	12.5	8	40.6	N	N	N	N	NR
1817	1519286	1032	AK	5/20/2023	60	M	P	5/18/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	5/20/2023	Y	Y	N	N	Y	N	N	N	N	Y	Y	N	N	N	N	11.8	9.5	76.8	N	N	N	Y	NR
1819	1520579	1034	PS	5/20/2023	59	M	N	5/20/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	5/20/2023	Y	Y	N	N	Y	N	N	N	N	Y	N	N	N	N	N	10.9	10.2	72	N	N	N	Y	NR
1820	1479267	1036	BS	5/20/2023	63	M	N	5/19/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	5/20/2023	N	N	N	N	Y	N	Y	N	N	N	N	N	N	N	N	9	10	73	N	N	N	N	NR
1821	1520216	1037	KS	5/20/2023	73	M	N	5/19/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	5/20/2023	Y	Y	Y	N	Y	Y	N	N	N	Y	N	N	N	N	N	10.2	14.7	84	N	N	N	Y	NR
1823	423793	1039	SB	5/20/2023	62	F	N	5/20/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	5/20/2023	Y	Y	N	N	Y	Y	N	N	N	N	Y	N	N	N	N	8.2	13.4	65.7	N	Y	N	N	NR
1824	1521164	1040	SC	5/20/2023	74	M	N	5/20/2023	WARD	RENAL DISEASE	SERUM	5/20/2023	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	7.6	24	83.5	N	Y	N	N	NR
1825	1511878	1041	KK	5/21/2023	65	M	N	5/5/2023	ICU	NEUROLOGICAL DISEASE	SERUM	5/21/2023	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	8.2	10.6	84.1	N	N	N	Y	NR
1826	1465989	1042	MR	5/21/2023	75	M	N	5/15/2023	WARD	RENAL DISEASE	SERUM	5/21/2023	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	6.9	13.2	80.5	N	Y	N	N	NR
1827	1515635	1043	BD	5/21/2023	75	F	N	5/11/2023	WARD	GENERAL SURGERY	SERUM	5/21/2023	N	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	12.6	8	87.4	N	N	N	N	NR
1828	1521182	1044	SN	5/21/2023	79	F	N	5/21/2023	WARD	CARDIOVASCULAR DISEASE	SERUM	5/21/2023	N	N	N	Y	Y	Y	N	N	N	N	N	N	N	N	N	8.4	7.9	65	N	Y	N	N	NR
1829	1519882	1045	SD	5/21/2023	33	F	N	5/18/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	5/21/2023	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	12.3	10.5	70	N	N	N	N	NR

S. no	MRD No.	Lab No	Distribution of clinical samples received	Fungal smear Positive for Hyaline Septate Fungal Hyphae	CANDIDA IN (BODY FLUIDS AND BLOOD CULTURE)	CANDIDA IN BODY FUILDS	FUNGAL CULTURE FOR ASPERGILLUS SPECIES	Fungal Cuture	GMSAASSAY	1-3 BDG	PTZ	ANTIFUNGAL	Heamo Dylasis	AUGMENTIN	MEROPENEM	Provisional diagnosis	Outcome	TOTAL EORTC PATIENTS	PROVEN	POSSIBLE	PROBABLE	NO INVASIVE ASPERGILLOSI
1774	1516336	988	PLEURAL FLUID	Neg	-	-	Neg	NG	0.1	0.02	N	N	N	N	Y	PANCREATITIS	DISCHARGE ON REQUEST	N	N	N	N	Y
1775	1502444	989	NR	NR	-	-	NR	NR	0.77	0.59	N	Y	N	N	Y	PANCREATIC HEAD MALIGNANCY	DISCHARGE	Y	N	Y	N	N
1776	1515324	990	SPUTUM	Neg	-	-	Neg	CANDIDA	0.12	-	N	N	N	N	N	ILD	DAMA	N	N	N	N	Y
1777	1515469	991	PERICARDIAL FLUID	Neg	-	-	Neg	NG	0.19	0.03	N	N	N	N	Y	CAD	DAMA	N	N	N	N	Y
1778	1516153	992	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.15	0.05	N	N	N	N	Y	AKI, CLD, SEPSIS	DISCHARGE	N	N	N	N	Y
1779	1517105	993	PLEURAL FLUID	Neg	-	-	Neg	NG	0.15	0.03	N	Y	N	N	Y	CAD, AKI, LRTI	DISCHARGE	N	N	N	N	Y
1780	883889	994	SPUTUM	Neg	-	-	Neg	CANDIDA	0.17	0.02	N	Y	N	N	Y	CKD, LRTI	DISCHARGE	Y	N	Y	N	N
1781	1215404	995	NR	NR	-	-	NR	NR	0.14	0.05	N	N	N	N	Y	CLD, PORTAL HTN	DISCHARGE	N	N	N	N	Y
1783	1486603	997	NR	NR	-	-	NR	NR	0.1	0.2	N	N	N	N	Y	CKD	DISCHARGE	N	N	N	N	Y
1784	1292498	998	SPUTUM	Neg	-	-	Neg	NG	0.1	8.64	N	Y	N	N	N	LRTI, CKD, FUNGAL SEPSIS	DAMA	Y	N	Y	Y	N
1785	1488302	999	PLEURAL FLUID	Neg	-	-	Neg	NG	0.1	0.05	N	N	N	N	Y	PULMONDLE	DISCHARGE	N	N	N	N	Y
1786	1517150	1000	URINE	Neg	-	-	Neg	NG	0.1	0.03	N	N	N	N	Y	CLD, PORTAL HTN	DISCHARGE	N	N	N	N	Y
1787	1512634	1001	NR	NR	-	-	NR	NR	0.1	0.02	N	N	N	N	Y	CHOLELITHIASIS	DISCHARGE	N	N	N	N	Y
1788	1512975	1002	SPUTUM	Neg	-	-	Neg	NG	0.1	0.02	N	Y	N	N	Y	SEPSIS, CKD, KOCH'S	DAMA	N	N	N	N	Y
1789	1517881	1004	SPUTUM	P	-	-	P	ASPERGILLUS FLAVUS	1.27	11.47	N	Y	N	N	Y	LRTI	DISCHARGE	Y	N	Y	N	N
1790	1517120	1005	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.1	0.02	N	Y	N	N	Y	SHOCK, ILD, MULTIORGAN DISFUNCTION	DISCHARGE	N	N	N	N	Y
1791	1507781	1006	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.03	0.1	N	N	N	N	Y	MENINGITIS	DISCHARGE	N	N	N	N	Y
1792	1518110	1007	URINE	Neg	-	-	Neg	NG	0.1	0.11	N	N	N	N	Y	CKD, POST RENAL TRANSPLNAT	DISCHARGE	Y	N	Y	N	N
1793	208490	1008	URINE	Neg	-	-	Neg	NG	0.03	0.1	N	N	N	N	Y	CKD, POST RENAL TRANSPLNAT	DISCHARGE	N	N	N	N	Y
1794	1518242	1009	SPUTUM	Neg	-	-	Neg	NG	0.13	0.02	N	N	N	N	Y	PLEURAL EFFUSION	DISCHARGE	N	N	N	N	Y
1795	1518010	1010	SPUTUM	Neg	-	-	Neg	CANDIDA	0.1	11.11	N	Y	N	N	Y	LRTI, RA	DISCHARGE	N	N	N	N	Y
1797	1518608	1012	NR	NR	-	-	NR	NR	0.1	0.02	N	N	Y	N	Y	CIRRHOSIS	DISCHARGE	N	N	N	N	Y
1798	1350118	1013	SPUTUM	P	-	-	P	ASPERGILLUS FLAVUS	0.1	-	N	Y	N	N	N	NARCODSOSES	DISCHARGE	Y	N	Y	Y	N
1799	1513517	1014	URINE	Neg	-	-	Neg	NG	0.1	0.02	N	N	N	N	Y	CLD	DISCHARGE	N	N	N	N	Y
1800	1519164	1015	NR	NR	-	-	NR	NR	0.1	0.04	N	N	N	N	Y	LRTI	DAMA	N	N	N	N	Y
1803	1516319	1018	SPUTUM	Neg	-	-	Neg	CANDIDA	0.1	0.02	N	Y	N	N	Y	TURP, UTI, AKI	DISCHARGE	N	N	N	N	Y
1804	1519231	1019	NR	NR	Y	-	NR	NR	0.1	10.44	N	Y	Y	N	Y	CKD	DAMA	N	N	N	N	Y
1806	1519210	1021	SPUTUM	Neg	-	-	Neg	NG	9.56	0.02	N	Y	N	N	N	LRTI	DISCHARGE	N	N	N	N	Y
1807	1135109	1022	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	CANDIDA	0.15	0.02	N	Y	N	N	Y	LRTI	DISCHARGE	N	N	N	N	Y
1808	1514131	1023	NR	NR	-	-	NR	NR	0.2	-	N	N	N	N	Y	VOMITING	DISCHARGE	N	N	N	N	Y
1809	1514722	1024	URINE	Neg	-	-	Neg	NG	0.1	0.02	N	N	N	N	Y	CLD	DISCHARGE	N	N	N	N	Y
1810	1519832	1025	SPUTUM	Neg	-	-	Neg	CANDIDA	0.1	0.02	N	Y	N	N	Y	LRTI, CKD, FUNGAL SEPSIS	DISCHARGE	Y	N	Y	N	N
1811	1511102	1026	SPUTUM	Neg	-	-	Neg	NG	0.1	0.02	N	N	N	N	N	ASTHMA, AKI, SEPSIS	DISCHARGE	N	N	N	N	Y
1812	1517003	1027	SPUTUM	Neg	-	-	Neg	NG	0.1	0.02	N	N	N	N	N	CAD, AKI, PANCREATITIS	DISCHARGE	N	N	N	N	Y
1813	1520513	1028	SPUTUM	Neg	-	-	Neg	NG	0.1	0.02	N	Y	N	N	N	LRTI, CAD	DISCHARGE	N	N	N	N	Y
1814	1519744	1029	SPUTUM	Neg	-	-	Neg	NG	0.22	0.02	N	N	N	N	Y	CLD, PORTAL HTN	DAMA	N	N	N	N	Y
1815	1520539	1030	ASCITIC FLUID	Neg	-	-	Neg	NG	0.1	0.02	N	N	N	N	Y	NECROTISING	DISCHARGE	N	N	N	N	Y
1816	1518564	1031	NR	NR	-	-	NR	NR	0.1	0.02	N	N	N	N	Y	AUTO IMMUNE LIVER DISEASE	DAMA	N	N	N	N	Y
1817	1519286	1032	NR	NR	-	-	NR	NR	8.93	0.14	N	Y	N	N	Y	COPD	DAMA	Y	N	Y	Y	N
1819	1520579	1034	SPUTUM	Neg	-	-	Neg	NG	0.1	0.02	N	Y	N	N	N	KOCHS	DISCHARGE	N	N	N	N	Y
1820	1479267	1036	ASCITIC FLUID	Neg	-	-	Neg	NG	0.1	0.73	N	N	N	N	Y	HYPATOCELULAR CARCINOMA	DISCHARGE	N	N	N	N	Y
1821	1520216	1037	SPUTUM	Neg	-	-	Neg	CANDIDA	0.1	0.02	N	Y	N	N	Y	CAD, LRTI	DISCHARGE	N	N	N	N	Y
1823	423793	1039	SPUTUM	P	-	-	P	ASPERGILLUS FLAVUS	0.1	-	N	Y	N	N	N	LRTI	DISCHARGE	Y	N	Y	Y	N
1824	1521164	1040	SPUTUM	Neg	-	-	Neg	CANDIDA	0.1	0.02	N	Y	N	N	Y	CKD	DISCHARGE	N	N	N	N	Y
1825	1511878	1041	SPUTUM	Neg	-	-	Neg	NG	0.1	0.02	N	N	N	N	Y	IVH	DISCHARGE	N	N	N	N	Y
1826	1465989	1042	URINE	Neg	-	-	Neg	NG	0.1	0.02	N	N	N	N	Y	LRTI	DISCHARGE	N	N	N	N	Y
1827	1515635	1043	NR	NR	-	-	NR	NR	0.23	0.02	N	N	N	N	Y	CHOLELITHIASIS	DISCHARGE ON REQUEST	N	N	N	N	Y
1828	1521182	1044	SPUTUM	Neg	-	-	Neg	NG	0.1	0.02	N	N	N	N	Y	AKI, CKD, LRTI	EXPIRED	N	N	N	N	Y
1829	1519882	1045	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	CANDIDA	0.1	0.05	N	Y	N	N	Y	LIVER DISEASE	DISCHARGE ON REQUEST	N	N	N	N	Y

S. no	MRD No.	Lab No	NAME	DOR Sample	AGE	SEX	GMRepeat	DOA	AREA	SUB AREA WISE	Sample	DOR Sample	FEVER	COUGH	SOB	CHEST PAIN	DM	HTN	Alcoholic	Smoker	Neutropenia	TBHistory	Chronic steroid use	Solid organ transplantation	Malignancy	HIV	HCV	HB	TLC/DLC	NEUTROPHIL COUNT	CT CHEST _PLEURAL EFFUSION	CONSOLIDATION IN LUNG	CAVITATION	RETICULONODULAR OPACITIES	Histopathology for aspergillus species
1830	1520099	1046	N	5/21/2023	24	F	N	5/19/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	5/21/2023	Y	Y	N	N	Y	N	N	N	N	N	N	N	N	N	N	8.8	7.5	59.7	N	N	N	Y	NR
1831	1520041	1047	RK	5/21/2023	41	F	N	5/20/2023	ICU	NEUROLOGICAL DISEASE	SERUM	5/21/2023	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	N	10	8.1	88.8	N	N	N	N	NR
1832	1428641	1048	S	5/21/2023	42	F	N	5/21/2023	WARD	RENAL DISEASE	SERUM	5/21/2023	Y	Y	N	N	N	Y	N	N	N	N	N	N	N	N	N	7.9	5.5	69.3	N	N	N	Y	NR
1833	1521149	1049	SK	5/21/2023	80	F	N	5/20/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	5/21/2023	N	Y	Y	N	Y	Y	N	N	N	N	Y	N	N	N	N	10.2	7	82.1	N	N	N	N	NR
1834	1521171	1050	BS	5/22/2023	19	M	N	5/20/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	5/22/2023	Y	N	Y	N	N	N	N	N	N	N	Y	N	N	N	N	7.6	22.7	77.1	N	Y	N	N	NR
1835	1521138	1051	NS	5/22/2023	45	M	N	5/20/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	5/22/2023	Y	Y	N	N	Y	Y	Y	N	N	N	N	N	N	N	N	12.2	52.7	87.7	Y	N	N	N	NR
1837	1521602	1053	BS	5/22/2023	73	M	N	5/22/2023	WARD	RENAL DISEASE	SERUM	5/22/2023	Y	Y	N	N	Y	Y	N	N	N	Y	N	N	N	N	N	9.6	39.3	93.6	N	Y	N	N	NR
1838	1521894	1054	AA	5/22/2023	86	M	N	5/22/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	5/22/2023	Y	Y	N	N	N	N	Y	Y	N	N	N	N	N	N	N	9.4	8.8	74.9	N	N	N	N	NR
1840	1521253	1056	SJ	5/23/2023	50	F	N	5/21/2023	WARD	RENAL DISEASE	SERUM	5/23/2023	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	7.6	10.1	76.5	N	Y	N	N	NR
1841	1520574	1057	JS	5/23/2023	52	M	N	5/20/2023	WARD	GENERAL SURGERY	SERUM	5/23/2023	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	9.1	13.7	89.6	N	N	N	N	NR
1842	1510847	1058	RK	5/23/2023	63	F	N	5/4/2023	WARD	CARDIOVASCULAR DISEASE	SERUM	5/23/2023	N	Y	N	Y	N	Y	N	N	N	N	N	N	N	N	N	10	10	61	N	Y	N	N	NR
1843	1520549	1059	MA	5/23/2023	67	M	N	5/19/2023	WARD	CARDIOVASCULAR DISEASE	SERUM	5/23/2023	N	N	Y	Y	Y	Y	N	N	N	N	N	N	N	N	N	10	13	72	N	N	N	N	NR
1845	1482337	1061	AC	5/23/2023	74	M	N	5/18/2023	WARD	ONCOLOGICAL	SERUM	5/23/2023	N	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	9.2	10.1	43.8	N	N	N	N	NR
1846	1519879	1062	JS	5/24/2023	45	M	N	5/20/2023	WARD	ENDOCRINOLOGY	SERUM	5/24/2023	N	N	N	N	Y	N	Y	N	N	N	N	N	N	N	N	6.7	21.2	91.4	Y	N	N	N	NR
1849	1522469	1065	SK	5/25/2023	56	F	N	5/23/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	5/25/2023	N	Y	Y	N	N	N	N	N	N	Y	N	N	N	N	N	9.8	11.2	77.6	N	N	N	N	NR
1850	1523105	1066	SK	5/25/2023	52	F	N	5/24/2023	WARD	RENAL DISEASE	SERUM	5/25/2023	Y	Y	N	N	Y	N	N	N	Y	N	N	N	N	N	11.1	8.1	58.7	N	N	N	Y	NR
1851	1520383	1067	VG	5/25/2023	73	M	N	5/19/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	5/25/2023	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	9.9	11.2	80	N	N	N	Y	NR
1852	1521910	1068	HK	5/25/2023	70	F	N	5/22/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	5/25/2023	Y	Y	Y	N	N	Y	N	N	N	Y	N	N	N	N	N	7.8	13.4	86	N	N	N	N	NR
1853	100498	1069	RS	5/25/2023	86	M	N	5/17/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	5/25/2023	N	N	Y	N	N	N	N	N	N	N	N	N	N	N	N	12	7	79	N	N	N	N	NR
1855	948423	1071	SR	5/26/2023	45	F	N	5/14/2023	WARD	RENAL DISEASE	SERUM	5/26/2023	N	Y	Y	N	Y	N	N	N	N	N	N	N	N	N	N	6.8	7.3	72.5	N	Y	N	N	NR
1856	1179648	1072	GK	5/26/2023	41	F	N	5/25/2023	WARD	RENAL DISEASE	SERUM	5/26/2023	Y	Y	Y	N	N	N	N	N	N	N	N	Y	N	N	N	10.7	6.44	75.5	N	N	N	Y	NR
1857	1513524	1073	RS	5/26/2023	54	M	N	5/8/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	5/26/2023	N	N	N	N	N	N	Y	N	N	N	N	N	N	N	N	10.7	13.5	86.3	N	Y	N	N	NR
1858	1210843	1074	BK	5/26/2023	56	M	N	5/13/2023	WARD	RENAL DISEASE	SERUM	5/26/2023	N	Y	N	Y	Y	N	N	N	N	N	N	N	N	N	N	10.1	10.9	96.8	N	N	N	Y	NR
1859	1523731	1075	AS	5/26/2023	37	M	N	5/26/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	5/26/2023	Y	Y	N	Y	N	N	N	N	N	N	N	N	N	N	N	13.2	12.7	57.4	N	N	N	N	NR
1860	1347756	1076	RS	5/27/2023	51	M	N	5/23/2023	WARD	RENAL DISEASE	SERUM	5/27/2023	N	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	7.1	5.9	59.5	N	N	N	N	NR
1861	808718	1077	SP	5/27/2023	54	M	N	5/25/2023	WARD	RENAL DISEASE	SERUM	5/27/2023	Y	N	Y	N	Y	Y	N	N	N	N	N	N	N	N	N	7.3	6.3	60	N	N	N	Y	NR
1862	1524515	1078	DJ	5/27/2023	70	M	N	5/27/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	5/27/2023	Y	N	Y	N	N	N	N	N	N	N	Y	N	N	N	N	12.2	8.8	87.6	N	N	N	N	NR
1863	1195327	1079	MM	5/27/2023	39	F	N	5/23/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	5/27/2023	N	N	N	N	Y	N	Y	N	N	N	N	N	N	N	N	8.2	5.2	66.3	N	N	N	N	NR
1864	1524505	1080	G	5/27/2023	56	F	N	5/27/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	5/27/2023	N	N	Y	N	Y	Y	N	N	N	N	Y	N	N	N	N	15.7	13.3	70.8	N	Y	N	N	NR
1865	1524038	1081	SS	5/27/2023	61	M	N	5/26/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	5/27/2023	Y	N	Y	N	Y	Y	N	N	N	N	N	N	N	N	N	12.2	9.2	68.3	N	N	N	N	NR
1866	1523677	1082	H	5/27/2023	21	M	N	5/25/2023	WARD	RENAL DISEASE	SERUM	5/27/2023	Y	N	Y	N	N	N	N	N	N	N	Y	N	N	N	N	7.1	8.69	65.6	N	N	N	N	NR
1867	658078	1083	BK	5/28/2023	56	F	N	5/25/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	5/28/2023	N	N	N	N	Y	N	N	N	N	N	N	N	N	N	N	13.5	32.6	96.4	N	N	N	Y	NR
1868	1525138	1084	MS	5/28/2023	38	M	N	5/28/2023	WARD	RENAL DISEASE	SERUM	5/28/2023	Y	N	Y	N	Y	Y	N	N	N	N	N	N	N	N	N	8	8.6	70.1	N	N	N	N	NR
1869	1522841	1085	MK	5/28/2023	45	F	N	5/24/2023	WARD	RENAL DISEASE	SERUM	5/28/2023	Y	N	N	N	N	N	N	N	N	N	Y	N	N	N	N	8.9	10.8	65.6	N	N	N	N	NR
1870	1525178	1087	JS	5/29/2023	61	M	N	5/28/2023	WARD	CARDIOVASCULAR DISEASE	SERUM	5/29/2023	N	N	N	Y	N	N	N	N	N	N	N	N	N	N	N	9.4	10	63	N	N	N	N	NR
1871	1517703	1088	IK	5/29/2023	85	M	N	5/15/2023	WARD	GENERAL SURGERY	SERUM	5/29/2023	Y	Y	N	N	Y	N	N	N	N	N	N	N	N	N	N	5.1	27.1	93.6	N	Y	N	N	NR
1872	1520550	1089	LR	5/29/2023	44	M	N	5/19/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	5/29/2023	N	N	N	N	Y	N	Y	N	N	N	N	N	N	N	N	11	20.7	70.4	Y	N	N	N	NR
1873	1525134	1090	RG	5/29/2023	59	M	P	5/28/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	5/29/2023	Y	Y	Y	N	Y	Y	N	N	N	N	Y	N	N	N	N	12.1	10.52	86.7	N	N	N	Y	NR
1874	51010	1091	MS	5/29/2023	60	M	N	5/28/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	5/29/2023	N	N	N	N	Y	N	N	N	N	N	N	N	N	N	N	9.1	12.6	80.8	Y	N	N	N	NR
1875	1525180	1092	JK	5/29/2023	65	F	N	5/28/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	5/29/2023	Y	N	Y	N	Y	N	N	N	N	Y	N	N	N	N	N	6.9	9.1	86.8	N	N	N	Y	NR
1879	1493198	1096	TR	5/30/2023	68	M	N	5/18/2023	ICU	NEUROLOGICAL DISEASE	SERUM	5/30/2023	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	12.2	11.7	72.9	N	N	N	N	NR
1881	1518227	1098	JK	5/30/2023	53	F	N	5/29/2023	WARD	RENAL DISEASE	SERUM	5/30/2023	N	Y	N	Y	N	Y	N	N	N	N	Y	N	N	N	N	8.5	7.6	69.4	N	N	N	N	NR
1882	1512567	1099	SS	5/30/2023	32	M	N	5/7/2023	WARD	GENERAL SURGERY	SERUM	5/30/2023	N	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	6.8	15.1	73	N	N	N	N	NR
1884	1526282	1101	RK	5/30/2023	48	M	N	4/23/2023	WARD	CARDIOVASCULAR DISEASE	SERUM	5/30/2023	N	N	N	Y	Y	Y	N	N	N	N	N	N	N	N	N	11	7	44.9	N	N	N	N	NR
1885	1523661	1102	SS	5/31/2023	64	F	N	5/25/2023	WARD	RENAL DISEASE	SERUM	5/31/2023	N	N	N	N	Y	Y	N	N	N	N	N	N	N	N	N	8.6	17.4	89.1	N	N	N	N	NR
1886	1518556	1103	SG	5/30/2023	77	M	N	5/16/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	5/30/2023	N	Y	Y	Y	Y	N	N	N	N	N	N	N	N	N	N	14.5	13	87.5	Y	N	N	N	NR
1888	1526717	1105	S	5/30/2023	51	M	N	5/30/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	5/30/2023	Y	Y	N	N	Y	Y	N	N	N	Y	N	N	N	N	N	9.7	3.3	67.9	N	N	N	N	NR
1889	1526083	1106	SS	5/31/2023	37	F	N	5/30/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	5/31/2023	N	N	N	N	Y	N	N	N	N	N	N	N	N	N	N	6	10.2	68.3	N	N	N	N	NR
1891	181386	1108	PS	6/1/2023	68	F	N	5/22/2023	WARD	ENDOCRINOLOGY	SERUM	6/1/2023	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	10.7	11.6	89.3	Y	N	N	N	NR
1892	1340332	1109	SK	6/1/2023	68	F	N	5/30/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	6/1/2023	Y	Y	N	N	N	N	N	N	N	Y	N	N	N	N	N	11.4	19.8	79.5	N	Y	N	N	NR
1893	1523686	1110	SK	6/1/2023	39	M	N	5/25/2023	WARD	GENERAL SURGERY	SERUM	6/1/2023	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	8.6	14.6	73.9	N	N	N	N	NR

S. no	MRD No.	Lab No	Distribution of clinical samples received	Fungal smear Positive for Hyaline Septate Fungal Hyphae	CANDIDA IN (BODY FLUIDS AND BLOOD CULTURE)	CANDIDA IN BODY FUILDS	FUNGAL CULTURE FOR ASPERGILLUS SPECIES	Fungal Cuture	GMSAASSAY	1-3 BDG	PTZ	ANTIFUNGAL	Heamo Dylasis	AUGMENTIN	MEROPENEM	Provisional diagnosis	Outcome	TOTAL EORTC PATIENTS	PROVEN	POSSIBLE	PROBABLE	NO INVASIVE ASPERGILLOSI
1830	1520099	1046	SPUTUM	Neg	-	-	Neg	NG	0.1	0.02	N	Y	N	N	Y	UTI	DAMA	N	N	N	N	Y
1831	1520041	1047	SPUTUM	Neg	-	-	Neg	NG	0.11	0.16	N	N	N	N	Y	THALAMOCAPSULAR BLEED	DAMA	N	N	N	N	Y
1832	1428641	1048	NR	NR	-	-	NR	NR	0.15	0.02	N	N	N	N	Y	GBM DISEASE	DISCHARGE	N	N	N	N	Y
1833	1521149	1049	URINE	Neg	Y	Y	Neg	CANDIDA	0.1	-	N	Y	N	N	Y	UTI, ASTHMA	DISCHARGE	N	N	N	N	Y
1834	1521171	1050	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.21	0.04	N	Y	N	N	Y	LIVER DISEASE	DISCHARGE	Y	N	Y	N	N
1835	1521138	1051	URINE	Neg	-	-	Neg	NG	0.1	0.02	N	Y	N	N	Y	LIVER FAILURE, SEPSIS	DISCHARGE	N	N	N	N	Y
1837	1521602	1053	SPUTUM	Neg	-	-	Neg	NG	0.1	0.04	N	N	N	N	N	CKD, SEPSIS	DISCHARGE	N	N	N	N	Y
1838	1521894	1054	NR	NR	-	-	NR	NR	0.1	-	N	N	N	N	N	LRTI, COPD, AKI	DISCHARGE	N	N	N	N	Y
1840	1521253	1056	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.1	0.02	N	N	N	N	Y	CKD	DISCHARGE	N	N	N	N	Y
1841	1520574	1057	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	CANDIDA	0.1	0.1	N	N	N	N	Y	POLY. TRAUMA	DISCHARGE	N	N	N	N	Y
1842	1510847	1058	SPUTUM	Neg	-	-	Neg	NG	0.1	0.02	N	Y	N	N	Y	LRTI, UTI, HEART FAILURE	EXPIRED	N	N	N	N	Y
1843	1520549	1059	PERICARDIAL FLUID	Neg	-	-	Neg	NG	0.1	0.02	N	N	N	N	Y	LRTI	DISCHARGE	N	N	N	N	Y
1845	1482337	1061	URINE	Neg	-	-	Neg	NG	0.17	-	N	N	N	N	Y	ALLERGIC	DAMA	N	N	N	N	Y
1846	1519879	1062	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	CANDIDA	0.1	0.04	N	N	N	N	Y	CLD WITH PORTAL HTN	DISCHARGE	N	N	N	N	Y
1849	1522469	1065	SPUTUM	Neg	-	-	Neg	NG	0.1	-	N	N	N	N	N	ASTHMA, ABPA	DISCHARGE	N	N	N	N	Y
1850	1523105	1066	SPUTUM	Neg	-	-	Neg	NG	0.1	0.02	N	N	Y	N	N	AKI, CKD, LRTI	DISCHARGE	N	N	N	N	Y
1851	1520383	1067	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.1	-	N	N	N	N	Y	COPD, PNAUMONIA	DISCHARGE	N	N	N	N	Y
1852	1521910	1068	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.1	0.02	N	N	N	N	Y	UTI SEPSIS	DISCHARGE	N	N	N	N	Y
1853	100498	1069	NR	NR	-	-	NR	NR	0.3	-	N	N	N	N	N	SOB	DISCHARGE	N	N	N	N	Y
1855	948423	1071	SPUTUM	Neg	-	-	Neg	NG	0.1	0.02	N	N	N	N	Y	DM	DISCHARGE	N	N	N	N	Y
1856	1179648	1072	NR	NR	-	-	NR	NR	0.1	0.02	N	N	Y	N	Y	LRTI, CKD	DISCHARGE	Y	N	Y	N	N
1857	1513524	1073	ASCITIC FLUID	Neg	-	-	Neg	NG	0.1	0.03	N	N	N	N	Y	HTN, CIRRHOSIS	DISCHARGE	N	N	N	N	Y
1858	1210843	1074	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	CANDIDA	0.1	0.02	N	Y	N	N	Y	LRTI	DISCHARGE ON REQUEST	N	N	N	N	Y
1859	1523731	1075	SPUTUM	Neg	-	-	Neg	NG	0.1	0.02	N	N	N	N	Y	ASCITES	DISCHARGE ON REQUEST	N	N	N	N	Y
1860	1347756	1076	NR	NR	-	-	NR	NR	0.1	0.02	N	N	Y	N	Y	CKD	DAMA	N	N	N	N	Y
1861	808718	1077	PLEURAL FLUID	Neg	-	-	Neg	NG	0.1	0.02	N	N	N	N	Y	CKD	DAMA	N	N	N	N	Y
1862	1524515	1078	SPUTUM	Neg	-	-	Neg	CANDIDA	0.1	0.02	N	Y	N	N	N	ABPA, ASTHMA	DISCHARGE	N	N	N	N	Y
1863	1195327	1079	NR	NR	-	-	NR	NR	0.1	0.03	N	N	N	N	Y	PANCREATITIS	DISCHARGE	N	N	N	N	Y
1864	1524505	1080	NR	NR	-	-	NR	NR	0.1	-	N	N	N	N	Y	SEPSIS, AKI	DISCHARGE	Y	N	Y	N	N
1865	1524038	1081	SPUTUM	Neg	-	-	Neg	CANDIDA	0.1	0.15	N	Y	N	N	Y	LRTI	DISCHARGE	N	N	N	N	Y
1866	1523677	1082	ENDOTRACHEAL SECRETIONS	P	-	-	P	ASPERGILLUS FUMIGATUS	0.1	0.25	N	Y	N	N	Y	CKD, LRTI	DAMA	Y	N	Y	N	N
1867	658078	1083	ASCITIC FLUID	Neg	-	-	Neg	NG	0.1	0.02	N	N	N	N	Y	CIRRHOSIS, HTN	DISCHARGE	N	N	N	N	Y
1868	1525138	1084	NASAL MUCOSA	Neg	-	-	Neg	NG	0.1	0.02	N	N	N	N	N	CKD, SEPSIS	DISCHARGE	N	N	N	N	Y
1869	1522841	1085	NR	NR	-	-	NR	NR	0.1	0.02	N	N	N	N	Y	SHOCK	DAMA	N	N	N	N	Y
1870	1525178	1087	PERICARDIAL FLUID	Neg	-	-	Neg	NG	0.1	0.02	N	N	N	N	Y	CAD	DISCHARGE	N	N	N	N	Y
1871	1517703	1088	SPUTUM	Neg	-	-	Neg	NG	0.1	0.05	N	N	N	N	Y	ASCITES	DISCHARGE	N	N	N	N	Y
1872	1520550	1089	NR	NR	-	-	NR	NR	0.1	0.02	N	N	N	N	Y	ASCITES, CIRRHOSIS, HTN	DISCHARGE	N	N	N	N	Y
1873	1525134	1090	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	9.85	0.02	N	Y	N	N	Y	FUNGAL PNEUMONIA	DISCHARGE	Y	N	Y	Y	N
1874	51010	1091	ASCITIC FLUID	Neg	-	-	Neg	NG	0.1	0.02	N	N	N	N	Y	CIRRHOSIS, HTN	DISCHARGE	N	N	N	N	Y
1875	1525180	1092	SPUTUM	Neg	-	-	Neg	NG	0.1	0.02	N	N	N	N	N	KOCHS	DISCHARGE	N	N	N	N	Y
1879	1493198	1096	NR	NR	-	-	NR	NR	0.1	0.04	N	N	N	N	Y	IVH	DISCHARGE	N	N	N	N	Y
1881	1518227	1098	SPUTUM	Neg	-	-	Neg	CANDIDA	0.1	0.11	N	N	Y	N	Y	CKD	DISCHARGE	N	N	N	N	Y
1882	1512567	1099	TISSUE	Neg	-	-	Neg	NG	0.1	-	N	N	N	N	Y	DRY COUGH	DISCHARGE	N	N	N	N	Y
1884	1526282	1101	SPUTUM	Neg	-	-	Neg	NG	0.1	-	N	N	N	N	Y	LRTI	DISCHARGE	N	N	N	N	Y
1885	1523661	1102	NR	NR	-	-	NR	NR	0.1	0.02	N	N	Y	N	Y	AKI, SEPSIS	DAMA	N	N	N	N	Y
1886	1518556	1103	NR	NR	-	-	NR	NR	0.1	0.04	N	N	N	N	Y	LRTI	DISCHARGE	N	N	N	N	Y
1888	1526717	1105	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	CANDIDA	0.21	-	N	N	N	N	N	LRTI	DISCHARGE	N	N	N	N	Y
1889	1526083	1106	ASCITIC FLUID	Neg	-	-	Neg	NG	0.1	0.02	N	N	N	N	Y	PANCREATITIS	DISCHARGE	N	N	N	N	Y
1891	181386	1108	ASCITIC FLUID	Neg	-	-	Neg	NG	0.13	0.02	N	N	N	N	Y	CLD, PORTAL HTN	DISCHARGE	N	N	N	N	Y
1892	1340332	1109	SPUTUM	Neg	-	-	Neg	CANDIDA	11.29	-	N	Y	N	N	N	LRTI, SEPSIS	DISCHARGE	Y	N	Y	Y	N
1893	1523686	1110	PUS	Neg	-	-	Neg	NG	0.1	0.02	N	N	N	N	Y	FISTULA IN ABSCESS	DISCHARGE	N	N	N	N	Y

S. no	MRD No.	Lab No	NAME	DOR Sample	AGE	SEX	GMRepeat	DOA	AREA	SUB AREA WISE	Sample	DOR Sample	FEVER	COUGH	SOB	CHEST PAIN	DM	HTN	Alcoholic	Smoker	Neutropenia	TBHistory	Chronic steroid use	Solid organ transplantation	Malignancy	HIV	HCV	HB	TLC/DLC	NEUTROPHIL COUNT	CT CHEST _PLEURAL EFFUSION	CONSOLIDATION IN LUNG	CAVITATION	RETICULONODULAR OPACITIES	Histopathology for aspergillus species
1895	151674	1112	AP	6/1/2023	29	M	N	5/31/2023	ICU	RENAL DISEASE	SERUM	6/1/2023	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	13	9.18	65	N	N	N	N	Y
1896	298087	1113	SR	6/1/2023	80	F	N	5/31/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	6/1/2023	N	Y	Y	N	Y	Y	N	N	N	N	N	N	N	N	N	9	11	69	N	Y	N	N	NR
1897	1527878	1114	JK	6/1/2023	55	M	N	6/1/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	6/1/2023	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	10	12	79	N	N	N	N	NR
1898	1525082	1115	GS	6/2/2023	56	M	N	5/27/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	6/2/2023	Y	N	Y	N	N	N	N	N	N	N	N	N	N	N	N	12.1	19.8	93.8	N	N	N	N	NR
1899	1526803	1116	M	6/2/2023	19	F	N	5/31/2023	WARD	CARDIOVASCULAR DISEASE	SERUM	6/2/2023	N	N	N	Y	N	Y	N	N	N	Y	N	N	N	N	N	6.9	5	85.4	N	N	N	Y	NR
1902	1525936	1119	SK	6/2/2023	78	M	N	5/29/2023	WARD	RENAL DISEASE	SERUM	6/2/2023	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	12.5	10	61.3	N	N	N	N	NR
1903	1407686	1120	BK	6/2/2023	82	M	N	6/1/2023	WARD	RENAL DISEASE	SERUM	6/2/2023	Y	Y	N	N	Y	Y	N	N	N	Y	N	N	N	N	N	7.7	10	94.1	N	Y	N	N	NR
1904	1527620	1121	MS	6/3/2023	67	F	N	6/1/2023	WARD	RENAL DISEASE	SERUM	6/3/2023	N	Y	Y	N	Y	Y	N	N	N	N	N	N	N	N	N	10	17	72	N	Y	N	N	NR
1905	1518527	1122	MK	6/3/2023	48	F	N	5/16/2023	WARD	RENAL DISEASE	SERUM	6/3/2023	Y	Y	N	N	Y	Y	Y	N	N	N	N	Y	N	N	N	6.6	10.1	80.1	N	N	N	Y	NR
1906	1528726	1123	AS	6/3/2023	45	M	N	6/2/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	6/3/2023	N	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	10	20	96	N	N	N	N	NR
1907	1526763	1124	AT	6/3/2023	18	M	N	5/30/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	6/3/2023	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	13.9	8.4	81	N	N	N	N	NR
1908	1520745	1125	PK	6/3/2023	63	F	N	5/20/2023	WARD	RENAL DISEASE	SERUM	6/3/2023	Y	Y	N	N	Y	Y	Y	N	N	N	N	N	N	N	N	12.3	4.2	67.9	N	Y	N	Y	NR
1909	1521210	1126	TS	6/3/2023	58	M	N	6/2/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	6/3/2023	N	N	N	N	Y	Y	Y	N	N	N	N	N	N	N	N	8.1	20.1	86.3	N	N	N	N	NR
1910	1359957	1127	HS	6/3/2023	47	M	N	6/3/2023	WARD	CARDIOVASCULAR DISEASE	SERUM	6/3/2023	N	N	Y	Y	N	Y	N	N	N	N	N	N	N	N	N	8.2	4.2	72	N	N	N	Y	NR
1911	1529242	1128	AS	6/4/2023	30	M	N	6/3/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	6/4/2023	Y	Y	N	N	Y	N	N	N	N	Y	N	N	N	N	N	14.7	12.1	71	N	N	N	N	NR
1912	1527418	1129	AC	6/4/2023	73	M	N	5/31/2023	WARD	CARDIOVASCULAR DISEASE	SERUM	6/4/2023	N	Y	N	Y	Y	Y	N	N	N	N	N	N	N	N	N	10	12	79	N	Y	N	N	NR
1913	1521165	1130	VK	6/4/2023	46	M	N	5/20/2023	WARD	CARDIOVASCULAR DISEASE	SERUM	6/4/2023	N	Y	N	Y	Y	Y	N	N	N	N	N	N	N	N	N	11	15	90	N	N	N	Y	NR
1915	1524225	1132	MK	6/5/2023	69	F	N	5/29/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	6/5/2023	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	10.6	13.9	78.1	N	N	N	N	NR
1916	1008702	1133	SS	6/4/2023	54	M	N	5/31/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	6/4/2023	Y	Y	N	Y	Y	Y	N	N	N	N	N	N	N	N	N	9.9	6.8	72.3	N	N	N	Y	NR
1917	1529453	1134	BK	6/5/2023	57	F	N	6/4/2023	WARD	RENAL DISEASE	SERUM	6/5/2023	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	9.5	10.2	66.4	N	Y	N	N	NR
1918	1529052	1135	BS	6/5/2023	85	M	N	6/3/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	6/5/2023	N	Y	Y	N	Y	Y	N	N	N	Y	N	N	N	N	N	10.3	10.1	81.1	N	N	N	Y	NR
1919	1524486	1136	MS	6/5/2023	68	M	N	5/26/2023	WARD	CARDIOVASCULAR DISEASE	SERUM	6/5/2023	N	Y	Y	Y	Y	Y	N	N	N	Y	Y	N	N	N	N	12	14	87	N	N	N	N	NR
1920	953978	1137	JK	6/5/2023	66	F	N	6/1/2023	WARD	ONCOLOGICAL	SERUM	6/5/2023	N	Y	N	N	N	N	N	N	N	N	N	Y	N	N	9.9	4.3	77.2	N	N	N	N	NR
1922	1507140	1139	AS	6/6/2023	35	M	N	5/30/2023	WARD	ENDOCRINOLOGY	SERUM	6/6/2023	N	Y	Y	N	N	N	Y	N	N	N	N	N	N	N	N	10.9	16.87	69.3	N	N	N	N	NR
1923	1525843	1140	GK	6/6/2023	67	F	N	5/29/2023	WARD	ONCOLOGICAL	SERUM	6/6/2023	N	Y	Y	N	N	N	N	N	N	N	N	Y	N	N	10.5	14.39	93.4	N	N	N	N	NR
1924	118852	1141	DK	6/6/2023	67	M	N	6/3/2023	WARD	ENDOCRINOLOGY	SERUM	6/6/2023	Y	Y	N	N	Y	Y	N	N	N	N	Y	N	N	N	Y	10.8	12.8	89.1	N	N	N	N	NR
1926	1529316	1143	TL	6/6/2023	56	M	N	6/3/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	6/6/2023	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	10.9	24.5	88.7	N	Y	N	N	NR
1927	1526330	1144	HS	6/6/2023	55	M	N	5/30/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	6/6/2023	N	Y	Y	N	Y	Y	N	N	N	N	N	N	N	N	Y	12.8	29.3	95	N	N	N	N	NR
1929	608412	1146	AK	6/6/2023	37	M	N	6/5/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	6/6/2023	N	Y	Y	N	N	N	N	N	N	N	Y	N	N	N	N	10.8	15.3	51.7	N	N	N	N	NR
1931	1530998	1148	KK	6/6/2023	19	F	N	6/6/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	6/6/2023	Y	Y	N	Y	N	N	N	N	N	N	Y	N	N	N	N	10.9	30.6	90.6	N	N	N	N	NR
1932	1529343	1149	ON	6/7/2023	63	M	N	6/3/2023	ICU	NEUROLOGICAL DISEASE	SERUM	6/7/2023	Y	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	7.3	17	80	N	N	N	N	NR
1933	1496824	1150	PS	6/7/2023	49	M	N	5/31/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	6/7/2023	N	N	N	N	N	N	N	N	N	N	N	N	Y	N	N	7.3	7.3	73	N	N	N	N	NR
1935	1522477	1152	PK	6/7/2023	36	M	N	5/23/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	6/7/2023	Y	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	8.2	24.5	52.7	N	N	N	N	NR
1936	1526301	1153	BS	6/7/2023	66	M	N	5/30/2023	WARD	RENAL DISEASE	SERUM	6/7/2023	N	Y	Y	N	Y	Y	N	N	N	N	N	N	N	N	N	8.5	7.5	86.6	N	N	N	N	NR
1937	1531702	1154	SK	6/7/2023	68	M	N	6/7/2023	WARD	RENAL DISEASE	SERUM	6/7/2023	Y	Y	N	N	Y	Y	N	N	N	N	Y	N	N	N	N	10.2	4.32	70.8	N	N	N	Y	NR
1938	1527954	1155	VS	6/8/2023	61	M	N	6/1/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	6/8/2023	Y	Y	N	N	Y	Y	Y	Y	N	N	Y	N	N	N	N	8.2	27.7	83.7	N	Y	N	N	NR
1939	1525111	1156	SS	6/8/2023	26	M	N	5/28/2023	WARD	GENERAL SURGERY	SERUM	6/8/2023	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	9.3	7.3	76.3	N	N	N	Y	NR
1940	1525046	1157	TS	6/8/2023	37	M	N	5/27/2023	ICU	CARDIOVASCULAR DISEASE	SERUM	6/8/2023	N	N	Y	N	N	N	N	N	N	N	N	N	N	N	N	10	15	89	N	N	N	N	NR
1941	1531731	1158	DD	6/8/2023	21	M	N	6/8/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	6/8/2023	Y	Y	N	N	Y	N	N	N	N	N	N	N	N	N	N	10.5	18.6	73.2	N	N	N	N	NR
1942	901418	1159	RK	6/9/2023	59	F	N	6/4/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	6/9/2023	N	N	N	N	Y	Y	N	N	N	N	N	N	N	N	N	11	25.6	81.7	N	Y	N	N	NR
1943	1523718	1160	GG	6/9/2023	30	M	N	5/25/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	6/9/2023	Y	Y	N	N	N	N	Y	Y	N	N	N	N	N	N	N	9.6	22.6	90.3	N	N	N	N	NR
1944	1349877	1161	LD	6/9/2023	79	M	N	6/7/2023	WARD	RENAL DISEASE	SERUM	6/9/2023	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	6	6.2	77.6	N	N	N	N	NR
1945	962786	1162	GS	6/9/2023	60	M	N	6/1/2023	WARD	RENAL DISEASE	SERUM	6/9/2023	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	7.7	10.9	84.7	N	Y	N	Y	NR
1947	1531600	1164	SS	6/9/2023	30	M	N	6/7/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	6/9/2023	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	11	9.8	86	N	N	N	Y	NR
1948	1532373	1165	BS	6/9/2023	55	M	N	6/8/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	6/9/2023	Y	Y	N	N	Y	Y	Y	N	N	N	N	N	N	N	N	8.2	19.2	82.8	N	N	N	Y	NR
1949	1532460	1166	KK	6/9/2023	43	F	N	6/9/2023	WARD	ACUTE FEBRILE ILLNESS	SERUM	6/9/2023	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	11.1	8.6	51.4	N	N	N	N	NR
1951	1525883	1168	AS	6/10/2023	36	M	N	5/29/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	6/10/2023	N	N	N	N	N	N	Y	Y	N	N	N	N	N	N	N	9.2	11.8	78.3	N	N	N	N	NR
1952	1426847	1169	MK	6/10/2023	70	F	N	6/9/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	6/10/2023	Y	Y	N	N	N	Y	N	N	N	N	Y	N	N	N	N	13.2	14.73	65.4	N	N	N	Y	NR
1953	863381	1170	SK	6/10/2023	73	M	N	6/1/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	6/10/2023	N	N	N	N	N	N	Y	N	N	N	N	N	N	N	N	10.9	18.4	94.6	N	N	N	N	NR

S. no	MRD No.	Lab No	Distribution of clinical samples received	Fungal smear Positive for Hyaline Septate Fungal Hyphae	CANDIDA IN (BODY FLUIDS AND BLOOD CULTURE)	CANDIDA IN BODY FUILDS	FUNGAL CULTURE FOR ASPERGILLUS SPECIES	Fungal Cuture	GMSAASSAY	1-3 BDG	PTZ	ANTIFUNGAL	Heamo Dylasis	AUGMENTIN	MEROPENEM	Provisional diagnosis	Outcome	TOTAL EORTC PATIENTS	PROVEN	POSSIBLE	PROBABLE	NO INVASIVE ASPERGILLOSI
1895	151674	1112	URINE	P	-	-	P	ASPERGILLUS FUMIGATUS	1.24	-	N	Y	N	N	Y	PYELONEPHRITIS	DISCHARGE	Y	Y	N	N	N
1896	298087	1113	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.1	-	N	N	N	N	Y	COPD, SEPSIS	DISCHARGE	N	N	N	N	Y
1897	1527878	1114	NR	NR	-	-	NR	NR	0.14	-	N	N	N	N	Y	CIRRHOSIS	DISCHARGE	N	N	N	N	Y
1898	1525082	1115	URINE	Neg	-	-	Neg	NG	0.1	-	N	N	N	N	Y	PYELONEPHRITIS	DISCHARGE	N	N	N	N	Y
1899	1526803	1116	URINE	Neg	-	-	Neg	NG	0.1	0.02	Y	N	N	N	N	AKI	DISCHARGE	N	N	N	N	Y
1902	1525936	1119	SPUTUM	Neg	-	-	Neg	CANDIDA	0.1	0.02	N	N	N	N	N	LRTI, BPH	DISCHARGE	N	N	N	N	Y
1903	1407686	1120	PLEURAL FLUID	Neg	-	-	Neg	NG	0.1	0.02	N	N	Y	N	Y	CKD, LRTI, KOCHS	EXPIRED	N	N	N	N	Y
1904	1527620	1121	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	CANDIDA	0.1	0.52	N	Y	N	N	Y	CHOLELITHIASIS	DAMA	N	N	N	N	Y
1905	1518527	1122	URINE	Neg	-	-	Neg	NG	0.1	0.02	N	Y	Y	N	N	CKD, LRTI	DISCHARGE	Y	N	Y	N	N
1906	1528726	1123	URINE	Neg	-	-	Neg	NG	0.1	0.02	N	N	N	N	Y	CLD, PORTAL HTN	DAMA	N	N	N	N	Y
1907	1526763	1124	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.1	0.02	N	N	N	N	Y	PLEURAL EFFUSION	DISCHARGE ON REQUEST	N	N	N	N	Y
1908	1520745	1125	SPUTUM	Neg	-	-	Neg	NG	0.1	0.02	N	N	N	N	Y	CKD	DISCHARGE ON REQUEST	N	N	N	N	Y
1909	1521210	1126	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	CANDIDA	0.1	0.05	N	N	N	N	Y	CLD, PORTAL HTN	DISCHARGE	N	N	N	N	Y
1910	1359957	1127	ASCITIC FLUID	Neg	-	-	Neg	NG	0.13	0.02	N	N	N	N	Y	CKD	DISCHARGE	N	N	N	N	Y
1911	1529242	1128	SPUTUM	Neg	-	-	Neg	CANDIDA	0.1	-	N	Y	N	N	Y	KOCHS	DISCHARGE	N	N	N	N	Y
1912	1527418	1129	CSF	Neg	-	-	Neg	NG	0.1	0.03	N	N	N	N	Y	CAD	DISCHARGE	N	N	N	N	Y
1913	1521165	1130	SPUTUM	Neg	-	-	Neg	CANDIDA	0.1	0.12	N	Y	N	N	N	LRTI	DISCHARGE	N	N	N	N	Y
1915	1524225	1132	SPUTUM	Neg	-	-	Neg	CANDIDA	0.1	-	N	Y	N	N	Y	LRTI, AKI	DISCHARGE	N	N	N	N	Y
1916	1008702	1133	URINE	Neg	-	-	Neg	NG	0.14	0.02	N	N	N	N	N	CIRRHOSIS, LRTI	DAMA	N	N	N	N	Y
1917	1529453	1134	URINE	Neg	-	-	Neg	NG	0.1	0.02	N	N	Y	N	Y	CKD	DISCHARGE	N	N	N	N	Y
1918	1529052	1135	SPUTUM	Neg	-	-	Neg	CANDIDA	0.18	-	N	Y	N	N	N	COPD, KOCHS	DISCHARGE	N	N	N	N	Y
1919	1524486	1136	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.1	0.03	N	N	N	N	Y	LRTI, SEPSIS	DISCHARGE	N	N	N	N	Y
1920	953978	1137	NR	NR	-	-	NR	NR	0.1	0.02	N	N	N	N	N	CA BREAST	DISCHARGE	N	N	N	N	Y
1922	1507140	1139	ASCITIC FLUID	Neg	-	-	Neg	NG	0.1	-	N	N	N	N	Y	CLD WITH PORTAL HTN	DISCHARGE	N	N	N	N	Y
1923	1525843	1140	SPUTUM	Neg	-	-	Neg	NG	0.1	0.02	N	Y	N	N	Y	CA BREAST	DISCHARGE	N	N	N	N	Y
1924	118852	1141	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.1	0.02	N	Y	N	N	Y	ASTHMA, UTI	DISCHARGE	N	N	N	N	Y
1926	1529316	1143	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	CANDIDA	0.97	0.21	N	Y	N	N	Y	ASCITES, KIDNEY DISEASE	DISCHARGE	N	N	N	N	Y
1927	1526330	1144	SPUTUM	Neg	-	-	Neg	CANDIDA	0.1	0.03	Y	Y	N	N	N	KOCHS	DISCHARGE	N	N	N	N	Y
1929	608412	1146	SPUTUM	Neg	-	-	Neg	NG	0.1	-	N	N	N	N	N	KOCHS	DISCHARGE	N	N	N	N	Y
1931	1530998	1148	SPUTUM	Neg	-	-	Neg	NG	2.59	0.02	N	Y	N	N	N	ARDS	DISCHARGE	Y	N	Y	N	N
1932	1529343	1149	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.1	-	N	N	N	N	Y	COUGH WITH EXPECTORATION	DISCHARGE	N	N	N	N	Y
1933	1496824	1150	SPUTUM	Neg	-	-	Neg	NG	0.1	0.05	N	N	N	N	N	LUNG DISEASE	DISCHARGE	N	N	N	N	Y
1935	1522477	1152	SPUTUM	Neg	-	-	Neg	CANDIDA	0.1	0.02	N	Y	N	N	Y	LIVER DISEASE	DISCHARGE	N	N	N	N	Y
1936	1526301	1153	SPUTUM	Neg	-	-	Neg	NG	0.1	-	N	N	Y	N	Y	CKD, SEPSIS	DISCHARGE	N	N	N	N	Y
1937	1531702	1154	SPUTUM	Neg	-	-	Neg	CANDIDA	0.56	0.02	N	Y	N	N	N	CKD, LRTI	EXPIRED	Y	N	Y	Y	N
1938	1527954	1155	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.1	-	N	N	N	N	N	COPD, LRTI	DISCHARGE	Y	N	Y	N	N
1939	1525111	1156	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.1	0.02	N	N	N	N	Y	SPINE INJURY	DISCHARGE	N	N	N	N	Y
1940	1525046	1157	WOUND SWAB	Neg	-	-	Neg	NG	0.6	-	N	N	N	N	Y	AKI	DISCHARGE	N	N	N	N	Y
1941	1531731	1158	URINE	Neg	-	-	Neg	NG	0.1	0.02	N	N	N	N	Y	PANCREATITIS	DISCHARGE	N	N	N	N	Y
1942	901418	1159	SPUTUM	Neg	-	-	Neg	CANDIDA	0.1	0.02	N	Y	N	N	Y	CHOLELITHIASIS	DISCHARGE	N	N	N	N	Y
1943	1523718	1160	PER CUTANEOUS DRAIN	Neg	-	-	Neg	NG	0.1	0.02	N	N	N	N	Y	PANCREATITIS	DISCHARGE	N	N	N	N	Y
1944	1349877	1161	URINE	Neg	-	-	Neg	NG	0.1	0.04	N	N	N	N	Y	CKD, SEPSIS	DISCHARGE	N	N	N	N	Y
1945	962786	1162	URINE	Neg	-	-	Neg	NG	0.1	0.12	N	N	N	N	Y	CKD, LRTI	DISCHARGE	N	N	N	N	Y
1947	1531600	1164	SPUTUM	Neg	-	-	Neg	CANDIDA	0.1	-	N	Y	N	N	N	IV DRUG ABUSER	DISCHARGE	N	N	N	N	Y
1948	1532373	1165	SPUTUM	Neg	-	-	Neg	NG	0.1	-	N	Y	N	N	N	LRTI	DISCHARGE	N	N	N	N	Y
1949	1532460	1166	SPUTUM	Neg	-	-	Neg	NG	0.1	-	N	N	N	N	N	FIBRILE ILLNESS	DISCHARGE	N	N	N	N	Y
1951	1525883	1168	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.11	0.02	N	N	N	N	Y	CLD, PORTAL HTN	DISCHARGE	N	N	N	N	Y
1952	1426847	1169	SPUTUM	Neg	-	-	Neg	NG	0.1	0.02	N	Y	N	N	N	SEPSIS, LRTI, UTI	DISCHARGE	Y	N	Y	N	N
1953	863381	1170	NR	NR	-	-	NR	NR	0.1	0.05	N	N	N	N	Y	LIVER DISEASE	DISCHARGE	N	N	N	N	Y

S. no	MRD No.	Lab No	NAME	DOR Sample	AGE	SEX	GMRepeat	DOA	AREA	SUB AREA WISE	Sample	DOR Sample	FEVER	COUGH	SOB	CHEST PAIN	DM	HTN	Alcoholic	Smoker	Neutropenia	TBHistory	Chronic steroid use	Solid organ transplantation	Malignancy	HIV	HCV	HB	TLC/DLC	NEUTROPHIL COUNT	CT CHEST _PLEURAL EFFUSION	CONSOLIDATION IN LUNG	CAVITATION	RETICULONODULAR OPACITIES	Histopathology for aspergillus species
1954	1185441	1171	GR	6/11/2023	68	M	N	6/3/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	6/11/2023	N	N	N	N	Y	N	Y	N	N	N	N	N	Y	N	N	8.4	6.9	60.8	N	N	N	N	NR
1955	1251066	1172	KK	6/11/2023	70	F	N	5/31/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	6/11/2023	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	9.5	12.3	83	N	N	N	N	NR
1956	1201778	1173	VL	6/11/2023	63	F	N	6/10/2023	WARD	RENAL DISEASE	SERUM	6/11/2023	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	9.1	23.6	91	N	N	N	Y	NR
1957	1226213	1174	RK	6/11/2023	67	F	N	6/3/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	6/11/2023	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	7.7	14.1	94.3	N	N	N	Y	NR
1958	1531723	1175	HS	6/12/2023	18	M	N	6/7/2023	WARD	GENERAL SURGERY	SERUM	6/12/2023	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	11.3	35.2	89.4	N	N	N	N	NR
1959	1240642	1176	DK	6/12/2023	75	F	N	6/8/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	6/12/2023	Y	Y	N	Y	N	N	N	N	N	N	N	N	N	N	N	6.6	18.5	93.7	N	N	N	Y	NR
1961	1526145	1178	SK	6/13/2023	60	F	N	6/13/2023	WARD	RHEUMATOLOGY	SERUM	6/13/2023	N	Y	N	N	N	N	N	N	N	N	Y	N	N	N	N	9.4	7.2	42.2	N	Y	N	N	NR
1962	1527434	1179	RB	6/14/2023	75	M	N	6/1/2023	WARD	NEUROLOGICAL DISEASE	SERUM	6/14/2023	N	N	N	N	N	Y	N	N	N	N	N	N	N	N	N	11.6	8.89	69.8	N	N	N	N	NR
1964	1530207	1181	RG	6/14/2023	53	M	N	6/5/2023	WARD	NEUROLOGICAL DISEASE	SERUM	6/14/2023	N	N	N	N	Y	Y	N	N	N	N	N	N	N	N	N	8.2	9.92	70.9	N	N	N	Y	NR
1965	1406291	1182	HK	6/14/2023	72	F	N	6/6/2023	WARD	NEUROLOGICAL DISEASE	SERUM	6/14/2023	Y	Y	N	N	N	N	N	N	N	Y	N	N	Y	N	N	10.3	8.7	68.8	N	N	N	N	NR
1966	1479541	1183	SS	6/15/2023	32	F	N	6/8/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	6/15/2023	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	N	5.6	20.1	72.9	N	N	N	N	NR
1967	1534697	1184	SL	6/15/2023	60	F	N	6/13/2023	WARD	CARDIOVASCULAR DISEASE	SERUM	6/15/2023	N	N	Y	Y	Y	Y	N	N	N	N	Y	N	N	N	N	8.8	12	85	N	N	N	N	NR
1968	1483720	1185	DS	-	36	M	N	5/27/2023	WARD	GENERAL SURGERY	SERUM	-	Y	Y	N	N	N	N	N	N	N	Y	N	N	N	N	N	3.2	47.5	69	N	N	N	Y	NR
1969	1370887	1186	UR	6/16/2023	64	F	N	6/15/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	6/16/2023	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	N	9.9	66.5	80.4	N	Y	N	N	NR
1971	1536931	1188	HK	6/16/2023	60	F	N	6/16/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	6/16/2023	Y	Y	N	N	N	N	N	N	N	N	Y	N	N	N	N	8.4	10.75	91.5	N	N	N	Y	NR
1972	1533135	1189	KR	6/16/2023	58	F	N	6/9/2023	WARD	CARDIOVASCULAR DISEASE	SERUM	6/16/2023	N	N	Y	Y	Y	N	N	N	N	N	N	N	N	N	N	11	10.5	96	N	N	N	N	NR
1973	1020738	1190	PA	6/16/2023	49	F	N	6/16/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	6/16/2023	Y	Y	Y	N	Y	Y	N	N	N	N	N	N	Y	N	N	8.3	16.3	95.1	N	Y	N	N	NR
1974	1520586	1191	KS	6/16/2023	55	M	N	5/20/2023	WARD	GENERAL SURGERY	SERUM	6/16/2023	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	10.5	9.4	74	N	N	N	N	NR
1975	1292393	1192	P	6/16/2023	57	F	N	6/16/2023	WARD	RHEUMATOLOGY	SERUM	6/16/2023	N	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	10	8	70	N	N	N	N	NR
1976	1536543	1193	HS	6/17/2023	21	M	N	6/16/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	6/17/2023	N	N	N	N	Y	N	N	N	N	N	N	N	N	N	N	14.9	9.9	76.2	N	N	N	N	NR
1977	1522562	1194	S	6/17/2023	40	F	N	6/16/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	6/17/2023	N	Y	Y	N	Y	N	N	N	N	Y	N	N	N	N	N	8.5	11.3	71.2	N	N	N	Y	NR
1980	1537304	1197	MS	6/17/2023	70	M	N	6/16/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	6/17/2023	N	Y	Y	N	Y	N	N	N	N	Y	N	N	N	Y	11.7	10.8	81.5	N	Y	N	N	NR
1981	1252954	1198	SK	6/17/2023	61	F	N	6/9/2023	WARD	ONCOLOGICAL	SERUM	6/17/2023	N	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	10.9	7	49.5	N	N	N	N	NR
1982	1364568	1199	PS	6/17/2023	76	M	N	6/1/2023	WARD	ONCOLOGICAL	SERUM	6/17/2023	N	N	N	N	N	Y	N	N	N	N	N	N	Y	N	N	5.4	2	50	N	N	N	Y	NR
1983	1370229	1200	TR	6/18/2023	55	M	N	6/15/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	6/18/2023	Y	N	N	N	N	N	Y	N	N	N	N	N	N	N	N	8.5	6.7	87.1	N	N	N	Y	NR
1984	1537295	1201	JS	6/18/2023	65	M	N	6/16/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	6/18/2023	Y	Y	N	Y	Y	Y	N	N	N	N	N	N	N	N	N	10.3	5.7	89.5	N	N	N	N	NR
1985	1537907	1202	LK	6/18/2023	52	M	N	6/18/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	6/18/2023	Y	N	N	N	N	N	Y	N	N	N	N	N	N	N	N	10.8	14.2	73.2	N	N	N	N	NR
1987	1537892	1204	DD	6/19/2023	65	M	N	6/18/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	6/19/2023	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	8.1	18.7	91.4	N	N	N	Y	NR
1988	1353705	1205	SP	6/19/2023	63	F	N	5/22/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	6/19/2023	Y	Y	N	N	N	Y	N	N	N	N	Y	N	N	N	N	7.9	6.7	70.2	N	N	N	N	NR
1989	1538771	1206	IS	6/20/2023	78	M	N	6/19/2023	WARD	CARDIOVASCULAR DISEASE	SERUM	6/20/2023	N	N	Y	Y	Y	Y	N	N	N	N	N	N	N	N	N	10	13	61	N	N	N	N	NR
1990	1538336	1207	MS	6/20/2023	69	M	N	6/19/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	6/20/2023	Y	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	11.7	10.16	86.4	N	N	N	Y	NR
1991	1537915	1208	GS	6/20/2023	65	M	N	6/18/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	6/20/2023	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	8.5	12.69	76.7	N	N	N	N	NR
1992	459700	1209	SS	6/20/2023	84	M	N	6/9/2023	ICU	CARDIOVASCULAR DISEASE	SERUM	6/20/2023	Y	Y	Y	Y	Y	Y	N	N	N	N	N	N	N	N	N	7.8	11	75	N	Y	N	N	NR
1993	1539190	1210	CS	6/20/2023	55	M	N	6/20/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	6/20/2023	Y	Y	N	N	N	Y	N	N	N	Y	Y	N	N	N	N	7.4	12.1	91	N	N	N	Y	NR
1994	1534702	1211	NB	6/21/2023	36	F	N	6/13/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	6/21/2023	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	7.9	16.9	77.6	N	Y	N	N	NR
1996	108208	1213	CK	6/21/2023	49	F	N	6/20/2023	WARD	ENDOCRINOLOGY	SERUM	6/21/2023	N	N	N	N	N	N	Y	Y	N	N	N	N	N	N	N	8.7	6.65	75.5	N	N	N	N	NR
1997	1536541	1214	RD	6/21/2023	56	F	N	6/16/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	6/21/2023	Y	Y	N	N	N	N	Y	Y	N	N	N	N	N	N	N	9.2	31.7	86	N	N	N	N	NR
1998	947776	1215	R	6/21/2023	35	M	N	6/20/2023	WARD	GENERAL SURGERY	SERUM	6/21/2023	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	13.9	9.12	60.2	N	N	N	N	NR
1999	1435922	1216	BL	6/22/2023	75	M	N	6/20/2023	WARD	RENAL DISEASE	SERUM	6/22/2023	Y	Y	N	N	Y	Y	N	N	N	N	Y	N	N	N	N	9.7	2.4	92.9	N	N	N	Y	NR
2000	340994	1217	HK	6/22/2023	61	F	N	6/12/2023	WARD	RENAL DISEASE	SERUM	6/22/2023	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	10.4	17.9	76	N	N	N	Y	NR
2002	1539978	1219	AS	6/22/2023	46	M	N	6/21/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	6/22/2023	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	10.4	13.4	51.1	N	N	N	Y	NR
2003	1536327	1220	VS	6/22/2023	45	M	N	6/15/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	6/22/2023	N	N	N	N	N	N	Y	N	N	N	N	N	N	N	N	8.6	8.44	66.9	N	N	N	Y	NR
2004	1539939	1221	KS	6/22/2023	78	M	N	6/21/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	6/22/2023	Y	Y	N	Y	N	N	N	N	N	N	N	N	N	N	N	8.1	23.7	91.5	N	N	N	Y	NR
2005	1536421	1222	NS	6/22/2023	65	M	N	6/15/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	6/22/2023	Y	Y	N	N	Y	Y	Y	N	N	N	Y	N	N	N	Y	8.3	8.53	65.7	N	N	N	Y	NR
2007	1535345	1224	HS	6/23/2023	47	M	N	6/14/2023	WARD	ENDOCRINOLOGY	SERUM	6/23/2023	N	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	9.3	12.4	69.7	N	Y	N	N	NR
2009	1531737	1226	BS	6/23/2023	40	M	N	6/8/2023	WARD	GENERAL SURGERY	SERUM	6/23/2023	N	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	9.9	13.5	75.4	N	Y	N	N	NR
2010	1535947	1227	GS	6/23/2023	40	M	N	6/14/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	6/23/2023	Y	N	N	N	N	N	Y	N	N	N	N	N	N	N	N	9.7	17.93	78.3	N	N	N	N	NR
2011	1541752	1228	GS	6/26/2023	69	M	N	6/25/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	6/26/2023	N	Y	N	N	Y	N	Y	N	N	N	N	N	N	N	N	10.7	11.1	65.8	N	N	N	N	NR

S. no	MRD No.	Lab No	Distribution of clinical samples received	Fungal smear Positive for Hyaline Septate Fungal Hyphae	CANDIDA IN (BODY FLUIDS AND BLOOD CULTURE)	CANDIDA IN BODY FUILDS	FUNGAL CULTURE FOR ASPERGILLUS SPECIES	Fungal Cuture	GMSAASSAY	1-3 BDG	PTZ	ANTIFUNGAL	Heamo Dylasis	AUGMENTIN	MEROPENEM	Provisional diagnosis	Outcome	TOTAL EORTC PATIENTS	PROVEN	POSSIBLE	PROBABLE	NO INVASIVE ASPERGILLOSI
1954	1185441	1171	NR	NR	-	-	NR	NR	0.1	0.02	N	N	N	N	Y	HEPATOCELLULAR CARCINOMA	DISCHARGE	N	N	N	N	Y
1955	1251066	1172	PER CUTANEOUS DRAIN	Neg	-	-	Neg	NG	0.1	-	N	N	N	N	Y	CLIAC DISEASE, UTI, LRTI, AKI	DISCHARGE	N	N	N	N	Y
1956	1201778	1173	NR	NR	-	-	NR	NR	0.1	0.03	N	N	N	N	Y	CKD, LRTI	DISCHARGE	N	N	N	N	Y
1957	1226213	1174	NR	NR	-	-	NR	NR	0.1	0.02	N	Y	N	N	Y	COPD, LRTI	DISCHARGE	N	N	N	N	Y
1958	1531723	1175	PER CUTANEOUS DRAIN	Neg	-	-	Neg	NG	0.1	0.02	N	N	N	N	Y	PANCREATITIS	DISCHARGE	N	N	N	N	Y
1959	1240642	1176	NR	NR	-	-	NR	NR	0.1	0.02	N	N	N	N	Y	PNEUMONIA	DISCHARGE ON REQUEST	N	N	N	N	Y
1961	1526145	1178	PER CUTANEOUS DRAIN	Neg	-	-	Neg	NG	0.1	12.25	N	Y	N	N	N	LRTI	DISCHARGE	Y	N	Y	Y	N
1962	1527434	1179	NR	NR	-	-	NR	NR	0.1	0.02	N	N	N	N	N	CVA, SEPSIS	DISCHARGE	N	N	N	N	Y
1964	1530207	1181	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.1	0.05	N	N	N	N	N	STROKE	DISCHARGE	N	N	N	N	Y
1965	1406291	1182	SPUTUM	Neg	-	-	Neg	NG	0.1	0.03	N	N	N	N	N	KOCHS, CARCINOMA	DAMA	N	N	N	N	Y
1966	1479541	1183	URINE	Neg	-	-	Neg	NG	0.1	0.02	N	N	N	N	Y	HEP. A +VE	DISCHARGE	N	N	N	N	Y
1967	1534697	1184	NR	NR	-	-	NR	NR	0.1	0.02	N	N	N	N	N	COPD, CAD	DISCHARGE	N	N	N	N	Y
1968	1483720	1185	WOUND SWAB	Neg	-	-	Neg	NG	0.9	0.02	N	N	N	N	N	TB	DISCHARGE	N	N	N	N	Y
1969	1370887	1186	NR	NR	-	-	NR	NR	0.1	0.34	N	N	N	N	Y	PYELONEPHRITIS	DISCHARGE	N	N	N	N	Y
1971	1536931	1188	SPUTUM	Neg	-	-	Neg	NG	0.1	-	N	N	N	N	Y	ABPA, ASTHMA, LRTI	DISCHARGE	Y	N	Y	N	N
1972	1533135	1189	NR	NR	-	-	NR	NR	0.1	0.02	N	N	N	N	N	UTI, URO SEPSIS	DISCHARGE	N	N	N	N	Y
1973	1020738	1190	NR	NR	-	-	NR	NR	0.1	0.02	Y	N	N	N	N	METASTATIC	DAMA	Y	N	Y	N	N
1974	1520586	1191	NR	NR	-	-	NR	NR	0.1	0.13	N	N	N	N	N	UTI SEPSIS	DISCHARGE	N	N	N	N	Y
1975	1292393	1192	SPUTUM	Neg	-	-	Neg	NG	0.1	0.03	N	N	N	N	Y	ARTHRITIS	DISCHARGE	N	N	N	N	Y
1976	1536543	1193	NR	NR	-	-	NR	NR	0.1	0.02	N	N	N	N	Y	HEPATOMEGALY	DISCHARGE	N	N	N	N	Y
1977	1522562	1194	SPUTUM	Neg	-	-	Neg	NG	0.1	0.02	N	N	N	N	N	KOCHS	DISCHARGE	N	N	N	N	Y
1980	1537304	1197	NR	NR	-	-	NR	NR	0.1	-	N	N	N	N	N	COPD, ASTHMA, ABPA	DISCHARGE	Y	N	Y	N	N
1981	1252954	1198	NR	NR	-	-	NR	NR	0.18	0.02	N	N	N	N	N	CA VVULA	DISCHARGE	N	N	N	N	Y
1982	1364568	1199	NR	NR	-	-	NR	NR	0.1	0.02	N	N	N	N	N	HYPOTHYROIDISM	DISCHARGE	Y	N	Y	N	N
1983	1370229	1200	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.1	0.02	N	N	N	N	Y	CIRRHOSIS, PORTAL HTN	DISCHARGE	N	N	N	N	Y
1984	1537295	1201	SPUTUM	Neg	-	-	Neg	NG	0.1	-	N	N	N	N	Y	COPD, LRTI	DISCHARGE ON REQUEST	N	N	N	N	Y
1985	1537907	1202	NR	NR	-	-	NR	NR	0.1	0.02	N	N	N	N	Y	CLD WITH PORTAL HTN	DISCHARGE	N	N	N	N	Y
1987	1537892	1204	NR	NR	-	-	NR	NR	0.1	-	N	N	N	N	Y	PNEUMONOTHORAX	DAMA	N	N	N	N	Y
1988	1353705	1205	NR	NR	-	-	NR	NR	0.8	-	N	N	N	N	N	CAD, CALIAC DISEASE	DISCHARGE	Y	N	Y	N	N
1989	1538771	1206	PLEURAL FLUID	Neg	-	-	Neg	NG	0.1	0.02	N	N	N	N	Y	LRTI	DISCHARGE	N	N	N	N	Y
1990	1538336	1207	NR	NR	-	-	NR	NR	0.1	-	N	N	N	N	N	TB	DISCHARGE	N	N	N	N	Y
1991	1537915	1208	SPUTUM	Neg	-	-	Neg	NG	0.1	0.02	N	N	N	N	Y	LUNG MASS	DISCHARGE	N	N	N	N	Y
1992	459700	1209	SPUTUM	Neg	-	-	Neg	CANDIDA	0.1	0.02	N	N	Y	N	N	CKD	DISCHARGE	N	N	N	N	Y
1993	1539190	1210	SPUTUM	Neg	-	-	Neg	NG	0.1	0.02	N	N	N	N	N	SEPSIS, AKI, KOCHS	DISCHARGE	Y	N	Y	N	N
1994	1534702	1211	SPUTUM	Neg	-	-	Neg	CANDIDA	0.1	-	N	N	N	N	N	SEPSIS, AKI, ASCITES	DAMA	N	N	N	N	Y
1996	108208	1213	NR	NR	-	-	NR	NR	0.1	0.02	N	N	N	N	Y	CLD WITH PORTAL HTN	DISCHARGE	N	N	N	N	Y
1997	1536541	1214	ENDOTRACHEAL SECRETIONS	P	-	-	P	ASPERGILLUS FUMIGATUS	0.1	0.02	N	N	N	N	Y	CLD WITH PORTAL HTN	DISCHARGE	N	N	N	N	Y
1998	947776	1215	NASAL MUCOSA	Neg	-	-	Neg	NG	0.1	-	N	Y	N	N	N	FUNGAL SINUSITIS	DISCHARGE	N	N	N	N	Y
1999	1435922	1216	PER CUTANEOUS DRAIN	Neg	-	-	Neg	NG	0.1	0.02	N	N	N	N	Y	SEPSIS, UTI	DAMA	Y	N	Y	N	N
2000	340994	1217	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.1	0.02	N	Y	Y	N	N	CKD, FUNGAL SEPSIS	DISCHARGE	N	N	N	N	Y
2002	1539978	1219	SPUTUM	Neg	-	-	Neg	NG	0.1	0.02	N	N	N	N	Y	FUNGAL SEPSIS, LRTI	DISCHARGE	N	N	N	N	Y
2003	1536327	1220	SPUTUM	Neg	-	-	Neg	NG	0.1	0.02	N	N	N	N	Y	CLD WITH PORTAL HTN	DISCHARGE	N	N	N	N	Y
2004	1539939	1221	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.1	-	N	N	N	N	Y	SEPSIS, LRTI, UTI	DISCHARGE	N	N	N	N	Y
2005	1536421	1222	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.1	0.12	N	N	N	N	Y	LRTI, UTI	DISCHARGE	Y	N	Y	N	N
2007	1535345	1224	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.1	0.02	N	N	N	N	Y	NECROTISING	DISCHARGE	N	N	N	N	Y
2009	1531737	1226	NR	NR	-	-	NR	NR	0.1	0.02	N	N	N	N	Y	PANCREATITIS	DISCHARGE	N	N	N	N	Y
2010	1535947	1227	PLEURAL FLUID	Neg	-	-	Neg	NG	0.1	0.02	N	N	N	N	Y	PANCREATITIS	DISCHARGE	N	N	N	N	Y
2011	1541752	1228	PER CUTANEOUS DRAIN	Neg	-	-	Neg	NG	0.1	0.02	N	N	N	N	N	PANCREATITIS	DISCHARGE	N	N	N	N	Y

S. no	MRD No.	Lab No	NAME	DOR Sample	AGE	SEX	GMRepeat	DOA	AREA	SUB AREA WISE	Sample	DOR Sample	FEVER	COUGH	SOB	CHEST PAIN	DM	HTN	Alcoholic	Smoker	Neutropenia	TBHistory	Chronic steroid use	Solid organ transplantation	Malignancy	HIV	HCV	HB	TLC/DLC	NEUTROPHIL COUNT	CT CHEST _PLEURAL EFFUSION	CONSOLIDATION IN LUNG	CAVITATION	RETICULONODULAR OPACITIES	Histopathology for aspergillus species
2012	1537839	1229	LS	6/26/2023	34	M	N	6/17/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	6/26/2023	Y	Y	N	N	N	N	N	N	N	N	N	N	Y	N	Y	11.7	8.3	72.1	N	N	N	N	NR
2013	38270	1230	CK	6/26/2023	65	F	N	6/25/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	6/26/2023	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	11.2	8.4	77.1	N	N	N	Y	NR
2014	1540001	1231	KS	6/26/2023	57	M	N	6/22/2023	WARD	RENAL DISEASE	SERUM	6/26/2023	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	6.5	7.34	84	N	N	N	N	NR
2015	1355124	1232	SS	6/26/2023	66	M	N	6/24/2023	WARD	NEUROLOGICAL DISEASE	SERUM	6/26/2023	Y	Y	N	N	N	N	N	N	N	N	Y	N	N	N	N	9.9	9.2	81	N	Y	N	N	NR
2016	1542355	1233	JK	6/26/2023	27	F	N	6/26/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	6/26/2023	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	10	12	79	N	Y	N	N	NR
2017	1514155	1234	JS	6/27/2023	49	F	N	6/24/2023	WARD	RENAL DISEASE	SERUM	6/27/2023	N	Y	N	N	N	N	N	N	N	N	Y	Y	N	N	N	11.5	28.8	95	N	N	N	Y	NR
2019	1537759	1236	HS	6/27/2023	33	M	N	6/17/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	6/27/2023	Y	Y	N	N	Y	N	N	N	N	N	N	N	N	N	N	11.9	14	68.7	N	N	N	N	NR
2020	1535914	1237	AS	6/27/2023	68	F	N	6/14/2023	ICU	CARDIOVASCULAR DISEASE	SERUM	6/27/2023	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	8.2	11.7	77.3	N	Y	N	N	NR
2021	1542384	1238	JS	6/27/2023	21	M	N	6/26/2023	WARD	RENAL DISEASE	SERUM	6/27/2023	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	11.1	10.8	78.1	N	N	N	N	NR
2023	1543068	1240	KP	6/28/2023	67	M	N	6/27/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	6/28/2023	Y	Y	N	N	N	N	N	N	N	N	Y	N	N	N	N	10	14.57	83.2	N	N	N	N	NR
2024	1543070	1241	DS	6/28/2023	44	M	N	6/27/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	6/28/2023	Y	Y	N	N	Y	N	N	N	N	N	N	N	N	N	N	11.9	25.9	53	N	N	N	N	NR
2025	1540472	1242	D	6/28/2023	73	M	N	6/22/2023	WARD	RENAL DISEASE	SERUM	6/28/2023	Y	Y	N	Y	Y	Y	N	N	N	N	N	N	N	N	N	9	23.7	84.3	N	N	N	Y	NR
2026	1532448	1243	JS	6/28/2023	70	M	N	6/9/2023	ICU	CARDIOVASCULAR DISEASE	SERUM	6/28/2023	N	N	Y	N	Y	Y	N	N	N	N	N	N	N	N	N	8.8	14.9	68	N	N	N	N	NR
2027	520585	1244	MK	6/28/2023	69	F	N	6/20/2023	WARD	ONCOLOGICAL	SERUM	6/28/2023	Y	Y	N	N	N	N	N	N	N	N	N	N	Y	N	N	7.4	5.5	64.4	N	Y	N	N	NR
2028	1521456	1245	AG	6/28/2023	61	F	N	6/20/2023	WARD	NEUROLOGICAL DISEASE	SERUM	6/28/2023	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	12.5	19.56	91.6	N	N	N	N	NR
2029	254176	1246	HS	6/30/2023	49	M	N	6/25/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	6/30/2023	Y	Y	N	N	N	N	Y	N	N	N	N	N	N	Y	N	10	17	92	N	N	N	Y	NR
2030	1529325	1247	GS	6/30/2023	34	M	N	6/3/2023	WARD	GENERAL SURGERY	SERUM	6/30/2023	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	7.9	7.4	81.2	N	N	N	N	NR
2031	1370998	2205	VL	10/11/2023	53	F	N	10/8/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	10/11/2023	N	N	N	N	N	Y	N	N	N	N	N	N	N	N	N	8.6	5	72	N	N	N	N	NR
2032	1228626	2227	OP	10/16/2023	59	M	N	10/13/2023	ICU	GASTROINTESTINAL TRACT DISEASE	SERUM	10/16/2023	N	N	N	N	N	N	N	N	N	N	Y	N	N	N	N	9.6	5.7	49	N	N	N	Y	NR
2033	1607884	2226	S	10/15/2023	30	F	N	10/14/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	10/15/2023	Y	Y	Y	N	Y	N	N	N	N	N	Y	N	N	N	N	12.3	12	74	N	N	N	N	NR
2034	1607823	2225	JS	10/15/2023	40	M	N	10/19/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	10/15/2023	Y	Y	N	Y	N	N	N	N	N	N	Y	N	N	N	N	13.8	11	94	N	N	N	N	NR
2035	1604156	2206	SS	10/11/2023	57	M	N	10/9/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	10/11/2023	N	Y	N	Y	Y	Y	N	N	N	N	N	N	N	N	N	13	11	87	N	N	N	Y	NR
2036	1622084	2222	M	10/16/2023	18	M	N	10/5/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	10/16/2023	N	N	N	N	N	N	N	N	N	N	Y	N	N	N	N	15	3.69	87	N	N	N	N	NR
2037	1607762	2218	SS	10/14/2023	42	M	N	10/13/2023	WARD	ACUTE FEBRILE ILLNESS	SERUM	10/14/2023	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	10	12	79	N	N	N	N	NR
2038	1606440	2217	R	10/14/2023	29	M	N	10/11/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	10/14/2023	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	10	14	82	N	N	N	N	NR
2039	1475413	2216	RK	10/14/2023	58	M	N	10/12/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	10/14/2023	N	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	10	22	79	N	N	N	N	NR
2040	1604973	2215	RL	10/13/2023	79	M	N	10/13/2023	WARD	CARDIOVASCULAR DISEASE	SERUM	10/13/2023	Y	N	N	Y	Y	Y	N	N	N	N	N	N	N	N	N	13	47	87	N	N	N	N	NR
2041	1606017	2214	S	10/13/2023	42	M	N	10/12/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	10/13/2023	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	9.9	15	74.8	N	Y	N	N	NR
2042	1606889	2213	H	10/13/2023	18	M	N	10/12/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	10/13/2023	N	Y	N	N	N	N	N	N	N	N	Y	N	N	N	N	12	8	60.5	N	N	N	N	NR
2043	453161	2210	H	10/12/2023	75	F	N	10/11/2023	WARD	CARDIOVASCULAR DISEASE	SERUM	10/12/2023	Y	N	Y	Y	N	Y	N	N	N	N	N	N	N	N	N	9.4	16	75	N	N	N	Y	NR
2044	1026840	2209	MK	10/12/2023	52	F	N	10/8/2023	WARD	RENAL DISEASE	SERUM	10/12/2023	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	6.3	8	63	N	N	N	Y	NR
2045	1595651	2211	J	10/12/2023	70	M	N	9/24/2023	ICU	GASTROINTESTINAL TRACT DISEASE	SERUM	10/12/2023	Y	Y	N	N	Y	N	N	N	N	N	N	N	N	N	N	11.3	11	85	N	N	N	Y	NR
2046	1474504	2212	V	10/12/2023	62	M	N	10/16/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	10/12/2023	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	11	19	73	N	N	N	N	NR
2047	456106	2208	SK	10/11/2023	73	F	N	10/8/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	10/11/2023	Y	Y	N	N	N	Y	N	N	N	N	N	N	N	N	N	9.4	39	92	N	N	N	N	NR
2048	1606375	2207	KK	10/11/2023	63	M	N	10/11/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	10/11/2023	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	11	20	94	N	N	N	Y	NR
2049	1607800	2224	K	10/15/2023	42	M	N	10/13/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	10/15/2023	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	9.4	6.8	80	N	N	N	Y	NR
2050	1608480	2223	RC	10/15/2023	77	M	N	10/15/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	10/15/2023	Y	Y	N	N	N	N	Y	Y	N	N	Y	N	N	N	N	15.7	9	66	N	N	N	Y	NR
2051	1300438	2172	RK	10/21/2023	47	M	N	9/30/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	10/21/2023	N	N	N	N	N	N	Y	N	N	N	N	N	N	N	N	10	4.5	77	N	N	N	N	NR
2052	1592472	2154	S	10/1/2023	36	M	N	9/19/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	10/1/2023	N	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	11.3	7.5	83	N	Y	N	N	NR
2053	1594162	2155	NK	10/1/2023	76	F	N	9/21/2023	ICU	GASTROINTESTINAL TRACT DISEASE	SERUM	10/1/2023	N	N	N	N	N	Y	N	N	N	N	N	N	N	N	N	7.3	5.2	49	N	N	N	Y	NR
2054	1270017	2156	GS	10/1/2023	90	M	N	9/12/2023	ICU	CARDIOVASCULAR DISEASE	SERUM	10/1/2023	N	N	N	Y	N	Y	N	N	N	N	N	N	N	N	N	8.2	18	90	N	N	N	N	NR
2055	1597712	2157	MS	10/1/2023	59	M	N	9/27/2023	WARD	RENAL DISEASE	SERUM	10/1/2023	N	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	8.3	8.7	66	N	N	N	N	NR
2056	1593619	2158	PS	10/2/2023	45	F	N	9/21/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	10/2/2023	N	N	N	N	N	N	Y	N	N	N	N	N	N	N	N	13	16	85.5	N	N	N	Y	NR
2057	1594958	2159	KK	10/2/2023	69	M	N	9/23/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	10/2/2023	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	7.6	5.9	60	N	N	N	N	NR
2058	1305071	2160	RS	10/3/2023	51	M	N	9/27/2023	WARD	RENAL DISEASE	SERUM	10/3/2023	Y	Y	N	N	N	Y	N	N	N	N	N	N	N	N	N	9.7	4.6	66.6	N	N	N	N	NR
2059	1600261	2161	SB	10/3/2023	50	F	N	9/27/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	10/3/2023	Y	Y	N	N	Y	N	N	N	N	N	N	N	N	N	N	11	81.6	92.6	N	N	N	Y	NR
2060	1595813	2162	BS	10/3/2023	53	M	N	9/25/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	10/3/2023	N	N	N	N	N	N	Y	Y	N	N	Y	N	N	N	N	9.8	21	75	N	N	N	N	NR

S. no	MRD No.	Lab No	Distribution of clinical samples received	Fungal smear Positive for Hyaline Septate Fungal Hyphae	CANDIDA IN (BODY FLUIDS AND BLOOD CULTURE)	CANDIDA IN BODY FUILDS	FUNGAL CULTURE FOR ASPERGILLUS SPECIES	Fungal Cuture	GMSAASSAY	1-3 BDG	PTZ	ANTIFUNGAL	Heamo Dylasis	AUGMENTIN	MEROPENEM	Provisional diagnosis	Outcome	TOTAL EORTC PATIENTS	PROVEN	POSSIBLE	PROBABLE	NO INVASIVE ASPERGILLOSI
2012	1537839	1229	SPUTUM	Neg	-	-	Neg	NG	0.1	0.02	N	N	N	N	Y	CARCINOMA	DISCHARGE	N	N	N	N	Y
2013	38270	1230	NR	NR	-	-	NR	NR	0.1	-	N	N	N	N	N	CVA	DISCHARGE	N	N	N	N	Y
2014	1540001	1231	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.1	0.05	N	N	N	N	Y	LRTI, SEPSIS	DISCHARGE	N	N	N	N	Y
2015	1355124	1232	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.1	-	N	N	N	N	Y	LRTI	DAMA	Y	N	Y	N	N
2016	1542355	1233	NR	NR	-	-	NR	NR	0.22	0.03	N	N	N	N	Y	PANCREATITIS	DAMA	N	N	N	N	Y
2017	1514155	1234	NR	NR	-	-	NR	NR	0.99	0.16	N	N	N	N	N	POST RENAL TRANSPLANT	DAMA	Y	N	Y	Y	N
2019	1537759	1236	PER CUTANEOUS DRAIN	Neg	-	-	Neg	NG	0.1	0.02	N	N	N	N	Y	PANCREATITIS	DISCHARGE	N	N	N	N	Y
2020	1535914	1237	NR	NR	-	-	NR	NR	0.1	0.03	N	N	N	N	Y	UTI	DISCHARGE	N	N	N	N	Y
2021	1542384	1238	PUS	Neg	-	-	Neg	NG	0.1	0.06	N	Y	N	N	N	AKI, HEP.A +VE	DISCHARGE	N	N	N	N	Y
2023	1543068	1240	SPUTUM	Neg	-	-	Neg	CANDIDA	0.52	0.02	N	N	N	N	N	ARTHRITIS	DISCHARGE	Y	N	Y	N	N
2024	1543070	1241	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.22	0.02	N	N	N	N	Y	LRTI	DISCHARGE	N	N	N	N	Y
2025	1540472	1242	SPUTUM	Neg	-	-	Neg	CANDIDA	0.1	-	N	Y	Y	N	Y	LRTI, CKD	DISCHARGE	N	N	N	N	Y
2026	1532448	1243	PER CUTANEOUS DRAIN	Neg	-	-	Neg	NG	0.1	0.02	N	N	N	N	N	CVA, SEPSIS, AKI	DISCHARGE	N	N	N	N	Y
2027	520585	1244	SPUTUM	Neg	-	-	Neg	NG	0.1	0.02	N	N	N	N	N	KOCHS, AKI	DISCHARGE	Y	N	Y	N	N
2028	1521456	1245	NR	NR	-	-	NR	NR	0.1	8.47	N	N	N	N	Y	DEMYELINATING DISEASE	DISCHARGE	N	N	N	N	Y
2029	254176	1246	SPUTUM	Neg	-	-	Neg	CANDIDA	11.82	0.05	N	N	N	N	N	INFECTIVE ENDOCARDITIS	DISCHARGE	Y	N	Y	Y	N
2030	1529325	1247	TISSUE	Neg	-	-	Neg	NG	0.11	-	N	N	N	N	Y	BURN	DISCHARGE	N	N	N	N	Y
2031	1370998	2205	NR	NR	-	-	NR	NR	0.1	0.02	N	N	N	N	Y	LIVER DISEASE	DISCHARGE	N	N	N	N	Y
2032	1228626	2227	ASCITIC FLUID	Neg	-	-	Neg	NG	1.25	-	N	Y	N	N	Y	CIRRHOSIS, PORTAL HTN	DAMA	Y	N	Y	Y	N
2033	1607884	2226	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.1	0.04	N	N	N	N	Y	ARDS, LRTI	DISCHARGE ON REQUEST	N	N	N	N	Y
2034	1607823	2225	SPUTUM	Neg	-	-	Neg	NG	0.1	10.62	N	Y	N	N	N	ASTHMA	DISCHARGE ON REQUEST	N	N	N	N	Y
2035	1604156	2206	SPUTUM	Neg	-	-	Neg	NG	0.1	-	N	N	N	N	N	LRTI	DISCHARGE	N	N	N	N	Y
2036	1622084	2222	NR	NR	-	-	NR	NR	0.1	0.02	N	Y	N	N	Y	PANCREATITIS	DISCHARGE	N	N	N	N	Y
2037	1607762	2218	NR	NR	-	-	NR	NR	0.21	0.02	N	N	N	N	Y	ACUTE FIBRILE ILLNESS	DISCHARGE	N	N	N	N	Y
2038	1606440	2217	NR	NR	-	-	NR	NR	0.27	0.02	N	N	N	N	Y	PANCREATITIS	DISCHARGE	N	N	N	N	Y
2039	1475413	2216	NR	NR	-	-	NR	NR	0.1	0.02	N	N	N	N	Y	CHOLITITHIASIS	DISCHARGE	N	N	N	N	Y
2040	1604973	2215	NR	NR	-	-	NR	NR	0.11	0.02	N	Y	N	N	Y	LRTI, AFI	DISCHARGE	N	N	N	N	Y
2041	1606017	2214	SPUTUM	Neg	-	-	Neg	NG	0.21	-	N	Y	N	N	N	CHOLITITHIASIS, SMOKER	DISCHARGE ON REQUEST	N	N	N	N	Y
2042	1606889	2213	SPUTUM	Neg	-	-	Neg	NG	0.1	-	N	Y	N	N	N	LRTI	DISCHARGE	N	N	N	N	Y
2043	453161	2210	NR	NR	-	-	NR	NR	0.1	0.02	N	N	N	N	Y	LRTI	DISCHARGE	N	N	N	N	Y
2044	1026840	2209	NR	NR	-	-	NR	NR	0.2	0.1	N	N	N	N	Y	CKD	DISCHARGE	N	N	N	N	Y
2045	1595651	2211	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	8.63	0.1	N	Y	N	N	Y	LRTI	DISCHARGE	N	N	N	N	Y
2046	1474504	2212	SPUTUM	Neg	-	-	Neg	NG	0.1	-	N	N	N	N	Y	ACUTE FIBRILE ILLNESS	DISCHARGE	N	N	N	N	Y
2047	456106	2208	SPUTUM	Neg	-	-	Neg	NG	0.34	-	N	N	N	N	Y	PNEUMONIA	DISCHARGE	N	N	N	N	Y
2048	1606375	2207	PLEURAL FLUID	Neg	-	-	Neg	NG	1.28	-	N	N	N	N	Y	LRTI	DISCHARGE	N	N	N	N	Y
2049	1607800	2224	NR	NR	-	-	NR	NR	0.13	0.26	N	Y	N	N	Y	ACUTE FIBRILE ILLNESS, LRTI, UTI	DISCHARGE ON REQUEST	N	N	N	N	Y
2050	1608480	2223	NR	NR	-	-	NR	NR	0.13	-	N	N	N	N	Y	COPD, UTI, KOCHS	DAMA	Y	N	Y	N	N
2051	1300438	2172	NR	NR	-	-	NR	NR	0.1	0.02	N	N	N	N	Y	CIRRHOSIS, PORTAL HTN	DISCHARGE	N	N	N	N	Y
2052	1592472	2154	PER CUTANEOUS DRAIN	Neg	-	-	Neg	NG	0.19	0.02	N	N	N	N	Y	NECROTISING	DISCHARGE	N	N	N	N	Y
2053	1594162	2155	NR	NR	-	-	NR	NR	0.1	-	N	N	N	N	Y	LIVER DISEASE	DISCHARGE	N	N	N	N	Y
2054	1270017	2156	SPUTUM	Neg	-	-	Neg	NG	0.1	0.02	N	N	N	N	N	DVT LEG	DISCHARGE	N	N	N	N	Y
2055	1597712	2157	NR	NR	-	-	NR	NR	0.1	0.02	N	N	Y	N	Y	AKI	DISCHARGE	N	N	N	N	Y
2056	1593619	2158	NR	NR	Y	-	NR	NR	0.1	0.02	N	N	N	N	Y	NECROTISING	DISCHARGE	N	N	N	N	Y
2057	1594958	2159	SPUTUM	Neg	-	-	Neg	NG	2.86	0.22	N	N	N	N	N	LRTI	DISCHARGE	N	N	N	N	Y
2058	1305071	2160	SPUTUM	Neg	-	-	Neg	NG	0.1	0.02	N	N	N	N	Y	CKD	DISCHARGE	N	N	N	N	Y
2059	1600261	2161	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.1	0.02	N	N	N	N	Y	PNEUMONIA	DISCHARGE	N	N	N	N	Y
2060	1595813	2162	NR	NR	-	-	NR	NR	0.71	0.02	N	Y	N	N	N	PERIPANCREATIC COLLECTION	DISCHARGE	Y	N	Y	N	N

S. no	MRD No.	Lab No	NAME	DOR Sample	AGE	SEX	GMRepeat	DOA	AREA	SUB AREA WISE	Sample	DOR Sample	FEVER	COUGH	SOB	CHEST PAIN	DM	HTN	Alcoholic	Smoker	Neutropenia	TBHistory	Chronic steroid use	Solid organ transplantation	Malignancy	HIV	HCV	HB	TLC/DLC	NEUTROPHIL COUNT	CT CHEST _PLEURAL EFFUSION	CONSOLIDATION IN LUNG	CAVITATION	RETICULONODULAR OPACITIES	Histopathology for aspergillus species
2061	1596373	2163	KK	10/3/2023	70	M	N	9/25/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	10/3/2023	Y	Y	N	N	Y	N	N	N	N	N	N	N	N	N	N	14	26	77	N	N	N	N	NR
2062	1600070	2164	SM	10/3/2023	49	F	N	10/2/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	10/3/2023	Y	Y	N	N	Y	Y	N	N	N	Y	N	N	N	N	N	8.6	8.9	69	N	N	N	Y	NR
2063	1596394	2165	MK	10/3/2023	50	F	N	9/25/2023	WARD	CARDIOVASCULAR DISEASE	SERUM	10/3/2023	Y	N	N	Y	Y	Y	N	N	N	N	N	N	N	N	N	9.4	18	91	N	N	N	N	NR
2064	1599612	2166	GS	10/3/2023	31	M	N	9/30/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	10/3/2023	N	N	N	N	N	N	Y	N	N	N	N	N	N	N	N	10.7	6	59	N	N	N	N	NR
2065	1592972	2167	NK	10/3/2023	59	F	N	9/19/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	10/3/2023	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	13.7	13	90	N	N	N	N	NR
2066	1596506	2168	AC	10/4/2023	38	M	N	9/29/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	10/4/2023	Y	Y	N	N	N	N	N	N	N	Y	N	N	N	N	N	14	9.1	70	N	N	N	Y	NR
2067	1549076	2170	R	10/4/2023	50	M	N	10/3/2023	WARD	RENAL DISEASE	SERUM	10/4/2023	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	9.2	4	60	N	N	N	N	NR
2068	1600176	2171	SD	10/4/2023	55	F	P	10/2/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	10/4/2023	Y	Y	N	N	Y	Y	N	N	N	N	Y	N	N	N	N	10.7	7	82	N	N	N	N	NR
2069	1601832	2173	KK	10/4/2023	65	M	N	10/4/2023	WARD	ACUTE FEBRILE ILLNESS	SERUM	10/4/2023	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	8.9	15	92	N	N	N	Y	NR
2070	1236124	2174	SS	10/5/2023	27	M	N	10/3/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	10/5/2023	N	N	N	N	N	N	N	N	Y	N	Y	N	N	N	N	6.6	6.8	40	N	N	N	N	NR
2071	1596363	2175	TC	10/5/2023	65	M	N	9/25/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	10/5/2023	N	N	N	N	Y	Y	N	N	N	N	Y	N	N	N	N	14	5.4	86	Y	N	N	N	NR
2072	1586297	2176	K	10/5/2023	32	F	N	10/3/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	10/5/2023	N	Y	N	N	N	N	N	N	N	Y	N	N	N	N	N	8.2	2.9	90	N	N	N	N	NR
2073	1583771	2177	AS	10/5/2023	38	M	N	9/28/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	10/5/2023	N	N	N	N	N	N	Y	N	N	N	N	N	N	N	N	11	12	74	N	N	N	N	NR
2074	1000324	2178	NJ	10/5/2023	36	F	N	9/29/2023	WARD	RENAL DISEASE	SERUM	10/5/2023	Y	Y	N	N	N	Y	N	N	N	N	Y	N	N	N	N	9	6.7	82	N	N	N	N	NR
2075	44771	2179	TS	10/6/2023	72	M	N	9/26/2023	WARD	CARDIOVASCULAR DISEASE	SERUM	10/6/2023	N	N	N	Y	N	N	N	N	N	N	N	N	N	N	N	10	6.7	81	Y	N	N	N	NR
2076	1559637	2180	PG	10/6/2023	42	M	N	9/27/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	10/6/2023	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	13	10	60	N	N	N	N	NR
2077	1593541	2181	AS	10/7/2023	73	M	N	9/20/2023	WARD	CARDIOVASCULAR DISEASE	SERUM	10/7/2023	N	N	N	Y	N	N	N	N	N	N	N	N	N	N	N	6.6	21	85	N	N	N	N	NR
2078	1597631	2182	MS	10/6/2023	46	M	N	9/20/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	10/6/2023	N	N	N	Y	N	N	N	N	N	N	N	N	N	N	N	10.3	10	81	Y	N	N	N	NR
2079	1188690	2183	RK	10/6/2023	59	M	N	10/5/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	10/6/2023	Y	Y	N	N	N	N	N	N	N	Y	Y	N	N	N	N	13	1.6	83	Y	N	N	N	NR
2080	1516465	2184	SK	10/6/2023	55	M	N	9/30/2023	WARD	NEUROLOGICAL DISEASE	SERUM	10/6/2023	N	N	N	N	Y	Y	N	N	N	N	Y	N	N	N	N	10	11	72	N	N	N	N	NR
2081	1590894	2185	AP	10/7/2023	55	F	N	9/26/2023	WARD	CARDIOVASCULAR DISEASE	SERUM	10/7/2023	N	Y	Y	Y	Y	Y	N	N	N	N	N	N	N	N	N	12	4.3	89	N	Y	N	N	NR
2082	736673	2186	KL	10/7/2023	63	M	N	9/26/2023	WARD	ONCOLOGICAL	SERUM	10/7/2023	N	N	N	N	Y	N	N	N	N	N	N	Y	N	N	5.8	4.9	88	N	N	N	N	NR
2083	1601119	2187	RD	10/7/2023	57	F	N	10/4/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	10/7/2023	Y	Y	N	N	Y	N	N	N	N	N	Y	N	N	N	N	10	9	87	N	N	N	N	NR
2084	1597800	2188	K	10/7/2023	22	M	N	9/27/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	10/7/2023	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	N	11	18	78	N	Y	N	Y	NR
2085	512921	2189	GK	10/7/2023	79	F	N	10/6/2023	WARD	CARDIOVASCULAR DISEASE	SERUM	10/7/2023	N	Y	N	Y	Y	Y	N	N	N	N	N	N	N	N	N	10	10	82	N	N	N	N	NR
2087	1603854	2191	BK	10/7/2023	50	F	N	10/7/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	10/7/2023	Y	N	Y	N	N	N	N	N	N	N	N	N	N	N	N	12	12	84	N	N	N	N	NR
2088	1603984	2192	GK	10/7/2023	30	F	N	10/7/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	10/7/2023	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	N	10	20	79	N	Y	N	N	NR
2089	1465715	2193	R	10/8/2023	65	M	N	9/26/2023	ICU	GASTROINTESTINAL TRACT DISEASE	SERUM	10/8/2023	N	N	N	N	Y	Y	N	N	N	N	N	N	N	N	N	10	20	79	N	N	N	N	NR
2090	1468392	2194	V	10/8/2023	65	M	N	10/1/2023	WARD	CARDIOVASCULAR DISEASE	SERUM	10/8/2023	N	Y	Y	Y	Y	Y	N	N	N	N	N	N	N	N	N	13.7	8.8	76	N	Y	N	N	NR
2091	1572884	2195	S	10/9/2023	55	M	N	9/27/2023	WARD	ONCOLOGICAL	SERUM	10/9/2023	N	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	7.4	9.9	75	Y	N	N	N	NR
2092	134599	2196	AR	10/9/2023	65	F	N	10/7/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	10/9/2023	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	12	6.2	57	N	N	N	N	NR
2093	1603921	2197	S	10/10/2023	67	F	N	10/7/2023	ICU	CARDIOVASCULAR DISEASE	SERUM	10/10/2023	N	N	Y	Y	N	Y	N	N	N	N	Y	N	N	N	N	8.2	27	91	N	N	N	N	NR
2094	483865	2198	HR	10/10/2023	65	M	N	10/6/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	10/10/2023	N	Y	N	Y	Y	Y	N	N	N	N	N	N	N	N	N	10	13	79	N	N	N	N	NR
2095	696374	2199	SK	10/11/2023	79	M	N	10/5/2023	WARD	CARDIOVASCULAR DISEASE	SERUM	10/11/2023	N	N	Y	Y	Y	Y	N	N	N	N	Y	N	N	N	N	10	12	79	Y	N	N	N	NR
2096	1602884	2200	PS	10/10/2023	55	M	N	10/6/2023	WARD	CARDIOVASCULAR DISEASE	SERUM	10/10/2023	Y	Y	N	Y	Y	Y	N	N	N	N	N	N	N	N	N	10	9.8	74	N	N	Y	N	NR
2098	1605034	2202	PG	10/11/2023	63	M	N	10/9/2023	ICU	GASTROINTESTINAL TRACT DISEASE	SERUM	10/11/2023	N	N	N	N	N	Y	Y	N	N	N	N	N	N	N	N	14	5.9	78	N	N	N	N	NR
2099	1600159	2203	DS	10/11/2023	30	M	N	10/2/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	10/11/2023	Y	Y	N	N	N	N	N	N	Y	N	Y	N	N	N	N	12	10	35	N	N	N	N	NR
2100	1604096	2204	AA	10/11/2023	82	M	N	10/8/2023	WARD	RENAL DISEASE	SERUM	10/11/2023	Y	N	N	N	Y	Y	N	N	N	N	N	N	N	N	N	10.4	10	91.6	N	N	N	Y	NR
2101	1573119	2220	NS	10/14/2023	50	F	N	10/4/2023	ICU	GENERAL SURGERY	SERUM	10/14/2023	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	10	14	93	Y	N	N	N	NR
2102	1599941	2221	AK	10/14/2023	68	M	N	10/1/2023	WARD	CARDIOVASCULAR DISEASE	SERUM	10/14/2023	N	N	Y	Y	Y	Y	N	N	N	N	N	N	N	N	N	10	10	89	Y	N	N	N	NR
2103	1608607	2228	SK	10/17/2023	72	F	N	10/15/2023	WARD	CARDIOVASCULAR DISEASE	SERUM	10/17/2023	N	Y	N	Y	N	Y	N	N	N	N	Y	N	N	N	N	10	10	84	N	N	N	N	NR
2104	1603380	2229	AS	10/16/2023	31	F	N	10/7/2023	ICU	GENERAL SURGERY	SERUM	10/16/2023	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	9	4.5	75.5	N	N	N	N	NR
2105	104545	2230	SK	10/17/2023	63	F	N	10/13/2023	WARD	CARDIOVASCULAR DISEASE	SERUM	10/17/2023	N	Y	N	Y	Y	Y	N	N	N	N	N	N	N	N	N	10	16	72.5	Y	N	N	N	NR
2106	1608322	2231	K	10/17/2023	32	F	N	10/14/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	10/17/2023	Y	Y	N	Y	N	N	N	N	N	N	N	N	N	N	Y	10	5.2	88	Y	Y	Y	N	NR
2107	1601058	2232	SK	10/17/2023	65	M	N	10/8/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	10/17/2023	Y	N	N	N	Y	Y	N	N	N	N	N	N	N	N	N	15.3	2..3	68.1	N	N	N	N	NR
2108	1609847	2233	KD	10/18/2023	60	F	N	10/18/2023	WARD	GENERAL SURGERY	SERUM	10/18/2023	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	12.6	2	83	N	N	N	N	NR
2109	605713	2235	JS	10/18/2023	68	M	N	10/11/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	10/18/2023	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	12	20	72	N	N	N	Y	NR

S. no	MRD No.	Lab No	Distribution of clinical samples received	Fungal smear Positive for Hyaline Septate Fungal Hyphae	CANDIDA IN (BODY FLUIDS AND BLOOD CULTURE)	CANDIDA IN BODY FUILDS	FUNGAL CULTURE FOR ASPERGILLUS SPECIES	Fungal Cuture	GMSAASSAY	1-3 BDG	PTZ	ANTIFUNGAL	Heamo Dylasis	AUGMENTIN	MEROPENEM	Provisional diagnosis	Outcome	TOTAL EORTC PATIENTS	PROVEN	POSSIBLE	PROBABLE	NO INVASIVE ASPERGILLOSI
2061	1596373	2163	SPUTUM	Neg	-	-	Neg	NG	0.1	0.02	N	N	N	N	N	CVA	DISCHARGE	N	N	N	N	Y
2062	1600070	2164	SPUTUM	Neg	-	-	Neg	NG	0.1	-	N	N	N	N	N	KOCHS	DISCHARGE	N	N	N	N	Y
2063	1596394	2165	PERICARDIAL FLUID	Neg	-	-	Neg	NG	0.02	0.1	N	N	N	N	Y	LRTI, SEPSIS, RHD	DAMA	N	N	N	N	Y
2064	1599612	2166	NR	NR	-	-	NR	NR	0.15	-	N	N	N	N	Y	CIRRHOSIS, PORTAL HTN	DISCHARGE	N	N	N	N	Y
2065	1592972	2167	NR	NR	-	-	NR	NR	0.1	-	N	N	N	N	Y	NECROTISING	DISCHARGE	N	N	N	N	Y
2066	1596506	2168	SPUTUM	Neg	-	-	Neg	CANDIDA	0.1	-	N	N	N	N	N	KOCHS	DISCHARGE	N	N	N	N	Y
2067	1549076	2170	NR	NR	-	-	NR	NR	0.1	0.02	N	N	Y	N	N	KOCHS	DISCHARGE	N	N	N	N	Y
2068	1600176	2171	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	3.36	0.1	N	Y	N	N	N	COPD	DISCHARGE	N	N	N	N	Y
2069	1601832	2173	NASAL MUCOSA	Neg	-	-	Neg	NG	0.1	-	N	N	N	N	N	FIBRILE ILLNESS	DISCHARGE	N	N	N	N	Y
2070	1236124	2174	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	10.24	8.02	N	Y	N	N	Y	LIVER DISEASE	DISCHARGE	Y	N	Y	N	N
2071	1596363	2175	NR	NR	-	-	NR	NR	0.1	0.02	N	N	N	N	N	NECROTISING, PANCREATITIS	DISCHARGE	Y	N	Y	N	N
2072	1586297	2176	NR	NR	-	-	NR	NR	0.1	0.02	N	N	N	N	Y	ACUTE CVA	DISCHARGE	N	N	N	N	Y
2073	1583771	2177	SPUTUM	Neg	-	-	Neg	NG	0.1	-	N	N	N	N	Y	CLD WITH PORTAL HTN	DISCHARGE	N	N	N	N	Y
2074	1000324	2178	NR	NR	-	-	NR	NR	0.1	0.02	N	N	N	N	Y	CKD, UTI, AKI, SEPSIS	DISCHARGE	N	N	N	N	Y
2075	44771	2179	SPUTUM	Neg	-	-	Neg	NG	0.1	0.03	N	N	N	N	N	CKD, POST CABG	DISCHARGE	N	N	N	N	Y
2076	1559637	2180	NR	NR	-	-	NR	NR	0.1	0.02	N	N	N	N	Y	CHOLITITHIASIS	DISCHARGE	N	N	N	N	Y
2077	1593541	2181	NR	NR	-	-	NR	NR	0.1	-	N	Y	N	N	Y	HYDRONEPHROSIS	DISCHARGE	N	N	N	N	Y
2078	1597631	2182	ASCITIC FLUID	Neg	-	-	Neg	NG	0.1	-	N	N	N	N	N	HYDRONEPHROSIS	DISCHARGE	N	N	N	N	Y
2079	1188690	2183	SPUTUM	Neg	-	-	Neg	NG	0.87	-	N	Y	N	N	N	COPD	DISCHARGE	Y	N	Y	Y	N
2080	1516465	2184	SPUTUM	Neg	-	-	Neg	NG	0.81	0.67	N	N	N	N	N	LUMBER SPONDYLOSIS	DISCHARGE	Y	N	Y	N	N
2081	1590894	2185	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.21	0.02	N	N	N	N	N	CAD	DISCHARGE	N	N	N	N	Y
2082	736673	2186	NR	NR	-	-	NR	NR	0.17	-	N	N	N	N	N	PRIMARY T. CELL LYMPHOMA	DISCHARGE	N	N	N	N	Y
2083	1601119	2187	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	1.45	-	N	Y	N	N	N	ARDS, SEPSIS	DAMA	Y	N	Y	N	N
2084	1597800	2188	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.1	0.02	N	N	N	N	N	VIRAL HEPATITIS, AKI	DISCHARGE	N	N	N	N	Y
2085	512921	2189	NR	NR	-	-	NR	NR	0.1	0.02	N	Y	N	N	Y	CKD, UTI	DISCHARGE	N	N	N	N	Y
2087	1603854	2191	SPUTUM	Neg	-	-	Neg	NG	0.1	-	N	N	N	N	Y	LRTI, AKI	DISCHARGE	N	N	N	N	Y
2088	1603984	2192	SPUTUM	P	-	-	P	ASPERGILLUS FLAVUS	1.57	-	N	Y	N	N	Y	LRTI, UTI, SEPSIS	DISCHARGE	N	N	N	N	Y
2089	1465715	2193	NR	NR	-	-	NR	NR	0.1	0.02	N	N	N	N	Y	NECROTISING, PANCREATITIS	DISCHARGE	N	N	N	N	Y
2090	1468392	2194	NR	NR	-	-	NR	NR	0.02	0.12	N	N	N	N	N	COPD, CAD	DISCHARGE	N	N	N	N	Y
2091	1572884	2195	ASCITIC FLUID	Neg	-	-	Neg	NG	0.1	0.04	N	Y	N	N	Y	SEPSIS, AKI	DAMA	N	N	N	N	Y
2092	134599	2196	BAL	Neg	-	-	Neg	NG	0.68	-	N	Y	N	N	N	HTN	DAMA	N	N	N	N	Y
2093	1603921	2197	NR	NR	-	-	NR	NR	0.84	0.02	Y	N	N	N	Y	UTI, SEPSIS	DISCHARGE	Y	N	Y	N	N
2094	483865	2198	NR	NR	-	-	NR	NR	0.1	0.02	N	N	N	N	Y	ABPA	DISCHARGE	N	N	N	N	Y
2095	696374	2199	SPUTUM	Neg	-	-	Neg	NG	0.15	0.05	N	Y	N	N	Y	COPD, LRTI	DISCHARGE	Y	N	Y	N	N
2096	1602884	2200	SPUTUM	Neg	-	-	Neg	CANDIDA	0.1	-	Y	N	N	N	N	DENGUE	DISCHARGE	N	N	N	N	Y
2098	1605034	2202	NR	NR	-	-	NR	NR	0.1	0.02	N	N	N	N	Y	ACUTE PANCREATITIS	DISCHARGE	N	N	N	N	Y
2099	1600159	2203	NR	NR	-	-	NR	NR	0.12	-	N	N	N	N	Y	AKI, ARDS, SEPSIS	DAMA	N	N	N	N	Y
2100	1604096	2204	SPUTUM	Neg	-	-	Neg	CANDIDA	0.1	0.09	N	Y	Y	N	N	CKD, LRTI	DISCHARGE	N	N	N	N	Y
2101	1573119	2220	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.61	0.04	N	Y	N	N	Y	HEPATIC HEMANGIOMA	DISCHARGE	N	N	N	N	Y
2102	1599941	2221	PLEURAL FLUID	Neg	-	-	Neg	NG	0.93	0.02	N	N	N	N	N	CABG, TVD	DISCHARGE	N	N	N	N	Y
2103	1608607	2228	NR	NR	-	-	NR	NR	0.02	0.1	N	Y	N	N	N	OSA	DISCHARGE	Y	N	Y	N	N
2104	1603380	2229	NR	NR	-	-	NR	NR	0.45	0.03	N	N	N	N	N	CA OVARY, METASTASIS	DISCHARGE	N	N	N	N	Y
2105	104545	2230	PLEURAL FLUID	Neg	-	-	Neg	NG	0.1	0.02	N	N	N	N	N	CKD, CABG	DISCHARGE	N	N	N	N	Y
2106	1608322	2231	NR	NR	-	-	NR	NR	0.1	0.02	N	N	N	N	Y	ACUTE FIBRILE ILLNESS, LRTI, HCV+VE	DISCHARGE ON REQUEST	N	N	N	N	Y
2107	1601058	2232	NR	NR	-	-	NR	NR	0.1	0.02	N	N	N	N	N	CAD, DENGUE FEVER	DISCHARGE ON REQUEST	N	N	N	N	Y
2108	1609847	2233	TISSUE	Neg	-	-	Neg	NG	0.1	0.02	N	Y	N	N	Y	PERIANAL ABSCESS	DISCHARGE	N	N	N	N	Y
2109	605713	2235	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.1	0.6	N	N	N	N	Y	CKD	DISCHARGE	N	N	N	N	Y

S. no	MRD No.	Lab No	NAME	DOR Sample	AGE	SEX	GMRepeat	DOA	AREA	SUB AREA WISE	Sample	DOR Sample	FEVER	COUGH	SOB	CHEST PAIN	DM	HTN	Alcoholic	Smoker	Neutropenia	TBHistory	Chronic steroid use	Solid organ transplantation	Malignancy	HIV	HCV	HB	TLC/DLC	NEUTROPHIL COUNT	CT CHEST _PLEURAL EFFUSION	CONSOLIDATION IN LUNG	CAVITATION	RETICULONODULAR OPACITIES	Histopathology for aspergillus species
2110	1592562	2236	WR	10/18/2023	80	M	N	9/19/2023	ICU	GENERAL SURGERY	SERUM	10/18/2023	Y	Y	N	N	Y	Y	N	N	N	N	Y	N	N	N	N	10.6	7.9	66	Y	N	N	N	NR
2111	1609200	2237	M	10/18/2023	23	F	N	10/16/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	10/18/2023	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	13	12	90	N	N	N	N	NR
2112	1596894	2238	A	9/29/2023	55	F	N	9/26/2023	WARD	CARDIOVASCULAR DISEASE	SERUM	9/29/2023	Y	N	N	Y	N	N	Y	N	N	N	N	N	N	N	N	10	4.5	89	N	Y	N	Y	NR
2113	1472912	2239	KS	10/19/2023	55	M	N	10/7/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	10/19/2023	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	9	33	93	N	Y	N	Y	NR
2115	1605675	2241	P	10/19/2023	55	F	N	10/12/2023	WARD	GENERAL SURGERY	SERUM	10/19/2023	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	10.8	6.8	81.2	N	N	N	N	NR
2116	1565962	2242	AM	10/19/2023	65	M	N	8/6/2023	WARD	NEUROLOGICAL DISEASE	SERUM	10/19/2023	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	10	12	89	N	N	N	N	NR
2117	1609223	2243	HK	10/19/2023	37	M	N	10/16/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	10/19/2023	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	8.9	42	78	N	N	N	N	NR
2118	1576225	2244	B	10/19/2023	52	M	N	10/19/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	10/19/2023	Y	Y	N	N	N	N	N	N	N	Y	Y	N	N	N	N	10.5	8.1	63.9	N	Y	N	N	NR
2119	1608400	2245	KS	10/20/2023	70	M	N	10/14/2023	WARD	RENAL DISEASE	SERUM	10/20/2023	N	Y	Y	N	N	Y	Y	Y	N	N	N	N	N	N	N	11	41	90	N	N	N	Y	NR
2120	1608430	2246	S	10/20/2023	63	F	N	10/14/2023	WARD	NEUROLOGICAL DISEASE	SERUM	10/20/2023	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	8.8	21	74	N	N	N	Y	NR
2121	1610732	2247	MJ	10/21/2023	63	F	N	10/19/2023	WARD	GENERAL SURGERY	SERUM	10/21/2023	N	N	N	N	Y	Y	N	N	N	N	N	N	N	N	N	10	44	89	N	N	N	N	NR
2123	1611520	2249	KK	10/21/2023	80	F	N	10/21/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	10/21/2023	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	10	12	94	N	Y	N	N	NR
2124	678071	2250	G	10/21/2023	30	F	N	10/19/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	10/21/2023	N	Y	N	N	N	Y	N	N	N	N	Y	Y	N	N	N	10	14.2	85	N	Y	Y	N	NR
2125	1609766	2251	PC	10/21/2023	83	M	N	10/17/2023	ICU	CARDIOVASCULAR DISEASE	SERUM	10/21/2023	N	N	Y	Y	Y	Y	N	N	N	N	N	N	N	N	N	12	16	92	N	Y	N	N	NR
2126	1541629	2252	R	10/22/2023	67	M	N	10/6/2023	WARD	ONCOLOGICAL	SERUM	10/22/2023	Y	Y	N	Y	Y	Y	N	N	N	N	N	Y	N	N	8.5	8.8	71	N	N	Y	N	NR
2127	1609801	2253	AK	10/22/2023	27	F	N	10/17/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	10/22/2023	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	10	7.4	60	N	N	N	N	NR
2128	1519243	2254	OP	10/22/2023	65	M	N	10/9/2023	WARD	RENAL DISEASE	SERUM	10/22/2023	Y	N	Y	N	Y	Y	N	N	N	N	N	N	N	N	N	10.7	16	90	N	N	N	N	NR
2129	1004911	2255	SK	10/23/2023	62	M	N	10/14/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	10/23/2023	Y	N	N	N	N	N	N	N	Y	N	N	N	N	N	N	7.4	8	12	N	N	N	N	NR
2130	1609264	2257	NS	10/23/2023	45	M	N	10/16/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	10/23/2023	Y	Y	N	N	Y	N	N	N	N	N	N	N	N	N	N	10	21	68	N	Y	N	N	NR
2131	1608624	2258	VK	10/23/2023	63	M	N	10/16/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	10/23/2023	N	Y	Y	N	Y	N	N	N	N	N	N	N	N	N	N	9.8	18	93	Y	N	N	N	NR
2132	1611927	2259	KK	10/23/2023	60	F	N	10/21/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	10/23/2023	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	13	24	91	N	N	N	N	NR
2133	1608608	2260	V	10/24/2023	35	M	N	10/15/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	10/24/2023	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	10	10	75	N	N	N	N	NR
2134	1111756	2261	JS	10/25/2023	53	M	N	10/23/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	10/25/2023	N	Y	Y	N	Y	N	N	N	N	N	N	N	N	N	N	13	3.6	70	N	Y	N	N	NR
2135	1613694	2262	R	10/25/2023	56	M	N	10/25/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	10/25/2023	Y	Y	N	N	Y	N	N	N	N	N	N	N	N	N	N	10	22	95	N	N	N	N	NR
2136	1613056	2264	AK	10/26/2023	32	F	N	10/20/2023	WARD	CARDIOVASCULAR DISEASE	SERUM	10/26/2023	N	N	Y	Y	N	N	N	N	N	N	N	N	N	N	N	10	12	85	Y	N	N	N	NR
2137	1612023	2265	BK	10/26/2023	70	F	N	10/22/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	10/26/2023	N	N	Y	N	Y	Y	N	N	N	N	Y	N	N	N	N	14	19	96	N	N	N	Y	NR
2139	1613664	2268	GS	10/27/2023	80	M	N	10/25/2023	WARD	CARDIOVASCULAR DISEASE	SERUM	10/27/2023	N	Y	N	Y	Y	Y	N	N	N	N	N	N	N	N	N	11	14	95	N	N	N	N	NR
2140	1608528	2269	SK	10/27/2023	60	M	N	10/15/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	10/27/2023	Y	Y	N	Y	Y	N	N	N	N	N	Y	N	N	N	N	10	9	94	N	Y	N	N	NR
2141	1605743	2270	OP	10/27/2023	77	M	N	10/10/2023	WARD	RENAL DISEASE	SERUM	10/27/2023	N	N	N	N	Y	Y	N	N	N	N	N	N	Y	N	N	8.2	18	83	N	N	N	N	NR
2142	1614960	2272	KK	10/28/2023	33	F	N	10/28/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	10/28/2023	Y	N	Y	N	N	N	N	N	N	N	N	N	N	N	N	10.7	12	75	Y	N	N	N	NR
2143	1614891	2273	M	10/28/2023	40	M	N	10/27/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	10/28/2023	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	13	12	97	N	N	N	N	NR
2144	1615002	2274	A	10/28/2023	23	M	N	10/28/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	10/28/2023	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	14	16	70	N	Y	N	N	NR
2145	1610859	2275	DS	10/29/2023	20	M	N	10/19/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	10/29/2023	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	10	6	62	N	N	N	N	NR
2146	1567956	2275	KS	10/28/2023	70	M	N	10/23/2023	WARD	RENAL DISEASE	SERUM	10/28/2023	Y	Y	N	N	N	Y	N	N	N	N	N	N	N	N	N	12	7.5	64	N	N	N	Y	NR
2147	316092	2276	S	10/29/2023	77	M	N	10/30/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	10/29/2023	Y	Y	N	N	Y	Y	N	N	N	N	Y	N	N	N	N	10	11	91	N	N	N	Y	NR
2148	1604103	2277	H	10/29/2023	60	M	N	10/8/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	10/29/2023	Y	Y	N	N	N	Y	Y	Y	N	N	Y	N	N	N	N	9.1	18	83	N	N	Y	N	NR
2149	1615469	2278	V	10/29/2023	70	M	N	10/29/2023	WARD	CARDIOVASCULAR DISEASE	SERUM	10/29/2023	N	N	Y	Y	Y	Y	N	N	N	N	N	N	N	N	N	10	6.2	79	Y	N	N	N	NR
2150	1481093	2279	VK	10/30/2023	60	M	N	10/25/2023	WARD	RENAL DISEASE	SERUM	10/30/2023	Y	Y	N	N	Y	Y	N	N	N	Y	N	N	N	N	N	10	26	88	N	N	N	N	NR
2151	1614938	2280	BD	10/30/2023	73	M	N	10/28/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	10/30/2023	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	10	12	85	N	N	N	Y	NR
2152	1615842	2281	DS	10/30/2023	75	M	N	10/30/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	10/30/2023	Y	N	Y	N	Y	Y	N	N	N	N	N	N	N	N	N	10	16	88	N	Y	N	N	NR
2153	1615386	2282	MA	10/31/2023	48	M	N	10/29/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	10/31/2023	Y	N	N	N	Y	N	N	N	N	N	N	N	N	N	N	10	87	90	Y	N	N	N	NR
2154	421937	2283	BS	10/31/2023	75	M	N	10/31/2023	WARD	CARDIOVASCULAR DISEASE	SERUM	10/31/2023	Y	N	N	Y	Y	Y	N	N	N	N	Y	N	N	N	N	11	11	72	N	N	N	N	NR
2156	1611484	2286	GS	11/1/2023	31	M	N	11/1/2023	WARD	RENAL DISEASE	SERUM	11/1/2023	N	N	N	N	Y	Y	N	N	N	N	N	N	N	N	N	10	22	80	N	Y	N	N	NR
2157	1615462	2287	PD	11/1/2023	28	F	N	10/29/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/1/2023	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	10	4.5	45	N	Y	N	N	NR
2158	1615457	2289	KS	11/1/2023	66	M	N	10/29/2023	WARD	CARDIOVASCULAR DISEASE	SERUM	11/1/2023	Y	N	N	Y	Y	N	Y	N	N	N	N	N	N	N	N	11	18.3	79	N	N	N	N	NR
2159	1595567	2290	NK	11/5/2023	37	M	N	10/1/2023	ICU	NEUROLOGICAL DISEASE	SERUM	11/5/2023	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	N	13	14	92	N	N	N	Y	NR
2160	1609079	2292	JS	11/2/2023	63	M	P	10/16/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/2/2023	N	N	Y	N	Y	N	Y	Y	N	N	Y	N	N	N	N	11	17	85	N	N	N	Y	NR

S. no	MRD No.	Lab No	Distribution of clinical samples received	Fungal smear Positive for Hyaline Septate Fungal Hyphae	CANDIDA IN (BODY FLUIDS AND BLOOD CULTURE)	CANDIDA IN BODY FUILDS	FUNGAL CULTURE FOR ASPERGILLUS SPECIES	Fungal Cuture	GMSAASSAY	1-3 BDG	PTZ	ANTIFUNGAL	Heamo Dylasis	AUGMENTIN	MEROPENEM	Provisional diagnosis	Outcome	TOTAL EORTC PATIENTS	PROVEN	POSSIBLE	PROBABLE	NO INVASIVE ASPERGILLOSI
2110	1592562	2236	SPUTUM	Neg	-	-	Neg	NG	0.1	0.03	N	N	N	N	Y	CKD	DISCHARGE	Y	N	Y	N	N
2111	1609200	2237	NR	NR	-	-	NR	NR	0.1	0.03	N	N	N	N	Y	ACUTE GASTRITS	DISCHARGE	N	N	N	N	Y
2112	1596894	2238	ENDOTRACHEAL SECRETIONS	Neg	Y	-	Neg	NG	0.21	0.02	N	N	N	N	Y	LRTI	DISCHARGE	N	N	N	N	Y
2113	1472912	2239	NR	NR	-	-	NR	NR	0.2	0.03	N	N	N	N	N	PORTAL HTN, LIVER DISEASE	DISCHARGE	N	N	N	N	Y
2115	1605675	2241	NR	NR	-	-	NR	NR	0.1	-	N	N	N	N	N	NECROTISING, PANCREATITIS	DISCHARGE	N	N	N	N	Y
2116	1565962	2242	CSF	Neg	-	-	Neg	NG	0.1	-	N	N	N	N	N	ROAD SIDE ACCIDENT	DISCHARGE	N	N	N	N	Y
2117	1609223	2243	WOUND SWAB	Neg	-	-	Neg	NG	2.24	-	N	Y	N	N	Y	CHOLITITHIASIS	DISCHARGE	N	N	N	N	Y
2118	1576225	2244	SPUTUM	Neg	-	-	Neg	NG	0.1	-	N	N	N	N	N	KOCH'S	DISCHARGE	Y	N	Y	N	N
2119	1608400	2245	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.1	-	N	N	Y	N	Y	PANCREATITIS, CKD, PORTAL HTN, SEPSIS	DAMA	N	N	N	N	Y
2120	1608430	2246	PLEURAL FLUID	Neg	-	-	Neg	NG	0.1	8.07	N	Y	N	N	Y	GULLIAN BONE SYNDROME	DISCHARGE	N	N	N	N	Y
2121	1610732	2247	NR	NR	-	-	NR	NR	0.1	0.02	Y	N	N	N	Y	CHOLITITHIASIS	DISCHARGE	N	N	N	N	Y
2123	1611520	2249	SPUTUM	Neg	-	-	Neg	NG	0.1	0.45	N	N	N	N	Y	LRTI	DISCHARGE	N	N	N	N	Y
2124	678071	2250	SPUTUM	Neg	-	-	Neg	NG	2.5	0.1	N	Y	N	N	Y	CKD, OLD KOCH'S	DAMA	Y	N	Y	Y	N
2125	1609766	2251	SPUTUM	Neg	-	-	Neg	NG	0.17	0.77	N	N	N	N	Y	LRTI, UTI, AKI	DISCHARGE	N	N	N	N	Y
2126	1541629	2252	SPUTUM	Neg	-	-	Neg	NG	0.1	0.05	N	Y	N	N	Y	CA LUNG, LRTI, POST CABG	DAMA	Y	N	Y	N	N
2127	1609801	2253	SPUTUM	Neg	-	-	Neg	NG	0.1	0.02	N	N	N	N	Y	ACUTE FIBRILE ILLNESS, LRTI, SEPSIS	DAMA	N	N	N	N	Y
2128	1519243	2254	NR	NR	-	-	NR	NR	0.1	0.02	N	Y	N	N	Y	AKI, CKD, PNEUMONIA	DISCHARGE ON REQUEST	N	N	N	N	Y
2129	1004911	2255	NR	NR	-	-	NR	NR	0.1	0.02	N	N	N	N	Y	CIRRHOSI, PORTAL HTN	DISCHARGE	N	N	N	N	Y
2130	1609264	2257	SPUTUM	Neg	-	-	Neg	NG	1.11	-	N	Y	N	N	N	LRTI	DAMA	N	N	N	N	Y
2131	1608624	2258	NR	NR	-	-	NR	NR	0.1	8.65	N	N	N	N	N	LRTI, SEPSIS, CKD	DISCHARGE	N	N	N	N	Y
2132	1611927	2259	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	CANDIDA	0.1	0.02	N	Y	N	N	Y	ACUTE FIBRILE ILLNESS	DISCHARGE	N	N	N	N	Y
2133	1608608	2260	NR	NR	-	-	NR	NR	0.1	0.02	N	N	N	N	Y	PANCREATITIS	DISCHARGE	N	N	N	N	Y
2134	1111756	2261	SPUTUM	Neg	-	-	Neg	NG	0.1	-	N	Y	N	N	N	PNEUMONIA, AKI	DISCHARGE	N	N	N	N	Y
2135	1613694	2262	NR	NR	-	-	NR	NR	0.1	-	N	N	N	N	Y	LRTI	DISCHARGE	N	N	N	N	Y
2136	1613056	2264	SPUTUM	Neg	-	-	Neg	NG	0.1	0.02	N	N	N	N	N	CAD	DISCHARGE	N	N	N	N	Y
2137	1612023	2265	NR	NR	-	-	NR	NR	0.21	0.02	N	Y	N	N	Y	LRTI, ASTHMA	DAMA	Y	N	Y	N	N
2139	1613664	2268	PLEURAL FLUID	Neg	-	-	Neg	NG	0.12	0.02	N	N	N	N	Y	CAD	DISCHARGE	N	N	N	N	Y
2140	1608528	2269	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.1	0.02	N	N	N	N	Y	LRTI, PNEUMONIA	DISCHARGE	Y	N	Y	N	N
2141	1605743	2270	URINE	Neg	Y	Y	Neg	CANDIDA	0.1	0.02	N	Y	N	N	Y	AKI, UTI	DISCHARGE	N	N	N	N	Y
2142	1614960	2272	NR	NR	-	-	NR	NR	1.09	0.02	N	N	N	N	Y	ACUTE FIBRILE ILLNESS	DAMA	N	N	N	N	Y
2143	1614891	2273	NR	NR	-	-	NR	NR	0.1	0.63	N	Y	N	N	Y	PUO	DISCHARGE	N	N	N	N	Y
2144	1615002	2274	SPUTUM	Neg	-	-	Neg	NG	0.13	-	N	Y	N	N	N	CONSOLIDATION IN LUNG	DISCHARGE	N	N	N	N	Y
2145	1610859	2275	NR	NR	-	-	NR	NR	0.16	0.03	N	N	N	N	Y	ACUTE HEPATITIS	DISCHARGE	N	N	N	N	Y
2146	1567956	2275	URINE	Neg	-	-	Neg	NG	0.1	0.03	N	N	Y	N	Y	AKI, CKD, LRTI	DISCHARGE	N	N	N	N	Y
2147	316092	2276	PLEURAL FLUID	Neg	-	-	Neg	NG	0.1	-	N	N	N	N	Y	PNEUMONIA	DISCHARGE	Y	N	Y	N	N
2148	1604103	2277	SPUTUM	Neg	-	-	Neg	CANDIDA	8.81	-	N	Y	N	N	Y	COPD, PNEUMONITIS	DISCHARGE	Y	N	Y	Y	N
2149	1615469	2278	NR	NR	-	-	NR	NR	0.1	0.02	Y	N	N	N	N	CAD	DISCHARGE	N	N	N	N	Y
2150	1481093	2279	ASCITIC FLUID	Neg	-	-	Neg	NG	0.18	0.02	N	Y	N	N	Y	CKD, SEPSIS	DISCHARGE	N	N	N	N	Y
2151	1614938	2280	NR	NR	-	-	NR	NR	0.16	-	N	N	N	N	Y	COPD, ILD	DISCHARGE	N	N	N	N	Y
2152	1615842	2281	NR	NR	-	-	NR	NR	0.12	-	N	N	N	N	Y	PLEURAL EFFUSION, CONSOLIDATION	DISCHARGE	N	N	N	N	Y
2153	1615386	2282	NR	NR	-	-	NR	NR	0.16	0.02	N	N	N	N	Y	AFI, SEPSIS	DISCHARGE	N	N	N	N	Y
2154	421937	2283	SPUTUM	Neg	-	-	Neg	CANDIDA	0.1	0.04	N	N	N	N	N	BRONCHO PULMONARY ASP.	DISCHARGE	N	N	N	N	Y
2156	1611484	2286	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	CANDIDA	0.04	0.1	N	N	N	N	Y	DENGUE	DISCHARGE	N	N	N	N	Y
2157	1615462	2287	NR	NR	-	-	NR	NR	0.87	0.02	N	N	N	N	Y	SEPSIS	DISCHARGE	N	N	N	N	Y
2158	1615457	2289	NR	NR	-	-	NR	NR	0.1	0.02	N	N	Y	N	Y	SEPTICEMIA	DISCHARGE	N	N	N	N	Y
2159	1595567	2290	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.16	-	N	N	N	N	N	PANCREATITIS	DISCHARGE	N	N	N	N	Y
2160	1609079	2292	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	1.89	0.04	N	N	N	N	Y	COPD	DISCHARGE	Y	N	Y	Y	N

S. no	MRD No.	Lab No	NAME	DOR Sample	AGE	SEX	GMRepeat	DOA	AREA	SUB AREA WISE	Sample	DOR Sample	FEVER	COUGH	SOB	CHEST PAIN	DM	HTN	Alcoholic	Smoker	Neutropenia	TBHistory	Chronic steroid use	Solid organ transplantation	Malignancy	HIV	HCV	HB	TLC/DLC	NEUTROPHIL COUNT	CT CHEST _PLEURAL EFFUSION	CONSOLIDATION IN LUNG	CAVITATION	RETICULONODULAR OPACITIES	Histopathology for aspergillus species
2161	1616340	2293	J	11/2/2023	50	M	N	10/13/2023	WARD	RENAL DISEASE	SERUM	11/2/2023	Y	N	Y	N	Y	Y	N	N	N	N	N	N	N	N	N	7.7	5	79	N	N	N	N	NR
2162	1509930	2294	SS	11/2/2023	47	M	N	11/1/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	11/2/2023	Y	Y	N	N	N	N	Y	N	N	Y	Y	N	N	N	N	11.9	26	90	N	N	N	Y	NR
2163	1612399	2295	RS	11/2/2023	47	M	N	10/23/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/2/2023	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	13.1	17	72	N	N	N	N	NR
2164	1616716	2296	RL	11/2/2023	63	M	N	11/1/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	11/2/2023	N	N	N	N	Y	Y	Y	N	N	N	Y	N	N	N	N	10.7	10	74	N	N	N	N	NR
2165	1617706	2297	MG	11/3/2023	67	M	N	11/2/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	11/3/2023	N	N	N	N	Y	N	N	N	N	N	Y	N	N	N	N	9.4	7	76	N	N	N	Y	NR
2166	718437	2298	CK	11/3/2023	41	F	N	9/29/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/3/2023	N	Y	Y	N	N	N	N	N	N	Y	Y	N	N	N	N	9.4	11	73	N	N	N	N	NR
2167	1617753	2299	BS	11/3/2023	70	M	N	11/2/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/3/2023	Y	N	N	N	N	N	Y	Y	Y	N	N	N	N	N	N	9.4	0.84	28	N	N	N	Y	NR
2168	1609942	2300	VS	11/3/2023	35	M	N	10/18/2023	ICU	GASTROINTESTINAL TRACT DISEASE	SERUM	11/3/2023	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	10.4	32	87	N	N	N	N	NR
2169	1612810	2301	KK	11/3/2023	51	F	N	10/23/2023	WARD	CARDIOVASCULAR DISEASE	SERUM	11/3/2023	N	N	Y	Y	N	N	N	N	N	N	N	N	N	N	N	10	12	78	N	N	N	N	NR
2170	1582527	2302	SD	11/3/2023	58	F	N	11/2/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	11/3/2023	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	12	13	79	N	N	N	Y	NR
2172	1554310	2304	SK	11/5/2023	50	F	N	11/6/2023	WARD	RENAL DISEASE	SERUM	11/5/2023	N	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	8.2	5.09	58.8	N	Y	N	N	NR
2173	1581911	2305	MS	11/4/2023	23	M	N	10/7/2023	ICU	GASTROINTESTINAL TRACT DISEASE	SERUM	11/4/2023	N	N	Y	N	N	N	N	N	N	N	Y	N	N	N	N	8.7	16	70	N	N	N	N	NR
2174	1615284	2306	PL	11/4/2023	82	F	N	10/28/2023	ICU	GASTROINTESTINAL TRACT DISEASE	SERUM	11/4/2023	N	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	11.8	9.8	81	N	N	N	N	NR
2175	1618923	2307	GK	11/5/2023	76	F	N	11/4/2023	WARD	RENAL DISEASE	SERUM	11/5/2023	N	Y	N	N	N	Y	N	N	N	N	N	N	N	N	N	8.7	19	76	N	N	N	N	NR
2176	1612076	2308	KB	11/5/2023	81	M	N	10/22/2023	WARD	GENERAL SURGERY	SERUM	11/5/2023	N	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	16.3	3.2	83	N	Y	N	N	NR
2177	1616054	2309	JK	11/6/2023	60	F	N	10/30/2023	WARD	RENAL DISEASE	SERUM	11/6/2023	Y	N	Y	N	Y	N	N	N	N	N	Y	N	Y	N	N	10.7	6.9	73	N	N	N	Y	NR
2178	1615424	2310	K	11/6/2023	74	M	N	10/29/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/6/2023	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	15.1	3	85	N	Y	N	N	NR
2179	1580100	2311	VS	11/6/2023	85	M	N	11/6/2023	ICU	CARDIOVASCULAR DISEASE	SERUM	11/6/2023	Y	Y	N	Y	Y	Y	N	N	N	N	Y	N	N	N	N	10	11.5	75.8	N	N	N	N	NR
2180	1619709	2312	NM	11/7/2023	39	M	N	11/6/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/7/2023	Y	N	Y	Y	N	N	N	N	N	N	N	N	N	Y	N	12.1	5.4	89.1	N	N	N	N	NR
2181	1618968	2313	BM	11/7/2023	98	F	N	11/4/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/7/2023	Y	N	Y	Y	N	N	N	N	N	N	N	N	Y	N	N	12	10	93	Y	N	N	N	NR
2182	70082	2314	BD	11/7/2023	62	M	N	11/1/2023	WARD	RENAL DISEASE	SERUM	11/7/2023	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	7.2	8.7	72	N	N	N	N	NR
2183	6313	2315	V	11/7/2023	58	F	N	10/30/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/7/2023	N	N	Y	N	N	Y	N	N	N	N	N	N	N	N	N	12.1	8	68	N	N	N	N	NR
2184	1616157	2316	G	11/6/2023	55	M	N	10/30/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/6/2023	Y	N	N	N	Y	N	N	N	N	N	Y	N	N	N	N	14.8	5.1	66	N	N	N	N	NR
2185	1619792	2317	TS	11/8/2023	50	M	N	11/6/2023	WARD	RENAL DISEASE	SERUM	11/8/2023	Y	Y	N	N	N	Y	N	N	N	N	Y	Y	N	N	N	12	10	79	N	N	N	Y	NR
2186	1618729	2318	P	11/8/2023	41	F	N	11/4/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/8/2023	Y	Y	N	N	N	N	N	N	N	N	Y	N	N	N	N	10.4	7.6	72	N	N	N	Y	NR
2188	1619838	2320	SS	11/8/2023	46	M	N	11/7/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/8/2023	Y	Y	N	N	Y	N	N	N	N	Y	N	N	N	N	N	10	11	76	N	N	N	Y	NR
2190	27962	2322	AS	11/9/2023	58	M	N	10/25/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	11/9/2023	Y	N	N	N	N	N	N	N	N	N	Y	N	N	N	N	7.5	7	72	N	N	N	N	NR
2191	1335978	2323	GS	11/9/2023	75	M	N	11/5/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/9/2023	Y	Y	N	N	Y	Y	N	N	N	N	Y	N	N	N	N	11.6	6.7	68	N	N	N	Y	NR
2192	1618621	2324	RS	11/9/2023	68	M	N	11/4/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	11/9/2023	N	N	N	N	N	Y	N	N	N	N	N	N	N	N	N	9.2	12.1	86.9	N	N	N	N	NR
2193	22241	2325	MK	11/9/2023	64	F	N	11/4/2023	WARD	RENAL DISEASE	SERUM	11/9/2023	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	N	8.8	13	76.4	N	N	N	Y	NR
2196	1620275	2328	MK	11/9/2023	48	F	N	11/7/2023	WARD	ONCOLOGICAL	SERUM	11/9/2023	Y	Y	N	N	N	N	N	N	N	N	N	N	Y	N	N	12.7	18	83	N	N	N	N	NR
2197	1382102	2329	J	11/10/2023	64	M	N	11/26/2023	WARD	ONCOLOGICAL	SERUM	11/10/2023	Y	Y	N	N	N	N	Y	Y	N	N	Y	N	Y	N	N	8.1	17	84.2	N	N	N	N	NR
2199	1621339	2331	SK	11/10/2023	33	F	N	11/9/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/10/2023	Y	N	Y	N	N	N	N	N	N	N	N	N	N	N	N	9.2	23	89	N	N	N	N	NR
2200	1613858	2332	CK	11/10/2023	63	M	N	11/7/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/10/2023	N	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	11	71	66	N	N	N	Y	NR
2201	14-Feb	2333	HL	11/10/2023	50	M	N	11/2/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/10/2023	Y	Y	Y	N	N	Y	N	N	N	N	Y	N	N	N	N	11.2	17	88	N	N	N	N	NR
2202	1612819	2334	JS	11/11/2023	35	M	N	10/23/2023	WARD	GENERAL SURGERY	SERUM	11/11/2023	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	10.7	12.6	81.6	N	Y	N	N	NR
2203	1319014	2335	UR	11/11/2023	72	F	N	11/9/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/11/2023	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	12	13	76	N	N	N	Y	NR
2204	1576556	2336	PA	11/11/2023	50	M	N	11/10/2023	WARD	ONCOLOGICAL	SERUM	11/11/2023	Y	Y	N	N	N	N	N	N	N	N	N	N	Y	N	N	12	20	87	N	Y	N	N	NR
2205	1621359	2337	KK	11/11/2023	35	F	N	11/10/2023	WARD	RENAL DISEASE	SERUM	11/11/2023	Y	Y	N	N	Y	N	N	N	N	N	Y	N	N	N	N	8.9	7.1	83.2	N	N	N	Y	NR
2206	1585706	2338	HK	11/11/2023	67	F	N	11/11/2023	WARD	ONCOLOGICAL	SERUM	11/11/2023	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	N	11	0.3	69	N	N	N	N	NR
2207	1618240	2339	SD	11/11/2023	60	F	N	11/3/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/11/2023	N	N	Y	N	Y	N	N	N	N	Y	Y	N	N	N	N	14	8.8	90	N	N	N	Y	NR
2208	1621890	2340	M	11/11/2023	47	F	N	11/11/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/11/2023	Y	N	Y	N	N	N	N	N	N	N	Y	N	N	N	N	10.3	6.3	80	N	N	N	Y	NR
2209	1618947	2341	DR	11/12/2023	80	M	N	11/4/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	11/12/2023	N	Y	Y	Y	N	N	Y	Y	N	Y	Y	N	N	N	N	13	10	93	N	Y	N	N	NR
2211	1618445	2343	R	11/13/2023	57	M	N	11/4/2023	WARD	NEUROLOGICAL DISEASE	SERUM	11/13/2023	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	13	17	81.8	N	N	N	N	NR
2212	1620875	2344	B	11/13/2023	50	M	N	11/8/2023	WARD	GENERAL SURGERY	SERUM	11/13/2023	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	14	9	59.1	N	N	N	N	NR
2213	1617768	2345	P	11/13/2023	28	M	N	11/9/2023	WARD	CARDIOVASCULAR DISEASE	SERUM	11/13/2023	Y	N	N	Y	N	N	N	N	N	N	N	N	N	N	N	13.5	4.9	91	N	N	N	N	NR
2214	1622494	2346	V	11/13/2023	63	M	N	11/13/2023	ICU	CARDIOVASCULAR DISEASE	SERUM	11/13/2023	N	N	N	Y	Y	Y	N	N	N	N	N	N	N	N	N	12	24.9	60.9	N	N	N	N	NR
2215	1612056	2347	P	11/13/2023	57	F	N	11/10/2023	WARD	GENERAL SURGERY	SERUM	11/13/2023	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	11	15	84	N	N	N	N	NR
2216	1606785	2348	T	11/13/2023	46	M	N	10/12/2023	WARD	NEUROLOGICAL DISEASE	SERUM	11/13/2023	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	11	12	70	N	N	N	N	NR

S. no	MRD No.	Lab No	Distribution of clinical samples received	Fungal smear Positive for Hyaline Septate Fungal Hyphae	CANDIDA IN (BODY FLUIDS AND BLOOD CULTURE)	CANDIDA IN BODY FUILDS	FUNGAL CULTURE FOR ASPERGILLUS SPECIES	Fungal Cuture	GMSAASSAY	1-3 BDG	PTZ	ANTIFUNGAL	Heamo Dylasis	AUGMENTIN	MEROPENEM	Provisional diagnosis	Outcome	TOTAL EORTC PATIENTS	PROVEN	POSSIBLE	PROBABLE	NO INVASIVE ASPERGILLOSI
2161	1616340	2293	NR	NR	-	-	NR	NR	0.1	0.02	N	Y	N	N	Y	CKD, AKI	DISCHARGE	N	N	N	N	Y
2162	1509930	2294	SPUTUM	P	-	-	P	ASPERGILLUS FLAVUS	5.97	-	N	Y	N	N	Y	PULM. ASP., SEPSIS	DISCHARGE ON REQUEST	Y	N	Y	Y	N
2163	1612399	2295	ENDOTRACHEAL SECRETIONS	P	-	-	P	ASPERGILLUS FLAVUS	0.99	0.65	N	Y	N	N	Y	LRTI	DISCHARGE ON REQUEST	N	N	N	N	Y
2164	1616716	2296	ASCITIC FLUID	Neg	-	-	Neg	NG	0.1	-	N	N	N	N	Y	ASCITES	EXPIRED	N	N	N	N	Y
2165	1617706	2297	CSF	Neg	-	-	Neg	NG	0.63	0.02	N	Y	N	N	Y	CLD	DISCHARGE	Y	N	Y	Y	N
2166	718437	2298	SPUTUM	Neg	-	-	Neg	CANDIDA	0.11	-	N	Y	N	N	Y	ILD, TB	DISCHARGE	N	N	N	N	Y
2167	1617753	2299	SPUTUM	Neg	-	-	Neg	NG	0.13	-	N	N	N	N	Y	ARTHRITIS	DISCHARGE ON REQUEST	Y	N	Y	N	N
2168	1609942	2300	ASCITIC FLUID	Neg	-	-	Neg	NG	0.62	4.55	N	N	N	N	Y	PERFORATION	DISCHARGE	N	N	N	N	Y
2169	1612810	2301	NR	NR	-	-	NR	NR	0.1	-	Y	N	N	N	Y	CAD	DISCHARGE	N	N	N	N	Y
2170	1582527	2302	PLEURAL FLUID	Neg	-	-	Neg	NG	0.1	0.02	N	N	N	N	Y	CLD WITH PORTAL HTN	DISCHARGE	N	N	N	N	Y
2172	1554310	2304	ENDOTRACHEAL SECRETIONS	Neg	Y	-	Neg	CANDIDA	0.1	0.2	N	N	N	N	N	CKD, SEPSIS	DISCHARGE	N	N	N	N	Y
2173	1581911	2305	PLEURAL FLUID	Neg	-	-	Neg	NG	0.7	-	N	N	N	N	Y	NECROTISING, PANCREATITIS	DISCHARGE	Y	N	Y	N	N
2174	1615284	2306	PLEURAL FLUID	Neg	-	-	Neg	NG	0.1	0.12	N	N	N	N	Y	CLD WITH PORTAL HTN	DISCHARGE	N	N	N	N	Y
2175	1618923	2307	PLEURAL FLUID	Neg	-	-	Neg	NG	0.13	0.11	N	N	Y	N	N	UTI, CKD, AFI	DISCHARGE ON REQUEST	N	N	N	N	Y
2176	1612076	2308	NR	NR	Y	-	NR	NR	0.16	0.11	N	N	N	N	Y	HERNIA	DISCHARGE	N	N	N	N	Y
2177	1616054	2309	NR	NR	-	-	NR	NR	0.1	0.02	N	Y	Y	N	Y	AFI, AKI	DISCHARGE	Y	N	Y	N	N
2178	1615424	2310	SPUTUM	Neg	-	-	Neg	NG	12.35	8.14	Y	N	N	N	N	LRTI	DISCHARGE ON REQUEST	N	N	N	N	Y
2179	1580100	2311	NR	NR	-	-	NR	NR	0.1	-	N	N	N	N	Y	CAD, INFLUENZA	DAMA	N	N	N	N	Y
2180	1619709	2312	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.1	0.02	N	N	N	N	Y	HIV+VE	DISCHARGE	N	N	N	N	Y
2181	1618968	2313	SPUTUM	Neg	-	-	Neg	NG	0.1	0.02	N	N	N	N	Y	CARCINOMA	DISCHARGE	Y	N	Y	N	N
2182	70082	2314	NR	NR	-	-	NR	NR	0.1	0.04	N	Y	N	N	Y	AKI	DISCHARGE	N	N	N	N	Y
2183	6313	2315	SPUTUM	Neg	-	-	Neg	NG	0.1	0.07	N	N	N	N	Y	SEPSIS	DAMA	N	N	N	N	Y
2184	1616157	2316	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	CANDIDA	5.81	0.13	N	N	N	N	Y	AKI, SEPSIS	DISCHARGE	Y	N	Y	N	N
2185	1619792	2317	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.12	0.02	N	Y	N	N	Y	SEPSIS, AKI	DISCHARGE ON REQUEST	Y	N	Y	N	N
2186	1618729	2318	SPUTUM	Neg	-	-	Neg	NG	0.1	-	N	N	N	N	Y	ASTHMA, LRTI, ABPA	DISCHARGE	Y	N	Y	N	N
2188	1619838	2320	SPUTUM	Neg	-	-	Neg	NG	0.1	-	Y	N	N	N	N	TB	DISCHARGE ON REQUEST	N	N	N	N	Y
2190	27962	2322	SPUTUM	Neg	-	-	Neg	NG	3.73	0.21	N	Y	N	N	Y	CLD WITH PORTAL HTN	DISCHARGE	Y	N	Y	N	N
2191	1335978	2323	SPUTUM	Neg	-	-	Neg	CANDIDA	2.13	0.13	N	Y	N	N	Y	CLD, KOCHS	DAMA	Y	N	Y	Y	N
2192	1618621	2324	NR	NR	-	-	NR	NR	0.22	0.02	N	N	N	N	Y	PANCREATITIS	DISCHARGE	N	N	N	N	Y
2193	22241	2325	SPUTUM	P	-	-	P	ASPERGILLUS FLAVUS	0.1	0.02	N	N	Y	N	Y	ASTHMA, CKD	DISCHARGE	N	N	N	N	Y
2196	1620275	2328	NR	NR	-	-	NR	NR	0.1	0.02	N	N	N	N	Y	CA BREAST	DISCHARGE	N	N	N	N	Y
2197	1382102	2329	NR	NR	-	-	NR	NR	0.14	-	N	N	N	N	N	CA LUNG, ON CHEMEOTHERAPY	DAMA	N	N	N	N	Y
2199	1621339	2331	NR	NR	-	-	NR	NR	0.5	0.3	N	Y	N	N	Y	VIRAL PNEUMONIA	DISCHARGE	N	N	N	N	Y
2200	1613858	2332	NR	NR	-	-	NR	NR	0.2	-	N	N	N	N	Y	VIRAL PNEUMONIA	DISCHARGE	N	N	N	N	Y
2201	14-Feb	2333	SPUTUM	Neg	-	-	Neg	CANDIDA	0.1	0.07	N	N	N	N	Y	LRTI	DISCHARGE	N	N	N	N	Y
2202	1612819	2334	NR	NR	-	-	NR	NR	0.1	0.02	N	N	N	N	Y	ROAD SIDE ACCIDENT	DISCHARGE	N	N	N	N	Y
2203	1319014	2335	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.1	0.05	N	N	N	N	Y	LRTI, CAD	DISCHARGE	N	N	N	N	Y
2204	1576556	2336	PLEURAL FLUID	Neg	-	-	Neg	NG	0.1	0.04	N	N	N	N	Y	LRTI	DISCHARGE	Y	N	Y	N	N
2205	1621359	2337	SPUTUM	P	-	-	P	ASPERGILLUS FUMIGATUS	0.89	0.2	N	Y	N	N	Y	AFI, LRTI, SEPSIS	DAMA	Y	N	Y	Y	N
2206	1585706	2338	NR	NR	-	-	NR	NR	0.17	0.2	N	N	N	N	N	MULTIPLE MYCLOMA	DISCHARGE	N	N	N	N	Y
2207	1618240	2339	SPUTUM	Neg	-	-	Neg	NG	0.1	-	N	Y	N	N	Y	KOCHS	DISCHARGE ON REQUEST	Y	N	Y	N	N
2208	1621890	2340	NR	NR	-	-	NR	NR	0.8	3.2	Y	Y	N	N	N	LRTI, ARTHRITIS	DISCHARGE ON REQUEST	Y	N	Y	Y	N
2209	1618947	2341	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.56	-	N	N	N	N	N	COPD, LRTI	DAMA	Y	N	Y	Y	N
2211	1618445	2343	NR	NR	-	-	NR	NR	0.1	0.04	N	N	N	N	Y	SDH, SAH	DISCHARGE	N	N	N	N	Y
2212	1620875	2344	NR	NR	-	-	NR	NR	0.1	0.08	N	N	N	N	Y	BLAST INJURY	DISCHARGE	N	N	N	N	Y
2213	1617768	2345	ASCITIC FLUID	Neg	-	-	Neg	NG	0.22	0.02	N	N	N	N	N	ARDS	DISCHARGE	N	N	N	N	Y
2214	1622494	2346	NR	NR	-	-	NR	NR	0.88	0.02	Y	N	N	N	Y	CAD	DISCHARGE	N	N	N	N	Y
2215	1612056	2347	NR	NR	-	-	NR	NR	0.19	-	N	N	N	N	Y	AFI	DISCHARGE	N	N	N	N	Y
2216	1606785	2348	SPUTUM	Neg	-	-	Neg	CANDIDA	0.1	-	N	N	N	N	Y	SPINE INJURY	DISCHARGE	N	N	N	N	Y

S. no	MRD No.	Lab No	NAME	DOR Sample	AGE	SEX	GMRepeat	DOA	AREA	SUB AREA WISE	Sample	DOR Sample	FEVER	COUGH	SOB	CHEST PAIN	DM	HTN	Alcoholic	Smoker	Neutropenia	TBHistory	Chronic steroid use	Solid organ transplantation	Malignancy	HIV	HCV	HB	TLC/DLC	NEUTROPHIL COUNT	CT CHEST _PLEURAL EFFUSION	CONSOLIDATION IN LUNG	CAVITATION	RETICULONODULAR OPACITIES	Histopathology for aspergillus species
2217	110535	2349	SR	11/14/2023	65	F	N	11/11/2023	WARD	RENAL DISEASE	SERUM	11/14/2023	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	7.6	8.8	73	N	N	N	Y	NR
2218	1621210	2350	S	11/14/2023	56	M	N	11/9/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	11/14/2023	N	N	N	N	N	N	N	N	N	N	Y	N	N	N	N	12	19	85	N	N	N	N	NR
2221	924903	2353	A	11/15/2023	58	M	N	11/11/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/15/2023	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	9.3	10	89	N	N	N	Y	NR
2222	1619116	2354	M	11/15/2023	50	M	N	11/5/2023	ICU	CARDIOVASCULAR DISEASE	SERUM	11/15/2023	N	N	Y	Y	N	Y	N	N	N	N	N	N	N	N	N	13	11	84	N	Y	N	N	NR
2223	1610326	2355	K	11/15/2023	79	F	N	10/18/2023	WARD	RENAL DISEASE	SERUM	11/15/2023	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	12	15	93	N	N	N	N	NR
2225	1623786	2357	LC	11/15/2023	63	M	N	10/12/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/15/2023	Y	Y	N	N	N	N	N	N	N	N	N	Y	N	N	N	8.8	7.1	71.3	N	N	N	Y	NR
2226	1621444	2358	CR	11/16/2023	72	F	N	11/10/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/16/2023	Y	Y	Y	N	N	Y	N	N	N	N	N	N	N	N	N	11.2	7.4	75	N	Y	N	N	NR
2227	25898	2359	MS	11/15/2023	79	M	N	11/7/2023	ICU	CARDIOVASCULAR DISEASE	SERUM	11/15/2023	N	Y	N	Y	Y	Y	N	N	N	N	N	N	N	N	N	11	12	91	N	Y	N	N	NR
2228	1623238	2360	JS	11/16/2023	28	M	N	11/15/2023	ICU	GASTROINTESTINAL TRACT DISEASE	SERUM	11/16/2023	N	N	N	N	N	N	N	N	N	N	Y	N	N	N	N	9.7	21	86	N	Y	N	N	NR
2229	1620891	2361	H	11/16/2023	75	M	N	11/8/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	11/16/2023	N	Y	Y	N	N	N	Y	Y	N	N	N	N	N	N	N	12	14	90	N	N	N	Y	NR
2230	1621860	2362	J	11/16/2023	50	M	N	11/11/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	11/16/2023	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	8.8	8.2	88	N	N	N	N	NR
2231	1612044	2363	J	11/16/2023	23	M	N	11/6/2023	WARD	CARDIOVASCULAR DISEASE	SERUM	11/16/2023	N	N	N	Y	N	N	N	N	N	N	N	N	N	N	N	8.7	20.7	77	N	N	N	N	NR
2233	1622053	2365	AK	11/17/2023	69	M	N	11/11/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/17/2023	Y	N	Y	N	Y	Y	N	N	N	N	N	N	N	N	N	11	19	65	N	N	N	Y	NR
2234	1622087	2366	S	11/17/2023	38	F	N	11/11/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/17/2023	Y	N	Y	N	N	Y	N	N	N	N	N	N	N	N	N	11	3	67	N	N	N	N	NR
2235	1604087	2367	G	11/17/2023	57	M	N	11/1/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/17/2023	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	N	9.1	19	60	N	N	N	N	NR
2236	1621314	2368	G	11/17/2023	75	F	N	11/9/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/17/2023	N	N	Y	Y	Y	Y	N	N	N	N	N	N	N	N	N	10	14	85	N	Y	N	N	NR
2237	1622116	2369	RG	11/17/2023	65	M	N	11/11/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/17/2023	N	Y	N	Y	Y	N	N	N	N	N	N	N	N	N	N	6.8	16	95	N	Y	N	N	NR
2239	1623152	2371	PK	11/18/2023	61	F	N	11/14/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/18/2023	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	10	7.7	89	N	N	N	N	NR
2240	628842	2372	S	11/18/2023	87	M	N	11/15/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/18/2023	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	10	31	92	N	N	N	Y	NR
2242	1623303	2375	RG	11/19/2023	23	M	N	11/15/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/19/2023	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	8.9	6	82	N	N	N	Y	NR
2243	1622072	2376	SP	11/20/2023	59	M	N	11/11/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	11/20/2023	N	N	N	N	N	N	Y	N	N	N	N	N	N	N	N	16.1	17	92	N	N	N	N	NR
2244	1624391	2377	A	11/20/2023	72	M	N	11/16/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/20/2023	Y	Y	N	N	Y	Y	N	N	N	N	Y	N	N	N	N	10	14	68	N	N	N	Y	NR
2245	1619773	2378	RS	11/20/2023	70	M	P	11/7/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/20/2023	Y	N	Y	N	N	N	Y	N	N	N	N	N	N	N	N	9.9	12	60.8	N	N	N	N	NR
2246	1625154	2379	BK	11/20/2023	80	F	N	11/18/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	11/20/2023	Y	Y	N	Y	N	N	N	N	N	N	N	N	N	N	N	8.2	7.3	69.1	N	N	N	Y	NR
2247	1625676	2380	JK	11/20/2023	60	M	N	12/11/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/20/2023	Y	Y	N	N	N	Y	Y	N	N	N	N	N	N	N	N	11	10.8	84	N	Y	N	N	NR
2248	1625106	2381	S	11/21/2023	44	M	N	11/17/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/21/2023	Y	Y	N	N	Y	N	Y	N	N	N	Y	N	N	N	N	10	11	79	N	N	N	Y	NR
2249	1624205	2383	HS	11/21/2023	24	M	N	11/16/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/21/2023	Y	N	N	N	N	N	Y	N	N	N	N	N	N	N	N	10	12	98	N	N	N	N	NR
2250	1626417	2385	H	11/21/2023	44	M	N	11/20/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/21/2023	Y	N	N	N	N	N	Y	N	N	N	N	N	N	N	N	12.5	5.06	67	N	N	N	Y	NR
2251	1622127	2386	VP	11/21/2023	30	M	N	11/12/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/21/2023	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	20	10	86	N	N	N	N	NR
2252	1622582	2387	RS	11/22/2023	38	M	N	11/13/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/22/2023	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	13	11	55	N	N	N	N	NR
2253	1623884	2388	B	11/22/2023	55	M	N	11/15/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/22/2023	Y	Y	N	N	Y	Y	N	N	N	N	N	N	N	N	N	10.7	11	61	N	Y	N	N	NR
2254	1626966	2389	KK	11/22/2023	24	F	N	11/1/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	11/22/2023	N	Y	N	N	N	N	N	N	N	N	Y	N	N	N	N	10	10	94	N	N	N	N	NR
2255	1627638	2390	KS	11/22/2023	73	M	N	11/22/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/22/2023	N	N	Y	N	Y	Y	N	N	N	N	N	N	N	N	N	9.5	12	81	N	N	N	Y	NR
2256	1626790	2391	H	11/23/2023	65	F	N	11/21/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/23/2023	Y	Y	Y	N	N	N	N	N	N	N	Y	N	N	N	N	11.7	24	86	N	N	N	Y	NR
2257	1626410	2392	M	11/23/2023	31	F	N	11/20/2023	ICU	GASTROINTESTINAL TRACT DISEASE	SERUM	11/23/2023	N	N	N	N	N	N	N	N	N	N	Y	N	N	N	N	4.2	36	88	N	N	N	N	NR
2259	1623842	2394	M	11/24/2023	50	M	N	11/15/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	11/24/2023	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	16	17	91	N	N	N	N	NR
2260	1187606	2395	SP	11/24/2023	36	M	N	11/22/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	11/24/2023	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	11.6	15	87	N	N	N	N	NR
2261	1084234	2396	S	11/24/2023	57	F	P	11/20/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/24/2023	Y	Y	N	N	Y	N	N	N	N	N	N	N	N	N	N	8.4	7.2	55	N	N	N	Y	NR
2262	1622093	2397	RS	11/24/2023	54	M	N	11/11/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/24/2023	Y	Y	N	N	Y	N	N	N	Y	N	N	N	N	N	N	6.4	15	15	N	N	N	Y	NR
2263	1016534	2398	BS	11/24/2023	63	M	N	11/19/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/24/2023	N	N	Y	Y	Y	Y	Y	N	N	N	Y	N	N	N	N	10	22	79	N	Y	N	Y	NR
2264	1628845	2399	S	11/25/2023	61	F	N	11/24/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/25/2023	Y	Y	N	N	N	Y	N	N	N	N	Y	N	N	N	N	10	22	79	N	N	N	N	NR
2265	1625089	2400	RL	11/25/2023	75	M	N	11/17/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/25/2023	Y	N	Y	N	Y	N	N	N	N	N	Y	N	N	N	N	9.2	14	91	N	N	N	N	NR
2266	1263057	2401	M	11/25/2023	49	M	N	11/24/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	11/25/2023	Y	N	N	N	N	N	Y	N	N	N	N	N	N	N	N	6.4	15	55	N	N	N	Y	NR

S. no	MRD No.	Lab No	Distribution of clinical samples received	Fungal smear Positive for Hyaline Septate Fungal Hyphae	CANDIDA IN (BODY FLUIDS AND BLOOD CULTURE)	CANDIDA IN BODY FUILDS	FUNGAL CULTURE FOR ASPERGILLUS SPECIES	Fungal Cuture	GMSAASSAY	1-3 BDG	PTZ	ANTIFUNGAL	Heamo Dylasis	AUGMENTIN	MEROPENEM	Provisional diagnosis	Outcome	TOTAL EORTC PATIENTS	PROVEN	POSSIBLE	PROBABLE	NO INVASIVE ASPERGILLOSI
2217	110535	2349	SPUTUM	P	-	-	P	ASPERGILLUS FUMIGATUS	12.8	8.38	N	Y	N	N	Y	LRTI	DISCHARGE ON REQUEST	N	N	N	N	Y
2218	1621210	2350	NR	NR	-	-	NR	NR	2.18	-	N	Y	N	N	Y	PANCREATITIS	DISCHARGE	Y	N	Y	Y	N
2221	924903	2353	ENDOTRACHEAL SECRETIONS	P	-	-	P	ASPERGILLUS FLAVUS	0.14	0.02	N	Y	N	N	Y	LRTI, SEPSIS	DISCHARGE	N	N	N	N	Y
2222	1619116	2354	NR	NR	-	-	NR	NR	0.57	0.15	Y	N	N	N	Y	CAD	DISCHARGE	N	N	N	N	Y
2223	1610326	2355	SPUTUM	Neg	-	-	Neg	CANDIDA	0.1	0.04	N	Y	N	N	Y	CAD, AKI	DISCHARGE ON REQUEST	N	N	N	N	Y
2225	1623786	2357	SPUTUM	Neg	-	-	Neg	CANDIDA	0.1	-	N	Y	N	N	Y	LUNG DISEASE	DAMA	Y	N	Y	N	N
2226	1621444	2358	SPUTUM	Neg	-	-	Neg	NG	0.1	0.02	N	N	N	N	Y	COPD, LRTI	DAMA	N	N	N	N	Y
2227	25898	2359	NR	NR	-	-	NR	NR	0.1	0.29	Y	Y	N	N	Y	AFI, CKD	DISCHARGE	N	N	N	N	Y
2228	1623238	2360	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.75	-	N	Y	N	N	Y	NECROTISING, PANCREATITIS	DISCHARGE	Y	N	Y	Y	N
2229	1620891	2361	SPUTUM	Neg	-	-	Neg	CANDIDA	0.1	0.13	N	Y	N	N	Y	COPD, LRTI	DISCHARGE ON REQUEST	N	N	N	N	Y
2230	1621860	2362	NR	NR	-	-	NR	NR	0.19	-	N	N	N	N	Y	CKD	DISCHARGE	N	N	N	N	Y
2231	1612044	2363	SPUTUM	Neg	-	-	Neg	CANDIDA	0.1	0.02	Y	N	N	N	Y	LRTI	DISCHARGE	N	N	N	N	Y
2233	1622053	2365	ENDOTRACHEAL SECRETIONS	P	-	-	P	ASPERGILLUS FLAVUS	0.12	0.02	N	Y	Y	N	N	LRTI, CLD	DAMA	N	N	N	N	Y
2234	1622087	2366	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	2.23	-	N	Y	N	N	Y	VIRAL PNEUMONIA	DISCHARGE	N	N	N	N	Y
2235	1604087	2367	NR	NR	-	-	NR	NR	0.1	-	N	N	N	N	Y	PULM. EMBOLISM	DISCHARGE ON REQUEST	N	N	N	N	Y
2236	1621314	2368	NR	NR	-	-	NR	NR	0.2	0.03	Y	N	N	N	Y	AKD	DISCHARGE	N	N	N	N	Y
2237	1622116	2369	ENDOTRACHEAL SECRETIONS	P	-	-	P	ASPERGILLUS FLAVUS	8.55	8.45	Y	Y	N	N	N	CAD	DISCHARGE	N	N	N	N	Y
2239	1623152	2371	NR	NR	-	-	NR	NR	0.8	0.02	N	N	N	N	Y	VIRAL PNEUMONIA	DAMA	N	N	N	N	Y
2240	628842	2372	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	CANDIDA	0.18	0.1	N	N	N	N	Y	COPD	DISCHARGE	N	N	N	N	Y
2242	1623303	2375	PUS	Neg	-	-	Neg	NG	8.21	0.68	N	N	N	N	N	DENGUE	DISCHARGE	N	N	N	N	Y
2243	1622072	2376	PLEURAL FLUID	Neg	-	-	Neg	NG	0.19	0.02	N	N	N	N	Y	PANCREATITIS	DISCHARGE	N	N	N	N	Y
2244	1624391	2377	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.1	-	N	Y	N	N	Y	LRTI, SEPSIS	DISCHARGE	Y	N	Y	N	N
2245	1619773	2378	NR	NR	-	-	NR	NR	6.61	0.02	N	N	N	N	Y	LRTI	DISCHARGE	N	N	N	N	Y
2246	1625154	2379	SPUTUM	Neg	-	-	Neg	CANDIDA	0.3	0.02	N	N	N	N	N	KOCHS	DISCHARGE ON REQUEST	N	N	N	N	Y
2247	1625676	2380	SPUTUM	Neg	-	-	Neg	NG	0.1	-	Y	N	N	N	N	COPD	DAMA	N	N	N	N	Y
2248	1625106	2381	SPUTUM	Neg	-	-	Neg	CANDIDA	0.1	0.13	N	N	N	N	Y	COPD, SEPSIS	DAMA	Y	N	Y	N	N
2249	1624205	2383	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	CANDIDA	0.1	-	N	N	N	N	N	VIRAL PNEUMONIA	DISCHARGE	N	N	N	N	Y
2250	1626417	2385	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	CANDIDA	0.52	0.02	N	N	N	N	N	CLD, FUNGAL SEPSIS	DAMA	N	N	N	N	Y
2251	1622127	2386	TISSUE	Neg	-	-	Neg	NG	0.1	-	N	N	N	N	Y	LRTI	DISCHARGE	N	N	N	N	Y
2252	1622582	2387	NR	NR	-	-	NR	NR	0.1	0.02	N	N	N	N	Y	SDH	DISCHARGE	N	N	N	N	Y
2253	1623884	2388	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.14	0.02	N	N	N	N	Y	LRTI	DISCHARGE	N	N	N	N	Y
2254	1626966	2389	NR	NR	-	-	NR	NR	0.74	-	N	Y	N	N	Y	FUNGAL SEPSIS	DISCHARGE	Y	N	Y	N	N
2255	1627638	2390	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.11	-	N	N	N	N	Y	CKD, LRTI	DISCHARGE ON REQUEST	N	N	N	N	Y
2256	1626790	2391	SPUTUM	Neg	-	-	Neg	CANDIDA	0.22	0.17	N	Y	N	N	N	LRTI, AFI	DISCHARGE	Y	N	Y	N	N
2257	1626410	2392	NR	NR	-	-	NR	NR	0.79	0.02	N	N	N	N	Y	PANCREATITIS	DISCHARGE	Y	N	Y	N	N
2259	1623842	2394	NR	NR	-	-	NR	NR	0.1	0.03	N	N	N	N	Y	PANCREATITIS	DISCHARGE	N	N	N	N	Y
2260	1187606	2395	NR	NR	-	-	NR	NR	0.1	0.02	N	N	N	N	Y	LRTI	DISCHARGE	N	N	N	N	Y
2261	1084234	2396	SPUTUM	Neg	-	-	Neg	NG	0.53	-	N	N	N	N	Y	CELLULITIS	DISCHARGE	N	N	N	N	Y
2262	1622093	2397	PLEURAL FLUID	Neg	-	-	Neg	NG	0.22	-	N	N	N	N	Y	LRTI, AKI, SEPSIS	DISCHARGE	Y	N	Y	N	N
2263	1016534	2398	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.23	0.24	N	N	N	N	Y	LRTI, SEPSIS	DISCHARGE	Y	N	Y	N	N
2264	1628845	2399	SPUTUM	Neg	-	-	Neg	CANDIDA	0.1	0.02	N	N	N	N	N	ILD	DISCHARGE	N	N	N	N	Y
2265	1625089	2400	SPUTUM	Neg	-	-	Neg	CANDIDA	0.22	8.6	N	N	N	N	Y	KOCHS	DAMA	N	N	N	N	Y
2266	1263057	2401	ASCITIC FLUID	Neg	-	-	Neg	NG	0.28	109.5	N	Y	N	N	Y	CLD WITH PORTAL HTN	DISCHARGE	N	N	N	N	Y

S. no	MRD No.	Lab No	NAME	DOR Sample	AGE	SEX	GMRepeat	DOA	AREA	SUB AREA WISE	Sample	DOR Sample	FEVER	COUGH	SOB	CHEST PAIN	DM	HTN	Alcoholic	Smoker	Neutropenia	TBHistory	Chronic steroid use	Solid organ transplantation	Malignancy	HIV	HCV	HB	TLC/DLC	NEUTROPHIL COUNT	CT CHEST _PLEURAL EFFUSION	CONSOLIDATION IN LUNG	CAVITATION	RETICULONODULAR OPACITIES	Histopathology for aspergillus species
2267	1441277	2402	M	11/25/2023	55	M	N	11/23/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	11/25/2023	N	N	N	N	N	N	Y	N	N	N	N	N	N	N	N	13.2	17	74	N	N	N	Y	NR
2268	1625547	2403	D	11/25/2023	38	M	N	11/18/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/25/2023	Y	N	Y	N	N	N	N	N	N	N	N	N	N	N	N	7.2	8.9	62.2	N	N	N	Y	NR
2269	1624699	2404	GS	11/25/2023	32	M	N	11/19/2023	ICU	GASTROINTESTINAL TRACT DISEASE	SERUM	11/25/2023	N	Y	N	N	N	N	N	N	N	N	Y	N	N	N	N	14.2	18	90	N	N	N	N	NR
2270	162652	2405	R	11/25/2023	70	M	N	11/23/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	11/25/2023	N	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	10.3	14	91.7	N	Y	N	N	NR
2271	891273	2406	T	11/26/2023	77	M	N	11/25/2023	WARD	RENAL DISEASE	SERUM	11/26/2023	Y	Y	Y	N	Y	N	N	N	N	N	N	N	N	N	N	10	10	68	N	N	N	N	NR
2272	1600230	2407	S	11/26/2023	52	M	N	10/2/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/26/2023	N	N	Y	N	N	Y	N	N	N	N	N	N	N	N	N	11	13	64	N	N	N	N	NR
2273	1629301	2408	Y	11/26/2023	52	M	N	11/25/2023	WARD	RENAL DISEASE	SERUM	11/26/2023	N	Y	N	N	Y	Y	Y	N	N	N	Y	N	N	N	N	6.8	11	94	N	N	N	Y	NR
2274	214435	2410	J	11/27/2023	46	M	N	11/13/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	11/27/2023	N	N	N	N	N	N	N	N	N	N	Y	N	N	N	N	8.3	14	81	N	Y	N	N	NR
2276	1628868	2412	S	11/27/2023	63	F	N	11/25/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/27/2023	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	Y	9.4	3.2	81	N	N	N	Y	NR
2277	859282	2413	K	11/27/2023	63	M	N	11/25/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	11/27/2023	Y	Y	Y	N	N	Y	N	N	N	N	N	N	N	N	N	13	14	92	N	Y	N	N	NR
2278	58356	2414	S	11/27/2023	70	F	N	11/22/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/27/2023	N	Y	Y	Y	Y	Y	N	N	N	N	N	N	N	N	N	7.3	6.6	66	N	N	N	Y	NR
2279	1625077	2415	JK	11/27/2023	55	F	N	11/17/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/27/2023	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	N	11.4	24	83	N	N	N	N	NR
2280	1629807	2416	A	11/28/2023	75	F	N	11/27/2023	ICU	RESPIRATORY TRACT DISEASE	SERUM	11/28/2023	N	N	Y	N	N	Y	N	N	N	N	N	N	N	N	N	8.3	7	78	N	N	N	N	NR
2281	1625716	2417	R	11/28/2023	39	F	N	11/20/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	11/28/2023	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	13	27	91.3	N	N	N	N	NR
2282	1627259	2418	R	11/28/2023	73	M	N	11/22/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/28/2023	N	N	Y	Y	N	Y	N	N	N	N	Y	N	N	N	N	10	10	95	N	N	N	N	NR
2283	1629308	2419	G	11/28/2023	70	M	N	11/25/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/28/2023	N	Y	Y	Y	Y	Y	N	N	N	N	Y	N	N	N	N	13.7	9.2	84	N	N	N	N	NR
2284	1576402	2420	R	11/28/2023	67	M	N	11/21/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/28/2023	Y	Y	N	Y	N	N	N	N	N	N	Y	N	N	N	N	12	15	76	N	N	N	Y	NR
2285	1626881	2421	MY	11/28/2023	35	M	N	11/21/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/28/2023	Y	N	N	N	N	Y	N	N	N	Y	Y	N	N	N	N	12	28	95	N	N	N	N	NR
2286	884479	2422	GD	11/29/2023	67	M	N	11/22/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/29/2023	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	10	7.6	85	N	N	N	Y	NR
2288	1601100	2424	Y	11/29/2023	60	M	N	11/20/2023	ICU	GASTROINTESTINAL TRACT DISEASE	SERUM	11/29/2023	N	N	N	N	N	N	Y	N	N	N	N	N	N	N	N	10.2	5	50	N	N	N	N	NR
2291	1213473	2427	SK	11/29/2023	80	M	N	11/21/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/29/2023	N	Y	N	N	N	Y	N	N	N	N	Y	N	N	N	N	14	90	79	N	N	N	Y	NR
2292	1629847	2428	D	11/30/2023	32	M	N	11/27/2023	WARD	GASTROINTESTINAL TRACT DISEASE	SERUM	11/30/2023	N	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	11	14	84	N	N	N	Y	NR
2293	1631159	2429	T	11/30/2023	21	M	N	11/30/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/30/2023	Y	Y	N	N	N	N	N	N	N	N	N	N	N	N	N	11.2	23	97	N	Y	N	Y	NR
2294	1622524	2430	M	11/30/2023	35	F	N	11/29/2023	WARD	RESPIRATORY TRACT DISEASE	SERUM	11/30/2023	N	Y	N	N	Y	N	N	N	Y	N	Y	N	N	N	N	11.1	16	9.7	N	N	N	N	NR
2295	1471217	2431	D	11/30/2023	57	M	P	11/24/2023	WARD	RENAL DISEASE	SERUM	11/30/2023	Y	Y	N	N	Y	Y	N	N	N	N	N	Y	N	N	N	5.4	4	78	N	N	N	N	NR

S. no	MRD No.	Lab No	Distribution of clinical samples received	Fungal smear Positive for Hyaline Septate Fungal Hyphae	CANDIDA IN (BODY FLUIDS AND BLOOD CULTURE)	CANDIDA IN BODY FUILDS	FUNGAL CULTURE FOR ASPERGILLUS SPECIES	Fungal Cuture	GMSAASSAY	1-3 BDG	PTZ	ANTIFUNGAL	Heamo Dylasis	AUGMENTIN	MEROPENEM	Provisional diagnosis	Outcome	TOTAL EORTC PATIENTS	PROVEN	POSSIBLE	PROBABLE	NO INVASIVE ASPERGILLOSI
2267	1441277	2402	ASCITIC FLUID	Neg	-	-	Neg	NG	0.18	-	N	N	N	N	Y	CLD WITH PORTAL HTN	DISCHARGE	N	N	N	N	Y
2268	1625547	2403	NR	NR	-	-	NR	NR	0.71	0.05	N	Y	N	N	Y	LRTI, SEPSIS	DISCHARGE	N	N	N	N	Y
2269	1624699	2404	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	2.07	0.02	N	Y	N	N	Y	CLD WITH PORTAL HTN	DISCHARGE	Y	N	Y	N	N
2270	162652	2405	SPUTUM	Neg	-	-	Neg	NG	0.1	0.2	N	N	N	N	N	LRTI, CKD	DISCHARGE ON REQUEST	N	N	N	N	Y
2271	891273	2406	NR	NR	-	-	NR	NR	0.13	0.02	N	N	N	N	Y	AKI, LRTI	DISCHARGE	N	N	N	N	Y
2272	1600230	2407	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.11	0.02	N	N	N	N	Y	LRTI, STROKE	DISCHARGE	N	N	N	N	Y
2273	1629301	2408	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.11	0.02	N	N	N	N	Y	CKD, LRTI	DISCHARGE	Y	N	Y	N	N
2274	214435	2410	ASCITIC FLUID	Neg	-	-	Neg	NG	8.04	0.15	N	Y	N	N	Y	CLD WITH PORTAL HTN	DISCHARGE	Y	N	Y	Y	N
2276	1628868	2412	SPUTUM	Neg	-	-	Neg	CANDIDA	0.1	0.02	N	Y	N	N	Y	LRTI, ABPA	DISCHARGE	N	N	N	N	Y
2277	859282	2413	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	NG	0.1	0.63	N	Y	N	N	N	SEPSIS, ILD	DISCHARGE	N	N	N	N	Y
2278	58356	2414	NR	NR	-	-	NR	NR	0.1	0.03	Y	N	N	N	N	COPD, LRTI	DISCHARGE	N	N	N	N	Y
2279	1625077	2415	NR	NR	-	-	NR	NR	0.1	0.04	N	Y	N	N	N	SEPSIS	DISCHARGE ON REQUEST	N	N	N	N	Y
2280	1629807	2416	SPUTUM	Neg	-	-	Neg	NG	0.18	0.1	N	N	N	N	Y	UTI	DAMA	N	N	N	N	Y
2281	1625716	2417	NR	NR	-	-	NR	NR	0.17	0.03	N	N	N	N	Y	NECROTISING, PANCREATITIS	DISCHARGE	N	N	N	N	Y
2282	1627259	2418	SPUTUM	Neg	-	-	Neg	CANDIDA	0.2	-	N	N	N	N	Y	OLD CVA, LRTI	DISCHARGE	N	N	N	N	Y
2283	1629308	2419	NR	NR	-	-	NR	NR	0.67	0.03	N	Y	N	N	Y	LRTI	DISCHARGE	Y	N	Y	N	N
2284	1576402	2420	NR	NR	-	-	NR	NR	0.1	0.02	Y	N	N	N	Y	UTI,CAD	DISCHARGE	Y	N	Y	N	N
2285	1626881	2421	ENDOTRACHEAL SECRETIONS	Neg	-	-	Neg	CANDIDA	1.87	0.09	N	N	N	N	N	LRTI, CKD	DAMA	Y	N	Y	N	N
2286	884479	2422	NR	NR	-	-	NR	NR	0.11	0.02	N	N	N	N	Y	VAT	DISCHARGE ON REQUEST	N	N	N	N	Y
2288	1601100	2424	NR	NR	-	-	NR	NR	0.12	-	N	N	N	N	Y	LIVER DISEASE	DISCHARGE	N	N	N	N	Y
2291	1213473	2427	SPUTUM	Neg	-	-	Neg	CANDIDA	0.1	0.02	N	N	N	N	Y	LRTI, AKI	DISCHARGE	Y	N	Y	N	N
2292	1629847	2428	SPUTUM	Neg	-	-	Neg	NG	0.1	0.02	N	N	N	N	Y	PANCREATITIS	DISCHARGE	N	N	N	N	Y
2293	1631159	2429	SPUTUM	Neg	-	-	Neg	NG	0.1	-	N	N	N	N	Y	LRTI	DAMA	N	N	N	N	Y
2294	1622524	2430	NR	NR	-	-	NR	NR	0.1	0.03	N	N	N	N	N	COUGH	DISCHARGE	N	N	N	N	Y
2295	1471217	2431	PLEURAL FLUID	Neg	-	-	Neg	NG	8.35	8.32	N	N	N	N	Y	CKD	DISCHARGE	Y	N	Y	N	N

Baba Farid University
of Health Sciences
Sadiq Road
Faridkot-151 203 (Pb). INDIA.
Phone : 01639-256232,256236
Tele/Fax : 01639-256235
Email – Thesisbfuhs@gmail.com

34

No. BFUHS/2K23p-TH/ 20

Date 1/1/2024

The Principal
Dayanand Medical College & Hospital
Ludhiana

Subject:: Approval of Plan of Thesis.

This is to inform you that the Faculty of Medical Sciences in its meeting held on 25.09.2023 has approved the plan of thesis of **Sabri**, a student of your college for **MD Microbiology** along with the names of Supervisor/Co-Supervisor as under:-

Topic Plan of Thesis
To study the role of biomarkers in the diagnosis of invasive aspergillosis .

Supervisor	**Co-Supervisor:-**	**Co-Supervisor:-**
Dr. Jyoti Chaudhary	Dr. Veenu Gupta	Dr. Akashdeep Singh
Assoc. Prof.	Prof. & Head	Prof. & Head
Dept. of Microbiology	Dept. of Microbiology	Dept. of Pulmonary Medicine

The student may submit the thesis in triplicate alongwith the plan in triplicate also, to the Controller of Examinations, BFUHS, Faridkot, at least six months before the commencement of theory examination, if he/she is otherwise eligible to take the examination. He /She may be directed to attach a photocopy of this letter with the forwarding letter while submitting thesis in the University along with the letter of approval of University for change of supervisor/Co-Supervisor, change of topic, if any.

1/1/2024
Controller of Examinations

Note :

1. *If any discrepancy found regarding topic of thesis or Supervisor/Co-Supervisor, inform undersigned within one month after issue of this letter.*

TO STUDY THE ROLE OF BIOMARKERS IN THE DIAGNOSIS OF INVASIVE ASPERGILLOSIS

THESIS PROPOSAL

FOR APPROVAL OF SUBJECT OF THESIS TO BE SUBMITTED IN

PARTIAL FULFILMENT OF THE REQUIREMENTS

FOR THE DEGREE OF

MD

IN

MICROBIOLOGY

OF THE

BABA FARID UNIVERSITY OF HEALTH SCIENCES

FARIDKOT

June, 2022

Dr. SABRI

DEPARTMENT OF MICROBIOLOGY
DAYANAND MEDICAL COLLEGE AND HOSPITAL
LUDHIANA

ABSTRACT OF PLAN OF THESIS

Title	TO STUDY THE ROLE OF BIOMARKERS IN THE DIAGNOSIS OF INVASIVE ASPERGILLOSIS
For the degree of	MD MICROBIOLOGY
Name of the candidate	Dr. Sabri
Supervisor	Dr. Jyoti Chaudhary, Associate Professor, Department of Microbiology, DMCH, Ludhiana
Co-Supervisor	Dr. Veenu Gupta, Professor & Head Department of Microbiology, DMCH, Ludhiana Dr. Akashdeep Singh, Professor & Head Department of Pulmonary Medicine, DMCH, Ludhiana
Institution	Dayanand Medical College and Hospital,Ludhiana
University	Baba Farid University of Health Sciences, Faridkot

INTRODUCTION: IA is associated with high morbidity and mortality particularly in high risk patients such as immunocompromised patients and individuals with hematological malignancies. Early diagnosis is needed for effective management of IA.

AIMS AND OBJECTIVES:

1. To study the clinico-mycological profile of the admitted patients suspected for invasive aspergillosis.
2. To study the positivity and the variables affecting the fungal biomarkers (GM assay /(1-3) BDG) in the patients admitted with suspicion of invasive aspergillosis.

MATERIALS AND METHODS: This prospective study will be a conducted over a period of one year in the Department of Microbiology, Dayanand Medical College and Hospital, Ludhiana .All adult patients admitted in various wards and ICUS of Dayanand Medical College and Hospital, Ludhiana with suspicion of IA whose requisition for GM assay received in the Microbiology department will be included. Samples such as blood , respiratory samples(sputum, endotracheal secretions ,BAL) biopsy etc will be collected. Samples for KOH mount & fungal culture will be processed as per standard protocol. GM & (1-3) BDG will be performed as per kit protocol. Results will be statistically analysed.

KEYWORDS: IA(Invasive aspergillosis), GM(Galactomannan), (1-3)BGD(Beta d glucan)

(Signature) Candidate | (Signature) Co-supervisor | (Signature) Co-supervisor | (Signature) Supervisor | (Signature) Principal

CERTIFICATE OF FACILITIES AVAILABLE

This is to certify that the facilities for work on the subject of thesis titled **"TO STUDY THE ROLE OF BIOMARKERS IN THE DIAGNOSIS OF INVASIVE ASPERGILLOSIS"** exist in the Department of Pediatrics at Dayanand Medical College and Hospital, Ludhiana and will be provided to the candidate. We will see that the data being included in the thesis are genuine and is collected by the candidate herself under our supervision and guidance.

Supervisor

Dr. Jyoti Chaudhary
Associate Professor
Department of Microbiology
DMCH, Ludhiana

Co-Supervisor

Dr. Veenu Gupta
Professor & Head
Department of Microbiology
DMCH, Ludhiana

Dr Akashdeep Singh
Professor & Head
Department of Pulmonary medicine
DMCH, Ludhiana

Head of the Department

Dr. Veenu Gupta
Professor & Head
Department of Microbiology
DMCH, Ludhiana

Place : Ludhiana

Date : 20/9/22

APPROVAL PROFORMA
BY
RESEARCH & ETHICAL COMMITTEE
DAYANAND MEDICAL COLLEGE & HOSPITAL, LUDHIANA

Name of candidate	DR. SABRI
Department	MICROBIOLOGY
Topic of Thesis	TO STUDY THE ROLE OF BIOMARKERS IN THE DIAGNOSIS OF INVASIVE ASPERGILLOSIS
Likely date of appearing in PG examination	MARCH,2024
Date of enrollment	7/03/2022
Name of Head of Department	Dr. Veenu Gupta
1) Supervisor **2) Co-Supervisor**	Dr. Jyoti Chaudhary Dr. Veenu Gupta Dr. Akashdeep Singh
Signature of Members of Research Committee with Stamp	**Signature of Members of Ethics Committee with Stamp**
Dr. Harpreet Kaur (Professor & Head, Pathology)	Mr. R K Sharma (Legal Expert)
Dr. Jaspal Singh (Professor & Head, Surgery)	Dr. Ramit Mahajan (Associate Professor, Gastroenterology)
Dr. Dinesh Gupta (Professor & Head, Medicine)	Dr. Anu Sharma (Professor, Anatomy)
Dr. Sandeep Kaushal (Dean Academics & Professor & Head, Pharmacology)	Dr. Sandeep Kaushal (Dean Academics & Professor & Head, Pharmacology)
Dr. Gurpreet S Wander (Vice Principal)	Dr. Gurpreet S Wander (Vice Principal & Professor & Head, Cardiology)
	Dr. Gagandeep Singh (Secretary, Ethics Committee Professor & Head, Neurology)

Approved: Yes / ~~No~~

Dr. Sandeep Puri
Chairperson
Research Committee

Chairperson
Research Committee

Approved: Yes / ~~No~~

Prof. Arvind Malhotra
Chairperson
Ethics Committee

Chairperson
Ethics Committee

BABA FARID UNIVERSITY OF HEALTH SCIENCES, FARIDKOT

PROFORMA FOR REGISTRATION OF SUBJECT FOR DISSERTATION

1	NAME OF THE CANDIDATE AND ADDRESS	DR. SABRI
2	NAME OF THE INSTITUTE	Dayanand Medical College and Hospital, Ludhiana
3	COURSE OF STUDY AND SUBJECT	MD Microbiology
4	DATE OF ADMISSION OF COURSE	7th March 2022
5	TITLE OF THE TOPIC	TO STUDY THE ROLE OF BIOMARKERS IN THE DIAGNOSIS OF INVASIVE ASPERGILLOSIS

6. BRIEF RESUME OF THE INTENDED WORK

6.1 NEED FOR THE STUDY

Aspergillus species are ubiquitous, saprophytic fungi.. Aspergillus species cause a wide range of diseases such as chronic necrotizing aspergillosis, keratitis, fungal sinusitis and invasive aspergillosis especially in high risk patient (immunocompromised patients, individuals with hematological malignancies such as leukemia; solid-organ and hematopoietic stem cell transplant patients patients on prolonged corticosteroid therapy). Other types of aspergillosis includes allergic bronchoplumonary aspergillosis(ABPA), allergic aspergillus sinusitis, aspergilloma, chronic pulmonary aspergillosis,cutaneous aspergillosis. The most common aetiological agent of IA, Aspergillus fumigatus, with airborne conidia leading to almost universal and constant exposure in almost all humans [1]. Invasive aspergillosis (IA) remains a significant cause of morbidity and mortality in immunocompromised patients. Some studies have reported IA among immunocompetent patients as well.[2,3]

The signs and symptoms of IA are generally nonspecific, and typically involve persistent fever not responding to the antibacterial therapy.[4] Cough, dysnpnea. IA principally involves sinopulmonary tract as it is the most common route of entry for the Aspergillus spores & vascular invasion presents as pleuritic chest, hemoptysis. Disseminated aspergillosis may involve CNS manifests as seizures or focal neurological signs or stroke.[5] Diagnosis of IA is a challenge. The culture-based diagnostic methods have limited performance due to low sensitivity and long turn around time but important for detection of antifungal resistance. Non-culture-based methods such as galactomannan assay and 1-3 B D Glucan assay are being increasingly used for diagnosis of IA. Invasive aspergillosis is rarely proven by direct microbiological detection or autopsy, and often remains a possible, probable or proven diagnosis depending on a combination of clinical, radiological, and microbiological criteria on the

basis of EORTC CRITERIA which includes host factors(>10 days neutropenia, >3 weeks corticosteroids T cells or B cells immunosuppresant , inherited severe immunodeficiency), clinical features in CT findings, and mycological evisdence (direct microscopy) GM antigen, 1-3 B-D G assay.

Galactomannan assay is specific for IA and detects circulating galactomannan (GM) with a sandwich enzyme-linked immunosorbent assay (ELISA) (Platelia Aspergillus; Bio-Rad, Marnes-la Coquette, France). The 1-3 B D Glucan assay has broader spectrum and also detects other invasive fungal diseases such as candidiases, pneumocystis jrovecii pneumonia except mucor mycosis, cryptococcosis. BDG is a protease zymogen-based colorimetric assay for the qualitative detection of (1-3) B-D- Glucan which is a component of the cell walls of most fungi released in the serum of patients having IFD. [4]

Studies have reported various confounding factors for these biomarkers assays leads to false positive results. Variables in GM immunoassay includes antifungal drugs (amphotericin B, voriconazole, itraconazole), antibiotics such as piperacillin tazobactam, amoxacillinclavulanic acid, steroids, neutropenia and Variables in (1-3) B-D Glucan includes the patients on hemodialysis [6,7] Immunoglobulin products,Concurrent bacteremia, antibiotics.

Among the available methods for diagnosis of IA. Histopathological examination is an invasive procedure, though it is confirmatory, it cannot be done in all cases. Radiological findings are non specific ,fungal culture has low sensitivity and time consuming. The fungal biomarkers assays do not require an invasive sample-collection procedure and offer advantage of early diagnosis than culture based methods.GM is also used as a surrogate marker to follow the efficacy of treatment.[8] There are limited data describing changes in serum BDG titers in patients treated for IFIs.[9,10] There is an urgent need for

more reliable, easily applicable and non-invasive tests that can be used to assess response.

Timely detection and initiation of appropriate antifungal therapy is a critical component that helps to reduce overall morbidity and mortality therefore the study was planned with objective to study the clinicomycological profile and the positivity of galactomannan assay & (1-3)b D Glucan assay in admitted patients supspected for invasive aspergillosis and to analyse the variables affecting galactomannan assay and(1-3) b D Glucan assay.

6.2 REVIEW OF LITERATURE

Aspergillosis, which can be defined as an infection or disease caused by fungi in the genus Aspergillus which constitutes a wide range of disease entities that form a continuumfrom allergic reactions to disseminated invasive disease inimmunocompromised patients.[11] The specific term invasive aspergillosis (IA), is defined in relation to the primary organ affected. Invasive pulmonary aspergillosis (IPA)is commonly considered to be defined by invasion of the pulmonary parenchyma by the growing hyphae of Aspergillus.[12]

Fungal infections have recently emerged as a world-wide health care problem, owing to extensive use of broad spectrum antibiotics, immunosuppressive agents and increasing population of terminally ill and debilitated patients.

Aspergillus infection is the commonest invasive fungal infection which involves respiratory tract. It can be ascribed to pervasive presence of the fungal spores in soil, water, decaying vegetation, indoor environment, including hospitals. Aspergillus was first detected in 1729 and it received its name due to its resemblance to an aspergillum which was used to sprinkle holy water [13] Man acquires the infection through inhalation of fungal spores, though infection has also been documented following exposure to water aerosols contaminated with Aspergillus spores and Aspergillusfumigatus, in particular, is the most important air borne saprophytic fungus.[14]

Invasive aspergillosis (IA), an infection caused by fungi in the genus Aspergillus, most commonly seen in patients with immunological deficits, particularly acute leukaemia and stem cell transplantation. It has been associated with high rates of mortality in previous years.[15] Diagnosing IA has long been problematic owing to the inability to culture the main causal agent A. fumigatus from blood. Microscopic examination and culture of respiratory tract specimens have lacked sensitivity, and biopsy tissue for histopathological examination is rarely obtainable. Thus for many years there has been a great interest in

nonculture-based techniques such as the detection of galactomannan, β-D-glucan, and DNA by PCR-based methods. A multicenter prospective study comparing 170 patients without signs of invasive fungal infection and 163 patients with proven (142 patients) or probable (21 patients) invasive fungal infection found a 64.4% sensitivity, 92.4% specificity, 89% positive predictive value, and 73% negative predictive value of BG assay.[16]

Identification of A. fumigatus is based predominantly upon the morphology of the conidia and conidiophores. The organism is characterized by green echinulate conidia, 2.5 to 3 μm in diameter, produced in chains basipetally from greenish phialides, 6 to 8 by 2 to 3 μm in size. A few isolates of A. fumigatus are pigmentless and produce white conidia.[17]

In a study on non-invasive methods of IA illustrated that (1-3)- beta-D-glucan and galactomannan assay have high sensitivity and specificity but are more useful when used together as a diagnostic strategy for patients with invasive aspergillosis.[18]

6.3 AIMS AND OBJECTIVES OF THE STUDY

- To study the clinicomycological profile and the positivity of galactomannan assay and (1-3)b D Glucan assay in admitted patients supspected for invasive aspergillosis.
- To analyse the variables affecting galactomannan assay and (1-3) b D Glucan assay.

7. MATERIALS AND METHODS

This prospective study will be a conducted over a period of one year in the Department of Microbiology, Dayanand Medical College and Hospital, Ludhiana.

7.1 Source of Data:

All patients admitted in various wards and ICUS of Dayanand Medical College and Hospital, Ludhiana with suspicion of Invasive asperigillosis whose requisition for GM assay received in the microbiology department will be included.

7.2 METHOD OF COLLECTION OF DATA

Inclusion Criteria:

- All patients above 18 years of age in ICUS and wards

Exclusion Criteria:

- All patients of pediatric age group.

METHOD OF COLLECTION

The data collected will entered in a prestructured proforma which will include patient's details: Name, age, gender, CR.No., Lab.ID no., date of admission, provisional clinical diagnosis, risk factors, treatment history, hemogram, radiological evaluation, histopathological evaluation, microbiological evaluation (Galactomannan assay, (1-3) B – D glucan assay fungal smear/ fungal culture),clinical outcome

Samples collected:-

Blood Five ml blood was collected by venipuncture in sterile plain vials taking all aseptic precautions**.**

Sputum:- Sputum was collected in a wide mouthed, sterile, leak-proof, screw capped container under all aspectic precautions

Endotracheal secretions: ET secretion was collected using a 22-inch Ramson's 12 F suction catheter with a mucus extractor which was gently introduced through the endotracheal tube for a distance of approximately 25–26 cm. Gentle aspiration was then performed without instilling saline and the catheter was withdrawn from the endotracheal tube. About 2 ml of sterile 0.9% normal saline was injected into it with a syringe to flush the exudates into a sterile container for collection.

BAL: Sample was collected using flexible fiberoptic bronchoscope. About 30-50 ml of physiological saline was infused through fiberoptic bronchoscope into peripheral bronchiolar ramification. The saline was then aspirated and collected in a sterile, robust and leak proof container.

Body fluids, Boipsy specimen from patients.

1) Galactomannan Antigen detection test

It is a one-stage immunoenzymatic sandwich microplate assay which detects galactomannan in human serum. The assay uses rat EBA-2 monoclonal antibodies, which are directed against Aspergillus galactomannan.–Semi-quantitative determination of Aspergillus GM antigen in serum–was done using Platelia Aspergillus EIA (enzyme immunoassay) kit (*Bio-Rad,*-France) as per manufacturer's instructions.

Interpretation:

➢ Sera with an index < 0.50 were considered as negative for galactomannan antigen.

➢ Sera with an index ≥ 0.50 were considered as positive for galactomannan antigen.

Variables such as Mold active antifungal drugs (amphotericin B, voriconazole, itraconazole), piperacillin-tazobactam, amoxacillin-clavulanic acid, steroids, neutropenia were studied.

2) (1-3) b D Glucan assay

The aasay is based upon modificationnof the limulus amebocyte Lysate (LAL) pathway. This kinetic assay is based upon the determination of the rate of optical density increase produced by a sample. This rate will be interpreted against a standard curve to produce estimate if (1-3) B –D glucan concentration in the sample. The test results are expressed in pictogram/ml.

Interpretation:

NEGATIVE RESULT

(1-3)B-D-glucan values <60 pg/ml are interpreted as negative results.

INDETERMINATE RESULT

Values from 60 to 79 pg/ml are interpreted as negative results.

POSITIVE RESULT

Values >80 pg/ml are interpreted as positive results.

Microscopic examination and culture of fungus:-

I. Direct microscopic examination [31,51]

Potassium hydroxide mount: Composition of KOH:-

Potassium hydroxide 10 gm

Glycerol 10 ml

Distilled water 80 ml

These ingredients were mixed properly and solution was stored at room temperature.

Slide KOH :- A drop of potassium hydroxide solution was placed on a clean microscopic slide. The sample was transferred to the drop of KOH and mixed gently with inoculating loop. A cover slip was placed over it.

Clearing was hastened by gently heating the preparation over the flame of a Bunsen burner, taking care to prevent drying. It was then examined microscopically under low (10×) and high (40×) power objectives.

Tube KOH:- Tube KOH method was used for biopsy specimens which take longer time for dissolution. The tissue was put in 10-20% KOH and was kept in an incubator at 37°C for dissolution. It was then examined microscopically under low (10×) and high (40×) power objectives.

Presumptive identification was made based on direct microscopic examination of material from clinical sample. Hyaline septate fungal hyphae with acute angle branching were suggestive of *Aspergillus* species.

Fungal culture using :-

a)Sabouraud dextrose agar (SDA) with antibiotics and witout cycloheximide:-

Composition and preparation:

Peptone 10 gm

Dextrose 40 gm

Agar 20 gm

Distilled water 1000 ml

Chloramphenicol 50 mg

Gentamicin 20 mg

All ingredients were dissolved by boiling; antibiotics were addedinto SDA while boiling but before autoclaving. Chloramphenicol/ gentamicin were dissolved in 10 ml of 95% alcohol and added to boiling medium. The medium was dispensed in tubes and autoclaved at 121ºC for 15 minutes and final pH was adjusted to 5.6. The medium was allowed to cool in slanting position and stored in the refrigerator.

b) Sabouraud dextrose agar (SDA) with antibiotics and cycloheximide

All ingredients of SDA with antibiotics were mixed properly and following antibiotic was added while boiling but before autoclaving: Cycloheximide 500mg/1000ml Cycloheximide was dissolved in 10ml acetone, added to boiling medium and mixed properly. The medium was removed from heating and mixed well. It was dispensed in tubes and autoclaved at 121ºC for 15 minutes and final pH was adjusted to 5.6. The medium was dispensed in tubes and allowed to cool in slanting position and stored in the refrigerator.

Processing of sample for fungal culture:-

The samples were inoculated on two tubes of Sabouraud dextrose agar (SDA) with antibiotics (chloramphenicol 50mg/1L and gentamicin 20mg/1L) and cycloheximide (500mg/1L) and two tubes of SDA with antibiotics but without cycloheximide. One set of tubes was incubated at 25ºC. Similarly, other set were incubated at 37ºC. The inoculated media were kept for a minimum period of three weeks. Tubes were examined daily during 1st week and on alternate days in 2nd and 3rd week. The growth obtained was identified on the basis of colony morphology, pigment production and microscopic examination of lactophenol cotton blue (LCB) preparation.

c) Lactophenol cotton blue mount preparation:-

Composition and preparation

Phenol crystals 20 ml

Lactic acid 20 ml

Glycerol 40 ml

Distilled water 20 ml

Cotton blue 0.05 gm

All reagents were mixed properly and cotton blue stain was dissolved in distilled water before mixing with remaining reagents.

1) Tease mount preparation

Growth on culture tubes was teased out on a glass slide in a drop of LCB stain using two teasing needles. Coverslip was placed over it and examined under microscope to study morphological features of fungal isolates

2) Transparency Tape method of preparing LCB mount

A drop of LCB was placed on a clean microscope slide. A piece of clear vinyl adhesive tape 6-7 cm long was held with forceps and introduced into the culture tube. The centre of the adhesive side of the tape was allowed to touch the colony lightly under its own weight. The tape was transferred to the slide, placing the area with adhered mycelium on to the lactophenol cotton blue. Growth of *Aspergill* species was taken as significant and processed for identification

Mycological criteria

- Positive indirect tests by galactomannan antigen detection
- Positive direct test by smear/culture

Diagnosis Criteria+

Proven IA:- Histopathological evidence of tissue invasion by filamentous fungi, Isolation of *Aspergillus* species from a normally sterile but clinically infected body site

Probable IA One microbiological criteria, and One host criteria, and Clinical criteria

Possible IA Host criteria, and Presence of microbiological criteria, or Clinical criteria

OUTCOME

Clinicomycological and serological profile of suspected Invasive Aspergillosis cases will be correlated.

STATISTICAL ANALYSIS

Data will be described in terms of range; mean ±standard deviation (± SD), frequencies (number of cases) and relative frequencies (percentages) as appropriate. All statistical calculations will be done using SPSS (Statistical Package for the Social Science) SPSS 21 version statistical program for Microsoft Windows.

7.3 DOES THE STUDY REQUIRE ANY INVESTIGATIONS OR INTERVENTIONS TO BE CONDUCTED ON PATIENTS OR OTHER HUMANS OR ANIMALS? IF SO, PLEASE DESCRIBE BRIEFLY.

No

7.4 HAS ETHICAL CLEARANCE BEEN OBTAINED FROM YOUR INSTITUTION IN CASE OF 7.3?

Attached herewith

REFERENCES

1. Barton RC. Laboratory diagnosis of invasive aspergillosis: from diagnosis to prediction of outcome. Scientifica (Cairo). 2013;2013:459405.
2. Reichenberger F, Habicht JM, Gratwohl A, Tamm M. Diagnosis and treatment of invasive pulmonary aspergillosis in neutropenic patients. Eur Respir J. 2002;19:743-55..
3. Park DW, Yhi JY, Koo G, Jung SJ, Kwak HJ, Moon JY, et al. Fatal clinical course of probable invasive pulmonary aspergillosis with influenza B infection in an immunocompetent patient. Tuberc Respir Dis (Seoul). 2014;77:141-4.
4. Marty FM, Koo S. Role of (1→3)-β-D-glucan in the diagnosis of invasive aspergillosis. Med. Mycol. 2009;47:S233–40.
5. Sherif R, Segal BH. Pulmonary aspergillosis: clinical presentation, diagnostic tests, management and complications. Curr Opin Pulm Med. 2010;16:242-50.
6. Kanda H, Kubo K, Hamasaki K, Kanda Y, Nakao A, Kitamura T, et al. Influence of various hemodialysis membranes on the plasma (1→ 3)-β-D-glucan level. Kidney international. 2001;60:319-23.
7. Kato A, Takita T, Furuhashi M, Takahashi T, Maruyama Y, Hishida A. Elevation of blood (1→3)-beta-D-glucan concentrations in hemodialysis patients. Nephron. 2001;89:15-9.
8. Bergeron A, Porcher R, Menotti J, Poirot JL, Chagnon K, Vekhoff A, et al. Prospective evaluation of clinical and biological markers to predict the outcome of invasive pulmonary aspergillosis in hematological patients. J Clin Microbiol. 2012;50:823-30.
9. Pazos C, Ponton J, Del Palacio A. Contribution of (1->3)-beta-D-glucan chromogenic assay to diagnosis and therapeutic monitoring of invasive aspergillosis in neutropenic adult patients: a comparison with serial screening for circulating galactomannan. J Clin Microbiol. 2005;43:299–305.

10. Koo S, Baden LR, Marty FM. Post-diagnostic kinetics of the (1 —> 3)-beta-D-glucan assay in invasive aspergillosis, invasive candidiasis and Pneumocystis jirovecii pneumonia. Clin Microbiol Infect. 2012;18:E122–7.
11. Latge JP. Aspergillusfumigatus and aspergillosis. Clinical Microbiology Reviews. 1999;12:310–50.
12. Hope WW, Walsh TJ, Denning DW. The invasive and saprophytic syndromes due to Aspergillus spp. Medical Mycology. 2005;43:S207–38.
13. Vaideeswar P, Prasad S, Deshpande JR, Pandit SP. Invasive pulmonary aspergillosis: A study of 39 cases at autopsy. J Postgrad Med. 2004;50:21-6.
14. Xiao-dong Z, Xiao-peng H, Hang Y, Wei W, Xin Z, Lin-lin M, et al. Aspergillus pneumonia in renal transplant recipients. Chin Med J (Engl). 2008;121:791-4
15. Prakash V, Mishra PP, Verma SK, Sinha S, Sharma M. Prevalence and fungal profile of pulmonary aspergillosis in Immunocompromis and immunocompetent patients of a tertiary care hospital. Int J Med Res Health Sci. 2014;3:92-7.
16. Hachem RY, Kontoyiannis DP, Chemaly RF, Jiang Y, Reitzel R, Raad I. Utility of galactomannan enzyme immunoassay and (1,3) beta-Dglucan in diagnosis of invasive fungal infections: low sensitivity for Aspergillusfumigatus infection in hematologic malignancy patients. J ClinMicrobiol. 2009;47:129-33
17. Sarfati J, Diaquin M, Debeaupuis JP, Paris S, Latgé JP. Cell wall antigens in Aspergillusfumigatus. Arch Med Res. 1993;24:269-74.
18. Huang L, He H, Ding Y, Jin J, Zhan Q. Values of radiological examinations for the diagnosis and prognosis of invasive bronchial-pulmonary aspergillosis in critically ill patients with chronic obstructive pulmonary diseases. Clin Respir J. 2018;12:499-509.

PROFORMA

Sr. No: Lab No:

Name: Date of admission:

MRD No: Ward:

Admission No: Date of Receiving Sample:

Sample

Chief complaints:

History of present illness:

Past history:

Risk factors:

1. Neutropenia

2. Steroid induced immunosupression

3. Malignancy/Chemotherapy

4.Immunocompromised/HIV

5.Solid Organ transplantation/ HSCT

Treatment history:

Investigations:- Hb/ TLC/DLC/Neutrophil count

Radiological evaluation:

Histopathological evaluation:

Signature of Candidate **Signature of Supervisor**

Date of sample collection:

Specimen:

Microbiological evaluation: 1)Fungal smear/Culture

2) Galactomannan assay

3)(1-3) B-D glucan assay

Variables affecting GM test:- Antibiotics

Antifungals

Neutropenia

Variables affecting 1-3 BDG test:-Hemodialysis

Steroids

Provisional diagnosis:

Outcome:

Others:

Signature of Candidate **Signature of Supervisor**

INFORMED PATIENT CONSENT

Date: _____

I…….D/o, W/o, S/o……..…… am willing to participate in the study **"TO STUDY THE ROLE OF BIOMARKERS IN THE DIAGNOSIS OF INVASIVE ASPERGILLOSIS"** The procedure with its complications has been explained to me in local vernacular language. I have fully understood that no special tests and extra expenditure in any form, merely for the purpose of thesis is being carried out. I am free to opt out the study any time without assigning any reason.

……. ……
Signature of the Witness Signature of the patient

Name:

Signature of Candidate **Signature of Supervisor**

मरीज अनुमति फार्म

तिथि _____

मैं _____ पत्नी/पुत्र/पुत्री _____

निवासी _____

इस शोधकार्य "**TO STUDY THE ROLE OF BIOMARKERS IN THE DIAGNOSIS OF INVASIVE ASPERGILLOSIS**" में भाग लेने के लिए सहमत हूँ। मैं इस शोधकार्य में भाग लेने के लिए अपनी स्वेच्छा से तैयार हूँ। मैं पुष्टि करता/करती हूँ की यह स्वीकृति देने के लिए मुझे कोई आर्थिक प्रलोभन नहीं दिया गया और न ही दबाव डाला गया है। मुझे इस शोधकार्य का उद्देश्य स्पष्ट कर दिया गया है और मुझे यह विश्वास है की यह विज्ञान और मानवता के लाभ के लिए है। मुझे इस शोधकार्य में होने वाले जोखिम के बारे में समझा दिया गया है और मेरी समझ में यह जोखिम बहुत मामुली है।

मैं इस शोधकार्य में भाग लेने के सम्बन्ध में किसी भी समय अपनी अस्वीकृति व्यक्त कर सकता/सकती हूँ और मेरे अस्वीकृति व्यक्त करने का मेरे इलाज पर कोई प्रभाव नहीं पड़ेगा।

_____	_____
गवाह के हस्ताक्षर	रोगी के हस्ताक्षर/अंगूठे का निशान
नाम:	नाम:

_____

अन्वेषक के हस्ताक्षर

_____

विद्यार्थी के हस्ताक्षर

ਮਰੀਜ਼ ਰਜ਼ਾਮੰਦੀ ਫਾਰਮ

ਮਿਤੀ_____

ਮੈ_____ਪਤਨੀ/ਪੁੱਤਰ/ਪੁੱਤਰੀ_____

ਵਾਸੀ _____

“TO STUDY THE ROLE OF BIOMARKERS IN THE DIAGNOSIS OF INVASIVE ASPERGILLOSIS” ਤੇ ਚਲ ਰਹੀ ਖੋਜ ਵਿਚ ਹਿੱਸਾ ਲੈਣ ਲਈ ਰਜ਼ਾਮੰਦ ਹਾਂ। ਇਸ ਖੋਜ ਕੰਮ ਵਿਚ ਹਿੱਸਾ ਲੈਣ ਲਈ ਮੈ ਆਪਣੀ ਮਰਜ਼ੀ ਨਾਲ ਤਿਆਰ ਹਾਂ। ਮੈ ਇਹ ਦਸਣਾ ਚਾਹੁੰਦਾ ਹਾਂ/ ਚਾਹੁੰਦੀ ਹਾਂ ਕੇ ਇਹ ਰਜ਼ਾਮੰਦੀ ਦੇਣ ਵਾਸਤੇ ਮੈਨੂ ਕਿਸੇ ਵੀ ਤਰਾਂ ਦਾ ਲੋਭ-ਲਾਲਚ ਨਹੀ ਦਿੱਤਾ ਗਿਆ ਅਤੇ ਨਾ ਹੀ ਕੋਈ ਦਬਾ ਪਾਇਆ ਗਿਆ ਹੈ। ਮੈਨੂ ਇਸ ਖੋਜ ਦਾ ਮਨੋਰਥ ਸਮਝਾ ਦਿੱਤਾ ਗਿਆ ਹੈ ਅਤੇ ਮੈਨੂ ਇਹ ਭਰੋਸਾ ਦਵਾਇਆ ਗਿਆ ਹੈ ਕੇ ਇਹ ਖੋਜ ਵਿਗਿਆਨ ਅਤੇ ਮਾਨਵਤਾ ਦੀ ਭਲਾਈ ਲਈ ਹੈ। ਮੈਨੂ ਇਸ ਖੋਜ ਵਿਚ ਹੋਣ ਵਾਲੇ ਖਤਰੇ ਬਾਰੇ ਸਮਝਾ ਦਿੱਤਾ ਗਿਆ ਹੈ ਅਤੇ ਮੈਨੂ ਇਹ ਯਕੀਨ ਹੈ ਕੇ ਇਹ ਖਤਰਾ ਬਹੁਤ ਮਾਮੂਲੀ ਹੈ। ਮੈਨੂ ਇਸ ਖੋਜ ਕੰਮ ਵਿਚ ਹਿੱਸਾ ਲੈਣ ਦਾ ਢੰਗ – ਤਰੀਕਾ ਸਮਝਾ ਦਿੱਤਾ ਗਿਆ ਹੈ।

ਮੈ ਇਸ ਖੋਜ ਕੰਮ ਵਿਚ ਹਿੱਸਾ ਲੈਣ ਬਾਰੇ ਆਪਣੀ ਰਜ਼ਾਮੰਦੀ ਕਿਸੇ ਵੀ ਸਮੇ ਵਾਪਸ ਲੈ ਸਕਦਾ ਹਾਂ/ ਸਕਦੀ ਹਾਂ ਅਤੇ ਮੇਰੀ ਰਜ਼ਾਮੰਦੀ ਵਾਪਸ ਲੈਣ ਦਾ ਮੇਰੇ ਇਲਾਜ ਤੇ ਕੋਈ ਅਸਰ ਨਹੀ ਹੋਵੇਗਾ।

_____ _____

ਗਵਾਹ ਦੇ ਹਸਤਾਖਰ ਮਰੀਜ਼ ਦੇ ਹਸਤਾਖਰ

ਮਿਤੀ_____ ਮਿਤੀ_____

ਪਤਾ _____ ਪਤਾ _____

_____

ਨਿਰੀਖਕ ਦੇ ਹਸਤਾਖਰ

_____

ਸਿਖਿਆਰਥੀ ਦੇ ਹਸਤਾਖਰ